Rank,NCT Number,Title,Recruitment,Study Results,Conditions,Interventions,Sponsor/Collaborators,Gender,Age,Phases,Enrollment,Funded Bys,Study Types,Study Designs,Other IDs,First Received,Start Date,Completion Date,Last Updated,Last Verified,Results First Received,Acronym,Primary Completion Date,Outcome Measures,URL
311,NCT00004604,Biological Therapy in Treating Patients With Metastatic Cancer,Completed,No Results Available,Breast Cancer|Colorectal Cancer|Extrahepatic Bile Duct Cancer|Gallbladder Cancer|Gastric Cancer|Head and Neck Cancer|Liver Cancer|Lung Cancer|Metastatic Cancer|Ovarian Cancer|Pancreatic Cancer|Testicular Germ Cell Tumor,Biological: CEA RNA-pulsed DC cancer vaccine,Duke University|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,24,Other|NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000065619|1817,2-May-00,2/1/1997,7/1/2002,2/21/2013,Feb-13,No Study Results Posted,null,Jun-01,Safety|Immune response,https://ClinicalTrials.gov/show/NCT00004604
837,NCT00002925,Combination Chemotherapy Plus PSC 833 Followed by Interleukin-2 in Treating Patients With Acute Myelogenous Leukemia,Completed,No Results Available,Leukemia,Drug: ara-C|Drug: Daunorubicin|Drug: Etoposide|Drug: PSC-833|Biological: Aldesleukin,National Cancer Institute (NCI),Both,"15 Years to 59 Years   (Child, Adult)",Phase 1|Phase 2,410,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000065333|U10CA031946|CLB-9621,1-Nov-99,2/1/1997,6/1/2010,11/29/2012,Mar-11,No Study Results Posted,null,Nov-03,,https://ClinicalTrials.gov/show/NCT00002925
412,NCT00003025,Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic Cancer,Completed,No Results Available,Pancreatic Cancer,Biological: vitespen,Memorial Sloan Kettering Cancer Center,Both,"18 Years and older   (Adult, Senior)",Phase 1,16,Other,Interventional,Primary Purpose: Treatment,97-034|CDR0000065613|ANTIGENICS-C-100-01|NCI-G97-1271,1-Nov-99,3/1/1997,7/1/2002,7/1/2013,Jul-13,No Study Results Posted,null,Jul-02,,https://ClinicalTrials.gov/show/NCT00003025
493,NCT00002968,Edrecolomab in Treating Patients With Stage II Colon Cancer,Completed,No Results Available,Mucinous Adenocarcinoma of the Colon|Signet Ring Adenocarcinoma of the Colon|Stage IIA Colon Cancer|Stage IIB Colon Cancer|Stage IIC Colon Cancer,Biological: edrecolomab|Other: laboratory biomarker analysis,National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 3,2100,NIH,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,NCI-2012-02826|NCIC CTG CO.14|CLB-9581|CDR0000065473|C9581|CAN-NCIC-CO14|U10CA031946,1-Nov-99,5/1/1997,null,6/4/2013,Jun-13,No Study Results Posted,null,Jul-03,Survival|Disease-free intervals|Disease-free survival,https://ClinicalTrials.gov/show/NCT00002968
360,NCT00004024,Biological Therapy Following Surgery and Radiation Therapy in Treating Patients With Primary or Recurrent Astrocytoma or Oligodendroglioma,Completed,No Results Available,Brain and Central Nervous System Tumors,Biological: aldesleukin|Biological: autologous tumor cell vaccine|Biological: muromonab-CD3|Biological: sargramostim|Biological: therapeutic autologous lymphocytes|Procedure: surgical procedure|Radiation: radiation therapy,Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 2,60,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000067243|P30CA022453|WSU-C-1403-BT|NCI-G99-1567,1-Nov-99,6/1/1997,1/1/2004,4/3/2013,Apr-13,No Study Results Posted,null,Jan-04,,https://ClinicalTrials.gov/show/NCT00004024
453,NCT00004022,Biological Therapy Following Surgery in Treating Patients With Stage III or Stage IV Melanoma,Completed,No Results Available,Melanoma (Skin),Biological: aldesleukin|Biological: autologous tumor cell vaccine|Biological: muromonab-CD3|Biological: therapeutic autologous lymphocytes|Procedure: surgical procedure,Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 2,null,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000067241|P30CA022453|WSU-C-1403-ME|NCI-G99-1565,1-Nov-99,6/1/1997,1/1/2004,4/3/2013,Apr-13,No Study Results Posted,null,Jan-04,,https://ClinicalTrials.gov/show/NCT00004022
922,NCT00309517,Randomized Study on Neoadjuvant Radio-Chemotherapy in Rectal Carcinoma Dukes B and C,Terminated,No Results Available,"Rectal Cancer Dukes B, Dukes C",Drug: Fluourouracil|Drug: Leucovorin|Drug: MAb 17-1A,Austrian Breast & Colorectal Cancer Study Group,Both,"18 Years to 80 Years   (Adult, Senior)",Phase 3,700,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ABSCG 92,31-Mar-06,7/1/1997,null,3/31/2006,Oct-00,No Study Results Posted,null,null,Local recurrence-free survival|Overall survival,https://ClinicalTrials.gov/show/NCT00309517
430,NCT00003185,Biological Therapy in Treating Patients With Glioblastoma Multiforme,Completed,No Results Available,Brain and Central Nervous System Tumors,Biological: autologous tumor cell vaccine|Biological: sargramostim|Biological: tumor-draining lymph node lymphocyte therapy|Drug: cyclophosphamide|Procedure: conventional surgery,The Cleveland Clinic|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 2,40,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000066013|CCF-BB-IND-6154|NCI-H98-0008,1-Nov-99,8/1/1997,7/1/1998,12/3/2013,Dec-08,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00003185
413,NCT00003199,Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer,Completed,No Results Available,Estrogen Receptor-negative Breast Cancer|Estrogen Receptor-positive Breast Cancer|Inflammatory Breast Cancer|Male Breast Cancer|Progesterone Receptor-negative Breast Cancer|Progesterone Receptor-positive Breast Cancer|Stage IIIB Breast Cancer|Stage IV Breast Cancer,Drug: tamoxifen citrate|Drug: busulfan|Drug: thiotepa|Drug: melphalan|Biological: aldesleukin|Biological: sargramostim|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),Both,19 Years to 65 Years   (Adult),Phase 2,70,Other|NIH,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PSOC 1605|NCI-2010-00728,1-Nov-99,11/1/1997,null,7/8/2011,Jul-11,No Study Results Posted,null,Dec-09,Disease-free survival|Overall survival|Toxicity rate,https://ClinicalTrials.gov/show/NCT00003199
800,NCT00001685,"Immunization of HLA-A201 Patients With Metastatic Melanoma Using a Combination of Immunodominant Peptides From Three Melanoma Antigens, MART-1, GP100 and Tyrosinase",Completed,No Results Available,Melanoma|Neoplasm Metastasis,"Biological: Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase",National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"Child, Adult, Senior",Phase 2,114,NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Primary Purpose: Treatment,980023|98-C-0023,3-Nov-99,11/1/1997,9/1/2000,3/3/2008,Oct-99,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00001685
156,NCT00026897,Trafficking of Indium-III-Labeled Cultured Immune Cells in Patients Undergoing Immunotherapy for Advanced Cancer,Completed,No Results Available,Neoplasm,Procedure: Gamma-camera imaging|Procedure: Low-risk biopsy,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"Child, Adult, Senior",Phase 2,100,NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Primary Purpose: Treatment,980033|98-C-0033,14-Nov-01,12/1/1997,12/1/2002,3/3/2008,Dec-02,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00026897
714,NCT00003190,Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia,Completed,No Results Available,Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Untreated Adult Acute Myeloid Leukemia,Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: etoposide|Drug: valspodar,National Cancer Institute (NCI),Both,"60 Years and older   (Adult, Senior)",Phase 3,640,NIH,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,NCI-2012-02793|CALGB-9720|U10CA031946,1-Nov-99,1/1/1998,null,6/3/2013,Jun-13,No Study Results Posted,null,Aug-02,Disease-free survival|Overall survival,https://ClinicalTrials.gov/show/NCT00003190
744,NCT00003153,Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation,Completed,No Results Available,Multiple Myeloma and Plasma Cell Neoplasm,Biological: therapeutic allogeneic lymphocytes,Eastern Cooperative Oncology Group|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 2,22,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000065938|ECOG-E1A97,1-Nov-99,2/1/1998,null,2/25/2009,Jul-04,No Study Results Posted,null,Feb-07,,https://ClinicalTrials.gov/show/NCT00003153
372,NCT00003408,Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer,Completed,No Results Available,Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Kidney Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Neuroblastoma|Ovarian Cancer|Sarcoma|Testicular Germ Cell Tumor,Biological: aldesleukin|Biological: recombinant interferon alfa|Biological: sargramostim,Cancer Treatment Centers of America|National Cancer Institute (NCI),Both,"Child, Adult, Senior",Phase 2,40,Other,Interventional,Primary Purpose: Treatment,CDR0000066418|MRMC-CTCA-9801|NCI-V98-1449,1-Nov-99,4/1/1998,3/1/2000,3/25/2013,Apr-03,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00003408
52,NCT00003543,Monoclonal Antibody Therapy Plus Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer,Completed,No Results Available,Colorectal Cancer,Biological: monoclonal antibody A33|Drug: carmustine|Drug: fluorouracil|Drug: streptozocin|Drug: vincristine sulfate,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,18,Other|NIH,Interventional,Primary Purpose: Treatment,98-056|CDR0000066597|NCI-H98-0022,1-Nov-99,6/1/1998,8/1/2002,6/25/2013,Jun-13,No Study Results Posted,null,Aug-02,,https://ClinicalTrials.gov/show/NCT00003543
123,NCT00003432,Immunotherapy in Treating Patients With Metastatic Breast Cancer,Terminated,No Results Available,Breast Cancer,Biological: carcinoembryonic antigen RNA-pulsed DC cancer vaccine,Duke University|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,4,Other|NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2030|IRB 2030|CDR0000066458,1-Nov-99,6/1/1998,11/1/2002,11/5/2013,Nov-13,No Study Results Posted,null,Nov-02,Evaluate the ability of active immunotherapy with carcinoembryonic antigen (CEA) RNA pulsed dendritic cells to induce CEA specific T cells in patients with metastatic breast cancer in complete remission following peripheral blood stem cell transplant.|Determine the clinical efficacy in terms of overall and recurrence free survival of immunotherapy with CEA RNA pulsed dendritic cells in this patients population.,https://ClinicalTrials.gov/show/NCT00003432
135,NCT00003433,Immunotherapy in Treating Patients With Resected Liver Metastases From Colon Cancer,Completed,No Results Available,Colorectal Cancer|Metastatic Cancer,Biological: carcinoembryonic antigen RNA-pulsed DC cancer vaccine,Duke Cancer Institute|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,null,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000066459|DUMC-2031-00-11R3|DUMC-2176-99-12R2|DUMC-97146|NCI-G98-1456,1-Nov-99,6/1/1998,8/1/2003,6/20/2013,Nov-02,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00003433
389,NCT00019357,Interleukin-2 Plus Activated White Blood Cells in Treating Patients With Cancer That Has Not Responded to Chemotherapy or Radiation Therapy,Completed,No Results Available,"Unspecified Adult Solid Tumor, Protocol Specific",Biological: aldesleukin|Biological: therapeutic autologous lymphocytes|Biological: therapeutic tumor infiltrating lymphocytes,National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,null,NIH,Interventional,Primary Purpose: Treatment,CDR0000065811|NCI-97-C-0144|NCI-T97-0059,11-Jul-01,6/1/1998,null,4/28/2015,Aug-01,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00019357
500,NCT00003434,"Biological Therapy in Stage I, Stage II, or Stage III Surgically Resected Pancreatic Cancer",Terminated,No Results Available,Pancreatic Cancer,Biological: carcinoembryonic antigen peptide 1|Biological: hepatitis B antigen peptide,Duke University|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,8,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,1259|DUMC-97093|NCI-G98-1457|CDR0000066460,1-Nov-99,6/1/1998,8/1/2002,2/7/2014,Feb-14,No Study Results Posted,null,Aug-02,Progression Free Survival,https://ClinicalTrials.gov/show/NCT00003434
41,NCT00148993,Allogeneic Tumor Cell Vaccination in Patients With Solid Tumors,Withdrawn,No Results Available,Metastatic Solid Tumors,Biological: Tumor Cell Vaccine,Hadassah Medical Organization|The International Center for Cell Therapy & Cancer Immunotherapy (CTCI),Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,100,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label,100798-HMO-CTIL,7-Sep-05,7/1/1998,7/1/2005,4/7/2011,Jul-05,No Study Results Posted,null,null,"Investigate the feasibility of anti-tumor immune response by allogeneic tumor cell vaccine using tumor cells that share MHC determinants with the patient.|Investigate the feasibility of immune responses against cancer cells by combining allogeneic TCV with indomethacin, cimetidine, tetanus and rIL-2.",https://ClinicalTrials.gov/show/NCT00148993
465,NCT00003647,Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma,Completed,No Results Available,Stage IV Melanoma|Stage III Melanoma|Recurrent Melanoma,Drug: allovectin-7|Drug: allovectin-7/dacarbazine|Drug: dacarbazine,Vical,null,"18 Years and older   (Adult, Senior)",Phase 3,null,Industry,Interventional,Primary Purpose: Treatment,CDR0000066736|VCL-1005-301,1-Nov-99,7/1/1998,9/1/2002,7/23/2008,Jul-08,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00003647
851,NCT00001705,Immunization of Patients With Metastatic Melanoma Using the GP100 Peptide Preceded by an Endoplasmic Reticulum Insertion Signal Sequence,Completed,No Results Available,Melanoma|Neoplasm Metastasis,Drug: GP100 peptide|Drug: IL-2,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"Child, Adult, Senior",Phase 2,141,NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Primary Purpose: Treatment,980142|98-C-0142,3-Nov-99,7/1/1998,6/1/2001,3/3/2008,Jul-00,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00001705
1126,NCT00003991,Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid Leukemia,Completed,No Results Available,Leukemia,Biological: aldesleukin|Drug: histamine dihydrochloride,Maxim Pharmaceuticals|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 3,360,Industry,Interventional,Allocation: Randomized|Primary Purpose: Treatment,CDR0000067196|MAXIM-MP-MA-0201|CWRU-MAXI-1998,1-Nov-99,7/1/1998,8/1/2011,11/5/2013,Dec-11,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00003991
354,NCT00003887,Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation,Completed,No Results Available,Breast Cancer|Chronic Myeloproliferative Disorders|Gestational Trophoblastic Tumor|Kidney Cancer|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes|Neuroblastoma|Ovarian Cancer|Sarcoma|Testicular Germ Cell Tumor,Biological: peripheral blood lymphocyte therapy,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),Both,"1 Year to 70 Years   (Child, Adult, Senior)",Phase 2,null,Other|NIH,Interventional,Primary Purpose: Treatment,600.03|FHCRC-600.03|NCI-H99-0031|CDR0000067056,1-Nov-99,8/1/1998,2/1/2003,11/28/2011,Nov-11,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00003887
636,NCT00186862,Gene Modified Allogeneic Neuroblastoma Cells For Treatment of Relapsed/Refractory Neuroblastoma,Completed,No Results Available,Neuroblastoma,Drug: Interleukin-2,St. Jude Children's Research Hospital|Texas Children's Cancer Center|National Cancer Institute (NCI),Both,"up to 21 Years   (Child, Adult)",Phase 1,24,Other|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CYCHAL,12-Sep-05,8/1/1998,10/1/2007,6/2/2008,Jun-08,No Study Results Posted,null,Apr-00,• To determine the safety of up to eight subcutaneous injections of allogeneic neuroblastoma cells that have been genetically modified by retroviral vectors to secrete lymphotactin and Interleukin-2,https://ClinicalTrials.gov/show/NCT00186862
732,NCT00001703,Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma,Terminated,Has Results,Renal Cell Carcinoma,Biological: incomplete Freund's adjuvant|Biological: von Hippel-Lindau peptide vaccine,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years and older   (Adult, Senior)",Phase 2,6,NIH,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,980139|98-C-0139,3-Nov-99,8/1/1998,11/1/2008,7/16/2014,Jul-14,17-May-11,null,Nov-08,Percentage of Participants Who Generated an Immune Response|The Number of Participants With Adverse Events.,https://ClinicalTrials.gov/show/NCT00001703
1038,NCT00110578,Safety and Effectiveness of Immunotherapy With Autologous HIV-Specific CD8 Cells in HIV Infected Adults,Completed,No Results Available,HIV Infections,Procedure: Adoptive transfer of HIV-specific CD8+ T cells|Drug: Aldesleukin,National Institute of Allergy and Infectious Diseases (NIAID),Both,18 Years to 65 Years   (Adult),Phase 1,24,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,5U01AI054334-02|AI54334,10-May-05,9/1/1998,4/1/2005,8/7/2008,Jul-07,No Study Results Posted,null,null,"To determine the safety of administering CD8+ HIV-specific CTL clones followed by subcutaneous IL-2 (Proleukin, Chiron) daily for up to 21 days|To identify a regimen of IL-2 that will improve the in vivo persistence and function of adoptively transferred CD8+ HIV-specific CTL|To determine whether the administration of IL-2 prolongs the antiviral activity of transferred CD8+ HIV-specific CTL|To determine if IL-2 promotes the accumulation of adoptively transferred CD8+ HIV-specific CTL in lymph nodes",https://ClinicalTrials.gov/show/NCT00110578
826,NCT00003875,Busulfan and Etoposide Followed by Peripheral Blood Stem Cell Transplant and Low-Dose Aldesleukin in Treating Patients With Acute Myeloid Leukemia,Completed,No Results Available,Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Childhood Acute Myeloid Leukemia in Remission|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia,Drug: busulfan|Drug: etoposide|Biological: aldesleukin|Procedure: peripheral blood stem cell transplantation,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),Both,"up to 65 Years   (Child, Adult)",Phase 2,62,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,1315.00|NCI-2011-00439|P30CA015704,1-Nov-99,11/1/1998,null,8/4/2015,Aug-15,No Study Results Posted,null,Apr-12,Overall survival of patients on busulfan and etoposide followed by stem cell rescue and aldesleukin|Toxicity associated with high-dose busulfan and etoposide followed by stem cell rescue and aldesleukin|Rate of relapse associated with the regimen,https://ClinicalTrials.gov/show/NCT00003875
400,NCT00140374,Vaccination Priming and Vaccine Boosting Trial of Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines (GVAX® Vaccine for Prostate Cancer),Completed,No Results Available,Prostate Cancer,Biological: Immunotherapy allogeneic GM-CSF secreting cellular vaccine,Cell Genesys,Male,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,36,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,G-9705A,30-Aug-05,12/1/1998,2/1/2001,8/30/2005,Aug-05,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00140374
408,NCT00003780,Chemotherapy Compared to Biological Therapy in Treating Patients With Cancer of the Pancreas,"Active, not recruiting",No Results Available,Pancreatic Cancer,Biological: tumor infiltrating lymphocyte therapy|Drug: gemcitabine hydrochloride,Meyer Pharmaceuticals|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 2,150,Industry,Interventional,Allocation: Randomized|Primary Purpose: Treatment,CDR0000066912|MEYER-AIT-PAN-201,1-Nov-99,12/1/1998,null,12/18/2013,May-07,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00003780
420,NCT00107354,"Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant",Completed,No Results Available,Leukemia|Myelodysplastic Syndromes,Biological: aldesleukin|Biological: therapeutic allogeneic lymphocytes|Biological: therapeutic autologous lymphocytes|Drug: cytarabine|Drug: etoposide|Drug: mitoxantrone hydrochloride|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation,Fred Hutchinson Cancer Research Center,Both,"14 Years and older   (Child, Adult, Senior)",Phase 1,null,Other,Interventional,Masking: Open Label|Primary Purpose: Treatment,1334.00|CDR0000407784,5-Apr-05,12/1/1998,null,9/16/2010,Sep-10,No Study Results Posted,null,Aug-09,Toxicity|In vivo persistence of adoptively transferred T cells|Migration of adoptively transferred T cells to the bone marrow|Antileukemic activity,https://ClinicalTrials.gov/show/NCT00107354
502,NCT00003553,Peripheral Stem Cell Transplant in Treating Patients With Metastatic Kidney Cancer,Recruiting,No Results Available,Kidney Cancer,Biological: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: cyclosporine|Drug: fludarabine phosphate|Drug: methotrexate|Drug: mycophenolate mofetil,"National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)",Both,"18 Years to 80 Years   (Adult, Senior)",Phase 2,80,NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000066610|NHLBI-97-H-0196,1-Nov-99,1/1/1999,null,6/23/2009,Jun-09,No Study Results Posted,null,Dec-09,"Graft vs tumor effect as measured by CT scan at days 30, 60, and 100 following transplant|Disease-free survival as measured by CT scan at 6 months and 1 year",https://ClinicalTrials.gov/show/NCT00003553
907,NCT00003552,Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Melanoma,Terminated,No Results Available,Stage IV Melanoma|Recurrent Melanoma,Drug: allogeneic lymphocytes|Drug: anti-thymocyte globulin|Drug: cyclophosphamide|Drug: fludarabine,"National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)",null,18 Years to 60 Years   (Adult),Phase 1|Phase 2,null,NIH,Interventional,Primary Purpose: Treatment,CDR0000066609|NHLBI-98-H-0006,1-Mar-07,1/1/1999,10/1/2002,4/27/2015,Dec-01,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00003552
533,NCT00331526,Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme,Completed,No Results Available,Brain and Central Nervous System Tumors,Biological: aldesleukin|Biological: therapeutic autologous lymphocytes|Procedure: adjuvant therapy|Procedure: conventional surgery,Hoag Memorial Hospital Presbyterian,Both,"16 Years and older   (Child, Adult, Senior)",Phase 2,83,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000471241|HOAG-CBRG-98-09,30-May-06,2/1/1999,4/1/2012,3/22/2013,Mar-13,No Study Results Posted,null,Dec-08,Side effects and toxicity|Progression-free survival and overall survival,https://ClinicalTrials.gov/show/NCT00331526
1189,NCT00001862,TNRF:Fc to Treat Eye Inflammation in Juvenile Rheumatoid Arthritis,Completed,No Results Available,Juvenile Rheumatoid Arthritis|Uveitis,Drug: Enbrel,National Eye Institute (NEI)|National Institutes of Health Clinical Center (CC),Both,"Child, Adult, Senior",Phase 2,15,NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Primary Purpose: Treatment,990047|99-EI-0047,3-Nov-99,2/1/1999,3/1/2003,3/3/2008,Mar-03,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00001862
451,NCT00003727,Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia,Completed,No Results Available,Leukemia,Biological: filgrastim|Biological: recombinant interferon alfa|Biological: sargramostim|Biological: therapeutic autologous lymphocytes|Drug: carmustine|Drug: cyclophosphamide|Drug: etoposide|Drug: gemcitabine hydrochloride|Drug: melphalan|Procedure: bone marrow ablation with stem cell support|Procedure: in vitro-treated peripheral blood stem cell transplantation,University of Maryland|University of Maryland Greenebaum Cancer Center,Both,"Child, Adult, Senior",Phase 2,22,Other,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000066839|MSGCC-9851|MSGCC-1198006|NCI-V98-1513,1-Nov-99,3/1/1999,2/1/2008,9/23/2009,Sep-09,No Study Results Posted,null,Mar-05,"Response (i.e., major cytogenetic or molecular response) within 12 months after completion of study therapy|Mortality rate",https://ClinicalTrials.gov/show/NCT00003727
615,NCT00004016,Interferon Gamma in Treating Patients With Recurrent or Metastatic Melanoma or Other Solid Tumors,Completed,No Results Available,"Melanoma (Skin)|Unspecified Adult Solid Tumor, Protocol Specific",Biological: recombinant interferon gamma,University of Rochester|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,null,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000067234|P30CA011198|URCC-U2698|TRANSGENE-TG1041.01|NCI-G99-1559,1-Nov-99,4/1/1999,null,6/5/2013,Jun-13,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00004016
1089,NCT00003792,Vaccine Therapy in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Melanoma (Skin),Biological: MART-1 antigen|Biological: filgrastim|Biological: flu matrix peptide p58-66|Biological: gp100 antigen|Biological: recombinant MAGE-3.1 antigen|Biological: tyrosinase peptide|Procedure: in vitro-treated peripheral blood stem cell transplantation,Baylor Health Care System|National Cancer Institute (NCI),Both,"18 Years to 80 Years   (Adult, Senior)",Phase 1,null,Other|NIH,Interventional,Primary Purpose: Treatment,BAYUMC-098004|CDR0000066935|NCI-T98-0054,1-Nov-99,4/1/1999,10/1/2006,6/25/2013,Oct-06,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00003792
361,NCT00005993,"Biological Therapies Following Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, or Advanced Breast Cancer",Terminated,No Results Available,Breast Cancer|Lymphoma,Drug: aldesleukin|Drug: filgrastim|Drug: recombinant human stem cell factor|Procedure: peripheral blood stem cell transplantation,"Masonic Cancer Center, University of Minnesota|National Cancer Institute (NCI)",Both,18 Years to 65 Years   (Adult),Phase 1,null,Other|NIH,Interventional,Primary Purpose: Treatment,1999LS022|MT1998-21|NCI-G00-1803,5-Jul-00,5/1/1999,7/1/2005,10/9/2012,Oct-12,No Study Results Posted,null,Jul-05,,https://ClinicalTrials.gov/show/NCT00005993
384,NCT00140400,Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate Cancer,Completed,No Results Available,Prostate Cancer,Biological: Immunotherapy allogeneic GM-CSF secreting cellular vaccine,Cell Genesys,Male,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,50,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,G-9803,30-Aug-05,5/1/1999,1/1/2001,8/30/2005,Aug-05,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00140400
407,NCT00140387,Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®),Completed,No Results Available,Prostate Cancer,Biological: Immunotherapy allogeneic GM-CSF secreting cellular vaccine,Cell Genesys,Male,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,20,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,G-9802,30-Aug-05,5/1/1999,3/1/2001,8/30/2005,Aug-05,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00140387
470,NCT00112216,Immunotherapy of Melanoma Patients,Completed,No Results Available,Melanoma,Biological: Melan-A analog peptide|Biological: FluMa peptide|Biological: Mage-A10 peptide|Biological: SB AS-2 adjuvant|Biological: Montanide adjuvant,Centre Hospitalier Universitaire Vaudois,Both,"18 Years and older   (Adult, Senior)",Phase 1,9,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,LUD 1998-009,31-May-05,5/1/1999,6/1/2007,4/23/2013,Mar-09,No Study Results Posted,null,Jun-07,"Melan-A, Flu and Mage specific CD8+ T-cell reactivity obtained from different body sites (vaccine site draining lymph node, other lymph node) will be measured by Tetramers and Elispot assays|Safety and toxicity of antigenic peptides administered with high dose adjuvant will be assessed according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) scale",https://ClinicalTrials.gov/show/NCT00112216
381,NCT00004050,Leuvectin Followed By Surgery in Treating Patients With Stage II or Stage III Prostate Cancer,Terminated,No Results Available,Prostate Cancer,Biological: Leuvectin,Vical|Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI),Male,"18 Years and older   (Adult, Senior)",Phase 2,13,Industry|Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,VCL-1102-202|UCLA-9901077-03B|CDR0000067244|NCI-G99-1568,10-Dec-99,6/1/1999,4/1/2003,7/25/2014,Jul-14,No Study Results Posted,null,Apr-03,Disease recurrence|Safety of Leuvectin,https://ClinicalTrials.gov/show/NCT00004050
574,NCT00005038,Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Metastatic Kidney Cancer,"Active, not recruiting",No Results Available,Kidney Cancer,Biological: aldesleukin|Drug: histamine dihydrochloride,The Christie NHS Foundation Trust|National Cancer Institute (NCI),Both,"18 Years to 75 Years   (Adult, Senior)",Phase 2,null,Other,Interventional,Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment,CDR0000067627|CHNT-IL2-MAXAMINE|EU-99048|MAXIM-MP-502,6-Apr-00,6/1/1999,null,9/19/2013,Jun-01,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00005038
701,NCT00001823,Evaluation for NCI Surgery Branch Clinical Studies,Recruiting,No Results Available,Synovial Cell Cancer|Melanoma|Colorectal Cancer|Lung Cancer|Bladder Cancer,,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"16 Years to 80 Years   (Child, Adult, Senior)",,6000,NIH,Observational,Time Perspective: Prospective,990128|99-C-0128,3-Nov-99,6/1/1999,null,3/22/2016,Mar-16,No Study Results Posted,null,null,To permit evaluation of patients referred to the NCI Surgery Branch in order to identify individuals who will be suitable candidates for Surgery Branch clinical research protocols.,https://ClinicalTrials.gov/show/NCT00001823
795,NCT00004197,Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma,Completed,No Results Available,Lymphoma,Biological: keyhole limpet hemocyanin|Biological: sargramostim|Biological: tumor cell-based vaccine therapy|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: mitoxantrone hydrochloride|Drug: prednisone|Drug: vincristine sulfate,University of Nebraska|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 2,null,Other|NIH,Interventional,Primary Purpose: Treatment,197-99|P30CA036727|UNMC-197-99|GENITOPE-9902|SUMC-9902,21-Jan-00,6/1/1999,11/1/2003,6/23/2010,Jun-10,No Study Results Posted,null,Jan-02,,https://ClinicalTrials.gov/show/NCT00004197
810,NCT00004198,Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma,Completed,No Results Available,Lymphoma,Biological: keyhole limpet hemocyanin|Biological: sargramostim|Biological: tumor cell-based vaccine therapy,University of Nebraska|National Cancer Institute (NCI)|Genitope Corporation,Both,"18 Years and older   (Adult, Senior)",Phase 2,null,Other|NIH|Industry,Interventional,Primary Purpose: Treatment,196-99|P30CA036727|UNMC-196-99|GENITOPE-9901,21-Jan-00,6/1/1999,11/1/2003,6/23/2010,Jun-10,No Study Results Posted,null,Jan-02,,https://ClinicalTrials.gov/show/NCT00004198
474,NCT00004211,Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer,Completed,No Results Available,Prostate Cancer,Biological: PSA RNA-pulsed dendritic cell vaccine,Duke University|National Cancer Institute (NCI),Male,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,17,Other|NIH,Interventional,Primary Purpose: Treatment,0408|DUMC-000408-00-3R1|DUMC-0446-99-3|DUMC-DORIS-99031|NCI-G99-1655|CDR0000067460,21-Jan-00,7/1/1999,1/1/2002,3/19/2013,Jan-05,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00004211
484,NCT00004248,Doxorubicin and Interleukin-2 in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery,Completed,No Results Available,Liver Cancer,Biological: aldesleukin|Drug: doxorubicin hydrochloride,Roswell Park Cancer Institute,Both,"18 Years and older   (Adult, Senior)",Phase 2,24,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Treatment,CDR0000067494|RPCI-RP-9814,28-Jan-00,7/1/1999,5/1/2001,3/3/2011,Mar-11,No Study Results Posted,null,Jun-00,,https://ClinicalTrials.gov/show/NCT00004248
589,NCT00001827,p53 Vaccine for Ovarian Cancer,Terminated,No Results Available,Ovarian Neoplasm,Biological: aldesleukin|Biological: incomplete Freund's adjuvant|Biological: p53 peptide vaccine|Biological: sargramostim|Biological: therapeutic autologous dendritic cells|Procedure: in vitro-treated peripheral blood stem cell transplantation,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Female,"18 Years and older   (Adult, Senior)",Phase 2,21,NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,990137|99-C-0137,3-Nov-99,7/1/1999,1/1/2013,2/19/2014,Jan-13,No Study Results Posted,null,Dec-07,Cellular immunity as measured by Elispot assay and 51 Cr-release assay at baseline and every 3 weeks.|Toxicity as measured by Common Toxicity Criteria v2.0 at baseline and every 3 weeks.,https://ClinicalTrials.gov/show/NCT00001827
953,NCT00001830,Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants,Completed,No Results Available,Chronic Lymphocytic Leukemia|Graft vs Host Disease|Hodgkin's Disease|Multiple Myeloma|Non Hodgkin's Lymphoma,Drug: Th2 cells in allo HSCTT|Drug: Th2 Cells,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"12 Years to 75 Years   (Child, Adult, Senior)",Phase 1,110,NIH,Interventional,Primary Purpose: Treatment,990143|99-C-0143,3-Nov-99,7/1/1999,5/1/2015,5/20/2015,May-15,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00001830
758,NCT00001832,Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma,Completed,Has Results,Melanoma|Neoplasm Metastasis,Drug: gp100:209-217 (210M)|Drug: Montanide ISA-51|Drug: IL-2|Drug: MART-1:26-35(27L)|Biological: Abl cells|Drug: Fludarabine|Drug: Cyclophosphamide|Biological: GCSF (Growth colony stimulating factor)|Procedure: Apheresis,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"7 Years and older   (Child, Adult, Senior)",Phase 2,170,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,990158|99-C-0158,3-Nov-99,8/1/1999,5/1/2010,12/19/2012,Dec-12,7-Nov-12,null,May-10,Clinical Response|Number of Participants With Adverse Events,https://ClinicalTrials.gov/show/NCT00001832
54,NCT00281931,"Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia","Active, not recruiting",No Results Available,Leukemia,Biological: rituximab|Drug: cyclophosphamide|Drug: fludarabine phosphate,German CLL Study Group|National Cancer Institute (NCI),Both,"18 Years to 75 Years   (Adult, Senior)",Phase 2,21,Other,Interventional,Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment,CDR0000454581|GCLLSG-PLL1|EU-20563,24-Jan-06,9/1/1999,null,11/5/2013,Jul-07,No Study Results Posted,null,null,Overall survival|Progression-free survival|Toxicity,https://ClinicalTrials.gov/show/NCT00281931
1113,NCT00243594,Dendritic Cell Vaccination in Melanoma Patients Scheduled for Regional Lymph Node Dissection,Completed,No Results Available,Melanoma Stage III or IV,Biological: Peptide-pulsed dendritic cells,Radboud University|Dutch Cancer Society,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1|Phase 2,40,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2004-3126|KUN99-1950,21-Oct-05,9/1/1999,null,2/18/2009,Feb-09,No Study Results Posted,null,Jan-09,Immune response|Migration efficacy|Clinical response,https://ClinicalTrials.gov/show/NCT00243594
444,NCT00005947,Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy,Completed,Has Results,Prostate Cancer,Biological: sipuleucel-T|Biological: Placebo,Dendreon,Male,"18 Years and older   (Adult, Senior)",Phase 3,127,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D9901 CDR0000067868|DEN-D9901|NCI-G00-1789,5-Jul-00,11/1/1999,9/1/2004,10/8/2010,Oct-10,28-May-10,null,Sep-04,Time to Objective Disease Progression|Overall Survival,https://ClinicalTrials.gov/show/NCT00005947
769,NCT00005628,Vaccine Therapy in Treating Patients With Recurrent Soft Tissue Sarcoma,Completed,No Results Available,Sarcoma,Biological: vitespen,Memorial Sloan Kettering Cancer Center|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 2,null,Other|NIH,Interventional,Primary Purpose: Treatment,99-077|CDR0000067781|NCI-H00-0052,2-May-00,11/1/1999,8/1/2001,6/18/2013,Jun-13,No Study Results Posted,null,Aug-01,,https://ClinicalTrials.gov/show/NCT00005628
1014,NCT00005801,Total-Body Irradiation Plus Stem Cell Transplantation And White Blood Cell Infusion in Treating Older Patients With Acute Myeloid Leukemia,Completed,No Results Available,Leukemia,Biological: therapeutic allogeneic lymphocytes|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy,"University of Colorado, Denver|National Cancer Institute (NCI)",Both,"55 Years to 74 Years   (Adult, Senior)",Phase 2,null,Other|NIH,Interventional,Primary Purpose: Treatment,00-0119|UCHSC-00119|FHCRC-1406.00|NCI-G00-1778,2-Jun-00,11/1/1999,9/1/2001,11/14/2013,Sep-01,No Study Results Posted,null,Sep-01,,https://ClinicalTrials.gov/show/NCT00005801
1283,NCT00291369,Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis,Completed,No Results Available,Metastatic Renal Cell Carcinoma,Drug: Interleukin-2|Drug: Interferon alfa|Drug: medroxyprogesterone acetate,Centre Leon Berard|French Immunotherapy Intergroup|SCAPP (Sub-Cutaneous Administration Proleukin Program),Both,"18 Years and older   (Adult, Senior)",Phase 3,456,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,PERCY QUATTRO|ET99-058,13-Feb-06,12/1/1999,2/1/2005,2/15/2006,Feb-06,No Study Results Posted,null,null,Overall survival|Progression-free survival|Objective response rate|Toxicity|Quality of life,https://ClinicalTrials.gov/show/NCT00291369
388,NCT00005956,Biological Therapy in Treating Patients With Advanced Cancer,Completed,No Results Available,Breast Cancer|Gastric Cancer|Ovarian Cancer,Biological: HER-2/neu intracellular domain protein|Biological: therapeutic autologous dendritic cells,Duke University|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",,3,Other|NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,1309|6542|1528|CDR0000067937,5-Jul-00,2/1/2000,7/1/2002,7/7/2014,Mar-13,No Study Results Posted,null,Aug-01,Safety,https://ClinicalTrials.gov/show/NCT00005956
390,NCT00005816,Vaccine Therapy in Treating Patients With Stage III or Stage IV Kidney Cancer,Completed,No Results Available,Kidney Cancer,Biological: therapeutic autologous dendritic cells|Procedure: conventional surgery,Duke University|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,15,Other|NIH,Interventional,Primary Purpose: Treatment,1716|DUMC-1862-99-10|DUMC-DORIS-99124|DUMC-GCRC-839|NCI-G00-1787|CDR0000067820|1R01CA089102-01,2-Jun-00,2/1/2000,8/1/2002,3/19/2013,Dec-08,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00005816
431,NCT00041652,Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer,Completed,No Results Available,Colorectal Cancer|Colon Cancer|Rectal Cancer|Colorectal Neoplasms|Colorectal Carcinoma|Breast Cancer|Breast Neoplasms,Drug: hMN14 (labetuzumab),"Immunomedics, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,30,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IM-T-hMN14-04,11-Jul-02,2/1/2000,6/1/2003,10/21/2005,Oct-05,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00041652
476,NCT00006244,"Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma",Completed,No Results Available,Refractory Multiple Myeloma|Stage I Multiple Myeloma|Stage II Multiple Myeloma|Stage III Multiple Myeloma,Drug: melphalan|Biological: recombinant interferon alfa|Biological: aldesleukin|Procedure: in vitro-treated peripheral blood stem cell transplantation,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),Both,"18 Years to 69 Years   (Adult, Senior)",Phase 2,36,Other|NIH,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,1461.00|NCI-2011-01313,11-Sep-00,2/1/2000,null,6/1/2016,Jun-16,No Study Results Posted,null,Apr-16,"Overall survival|Initial response to therapy (complete response, partial response, or progression of disease)|Time to disease progression|Number of patients experiencing grade 3-4 regimen related toxicity",https://ClinicalTrials.gov/show/NCT00006244
878,NCT00005606,Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation,Completed,No Results Available,Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm,Biological: allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|Biological: autologous Epstein-Barr virus-specific cytotoxic T lymphocytes,Northwestern University|National Cancer Institute (NCI),Both,"Child, Adult, Senior",Phase 2,null,Other|NIH,Interventional,Primary Purpose: Treatment,NU 98H1|NU-98H1|NCI-G00-1739,2-May-00,2/1/2000,9/1/2003,5/31/2012,May-12,No Study Results Posted,null,Sep-03,,https://ClinicalTrials.gov/show/NCT00005606
1098,NCT00005943,Gene Therapy in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Melanoma (Skin),Biological: aldesleukin|Biological: staphylococcal enterotoxin B,"University of Colorado, Denver|National Cancer Institute (NCI)",Both,"18 Years and older   (Adult, Senior)",Phase 1,null,Other|NIH,Interventional,Primary Purpose: Treatment,95-0526.cc,5-Jul-00,2/1/2000,9/1/2001,5/28/2013,Oct-01,No Study Results Posted,null,Sep-01,,https://ClinicalTrials.gov/show/NCT00005943
89,NCT00393107,Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab,Completed,No Results Available,Follicular Lymphoma,"Drug: rituximab|Drug: rituximab,fludarabine, cyclophosphamide",Gruppo Italiano Studio Linfomi,Both,"18 Years to 70 Years   (Adult, Senior)",Phase 2,54,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,FR2|FolRec02|GislFR2,25-Oct-06,3/1/2000,8/1/2006,10/25/2006,Oct-06,No Study Results Posted,null,null,Toxicity during the treatment period|Efficacy evaluated in terms of complete and partial response 1 month after the end of therapy|Efficacy evaluated in terms of molecular response ( bone marrow Bcl2 negativity after treatment),https://ClinicalTrials.gov/show/NCT00393107
228,NCT00143884,Study of Low Intensity Conditioning and Immunotherapy for High-Risk Cancers of the Blood,Terminated,No Results Available,"Leukemia|Lymphoma, Low-Grade|Lymphoma, Non-Hodgkin's|Multiple Myeloma|Myelodysplastic Syndromes",Procedure: Reduced intensity conditioning|Procedure: Prophylactic donor leukocyte infusions,University of Michigan Cancer Center,Both,"Child, Adult, Senior",Phase 2,30,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Educational/Counseling/Training,UMCC 9979,31-Aug-05,3/1/2000,null,4/20/2007,Jan-07,No Study Results Posted,null,null,To conduct a phase I-II trial of prophylactic cellular immunotherapy after allogeneic hematopoietic stem cell therapy using low intensity conditioning for high-risk hematological malignancies|To evaluate both surrogate markers of GVHD (with a cytokine panel) and minimal residual disease and correlate these with clinical outcomes during the above trial,https://ClinicalTrials.gov/show/NCT00143884
359,NCT00017537,Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer,Withdrawn,No Results Available,"Breast Cancer|Gastric Cancer|Lung Cancer|Ovarian Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Biological: MVF-HER-2(628-647)-CRL 1005 vaccine,University of Alabama at Birmingham|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,0,Other|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000068700|UAB-0020|NCI-G01-1955,6-Jun-01,3/1/2000,3/1/2005,8/2/2013,Nov-12,No Study Results Posted,null,Mar-05,Determine the optimum biologic dose of MVF-HER-2 (628-647)-CRL 1005 vaccine that will induce snit-HER-2 antibody in patients with metastatic or recurrent cancer|Characterize the nature and severity of toxicity of this drug in these patients.|Document any clinical responses to this drug in these patients.,https://ClinicalTrials.gov/show/NCT00017537
432,NCT00005045,Carboxyamidotriazole in Treating Patients With Advanced Kidney Cancer,Completed,No Results Available,Kidney Cancer,Drug: carboxyamidotriazole,Eastern Cooperative Oncology Group|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 2,null,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000067636|ECOG-4896,6-Apr-00,3/1/2000,6/1/2004,6/20/2013,Dec-05,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00005045
585,NCT00176761,Tumor-Pulsed Dendritic Cells Used as a Tumor Vaccine,Terminated,No Results Available,Metastatic Colorectal Cancer,Drug: Interleukin-2 (IL-2),University of Michigan Cancer Center|University of Michigan,Both,"18 Years and older   (Adult, Senior)",Phase 2,27,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,UMCC 9947|GCRC Protocol #1673,9-Sep-05,3/1/2000,5/1/2006,9/6/2006,Sep-06,No Study Results Posted,null,null,To assess the antitumor response of this immunotherapy regimen.|To characterize the immune response (as defined in Section VII) to the tumor-pulsed dendritic cell vaccine combined with IL-2 administration in patients with metastatic colorectal cancer.|To evaluate the toxicity of this treatment regimen.,https://ClinicalTrials.gov/show/NCT00176761
848,NCT00081809,A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent Lymphoma,Completed,No Results Available,"Lymphoma, Follicular|Lymphoma, Small Lymphocytic",Drug: autologous human tumor-derived HSPPC-96,"Agenus, Inc.",Both,"Child, Adult, Senior",Phase 2,35,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,C-100-09|MDACC Protocol ID99-354,20-Apr-04,3/1/2000,6/1/2005,9/6/2012,Sep-12,No Study Results Posted,null,Jun-05,,https://ClinicalTrials.gov/show/NCT00081809
457,NCT00004881,Vaccine Therapy in Treating Patients With Advanced Cancer,Completed,No Results Available,"Unspecified Adult Solid Tumor, Protocol Specific",Biological: MVA-MUC1-IL2 vaccine,Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,null,Other|NIH,Interventional,Primary Purpose: Treatment,TRANSGENE-TG4010.01|UCLA-9909055-01B|CDR0000067544|NCI-G00-1677,7-Mar-00,4/1/2000,5/1/2004,6/25/2013,Feb-01,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00004881
580,NCT00005655,Combination Therapy of Interleukin-12 and Interleukin-2 to Treat Advanced Cancer,Completed,No Results Available,Kidney Neoplasm|Lung Neoplasm|Sarcoma|Breast Neoplasm,Biological: rh IL-12|Biological: rh IL-2,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 99 Years   (Adult, Senior)",Phase 1,39,NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,000121|00-C-0121,4-May-00,4/1/2000,10/1/2010,3/16/2016,Mar-16,No Study Results Posted,null,Oct-10,MTD and DLTof IL-12 in combination with IL-2,https://ClinicalTrials.gov/show/NCT00005655
188,NCT01133704,"Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer",Completed,Has Results,Hormone-Refractory Prostate Cancer,Biological: sipuleucel-T|Biological: APC-Placebo,Dendreon,Male,"18 Years and older   (Adult, Senior)",Phase 3,98,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",D9902A,27-May-10,5/1/2000,5/1/2005,9/2/2010,Sep-10,1-Jun-10,null,Mar-03,Overall Time to Disease Progression|Overall Survival,https://ClinicalTrials.gov/show/NCT01133704
798,NCT00006480,Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma,Completed,No Results Available,Neuroblastoma,Biological: aldesleukin|Biological: therapeutic autologous lymphocytes|Drug: chemotherapy|Drug: ganciclovir,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),Both,1 Year to 17 Years   (Child),Phase 1,null,Other|NIH,Interventional,Primary Purpose: Treatment,1524.00|FHCRC-1524.00|NCI-H00-0065|CDR0000068310,6-Nov-00,5/1/2000,3/1/2005,9/17/2010,Sep-10,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00006480
33,NCT00899821,Microsphere-Delivered Cytokines in Increasing Tumor Response in Lymphocytes From Patients With Head and Neck Cancer,Completed,No Results Available,Head and Neck Cancer,Biological: aldesleukin|Biological: recombinant interleukin-12|Biological: sargramostim|Other: immunologic technique|Procedure: biopsy,New York University School of Medicine|National Cancer Institute (NCI),Both,"20 Years to 80 Years   (Adult, Senior)",,null,Other|NIH,Interventional,,CDR0000280490|NYU-9916,9-May-09,6/1/2000,null,11/8/2012,Dec-08,No Study Results Posted,null,Dec-04,Local and sustained cytokine combinations in evaluating antitumor response in human peripheral blood lymphocytes obtained from patients with squamous cell carcinoma of the head and neck|Vaccine potential in provoking or enhancing long-term systemic immunity against head and neck cancer|Response rate,https://ClinicalTrials.gov/show/NCT00899821
455,NCT00020254,Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer,Completed,No Results Available,Prostate Cancer,Biological: aldesleukin|Biological: recombinant fowlpox-prostate specific antigen vaccine|Biological: recombinant vaccinia prostate-specific antigen vaccine|Biological: recombinant vaccinia-B7.1 vaccine|Biological: sargramostim|Drug: nilutamide,National Cancer Institute (NCI),Male,"18 Years and older   (Adult, Senior)",Phase 2,null,NIH,Interventional,Allocation: Randomized|Primary Purpose: Treatment,CDR0000068106|NCI-00-C-0137|MB-NAVY-99-04|NCI-T99-0097,11-Jul-01,6/1/2000,null,4/28/2015,Apr-03,No Study Results Posted,null,Oct-04,,https://ClinicalTrials.gov/show/NCT00020254
568,NCT00005916,PSA-Based Vaccine and Radiotherapy to Treat Localized Prostate Cancer,Completed,No Results Available,Prostate Cancer|Prostate Neoplasm,Drug: rV-PSA|Drug: rF-PSA|Drug: rV-B7.1,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Male,"18 Years and older   (Adult, Senior)",Phase 2,48,NIH,Interventional,Primary Purpose: Treatment,000154|00-C-0154,30-Jun-06,6/1/2000,12/1/2005,9/26/2015,Dec-05,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00005916
834,NCT00033904,Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer,Completed,No Results Available,Renal Cell Carcinoma,Drug: autologous human tumor-derived HSPPC-96,"Agenus, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 3,650,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,C-100-12 Part I,12-Apr-02,6/1/2000,4/1/2007,9/6/2012,Sep-12,No Study Results Posted,null,Apr-07,,https://ClinicalTrials.gov/show/NCT00033904
487,NCT00006123,Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer,"Active, not recruiting",No Results Available,Breast Cancer,Biological: trastuzumab|Drug: carboplatin|Drug: carmustine|Drug: cisplatin|Drug: cyclophosphamide|Drug: thiotepa|Procedure: peripheral blood stem cell transplantation,Beth Israel Deaconess Medical Center|National Cancer Institute (NCI),Female,18 Years to 65 Years   (Adult),Phase 1|Phase 2,null,Other,Interventional,Primary Purpose: Treatment,CDR0000068138|BIH-99-12|BIH-W-99-0053-FB|NCI-V00-1610,3-Aug-00,7/1/2000,null,2/6/2009,Dec-06,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00006123
514,NCT00012064,Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma,Completed,No Results Available,Melanoma (Skin),Biological: therapeutic autologous dendritic cells,"Caladrius Biosciences, Inc.",Both,"16 Years and older   (Child, Adult, Senior)",Phase 1|Phase 2,56,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000068481|HOAG-VACCINE-MEL|NCI-V01-1646,3-Mar-01,7/1/2000,4/1/2011,1/27/2014,Aug-13,No Study Results Posted,null,Apr-11,"To determine the safety of administration of irradiated autologous tumor cells that have been incubated in vitro with gamma interferon, and subsequently injected subcutaneously with autologous dendritic cells and GMCSF|To determine the frequency of conversion of delayed tumor hypersensitivity (DTH) tests with irradiated autologous tumor cells, in patients who received an autologous dendritic cell/tumor cell vaccine with GMCSF|To determine the objective tumor response rate in patients with metastatic melanoma who still had measurable disease at the time vaccine treatment was given",https://ClinicalTrials.gov/show/NCT00012064
931,NCT00023647,Vaccine Therapy in Treating Patients With Stage IV Melanoma,Completed,No Results Available,Melanoma (Skin),Biological: Synchrotope TA2M|Biological: Synchrotope TA2M|Biological: Synchrotope TA2M,Mannkind Corporation,Both,"18 Years and older   (Adult, Senior)",Phase 1,26,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000068847|CTL-207-216|CTL-BB-IND-9146|LAC-USC-10M001|NCI-V01-1666,13-Sep-01,7/1/2000,11/1/2002,7/9/2012,Jul-12,No Study Results Posted,null,Apr-02,"Frequency of adverse events assessed by complete blood count, blood chemistry, polymerase chain reaction, physical examination and urinalysis|Change in magnitude of antigen-specific cytotoxic t-lymphocyte in peripheral blood mononuclear cells|Assessment of delayed-type hypersensitivity to intradermal injections 24 hours after injection|Change in size of target lesions by x-ray computed tomography before (day 0) and after (day 56)treatment",https://ClinicalTrials.gov/show/NCT00023647
165,NCT00157209,Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer),Completed,Has Results,"Lung Neoplasms|Carcinoma, Non-Small-Cell Lung",Biological: Tecemotide (L-BLP25)|Drug: Single low dose cyclophosphamide|Other: Best Supportive Care (BSC),Merck KGaA,Both,"18 Years and older   (Adult, Senior)",Phase 2,171,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,B25-LG-304 / EMR 63325-005,8-Sep-05,8/1/2000,7/1/2012,10/19/2015,Oct-15,23-Jul-15,null,Mar-06,"Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, TEAEs Leading to Death, and TEAEs With Cancer and Leukemia Group B (CALGB) Toxicity Grade 3 or 4|Overall Survival Time|Functional Assessment of Cancer Therapy (FACT-L) Questionnaire Score|Number of Participants With Positive T-cell Proliferation|Number of Participants With Elevated CA27-29 Antigen Levels",https://ClinicalTrials.gov/show/NCT00157209
754,NCT00005987,"Filgrastim Compared With Sargramostim Plus Chemotherapy, Peripheral Stem Cell Transplantation, and Interferon Alfa in Treating Patients With Multiple Myeloma",Terminated,No Results Available,Multiple Myeloma and Plasma Cell Neoplasm,Drug: carmustine|Drug: cyclophosphamide|Drug: dexamethasone|Drug: etoposide|Drug: filgrastim|Drug: mitoxantrone hydrochloride|Drug: recombinant interferon alfa|Drug: sargramostim|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Procedure: radiation therapy,"Masonic Cancer Center, University of Minnesota",Both,"up to 70 Years   (Child, Adult, Senior)",Phase 2,87,Other,Interventional,Allocation: Randomized|Primary Purpose: Treatment,1996LS137|UMN-MT-9216|UMN-MT-1992-16,5-Jul-00,8/1/2000,7/1/2003,10/9/2012,Oct-12,No Study Results Posted,null,Jul-03,,https://ClinicalTrials.gov/show/NCT00005987
723,NCT00012207,Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma,Completed,No Results Available,Leukemia|Lymphoma,Biological: aldesleukin|Biological: therapeutic autologous lymphocytes|Drug: cyclophosphamide|Drug: prednisone|Drug: vincristine sulfate|Procedure: adjuvant therapy,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),Both,"Child, Adult, Senior",Phase 1,12,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,1503.00|FHCRC-1503.00|NCI-G01-1921|CDR0000068494,3-Mar-01,9/1/2000,7/1/2010,8/20/2010,Aug-10,No Study Results Posted,null,null,"Safety and toxicity by NCI CTC toxicity scale in patients w/ recurr. or refract. CD20+ follicular lymphoma who are not candidates for high dose chemoradiotx and stem cell transplant during each infusion, weekly for 4 wks and then monthly for a yr|Duration of in vivo persistence of adoptively transferred CD20-specific CD8+ T cell clones by flow cytometry and quantitative polymerase chain reaction (qPCR) during each infusion, weekly for 4 weeks, and then monthly for a year|Trafficking of CD8+ CD20-specific T cell clones to lymph nodes by Gamma camera imaging during each infusion, weekly for 4 weeks, and then monthly for a year|Development of host anti-scFvFc:zeta (and anti-NeoR) immune responses by ELISA and chromium release assays during each infusion, weekly for 4 weeks, and then monthly for a year|Tumor responses to cyclophosphamide, vincristine, and prednisone (CVP) and to cytotoxic T-lymphocyte (CTL) infusions by Cheson criteria during each infusion, weekly for 4 weeks, and then monthly for a year",https://ClinicalTrials.gov/show/NCT00012207
854,NCT00034372,Multicenter Clinical Trial of Intravenous OvaRex MAb-B43.13 as Post-Chemotherapy Consolidation for Ovarian Carcinoma,Terminated,No Results Available,Ovarian Neoplasms,Drug: oregovomab,Unither Pharmaceuticals,Female,"18 Years and older   (Adult, Senior)",Phase 2,102,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,OVA-Gy-15,26-Apr-02,9/1/2000,12/1/2007,12/13/2007,Dec-07,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00034372
1175,NCT00429039,A Study to Accelerate Immune System Recovery Following Stem Cell Transplantation,Terminated,No Results Available,ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION,Drug: L-leucyl-L-leucine methyl ester (LLME),Thomas Jefferson University|National Cancer Institute (NCI),Both,"16 Years and older   (Child, Adult, Senior)",Phase 2,21,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,01.0082|2000-66,29-Jan-07,9/1/2000,8/1/2009,12/3/2014,Dec-14,No Study Results Posted,null,Oct-07,,https://ClinicalTrials.gov/show/NCT00429039
491,NCT00948480,Vaccine Biotherapy of Cancer: Autologous Tumor Cells and Dendritic Cells,Completed,No Results Available,Metastatic Melanoma,Biological: Autologous tumor cells plus dendritic cells|Drug: GM-CSF,Hoag Memorial Hospital Presbyterian,Both,"16 Years and older   (Child, Adult, Senior)",Phase 2,56,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,DC Melanoma,28-Jul-09,10/1/2000,9/1/2007,7/13/2016,Jul-16,No Study Results Posted,DCVaccineMel,Sep-07,event-free survival [death or disease progression]|Overall survival,https://ClinicalTrials.gov/show/NCT00948480
559,NCT00005995,AE-941 in Treating Patients With Metastatic Kidney Cancer,Completed,No Results Available,Kidney Cancer,Drug: shark cartilage extract AE-941,AEterna Zentaris,Both,"18 Years and older   (Adult, Senior)",Phase 3,null,Industry,Interventional,Primary Purpose: Treatment,CDR0000067999|AETERNA-AE-RC-99-02|CAN-CCI-ETH-00-32-17|CCF-IRB-3664|JGH-00023|UCMC-0006305|UPCC-2800,5-Jul-00,10/1/2000,null,3/4/2013,Feb-08,No Study Results Posted,null,Mar-07,,https://ClinicalTrials.gov/show/NCT00005995
242,NCT00720031,Treatment of Metastatic Melanoma With Autologous Melan-A/MART-1 Specific CTL Clones,Completed,No Results Available,Immunotherapy,Biological: autologous Melan-A/MART-1 specific CTL clones,Nantes University Hospital,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,16,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,BRD 98/9-C,18-Jul-08,11/1/2000,5/1/2008,7/22/2008,Jul-08,No Study Results Posted,null,May-08,"Evaluate the efficacy of an adoptive immunotherapy specific for Melan-A/MART1 antigen in metastatic melanoma patients whose tumor express this antigen but also HLA-A2|Evaluate whether infused T cell clones migrate to tumor sites. For this purpose, infused T cell clones will be characterized according to their Vß and Valpha using antibodies and/or PCR|Evaluate whether infused T cell clones transfer a specific immunity.|evaluate infused Melan-A/MART1 reactive T cell clones tolerance",https://ClinicalTrials.gov/show/NCT00720031
323,NCT00006363,"Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia",Completed,No Results Available,Adult Acute Basophilic Leukemia|Adult Acute Eosinophilic Leukemia|Adult Acute Erythroid Leukemia (M6)|Adult Acute Megakaryoblastic Leukemia (M7)|Adult Acute Minimally Differentiated Myeloid Leukemia (M0)|Adult Acute Monoblastic Leukemia (M5a)|Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)|Adult Acute Monocytic Leukemia (M5b)|Adult Acute Myeloblastic Leukemia With Maturation (M2)|Adult Acute Myeloblastic Leukemia Without Maturation (M1)|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Adult Acute Myelomonocytic Leukemia (M4)|Adult Erythroleukemia (M6a)|Adult Pure Erythroid Leukemia (M6b)|Childhood Acute Basophilic Leukemia|Childhood Acute Eosinophilic Leukemia|Childhood Acute Erythroleukemia (M6)|Childhood Acute Megakaryocytic Leukemia (M7)|Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)|Childhood Acute Monoblastic Leukemia (M5a)|Childhood Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5)|Childhood Acute Monocytic Leukemia (M5b)|Childhood Acute Myeloblastic Leukemia With Maturation (M2)|Childhood Acute Myeloblastic Leukemia Without Maturation (M1)|Childhood Acute Myelomonocytic Leukemia (M4)|Childhood Myelodysplastic Syndromes|de Novo Myelodysplastic Syndromes|Untreated Adult Acute Myeloid Leukemia|Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies,Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: etoposide|Drug: valspodar|Biological: filgrastim|Drug: busulfan|Procedure: autologous hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation|Biological: aldesleukin|Other: clinical observation|Other: pharmacological study,National Cancer Institute (NCI),Both,"15 Years to 59 Years   (Child, Adult)",Phase 3,720,NIH,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,NCI-2012-02824|CALGB-19808|U10CA031946,4-Oct-00,11/1/2000,null,6/3/2013,Jun-13,No Study Results Posted,null,Jun-05,Disease-free survival|Overall survival|Estimates of disease-free survival curves|Estimates of overall survival curves|Toxicities and adverse events assessed using National Cancer Institute (NCI) Common Toxicity Criteria (CTC),https://ClinicalTrials.gov/show/NCT00006363
391,NCT00005072,Leuvectin in Treating Patients With Locally Recurrent Prostate Cancer,Terminated,No Results Available,Prostate Cancer,Biological: Leuvectin,Vical|Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI),Male,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,25,Industry|Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,VCL-1102-203|UCLA-9906108|CDR0000067677|NCI-G00-1721,6-Apr-00,11/1/2000,4/1/2003,7/25/2014,Jul-14,No Study Results Posted,null,Apr-03,Safety of Leuvectin,https://ClinicalTrials.gov/show/NCT00005072
454,NCT00010127,Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer,Terminated,No Results Available,Prostate Cancer,Biological: therapeutic autologous dendritic cells,Duke University|National Cancer Institute (NCI),Male,"18 Years and older   (Adult, Senior)",Phase 1,3,Other|NIH,Interventional,Primary Purpose: Treatment,0759|DUMC-000759-00-4R1|DUMC-DORIS-99043|NCI-G00-1910|CDR0000068447,2-Feb-01,11/1/2000,3/1/2003,3/19/2013,Dec-08,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00010127
1021,NCT00017290,Combination Chemotherapy Followed By Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma,"Active, not recruiting",No Results Available,Lymphoma,Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine|Biological: keyhole limpet hemocyanin|Biological: sargramostim|Drug: cyclophosphamide|Drug: prednisone|Drug: vincristine sulfate,Genitope Corporation|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 3,null,Industry,Interventional,Allocation: Randomized|Masking: Double-Blind|Primary Purpose: Treatment,CDR0000068673|GENITOPE-G2000-03|CUMC-0101-142|UCLA-0010061,6-Jun-01,11/1/2000,null,12/3/2013,Aug-02,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00017290
1139,NCT00006515,Late Effects of Treatment for Sarcomas in Children,Completed,No Results Available,Sarcoma,,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"7 Years and older   (Child, Adult, Senior)",,39,NIH,Observational,,010037|01-C-0037,21-Nov-00,11/1/2000,11/1/2011,9/26/2015,Nov-11,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00006515
742,NCT00027131,Vaccination Against High Risk Breast Cancer Using Tumor Derived Heat Shock Protein 70,Terminated,No Results Available,Breast Neoplasms,Biological: Heat Shock Protein 70-peptide complexes (HSP70),University of Connecticut Health Center,Female,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,15,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,01-062,27-Nov-01,12/1/2000,10/1/2002,10/7/2008,Oct-08,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00027131
763,NCT00167414,Study for Using Radiosurgery on Limited Metastases of Breast Cancer,"Active, not recruiting",No Results Available,"Breast Cancer, Metastatic",Procedure: Hypofractionated Stereotactic Body Radiation Therapy|Radiation: Hypofractionated Stereotactic Body Radiation Therapy,University of Rochester,Female,"Child, Adult, Senior",Phase 2,49,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,URCC 8700,9-Sep-05,12/1/2000,10/1/2021,5/24/2016,May-16,No Study Results Posted,null,Oct-21,"Overall survival|Response (clinical, chemical [CA 27-29] and radiological), and quality of life correlation with pro-apoptotic, inflammatory, and anabolic cytokine profiles",https://ClinicalTrials.gov/show/NCT00167414
376,NCT00044356,Phase II Trial of Allovectin-7® for Metastatic Melanoma,Completed,No Results Available,Melanoma|Metastatic Melanoma|Malignant Melanoma|Skin Cancer,Genetic: Allovectin-7®,Vical,Both,"18 Years and older   (Adult, Senior)",Phase 2,133,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,VCL-1005-208,26-Aug-02,2/1/2001,9/1/2004,7/5/2011,Jul-11,No Study Results Posted,null,Aug-04,,https://ClinicalTrials.gov/show/NCT00044356
599,NCT00020462,"Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III, Stage IV, or Recurrent Follicular Lymphoma",Completed,No Results Available,Lymphoma,Biological: aldesleukin|Biological: autologous tumor cell vaccine,National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,null,NIH,Interventional,Primary Purpose: Treatment,CDR0000068505|NCI-01-C-0069,11-Jul-01,2/1/2001,null,4/29/2015,Dec-08,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00020462
739,NCT00004188,Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma,Completed,No Results Available,Neuroblastoma,Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: isotretinoin|Drug: melphalan|Drug: topotecan hydrochloride|Drug: vincristine sulfate|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: conventional surgery|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy,Children's Oncology Group|National Cancer Institute (NCI),Both,"up to 30 Years   (Child, Adult)",Phase 3,495,Other|NIH,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,A3973|COG-A3973|CCG-A3973|POG-A3973|CCG-39703|FHCRC-1631.00|CDR0000067429,21-Jan-00,2/1/2001,null,5/16/2013,May-13,No Study Results Posted,null,Oct-07,"Event-free survival rate|Rate of occurrence of toxic (non disease-related) deaths where a toxic death will be ""counted"" if it occurs prior to the initiation of the immunotherapy|Time to engraftment|CD34 content|Tumor content as measured by reverse transcriptase polymerase chain reaction",https://ClinicalTrials.gov/show/NCT00004188
1153,NCT00011908,Humanized LL2IGG to Treat Systemic Lupus Erythematosus,Completed,No Results Available,Systemic Lupus Erythematosus,Drug: hLL2 (Epratuzumab),National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|National Institutes of Health Clinical Center (CC),Both,"Child, Adult, Senior",Phase 1,20,NIH,Interventional,Endpoint Classification: Safety Study|Primary Purpose: Treatment,010108|01-AR-0108,3-Mar-01,2/1/2001,1/1/2003,3/3/2008,Jan-03,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00011908
297,NCT00576537,Tumor Lysate Pulsed Dendritic Cell Immunotherapy for Patients With Brain Tumors,Completed,No Results Available,Glioblastoma,Biological: Dendritic Cell Immunotherapy|Biological: Dendritic Cell Vaccine|Biological: Dendritic Cell Vaccine,Cedars-Sinai Medical Center,Both,"Child, Adult, Senior",Phase 2,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,3368,18-Dec-07,3/1/2001,10/1/2011,2/18/2013,Feb-13,No Study Results Posted,null,Oct-11,Evaluate the safety/toxicity of subcutaneous injections of autologous dendritic cells,https://ClinicalTrials.gov/show/NCT00576537
371,NCT00016133,Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That Has Been Removed During Surgery,Completed,No Results Available,Colorectal Cancer,Biological: BCG vaccine|Biological: autologous tumor cell vaccine|Drug: fluorouracil|Drug: leucovorin calcium|Procedure: adjuvant therapy,Intracel|National Cancer Institute (NCI),Both,"21 Years to 85 Years   (Adult, Senior)",Phase 1|Phase 2,null,Industry,Interventional,Primary Purpose: Treatment,INTRACEL-ASI-2002|CDR0000068597,6-May-01,3/1/2001,8/1/2004,5/29/2013,Jul-04,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00016133
379,NCT00006470,Vaccine Therapy Plus Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer That Has Been Completely Removed in Surgery,Completed,No Results Available,Lung Cancer,Biological: monoclonal antibody 11D10 anti-idiotype vaccine|Biological: monoclonal antibody 3H1 anti-idiotype vaccine|Radiation: radiation therapy,Radiation Therapy Oncology Group|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 2,null,Other|NIH,Interventional,Primary Purpose: Treatment,RTOG-9909|CDR0000068293,6-Nov-00,3/1/2001,null,8/9/2013,Aug-13,No Study Results Posted,null,Dec-04,,https://ClinicalTrials.gov/show/NCT00006470
601,NCT00036426,Idiotype Vaccine for Low-Grade Non-Hodgkin's Lymphoma,"Active, not recruiting",No Results Available,"Lymphoma, Low-Grade",Biological: FavId (Id-KLH) active immunotherapy,Favrille,Both,"18 Years and older   (Adult, Senior)",Phase 2,22,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,FavId-01,9-May-02,3/1/2001,null,6/23/2005,Oct-04,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00036426
1011,NCT00006265,Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,Completed,No Results Available,Leukemia,Drug: ara-C|Biological: gemtuzumab ozogamicin,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI),Both,"17 Years and older   (Child, Adult, Senior)",Phase 2,60,Other|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CALGB-19902|U10CA031946|CDR0000068208,11-Sep-00,3/1/2001,5/1/2005,7/12/2016,Jul-16,No Study Results Posted,null,Dec-04,Complete remission rate|Toxicity,https://ClinicalTrials.gov/show/NCT00006265
857,NCT00012298,Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma,Terminated,Has Results,Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia,Biological: rituximab|Biological: yttrium Y 90 ibritumomab tiuxetan|Biological: indium In 111 ibritumomab tiuxetan|Biological: oprelvekin|Biological: filgrastim,National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,81,NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NCI-2009-00008|CDR0000068503|MC998C|312,3-Mar-01,4/1/2001,4/1/2010,11/4/2015,Dec-12,4-Nov-15,null,Apr-10,Maximum Tolerated Dose (MTD) of Yttrium Y-90 Ibritumomab Tiuxetan (Y2B8) With and Without Filgrastim (G-CSF) and Interleukin-11 (IL-11) (Phase I)|Toxicity of Single-dose Y2B8 Radioimmunotherapy With and Without the Use of Growth Factors (Phase I)|Proportion of Patients Who Receive 2 Sequential Doses of Y2B8 Immunotherapy and Are Progression-free (Phase II)|Association Between the Amounts of Tumor Radiation Indicated by the In2B8 Scan and Tumor Response (Phase I)|Association Between In2B8 Scan and Positron Emission Tomography Scan Results (Phase I)|Appearance of Tumor and Normal Organ Images on the Second In2B8 Scan (Phase I)|Survival (Phase II)|Time to Disease Progression (Phase II)|Tumor Response Rate (Phase II),https://ClinicalTrials.gov/show/NCT00012298
1093,NCT00017355,Vaccine Therapy in Treating Patients With Metastatic Melanoma,"Active, not recruiting",No Results Available,Melanoma (Skin),Biological: filgrastim|Biological: therapeutic autologous dendritic cells,Baylor Health Care System|National Cancer Institute (NCI),Both,"21 Years and older   (Adult, Senior)",Phase 1,null,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000068680|BAYUMC-000048|NCI-4170,6-Jun-01,4/1/2001,null,9/16/2013,Mar-03,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00017355
1198,NCT00143871,Study of Rituximab Plus High-Dose Chemotherapy Non-Hodgkin's Lymphoma,Completed,No Results Available,"Lymphoma, Non-Hodgkin's",Drug: Rituximab,University of Michigan Cancer Center,Both,"Child, Adult, Senior",Phase 2,35,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,UMCC 0074,31-Aug-05,4/1/2001,1/1/2007,1/30/2012,Jan-12,No Study Results Posted,null,Dec-06,"Assess safety and toxicity after rituximab and high-dose chemotherapy|Assess CD20 depletion in leukapheresis products after rituximab and high-dose chemotherapy, and monitor CD20 recovery post-transplant|Assess the response rate after rituximab and high-dose chemotherapy with autologous peripheral blood progenitor cell (PBPC) support, for patients with relapsed CD20+ Non-Hodgkin's lymphoma (NHL)|Assess progression-free and overall survival after rituximab and high-dose chemotherapy with PBPC support",https://ClinicalTrials.gov/show/NCT00143871
479,NCT00023842,BCG With or Without Mitomycin in Treating Patients With Bladder Cancer,Completed,No Results Available,Bladder Cancer,Biological: BCG vaccine|Drug: mitomycin C|Procedure: adjuvant therapy|Procedure: conventional surgery,European Organisation for Research and Treatment of Cancer - EORTC,Both,"Child, Adult, Senior",Phase 2,97,Other,Interventional,Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment,EORTC-30993|AURO-EORTC-30993|FINNBLADDER-EORTC-30993|GAUO-EORTC-30993|SEUG-EORTC-30993|UKCCCR-EORTC-30993|NCRI-EORTC-30993,13-Sep-01,6/1/2001,null,9/20/2012,Sep-12,No Study Results Posted,null,Feb-05,,https://ClinicalTrials.gov/show/NCT00023842
685,NCT00021424,Vaccine Therapy in Treating Patients With Stage IV Head and Neck Cancer,Completed,No Results Available,Head and Neck Cancer|Metastatic Cancer,Biological: recombinant fowlpox-TRICOM vaccine,National Institute on Deafness and Other Communication Disorders (NIDCD)|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,null,NIH,Interventional,Primary Purpose: Treatment,CDR0000068782|NCI-01-DC-0006|NCI-3210,11-Jul-01,6/1/2001,null,4/29/2015,Aug-02,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00021424
692,NCT00020943,Chemotherapy and Rituximab With Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma,Completed,No Results Available,Lymphoma,Biological: filgrastim|Biological: rituximab|Drug: carmustine|Drug: cyclophosphamide|Drug: cytarabine|Drug: doxorubicin hydrochloride|Drug: etoposide|Drug: leucovorin calcium|Drug: methotrexate|Drug: prednisone|Drug: vincristine sulfate|Procedure: peripheral blood stem cell transplantation,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI),Both,"18 Years to 69 Years   (Adult, Senior)",Phase 2,79,Other|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CALGB-59909|U10CA031946|CDR0000068732,11-Jul-01,6/1/2001,9/1/2009,7/15/2016,Jul-16,No Study Results Posted,null,Dec-06,Progression Free Survival|Response|Survival,https://ClinicalTrials.gov/show/NCT00020943
789,NCT00779402,Provenge (TM) for the Treatment of Hormone Sensitive Prostate Cancer,Completed,No Results Available,Prostate Cancer,Other: Placebo|Biological: Provenge,Dendreon,Male,"19 Years to 79 Years   (Adult, Senior)",Phase 3,176,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Pharmacodynamics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",P-11,22-Oct-08,9/1/2001,4/1/2015,4/21/2016,Apr-16,No Study Results Posted,PROTECT,Aug-06,time to biochemical failure,https://ClinicalTrials.gov/show/NCT00779402
886,NCT00022685,Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma,"Active, not recruiting",No Results Available,Lymphoma,Biological: epratuzumab,Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 3,null,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000068842|UCLA-0009041|IM-T-hLL2-07|UCLA-BB-IND-7124|NCI-G01-2004,10-Aug-01,9/1/2001,null,12/18/2013,Apr-03,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00022685
418,NCT00027573,Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Unresectable Kidney Cancer,Completed,No Results Available,Kidney Cancer,Biological: filgrastim|Biological: therapeutic allogeneic lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate|Drug: methotrexate|Drug: tacrolimus|Procedure: peripheral blood stem cell transplantation,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI),Both,"up to 60 Years   (Child, Adult)",Phase 2,36,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CALGB-90003|U10CA031946|CDR0000069044,7-Dec-01,10/1/2001,6/1/2006,7/12/2016,Jul-16,No Study Results Posted,null,Jun-06,Overall response rate|Overall survival|Disease-free survival|Treatment-related mortality|Percentage of donor chimerism in patients treated,https://ClinicalTrials.gov/show/NCT00027573
547,NCT00031278,Safety And Efficacy Study Of The Combination Of CpG 7909 And Herceptin In Patients With Metastatic Breast Cancer,Completed,No Results Available,"Carcinoma, Metastatic Breast",Drug: CPG 7909|Drug: Herceptin®|Drug: CPG 7909|Drug: Herceptin®|Drug: CPG 7909|Drug: Herceptin®|Drug: CPG 7909|Drug: Herceptin®,Pfizer,Female,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,12,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,C005|A8501020,28-Feb-02,10/1/2001,6/1/2003,5/26/2011,May-11,No Study Results Posted,null,Jun-03,"Phase I: To evaluate the safety, tolerability and and MTD of several dose levels of CPG 7909 of CPG 7909 in combination with the standard Herceptin® treatment in patients with metastatic breast cancer|Phase II: Evaluate tumor response and safety of CPG 7909 in combination with Herceptin® in patients with metastatic breast cancer|Phase I: To evaluate tumor response, duration of response, time to disease progression, and survival time|Phase II: To evaluate duration of response, time to disease progression, and survival time",https://ClinicalTrials.gov/show/NCT00031278
1006,NCT00026312,"Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma","Active, not recruiting",No Results Available,Localized Resectable Neuroblastoma|Localized Unresectable Neuroblastoma|Recurrent Neuroblastoma|Regional Neuroblastoma|Stage 4 Neuroblastoma|Stage 4S Neuroblastoma,Biological: Aldesleukin|Biological: Dinutuximab|Drug: Isotretinoin|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Other: Quality-of-Life Assessment|Biological: Sargramostim,National Cancer Institute (NCI),Both,"up to 30 Years   (Child, Adult)",Phase 3,1660,NIH,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,NCI-2009-01064|CDR0000069018|COG-ANBL0032|PANBL0032_A33PAMDREVW01|ANBL0032|U10CA180886|U10CA030969|U10CA098543,9-Nov-01,10/1/2001,null,7/19/2016,Apr-16,No Study Results Posted,null,Dec-16,EFS|EFS of patients from the non-randomized portion of the trial|Historical data for the analogous patients|Incidence of toxicities assessed using Common Terminology Criteria for Adverse Events version 4.0|Number of courses of therapy delivered|OS|OS of patients from the non-randomized portion of the trial,https://ClinicalTrials.gov/show/NCT00026312
366,NCT00014131,Vaccine Therapy in Treating Patients With Kidney Cancer,Terminated,No Results Available,Kidney Cancer,Biological: Biological/Vaccine: therapeutic autologous dendritic cells.,"Caladrius Biosciences, Inc.",Both,"16 Years and older   (Child, Adult, Senior)",Phase 1|Phase 2,9,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000068493|HOAG-VACCINE-RN|NCI-V01-1647,10-Apr-01,11/1/2001,null,5/25/2016,Jun-14,No Study Results Posted,null,Dec-09,"Conversion of the delayed-type hypersensitivity (DTH) skin test as measured by metric skin ruler at week 4 and month 6 during vaccine therapy|Tumor response (partial response or complete response) as measured by RECIST at months 2 or 3 and 6 during study treatment, and 6 months after study completion|Progression-free survival as measured by RECIST at months 2 or 3 and 6 during study treatment and every 6 months after study completion|Event-free survival as measured by RECIST at months 2 or 3 and 6 during study treatment and every 6 months after study completion|Overall survival beginning at the date of study entry",https://ClinicalTrials.gov/show/NCT00014131
842,NCT00045357,Biological Therapy in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Melanoma (Skin),Biological: therapeutic autologous lymphocytes,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1,18,Other|NIH,Interventional,Primary Purpose: Treatment,1585.00|FHCRC-1585.00|NCI-H02-0093|CDR0000256867,6-Sep-02,11/1/2001,8/1/2008,9/20/2010,Sep-10,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00045357
195,NCT00046852,Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma,Completed,No Results Available,Infection|Multiple Myeloma and Plasma Cell Neoplasm,Biological: filgrastim|Biological: pneumococcal polyvalent vaccine|Biological: therapeutic autologous lymphocytes|Biological: therapeutic tumor infiltrating lymphocytes|Drug: carmustine|Drug: cyclophosphamide|Drug: melphalan|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation,University of Maryland|University of Maryland Greenebaum Cancer Center,Both,"18 Years to 80 Years   (Adult, Senior)",Phase 1|Phase 2,null,Other,Interventional,Allocation: Randomized|Primary Purpose: Treatment,CDR0000256870|MSGCC-0065|UPCC-6401|NCI-V02-1709,3-Oct-02,12/1/2001,2/1/2008,9/23/2009,Sep-09,No Study Results Posted,null,Nov-04,,https://ClinicalTrials.gov/show/NCT00046852
351,NCT00140348,Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine,Completed,No Results Available,Prostate Cancer,Biological: Immunotherapy allogeneic GM-CSF secreting cellular vaccine,Cell Genesys,Male,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,80,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,G-0010,30-Aug-05,12/1/2001,4/1/2005,12/18/2007,Dec-07,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00140348
1045,NCT00044564,Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma,Completed,No Results Available,"Carcinoma, Renal Cell",Drug: Bay 59-8862,Bayer,Both,"18 Years and older   (Adult, Senior)",Phase 2,54,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,100386,30-Aug-02,12/1/2001,1/1/2003,12/18/2014,Dec-14,No Study Results Posted,null,null,Objective overall tumor response rate calculated as the percentage of patients with complete and partial responses|Duration of response|Overall survival|Time to progression|Pharmacokinetics assessment|Qualitative and quantitative toxicity profile|Physical examinations|Vital signs data|Abnormal laboratory tests,https://ClinicalTrials.gov/show/NCT00044564
3,NCT00366275,"Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma",Completed,Has Results,Follicular Lymphoma,"Procedure: Immunochemotherapy, in vivo purging and autrotransplant",IRCCS Policlinico S. Matteo,Both,18 Years to 60 Years   (Adult),Phase 2,64,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ML17165|LNH 1-02,17-Aug-06,1/1/2002,9/1/2007,10/26/2012,Oct-12,18-Feb-09,null,Jan-07,Progression-free Survival,https://ClinicalTrials.gov/show/NCT00366275
82,NCT00155792,The Development of Human Papillomavirus Type 16 E7-Specific Human Immunologic Assays in Non-HLA2 Type Human Being,Recruiting,No Results Available,Cervical Cancer,,National Taiwan University Hospital,Female,"18 Years to 80 Years   (Adult, Senior)",,300,Other,Observational,Observational Model: Defined Population|Primary Purpose: Screening|Time Perspective: Cross-Sectional|Time Perspective: Prospective,9100208476,9-Sep-05,1/1/2002,12/1/2006,12/19/2005,Dec-01,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00155792
374,NCT00027534,Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer,Completed,No Results Available,Breast Cancer|Colorectal Cancer|Gallbladder Cancer|Gastric Cancer|Head and Neck Cancer|Liver Cancer|Ovarian Cancer|Pancreatic Cancer|Testicular Germ Cell Tumor,Biological: TRICOM-CEA(6D),"Michael Morse, MD|National Cancer Institute (NCI)|Duke University",Both,"18 Years and older   (Adult, Senior)",Phase 1,14,Other|NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2840|1R21CA094523|CDR0000069041,7-Dec-01,1/1/2002,10/1/2007,9/4/2014,Sep-14,No Study Results Posted,null,Oct-07,Safety|Immune response,https://ClinicalTrials.gov/show/NCT00027534
890,NCT00033228,Vaccine Therapy in Treating Patients With Stage IV Melanoma,Completed,No Results Available,Melanoma (Skin),Biological: MKC1106-MT|Biological: MKC1106-MT|Biological: MKC1106-MT,Mannkind Corporation,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,19,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000069252|CTL-26-35,9-Apr-02,1/1/2002,4/1/2003,5/11/2011,May-11,No Study Results Posted,null,Mar-03,The primary objective of the study was to evaluate the safety and tolerability of Synchrovax® pSEM Vaccine measured by the adverse event and severe adverse event profile.|The secondary objective of the study was to determine the immunological response of patients as measured by tetramer assay and to assess clinical response by LDH levels and radiological assessment of lesions.,https://ClinicalTrials.gov/show/NCT00033228
227,NCT00730613,Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma,Completed,No Results Available,Brain and Central Nervous System Tumors,Biological: therapeutic autologous lymphocytes|Genetic: gene expression analysis|Other: laboratory biomarker analysis,City of Hope Medical Center|National Cancer Institute (NCI),Both,"18 Years to 70 Years   (Adult, Senior)",,3,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,01020|P30CA033572|CHNMC-01020|CDR0000590506,7-Aug-08,2/1/2002,8/1/2011,8/11/2011,Aug-11,No Study Results Posted,null,Aug-11,Feasibility|Safety|Anti-tumor activity of adoptively transferred clones|Anti-IL 13 zetakine and anti-HyTK immune response in patients|Efficacy of ganciclovir for clone ablation (in the event of toxicity),https://ClinicalTrials.gov/show/NCT00730613
250,NCT00384891,Hyperthermia Treatment in Conjunction With Mitomycin C Versus Bacillus Calmette-Guérin Immunotherapy (BCG) for Superficial Bladder Cancer,Terminated,No Results Available,Urinary Bladder Diseases|Urinary Bladder Neoplasms|Urinary Bladder Cancer|Malignant Tumor of Urinary Bladder|Urologic Diseases|Urologic Neoplasms|Neoplasms|Neoplasms by Site,Device: Synergo + MMC|Drug: Bacillus Calmette-Guérin,Medical Enterprises Europe B.V.,Both,"18 Years and older   (Adult, Senior)",Phase 3,190,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,102.1,5-Oct-06,2/1/2002,12/1/2013,10/5/2014,Oct-14,No Study Results Posted,null,Dec-13,"Recurrence free survival|Proportion of complete response in CIS patients|Progression rate (to disease stage>T1) and/or metastatic disease|Local and systemic side effects, both subjective and objective",https://ClinicalTrials.gov/show/NCT00384891
776,NCT00052403,Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors,Withdrawn,No Results Available,"Unspecified Adult Solid Tumor, Protocol Specific",Drug: monoclonal antibody anti-anb3 integrin|Procedure: anti-cytokine therapy|Procedure: antiangiogenesis therapy|Procedure: antibody therapy|Procedure: biological response modifier therapy|Procedure: growth factor antagonist therapy|Procedure: monoclonal antibody therapy,Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,0,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000258300|WSU-C-2453|NCI-5496,24-Jan-03,2/1/2002,null,1/15/2014,Jan-14,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00052403
993,NCT01704716,High Risk Neuroblastoma Study 1.7 of SIOP-Europe (SIOPEN),Recruiting,No Results Available,Neuroblastoma,Drug: Vincristine|Drug: Aldesleukin|Drug: ch14.18/CHO|Drug: Carboplatin|Drug: Etoposide|Drug: Cisplatin|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: G-CSF|Drug: Busulfan|Drug: Melphalan,St. Anna Kinderkrebsforschung,Both,"1 Month to 21 Years   (Child, Adult)",Phase 3,2700,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,HR-NBL-1.7 / SIOPEN,5-Oct-12,2/1/2002,9/1/2016,4/25/2016,Apr-16,No Study Results Posted,null,Sep-16,Event Free Survival (R1: MAT therapy)|Event Free Survival (R4: immunotherapy)|Complete metastatic response (R3: Induction therapy)|Event free survival (R3: Induction therapy),https://ClinicalTrials.gov/show/NCT01704716
313,NCT01127074,Vaccination of Metastatic Breast Cancer Patients With a CD80-modified Allogeneic Cancer Cell Line (KS2422),Completed,No Results Available,Metastatic Breast Cancer,Biological: KS24.22 cells,"University Hospital Tuebingen|Paul Ehrlich Institute, Langen, Germany",Female,"18 Years to 80 Years   (Adult, Senior)",Phase 1,15,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,01 KV 9540,18-May-10,3/1/2002,1/1/2010,5/19/2010,May-10,No Study Results Posted,KS2422-vacc,Jul-08,safety of KS24.22 administration|feasibility|immunological response|progression free survival|overall survival,https://ClinicalTrials.gov/show/NCT01127074
860,NCT00034138,A Comparative Pharmacokinetics and Safety Study of OvaRex MAb-B43.13 in Patients With Ovarian Epithelial Carcinoma,Terminated,No Results Available,Ovarian Neoplasms,Drug: oregovomab,Unither Pharmaceuticals,Female,18 Years to 65 Years   (Adult),Phase 1|Phase 2,24,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,OVA-Gy-16,23-Apr-02,3/1/2002,12/1/2007,12/13/2007,Dec-07,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00034138
867,NCT00043407,CPG 7909 in Patients Wih Stage IV Renal Cell Cancer,Completed,No Results Available,"Carcinoma, Renal Cell",Drug: CPG 7909,Pfizer,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,42,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,"C010|CO10, A8501022",8-Aug-02,3/1/2002,9/1/2004,2/11/2009,Feb-09,No Study Results Posted,null,Sep-04,"To determine the tolerability of escalating doses of subcutaneously administered CPG 7909 Injection up to a maximum dose of 0.81 mg/kg in patients with metastatic renal cell cancer.|To establish the maximum tolerated dose for CPG 7909 Injection as monotherapy in patients with metastatic renal cell cancer up to a dose of 0.81mg/kg.|To estimate the overall tumor response rate of CpG 7909 according to the RECIST criteria in patients with metastatic renal cell cancer.|To assess tolerability relative to dose exposure, immunologic activity, the pharmacokinetic and pharmacodynamic profile of CPG 7909 Injection, time to progression, duration of response, and time to survival.",https://ClinicalTrials.gov/show/NCT00043407
1046,NCT00039000,Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma,Completed,No Results Available,Malignant Melanoma,Drug: HSPPC-96 or Oncophage,"Agenus, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 3,350,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,C-100-21,6-Jun-02,3/1/2002,12/1/2005,9/6/2012,Sep-12,No Study Results Posted,null,Dec-05,,https://ClinicalTrials.gov/show/NCT00039000
1217,NCT00988312,Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma,Completed,No Results Available,Multiple Myeloma|Plasmocytoma,Biological: autologous idiotype-protein pulsed dendritic cells,University Hospital Carl Gustav Carus,Both,"18 Years to 70 Years   (Adult, Senior)",Phase 1,9,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MyelomVak,1-Oct-09,3/1/2002,3/1/2004,10/1/2009,Oct-09,No Study Results Posted,null,Feb-04,Specific T-cell proliferation/cytokine secretion|number of T cells|monoclonal protein|plasmacells in bone marrow|vital signs,https://ClinicalTrials.gov/show/NCT00988312
171,NCT00149019,Immunotherapy of Cancer Using Donor Lymphocytes Labelled With In-vitro Bispecific Antibodies.,Withdrawn,No Results Available,Metastatic Solid Tumors,Drug: Cell therapy with bispecific antibodies,Hadassah Medical Organization,Both,"Child, Adult, Senior",Phase 2,12,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,240502-HMO-CTIL,7-Sep-05,5/1/2002,9/1/2005,4/7/2011,Sep-05,No Study Results Posted,null,null,The purpose will be to evaluate safety using donor lymphocytes labelled in-vitro with bispecific antibodies for metastatic cancer patients.|To evaluate primary efficacy using donor lymphocytes labelled in-vitro with bispecific antibodies for metastatic cancer patients.,https://ClinicalTrials.gov/show/NCT00149019
882,NCT00042913,Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma,"Active, not recruiting",No Results Available,Lymphoma,Biological: epratuzumab,Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 2,null,Other|NIH,Interventional,Allocation: Randomized|Primary Purpose: Treatment,CDR0000069484|UCLA-0201056|AMGEN-AMG-412-159|NCI-G02-2094,5-Aug-02,5/1/2002,null,12/18/2013,Sep-03,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00042913
1218,NCT00558220,R-MegaCHOP-ESHAP-BEAM in Patients With High-Risk Aggressive B-Cell Lymphomas,Completed,No Results Available,Diffuse Large B-Cell Lymphoma.|Primary Mediastinal B-Cell Lymphoma|Follicular Lymphoma Grade III,Procedure: immunotherapy|Procedure: Induction treatment part 1|Procedure: Induction treatment part 2 with PBPC collection|Procedure: Induction treatment part 3|Procedure: Consolidation treatment part 1: HD-chemotherapy with ASCT|Radiation: Consolidation treatment part 2: Radiotherapy,"Czech Lymphoma Study Group|Ministry of Health, Czech Republic|Hoffmann-La Roche",Both,18 Years to 65 Years   (Adult),Phase 2,106,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CLSG 5_02|NR-8231/3,12-Feb-07,5/1/2002,10/1/2006,11/10/2007,Nov-07,No Study Results Posted,R-MCEB,null,Progression-free survival|Complete remission and overall response rate|Overall survival,https://ClinicalTrials.gov/show/NCT00558220
1243,NCT00063648,Detection and Cytotoxic T Lymphocyte Therapy of Post-Transplant Lymphoproliferative Disorder After Liver Transplant,Completed,No Results Available,Liver Disease|Lymphoproliferative Disorders,Biological: EBV-specific autologous CTL,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),Both,"1 Month to 21 Years   (Child, Adult)",Phase 1,50,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention,PTLD (completed),1-Jul-03,5/1/2002,12/1/2007,1/12/2010,Jan-10,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00063648
627,NCT00245362,A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer,Completed,No Results Available,Metastatic Pancreatic Cancer|Nonresectable Pancreatic Cancer,Biological: CG 8020 and CG 2505,Cell Genesys,Both,"18 Years and older   (Adult, Senior)",Phase 2,50,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,P-0011,27-Oct-05,6/1/2002,6/1/2004,10/27/2005,Oct-05,No Study Results Posted,null,null,Safety|Efficacy measured by clinical benefit response|Progression-free survivial|Overall survival,https://ClinicalTrials.gov/show/NCT00245362
394,NCT00040092,A Study to Test the Effectiveness of Virulizin® Given in Combination With Standard Chemotherapy for Pancreatic Cancer,Completed,No Results Available,Pancreatic Cancer,Drug: Virulizin®,Aptose Biosciences Inc.,Both,"18 Years and older   (Adult, Senior)",Phase 3,400,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment,LOR/VIR/P03/002,19-Jun-02,7/1/2002,null,1/4/2008,Jan-08,No Study Results Posted,null,Jul-05,,https://ClinicalTrials.gov/show/NCT00040092
538,NCT00042497,Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma,Suspended,No Results Available,Melanoma,Biological: autologous dexosomes loaded with tumor-specific peptides,Anosys,Both,"18 Years and older   (Adult, Senior)",Phase 2,60,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,AN2002-04,30-Jul-02,7/1/2002,null,6/23/2005,Sep-02,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00042497
730,NCT00082459,"Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell Carcinoma",Terminated,No Results Available,Renal Cell Carcinoma,Biological: autologous human tumor-derived HSPPC-96,"Agenus, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 2,40,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,C-100-23,10-May-04,7/1/2002,12/1/2005,9/6/2012,Sep-12,No Study Results Posted,null,Dec-05,,https://ClinicalTrials.gov/show/NCT00082459
1012,NCT00041730,Rituxan Plus FavId (Idiotype Vaccine) for Low-grade Non-Hodgkin's Lymphoma,"Active, not recruiting",No Results Available,Non-Hodgkin's Lymphoma,Biological: Id-KLH,Favrille,Both,"18 Years and older   (Adult, Senior)",Phase 2,90,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,FavId-04,15-Jul-02,7/1/2002,null,9/29/2009,Oct-04,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00041730
1197,NCT00339430,HLA and KIR Associations With Infectious Viral Agents in an HIV Cohort of Women (WIHS),Completed,No Results Available,HIV,,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Female,"Child, Adult, Senior",,3500,NIH,Observational,,999902253|02-C-N253,19-Jun-06,7/1/2002,8/1/2010,9/26/2015,Aug-10,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00339430
4,NCT00594815,Combined Immunochemotherapy Followed By Reduced Dose Radiation Therapy (RT) for Patients With Newly Diagnosed Primary Central Nervous System Lymphoma,Completed,No Results Available,Lymphoma,"Drug: Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine",Memorial Sloan Kettering Cancer Center|Northwestern Memorial Hospital|Columbia University|Kentuckiana Cancer Institute|University of Virginia|University of Vermont,Both,"Child, Adult, Senior",,52,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,01-146,7-Jan-08,8/1/2002,2/1/2016,2/25/2016,Feb-16,No Study Results Posted,null,Feb-16,To determine safety and efficacy of combined immunochemotherapy followed by reduced dose radiation for patients wth newly diagnosed PCNSL.|Acute treatment related toxicity.|Overall 2 year disease free survival.|Response rate to initial combined immunochemotherapy.|Relapse rate following complete response.|Overall and progression free survival.|Neuro-cognitive outcome.,https://ClinicalTrials.gov/show/NCT00594815
145,NCT00283829,Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer,Completed,No Results Available,Prostate Cancer,Drug: docetaxel|Drug: IL2,University of Washington|Sanofi,Male,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,30,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,02-3017-A-04|IIT-16117|USI-IL2-01-012,26-Jan-06,9/1/2002,7/1/2006,11/28/2007,Nov-07,No Study Results Posted,null,null,To determine the feasibility of sequencing low dose SQ IL-2 with chemotherapy in patients with hormone refractory prostate cancer (HRPC) in an outpatient setting.|To determine the impact of docetaxel on the natural immune defense system in patients before IL-2 administration.,https://ClinicalTrials.gov/show/NCT00283829
536,NCT00052520,"Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation",Completed,No Results Available,Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Childhood Acute Lymphoblastic Leukemia|Childhood Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Chronic Myelomonocytic Leukemia|Essential Thrombocythemia|Polycythemia Vera|Previously Treated Myelodysplastic Syndromes|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Refractory Anemia With Excess Blasts|Refractory Anemia With Excess Blasts in Transformation|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia|T-cell Adult Acute Lymphoblastic Leukemia|T-cell Childhood Acute Lymphoblastic Leukemia,Biological: therapeutic allogeneic lymphocytes|Biological: aldesleukin|Procedure: peripheral blood stem cell transplantation|Procedure: allogeneic bone marrow transplantation|Other: laboratory biomarker analysis|Genetic: gene expression analysis|Other: immunologic technique|Other: flow cytometry|Genetic: polymerase chain reaction|Genetic: cytogenetic analysis|Other: staining method,Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium|National Cancer Institute (NCI)|Fred Hutchinson Cancer Research Center,Both,"Child, Adult, Senior",Phase 1|Phase 2,37,Other|NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,1655.00|NCI-2009-01471|P01CA018029,24-Jan-03,9/1/2002,6/1/2013,7/3/2013,Jul-13,No Study Results Posted,null,Apr-11,"Toxicity rate associated with infusing donor CD8+ CTL clones specific for WT1 in patients at high risk for post transplant relapse of CML, AML, or ALL|Relapse of disease",https://ClinicalTrials.gov/show/NCT00052520
565,NCT00052598,Therapeutic Autologous Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant,Terminated,No Results Available,Accelerated Phase Chronic Myelogenous Leukemia|Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)|Blastic Phase Chronic Myelogenous Leukemia|Childhood Chronic Myelogenous Leukemia|Childhood Myelodysplastic Syndromes|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Relapsing Chronic Myelogenous Leukemia|Secondary Acute Myeloid Leukemia,Biological: therapeutic allogeneic lymphocytes|Biological: aldesleukin|Other: laboratory biomarker analysis|Other: flow cytometry,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),Both,"Child, Adult, Senior",Phase 1|Phase 2,35,Other|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,1671.00|NCI-2010-00826|P01CA018029,24-Jan-03,9/1/2002,6/1/2011,7/12/2011,Jul-11,No Study Results Posted,null,Nov-09,Toxicity rate associated with infusing donor CD8+CTL clones specific for PR3|In vivo persistence of transferred T-cells and assessment of migration to the bone marrow|Duration of response as assessed by PCR or cytogenetic analysis of peripheral blood and bone marrow samples|Proportion of responders,https://ClinicalTrials.gov/show/NCT00052598
1211,NCT00046774,Monoclonal Antibody Treatment for Systemic Lupus Erythematosus,Completed,No Results Available,Systemic Lupus Erythematosus,Drug: MRA 003 US,National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)|National Institutes of Health Clinical Center (CC),Both,"18 Years and older   (Adult, Senior)",Phase 1,23,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,020272|02-AR-0272,2-Oct-02,9/1/2002,7/1/2007,4/21/2016,Apr-16,No Study Results Posted,null,Jan-07,Safety/tolerance of MRA in pts w/SLE|Clinical Pharmacokinetics of MRA,https://ClinicalTrials.gov/show/NCT00046774
292,NCT00045149,Biological Therapy in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Melanoma (Skin),Biological: aldesleukin|Biological: therapeutic tumor infiltrating lymphocytes,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1,null,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,1588.00|FHCRC-1588.00|NCI-H02-0091|CDR0000256451,6-Sep-02,10/1/2002,6/1/2005,5/5/2010,May-10,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00045149
1112,NCT00048464,T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant,"Active, not recruiting",No Results Available,Multiple Myeloma,Procedure: Infusion of Activated & Expanded Autologous T Cells,Xcyte Therapies,Both,"18 Years to 70 Years   (Adult, Senior)",Phase 1|Phase 2,35,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,XT003,31-Oct-02,10/1/2002,null,11/6/2006,Mar-05,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00048464
468,NCT00116597,Active Specific Intranodal Immunotherapy of Recombinant Vaccinia Virus in Locally Advanced to Metastatic Melanoma,Completed,No Results Available,Melanoma,Genetic: Intranodal immunization with a recombinant vaccinia virus expressing 5 transgenes|Biological: Intranodal booster immunizations with synthetic melanoma associated epitopes,"University Hospital, Basel, Switzerland",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,15,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,GT1999017/05.050|SNF grant NPF 37 4037-55151,29-Jun-05,11/1/2002,12/1/2008,12/1/2009,Dec-09,No Study Results Posted,null,Jul-07,"Safety evaluation|Clinical response|Immune response assessment|Survival (disease-free survival [DFS], overall survival [OS])|Dose adaptation",https://ClinicalTrials.gov/show/NCT00116597
1145,NCT01290120,Chemotherapy Plus Rituximab Combination for Adult Lymphoblastic Leukemia (B-ALL) and Burkitt's Non-Hodgkin Lymphoma,Completed,No Results Available,Burkitt Lymphoma|B-ALL,Drug: Chemotherapy-Rituximab combination,Northern Italy Leukemia Group,Both,"15 Years and older   (Child, Adult, Senior)",Phase 2,182,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NILG 2009-012950-19,2-Feb-11,11/1/2002,6/1/2014,9/15/2014,Sep-14,No Study Results Posted,null,Jun-14,Overall survival|Disease free survival|Cumulative incidence of relapse|Complete remission rate|Toxicity,https://ClinicalTrials.gov/show/NCT01290120
824,NCT00050375,Clinical Trial for Ovarian Cancer (OvaRex®),Terminated,No Results Available,Ovarian Cancer,Drug: oregovomab,Unither Pharmaceuticals,Female,"18 Years and older   (Adult, Senior)",Phase 3,354,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment,OVA-Gy-17,5-Dec-02,12/1/2002,12/1/2007,12/13/2007,Jun-06,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00050375
87,NCT00154583,Comparison of the Human Papillomavirus (HPV) Type 16 E7-Specific Immune Response Between a Normal Population and Patients With Cervical Lesions,Recruiting,No Results Available,Cervical Cancer,,National Taiwan University Hospital,Female,"18 Years to 80 Years   (Adult, Senior)",,500,Other,Observational,Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Cross-Sectional|Time Perspective: Prospective,9261701445,9-Sep-05,1/1/2003,12/1/2008,12/20/2006,Jan-03,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00154583
139,NCT00155766,Immunotherapy of Recurrent Cervical Cancers Using Dendritic Cells (DCs),Recruiting,No Results Available,Cervical Cancer,Biological: HPV16 E7 peptide-pulsed autologous DCs,National Taiwan University Hospital,Female,"18 Years to 75 Years   (Adult, Senior)",Phase 1,12,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,9100205963,9-Sep-05,1/1/2003,3/1/2006,12/19/2005,Jun-02,No Study Results Posted,null,null,1. Safety issues in patients receiving HPV16 E7 peptide-pulsed autologous DCs immunotherapy|1. Immunologic responses in patients receiving HPV16 E7 peptide-pulsed autologous DCs immunotherapy|2. Clinical response in patients receiving HPV16 E7 peptide-pulsed autologous DCs immunotherapy,https://ClinicalTrials.gov/show/NCT00155766
709,NCT00051311,Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers,Completed,No Results Available,Hematologic Neoplasms,Procedure: Stem cell transplantation,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 75 Years   (Adult, Senior)",Phase 2,62,NIH,Interventional,Primary Purpose: Treatment,030077|03-C-0077,8-Jan-03,1/1/2003,9/1/2014,11/7/2014,Sep-14,No Study Results Posted,null,Sep-14,,https://ClinicalTrials.gov/show/NCT00051311
1043,NCT00043420,CPG 7909 in Patients With Cutaneous T-Cell Lymphoma,Completed,No Results Available,"Lymphoma, T-Cell, Cutaneous",Drug: PF-3512676|Drug: PF-3512676|Drug: PF-3512676|Drug: PF-3512676|Drug: PF-3512676|Drug: PF-3512676|Drug: PF-3512676|Drug: PF-3512676,Pfizer,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,42,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,"C014|CO14, A8501014",8-Aug-02,1/1/2003,3/1/2007,2/11/2009,Feb-09,No Study Results Posted,null,Mar-07,"Safety: Adverse events, vital signs, clinical and laboratory parameters, physical exams, and ECGs|Efficacy: Evaluate tumor response as measured by the Composite Assessment of Index Lesion Disease Severity (CA). The primary endpoint will be the overall tumor response rate as assessed by the CA.|Secondary efficacy endpoints include disease response assessed by the PGA, duration of overall response, duration of CCR, duration of PR, time to response and time to progression of disease.",https://ClinicalTrials.gov/show/NCT00043420
1181,NCT00952237,Immune Mobilization of Autologous Peripheral Blood Stem Cells Using Interleukin-2 and GM-CSF,Completed,No Results Available,"Non-Hodgkin's Lymphoma|Hodgkin's Disease|Multiple Myeloma|Other Plasma Cell Dyscrasia (Waldenstrom, Amyloidosis)|Leukemia",Drug: GM-CSF|Drug: IL-2,Dartmouth-Hitchcock Medical Center,Both,"18 Years and older   (Adult, Senior)",Phase 1,13,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,D0227,4-Aug-09,1/1/2003,4/1/2011,5/4/2016,May-16,No Study Results Posted,null,Apr-11,Can IL-2 be administered with GM-CSF to efficiently mobilize autologous peripheral blood stem cells. This study will determine the maximum tolerated dose of IL-2 and the optimal biological dose with GM-CSF for stem cell mobilization.|Will immune-mobilized stem cell products be well tolerated once infused into patients and will engraft normally following high-dose chemotherapy and APBSCT.,https://ClinicalTrials.gov/show/NCT00952237
1247,NCT00337519,Allogeneic Stem Cell Transplantation in Chronic Lymphocytic Leukemia,"Active, not recruiting",No Results Available,Chronic Lymphocytic Leukemia,Procedure: allogeneic stem cell transplantation|Drug: Alemtuzumab,"Charite University, Berlin, Germany|University Hospital Carl Gustav Carus|Deutsche Klinik fuer Diagnostik",Both,"up to 65 Years   (Child, Adult)",Phase 2,82,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CLL #02|DJCLS-R03/01,15-Jun-06,1/1/2003,4/1/2009,1/28/2009,Jan-09,No Study Results Posted,null,Apr-09,Progression-free survival|safety according to common toxicity criteria (CTC)|rate of primary and secondary graft failure|rate of acute and chronic GVHD|response rate|chimerism,https://ClinicalTrials.gov/show/NCT00337519
1255,NCT00531310,Reduced Intensity AlloSCT in(CML) With Persistent Disease,Terminated,No Results Available,Chronic Myeloid Leukemia,"Drug: Reduced Intensity Conditioning, Busulfan and Fludarabine",Columbia University,Both,"up to 30 Years   (Child, Adult)",Phase 2,5,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,AAAA8191|CHNY-01-505,15-Sep-07,1/1/2003,6/1/2010,4/12/2011,Apr-11,No Study Results Posted,CML,Dec-07,To determine the toxicity associated with reduced intensity therapy and allogeneic SCT in selected patients with CML.,https://ClinicalTrials.gov/show/NCT00531310
665,NCT00089726,A Cancer Vaccine (CG8123) Given With and Without Cyclophosphamide for Advanced Stage Non-Small Cell Lung Cancer (NSCLC),Completed,No Results Available,"Lung Cancer|Carcinoma, Non-Small-Cell Lung",Biological: CG8123|Drug: Cyclophosphamide,Cell Genesys,Both,"18 Years and older   (Adult, Senior)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,D-0031,11-Aug-04,3/1/2003,1/1/2006,12/18/2007,Dec-07,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00089726
1007,NCT00058656,Autologous T Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) Patients,Completed,No Results Available,Chronic Lymphocytic Leukemia,Procedure: Infusion of Activated & Expanded Autologous T Cells,Xcyte Therapies,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,18,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,XT004,8-Apr-03,3/1/2003,null,11/20/2006,Jan-05,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00058656
1023,NCT00071955,Vaccine Therapy and Sargramostim After Rituximab in Treating Patients With Refractory or Progressive Non-Hodgkin's Lymphoma,Completed,No Results Available,Lymphoma,Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine|Biological: sargramostim,Genitope Corporation|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 2,null,Industry,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000269810|GENITOPE-2002-09|IUMC-0212-20,4-Nov-03,3/1/2003,1/1/2009,12/18/2013,Jan-06,No Study Results Posted,null,null,"Progression-free survival (PFS) in groups I and II and median PFS by Kaplan-Meier curves quarterly for 1 year and then twice a year after study completion|Immune response rates in patients who received at least 4 immunizations by anti-idiotype antibody and anti-KLH antibody assays during every other immunization, last immunization, 2 and 8 weeks post immunization, and then quarterly for 1 year|Clinical response in patients who received at least 1 immunization in groups I and II by modified Cheson criteria post-immunization and then every 6 months for 1 year|Safety at the start of immunization, every 8 weeks during immunization, 2 and 8 weeks post immunization, and then quarterly for 1 year",https://ClinicalTrials.gov/show/NCT00071955
1142,NCT00054834,Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma,Terminated,No Results Available,Non-Hodgkins Lymphoma,Drug: hLL2 (epratuzumab),"Immunomedics, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1,27,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IM-T-hLL2-14,11-Feb-03,3/1/2003,null,1/8/2008,Jan-08,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00054834
1199,NCT00141700,Study of Rituximab Plus High-Dose Chemotherapy Poor Prognosis Non-Hodgkin's Lymphoma,Terminated,No Results Available,"Lymphoma, Non-Hodgkin's",Drug: Rituximab,University of Michigan Cancer Center,Both,"Child, Adult, Senior",Phase 2,30,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,UMCC 2-51,30-Aug-05,3/1/2003,12/1/2005,12/28/2007,Dec-07,No Study Results Posted,null,Mar-05,Assess progression-free survival after rituximab and high-dose chemotherapy with autologous PBPC support;|Assess overall survival (OS) after rituximab and high-dose chemotherapy with PBPC support.|Assess safety and toxicity after rituximab and high-dose chemotherapy.|Assess CD20 recovery post-transplant,https://ClinicalTrials.gov/show/NCT00141700
1278,NCT00204659,"Phase II Study With Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With Gastric Diffuse Large B-Cell Non-Hodgkin`s Lymphoma",Completed,No Results Available,Primary Gastric Diffuse-Large B-Cell Lymphoma,Drug: Rituximab + CHOP chemotherapy,University Hospital Tuebingen|Hoffmann-La Roche,Both,"18 Years and older   (Adult, Senior)",Phase 2,30,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,64-03,14-Sep-05,3/1/2003,9/1/2008,10/17/2008,Sep-08,No Study Results Posted,null,Sep-08,Complete remission rate|Progression-free survival|Overall survival|Toxicity,https://ClinicalTrials.gov/show/NCT00204659
51,NCT00073879,"Fludarabine, Cyclophosphamide, and Alemtuzumab in Treating Patients With Recurrent or Metastatic Renal Cell Carcinoma (Kidney Cancer) Undergoing Allogeneic Stem Cell Transplantation",Completed,No Results Available,Kidney Cancer,Biological: alemtuzumab|Biological: graft-versus-tumor induction therapy|Drug: cyclophosphamide|Drug: fludarabine phosphate|Procedure: allogeneic bone marrow transplantation|Procedure: peripheral blood stem cell transplantation,Baylor College of Medicine,Both,"Child, Adult, Senior",,null,Other,Interventional,Primary Purpose: Treatment,CDR0000328247|BCM-H-8447,10-Dec-03,4/1/2003,4/1/2004,1/27/2015,Jan-15,No Study Results Posted,null,Apr-04,Number of patients with treatment related mortality,https://ClinicalTrials.gov/show/NCT00073879
208,NCT00112229,Immunotherapy of HLA-A2 Positive Stage III/IV Melanoma Patients,Completed,No Results Available,Melanoma,Biological: group 1|Biological: group 2|Biological: group 3|Biological: group 4,Centre Hospitalier Universitaire Vaudois|Ludwig Institute for Cancer Research,Both,"18 Years and older   (Adult, Senior)",Phase 1,29,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,LUD 2000-018,31-May-05,4/1/2003,6/1/2012,4/19/2013,Apr-13,No Study Results Posted,null,Aug-11,"Melan-A and Tyrosinase specific CD8+ T-cell reactivity will be measured by Tetramers and Elispot assays|Safety of vaccination will be assessed according to National Cancer Institute Common Toxicity Criteria (NCI CTC) scale|In patients with measurable disease, tumor response will be assessed radiologically",https://ClinicalTrials.gov/show/NCT00112229
833,NCT00061035,Evaluation of Transgenic Lymphocyte Immunization Vaccine in Subjects With Prostate Adenocarcinoma,Completed,No Results Available,Prostatic Neoplasms,Biological: Transgenic Lymphocyte Immunization Vaccine (TLI),Cosmo Bioscience,Male,"18 Years and older   (Adult, Senior)",Phase 1,18,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,TLI-CA-TRT-001,20-May-03,4/1/2003,null,8/26/2008,Aug-08,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00061035
862,NCT00431561,Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma,Completed,No Results Available,Glioblastoma|Anaplastic Astrocytoma,Drug: AP 12009 10 µM|Drug: AP 12009 80 µM|Drug: temozolomide or PCV|Device: Drug delivery system for administration of AP 12009|Procedure: Placement of Drug Delivery System,Isarna Therapeutics GmbH,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 2,141,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,AP 12009-G004,5-Feb-07,4/1/2003,3/1/2009,12/2/2013,Dec-13,No Study Results Posted,null,Mar-09,Overall response rate of two AP 12009 dose groups and control group assessed by the evaluation of tumor size on brain MRI scans|Overall survival|Response rates|Progression-free survival|Time to progression|Time to response|Best of all response rates assessed by survival status and variation of tumor size on brain MRI|Change of quality of life and Karnofsky Performance Status (KPS)|Best of all response rates|Safety and tolerability,https://ClinicalTrials.gov/show/NCT00431561
939,NCT00053014,"S0125, Chemotherapy, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Older Patients With Acute Myeloid Leukemia",Terminated,Has Results,Leukemia,Biological: therapeutic allogeneic lymphocytes|Drug: cyclosporine|Drug: fludarabine|Drug: mycophenolate mofetil|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy,Southwest Oncology Group|National Cancer Institute (NCI),Both,"55 Years to 69 Years   (Adult, Senior)",Phase 2,5,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,S0125|U10CA032102,27-Jan-03,4/1/2003,6/1/2006,3/5/2015,Mar-15,2-Jan-13,null,Jun-05,Overall Survival|Serious Adverse Events,https://ClinicalTrials.gov/show/NCT00053014
1022,NCT00143845,Study of Low-Intensity Conditioning for Allogeneic Stem Cell Transplant,Completed,Has Results,"Multiple Myeloma|Lymphocytic Leukemia, Chronic|Lymphoma, Low-Grade",Procedure: Reduced intensity conditioning|Procedure: Rapid immunosuppressive taper|Procedure: Prophylactic donor leukocyte infusions,University of Michigan Cancer Center,Both,"Child, Adult, Senior",Phase 2,54,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,UMCC 2-61,31-Aug-05,4/1/2003,2/1/2013,8/13/2014,Aug-14,19-May-14,null,Nov-10,Percentage of Participants With Acute Graft Versus Host Disease (GVHD) Grades 2-4|Percentage of Participants With Progression Free Survival|To Evaluate Surrogate Markers of GVHD and Correlate These With Clinical Outcomes During the Above Trial,https://ClinicalTrials.gov/show/NCT00143845
318,NCT00317759,Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma,Completed,No Results Available,Melanoma (Skin),Biological: therapeutic autologous lymphocytes|Drug: fludarabine phosphate,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1,12,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,1796.00|FHCRC-1796.00|CDR0000327817,24-Apr-06,5/1/2003,10/1/2008,9/30/2015,May-10,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00317759
588,NCT00106613,A Research Study for Patients With Metastatic Renal Cell Carcinoma,Completed,No Results Available,"Carcinoma, Renal Cell|Neoplasm Metastasis",Drug: FK228 (romidepsin),Celgene Corporation|Celgene,Both,"18 Years and older   (Adult, Senior)",Phase 2,30,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,FJ-228-0001,28-Mar-05,5/1/2003,8/1/2004,8/30/2012,Aug-12,No Study Results Posted,null,Aug-04,"To evaluate the rate of objective response (the best response of Complete Response (CR), Partial Response (PR)).|Rate of disease control, Complete Response, Partial Response, or Stable Disease|Time to objective disease progression.|Number of Participants with Adverse Events|Change from screening assessment to the final study visit in Karnofsky performance status.|Steady state plasma concentrations",https://ClinicalTrials.gov/show/NCT00106613
608,NCT00060528,Sequential Vaccinations in Prostate Cancer Patients,Completed,Has Results,Prostatic Neoplasms,Drug: Recombinant Fowlpox-GM-CSF|Drug: Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM)|Drug: Recombinant Vaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM)|Drug: Recombinant Human GM-CSF,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Male,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,32,NIH,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,030176|03-C-0176,7-May-03,5/1/2003,7/1/2011,6/5/2012,Jun-12,30-Nov-11,null,Oct-09,Number of Participants With an Immune Response|Percent of Participants With a Decrease (i.e. Greater Than or Equal to 30%) in PSA Levels|Number of Participants With an Objective Response|Overall Survival|The Number of Participants With Adverse Events,https://ClinicalTrials.gov/show/NCT00060528
750,NCT00070629,CPG 7909 Injection in Non-Small Cell Lung Cancer,Completed,No Results Available,"Carcinoma, Non-Small Cell Lung",Drug: CPG 7909|Drug: Chemotherapy|Drug: Chemotherapy,Pfizer,Both,"18 Years and older   (Adult, Senior)",Phase 2,116,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,C017|ProMune|CO17|A8501017,6-Oct-03,5/1/2003,7/1/2007,2/9/2009,Feb-09,No Study Results Posted,null,null,"Efficacy- overall response rate (CR & PR) according to the RECIST criteria|Safety- drug exposure, adverse events, laboratory tests, vital signs, ECG, and physical examinations|Secondary Efficacy|compare number of patients who achieve complete response, partial response, or stable disease (CR, PR, SD) between the two treatment groups|duration of overall response (CR, PR), survival time, and time to disease progression.|To assess the immunopharmacodynamic response to CPG 7909 Injection plus chemotherapy in responding vs nonresponding patients receiving chemotherapy or the combination.",https://ClinicalTrials.gov/show/NCT00070629
417,NCT00068510,Vaccine Therapy in Treating Patients With Malignant Glioma,Completed,No Results Available,Brain and Central Nervous System Tumors,Biological: therapeutic autologous dendritic cells,Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,28,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000327711|P30CA016042|UCLA-0304053,10-Sep-03,6/1/2003,9/1/2012,9/30/2015,Aug-13,No Study Results Posted,null,Sep-12,"Dose Limiting Toxicity|Time to tumor progression, overall survival and cellular immune responses in brain tumor patients injected with tumor lysate pulsed dendritic cells",https://ClinicalTrials.gov/show/NCT00068510
1273,NCT00802113,Autologous and Allogeneic Transplant for Relapsed Lymphoma,Completed,No Results Available,Non-Hodgkin's Lymphoma|Hodgkins Disease,"Drug: Fludarabine and Busulfan|Drug: Fludarabine, Busulfan and ATG",Columbia University|Duke University,Both,"up to 55 Years   (Child, Adult)",Phase 1|Phase 2,31,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AAAA5185|CHNY-01-501,5-May-08,6/1/2003,10/1/2014,4/22/2015,Apr-15,No Study Results Posted,null,Oct-14,Determination of response rates|Rate of progression-free distribution|Incidence of toxicities|Overall survival distribution rate|Distribution of time to neutrophil engraftment|Distribution of the time to platelet engraftment|Incidence of acute and chronic graft vs. host disease,https://ClinicalTrials.gov/show/NCT00802113
62,NCT00281918,Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia,Completed,Has Results,Leukemia,Drug: Rituximab|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate,Hoffmann-La Roche|German CLL Study Group,Both,"18 Years and older   (Adult, Senior)",Phase 3,817,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000454560|GCLLSG-CLL-8|EU-20560|ML17102,24-Jan-06,7/1/2003,10/1/2011,9/9/2013,Sep-13,21-Dec-09,CLL-8,Jul-07,Progression-free Survival (PFS)|Final Analysis: Time to Progression-free Survival Event|Event-free Survival (EFS)|Overall Survival (OS)|Disease-free Survival (DFS) of Patients With Confirmed Complete Response (CR).|Final Analysis: Time to Overall Survival Event|Final Analysis: Time to Event-free Survival Event|Final Analysis: Time to Disease-free Survival (DFS) Event in Participants With Complete Response (CR)|Final Analysis: Duration of Response|Final Analysis: Percentage of Participants With Complete Response (CR) and Partial Response|Final Analysis: Time to New Treatment for Chronic Lymphocytic Leukemia(CLL),https://ClinicalTrials.gov/show/NCT00281918
157,NCT00065442,Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy,Completed,Has Results,Prostate Cancer,Biological: Sipuleucel-T|Biological: APC-Placebo,Dendreon,Male,"18 Years and older   (Adult, Senior)",Phase 3,512,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",D9902B,23-Jul-03,7/1/2003,1/1/2009,9/2/2010,Sep-10,28-May-10,null,Jan-09,Overall Survival|Time to Objective Disease Progression,https://ClinicalTrials.gov/show/NCT00065442
503,NCT00248430,Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer,Completed,No Results Available,Graft Versus Host Disease|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm,Biological: aldesleukin|Biological: therapeutic allogeneic lymphocytes|Drug: melphalan|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation,Fred Hutchinson Cancer Research Center,Both,"18 Years to 69 Years   (Adult, Senior)",Phase 1|Phase 2,20,Other,Interventional,Primary Purpose: Treatment,1838.00|FHCRC-1838.00|CDR0000430694,3-Nov-05,8/1/2003,7/1/2007,9/20/2010,Sep-10,No Study Results Posted,null,null,"Feasibility|Toxicity|Extent, degree, and duration of donor chimerism|Complete response rate",https://ClinicalTrials.gov/show/NCT00248430
539,NCT00098085,Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer,Completed,No Results Available,Non-Small-Cell Lung Carcinoma|Lung Cancer|Pulmonary Cancer,Biological: HSPPC-96,"Agenus, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 2,20,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label,C-100-26,3-Dec-04,9/1/2003,null,3/6/2009,Mar-09,No Study Results Posted,null,Nov-07,"The primary goal of this trial is to determine if HSPPC-96 can be made from the tumor tissue of patients with resectable non-small cell lung cancer.|The secondary goals are to further characterize the safety and efficacy profile, to evaluate disease recurrence in patients, and to evaluate overall survival in patients receiving HSPPC-96.",https://ClinicalTrials.gov/show/NCT00098085
549,NCT00057915,Vaccine Therapy in Treating Patients With Refractory Stage IV Cancer,Completed,No Results Available,"Unspecified Adult Solid Tumor, Protocol Specific",Biological: CEA peptide 1-6D,Duke University|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,4,Other|NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,4180|5910,7-Apr-03,9/1/2003,9/1/2006,9/4/2014,Sep-14,No Study Results Posted,null,Aug-06,Safety|Immune response,https://ClinicalTrials.gov/show/NCT00057915
847,NCT00416819,Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma,Completed,No Results Available,Brain and Central Nervous System Tumors|Lymphoma,Biological: filgrastim|Biological: rituximab|Drug: cytarabine|Drug: etoposide phosphate|Drug: leucovorin calcium|Drug: methotrexate|Drug: temozolomide,"University of California, San Francisco|National Cancer Institute (NCI)",Both,"Child, Adult, Senior",,10,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000458052|UCSF-03301|UCSF-H9414-23160-02A,27-Dec-06,9/1/2003,2/1/2012,8/18/2015,Aug-15,No Study Results Posted,null,Dec-05,"rate of toxicity in patients with untreated primary CNS lymphoma|Efficacy in patients with untreated primary CNS lymphoma treated with induction therapy comprising high-dose methotrexate, leucovorin calcium, rituximab, and temozolomide followed by consolidation therapy comprising cytarabine and etoposide phosphate.",https://ClinicalTrials.gov/show/NCT00416819
1166,NCT00089453,Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant,Completed,No Results Available,Multiple Myeloma,Drug: Dexamethasone|Drug: Cyclophosphamide|Drug: Melphalan|Drug: Fludarabine|Drug: Bortezomide|Procedure: Leukapheresis|Drug: Interleukin|Procedure: Infusion #1|Procedure: Leukapheresis #2|Procedure: Infusion #2|Procedure: Auto Graft,University of Arkansas,Both,"18 Years and older   (Adult, Senior)",Phase 1,10,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,UARK 2003-18,5-Aug-04,9/1/2003,5/1/2010,4/17/2012,Apr-12,No Study Results Posted,null,May-10,"To induce anti-myeloma responses in patients with high risk or relapsed myeloma using combination chemo- and immunotherapy comprising sequentially.|To establish the response rate, disease free survival , overall survival , and toxicity of regimen.",https://ClinicalTrials.gov/show/NCT00089453
168,NCT00795977,Preoperative Intratumor Dendritic Cells Injection Immunotherapy for Patients With Pancreatic Cancer,"Active, not recruiting",No Results Available,Pancreatic Cancer,"Biological: dendritic cells, OK-432",Fukushima Medical University,Both,"20 Years and older   (Adult, Senior)",Phase 1|Phase 2,20,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,198,19-Nov-08,11/1/2003,11/1/2012,9/7/2011,Sep-11,No Study Results Posted,null,Nov-11,To establish the maximally tolerated dose (MTD) and dose limiting toxicities (DLT) of intratumoral autologous dendritic cell vaccination in combination with OK-432|To determine the overall response rate for this regimen as determined by overall and disease-free survival.|To evaluate the immune response of patients treated with this regimen based on the presence and characterization of tumor-infiltrating white blood cells,https://ClinicalTrials.gov/show/NCT00795977
289,NCT00070187,"Immunotherapy Using Cyclosporine, Interferon Gamma, and Interleukin-2 After High-Dose Myeloablative Chemotherapy With Autologous Stem Cell Transplantation in Treating Patients With Refractory or Relapsed Hodgkin's Lymphoma",Completed,No Results Available,Lymphoma,Biological: aldesleukin|Biological: filgrastim|Biological: recombinant interferon gamma|Drug: carmustine|Drug: cyclosporine|Drug: cytarabine|Drug: etoposide|Drug: melphalan|Procedure: autologous bone marrow transplantation|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation,Children's Oncology Group|National Cancer Institute (NCI),Both,"up to 30 Years   (Child, Adult)",Phase 2|Phase 3,24,Other|NIH,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,AHOD0121|CDR0000330135|COG-AHOD0121,3-Oct-03,11/1/2003,null,10/16/2013,Oct-13,No Study Results Posted,null,Jun-05,"Incidence of death, excluding death due to disease, during the period of time from day 0 (transplant) through day 100 post transplant",https://ClinicalTrials.gov/show/NCT00070187
949,NCT00670410,Autologous Transplant Followed by Allogeneic Transplant for High Risk Neuroblastoma,Terminated,No Results Available,Neuroblastoma,Procedure: Related donor transplant|Procedure: Cord blood transplant|Drug: Busulfan|Drug: Thymoglobulin|Drug: Fludarabine,Columbia University,Both,"up to 30 Years   (Child, Adult)",Phase 1,15,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AAAA7937|CHNY-01-502,29-Apr-08,11/1/2003,12/1/2010,6/22/2016,Jun-16,No Study Results Posted,null,Dec-10,Rate of engraftment following NAT/AlloSCT from either a related donor or umbilical cord donor.|Progression Free Survival (PFS) in patients with high-risk neuroblastoma receiving sequential MAT/AutoSCT and NAT/AlloSCT.|Overall Survival (OS) in patient with high-risk neuroblastoma receiving sequential MAT/AutoSCT and NAT/AlloSCT.,https://ClinicalTrials.gov/show/NCT00670410
20,NCT00226798,Immunochemotherapy for Metastatic Renal Cell Carcinoma,Recruiting,No Results Available,Adenocarcinoma Clear Cell,Drug: Capecitabine (Xeloda),Rambam Health Care Campus|Roche Pharma AG,Both,"18 Years to 80 Years   (Adult, Senior)",Phase 2,45,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,1747CTIL|Raphael Rubinov,26-Sep-05,12/1/2003,9/1/2005,12/31/2005,Sep-05,No Study Results Posted,null,null,Objective response|Toxicity,https://ClinicalTrials.gov/show/NCT00226798
611,NCT00228189,Carcinoembryonic Antigen-loaded Dendritic Cells in Advanced Colorectal Cancer Patients,Completed,No Results Available,Colorectal Cancer|Liver Metastases,Biological: CEA-loaded dendritic cell vaccine,Radboud University,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1|Phase 2,30,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,920-03-250|NWO920-03-250,27-Sep-05,12/1/2003,11/1/2010,11/26/2010,Nov-10,No Study Results Posted,null,Nov-10,immunological response against carcinoembryonic antigen and the control protein KLH|Toxicity,https://ClinicalTrials.gov/show/NCT00228189
917,NCT00151645,Efficacy of Activated Lymphocytes in Renal Cell Carcinoma.,Terminated,No Results Available,Metastatic Renal Cell Carcinoma,Drug: activated lymphocytes,"Rennes University Hospital|Ministry of Health, France",Both,"18 Years to 70 Years   (Adult, Senior)",Phase 2,36,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AFSSAPS 990434|PHRC/02-06|CIC0203/013,8-Sep-05,12/1/2003,7/1/2005,12/30/2005,Dec-05,No Study Results Posted,null,null,Objective response rate: partial or complete response during at least 4 weeks from week 22 after the beginning of the first cycle of cytokines.|- Disease free survival|- Overall survival|- Functional and phenotypic characteristics of injected cells|- Biological response,https://ClinicalTrials.gov/show/NCT00151645
1124,NCT00070642,CPG 7909 Injection in Melanoma,Completed,No Results Available,"Carcinoma, Melanoma",Drug: CPG 7909 Injection|Drug: dacarbazine|Drug: Chemotherapy|Drug: CPG 7909 Injection|Drug: CPG 7909 Injection,Pfizer,Both,"18 Years and older   (Adult, Senior)",Phase 2,184,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,"C023|CO23, A8501023",6-Oct-03,12/1/2003,12/1/2005,2/9/2009,Feb-09,No Study Results Posted,null,Dec-05,"Phase II: Assess the anti-neoplastic activity, as determined by overall response rate (complete plus partial responses) according to the RECIST criteria.|Phase III: Evaluate and compare the survival time of the two treatment groups, as selected in Phase II.|Phase III: Assess the overall response rate|Asses the degree of clinical benefit defined as the proportion of patients experiencing complete and partial responses as well as stable disease.|Determine the duration of response.|Determine the time to progression|Assess the pharmacokinetic profile and immunopharmacodynamic response to CPG 7909 Injection alone or in combination with DTIC, or DTIC alone (immunopharmacodynamic response only).|Describe the tolerability of CPG 7909 Injection alone, CPG 7909 Injection in combination with DTIC vs. DTIC alone",https://ClinicalTrials.gov/show/NCT00070642
95,NCT00209209,Induction Chemotherapy (R-CHOP Vs. R-FC) Followed by Interferon Maintenance Versus Rituximab Maintenance in MCL,Recruiting,No Results Available,"Lymphoma, Mantle-Cell",Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Fludarabine|Drug: Interferon-alpha|Drug: pegylated formula Interferon-alpha 2b|Procedure: chemotherapy: R-CHOP|Procedure: chemotherapy: R-FC|Procedure: Interferon maintenance|Procedure: Rituximab maintenance,European Mantle Cell Lymphoma Network|German Low Grade Lymphoma Study Group|Lymphoma Study Association|HOVON - Dutch Haemato-Oncology Association|Nordic Lymphoma Group,Both,"60 Years and older   (Adult, Senior)",Phase 3,570,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MCL2004-1,13-Sep-05,1/1/2004,12/1/2014,9/6/2012,Sep-12,No Study Results Posted,MCLelderly,Dec-14,First randomisation: Reduction of lymphoma mass measured by the complete remission (CR) rate|Second randomisation: progression-free survival after end of initial chemotherapy|Survival after registration / first randomisation / second randomisation|Survival after start / end of initial therapy|Time to treatment failure after start of initial therapy|Progression free survival after registration / first randomisation / second randomisation|Side-effects of initial therapy|Side-effects of maintenance therapy,https://ClinicalTrials.gov/show/NCT00209209
336,NCT00185874,Phase I Intratumoral Dendritic Cell Immunotherapy in Thermally Ablated Liver Metastases,Terminated,No Results Available,Liver Cancer,Biological: Intratumoral Dendritic Cell Immunotherapy|Biological: autologous dendritic cells,Stanford University|National Institutes of Health (NIH),Both,"18 Years and older   (Adult, Senior)",Phase 1,22,Other|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,HEP0002|NIH 16766,12-Sep-05,1/1/2004,10/1/2007,1/11/2010,Jan-10,No Study Results Posted,null,Oct-07,"To determine the feasibility of harvesting autologous dendritic cells (DC) for CT-guided intratumoral DC injection|To establish the maximally tolerated dose (MTD) and dose limiting toxicity (DLT) of intratumoral autologous dendritic cell vaccination in combination with radiofrequency ablation (RFA) of liver metastases.|To determine the toxicity of this regimen|To determine the activity of this regimen as determined by tumor marker response, pathologic response and radiographic response of treated lesions.|To evaluate the immune response of patients treated with RFA + DC based on the presence and characterization of tumor infiltrating white blood cells",https://ClinicalTrials.gov/show/NCT00185874
382,NCT00155935,The Development of Human Immunologic Assays Specific to Folate Receptor Antigen,Recruiting,No Results Available,Ovarian Cancer,Procedure: venous puncture,National Taiwan University Hospital,Female,"10 Years to 90 Years   (Child, Adult, Senior)",,50,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic,9261700718,9-Sep-05,1/1/2004,12/1/2008,8/10/2007,Jan-04,No Study Results Posted,null,null,To develop and utilize assays to measure CTLs to folate receptors|To evaluate the folate receptor-specific immunologic responses between normal controls and ovarian cancer patients,https://ClinicalTrials.gov/show/NCT00155935
881,NCT00087984,RNA-Loaded Dendritic Cell Cancer Vaccine,Completed,No Results Available,Renal Cell Carcinoma,Biological: MB-002,Argos Therapeutics,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,26,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MB-002-003,16-Jul-04,1/1/2004,9/1/2008,2/14/2013,Feb-13,No Study Results Posted,null,Sep-08,"To examine the safety of multiple administrations of MB-002 in patients with newly diagnosed, metastatic renal cell carcinoma.|To measure clinical antitumor activity including objective tumor response and an estimate of time to tumor progression (or progression-free interval).",https://ClinicalTrials.gov/show/NCT00087984
1219,NCT01560117,"Combination of Oral Fludarabine, Mitoxantrone Und Rituximab Induction Therapy and Rituximab Maintenance Therapy in Follicular B-Cell Lymphoma",Completed,No Results Available,Follicular T-NHL Lymphoma|Rituximab Maintenance,Drug: Rituximab,Arbeitsgemeinschaft medikamentoese Tumortherapie,Both,"18 Years and older   (Adult, Senior)",Phase 2,29,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Primary Purpose: Treatment,AGMT_NHL 9,16-Mar-12,1/1/2004,7/1/2010,3/20/2012,Mar-12,No Study Results Posted,null,Jul-09,conversion rate of bcl-2 in blood and bone marrow defined by PCR|Number of patients with a response after 8 weeks,https://ClinicalTrials.gov/show/NCT01560117
447,NCT00112242,Immunotherapy of Stage III/IV Melanoma Patients,Completed,No Results Available,Melanoma,Biological: Montanide + Melan-A analogue peptide|Biological: Montanide + Melan-A analog peptide + NY-ESO-1 analog peptide + Mage10 peptide|Biological: Montanide + CpG-7909 / PF-3512676+Melan-A analog peptide + NY-ESO-1 analog peptide + Mage10 peptide|Biological: Montanide + CpG-7909/PF-3512676 + Melan-A native and analog peptides + NY-ESO-1 long peptide + Mage10 peptide|Biological: Montanide + CpG-7909/PF-3512676 + Melan-A native and analog peptides + NY-ESO-1 long peptide + Mage10 peptide + low dose IL-2,Centre Hospitalier Universitaire Vaudois|Ludwig Institute for Cancer Research,Both,"18 Years and older   (Adult, Senior)",Phase 1,38,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,LUD 2001-003,31-May-05,2/1/2004,3/1/2013,4/19/2013,Apr-13,No Study Results Posted,null,Mar-13,"Safety of the vaccination will be assessed according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) scale|Immune response induced by vaccination with melanoma antigen peptides will be determined|In patients with measurable disease, tumor response will be assessed by radiology",https://ClinicalTrials.gov/show/NCT00112242
663,NCT00078494,Peptide Vaccine to Prevent Recurrence of Nasopharyngeal Cancer,Completed,No Results Available,Nasopharyngeal Neoplasms,Drug: EBV-LMP-2,National Institutes of Health Clinical Center (CC),Both,"Child, Adult, Senior",Phase 1,99,NIH,Interventional,Endpoint Classification: Safety Study|Primary Purpose: Treatment,040118|04-CC-0118,27-Feb-04,2/1/2004,5/1/2006,3/3/2008,May-06,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00078494
176,NCT00075569,SGN-00101 Immunotherapy in Treating Patients With Grade III Cervical Intraepithelial Neoplasia,Completed,No Results Available,Cervical Cancer|Precancerous Condition,Biological: HspE7,Albert Einstein College of Medicine of Yeshiva University|National Cancer Institute (NCI),Female,"18 Years and older   (Adult, Senior)",Phase 2,null,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Prevention,CDR0000347077|AECM-0309225|NCI-5850,9-Jan-04,3/1/2004,null,1/27/2010,Jan-06,No Study Results Posted,null,null,Rate of regression at 4-7 months after completion of treatment|Toxicity,https://ClinicalTrials.gov/show/NCT00075569
274,NCT00311467,Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma,Terminated,No Results Available,Renal Cell Cancer,"Drug: Capecitabine, Interferon, Interleukin",Central European Cooperative Oncology Group,Both,"19 Years to 75 Years   (Adult, Senior)",Phase 3,172,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CECOG RCC 1.3.001,5-Apr-06,3/1/2004,5/1/2007,5/15/2012,May-12,No Study Results Posted,null,May-07,"The primary study objective is to investigate whether the addition of capecitabine to interferon-alpha-interleukin-2 based immunotherapy may improve progression free survival when compared to immunotherapy alone.|The study's secondary objectives are to investigate differences in response rates, safety and survival.",https://ClinicalTrials.gov/show/NCT00311467
956,NCT00081783,Xcellerated T CellsTM for Non-Hodgkin’s Lymphoma (NHL) Patients,Recruiting,No Results Available,Non-Hodgkin's Lymphoma,Drug: Xcellerated T Cells,Xcyte Therapies,Both,"18 Years and older   (Adult, Senior)",Phase 2,40,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,XT009,20-Apr-04,3/1/2004,null,6/23/2005,Mar-05,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00081783
958,NCT00244946,"Combination Chemotherapy Followed By Autologous Stem Cell Transplant, and White Blood Cell Infusions in Treating Patients With Non-Hodgkin's Lymphoma",Completed,No Results Available,Lymphoma,Biological: therapeutic autologous lymphocytes|Drug: carmustine|Drug: cytarabine|Drug: etoposide|Drug: melphalan|Procedure: peripheral blood stem cell transplantation (PBSCT),Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI),Both,"15 Years to 70 Years   (Child, Adult, Senior)",Phase 1,15,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000446079|P30CA022453|WSU-2007-023|RWMC-0639446,25-Oct-05,3/1/2004,3/1/2013,3/25/2015,Mar-15,No Study Results Posted,null,Jan-10,To perform a dose escalation trial of ATC armed with CD20Bi immunotherapy after PBSCT to determine the maximum tolerated dose (MTD) of ATC armed with CD20BI.|Evaluate the toxicities of ATC infusions armed with CD20Bi|Evaluate immune B-cell recovery after ATC infusion|Evaluate response rates of infusions and compare relapse rates and overall survival to historical controls,https://ClinicalTrials.gov/show/NCT00244946
1095,NCT00847106,Augmentation of Dendritic Cell-Based Vaccines in Melanoma Patients by Depletion of Regulatory T Cells in Stage IV Melanoma Patients,Completed,No Results Available,Melanoma,Drug: Daclizumab|Biological: Dendritic cells,Radboud University|Dutch Cancer Society,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1|Phase 2,15,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2003-2893|KWF 2003-2893,18-Feb-09,3/1/2004,10/1/2005,2/18/2009,Feb-09,No Study Results Posted,null,Oct-05,Immune reponse|Clinical Response,https://ClinicalTrials.gov/show/NCT00847106
1252,NCT00596804,Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma,Completed,No Results Available,"Non-Hodgkin's Lymphoma|Lymphoma, Diffuse|Lymphoma, Diffuse, Mixed Lymphocytic-Histiocytic",Drug: veltuzumab,"Immunomedics, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,39,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IM-T-hA20-01EU,8-Jan-08,3/1/2004,11/1/2007,2/2/2012,Feb-12,No Study Results Posted,null,Nov-07,Safety of hA20 with this administration schedule and dosing|tolerance of hA20 with this administration schedule and dosing|immunogenicity of hA20 with this administration schedule and dosing|Pharmacodynamics of hA20|pharmacokinetics hA20|assess efficacy,https://ClinicalTrials.gov/show/NCT00596804
295,NCT00849290,Immunotherapy For Men With Objective Disease Progression On Protocol D9902 Part B (NCT00065442),Completed,Has Results,Metastatic Androgen Independent Prostate Cancer,Biological: APC8015F,Dendreon,Male,"18 Years and older   (Adult, Senior)",Phase 2,113,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PB01,19-Feb-09,4/1/2004,4/1/2009,3/12/2013,Mar-13,28-May-10,null,Jan-09,Safety of APC8015F by Review of Reported Adverse Events|To Evaluate the Efficacy of APC8015F in Delaying Prostate Specific Antigen Doubling Time and on Overall Clinical Response,https://ClinicalTrials.gov/show/NCT00849290
641,NCT00081848,Vaccine Therapy and Radiation to Liver Metastasis in Patients With CEA-Positive Solid Tumors,Completed,No Results Available,Liver Neoplasms,Drug: rV-CEA(6D)/TRICOM-rF-CEA(6D)/TRICOM|Drug: rF-CEA(6D)/TRICOM|Drug: Recombinant Fowlpox-GM-CSF|Drug: Celecoxib,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years and older   (Adult, Senior)",Phase 1,12,NIH,Interventional,Primary Purpose: Treatment,040167|04-C-0167,22-Apr-04,4/1/2004,8/1/2007,9/26/2015,Jan-12,No Study Results Posted,null,Aug-07,,https://ClinicalTrials.gov/show/NCT00081848
891,NCT00243529,Peptide-pulsed vs. RNA-transfected Dendritic Cell Vaccines in Melanoma Patients,Completed,No Results Available,Melanoma Stage III or IV,Biological: autologous dendritic cell vaccine,Radboud University|Dutch Cancer Society,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1|Phase 2,64,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,2003-2917|KWF 2003-2917,21-Oct-05,4/1/2004,null,9/28/2009,Feb-09,No Study Results Posted,null,Feb-09,Immune response|Safety,https://ClinicalTrials.gov/show/NCT00243529
818,NCT00145626,HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies,"Active, not recruiting",Has Results,Acute Myeloid Leukemia|Acute Lymphocytic Leukemia|Myelodysplasia|Chronic Myeloid Leukemia|Histiocytosis,Drug: Chemotherapy and antibodies|Device: Miltenyi Biotec CliniMACS|Procedure: Allogeneic stem cell transplantation,St. Jude Children's Research Hospital|Assisi Foundation,Both,up to 24 Months   (Child),Phase 2,40,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,INFT2|NCI-2011-03671,1-Sep-05,5/1/2004,6/1/2016,1/20/2016,Jan-16,8-Jun-15,null,Mar-15,One-year Survival|Number of Transplant-Related Adverse Outcomes: Regimen-Related Mortality|Number of Transplant-Related Adverse Outcomes: Engraftment Failure|Number of Transplant-Related Adverse Outcomes: Fatal Acute Graft-Versus Host Disease (GVHD)|Number of Transplant-related Adverse Outcomes|Number of Incidences of Chronic GVHD.|Factors Affecting One-year Survival: Median Age of Donor at HSCT|Factors Affecting One-year Survival: Median Dose of CD34|Factors Affecting One-year Survival: Median Dose of NK Cells|Factors Affecting One-year Survival: Disease Status at HSCT|Factors Affecting One-year Survival: Donor Type|Factors Affecting One-year Survival: Match N/6 HLA Loci|Factors Affecting One-year Survival: Minimal Residual Disease (MRD)|The Kinetics of Lymphohematopoietic Reconstitution.|The Incidence of and Risk Factors for Organ Dysfunction.|The Incidence of and Risk Factors for Long-term Neurocognitive Deficit.|The Frequency of and Clinical Relevance of Minimal Residual Disease (MRD) Before and After Transplantation,https://ClinicalTrials.gov/show/NCT00145626
47,NCT00274742,Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHL,Completed,Has Results,"Non-Hodgkin's Lymphoma, Relapsed",Biological: Blinatumomab (MT103),Amgen Research (Munich) GmbH,Both,"18 Years and older   (Adult, Senior)",Phase 1,76,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MT103-104,10-Jan-06,6/1/2004,4/1/2012,1/15/2015,Jan-15,23-Dec-14,null,Aug-11,Number of Participants With Adverse Events|Serum Concentration of Blinatumomab|Objective Tumor Response According to the Cheson Criteria (Without Minimal Response)|Objective Tumor Response According to the Cheson Criteria (With Minimal Response),https://ClinicalTrials.gov/show/NCT00274742
152,NCT00213655,URO-BCG-4 : Bladder Tumors Immunotherapy,Completed,No Results Available,Bladder Cancer,Biological: bladder tumor recurrence,"University Hospital, Rouen",Both,"Child, Adult, Senior",Phase 3,146,Other,Observational,Observational Model: Case Control|Time Perspective: Prospective,2003/081/HP,14-Sep-05,6/1/2004,12/1/2013,7/30/2014,Jul-14,No Study Results Posted,null,May-13,Tumoral response,https://ClinicalTrials.gov/show/NCT00213655
335,NCT00194714,Study of Combination Immunotherapy for the Generation of HER-2/Neu Specific Cytotoxic T Cells,Completed,No Results Available,Breast Cancer,Biological: HER2 CTL vaccine (plus trastuzumab),University of Washington|Cancer Treatment Research Foundation,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,22,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,6304|G-04-003,13-Sep-05,6/1/2004,null,5/7/2013,May-13,No Study Results Posted,null,Dec-07,Safety|Immune response|Overall survival,https://ClinicalTrials.gov/show/NCT00194714
592,NCT00520468,Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS,Completed,Has Results,Myelodysplastic Syndrome,Drug: Erythropoietin|Drug: Cyclosporin A|Drug: G-CSF|Drug: Prednisone,M.D. Anderson Cancer Center,Both,"Child, Adult, Senior",Phase 2,15,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2004-0253,23-Aug-07,6/1/2004,6/1/2009,8/1/2012,Aug-12,24-Sep-09,null,Jun-09,Number of Participants With Response,https://ClinicalTrials.gov/show/NCT00520468
614,NCT00182650,Cellular Adoptive Immunotherapy in Treating Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma,Completed,No Results Available,Lymphoma,Biological: aldesleukin|Biological: rituximab|Biological: therapeutic autologous lymphocytes|Drug: fludarabine phosphate,City of Hope Medical Center|National Cancer Institute (NCI),Both,"16 Years to 70 Years   (Child, Adult, Senior)",Phase 1,5,Other|NIH,Interventional,Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment,CDR0000438797|R21CA105824|P30CA033572|CHNMC-IRB-01160,15-Sep-05,6/1/2004,3/1/2008,12/23/2009,Dec-09,No Study Results Posted,null,Mar-08,,https://ClinicalTrials.gov/show/NCT00182650
668,NCT00090493,Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma,Completed,Has Results,Multiple Myeloma,Biological: MAGE-A3|Biological: MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY,University of Arkansas,Both,"18 Years to 70 Years   (Adult, Senior)",Phase 2|Phase 3,4,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,UARK 2003-26,26-Aug-04,6/1/2004,5/1/2012,5/16/2013,May-13,25-Jan-13,null,Jul-07,The Number of Participants Experiencing a Response to the Peptide Vaccines.,https://ClinicalTrials.gov/show/NCT00090493
1207,NCT00185757,Cytokine Induced Killer Cells as Post-Transplant Immunotherapy Following Allogeneic Hematopoietic Cell Transplantation,"Active, not recruiting",No Results Available,Multiple Myeloma|Blood and Marrow Transplant (BMT),Drug: Cytokine Induced Killer Cells,Robert Negrin|National Institutes of Health (NIH)|Stanford University,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1,20,Other|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,BMT162|95070|13644,12-Sep-05,6/1/2004,12/1/2012,12/13/2012,Dec-12,No Study Results Posted,null,Dec-12,To determine the feasibility of expanding allogeneic cytokine induced killer cells suitable for clinical application using a continuous perfusion culture system.|To determine the infusional toxicity of ex vivo expanded allogeneic CIK cells in patients with recurrent or refractory disease following allogeneic hematopoietic cell transplantation.|To determine the incidence of Graft-versus-Host Disease (GVHD) following infusion of allogeneic CIK cells.|To determine the maximum tolerated dose (MTD) of expanded CIK cells for infusion.|o determine the incidence of disease response following treatment with allogeneic CIK cells.|To assess donor-specific chimerism before and after treatment with allogeneic CIK cells.|To optimize the ex vivo expansion of CIK cells using a continuous perfusion culture system.,https://ClinicalTrials.gov/show/NCT00185757
7,NCT00946374,Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma,Recruiting,No Results Available,Mantle-Cell Lymphoma,Drug: Immunochemotherapy|Drug: High-dose BEAM plus autologous SCT|Other: HLA-identical allogenic SCT,Heidelberg University,Both,18 Years to 55 Years   (Adult),Phase 2,20,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,L-149/2003|BfArM: A-7140-00-37/4021157,24-Jul-09,7/1/2004,6/1/2011,7/24/2009,Jul-09,No Study Results Posted,HD-MCL2003,Dec-10,"Efficacy: ORR, OS, EFS|Toxicity according to WHO-Grading|GvL-effect after allogenic SCT|Comparison of OS between patients completing the protocol and patients not receiving allogenic SCT",https://ClinicalTrials.gov/show/NCT00946374
94,NCT00209222,Efficacy of R-CHOP vs R-CHOP/R-DHAP in Untreated MCL,Recruiting,No Results Available,"Lymphoma, Mantle-Cell",Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone|Drug: Cisplatinum|Drug: Ara-C|Drug: Dexamethasone|Drug: BCNU|Drug: Melphalan|Drug: Etoposide|Drug: G-CSF|Procedure: chemotherapy: R-CHOP|Procedure: chemotherapy: R-DHAP|Procedure: chemotherapy: Dexa-BEAM|Procedure: stem cell harvest|Procedure: total body irradiation|Procedure: high-dose chemotherapy: Cyclophosphamide|Procedure: high-dose chemotherapy: Ara-C /Melphalan,European Mantle Cell Lymphoma Network|German Low Grade Lymphoma Study Group|Lymphoma Study Association,Both,18 Years to 65 Years   (Adult),Phase 3,360,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MCL2004-2,13-Sep-05,7/1/2004,12/1/2014,9/7/2012,Jul-09,No Study Results Posted,null,Dec-14,time to treatment failure after start of therapy|complete remission (CR) rate|overall survival|progression-free survival|adverse events|serious infectious complications,https://ClinicalTrials.gov/show/NCT00209222
150,NCT00089856,GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer,Terminated,No Results Available,Prostate Cancer,Biological: Immunotherapy with allogeneic prostate vaccine|Drug: Chemotherapy (Taxotere and prednisone),Cell Genesys,Male,"18 Years and older   (Adult, Senior)",Phase 3,626,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,G-0029|(VITAL-1),16-Aug-04,7/1/2004,10/1/2008,11/3/2008,Nov-08,No Study Results Posted,null,Oct-08,Survival|Bone pain and bone related events,https://ClinicalTrials.gov/show/NCT00089856
435,NCT00088413,PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer,"Active, not recruiting",No Results Available,Adenocarcinoma|Colorectal Cancer|Ovarian Cancer|Breast Cancer,"Biological: PANVAC-V|Biological: PANVAC-F|Drug: Sargramostim (GM-CSF, Leukine)",National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 100 Years   (Adult, Senior)",Phase 1,51,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,040246|04-C-0246,23-Jul-04,7/1/2004,1/1/2018,4/7/2016,Mar-16,No Study Results Posted,null,Jan-17,Clinical response (ovarian cancer and breast cancer arms)|Safety and tolerability (colorectal cancer and non-colorectal cancer arms)|Anti-tumor responses|Safety and tolerability (ovarian cancer and breast cancer arms)|Immune response,https://ClinicalTrials.gov/show/NCT00088413
734,NCT00086632,Study of Ovarex® (Oregovomab) MAb With Front-Line Chemotherapy for Ovarian Cancer Treatment,Terminated,No Results Available,Ovarian Cancer,Drug: oregovomab,Unither Pharmaceuticals,Female,"up to 80 Years   (Child, Adult, Senior)",Phase 2,40,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,OVA-Gy-18,7-Jul-04,7/1/2004,12/1/2007,12/13/2007,Jan-06,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00086632
997,NCT00088400,Comparison of TransMID vs Standard Treatment of Cancerous Brain Tumors,Completed,No Results Available,Glioblastoma,Drug: TransMID,National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC),Both,"Child, Adult, Senior",Phase 3,30,NIH,Interventional,Endpoint Classification: Efficacy Study|Primary Purpose: Treatment,040244|04-N-0244,23-Jul-04,7/1/2004,11/1/2005,3/3/2008,Nov-05,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00088400
1104,NCT00160992,Adoptive Cell Transfer Combined With Peptide Vaccination in Transiently Immunosuppressed Melanoma Patients,Suspended,No Results Available,Melanoma,Biological: Melan-A analog peptide,"University of Lausanne Hospitals|Fond'action contre le cancer|Barletta Foundation|NCCR (National Center of Competence in Resaerch, Switzerland)",Both,"18 Years and older   (Adult, Senior)",Phase 1,6,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CePO-ITA-01,8-Sep-05,7/1/2004,8/1/2005,9/8/2005,Sep-05,No Study Results Posted,null,null,Toxicity and feasibility|Immunomonitoring of the immune reconstitution period,https://ClinicalTrials.gov/show/NCT00160992
398,NCT00176501,Irradiated Donor Lymphocytes in Treating Patients With Metastatic Kidney Cancer,Terminated,Has Results,Kidney Cancer,Biological: therapeutic allogeneic lymphocytes,"Rutgers, The State University of New Jersey|National Cancer Institute (NCI)",Both,"18 Years to 75 Years   (Adult, Senior)",Phase 2,3,Other|NIH,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000540187|P30CA072720|CINJ #080410,12-Sep-05,8/1/2004,8/1/2008,11/18/2013,Nov-13,18-Nov-13,null,Aug-08,Response Rate|Rate and Kinetics of Clinical/Radiological Response|Rate of Graft-vs-host Disease,https://ClinicalTrials.gov/show/NCT00176501
696,NCT00100906,Sequential ATRA Then IL-2 for Modulation of Dendritic Cells and Treatment of Metastatic Renal Cell Cancer,Completed,No Results Available,Kidney Cancer,Drug: IL-2|Drug: ATRA,H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)|National Institutes of Health (NIH)|Chiron Corporation,Both,"18 Years and older   (Adult, Senior)",Phase 2,18,Other|NIH|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MCC-13920|CA101324|CA84488,6-Jan-05,8/1/2004,7/1/2013,8/15/2013,Jul-13,No Study Results Posted,null,Jun-06,Ratio of Dendritic Cells (DC) to Circulating Immature Cells (ImC) Before and After Treatment|Frequency of Treatment-Related Side Effects|Overall Response Rate (ORR),https://ClinicalTrials.gov/show/NCT00100906
1020,NCT00258336,"Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma",Recruiting,No Results Available,Lymphoma,Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine|Biological: rituximab|Biological: sargramostim,Favrille|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 2,56,Industry,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000449719|FAV-ID-70|FAV-ID-LYM-31,22-Nov-05,8/1/2004,null,1/9/2014,Aug-08,No Study Results Posted,null,Nov-09,Event-free survival by Kaplan-Meier|Overall response rate (partial and complete response) at month 6 and any time|Time-to-progression by Kaplan-Meier|Duration of response|Immune response by cellular or humoral anti-idiotype response positive|Safety,https://ClinicalTrials.gov/show/NCT00258336
243,NCT00096382,"Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma",Completed,Has Results,Melanoma (Skin),Biological: aldesleukin|Biological: filgrastim|Biological: therapeutic tumor infiltrating lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate|Radiation: radiation therapy,National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 2,34,NIH,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,040288|04-C-0288|NCI-7025|NCI-PRMC-P6273|CDR0000393480,9-Nov-04,9/1/2004,1/1/2009,10/6/2015,Sep-15,20-Nov-12,null,Jan-09,Clinical Tumor Regression|Safety,https://ClinicalTrials.gov/show/NCT00096382
786,NCT00559026,Phase I/II Study of Chemo-Immunotherapy Combination in Melanoma Patients,Completed,No Results Available,Melanoma,Biological: Melan-A|Other: Melan-A plus Dacarbazine,Istituto Superiore di Sanità|Regina Elena Cancer Institute|University of Rome Tor Vergata,Both,"18 Years and older   (Adult, Senior)",Phase 1,10,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ISS-DTIC-melvacc1|2007-006447-42,15-Nov-07,9/1/2004,9/1/2006,11/15/2007,Nov-07,No Study Results Posted,DTIC-melvacc,null,Assessment of safety by evaluating local and systemic adverse reactions during the trial. Assessment of the vaccine-specific cellular immune responses|Assessment of relapse-free survival and overall survival calculated from the time of the first chemotherapy/vaccine injection. Evaluation by microarray analysis of the gene expression profiles of patients PBMC 24 h after DTIC administration.,https://ClinicalTrials.gov/show/NCT00559026
977,NCT00451022,Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies,Recruiting,No Results Available,Vaccine,,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 120 Years   (Adult, Senior)",,750,NIH,Observational,,040274|04-C-0274,20-Mar-07,9/1/2004,null,5/11/2016,Mar-16,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00451022
1177,NCT00285428,Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma,Completed,No Results Available,Non-Hodgkin's Lymphoma,Drug: hA20-humanized anti-CD20 antibody,"Immunomedics, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,82,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IM-T-hA20-01,31-Jan-06,9/1/2004,10/1/2007,2/2/2012,Feb-12,No Study Results Posted,null,Oct-07,Safety and tolerance of different dose levels|Lack of immunogenicity|Pharmacodynamics|Pharmacokinetics|Efficacy,https://ClinicalTrials.gov/show/NCT00285428
138,NCT00101257,Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer,Completed,No Results Available,Ovarian Cancer|Peritoneal Cavity Cancer,Biological: therapeutic autologous lymphocytes,Fred Hutchinson Cancer Research Center,Female,"18 Years to 75 Years   (Adult, Senior)",Phase 1,18,Other,Interventional,Primary Purpose: Treatment,1942.00|FHCRC-1942.00|CDR0000402870,7-Jan-05,10/1/2004,3/1/2010,5/5/2010,May-10,No Study Results Posted,null,null,Safety and toxicity|Duration of in vivo persistence|Antitumor effects,https://ClinicalTrials.gov/show/NCT00101257
345,NCT00101166,Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma,Completed,Has Results,Melanoma (Skin),Biological: Bystander-Based Autologous Tumor Cell Vaccine,H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)|American Society of Clinical Oncology|Society of Surgical Oncology (SSO),Both,"18 Years and older   (Adult, Senior)",Phase 2,43,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MCC-13639|0407-657,7-Jan-05,10/1/2004,3/1/2010,11/16/2012,Sep-12,18-Oct-12,null,Mar-10,Number of Participants With Partial Response|Number of Participants With Serious Adverse Events (SAEs) Related to Study Treatment|Number of Participants With Stable Disease|Time to Progression (TTP) in Months|Overall Survival (OS) in Months,https://ClinicalTrials.gov/show/NCT00101166
620,NCT00098774,Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Primary CNS Lymphoma,Completed,Has Results,Lymphoma,Biological: filgrastim|Biological: rituximab|Drug: cytarabine|Drug: etoposide|Drug: leucovorin calcium|Drug: methotrexate|Drug: temozolomide,Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI),Both,"Child, Adult, Senior",Phase 2,47,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CALGB-50202|U10CA031946|CDR0000398106,8-Dec-04,10/1/2004,9/1/2014,7/1/2016,Jul-16,26-Jun-14,null,Jan-10,Complete Response Rate After Remission Induction|4 Year Progression Free Rate|Change From Baseline in Mini-Mental Status Evaluation at 4 Months|4 Year Overall Survival Rate,https://ClinicalTrials.gov/show/NCT00098774
815,NCT00438880,"Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma",Completed,Has Results,Adult Non-Hodgkin Lymphoma|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue|Nodal Marginal Zone Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Splenic Marginal Zone Lymphoma|Waldenstrom Macroglobulinemia,Drug: Agatolimod Sodium|Radiation: Indium In-111 Ibritumomab Tiuxetan|Other: Laboratory Biomarker Analysis|Procedure: Radionuclide Imaging|Biological: Rituximab|Procedure: Single Photon Emission Computed Tomography|Radiation: Yttrium Y-90 Ibritumomab Tiuxetan,Mayo Clinic|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,38,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,LS0382|NCI-2009-01275|P30CA015083,20-Feb-07,10/1/2004,11/1/2014,1/4/2016,Sep-15,20-May-14,null,Oct-10,Maximum Tolerated Dose of CpG 7909 as Determined Using the Number of Participants With a DLT at Each Dose Level|Tumor Response|Progression-free Survival|Duration of Response,https://ClinicalTrials.gov/show/NCT00438880
658,NCT00096551,A Phase I Feasibility Study of an Intraprostatic PSA-Based Vaccine in Men With Prostate Cancer With Local Failure Following Radiotherapy or Cryotherapy or Clinical Progression on Androgen Deprivation Therapy in the Absence of Local Definitive Therapy,Completed,No Results Available,Prostatic Neoplasms,Drug: Recombinant Vaccinia-PSA(L155)/TRICOM (PROSTVAC-V/TRICOM)|Drug: Recombinant Fowlpox-PSA(L155)/TRICOM (PROSTVAC-F/TRICOM)|Drug: Recombinant Fowlpox-GM-CSF,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Male,"18 Years and older   (Adult, Senior)",Phase 1,21,NIH,Interventional,Primary Purpose: Treatment,050017|05-C-0017,7-Jul-06,11/1/2004,7/1/2011,9/23/2015,Jul-11,No Study Results Posted,null,Dec-09,,https://ClinicalTrials.gov/show/NCT00096551
932,NCT00101309,Vaccine Therapy and Interleukin-2 in Treating Young Patients With Relapsed or Refractory Ewing's Sarcoma or Neuroblastoma,"Active, not recruiting",No Results Available,Neuroblastoma|Sarcoma,Biological: aldesleukin|Biological: autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine|Biological: therapeutic autologous lymphocytes,Milton S. Hershey Medical Center|National Cancer Institute (NCI),Both,"1 Year to 30 Years   (Child, Adult)",Phase 1,10,Other,Interventional,Primary Purpose: Treatment,CDR0000404366|PSCI-18990,7-Jan-05,11/1/2004,null,12/17/2013,Nov-07,No Study Results Posted,null,Nov-07,,https://ClinicalTrials.gov/show/NCT00101309
740,NCT00157573,GM-CSF in Women With Recurrent Ovary Cancer,Completed,No Results Available,Ovarian Cancer|Primary Peritoneal Cancer|Fallopian Tube Cancer,"Drug: GM-CSF, Leukine",Massachusetts General Hospital|Dana-Farber Cancer Institute|Bayer,Female,"18 Years and older   (Adult, Senior)",Phase 2,70,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,04-305,8-Sep-05,12/1/2004,4/1/2010,4/27/2012,Apr-12,No Study Results Posted,null,Oct-08,To determine the time to treatment termination due to disease progression or toxicity|To determine the toxicity of this therapy|To determine the development of anti-Trag antibodies,https://ClinicalTrials.gov/show/NCT00157573
40,NCT00147901,"Study to Evaluate the Combination of Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)",Completed,No Results Available,B-cell Chronic Lymphocytic Leukemia,Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Alemtuzumab,University of Cologne|German CLL Study Group|MedacSchering Onkologie,Both,"18 Years and older   (Adult, Senior)",Phase 2,100,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CLL-2L,2-Sep-05,1/1/2005,null,1/26/2010,Jan-10,No Study Results Posted,null,null,Overall response rate (complete and partial response rate)|Toxicity|MRD response rate|Response rate in biological defined risk groups|Duration of response|Treatment administration (dose intensity)|Overall survival,https://ClinicalTrials.gov/show/NCT00147901
518,NCT00107185,Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma,Completed,No Results Available,Brain and Central Nervous System Tumors,Biological: therapeutic autologous dendritic cells,Jonsson Comprehensive Cancer Center|National Cancer Institute (NCI),Both,"1 Year to 18 Years   (Child, Adult)",Phase 1,7,Other|NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000420930|P30CA016042|UCLA-0410044-01,5-Apr-05,1/1/2005,3/1/2010,8/2/2012,Aug-12,No Study Results Posted,null,Oct-09,Dose-limiting toxicity of adjuvant vaccination with autologous tumor lysate-pulsed dendritic cells after surgical resection in pediatric patients with malignant glioma.|survival,https://ClinicalTrials.gov/show/NCT00107185
785,NCT00303667,Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant,Terminated,Has Results,Acute Myelogenous Leukemia,Biological: aldesleukin|Biological: natural killer cells|Drug: cyclophosphamide|Drug: fludarabine phosphate|Procedure: allogeneic hematopoietic stem cell transplantation|Radiation: total body irradiation|Biological: Thymoglobulin|Drug: Cyclosporin A|Drug: cyclophosphamide|Drug: fludarabine phosphate,"Masonic Cancer Center, University of Minnesota",Both,"18 Years to 70 Years   (Adult, Senior)",Phase 1|Phase 2,50,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2004LS042|UMN-MT2003-23|UMN-IRB-0405M60481,15-Mar-06,1/1/2005,3/1/2011,6/11/2015,Nov-11,11-Jun-15,null,Mar-11,Disease-free Survival at 6 Months|Disease-free Survival at 1 Year|In Vivo Expansion of a Donor NK Cells NK Cell Product|Number of Patients With Graft Failure|Incidence of Grade III-IV Acute Graft Versus Host Disease|Number of Patients With Treatment-Related Mortality|Incidence of Chronic Graft Versus Host Disease|Number of Patients With Disease Relapse|Incidence of Post-transplant Lymphoproliferative Disorder Disorder (PTLD),https://ClinicalTrials.gov/show/NCT00303667
21,NCT00927797,"Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)","Active, not recruiting",No Results Available,Immunocytoma/Morbus Waldenström|B-Cell Non-Hodgkin's Lymphoma|B-Cell Chronic Lymphocytic Leukemia,"Drug: Cyclophosphamide, Pentostatin, Rituximab","Heidelberg University|Diakonie Krankenhaus Schwäbisch Hall, Germany|Ludwig-Maximilians - University of Munich|Klinikum am Plattenwald, Bad Friedrichshall, Germany|Diakonieklinikum Stuttgart, Germany|Gemeinschaftspraxis Porowski & Koniczek, Heilbronn, Germany|Universitätsmedizin Mannheim",Both,"18 Years and older   (Adult, Senior)",Phase 2,185,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,L-278/2004|BfArM 4022892,23-Jun-09,2/1/2005,1/1/2012,6/24/2009,Jun-09,No Study Results Posted,PERLL,Jan-09,Efficacy: overall response rate|Toxicity according to WHO-Grading|Efficacy: complete remission rate|Efficacy: partial remission rate|Efficacy: progression-free survival,https://ClinicalTrials.gov/show/NCT00927797
409,NCT00103142,Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer,Completed,Has Results,Colorectal Cancer|Metastatic Cancer,Biological: falimarev|Biological: inalimarev|Biological: sargramostim|Biological: therapeutic autologous dendritic cells,"Michael Morse, MD|National Cancer Institute (NCI)|Duke University",Both,"18 Years and older   (Adult, Senior)",Phase 2,74,Other|NIH,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,Pro00007616|DUMC-5883-04-6RO|CDR000041079,7-Feb-05,2/1/2005,3/1/2013,10/11/2015,Oct-15,16-Jan-14,null,Jun-09,Recurrence-free Survival at 2 Years|Positive Immune Response as Measured by (Enzyme-linked Immunosorbent Spot) ELISpot Assay,https://ClinicalTrials.gov/show/NCT00103142
91,NCT00216034,Randomized Controlled Study of Postoperative Adjuvant Therapy for Gastric Cancer Using TS-1 or TS-1+PSK,Completed,No Results Available,Gastric Cancer,Drug: Tegafur-gimeracil-oteracil potassium (TS-1)|Drug: Krestin (PSK),Hokuriku-Kinki Immunochemotherapy Study Group,Both,"20 Years to 80 Years   (Adult, Senior)",Phase 3,255,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,HKIT-GC,18-Sep-05,3/1/2005,2/1/2016,6/6/2016,Jun-16,No Study Results Posted,null,Feb-16,"Time of recurrence (calculation of 3-year disease-free survival and overall survival rates)|Relations of survival rate with compliance, postoperative complication, QOL, adverse events, recurrence status, and expression of immune or tumor markers",https://ClinicalTrials.gov/show/NCT00216034
1223,NCT00460629,Prophylactic Transfer of Leukemia-reactive T Cells After Allogeneic Transplantation,Completed,No Results Available,Chronic Myeloid Leukemia,Procedure: Application of activated donor T cells,University Hospital Carl Gustav Carus,Both,18 Years to 60 Years   (Adult),Phase 1|Phase 2,20,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,EK126092000,12-Apr-07,3/1/2005,null,6/19/2013,Jun-13,No Study Results Posted,null,Dec-11,Feasibility of the infusion of in-vitro activated donor T cells|kinetic of BCR-ABL load after transplantation|Rate of acute and chronic GvHD|Rate of infectious complications,https://ClinicalTrials.gov/show/NCT00460629
1270,NCT01497002,Comparison of the OSHO Protocol to a Standard Arm Protocol of the German AML Intergroup in Patients With AML>60a,Recruiting,No Results Available,Acute Myeloid Leukaemia,Drug: Cytarabine|Drug: Cytarabine|Biological: human stem cells,University of Leipzig,Both,18 Years to 60 Years   (Adult),Phase 3,730,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,OSHO#069,21-Dec-11,4/1/2005,12/1/2013,12/22/2011,Mar-11,No Study Results Posted,AML 2004,Dec-13,comparison of event free survival (OSHO arm versus Standard intergroup arm),https://ClinicalTrials.gov/show/NCT01497002
288,NCT02429440,Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides,"Active, not recruiting",No Results Available,Renal Cell Cancer|Advanced Renal Cell Cancer,Biological: peptide vaccine|Drug: Granulocyte Macrophage Colony Stimulating Factor|Drug: Montanide ISA-51,University Hospital Tuebingen,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,40,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,231/2004,14-Apr-15,5/1/2005,6/1/2015,4/23/2015,Feb-15,No Study Results Posted,UroRCC,Oct-14,Tolerability|All Cause Mortality|Progression-free Survival|Immune Response,https://ClinicalTrials.gov/show/NCT02429440
671,NCT00126178,Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer,Terminated,No Results Available,Kidney Cancer|Renal Cell Carcinoma,Biological: HSPPC-96,"Agenus, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 3,600,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment,C-100-12 Part 2,2-Aug-05,5/1/2005,3/1/2006,9/6/2012,Sep-12,No Study Results Posted,null,Mar-06,To determine whether patients randomized to receive adjuvant HSPPC-96 (treatment) after surgical resection of the kidney cancer have improved recurrence-free survival as compared to patients who did not receive adjuvant treatment (observation)|To determine whether patients randomized to receive adjuvant HSPPC-96 have improved overall survival as compared to patients in the observation group (without adjuvant treatment)|To further characterize the safety profile of HSPPC-96,https://ClinicalTrials.gov/show/NCT00126178
961,NCT00200577,Tumor Infiltrating Lymphocytes Adjuvant Therapy of Melanoma,Completed,No Results Available,Melanoma,Drug: TIL + IL2,Nantes University Hospital,Both,"up to 75 Years   (Child, Adult, Senior)",Phase 3,70,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,BRD/04/1-D,12-Sep-05,5/1/2005,12/1/2012,1/30/2013,Jan-13,No Study Results Posted,TIL,Dec-12,"Determination of the duration of the relapse-free interval.|Physical examination, every 2 months until M18 then every 3 months until M36 then every 4 months up to 5 years, then once per year with a clinical examination only.|Abdominal echography will be performed at the screening visit, M4, M8, M12 and then every 6 months until 5ans.|CT-Scan will be performed before the first administration of study treatment (at the time of screening visit), every 6 months during 2 years and then every years up to 5 years.|Determine of overall survival|To define safety and toxicity of TIL/IL2 treatment|Evaluation of immunological responses|Analysis of the clinical, biological and histological factors on the survival of the patients",https://ClinicalTrials.gov/show/NCT00200577
570,NCT00113984,Vaccine and Antibody Treatment of Prostate Cancer,Completed,No Results Available,Prostatic Neoplasms,Biological: PROSTVAC-V/TRICOM|Biological: PROSTVAC-F/TRICOM|Drug: MDX-010|Drug: Sargramostim,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Male,"18 Years to 85 Years   (Adult, Senior)",Phase 1,30,NIH,Interventional,Primary Purpose: Treatment,050167|05-C-0167,11-Jun-05,6/1/2005,12/1/2011,10/4/2014,Nov-12,No Study Results Posted,null,Feb-08,"To determine the safety and tolerability of a combination of a fixed dose of vaccine and anti-CTLA4, which will be dose escalated.|To evaluate immunologic response (as measured by an increase in PSA specific T-cells measured by ELISPOT in HLA-A2+ patients), and clinical response (as measured by RECIST and PSA consensus criteria).",https://ClinicalTrials.gov/show/NCT00113984
988,NCT00257465,"Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma",Completed,No Results Available,Melanoma,"Biological: Autologous, DNP-modified vaccine (M-Vax)|Biological: Autologous, DNP-Modified Melanoma Vaccine|Biological: Autologous, DNP-Modified Vaccine|Biological: Autologous, DNP-Modified Vaccine|Biological: Autologous, DNP-Modified Vaccine",AVAX Technologies,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,82,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A/100/0401,22-Nov-05,6/1/2005,6/1/2008,12/2/2015,Dec-15,No Study Results Posted,null,Jun-08,Immune response to patients' own melanoma cells|Safety,https://ClinicalTrials.gov/show/NCT00257465
154,NCT00133224,Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients,Terminated,No Results Available,Prostate Cancer,Biological: Immunotherapy allogeneic GM-CSF secreting cellular vaccine|Drug: Chemotherapy (docetaxel and prednisone),Cell Genesys,Male,"18 Years and older   (Adult, Senior)",Phase 3,408,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,G-0034|VITAL-2,19-Aug-05,7/1/2005,6/1/2009,9/19/2008,Sep-08,No Study Results Posted,null,Aug-08,Survival|Time to disease progression. Time to pain progression.,https://ClinicalTrials.gov/show/NCT00133224
247,NCT00154713,Immunotherapy for Colorectal Cancers Using CEA-Pulsed Dendritic Cells and Subsequent IL-2 Treatment,Recruiting,No Results Available,Colorectal Cancer,Biological: CEA pulsed dendritic cells,"National Taiwan University Hospital|National Health Research Institutes, Taiwan",Both,"20 Years to 75 Years   (Adult, Senior)",Phase 1|Phase 2,37,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,27MD02,8-Sep-05,7/1/2005,7/1/2005,9/8/2005,Jul-05,No Study Results Posted,null,null,evaluate the clinical responses of vaccinated patients 6 weeks after the first injection|evaluate the safety of this treatment and the immune responses against CEA before and after the treatment 6 weeks after the first injection,https://ClinicalTrials.gov/show/NCT00154713
582,NCT00210470,A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer,Completed,Has Results,Squamous Cell Carcinoma of the Head and Neck,Biological: IRX-2|Drug: Cyclophosphamide|Drug: Indomethacin|Drug: Zinc|Drug: Omeprazole,IRX Therapeutics,Both,"18 Years to 80 Years   (Adult, Senior)",Phase 2,27,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IRX-2 2005-A,13-Sep-05,7/1/2005,12/1/2010,5/22/2012,May-12,6-Jan-12,null,Dec-10,Number of Participants With Adverse Events and Serious Adverse Events|Clinical and Histological Tumor Responses|Evaluate Patient Tolerance of Surgery and Post-operative Adjuvant Therapy;|Immune Competence as Measured by Lymphocyte Infiltration|Disease-free Survival|Overall Survival|Correlation of Tumor Response or Immune Competence (Lymphocyte Infiltration) With Disease-Free Survival or Overall Survival,https://ClinicalTrials.gov/show/NCT00210470
755,NCT00385788,Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease,"Active, not recruiting",No Results Available,Hodgkin's Disease,Drug: Gemcitabine|Drug: Fludarabine|Drug: Melphalan|Drug: Antithymocyte Globulin|Procedure: Allogeneic Stem Cell Infusion|Drug: Tacrolimus|Drug: Filgrastim (G-CSF)|Drug: Methotrexate,M.D. Anderson Cancer Center,Both,"up to 65 Years   (Child, Adult)",Phase 2,70,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2005-0015|NCI-2012-01376,9-Oct-06,7/1/2005,null,7/13/2016,Jul-16,No Study Results Posted,null,Jul-18,Number of Participants with Transplant Related Mortality,https://ClinicalTrials.gov/show/NCT00385788
812,NCT00134082,Rituximab and Cyclophosphamide Followed by Vaccine Therapy in Treating Patients With Relapsed Hodgkin Lymphoma,"Active, not recruiting",No Results Available,Lymphoma,Biological: Hodgkin's antigens-GM-CSF-expressing cell vaccine|Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide,Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI),Both,"18 Years to 120 Years   (Adult, Senior)",Phase 1|Phase 2,30,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,"J0528 , CDR0000441037|P50CA096888|P30CA006973|JHOC-J0528|NA_00035358",22-Aug-05,7/1/2005,12/1/2017,10/30/2015,Oct-15,No Study Results Posted,null,Oct-17,Safety and tolerability|Immunologic response|Relapse-free survival at 3 years|Overall survival at 3 years|Patterns of cellular immune reconstitution,https://ClinicalTrials.gov/show/NCT00134082
901,NCT00140855,A Study of Anti-CTLA4 Antibody in People With Advanced Synovial Sarcoma,Terminated,No Results Available,Synovial Sarcoma,Drug: Anti-CTLA4 (monoclonal antibody MDX-010),Ludwig Institute for Cancer Research|Medarex,Both,"13 Years and older   (Child, Adult, Senior)",Phase 2,17,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,LUD2002-010|MSKCC 04-128,30-Aug-05,7/1/2005,4/1/2007,4/4/2007,Apr-07,No Study Results Posted,null,null,"To determine the clinical response of patients with advanced synovial sarcoma following treatment with anti-CTLA4 (RECIST-defined complete response [CR] and partial response [PR]).|To determine the clinical benefit rate (CR + PR + stable disease [SD]) of patients with advanced synovial sarcoma following treatment with anti-CTLA4.|To evaluate NY-ESO-1 specific immunity (NY-ESO-1 and LAGE-1 antibody, CD8+ and CD4+ T cells, and delayed-type hypersensitivity [DTH]) induced by three doses of anti-CTLA4 antibody in patients with synovial sarcoma.|To determine the safety of anti-CTLA4 in patients with synovial sarcoma.",https://ClinicalTrials.gov/show/NCT00140855
306,NCT00143559,Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies,Completed,No Results Available,Leukemia|Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Juvenile Myelomonocytic Leukemia|Myelodysplastic Syndrome|Paroxysmal Nocturnal Hemoglobinuria|Hodgkin's Lymphoma|Non-Hodgkin Lymphoma,Drug: Systematic chemotherapy and antibodies|Procedure: Allogeneic stem cell transplantation|Device: Miltenyi CliniMACS,St. Jude Children's Research Hospital,Both,"2 Years to 21 Years   (Child, Adult)",Phase 2,17,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,HAPREF,1-Sep-05,8/1/2005,1/1/2009,1/28/2009,Jan-09,No Study Results Posted,null,Jul-06,To measure the rate of disease relapse by six months posttransplant in children and young adults with refractory hematologic malignancies who receive a haploidentical stem cell graft processed using the investigational CliniMACS cell sorting device.,https://ClinicalTrials.gov/show/NCT00143559
368,NCT00173394,The Assessment of Mesothelin Antigen Specific Immunologic Assays in Ovarian Cancer Patients,Recruiting,No Results Available,Ovarian Cancer,,National Taiwan University Hospital,Female,"18 Years to 80 Years   (Adult, Senior)",,250,Other,Observational,Observational Model: Defined Population|Observational Model: Natural History|Time Perspective: Cross-Sectional|Time Perspective: Retrospective/Prospective,9461700630,12-Sep-05,8/1/2005,12/1/2008,12/18/2006,Jul-05,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00173394
1080,NCT00790413,Haploidentical Stem Cell Transplantation in Neuroblastoma,"Active, not recruiting",No Results Available,Neuroblastoma,Drug: iodine I 131 metaiodobenzylguanidine|Drug: Fludarabine|Drug: Thiotepa|Procedure: T-cell depletion|Procedure: Haploidentical stem cell transplantation|Procedure: Donor Lymphocyte Infusion|Drug: Rituximab|Procedure: Co-transplantation of mesenchymal stem cells,Lund University Hospital,Both,"6 Months to 21 Years   (Child, Adult)",Phase 0,15,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,385/2005,12-Nov-08,8/1/2005,null,3/3/2016,Mar-16,No Study Results Posted,null,Dec-16,Engraftment rate|Overall survival|Immunological reconstitution|Incidence of acute graft versus host disease,https://ClinicalTrials.gov/show/NCT00790413
1144,NCT00611637,CMV pp65 Specific T Cell Adoptive Immunotherapy in Allogeneic Stem Cell Transplantation for Malignant Disease,Terminated,No Results Available,Allogeneic Stem Cell Transplantation,Biological: CMV pp65 Specific T Cells,H. Kim Lyerly|National Institutes of Health (NIH)|National Cancer Institute (NCI)|Duke University,Both,"18 Years and older   (Adult, Senior)",Phase 1,2,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label,4138-07-10R5|IND 11649,29-Jan-08,8/1/2005,6/1/2008,11/8/2012,Nov-12,No Study Results Posted,CMV-BMT,Feb-08,Number of CMV pp65 specific CD8+ T cells produced.|Development of grade III-IV GVHD or major organ toxicity.|Presence of CMV in peripheral blood.|Percentage of CD8+ T cells that are CMV pp65 specific.,https://ClinicalTrials.gov/show/NCT00611637
375,NCT00128622,Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer,Completed,No Results Available,"Breast Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer|Unspecified Adult Solid Tumor, Protocol Specific",Biological: denileukin diftitox|Biological: recombinant fowlpox-CEA(6D)/TRICOM vaccine|Biological: therapeutic autologous dendritic cells,H. Kim Lyerly|National Cancer Institute (NCI)|Duke University,Both,"18 Years and older   (Adult, Senior)",Phase 1,24,Other|NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000437795|DUMC-NCI-7042|NCI-7042,8-Aug-05,9/1/2005,5/1/2009,11/8/2012,Nov-12,No Study Results Posted,null,Mar-07,Safety as measured by rate of adverse events during study drug treatment|Rate of immune response as measured by ELISPot at week 10,https://ClinicalTrials.gov/show/NCT00128622
535,NCT00179309,Docetaxel Alone or in Combination With Vaccine to Treat Breast Cancer,Completed,Has Results,Breast Cancer,Drug: Docetaxel|Biological: PANVAC-V|Biological: PANVAC-F|Biological: Sargramostim,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 85 Years   (Adult, Senior)",Phase 2,48,NIH,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,050229|05-C-0229,15-Sep-05,9/1/2005,10/1/2013,6/30/2014,Jun-14,29-Apr-13,null,Feb-13,Progression-free Survival (PFS)|Number of Participants With Adverse Events,https://ClinicalTrials.gov/show/NCT00179309
560,NCT00324623,Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma,Completed,No Results Available,Melanoma (Skin),"Biological: Melan-A VLP vaccine, IMP321 adjuvant|Biological: adoptive immunotherapy|Biological: therapeutic autologous lymphocytes|Drug: cyclophosphamide|Drug: fludarabine phosphate",Prof. Serge Leyvraz|Centre Hospitalier Universitaire Vaudois,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1,8,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000468827|CHUV-CEPO-ITA-02|EU-20607,10-May-06,9/1/2005,null,11/19/2012,Nov-12,No Study Results Posted,null,Nov-11,"Phenotype, function, and T-cell receptor repertoire|Tumor response|Toxicity",https://ClinicalTrials.gov/show/NCT00324623
656,NCT00457587,Preclinical Study Towards an Immunotherapy in Adrenocortical Carcinoma,"Active, not recruiting",No Results Available,Adrenocortical Carcinoma|Cushing's Syndrome,,"University of Wuerzburg|Deutsche Krebshilfe e.V., Bonn (Germany)",Both,"18 Years and older   (Adult, Senior)",Phase 0,70,Other,Observational,Observational Model: Case Control|Time Perspective: Prospective,Wue-Immuno-ACC-83/05,4-Apr-07,9/1/2005,12/1/2016,9/9/2015,Sep-15,No Study Results Posted,null,Dec-11,To find reasonable antigens for a vaccination therapy in ACC|To investigate the role of tumor-induced suppression in ACC,https://ClinicalTrials.gov/show/NCT00457587
1206,NCT00190424,Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma,Completed,No Results Available,Glioblastoma,Drug: CpG-ODN,Assistance Publique - Hôpitaux de Paris,Both,"40 Years and older   (Adult, Senior)",Phase 2,80,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment,P050305|ISOPS 3,14-Sep-05,9/1/2005,10/1/2010,12/12/2012,Sep-05,No Study Results Posted,null,Oct-08,Survival|Progression-free survival|Tolerance,https://ClinicalTrials.gov/show/NCT00190424
1282,NCT00230035,Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST),Withdrawn,No Results Available,Systemic Lupus Erythematosus,Procedure: Leukapheresis|Procedure: Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT)|Procedure: Autologous CD34+HPC transplantation (HSCT)|Procedure: Plasmapheresis|Drug: Rabbit anti-thymocyte globulin|Drug: Methylprednisolone|Drug: Growth colony stimulating factor (G-CSF)|Drug: Corticosteroids|Drug: Mycophenolate mofetil|Drug: Azathioprine|Drug: Intravenous immunoglobulin|Drug: Methotrexate|Drug: Rituximab|Drug: Leflunomide,National Institute of Allergy and Infectious Diseases (NIAID),Both,18 Years to 60 Years   (Adult),Phase 2,0,NIH,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,DAIT SCSLE-01,28-Sep-05,9/1/2005,null,1/31/2013,Jan-13,No Study Results Posted,null,null,"Mortality resulting from treatment, underlying disease, or unrelated causes",https://ClinicalTrials.gov/show/NCT00230035
136,NCT00301730,Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung,Completed,No Results Available,Breast Cancer|Metastatic Cancer,Biological: aldesleukin|Biological: therapeutic tumor infiltrating lymphocytes|Biological: trastuzumab|Drug: paclitaxel|Procedure: conventional surgery,National Cancer Institute (NCI),Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1,1,NIH,Interventional,Primary Purpose: Treatment,CDR0000455626|NCI-05-C-9980|NCI-SE-05-03,9-Mar-06,10/1/2005,null,4/27/2015,Apr-06,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00301730
160,NCT00547144,Phase I/II Intratumoral DC Immunotherapy With Gemcitabine & XRT in Unresectable Pancreatic Cancer,Completed,No Results Available,Pancreatic Cancer,Drug: Gemcitabine|Procedure: Dendritic Cell Immunotherapy,George Albert Fisher|Stanford University,Both,"18 Years and older   (Adult, Senior)",Phase 1,2,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PANC0003|95935|1454,18-Oct-07,10/1/2005,4/1/2008,11/6/2012,Aug-12,No Study Results Posted,null,Apr-08,o evaluate the immune response of patients treated with this regimen based on the presence and characterization of tumor-infiltrating white blood cells.|Phase II: To determine the overall response rate for this regimen as determined by radiographic criteria.|Phase I: To establish the maximally tolerated dose (MTD) and dose limiting toxicities (DLT) of intratumoral autologous dendritic cell vaccination in combination with gemcitabine and stereotactic radiosurgery|To determine the time to tumor progression for this regimen.,https://ClinicalTrials.gov/show/NCT00547144
448,NCT00250861,Trial of Outpatient Immunotherapy With Rituximab and Aldesleukin (IL-2) vs. Rituximab Alone for Non-Hodgkin's Lymphoma,Terminated,No Results Available,Non-Hodgkin's Lymphoma,Drug: Rituximab|Drug: Aldesleukin,US Oncology Research|Chiron Corporation|Fred Hutchinson Cancer Research Center,Both,"18 Years and older   (Adult, Senior)",Phase 2,110,Industry|Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,US-I-IL2-04-029,7-Nov-05,10/1/2005,8/1/2007,4/17/2008,Apr-08,No Study Results Posted,null,Aug-07,,https://ClinicalTrials.gov/show/NCT00250861
1204,NCT00799799,Adoptive Immunotherapy of High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-mismatched Natural Killer Cells,Recruiting,No Results Available,Myeloblastic Leukemia,Biological: NK cells,University of Bologna,Both,"18 Years and older   (Adult, Senior)",Phase 1,15,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NK TRIAL,28-Nov-08,10/1/2005,12/1/2009,9/23/2009,Sep-09,No Study Results Posted,null,Dec-09,"To assess the feasibility of the selection and reinfusion of 5x10E6 haploidentical natural killer (NK) cells /Kg of body weight (target cell dose) in at least 40% of adult patients with active acute myeloblastic leukemia (AML) entering the study|To assess the feasibility of the reinfusion of the minimum accepted cell dose (1x10E6 haploidentical NK cells /Kg) in all patients enrolled into the protocol|To evaluate the microchimerism of AML patients receiving haploidentical human NK cells for adoptive immunotherapy|To evaluate, in vitro and in vivo, the antitumor activity of haploidentical NK cells infused in AML patients|To assess the percentage of patients entering complete remission (CR) after the reinfusion of highly purified haploidentical NK cells|To assess the disease-free and overall survival of AML patients infused with haploidentical NK cells|To assess the safety of infusion of haploidentical NK cells, following immunosuppressive chemotherapy, considered as the incidence of adverse event (graded according to WHO) and clinically significant abnormal laboratory values following reinfusion",https://ClinicalTrials.gov/show/NCT00799799
22,NCT00278408,Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma,Completed,No Results Available,Lymphoma,Biological: filgrastim|Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate|Radiation: radiation therapy,German High-Grade Non-Hodgkin's Lymphoma Study Group,Both,18 Years to 60 Years   (Adult),Phase 3,700,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000459796|DSHNHL-2004-3|EUDRACT-2005-005218-19|EU-205111,16-Jan-06,11/1/2005,11/1/2015,1/20/2016,Nov-15,No Study Results Posted,null,Nov-15,"Time to treatment failure (TTF) measured from day 1 of course 1 of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) therapy up to 3 years on study with life-long follow-up|Complete response (CR) rate until first relapse|Progression rate during treatment|Survival|Tumor control measured from day 1 of course 1 of CHOP therapy (non-tumor related events are censored)|Disease-free survival measured from day 1 of course 1 of CHOP therapy|Relapse-free survival of patients with complete response (CR) or unconfirmed complete response (CRu) following complete immunochemotherapy|Safety (adverse events, serious adverse events) assessed at 3 months after completion of study treatment|Consolidating radiotherapy",https://ClinicalTrials.gov/show/NCT00278408
116,NCT00278421,Rituximab and Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma,Recruiting,No Results Available,Lymphoma,Biological: rituximab|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: prednisone|Drug: vincristine sulfate,German High-Grade Non-Hodgkin's Lymphoma Study Group,Both,18 Years to 60 Years   (Adult),Phase 3,592,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000459685|DSHNHL-2004-2|EU-205110|EUDRACT-2005-00521738|DSHNHL-FLYER-6664,16-Jan-06,11/1/2005,12/1/2017,5/3/2016,Nov-15,No Study Results Posted,null,Dec-16,"Time to treatment failure (TTF) measured from day 1 of course 1 of Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) therapy up to 3 years on study with life-long follow-up|Complete response (CR) rate duration until first relapse|Progression rate during treatment|Survival|Tumor control measured from day 1 of course 1 of CHOP therapy (non-tumor related events are censored)|Disease-free survival measured from day 1 of course 1 of CHOP therapy|Safety (adverse events, serious adverse events) assessed at 3 months after treatment",https://ClinicalTrials.gov/show/NCT00278421
888,NCT00751270,Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas,Completed,No Results Available,Malignant Glioma|Glioblastoma Multiforme|Anaplastic Astrocytoma,Biological: AdV-tk|Drug: Valacyclovir,"Advantagene, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1,15,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,BrTK01,9-Sep-08,11/1/2005,1/1/2011,3/2/2016,Mar-16,No Study Results Posted,BrTK01,Jan-10,Safety of the intervention will be evaluated based on laboratory and clinical parameters graded using CTCAEver3.|Tumor Response|Progression-free Survival|Overall Survival|Quality of Life (QOL),https://ClinicalTrials.gov/show/NCT00751270
894,NCT00254891,Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer,Terminated,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: PF-3512676 + Paclitaxel + Carboplatin|Drug: Paclitaxel + Carboplatin,Pfizer,Both,"18 Years and older   (Adult, Senior)",Phase 3,828,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,A8501001,15-Nov-05,11/1/2005,7/1/2008,3/10/2015,Mar-15,No Study Results Posted,null,Jul-08,Overall Survival|Overall Objective Response|Time to Tumor Progression|Progression Free Survival|Duration of Response|Patient Reported Outcomes|Overall Safety Profile,https://ClinicalTrials.gov/show/NCT00254891
998,NCT00254904,Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC,Terminated,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: Cisplatin|Drug: Gemcitabine|Drug: PF-3512676|Drug: Cisplatin|Drug: Gemcitabine + Cisplatin,Pfizer,Both,"18 Years and older   (Adult, Senior)",Phase 3,839,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,A8501002,15-Nov-05,11/1/2005,6/1/2008,3/10/2015,Mar-15,No Study Results Posted,null,Jun-08,Overall Survival|Patient Reported Outcomes|Overall Safety Profile|Progression Free Survival|Time to Tumor Progression|Overall Objective Response|Duration of Response,https://ClinicalTrials.gov/show/NCT00254904
1051,NCT00257738,MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck,Recruiting,No Results Available,Squamous Cell Carcinoma of the Head and Neck,Biological: MAGE-A3|Biological: HPV-16 vaccine,University of Maryland|National Institute of Dental and Craniofacial Research (NIDCR),Both,"18 Years to 80 Years   (Adult, Senior)",Phase 1,90,Other|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,HP-00041372|R01DE015324,21-Nov-05,11/1/2005,12/1/2011,12/10/2009,Dec-09,No Study Results Posted,null,Dec-11,Toxicity: Maximum grade of each toxicity and percentage of patients experiencing toxicity.,https://ClinicalTrials.gov/show/NCT00257738
46,NCT00257530,Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis,Completed,No Results Available,Cutaneous Leishmaniasis,Drug: Imiquimod,Drugs for Neglected Diseases,Both,"5 Years to 65 Years   (Child, Adult)",Phase 3,80,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment,DNDi-IMQ-05,22-Nov-05,12/1/2005,6/1/2006,6/11/2008,Jun-08,No Study Results Posted,null,Jun-06,Time to healing|Reduction of scaring|Safety (measured by AE reporting) during treatment and follow up to 12 months,https://ClinicalTrials.gov/show/NCT00257530
238,NCT00278018,Peritumoral Injection of Immature Dendritic Cells to Irradiated Skin Metastases of Solid Tumors,Terminated,No Results Available,Cancer of Skin|Solid Tumors,Procedure: Immunotherapy treatment for solid tumors,Hadassah Medical Organization,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,20,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,immatureDC- HMO-CTIL,16-Jan-06,12/1/2005,12/1/2008,4/19/2015,Apr-07,No Study Results Posted,null,Dec-08,Complete evaluation of untreated lesions with physical examination and appropriate X-rays and/or scans will be performed four to six weeks after the last DC injection.|Immunological evaluation will be performed two weeks after the last DC injection.,https://ClinicalTrials.gov/show/NCT00278018
438,NCT00415818,Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer,Completed,No Results Available,"Carcinoma, Non-Small-Cell Lung",Biological: MVA-MUC1-IL2|Drug: 1st line Chemotherapy,Transgene,Both,"18 Years and older   (Adult, Senior)",Phase 2|Phase 3,148,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,TG4010.09,22-Dec-06,12/1/2005,3/1/2010,7/15/2014,Jul-14,No Study Results Posted,null,Mar-10,Progression free survival at 6 months|Response Rate according to WHO criteria|Time to progression|Overall survival|Quality of life,https://ClinicalTrials.gov/show/NCT00415818
731,NCT00987987,Amplifying Graft-Versus-Tumor Effect by Donor Regulatory T-Cell Depletion Before Donor Lymphocytes Infusion,Completed,No Results Available,Hematologic Neoplasms|Relapse,Procedure: donor lymphocyte infusion,Assistance Publique - Hôpitaux de Paris|Université Paris XII|Pierre and Marie Curie University,Both,"18 Years to 70 Years   (Adult, Senior)",Phase 1|Phase 2,21,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,P040441,30-Sep-09,12/1/2005,12/1/2009,1/21/2011,Sep-09,No Study Results Posted,ILD-Treg,Dec-09,"Incidence of ""severe"" GHVD (grade >II) following dDLI should be inferior to 40%.|The incidence of GVHD of any grade after dDLI|The anti-tumoral efficiency of dDLI to treat the relapse of the hematological malignancy|The survival and the survival without disease after dDLI",https://ClinicalTrials.gov/show/NCT00987987
1001,NCT00313768,Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC,Terminated,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: paclitaxel + carboplatin + bevacizumab|Drug: carboplatin + paclitaxel + bevacizumab + PF-3512676,Pfizer,Both,"18 Years and older   (Adult, Senior)",Phase 2,23,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,A8501003,10-Apr-06,12/1/2005,5/1/2008,9/24/2009,Sep-09,No Study Results Posted,null,May-08,Progression-free survival|Time to Tumor Progression|Overall Objective Response Rate|Duration of Response|Overall Survival|Overall safety profile,https://ClinicalTrials.gov/show/NCT00313768
1005,NCT00279058,The Role of Peptide-loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2,Completed,No Results Available,Metastatic Melanoma,Procedure: Immunotherapy treatment for melanoma,Hadassah Medical Organization,Both,18 Years to 65 Years   (Adult),Phase 1|Phase 2,24,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,pepDCIL2- HMO-CTIL,17-Jan-06,12/1/2005,12/1/2008,4/19/2015,Apr-07,No Study Results Posted,null,Dec-08,Complete evaluation of untreated lesions with physical examination and appropriate X-rays and/or scans will be performed four to six weeks after the last DC injection.|Immunological evaluation will be performed two weeks after the last DC injection.,https://ClinicalTrials.gov/show/NCT00279058
1225,NCT00271050,External Beam Radiotherapy and Zevalin for Management of Indolent B-Cell Non-Hodgkin's Lymphoma,Completed,No Results Available,"Lymphoma, B-Cell",Other: external beam radiotherapy plus 90-Y ibritumomab tiuxetan,The Cleveland Clinic,Both,"18 Years and older   (Adult, Senior)",Phase 1,12,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IRB 7883|CCF IRB 7883|Case 1405,28-Dec-05,12/1/2005,6/1/2010,12/20/2010,Dec-10,No Study Results Posted,null,Dec-07,PET and CT (w/oral and IV contrast),https://ClinicalTrials.gov/show/NCT00271050
66,NCT00280982,Dendritic Cell-based Immunotherapy in Mesothelioma,Completed,No Results Available,Malignant Pleural Mesothelioma,Biological: tumor lysate-loaded autologous dendritic cells,Erasmus Medical Center,Both,"18 Years and older   (Adult, Senior)",Phase 1,10,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MEC-2005-269|PMR-MM05-001,20-Jan-06,1/1/2006,9/1/2009,11/15/2010,Nov-10,No Study Results Posted,null,Sep-09,safety|tolerability,https://ClinicalTrials.gov/show/NCT00280982
163,NCT00588913,"Adoptive Immunotherapy, Aldesleukin, and Zoledronate in Treating Patients With Stage IV Kidney Cancer and Lung Metastases",Completed,No Results Available,Kidney Cancer|Metastatic Cancer,Biological: aldesleukin|Biological: therapeutic autologous lymphocytes|Drug: zoledronic acid,Tokyo Women's Medical University|National Cancer Institute (NCI),Both,"20 Years to 80 Years   (Adult, Senior)",Phase 1|Phase 2,20,Other,Interventional,Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment,TRIC-CTR-GU-05-01|CDR0000581156,20-Dec-07,1/1/2006,8/1/2009,7/9/2013,Aug-09,No Study Results Posted,null,Mar-09,Frequency and severity of adverse events based on NCI-CTCAE version 3.0|Proportion of gd T-cells in peripheral blood|Secondary doubling time of tumor growth|Overall response,https://ClinicalTrials.gov/show/NCT00588913
594,NCT00298298,DNP-Modified Autologous Tumor Cell Vaccine for Resectable Non-Small Cell Lung Cancer,Terminated,No Results Available,Non-Small Cell Lung Cancer - Completely Resectable,"Biological: L-Vax: Autologous, DNP-Modified NSCLC Vaccine",AVAX Technologies,Both,"Child, Adult, Senior",Phase 1|Phase 2,6,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A/100/0601,28-Feb-06,1/1/2006,1/1/2014,12/2/2015,Dec-15,No Study Results Posted,null,Jan-14,Cell-mediated immunity to autologous tumor cells.|Safety,https://ClinicalTrials.gov/show/NCT00298298
652,NCT00639639,Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,"Active, not recruiting",No Results Available,Malignant Neoplasms of Brain,Biological: tetanus toxoid|Biological: therapeutic autologous dendritic cells|Biological: therapeutic autologous lymphocytes,John Sampson|Duke University,Both,"18 Years and older   (Adult, Senior)",Phase 1,16,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,Pro00003877|CDR0000589624|DUMC-8108-07-1R1|Discretionary Funds,19-Mar-08,1/1/2006,12/1/2018,7/26/2016,Jul-16,No Study Results Posted,ATTAC,Jun-18,Feasibility and safety of vaccination with cytomegalovirus pp65-LAMP mRNA-loaded dendritic cells (DCs) with or without autologous lymphocyte transfer|Humoral and cellular immune responses|Time to progression|Differential ability of indium In-111-labeled DCs to track to the inguinal lymph nodes under different skin preparative conditions|Differential ability of indium In-111-labeled DCs to track to lymph nodes on the tumor bearing and non-tumor bearing side of the cervical lymph nodes|Immunologic cell infiltrate in recurrent tumors|Evidence of antigen-escape outgrowth in recurrent or progressive tumors,https://ClinicalTrials.gov/show/NCT00639639
700,NCT00323882,Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer,Completed,Has Results,Prostate Cancer|Neoplasm Metastasis,Drug: MDX-010,Bristol-Myers Squibb,Male,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,75,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CA184-017 ST|CA184-017,8-May-06,1/1/2006,7/1/2013,8/14/2014,Aug-14,23-Jul-14,null,Sep-09,"Number of Participants With Serious AEs (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Immune-related AEs - Treated Participants|Number of Participants With Best PSA Response at Day 85 by Category - PSA Evaluable Participants|Number of Participants With Best Overall PSA Response by Category - PSA Evaluable Participants|Number of Participants With Best Overall Tumor Response by Category - Tumor Evaluable Participants|Time to PSA Response at Day 85 in Participants With Complete Response (CR) or Confirmed Partial Response (PR) at Day 85|Overall Tumor Response Rate in 10 mg/kg Ipilimumab Monotherapy and Ipilimumab/XRT Combination Therapy|PSA Response Rate at Day 85 and Overall PSA Response Rate in 10 mg/kg Monotherapy and Combination Therapy|Number of Participants Who Died by Date of Primary Analysis and by Date of Completion of Follow Up - All Treated Participants|Overall Survival at Completion of Follow Up Period - Treated Participants|Number of Participants With On-Study Hematology Laboratory Tests Worst Common Terminology Criteria (CTC) Grade - Treated Participants|Number of Participants With On-Study Serum Chemistry Laboratory Tests Worst Common Terminology Criteria (CTC) Grade - Treated Participants|Number of Participants With Clinically Significant Electrocardiogram (ECG) Abnormalities at Baseline and During Treatment Period - Treated Participants|Number of Participants Positive for Human Anti-Human Antibodies (HAHA) - Treated Participants",https://ClinicalTrials.gov/show/NCT00323882
846,NCT00272649,Study Testing the Biologic Activity and Safety of an Immunotherapeutic in Patients With Newly Diagnosed Stage IV Kidney Cancer,Completed,No Results Available,Renal Cell Carcinoma,Biological: AGS-003,Argos Therapeutics,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,22,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AGS-003-004|Bukowski-8077|Logan-0506-05|Drabkin-05-0167|White-04-05-01A|Figlin-05-03-099-01,6-Jan-06,1/1/2006,2/1/2012,3/6/2013,Mar-13,No Study Results Posted,null,Feb-12,"1. Measure tumor response by RECIST as CR, PR, SD, PD. 2. Measure T-cell responses to vaccination using induction vaccination regimens.|Assess safety of multiple administrations of the Immunotherapeutic in subjects with newly diagnosed, metastatic Renal Cell Cancer Assess Overall Survival and Time to progression",https://ClinicalTrials.gov/show/NCT00272649
924,NCT00854399,Screening and Identification of Ovarian Cancers,Recruiting,No Results Available,Ovarian Cancer,Procedure: Staging surgery or debulking surgery,National Taiwan University Hospital,Female,"15 Years to 80 Years   (Child, Adult, Senior)",,250,Other,Interventional,Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Basic Science,200706002R,1-Apr-08,1/1/2006,12/1/2011,3/2/2009,Mar-09,No Study Results Posted,null,Jan-06,overall survival,https://ClinicalTrials.gov/show/NCT00854399
925,NCT00674349,Screening of Biomarkers on Endometrial Cancers,Recruiting,No Results Available,Endometrial Cancers,Procedure: surgery,National Taiwan University Hospital,Female,"15 Years to 80 Years   (Child, Adult, Senior)",,250,Other,Interventional,Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Basic Science,200706001R,4-May-08,1/1/2006,12/1/2011,7/21/2008,Jan-06,No Study Results Posted,null,Jan-07,overall survival,https://ClinicalTrials.gov/show/NCT00674349
1075,NCT00287131,Adoptive Cell Therapy Following Non-myeloablate Chemotherapy in Metastatic Melanoma Patients,Recruiting,No Results Available,Metastatic Melanoma,Procedure: Procedure - Adoptive cell transfer,Sheba Medical Center,Both,"18 Years and older   (Adult, Senior)",Phase 2,70,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SHEBA-04-3518-JS-CTIL,2-Feb-06,1/1/2006,11/1/2013,3/28/2012,Mar-12,No Study Results Posted,null,Dec-12,Response rate and toxicity,https://ClinicalTrials.gov/show/NCT00287131
36,NCT00842114,Rituximab and CVP Plus Interferon for Follicular Non Hodgkins Lymphoma (NHL),Completed,No Results Available,Non-Hodgkin's Lymphoma,Biological: R+CVP+IFN,"Fundación Leucemia y Linfoma, Spain|Roche Pharma AG",Both,"18 Years to 75 Years   (Adult, Senior)",Phase 2,50,Other|Industry,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,LNH-Pro-05|EudraCT Number:2005-004761-42,10-Feb-09,2/1/2006,3/1/2016,3/31/2016,Mar-16,No Study Results Posted,LNH-Pro-05,Mar-16,Progression-free survival (PFS) with the CVP + IFNalfa + Rituximab treatment|Overall response (ORR) and complete response (CR) rates. Overall Survival MRD by RT-PCR assay Toxicity,https://ClinicalTrials.gov/show/NCT00842114
751,NCT00348842,Newcastle Disease Virus (NDV) for Cancer Patients Resistant to Conventional Anti-cancer Modalities,Withdrawn,No Results Available,Metastatic Cancer|Newcastle Disease Virus (NDV),Procedure: Newcastle Virus,Hadassah Medical Organization,Both,"Child, Adult, Senior",Phase 2,null,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,397231205-HMO-CTIL,4-Jul-06,3/1/2006,6/1/2006,4/7/2011,Feb-06,No Study Results Posted,null,null,Safety and primary efficacy of NDV treatment in cancer patients who failed conventional modalities.,https://ClinicalTrials.gov/show/NCT00348842
821,NCT00453050,Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melanoma That Has Spread to Other Parts of the Skin,Completed,No Results Available,Melanoma (Skin)|Metastatic Cancer,Drug: imiquimod|Drug: indocyanine green solution|Other: flow cytometry|Other: immunologic technique|Other: laboratory biomarker analysis,University of Oklahoma|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,11,Other,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000536471|OU-12576|OU-ISPI,27-Mar-07,3/1/2006,null,5/5/2015,Nov-08,No Study Results Posted,null,Mar-09,Toxicity and tolerability by CTCAE version 3.0|Complete systemic and local response rates at 16 months|Immunologic parameters,https://ClinicalTrials.gov/show/NCT00453050
914,NCT00299962,Gene Therapy for Pleural Malignancies,"Active, not recruiting",No Results Available,Pleural Mesothelioma|Metastatic Pleural Effusions,Biological: Adenoviral-mediated Interferon-beta|Biological: SCH 721015,University of Pennsylvania|National Cancer Institute (NCI)|Biogen,Both,"18 Years and older   (Adult, Senior)",Phase 1,18,Other|NIH|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,803776|P01CA066726,3-Mar-06,3/1/2006,4/1/2023,12/22/2015,Dec-15,No Study Results Posted,null,Apr-23,"To determine toxicity of two doses of intrapleural BG00001 (Ad.hIFN-β over 8 days, and|To assess systemic and intrapleural cytokine responses as well as cellular and humoral immune responses after repeated BG00001 instillation,|and to assess, in a preliminary way, efficacy via tumor regression, time to progression and survival.",https://ClinicalTrials.gov/show/NCT00299962
255,NCT00316901,Positron Emission Tomography and CT Scan in Predicting Response in Patients With Metastatic Melanoma or Kidney Cancer Who Are Undergoing Cellular Adoptive Immunotherapy on a Surgery Branch Clinical Trial,Completed,No Results Available,Kidney Cancer|Melanoma (Skin),Procedure: computed tomography|Procedure: positron emission tomography|Radiation: fludeoxyglucose F 18,National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 2,70,NIH,Interventional,Primary Purpose: Diagnostic,060099|06-C-0099|NCI-P6831|CDR0000470868,19-Apr-06,4/1/2006,12/1/2007,3/14/2012,Mar-12,No Study Results Posted,null,Dec-07,Metabolic activity at visceral sites|Metabolic activity at metastatic sites|Differences in metabolic activity at visceral and metastatic sites in patients treated with intravenous and intraarterial cell infusions|Response of individual metastases in comparison with metabolic alterations,https://ClinicalTrials.gov/show/NCT00316901
459,NCT00616291,"Vaccine Therapy in Treating Patients With Metastatic, Progressive Prostate Cancer",Completed,No Results Available,Prostate Cancer,Biological: NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine,Baylor College of Medicine|National Cancer Institute (NCI),Male,"18 Years and older   (Adult, Senior)",Phase 1,14,Other|NIH,Interventional,Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000579579|P50CA058204|BCM-H-17274|BCM-SPORE-11-01-30-14,14-Feb-08,4/1/2006,7/1/2011,11/5/2012,Nov-12,No Study Results Posted,null,Jul-11,Tolerability|Toxicity|Immunological response,https://ClinicalTrials.gov/show/NCT00616291
994,NCT00321555,LMB-2 to Treat Hairy Cell Leukemia,Recruiting,No Results Available,Hairy Cell Leukemia,Drug: Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 100 Years   (Adult, Senior)",Phase 2,27,NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,060150|06-C-0150,3-May-06,4/1/2006,3/1/2019,6/30/2016,Jun-16,No Study Results Posted,null,Mar-18,Response rate|Duration of Response,https://ClinicalTrials.gov/show/NCT00321555
1044,NCT00378326,Immunotherapy of the Paraneoplastic Syndromes,Completed,Has Results,Paraneoplastic Syndromes,Drug: Tacrolimus,Rockefeller University,Both,"14 Years and older   (Child, Adult, Senior)",,26,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,RDA-0572,18-Sep-06,4/1/2006,5/1/2014,1/26/2016,Jan-16,2-Nov-15,null,May-14,Survival of Patients With Paraneoplastic Disease Who Are Treated With Tacrolimus|Cerebrospinal Fluid (CSF) Pleocytosis,https://ClinicalTrials.gov/show/NCT00378326
1066,NCT00660166,Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions,Completed,No Results Available,Lymphoma|Myeloma|Leukemia,Biological: NK-Cell Infusion,Tufts Medical Center|University of Minnesota - Clinical and Translational Science Institute,Both,"13 Years to 70 Years   (Child, Adult, Senior)",Phase 1,13,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,Allogeneic NKCell post ABMT,11-Apr-08,4/1/2006,6/1/2012,6/25/2012,Jun-12,No Study Results Posted,null,Jun-12,"An evaluation of general safety will be undertaken: · Number of systemic clinical and biological adverse events occurring during the study. · Number of patients who prematurely discontinued study treatment for reasons linked to the general safety.|Duration of donor NK cells in the recipient's blood|Patient survival at 100 days and at one year post treatment (all cause mortality)|Occurrence of new cancer during the first year post infusion of allogeneic NK-cells|Documented systemic infections during the first 30 days post infusion of allogeneic NK-cells.|Occurrence of other possible NK-infusions related complications such as,fever, capillary leak syndrome and/or allergic reaction.",https://ClinicalTrials.gov/show/NCT00660166
712,NCT00365872,External Beam Radiation With Intratumoral Injection of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma,Completed,Has Results,Soft Tissue Sarcoma,Biological: Dendritic Cell (DC) Injections|Procedure: Radiation therapy|Procedure: Complete Resection - Surgery for tumor removal,H. Lee Moffitt Cancer Center and Research Institute|Cancer Treatment Research Foundation,Both,"18 Years and older   (Adult, Senior)",Phase 2,17,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MCC-14497,17-Aug-06,5/1/2006,6/1/2012,2/10/2014,Jun-13,25-Jun-13,null,Jun-12,Overall Response Rate (ORR)|Occurrence of Significant (>/= Grade 2) Toxicity|Occurrence of Postoperative Wound Complications|Participants With No Evidence of Disease at Follow-up,https://ClinicalTrials.gov/show/NCT00365872
863,NCT00323115,Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme,Completed,Has Results,Glioblastoma Multiforme,Biological: Autologous Dendritic Cell|Drug: Temozolomide|Procedure: Radiotherapy|Biological: Dendritic Cell Vaccine,Dartmouth-Hitchcock Medical Center,Both,"18 Years and older   (Adult, Senior)",Phase 2,11,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,D0536,4-May-06,5/1/2006,7/1/2013,10/8/2015,Jun-14,24-Aug-12,null,Apr-08,Tumor-specific Cytotoxic T-cell Response|Feasibility and Toxicity Profile of Intra-nodal DC/Tumor Lysate Vaccination|Progression Free Survival (PFS)and Overall Survival (OS) Comparison to Prognostic Matched Historical Controls|Immunological Parameters With PFS vs Overall Survival|Radiological Response When There is Residual Enhancing Tumor at Baseline MRI,https://ClinicalTrials.gov/show/NCT00323115
1049,NCT00477035,Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies,Completed,No Results Available,Leukemia|Multiple Myeloma,Drug: CIK cells|Drug: busulfan|Drug: etoposide|Drug: bcnu|Drug: cyclophosphamide|Drug: gemcitabine|Drug: vinorelbine|Drug: melphalan,Stanford University,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1|Phase 2,22,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention,BMT173|95889,18-May-07,5/1/2006,3/1/2011,5/19/2011,May-11,No Study Results Posted,null,Mar-11,To document the toxicities of infusion of autologous CIK cells|Measure freedom from progression (FFP)|Measure event free survival|Measure overall survival|Measure disease response,https://ClinicalTrials.gov/show/NCT00477035
111,NCT00361413,Alefacept for Prevention of Graft Versus Host Disease (GVHD),Terminated,No Results Available,Graft Versus Host Disease,Drug: Alefacept (AMEVIVE®)|Drug: control group,Hadassah Medical Organization,Both,"14 Years to 75 Years   (Child, Adult, Senior)",Phase 3,26,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver)|Primary Purpose: Prevention",MYS-01-HMO-CTIL,31-Jul-06,6/1/2006,12/1/2013,4/19/2015,Dec-10,No Study Results Posted,null,Jul-13,Acute GVHD occurrence.|Acute GVHD grading.|Time to acute GVHD.|Chronic GVHD occurrence.|Chronic GVHD grading.|Engraftment/graft rejection.|Overall survival.|Disease free survival.|Infections.|Transplant-related mortality (TRM).|Immune reconstitution|Toxicity assessment according to the Common Terminology Criteria for Adverse Events (CTCAE),https://ClinicalTrials.gov/show/NCT00361413
239,NCT00405327,A Pilot Study of Tumor Cell Vaccine for High-risk Solid Tumor Patients Following Stem Cell Transplantation,"Active, not recruiting",No Results Available,Sarcoma|Neuroblastoma|Wilm's Tumor,Biological: Tumor lysate-pulsed dendritic cell (DC) vaccine|Other: Hematopoietic stem cell transplantation (HSCT),University of Michigan Cancer Center,Both,"up to 30 Years   (Child, Adult)",Phase 2,16,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,UMCC 2005.050|GCRC ID # 2191|HUM00002650,29-Nov-06,6/1/2006,9/1/2016,3/8/2016,Mar-16,No Study Results Posted,null,Jun-09,To estimate the rate of immune response of this immunotherapy treatment|To correlate and characterize the immune response to the clinical response.|To define immunologic endpoints that can serve as surrogates of clinical response.,https://ClinicalTrials.gov/show/NCT00405327
650,NCT00310037,"Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma","Active, not recruiting",No Results Available,Mantle Cell Lymphoma,Drug: bortezomib,"Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Millennium Pharmaceuticals, Inc.",Both,"18 Years to 69 Years   (Adult, Senior)",Phase 2,151,Other|NIH|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CALGB-50403|CDR0000466167,29-Mar-06,6/1/2006,null,6/17/2016,Jun-16,No Study Results Posted,null,Dec-13,"Progression-free survival|Overall survival|Complete response rate to intensive chemo-immunotherapy plus maintenance or consolidation bortezomib|Incidence of toxicity, graded according to Common Terminology Criteria for Adverse Events version 4.0",https://ClinicalTrials.gov/show/NCT00310037
778,NCT00345293,Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer,Completed,Has Results,Prostate Cancer,Biological: autologous dendritic cell vaccine (DC/PC3),Rockefeller University|Memorial Sloan Kettering Cancer Center,Male,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,13,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,RDA-0537,26-Jun-06,6/1/2006,3/1/2015,4/1/2016,Apr-16,24-Jun-15,null,Dec-13,Toxicity|Immunogenicity|Clinical Response,https://ClinicalTrials.gov/show/NCT00345293
1137,NCT00779883,A Phase I Trial of Autologous CLL B Cells Transduced to Express Chimeric CD154 (ISF35),Completed,No Results Available,Chronic Lymphocytic Leukemia,Biological: ISF35,"Memgen, LLC",Both,"18 Years and older   (Adult, Senior)",Phase 1,9,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CLL-35-101,23-Oct-08,6/1/2006,3/1/2008,10/23/2008,Oct-08,No Study Results Posted,null,Mar-08,"Assess the toxicity, tolerability, and safety of 1x10^8, 3x10^8, and 1x10^9 autologous Ad-ISF35-transduced CLL B cells given as a single intravenous infusion in patients with CLL.|Assess the anti-leukemia activity of a single intravenous dose by evaluating reduction in leukemia count, reduction in adenopathy and splenomegaly, and improvement in bone function.|Assess the quality of life with ISF35 treatment.|Assess pharmacodynamic endpoints including induction of T cell anti-leukemia immune responses, antibody production against autologous CLL B cells, and changes in bystander leukemia cell phenotype.",https://ClinicalTrials.gov/show/NCT00779883
1267,NCT00347971,Study of Recombinant Interleukin 21 in Combination With Rituxan for Non-Hodgkin's Lymphoma,Completed,No Results Available,"Lymphoma, Non-Hodgkin",Drug: recombinant human interleukin 21 and rituximab,ZymoGenetics,Both,"18 Years and older   (Adult, Senior)",Phase 1,23,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,4.94E+05,30-Jun-06,6/1/2006,4/1/2008,9/4/2008,Sep-08,No Study Results Posted,null,Apr-08,Incidence and severity of adverse events through 1 month after completing treatment|Incidence and grade of clinical laboratory abnormalities through 1 month after treatment|Disease response by the International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas 2 weeks after completion of the first treatment cycle|Immunogenicity by incidence of anti-rIL-21 antibodies up to 1 month after treatment,https://ClinicalTrials.gov/show/NCT00347971
43,NCT01130194,"Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma",Completed,No Results Available,Follicular Lymphoma,Other: Combination of treatment modalities,St. Louis University,Both,"18 Years to 80 Years   (Adult, Senior)",Phase 2,29,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IRB #14228,24-May-10,7/1/2006,6/1/2012,5/9/2014,May-14,No Study Results Posted,MasterPlan,Jun-12,Disease-free survival percentage(intention to treat)|Incidence of second malignancies,https://ClinicalTrials.gov/show/NCT01130194
269,NCT00367250,Safety Study of Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer,Recruiting,No Results Available,Metastatic Breast Cancer,Drug: Cetuximab|Drug: Trastuzumab,Medical University of Vienna,Female,"18 Years and older   (Adult, Senior)",Phase 1,32,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CETRA 01,21-Aug-06,7/1/2006,6/1/2011,9/27/2010,Sep-10,No Study Results Posted,null,Jun-11,Pharmacokinetics and drug/drug interaction of cetuximab and|Safety and tolerability of the combination treatment|Response,https://ClinicalTrials.gov/show/NCT00367250
496,NCT00351858,Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer,Terminated,No Results Available,Breast Neoplasms|Breast Cancer,Drug: ertumaxomab,Neovii Biotech,Female,"18 Years and older   (Adult, Senior)",Phase 2,40,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,FBT-IVREXBC 02|EudraT number: 2005-004294-21,12-Jul-06,7/1/2006,2/1/2009,4/30/2015,Apr-15,No Study Results Posted,IV REXBC 02,null,"To demonstrate clinical efficacy of the investigational trifunctional antibody ertumaxomab for the treatment of hormone therapy refractory advanced or metastatic breast cancer tumors (stage IIIb or IV) which are known to express Her-2/neu (1+ or 2+)|Time to progression|Duration of response|Time to response|Clinical benefit of ertumaxomab (defined as the rate of confirmed complete remission, partial remission and stable disease)|Tumor marker levels (CA 15-3 and CEA)",https://ClinicalTrials.gov/show/NCT00351858
510,NCT00507702,Identification of Key Blood Molecular Markers for Immunotherapy,Suspended,No Results Available,Squamous Cell Carcinoma|Adenocarcinoma|Neoplasms,Procedure: phlebotomy,Stanford University,Both,"18 Years and older   (Adult, Senior)",,300,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,VAR0017|97125,24-Jul-07,7/1/2006,7/1/2012,7/5/2012,Jul-12,No Study Results Posted,null,Jul-12,"To identify and evaluate the presence of pre-existing immunity related markers in peripheral human blood, to identify patients who may respond to IL-12 immunotherapy",https://ClinicalTrials.gov/show/NCT00507702
683,NCT01171729,Autologous Dendritic Cell Therapy for Hormone-Refractory Metastatic Prostate Cancer,Completed,No Results Available,Prostatic Cancer,Biological: Autologous dendritic cell,"Samsung Medical Center|National Cancer Center, Korea",Male,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,12,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2006-10-030,27-Jul-10,7/1/2006,5/1/2010,8/10/2010,Jul-10,No Study Results Posted,null,May-10,"PSA increment and absolute PSA response|Time to Progression|Overall Survival|Immune Response(DTH response, Interferon-gamma Elispot assay, proliferation assay, ELISA)|Clinical response",https://ClinicalTrials.gov/show/NCT01171729
716,NCT00447473,Trial of GM-CSF Given in Combination With Ketoconazole and Mitoxantrone in Patients With Progressive Prostate Cancer,Terminated,No Results Available,Prostatic Neoplasms,Drug: GM-CSF|Drug: Ketoconazole|Drug: Mitoxantrone,The Methodist Hospital System|Bayer,Male,"18 Years and older   (Adult, Senior)",Phase 2,31,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,HMRI IRB#0106-0010|PC-Keto-Mito.2006,12-Mar-07,7/1/2006,9/1/2008,3/15/2016,Mar-16,No Study Results Posted,null,Aug-08,To evaluate the effect of the combination of ketoconazole and mitoxantrone plus GM-CSF on time to clinical progression in patients with prostate cancer that has progressed on prior therapy.|To evaluate the objective response frequency of the combination of ketoconazole and mitoxantrone plus GM-CSF.|To investigate the safety of ketoconazole and mitoxantrone given in combination with GM-CSF.,https://ClinicalTrials.gov/show/NCT00447473
1135,NCT01289678,Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia,Recruiting,No Results Available,Acute Myelogenous Leukemia,Drug: Interleukin-2,Leo W. Jenkins Cancer Center,Both,"18 Years and older   (Adult, Senior)",Phase 2,14,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,LJCC 06-05,2-Feb-11,7/1/2006,6/1/2020,10/20/2014,Oct-14,No Study Results Posted,null,Dec-17,Event-free survival|Patient response,https://ClinicalTrials.gov/show/NCT01289678
1193,NCT00419081,Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens,Terminated,No Results Available,Leukemia|Lymphoma,"Drug: Forodesine Hydrochloride Sterile Solution, 5 mg/mL|Drug: Forodesine Hydrochloride Capsules (100 mg)",BioCryst Pharmaceuticals,Both,"18 Years and older   (Adult, Senior)",Phase 2,100,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,BCX1777-Tio-05-202,5-Jan-07,7/1/2006,3/1/2007,1/18/2012,Jan-12,No Study Results Posted,null,Mar-07,To determine the rate of complete remission for T lymphoblastic leukemia/lymphoma relapsed or refractory patients. The complete remission rate will be evaluated over the three-month Initial Treatment Period.|To determine the rate of CR achieved based on prior HSCT status|Assess safety and tolerability|Assess survival end points|Evaluate the maintenance and duration of response|Evaluate the proportion of patients able to proceed to HSCT|Evaluate the effects of this forodesine regimen on plasma levels of dGuo|Determine the effects of this forodesine regimen on clinical end points|Explore potential predictive biomarkers,https://ClinicalTrials.gov/show/NCT00419081
284,NCT00460694,Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies,Completed,No Results Available,Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Chronic Myeloid Leukemia|Non Hodgkin's Lymphoma|Hodgkin's Disease|Myelodysplastic Syndrome|Multiple Myeloma,Biological: infusion of allogeneic CIK cells,"Singapore General Hospital|National Medical Research Council (NMRC), Singapore",Both,"12 Years to 60 Years   (Child, Adult)",Phase 1|Phase 2,24,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CIK#2/2007|NMRC/1097/2006,12-Apr-07,8/1/2006,12/1/2012,5/18/2015,May-15,No Study Results Posted,alloCIK,Dec-12,Feasibility of expansion of frozen donor mononuclear cells into CIK|Toxicity including GVHD and marrow aplasia|Efficacy in terms of disease response as compared to previous treatment modality ie unmanipulated DLI,https://ClinicalTrials.gov/show/NCT00460694
889,NCT00321815,Trial Of Erlotinib With Or Without PF-3512676 In Advanced Non Small Cell Lung Cancer,Completed,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: PF-3512676 + Erlotinib|Drug: Erlotinib,Pfizer,Both,"18 Years and older   (Adult, Senior)",Phase 2,43,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,A8501006,3-May-06,8/1/2006,6/1/2010,12/16/2010,Dec-10,No Study Results Posted,null,Jun-10,Progression-Free Survival|Overall Safety Profile|Time to Tumor Progression|Overall Objective Response Rate|Duration of Response|Overall Survival,https://ClinicalTrials.gov/show/NCT00321815
1147,NCT00365937,Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides,Terminated,No Results Available,Melanoma,Biological: Immunological peptides and immunological adjuvants|Biological: HLA-A2 peptides|Biological: Montanide ISA51|Biological: IMP321,Cliniques universitaires Saint-Luc- Université Catholique de Louvain|Immutep S.A.,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,19,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,LUC 05-003,17-Aug-06,8/1/2006,8/1/2009,10/14/2010,Oct-10,No Study Results Posted,null,null,Primary: Determination of the cytolytic T lymphocyte response in the different arms.; Toxicity of the combination peptide and immunological adjuvants|Secondary: Disease-free survival.,https://ClinicalTrials.gov/show/NCT00365937
231,NCT00383994,"Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation","Active, not recruiting",No Results Available,"Lymphoma|Leukemia|Transplantation, Stem Cell|Lymphoid Malignancies|Disorder Related to Transplantation",Drug: GM-CSF|Drug: Rituximab|Biological: NK Cell Infusion,"M.D. Anderson Cancer Center|Bayer Healthcare Pharmaceuticals, Inc./Bayer Schering Pharma",Both,"Child, Adult, Senior",Phase 1,40,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2005-0234|NCI-2012-01375,2-Oct-06,9/1/2006,null,3/2/2016,Mar-16,No Study Results Posted,null,Sep-17,Dose-limiting toxicities (DLTs) for NK cells infusions after non-myeloablative transplantation for lymphoid malignancies,https://ClinicalTrials.gov/show/NCT00383994
572,NCT00397345,TroVax Renal Immunotherapy Survival Trial,Completed,No Results Available,Clear Cell Renal Carcinoma,Biological: Trovax,Oxford BioMedica,Both,"18 Years and older   (Adult, Senior)",Phase 3,700,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",TV3/001/06,8-Nov-06,9/1/2006,12/1/2009,6/4/2010,Jun-10,No Study Results Posted,null,Dec-09,overall survival,https://ClinicalTrials.gov/show/NCT00397345
832,NCT00321308,Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer,Terminated,No Results Available,"Carcinoma, Non-Small Cell Lung",Drug: pemetrexed|Drug: pemetrexed + PF-3512676,Pfizer,Both,"18 Years and older   (Adult, Senior)",Phase 2,36,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,A8501004,2-May-06,9/1/2006,1/1/2008,9/24/2009,Sep-09,No Study Results Posted,null,Jan-08,Progression-free survival|Overall Survival|Overall Safety Profile|Patient Reported Outcome|Time to Tumor Progression|Overall Objective Response Rate|Duration of Response,https://ClinicalTrials.gov/show/NCT00321308
69,NCT00397332,Alefacept for Chronic Graft Versus Host Disease,Completed,No Results Available,Resistant Chronic GVHD,Drug: Alefacept,Hadassah Medical Organization,Both,"up to 70 Years   (Child, Adult, Senior)",Phase 1|Phase 2,20,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MYS-05-HMO-CTIL,8-Nov-06,10/1/2006,7/1/2013,4/19/2015,Feb-11,No Study Results Posted,null,Jan-13,GVHD response.|Time to GVHD response|Overall survival.|Disease free survival.|Occurrence of infections.,https://ClinicalTrials.gov/show/NCT00397332
97,NCT00395252,Safety and Efficacy Therapy of Gemcitabine and Erbitux® to R0 or R1 Resected Pancreatic Cancer,Completed,No Results Available,Adenocarcinoma,Drug: Cetuximab (Erbitux®) and Gemcitabine,Carmen Schade-Brittinger|Philipps University Marburg Medical Center,Both,"18 Years and older   (Adult, Senior)",Phase 2,76,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,EUDRACT-No. 2005-005168-94,1-Nov-06,10/1/2006,1/1/2012,10/1/2015,Oct-15,No Study Results Posted,ATIP,Nov-10,disease free survival|Overall survival|Quality of life|Incidence of Adverse Events,https://ClinicalTrials.gov/show/NCT00395252
174,NCT00601796,"Vaccine Therapy, Tretinoin, and Cyclophosphamide in Treating Patients With Metastatic Lung Cancer",Completed,Has Results,Lung Cancer,Biological: Vaccine Treatment|Drug: Cyclophosphamide|Drug: All-trans retinoic acid (ATRA),H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)|National Institutes of Health (NIH),Both,"18 Years and older   (Adult, Senior)",Phase 2,24,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MCC-14744|P30CA076292|NIH-OBA-0608-801,19-Jan-08,10/1/2006,6/1/2012,5/15/2013,Feb-13,27-Feb-13,null,Jun-12,Number of Evaluable Participants With Tumor Response|Median Time to Progression (TTP)|Median Overall Survival (OS)|Number of Participants With Serious Adverse Events (SAEs),https://ClinicalTrials.gov/show/NCT00601796
728,NCT00521287,"Impaired Immunity in Patients With Cancer: Influence of Cancer Stage, Chemotherapy, and Cytomegalovirus Infection",Recruiting,No Results Available,Neoplasms,Other: Immune profiling and DC vaccine,Mackay Memorial Hospital,Both,"20 Years and older   (Adult, Senior)",Phase 2,150,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment,MMH-I-S-321|MMH-I-S-401,24-Aug-07,10/1/2006,12/1/2009,2/29/2008,Aug-07,No Study Results Posted,null,Sep-07,Immune status|Tumor response,https://ClinicalTrials.gov/show/NCT00521287
895,NCT00503321,Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Advanced Gastric Carcinoma,Terminated,No Results Available,Gastric Cancer,"Drug: Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK)|Drug: Tegafur/gimeracil/oteracil potassium (S-1)","Eastern Network of Cancer Immunological Therapy, Japan",Both,"20 Years and older   (Adult, Senior)",Phase 2|Phase 3,13,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ENCITJ-GC01,16-Jul-07,10/1/2006,8/1/2011,1/22/2009,Jan-09,No Study Results Posted,eNCIT-Japan,Aug-09,"progression-free survival|Anticancer effect, time to treatment failure (TTF), QOL (FACT-BRM), compliance, adverse drug reactions and immunological factors",https://ClinicalTrials.gov/show/NCT00503321
986,NCT00440973,Safety Study of Specific Tumor Target Drug Plus Immune System Therapy in Patients With Kidney Cancer,Terminated,No Results Available,"Carcinoma, Renal Cell",Drug: Bevacizumab|Drug: Interleukin-2,"The Methodist Hospital System|Genentech, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 2,6,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PAC IRB #03-0194-05|16117,23-Feb-07,10/1/2006,11/1/2007,3/15/2016,Mar-16,No Study Results Posted,null,Oct-07,time to progression|Collect data on tumor responses produced by interleukin-2 and Bevacizumab|Evaluate safety and toxicity of the combination of interleukin-2 and Bevacizumab for patients with progressive metastatic renal cell carcinoma.,https://ClinicalTrials.gov/show/NCT00440973
1205,NCT00394381,Autologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic Syndrome,Completed,No Results Available,"Acute Myeloid Leukemia|Myelodysplastic Syndrome, High Grade",Procedure: Infusion of autologous CIK cells,"Singapore General Hospital|National Medical Research Council (NMRC), Singapore",Both,"12 Years to 75 Years   (Child, Adult, Senior)",Phase 1|Phase 2,17,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CIK#1/2006,31-Oct-06,10/1/2006,1/1/2012,5/14/2012,May-12,No Study Results Posted,null,Jan-12,blood count changes|T lymphocyte subsets|T cell functions|adverse reactions|relapse rate|survival,https://ClinicalTrials.gov/show/NCT00394381
1208,NCT00389285,Study of Recombinant Interleukin 21 in Combination With Sorafenib for Metastatic Renal Cell Carcinoma,Completed,No Results Available,"Carcinoma, Renal Cell",Drug: rIL-21 only|Drug: rIL-21 + sorafenib,ZymoGenetics,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,52,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,494F01,16-Oct-06,10/1/2006,5/1/2009,5/26/2009,May-09,No Study Results Posted,null,May-09,"Safety profile, including incidence and severity of adverse events|Objective response rate at recommended dose of rIL-21|Progression-free survival at recommended dose of rIL-21|Pharmacokinetic profiles of rIL-21 and sorafenib",https://ClinicalTrials.gov/show/NCT00389285
117,NCT01679860,Intensive Chemo-immunotherapy as First Line Treatment in Adult Patients With Peripheral T- Cell Lymphoma,Completed,No Results Available,"Lymphoma, T-Cell, Peripheral",Procedure: Clin A. CHOP-CAMPATH (Chemo-immunotherapy) + SCT|Drug: Clin B (CHOP- CAMPATH) Chemo-immunotherapy,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",Both,18 Years to 60 Years   (Adult),Phase 2,92,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PTCL-062006-004234-33,30-Aug-12,11/1/2006,8/1/2012,9/3/2012,Sep-12,No Study Results Posted,PTCL-06,Dec-11,Efficacy|evaluation of OS (overall survival)|DFS (Disease Free Survival)|TRM (Treatment Related Mortality),https://ClinicalTrials.gov/show/NCT01679860
369,NCT00509457,GV 1001 Immunotherapy in Patients With Non-small Cell Lung Cancer (NSCLC),Completed,No Results Available,"Carcinoma, Non-Small-Cell Lung",Biological: GV 1001 Telomerase peptide,Oslo University Hospital|St. Olavs Hospital|Sorlandet Hospital HF,Both,"18 Years and older   (Adult, Senior)",,20,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2006-002646 11|2006-50 DNR,20-Jul-07,11/1/2006,8/1/2009,6/30/2011,Sep-09,No Study Results Posted,null,null,"To examine if combined chemoradiotherapy in patients with NSCLC followed by vaccination( immunotherapy) will increase the immunological response compared to previous experience|Number of T cell responders and DTH responders, time to progression of disease",https://ClinicalTrials.gov/show/NCT00509457
796,NCT00402883,"Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer",Terminated,Has Results,Lung Cancer,Drug: Bevacizumab|Drug: Pemetrexed|Procedure: Radiotherapy|Other: Folic Acid|Other: vitamin B12|Drug: carboplatin,"SCRI Development Innovations, LLC|Genentech, Inc.|Eli Lilly and Company",Both,"18 Years and older   (Adult, Senior)",Phase 2,5,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SCRI LUN 134,21-Nov-06,11/1/2006,1/1/2009,11/27/2013,Nov-13,15-Aug-13,null,Jan-09,Time to Progression|To Evaluate the Objective Response Rates|Overall Survival,https://ClinicalTrials.gov/show/NCT00402883
194,NCT00418574,Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients,Terminated,Has Results,Ovarian Cancer,Biological: Abagovomab|Biological: Placebo,Menarini Group,Female,"18 Years and older   (Adult, Senior)",Phase 2|Phase 3,888,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",ABA-01|AGO-OVAR 10|2006-002801-30,4-Jan-07,12/1/2006,6/1/2011,11/17/2011,Nov-11,1-Jul-11,MIMOSA,Dec-10,Recurrence Free Survival Evaluated by Clinical Event Adjudication Committee (CEAC)|Overall Survival|Safety|Time Course of Immunoresponse,https://ClinicalTrials.gov/show/NCT00418574
206,NCT00045968,Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer,"Active, not recruiting",No Results Available,Glioblastoma Multiforme|Glioblastoma|GBM|Grade IV Astrocytoma|Glioma|Brain Cancer|Brain Tumor,Drug: Dendritic cell immunotherapy,Northwest Biotherapeutics,Both,"18 Years to 70 Years   (Adult, Senior)",Phase 3,348,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",20221,17-Sep-02,12/1/2006,null,2/25/2016,Feb-16,No Study Results Posted,GBM,Sep-16,The primary objective of this study is to compare progression free survival from time of randomization between patients treated with DCVax-L and control patients.|The secondary objective is to compare overall survival and time to disease progression between DCVax-L treated and control patients.,https://ClinicalTrials.gov/show/NCT00045968
684,NCT00499577,"Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma",Completed,No Results Available,Multiple Myeloma and Plasma Cell Neoplasm,Biological: CMV pp65 peptide|Biological: hTERT I540/R572Y/D988Y multipeptide vaccine|Biological: pneumococcal polyvalent vaccine|Biological: survivin Sur1M2 peptide vaccine,University of Maryland Greenebaum Cancer Center|National Cancer Institute (NCI),Both,"18 Years to 80 Years   (Adult, Senior)",Phase 1|Phase 2,56,Other|NIH,Interventional,Primary Purpose: Treatment,CDR0000552988|MSGCC-0610-GCC|UPCC-0610-GCC,10-Jul-07,12/1/2006,null,1/9/2014,Aug-09,No Study Results Posted,null,Feb-09,Toxicity at 21 and 28 days post-transplant|T-cell responses against the hTERT vaccine as measured by tetramer assays at 100 days post-transplant|Paraprotein levels in the blood or urine and serum free light chain analyses at 60 days and at 6 months post-transplant|Cytotoxic T-cell responses against autologous myeloma cell at day 100 post-transplant via chromium-51 release or flow-based assays|Maximum clinical response|1 and 2-year event-free survival|Overall survival rates|CD4 and CD8 T-cell responses against cytomegalovirus (CMV) at days 60 and 100 post-transplantation by CFSE dye dilution assays|Composite binding antibody responses at days 60 and day 100 post-transplant by ELISA,https://ClinicalTrials.gov/show/NCT00499577
729,NCT01032681,"EMD 521873 in Advanced Solid Tumors, MTD Finding",Completed,No Results Available,Non-Hodgkin Lymphoma,Biological: EMD 521873|Biological: EMD 521873|Biological: EMD 521873,Merck KGaA,Both,"18 Years and older   (Adult, Senior)",Phase 1,66,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,EMR62235_001,11-Dec-09,12/1/2006,1/1/2012,7/30/2014,Oct-12,No Study Results Posted,null,Feb-11,"Assess the safety and tolerability of EMD 521873|To determine whether the MTD is reached with EMD 521873 doses of up to 1.5 mg/kg given alone or in combination with fixed, low-dose CPA in patients with metastatic or locally advanced solid tumors or B-cell non-Hodgkin lymphoma|Characterize the PK profile of EMD 521873 alone or in combination with fixed lowdose CPA|Evaluate the immunogenicity of EMD 521873 alone or in combination with CPA measured by the induction of o Specific antibodies against the genetically modified IL-2 o Fc-IL2-specific antibodies o Anti-idiotype antibodies|Collect evidence of best overall response, changes in serum tumor marker levels and best clinical response after treatment with EMD 521873 alone or in combination with CPA|Evaluate survival|Evaluate biological responses to EMD 521873 alone or in combination with CPA as measured by o Absolute cell numbers and ratios of lymphocyte subsets in defined combinations o Change in serum level of sIL2R and neopterin",https://ClinicalTrials.gov/show/NCT01032681
844,NCT00438984,"Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma",Completed,No Results Available,Recurrent Melanoma|Stage IV Melanoma,Drug: cyclophosphamide|Biological: therapeutic autologous lymphocytes|Biological: aldesleukin|Other: immunohistochemistry staining method|Procedure: biopsy|Other: laboratory biomarker analysis|Other: immunologic technique|Genetic: polymerase chain reaction,Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium|National Cancer Institute (NCI)|Fred Hutchinson Cancer Research Center,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1,11,Other|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2140.00|NCI-2010-01280|R21CA128283,20-Feb-07,12/1/2006,2/1/2012,3/14/2012,Mar-12,No Study Results Posted,null,Jan-11,The identification of a CY/IL-2 regimen that is considered to be safe|The identification of a CY/IL-2 regimen (among those considered safe) which yields the greatest effect on the duration of in vivo persistence of adoptively transferred CTL clones,https://ClinicalTrials.gov/show/NCT00438984
1002,NCT00834665,Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma,"Active, not recruiting",No Results Available,Multiple Myeloma,Biological: Telomerase (hTERT vaccine + pneumococcal conjugate vaccine (PCV))|Biological: PCV vaccine,University of Pennsylvania|University of Maryland,Both,"18 Years to 80 Years   (Adult, Senior)",Phase 1|Phase 2,56,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,UPCC 13406 / GCC610,3-Jan-08,12/1/2006,12/1/2015,1/31/2013,Jan-13,No Study Results Posted,null,Dec-15,Does combination therapy delay hematopoietic recovery or induce other autoimmune events.|Does combination therapy generate cytotoxic T-cell responses to autologous myeloma cells in-vivo.,https://ClinicalTrials.gov/show/NCT00834665
1019,NCT00415857,Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R),Terminated,Has Results,Leukemia,Biological: Peptide Vaccine (PR1 Peptide)|Drug: Peginterferon alfa-2b|Drug: Imatinib|Drug: GM-CSF,M.D. Anderson Cancer Center|The Vaccine Company,Both,"18 Years and older   (Adult, Senior)",Phase 2,5,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,2006-0360,22-Dec-06,12/1/2006,9/1/2013,3/28/2014,Mar-14,28-Mar-14,null,Sep-13,Molecular Response Rate|Number of Participants With Immunologic Response,https://ClinicalTrials.gov/show/NCT00415857
554,NCT01445132,Adoptive Cell Therapy for B-Cell Cancers in Patients After Stem Cell Transplantation,Completed,No Results Available,Chronic Lymphocytic Leukemia,Drug: Allogeneic Cell Therapy w/ Tumor-derived Lypho,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1,11,NIH,Interventional,Primary Purpose: Treatment,070064|07-C-0064,30-Sep-11,1/1/2007,4/1/2013,10/23/2014,Apr-13,No Study Results Posted,null,Apr-13,To evaluate the feasibility of administering ex-vivo costimulated/expanded tumor-derived lymphocytes (TDL) in patients with persistent or recurrent B-cell lymphoid malignancies (BCL) following treatment with allogeneic hematopoietic stem cell tr...|To determine the safety of administering TDL in patients with persistent/recurrent BCL following alloHSCT.,https://ClinicalTrials.gov/show/NCT01445132
618,NCT00409188,Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START),Completed,Has Results,Non-small Cell Lung Cancer,Biological: Tecemotide (L-BLP25)|Drug: Single low dose cyclophosphamide|Drug: Placebo,EMD Serono|Merck KGaA,Both,"18 Years and older   (Adult, Senior)",Phase 3,1513,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EMR 63325-001,7-Dec-06,1/1/2007,4/1/2015,10/19/2015,Oct-15,23-Jul-15,START,Apr-12,"Overall Survival|Time To Symptom Progression (TTSP) as Measured by the Lung Cancer Symptom Scale (LCSS)|Time To Progression (TTP)|One-, Two- and Three-year Survival Rate|Number of Participants With Treatment Emergent Adverse Events and Injection Site Reactions",https://ClinicalTrials.gov/show/NCT00409188
764,NCT00439465,Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma,"Active, not recruiting",No Results Available,Myeloma|Transplant-eligible Patients,Biological: Autologous ex-vivo expanded effector cells,Dartmouth-Hitchcock Medical Center|The Leukemia and Lymphoma Society,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 2,20,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,D0717|LLS-6061-06,21-Feb-07,1/1/2007,12/1/2018,5/23/2016,May-16,No Study Results Posted,null,Feb-18,"To establish the safety (toxicity), time to engraftment and clinical outcomes of myeloma patients treated with high dose melphalan, APBSCT& adoptive transfer of cytotoxic effector cells with IL-2 and GM-CSF.|Identify CD8+ effector cell-versus-myeloma effects in vivo by determining recovery,function& mechanism of tumor cell killing of PB CD8+ cells prior to& after completing therapy.",https://ClinicalTrials.gov/show/NCT00439465
957,NCT00548847,"Immunotherapy for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia (BP CML), and Myelodysplastic Syndrome (MDS) Relapse After Allogeneic Transplantation","Active, not recruiting",No Results Available,Leukemia,"Drug: GM-CSF, Interferon-α-2b",Emory University|Bayer,Both,"1 Year and older   (Child, Adult, Senior)",Phase 2,15,Other|Industry,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IRB00002219|2219,22-Oct-07,1/1/2007,5/1/2016,8/13/2015,Aug-15,No Study Results Posted,null,May-16,"To assess the efficacy of GM-CSF and pegylated interferon-alpha 2b when administered to patients with AML, ALL, blast phase CML, and MDS relapse after allogeneic transplantation, defined as progression-free survival of > 33% at 3 months|To evaluate overall survival at 6 months; evaluate overall responses; perform lab experiments to test hypothesis that exposure to interferon-alpha and GM-CSF up-regulates co-stimulatory molecule expression on relapsed acute leukemia cells",https://ClinicalTrials.gov/show/NCT00548847
1088,NCT00421525,Phase I/II Study of hLL1 in Multiple Myeloma,Completed,No Results Available,"Multiple Myeloma|Myeloma, Plasma-Cell|PLASMACYTOMA",Biological: milatuzumab,"Immunomedics, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,25,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PROTOCOL: IMMU-115-01,11-Jan-07,1/1/2007,null,10/3/2012,Oct-12,No Study Results Posted,null,Aug-09,"safety and tolerability of hLL1 administered twice weekly for 4 consecutive weeks|The secondary objectives are to obtain information on efficacy, pharmacodynamics, pharmacokinetics, and immunogenicity, and to determine the optimal dose for subsequent studies.",https://ClinicalTrials.gov/show/NCT00421525
1236,NCT00462761,A Phase I Study of AC220 in Patients With Relapsed/Refractory Acute Myeloid Leukemia Regardless of FLT3 Status,Completed,No Results Available,Acute Myeloid Leukemia|Leukemia|Myelodysplastic Syndrome|AML|MDS,Drug: AC220,Daiichi Sankyo Inc.,Both,"18 Years and older   (Adult, Senior)",Phase 1,76,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CP0001,17-Apr-07,1/1/2007,12/1/2009,10/29/2015,Oct-15,No Study Results Posted,null,Mar-09,Safety and tolerability|Determine Pharmacokinetic parameters,https://ClinicalTrials.gov/show/NCT00462761
1259,NCT00731744,Generation of Dendritic Cell Precursors From Cord Blood Stem Cells,Recruiting,No Results Available,Normal Full-Term Deliveries,Procedure: Normal full-term deliveries,National Taiwan University Hospital,Female,25 Years to 45 Years   (Adult),,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Basic Science,200706003R,7-Aug-08,1/1/2007,12/1/2010,8/8/2008,Aug-08,No Study Results Posted,null,Feb-07,"None, we isolate stem cells from cord blood.",https://ClinicalTrials.gov/show/NCT00731744
1266,NCT00429065,"Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.",Recruiting,No Results Available,Non-Hodgkin Lymphoma,Drug: Rituximab,Instituto Nacional de Cancerologia de Mexico,Both,"15 Years to 60 Years   (Child, Adult)",Phase 4,30,Other,Observational,Observational Model: Defined Population|Primary Purpose: Screening|Time Perspective: Longitudinal|Time Perspective: Prospective,Hemato INCAN 01/2007,30-Jan-07,1/1/2007,1/1/2007,1/30/2007,Jan-07,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00429065
1268,NCT00944567,A Clinico-Pathologic Study of Primary Mediastinal B-Cell Lymphoma,Completed,No Results Available,Primary Mediastinal B-Cell Lymphoma,,International Extranodal Lymphoma Study Group (IELSG),Both,"18 Years and older   (Adult, Senior)",,125,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IELSG26|EudraCT number 2006-005794-22,22-Jul-09,1/1/2007,null,11/5/2013,Nov-13,No Study Results Posted,null,May-11,response rate on PET scanning following initial chemo-immunotherapy,https://ClinicalTrials.gov/show/NCT00944567
9,NCT00801281,First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance.,"Active, not recruiting",No Results Available,Follicular Lymphoma|Marginal Zone Lymphoma|Small Lymphocytic Lymphoma|Lymphoplasmacytic Lymphoma,Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Prednisone 1|Drug: Prednisone 2,Polish Lymphoma Research Group,Both,"18 Years and older   (Adult, Senior)",Phase 3,250,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,R-CVP/CHOP,2-Dec-08,2/1/2007,6/1/2017,2/17/2016,Feb-16,No Study Results Posted,PLRG4,Jun-17,Event Free Survival|Response Rate,https://ClinicalTrials.gov/show/NCT00801281
263,NCT00431210,Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma,"Active, not recruiting",No Results Available,Nasopharyngeal Carcinoma,Biological: Epstein-Barr virus-specific adoptive T-cells immunotherapy,Dana-Farber Cancer Institute|Brigham and Women's Hospital,Both,"18 Years and older   (Adult, Senior)",,10,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,06-179,2-Feb-07,2/1/2007,12/1/2016,3/8/2016,Mar-16,No Study Results Posted,null,Jun-16,The feasibility and safety of generating and administrating and EBV-specific adoptive T cell in participants with incurable locoregional relapsed and/or distant metastatic EBV-associated NPC.|The ability to collect specimens and measure potential biologic correlate of response to therapy|time to progression in this patient population|median duration of response and median overall survival in this cohort of participants.,https://ClinicalTrials.gov/show/NCT00431210
358,NCT00534209,Vaccine Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer Who Have Finished First-Line Chemotherapy,Terminated,Has Results,Lung Cancer,Biological: Allogeneic B7.1/HLA-A1 transfected tumor cell vaccine|Other: Placebo,University of Miami Sylvester Comprehensive Cancer Center|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,1,Other|NIH,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",UMIAMI-20057158|SCCC-2005042|WIRB-20051678,20-Sep-07,2/1/2007,4/1/2010,11/30/2015,Nov-15,17-Jan-13,null,Apr-10,Preliminary Safety Profile (Phase I)|Progression-free Survival (Phase II)|Clinical Outcomes (Phase I)|The Adaptive Immune Response|Safety Profile (Phase II)|Response to Second-line Chemotherapy After Disease Progression (Phase II)|Overall Survival (Phase II),https://ClinicalTrials.gov/show/NCT00534209
467,NCT00393068,"Chemotherapy, Radiation Therapy and Immunotherapy Prior to Surgery in Operable Esophageal Cancer",Completed,Has Results,Esophageal Cancer,Drug: Erlotinib|Drug: Bevacizumab|Drug: Paclitaxel|Drug: Carboplatin|Drug: 5-FU|Procedure: Radiation therapy|Procedure: Surgery,"SCRI Development Innovations, LLC|Genentech, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 2,62,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SCRI GI 91,25-Oct-06,2/1/2007,8/1/2011,10/31/2012,Oct-12,22-Aug-12,null,Sep-09,Pathologic Complete Response (pCR) Rate|Progression-Free Survival|Overall Survival,https://ClinicalTrials.gov/show/NCT00393068
527,NCT00450619,153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer,Completed,Has Results,Prostate Cancer,Radiation: Samarium Sm 153 lexidronam pentasodium|Biological: Sargramostim|Biological: Recombinant vaccinia-TRICOM vaccine|Biological: Recombinant fowlpox-TRICOM vaccine,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Male,"18 Years and older   (Adult, Senior)",Phase 2,44,NIH,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,070106|07-C-0106,20-Mar-07,2/1/2007,11/1/2012,1/27/2016,Jan-16,10-May-13,null,Nov-12,Number of Patients With Stable Disease at 4 Months.|Progression Free Survival (PFS)|Toxicity,https://ClinicalTrials.gov/show/NCT00450619
545,NCT00450463,Vaccine Therapy With PROSTVAC/TRICOM and Flutamide Versus Flutamide Alone to Treat Prostate Cancer,"Active, not recruiting",No Results Available,Prostate Cancer,"Drug: Sargramostim (GM-CSF, Leukine)|Drug: Flutamide (Eulexin)|Biological: PROSTVAC-F/ TRICOM|Biological: PROSTVAC-V/TRICOM",National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Male,"18 Years to 110 Years   (Adult, Senior)",Phase 2,53,NIH,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,070107|07-C-0107,20-Mar-07,2/1/2007,1/1/2018,7/28/2016,Jul-16,No Study Results Posted,null,Jan-17,Time to treatment failure|Time to development of metastatic disease|Toxicity|Response rate|PSA and immune responses|Immunologic effects,https://ClinicalTrials.gov/show/NCT00450463
688,NCT00423254,Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.,Completed,No Results Available,"Ovarian|Melanoma|Renal|Prostate|Colorectal|Endometrial Carcinoma|Cervical Carcinoma|Testicular Cancer|Thyroid Cancer|Small Cell Lung Carcinoma|Mesothelioma|Breast Carcinoma|Esophageal Carcinoma|Gastric Cancer|Pancreatic Carcinoma|Neuroendocrine Cancer|Liver Cancer|Gallbladder Cancer|Biliary Tract Cancer|Anal Carcinoma|Bone Sarcomas|Soft Tissue Sarcomas|Carcinoma of Unknown Origin, Primary",Biological: PSMA/PRAME|Biological: PSMA/PRAME,Mannkind Corporation,Both,"18 Years and older   (Adult, Senior)",Phase 1,12,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MKC1106-PP-001,12-Jan-07,2/1/2007,11/1/2009,8/2/2010,Aug-10,No Study Results Posted,null,Sep-09,To determine the immunologic response to the treatment with MKC1106-PP regimen and 2) to determine the safety and adverse event profile of MKC1106-PP|to determine the blood plasmid levels by PCR analysis|measure cytokine levels|to describe any objective tumor responses to the treatment with MKC1106-PP,https://ClinicalTrials.gov/show/NCT00423254
1272,NCT00569231,Study With Candida Antigen for Treatment of Warts,Completed,Has Results,Warts|HPV,Drug: Candida Antigen,"University of Arkansas|Allermed Laboratories, Inc.",Both,18 Years to 50 Years   (Adult),Phase 1,18,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label,46487,6-Dec-07,2/1/2007,1/1/2010,12/29/2010,Dec-10,23-Nov-10,null,Jan-10,"Number of Participants With Clinical Resolution of Injected Wart|Number of Participants With Clinical Resolution of 1st Anatomically Distant, Non-injected Wart|Number of Participants With Clinical Resolution of 2nd Anatomically Distant, Non-injected Wart",https://ClinicalTrials.gov/show/NCT00569231
1279,NCT02316613,Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE),Completed,Has Results,Follicular Lymphoma,Drug: Rituximab,Hoffmann-La Roche,Both,"18 Years and older   (Adult, Senior)",,260,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,ML20248,28-Nov-14,2/1/2007,4/1/2013,1/28/2016,Jan-16,18-Nov-15,null,Apr-13,Percentage of Participants With Modalities of the Therapeutic Decision Before First Study Induction Treatment Phase|Percentage of Participants With Treatments Prescribed Over the First Study Induction Phase|Percentage of Participants With Chemotherapies Prescribed Over the First Study Induction Phase|Percentage of Participants With MabThera as Maintenance Therapy|Percentage of Participants With MabThera Maintenance Therapy and at Least One Observation Phase|Duration of MabThera Maintenance Therapy When Associated With Observation|Percentage of Participants With Prescription of Injection Prophylaxis|Percentage of Participants With Injection Prophylaxis Treatment|Percentage of Participants With Modalities of the Therapeutic Decision at First Study Disease Progression|Number of Participants With Therapeutic Management After the First Study Disease Progression|Percentage of Participants With Last Induction Treatment Response|Percentage of Participants With Number of Disease Progressions|Percentage of Participants With Disease Characteristics at First Study Disease Progression|Progression Free Survival (PFS)|Time to Next Treatment|Overall Survival (OS)|Number of Participants Who Used MabThera|MabThera Regimen: Dose of MabThera|MabThera Regimen: Infusion Duration|MabThera Regimen: Number of Cycles of MabThera|MabThera Regimen: Time Between Cycles|Percentage of Participants With Discontinuations and Modifications of MabThera During Maintenance Phase|Function Assessment of Chronic Illness Therapy-General (FACT-G) With Lymphoma-Specific Additional Concerns Subscale (Lym) Total Score|Number and Type of Hospitalization Associated With MabThera Perfusion,https://ClinicalTrials.gov/show/NCT02316613
226,NCT00697671,Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies,Completed,No Results Available,Acute Lymphoblastic Leukemia|Chronic Myelogenous Leukemia|Juvenile Myelomonocytic Leukemia|Myelodysplastic Syndrome|Non-Hodgkin's Lymphoma,Other: NK Cell Infusion|Biological: Immunotherapy|Device: Miltenyi Biotec CliniMACS device|Drug: Interleukin-2 (IL-2)|Drug: Clofarabine|Drug: Cyclophosphamide|Drug: Etoposide,St. Jude Children's Research Hospital|Assisi Foundation,Both,"up to 18 Years   (Child, Adult)",Phase 1,48,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,NKHEM,14-Apr-08,3/1/2007,5/1/2013,7/15/2013,Jul-13,No Study Results Posted,null,Feb-13,"To assess the safety of chemotherapy and IL-2 administration to facilitate transient NK-cell engraftment in research participants with chemotherapy refractory non-acute myelogenous leukemia (non-AML) hematologic malignancies|To study the persistence, phenotype and function of donor natural killer (NK) cells after infusion in research participants with chemotherapy refractory hematologic malignancies.|To explore the efficacy of NK cell infusion in research participants with chemotherapy refractory hematologic malignancies",https://ClinicalTrials.gov/show/NCT00697671
433,NCT00437502,"A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer",Completed,No Results Available,"Epithelial Ovarian, Tubal or Peritoneal Cancer",Biological: tumor peptide vaccine|Biological: tumor peptide vaccine,"Michael Morse, MD|Immunotope|Duke University",Female,"18 Years and older   (Adult, Senior)",Phase 1,8,Other|Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,Pro00013247,19-Feb-07,3/1/2007,1/1/2010,11/15/2012,Nov-12,No Study Results Posted,null,Jan-10,Date of first objective finding will be used to define the date of relapse,https://ClinicalTrials.gov/show/NCT00437502
436,NCT00626483,Basiliximab in Treating Patients With Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia,"Active, not recruiting",No Results Available,Malignant Neoplasms Brain,Biological: RNA-loaded dendritic cell vaccine|Drug: basiliximab,John Sampson|National Cancer Institute (NCI)|Duke University,Both,"18 Years to 120 Years   (Adult, Senior)",Phase 1,18,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,Pro00000581|P50CA108786|P30CA014236|SPORE Project 3|CDR0000579683,28-Feb-08,3/1/2007,6/1/2018,7/26/2016,Jul-16,No Study Results Posted,REGULATe,Dec-17,"Functional capacity of CD4+,CD25+, CD127- T-regulatory cells|Safety",https://ClinicalTrials.gov/show/NCT00626483
596,NCT00452140,Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer Progressing After Endocrine Treatment,Terminated,No Results Available,Metastatic Breast Cancer|Advanced Breast Cancer,Biological: ertumaxomab,Neovii Biotech,Female,"18 Years and older   (Adult, Senior)",Phase 2,40,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IV-ERT-BC-03|EudraT number: 2006-005017-36,26-Mar-07,3/1/2007,2/1/2009,5/18/2009,May-09,No Study Results Posted,null,null,Clinical efficacy measured by objective response rate (best response during the course of the study)|Efficacy:|Clinical benefit rate|Duration of response|Time to progression (TTP)|Safety:|Incidence of adverse events (AEs)|Presence of human anti-murine antibodies after ertumaxomab infusion|Vital signs|Laboratory parameters,https://ClinicalTrials.gov/show/NCT00452140
780,NCT00589875,Phase 2a Study of AdV-tk With Standard Radiation Therapy for Malignant Glioma (BrTK02),"Active, not recruiting",No Results Available,Malignant Glioma|Glioblastoma Multiforme|Anaplastic Astrocytoma,Biological: AdV-tk|Drug: Valacyclovir,"Advantagene, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 2,52,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,BrTK02,27-Dec-07,3/1/2007,12/1/2016,3/2/2016,Mar-16,No Study Results Posted,BrTK02,Dec-15,Expand the safety evaluation at the maximum dose of AdV-tk evaluated in a completed phase Ib study|Overall survival|Progression free survival|Quality of life,https://ClinicalTrials.gov/show/NCT00589875
838,NCT00626015,"Chemotherapy, Radiation Therapy, and Vaccine Therapy With Basiliximab in Treating Patients With Glioblastoma Multiforme That Has Been Removed by Surgery",Completed,No Results Available,Malignant Neoplasms of Brain,Biological: PEP-3-KLH conjugate vaccine|Biological: daclizumab|Drug: temozolomide|Other: placebo|Biological: PEP-3-KLH,John Sampson|National Cancer Institute (NCI)|Duke University,Both,"18 Years to 120 Years   (Adult, Senior)",Phase 1,16,Other|NIH,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,Pro00000947|R21CA132891|CDR0000579573,28-Feb-08,3/1/2007,2/1/2013,1/20/2016,Jan-16,No Study Results Posted,ZAP IT,Feb-13,Functional suppressive capacity of CD4+CD25+CD127- T-regulatory cells|Comparison of proliferative T-cell response to phytohemagglutinin (PHA) among treatment groups (with versus without daclizumab/basiliximab),https://ClinicalTrials.gov/show/NCT00626015
859,NCT00504257,Avastin in Combination With Docetaxel in Ovarian/Fallopian Tube/Peritoneum Carcinoma,Completed,Has Results,Fallopian Tube Cancer|Ovarian Cancer|Malignant Tumor of Peritoneum,Drug: Avastin|Drug: Docetaxel,"H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)|Genentech, Inc.|Sanofi",Female,"18 Years and older   (Adult, Senior)",Phase 2,45,Other|NIH|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MCC-14920|AVF3823s|IST13070,17-Jul-07,3/1/2007,10/1/2012,1/7/2014,May-13,28-May-13,null,Oct-12,Six Month Progression Free Survival (PFS)|Median Progression Free Survival|Overall Response Rate (RR)|Occurrence of Grade 3 or 4 Toxicity|Overall Survival (OS),https://ClinicalTrials.gov/show/NCT00504257
1025,NCT00457860,"Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease",Recruiting,No Results Available,Leukemia,Drug: Immunotoxin therapy|Drug: CAT-8015 immunotoxin|Procedure: Biological therapy,Cambridge Antibody Technology,Both,"18 Years and older   (Adult, Senior)",Phase 1,50,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CAT-8015-1002,5-Apr-07,3/1/2007,null,4/16/2007,Apr-07,No Study Results Posted,null,null,"Estimate the maximum dose that can be safely administered to a patient|Characterize the toxicity profile of CAT-8015|Study the clinical pharmacology of CAT-8015|Observe anti-tumor activity, if any|To assess the potential of CAT-8015 to induce antibodies|To Investigate the potential of biomarkers to predict any therapeutic or toxic response",https://ClinicalTrials.gov/show/NCT00457860
416,NCT00469820,"Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant",Terminated,No Results Available,Leukemia|Multiple Myeloma and Plasma Cell Neoplasm,Biological: autologous tumor cell vaccine|Biological: peripheral blood lymphocyte therapy,Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI),Both,"18 Years to 70 Years   (Adult, Senior)",Phase 1,1,Other|NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,J06118 CDR0000543531|P01CA015396|P30CA006973|JHOC-J06118,3-May-07,4/1/2007,3/1/2010,3/20/2014,Mar-14,No Study Results Posted,null,Mar-10,"Time to relapse|Overall survival|Safety and tolerability, in terms of incidence of graft-versus-host disease and local/systemic toxicities|Maximum tolerated dose of donor lymphocytes",https://ClinicalTrials.gov/show/NCT00469820
1016,NCT00462189,Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease,Recruiting,No Results Available,Leukemia|Hairy Cell Leukemia|HCL,Drug: Immunotoxin therapy|Drug: CAT-8015 Immunotoxin|Procedure: Biological therapy,Cambridge Antibody Technology,Both,"18 Years and older   (Adult, Senior)",Phase 1,40,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CAT-8015-1001,16-Apr-07,4/1/2007,null,4/16/2007,Apr-07,No Study Results Posted,null,null,"Estimate the maximum dose that can be safely administered to a patient|Characterize the toxicity profile of CAT-8015|Study the clinical pharmacology of CAT-8015|Observe anti-tumor activity, if any.|To assess the immunogenic potential of CAT-8015 to induce antibodies|To investigate the potential of biomarkers to predict any therapeutic or toxic response.",https://ClinicalTrials.gov/show/NCT00462189
8,NCT01458730,Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma,"Active, not recruiting",No Results Available,Central Nervous System Lymphoma,Drug: Immunochemotherapy,University of Aarhus|Nordic Cancer Union|Roche Pharma AG|Mundipharma Pte Ltd.|Schering-Plough,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 2,66,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,EudraCT No 2006-004772-12,15-Sep-11,5/1/2007,10/1/2020,11/15/2012,Nov-12,No Study Results Posted,null,Oct-10,Overall survival|response rate|neurotoxicity,https://ClinicalTrials.gov/show/NCT01458730
23,NCT00455572,Cancer Immunotherapy GSK1572932A as Adjuvant Therapy for Patients With Tumor-antigen-positive Non-Small Cell Lung Cancer,Terminated,No Results Available,"Lung Cancer, Non-Small Cell",Biological: Immunotherapeutic GSK1572932A|Drug: Cisplatin (CDDP)|Drug: Vinorelbine|Procedure: Radiotherapy,GlaxoSmithKline,Both,"18 Years and older   (Adult, Senior)",Phase 1,71,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,107240,2-Apr-07,5/1/2007,8/1/2013,8/7/2014,Aug-14,No Study Results Posted,null,Aug-13,"The anti-MAGE-A3 seroconversion|The anti-protein D seroconversion|The anti-CpG seroconversion|The MAGE-A3 cellular (T cell) response|Occurrence of adverse events, including abnormal hematological and biochemical laboratory values|Occurrence of serious adverse events",https://ClinicalTrials.gov/show/NCT00455572
100,NCT01446562,Y90 Ibritumomab Tiuxetan Post R-CHOP Chemotherapy for Advanced Stage Follicular Lymphoma,Completed,No Results Available,Follicular Lymphoma,Biological: Y90 Ibritumomab Tiuxetan RIT,Sunnybrook Health Sciences Centre,Both,"18 Years and older   (Adult, Senior)",Phase 2,34,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ZEVISS,11-Aug-11,5/1/2007,5/1/2016,6/15/2016,Jun-16,No Study Results Posted,ZEVISS,May-16,The primary endpoint for this study is the complete response rate measured 3 months after the dose of 90Y-RIT|toxicities|Conversion of partial responses to complete responses|Minimal residual disease|Time to treatment failure|Overall survival,https://ClinicalTrials.gov/show/NCT01446562
597,NCT00496860,Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies,Completed,Has Results,Progressive Metastatic Malignancies,Biological: ALT-801,Altor Bioscience Corporation,Both,"18 Years and older   (Adult, Senior)",Phase 1,26,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CA-ALT-801-01-06,3-Jul-07,5/1/2007,10/1/2009,7/17/2013,Jul-13,2-Apr-13,null,Oct-09,The Safety and Toxicity of ALT-801 in Patients With Progressive Metastatic Malignancies|The Maximum-tolerated Dose (MTD) of ALT-801|Clinical Antitumor Response to ALT-801|ALT-801 Induced Cell-mediated Immune Responses|Immunogenicity of ALT-801,https://ClinicalTrials.gov/show/NCT00496860
697,NCT00576641,Immunotherapy for Patients With Brain Stem Glioma and Glioblastoma,Completed,No Results Available,Brain Stem Glioma|Glioblastoma,Biological: autologous dendritic cells,Cedars-Sinai Medical Center,Both,"Child, Adult, Senior",Phase 1,22,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,6657,18-Dec-07,5/1/2007,4/1/2012,10/29/2014,Oct-14,No Study Results Posted,null,Jan-10,"Evaluate safety/toxicity of Dendritic cell vaccine, Monitor survival and time to progression and monitor the cellular immune responses.",https://ClinicalTrials.gov/show/NCT00576641
719,NCT00510471,Personalized Active Immunotherapy (Vaccine Therapy) and Sargramostim Given After Standard of Care Treatment With Rituximab and Chemotherapy for Initial Treatment With Lymphoma,Terminated,No Results Available,Non-Hodgkin's Lymphoma,Drug: autologous immunoglobulin idiotype-KLH conjugate vaccine,Genitope Corporation,Both,"18 Years and older   (Adult, Senior)",Phase 2,null,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label,2007-12,31-Jul-07,5/1/2007,null,3/14/2008,Mar-08,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00510471
969,NCT00481936,Study of the Safety of VB6-845 in Patients With Advanced Solid Tumours of Epithelial Origin,Terminated,No Results Available,"Neoplasms, Glandular and Epithelial",Drug: VB6-845,Viventia Bio,Both,"18 Years and older   (Adult, Senior)",Phase 1,15,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Health Services Research,VB6-845-01-I,31-May-07,5/1/2007,4/1/2008,12/22/2015,Dec-15,No Study Results Posted,null,Apr-08,"To determine the maximum tolerated dose of VB6-845 and to evaluate the safety and tolerability of VB6-845 when administered as a monotherapy IV infusion|To evaluate the pharmacokinetics, immunogenicity and exploratory efficacy of VB6-845",https://ClinicalTrials.gov/show/NCT00481936
1136,NCT00783588,A Phase I Extension Trial of Repeated Infusions of ISF35,Completed,No Results Available,Chronic Lymphocytic Leukemia,Biological: ISF35,"Memgen, LLC",Both,"18 Years and older   (Adult, Senior)",Phase 1,4,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CLL-35-102,30-Oct-08,5/1/2007,9/1/2008,10/30/2008,Oct-08,No Study Results Posted,null,Sep-08,"Assess the toxicity, tolerability, and safety of the repeat administration of 1x10^8, 3x10^8, or 1x10^9 autologous Ad-ISF35-transduced CLL B cells in up to 9 patients with CLL who tolerated previous treatment in MDACC Protocol 2004-0914.|Assess the anti-leukemia activity of the repeat administration of Ad-ISF35 transduced CLL B cells by evaluating reduction in leukemia count, reduction in adenopathy and splenomegaly, and improvement in bone marrow function.|Assess the quality of life with repeat Ad-ISF35 treatment.|Assess pharmacodynamic endpoints including induction of T cell anti-leukemia immune responses, antibody production against autologous CLL B cells, and changes in bystander leukemia cell phenotype.",https://ClinicalTrials.gov/show/NCT00783588
148,NCT00502463,Induction Chemotherapy Prior to Radio-immunotherapy in Head and Neck Cancer Stage III/IV - a Methodical Trial,"Active, not recruiting",No Results Available,Head and Neck Cancer,Procedure: radio-immunotherapy,Austrian South Oncology Group|Medical University of Graz,Both,"18 Years to 75 Years   (Adult, Senior)",,50,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ASOG-HNO1,15-Jul-07,6/1/2007,12/1/2013,7/30/2009,Jul-09,No Study Results Posted,ASOG-HNO1,Feb-09,locoregional tumour control|response rate toxicity progression free survival,https://ClinicalTrials.gov/show/NCT00502463
511,NCT00674791,Study of Cancer Peptides Vaccine Plus GM-CSF as Adjuvant Treatment for High Risk (TXN2-3M0) or Metastatic Breast Cancer With No Evidence of Disease,Completed,No Results Available,Breast Cancer,Biological: OCPM Immunotherapeutic Vaccine,Duke University|Immunotope,Both,"18 Years and older   (Adult, Senior)",Phase 1,13,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,Pro00000902,5-May-08,6/1/2007,1/1/2010,6/18/2013,Mar-11,No Study Results Posted,null,Jan-10,Safety/tolerability: Number of subjects with dose limiting toxicity after 3 immunizations.|Immunologic response: Number of subjects with tumor antigen specific immune response after 3 immunizations.,https://ClinicalTrials.gov/show/NCT00674791
621,NCT00513604,Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma,Completed,Has Results,"Melanoma|Malignant Melanoma|Melanoma, Experimental|Experimental Melanomas",Biological: aldesleukin|Biological: therapeutic autologous lymphocytes|Drug: Cyclophosphamide|Drug: Fludarabine phosphate|Radiation: Total body irradiation,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years and older   (Adult, Senior)",Phase 2,158,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,070176|07-C-0176,6-Aug-07,6/1/2007,11/1/2012,5/29/2013,May-13,19-Feb-13,null,Nov-12,Clinical Response|Toxicity,https://ClinicalTrials.gov/show/NCT00513604
1117,NCT00740415,"Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma",Completed,No Results Available,Lymphoma,Biological: rituximab|Drug: bortezomib|Drug: dexamethasone|Drug: Bendamustine,"French Innovative Leukemia Organisation|Janssen, LP|Mundipharma Pte Ltd.",Both,"65 Years to 80 Years   (Adult, Senior)",Phase 2,39,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000589544|-MANTEAU-2010-SA,22-Aug-08,6/1/2007,8/1/2015,3/15/2016,Mar-16,No Study Results Posted,ManteauRiBVD,May-11,Overall response rate after 4 courses of therapy,https://ClinicalTrials.gov/show/NCT00740415
80,NCT00553943,Phase II Study to Evaluate the Combination of Rituximab and DepoCyte® in the C5R Chemotherapy Protocol in Patients Between the Ages of 18 and 60 Years With Primary Cerebral Non-Hodgkin Lymphoma and Systemic Diffuse Large B-cell Lymphoma With Neuromeningeal Invasion at Diagnosis,Recruiting,No Results Available,"Lymphoma, Non-Hodgkin|Diffuse Large B-cell Lymphoma","Drug: Rituximab, Cytarabine",Lymphoma Study Association,Both,18 Years to 60 Years   (Adult),Phase 2,106,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,R-C5R 2006|R-C5R,5-Nov-07,7/1/2007,6/1/2013,10/22/2010,Oct-10,No Study Results Posted,null,Jun-11,"Response to treatment (CR/PR)|Toxicity, Overall survival, Time to progression",https://ClinicalTrials.gov/show/NCT00553943
191,NCT00585221,Study of Imatinib and Peginterferon α-2b in Gastrointestinal Stromal Tumor (GIST) Patients,Terminated,Has Results,"Gastrointestinal Stromal Tumors,|Cancer,|Solid Tumors",Drug: Peginterferon-alpha 2b (PegIFNa2b);|Drug: Imatinib,University of Utah|Schering-Plough,Both,"18 Years and older   (Adult, Senior)",Phase 2,8,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IRB_00022172,21-Dec-07,7/1/2007,7/1/2009,7/23/2013,Jul-13,15-Jun-12,null,Jul-09,Decrease in Tumor Size.|Time to Progression (TTP).,https://ClinicalTrials.gov/show/NCT00585221
629,NCT00516685,Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer (NSCLC) Stages IIIB/IV,Terminated,No Results Available,Non-small-cell Lung Cancer (NSCLC) Stage IIIb/IV,Biological: Recombinant Human rEGF-P64K/Montanide Vaccine,Bioven Sdn. Bhd.,Both,"18 Years and older   (Adult, Senior)",Phase 2|Phase 3,230,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CT 07-03,14-Aug-07,7/1/2007,null,9/29/2011,Sep-11,No Study Results Posted,NSCLC,null,"Survival|Assessment of immunogenecity, safety as well as preliminary assessment of objective response, time of progression and quality of life",https://ClinicalTrials.gov/show/NCT00516685
1060,NCT00510133,A Study of Active Immunotherapy With GRNVAC1 in Patients With Acute Myelogenous Leukemia (AML),Completed,No Results Available,Acute Myelogenous Leukemia,Biological: GRNVAC1,"Asterias Biotherapeutics, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 2,21,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,GRNVAC1 CP06-151,30-Jul-07,7/1/2007,8/1/2014,8/11/2014,Aug-14,No Study Results Posted,null,Dec-11,"Feasibility will be assessed by examining whether enough cells are collected during leukapheresis, whether enough vaccine is manufactured for at least 2 injections, and whether the patient is still in remission when the vaccine is released.|Immunological response, defined as the proportion of patients with a positive induction of hTERT-specific T cells to twice the pre-vaccination level, the proportion of patients with DTH, and event-free survival.",https://ClinicalTrials.gov/show/NCT00510133
216,NCT00923351,"Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma","Active, not recruiting",Has Results,"Neuroblastoma|Sarcoma|Rhabdomyosarcoma-Embryonal|Rhabdomyosarcoma- Alveolar|Neuroectodermal Tumors, Primitive, Peripheral",Drug: Tumor Purged/CD25 Depleted Lymphocytes|Biological: Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine|Drug: rhIL-7|Biological: Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"19 Months to 35 Years   (Child, Adult)",Phase 1|Phase 2,44,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,070206|07-C-0206,17-Jun-09,8/1/2007,7/1/2017,3/22/2016,Mar-16,9-Jul-13,null,Aug-12,Number of Participants With a Positive Immune Response as Evidenced by the Delayed Type of Hypersensitivity (DTH) Reaction Assay|Toxicity,https://ClinicalTrials.gov/show/NCT00923351
460,NCT00621452,"Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma",Completed,No Results Available,B-cell Chronic Lymphocytic Leukemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Nodal Marginal Zone B-cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Splenic Marginal Zone Lymphoma|Waldenström Macroglobulinemia,Biological: therapeutic autologous lymphocytes|Drug: cyclophosphamide|Biological: aldesleukin|Genetic: polymerase chain reaction|Genetic: gene rearrangement analysis|Procedure: lymph node biopsy|Biological: genetically engineered lymphocyte therapy|Procedure: bone marrow aspiration|Other: flow cytometry|Other: laboratory biomarker analysis|Other: enzyme-linked immunosorbent assay,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),Both,"Child, Adult, Senior",Phase 1,12,Other|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2154.00|NCI-2010-00416,21-Feb-08,8/1/2007,null,8/4/2014,Aug-14,No Study Results Posted,null,Jan-14,"Feasibility of transfecting and expanding the necessary numbers of T cells and the types of problems and toxicities which might be encountered, graded according the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0|Comparison of the percentages of CD20-specific T cells and malignant B cells present in the blood before and after each T cell infusion|Immune response as assessed by ELISA and percent chromium release in cytotoxicity assays|Absolute numbers of T cells expressing the chimeric T Cell receptor (cTCR) per cubic uL of blood",https://ClinicalTrials.gov/show/NCT00621452
532,NCT00512889,Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma,Completed,No Results Available,Melanoma (Skin),Biological: therapeutic autologous lymphocytes|Genetic: Use of an artificial antigen presenting cell (aAPC) to generate CTL|Drug: GM-CSF|Radiation: Irradiation of cutaneous tumor lesion,Dana-Farber Cancer Institute,Both,"18 Years and older   (Adult, Senior)",Phase 1,9,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,06-250,3-Aug-07,8/1/2007,1/1/2013,2/28/2013,Feb-13,No Study Results Posted,null,Feb-11,"Define the feasibility of generating large doses of MART1/Melan-A specific CTL following leukapheresis in this patient population|Describe the toxicity of two dose levels of adoptively transferred MART1/Melan-A specific CTL lines|Define the feasibility of combining the infusion of MART1/Melan-A specific CTL with the administration of GM-CSF +/- radiotherapy|Describe the toxicity of combining the infusion of MART1/Melan-A specific CTL with the administration of GM-CSF +/- radiotherapy|Evaluate function, phenotype, and trafficking of infused CTL.",https://ClinicalTrials.gov/show/NCT00512889
738,NCT00924001,Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma,Terminated,Has Results,"Melanoma|Malignant Melanoma|Melanoma, Experimental",Drug: DMF5 Melanoma Reactive TIL|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldesleukin,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,1,NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,070210|07-C-0210,17-Jun-09,8/1/2007,10/1/2010,10/18/2012,Oct-12,22-Dec-11,null,Oct-10,Number of Participants With an Objective Clinical Tumor Regression Response According to RECIST Criteria|Number of Participants With Adverse Events|Number of Participiants With In-vivo Survival of Infused Cells,https://ClinicalTrials.gov/show/NCT00924001
122,NCT00524953,Phase I Clinical Trial to Assess Safety of UV Phototherapy for the Prevention of GVHD Post Allogeneic SCT,Withdrawn,No Results Available,Allogeneic Transplantation (Non T-cell Depleted),Device: EUMATRON - EN 600 NT,Hadassah Medical Organization,Both,"14 Years to 70 Years   (Child, Adult, Senior)",Phase 1,0,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention,UV-GVHD - HMO-CTIL,4-Sep-07,9/1/2007,9/1/2013,6/10/2015,Aug-07,No Study Results Posted,null,Sep-13,"safety and tolerability of UV-c phototherapy for the Prevention of Graft versus Host Disease after allogeneic stem cell transplantation|monitoring immune system recovery, influence on survival rates, influence of stem cells origin on treatment & prevention of GVHD",https://ClinicalTrials.gov/show/NCT00524953
404,NCT00529984,A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing Malignancies,Completed,No Results Available,Colorectal Cancer|Breast Cancer|Lung Cancer|Pancreatic Cancer|Colon Cancer,Biological: AVX701|Biological: AVX701|Biological: AVX701|Biological: AVX701|Biological: AVX701,"AlphaVax, Inc.|Duke University",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,28,Industry|Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AVX701|P01CA078673-04,12-Sep-07,9/1/2007,5/1/2010,7/11/2012,Jul-12,No Study Results Posted,CEA(6D)VRP,May-10,determine the safety of immunization with CEA(6D) VRP|evaluate CEA-specific immune response to immunizations,https://ClinicalTrials.gov/show/NCT00529984
546,NCT00547235,Emergency Use of Adoptive Immunotherapy With CMV-Specific T Cells After Donor Bone Marrow Transplant of an Infant With Immunodeficiency Syndrome and CMV Infection,No longer available,No Results Available,Infection|Precancerous/Nonmalignant Condition,Biological: therapeutic allogeneic lymphocytes|Procedure: allogeneic bone marrow transplantation|Radiation: total-body irradiation,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),Female,up to 1 Year   (Child),,null,Other|NIH,Expanded Access,,2215.00|FHCRC-2215.00|CDR0000570998,19-Oct-07,9/1/2007,null,8/23/2010,Aug-10,No Study Results Posted,null,Dec-12,,https://ClinicalTrials.gov/show/NCT00547235
756,NCT00643097,Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme,"Active, not recruiting",Has Results,Malignant Neoplasms of Brain,Biological: PEP-3 vaccine|Biological: sargramostim|Drug: Temozolomide,John Sampson|National Institute of Neurological Disorders and Stroke (NINDS)|Duke University,Both,"18 Years and older   (Adult, Senior)",Phase 2,40,Other|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,Pro00004040|P50NS020023|CDR0000589632|DUMC-5421,25-Mar-08,9/1/2007,12/1/2016,10/15/2015,Oct-15,6-Jan-14,ACTIVATe,Jan-12,"Humoral and Cellular Immune Response|Clinical Efficacy of Vaccination, in Terms of Progression-free Survival (PFS)|Response to Vaccination|Toxicity to PEP-3 Vaccine Immunization",https://ClinicalTrials.gov/show/NCT00643097
927,NCT00553306,Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma,Completed,No Results Available,Recurrent Melanoma|Stage IV Melanoma,Biological: therapeutic autologous lymphocytes|Biological: aldesleukin|Drug: cyclophosphamide|Procedure: biopsy|Other: immunohistochemistry staining method|Other: flow cytometry|Genetic: polymerase chain reaction,Fred Hutchinson Cancer Research Center,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1|Phase 2,6,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2179.00|NCI-2010-01281,2-Nov-07,9/1/2007,null,4/21/2011,Apr-11,No Study Results Posted,null,Aug-10,Safety and toxicity as assessed by NCI CTC version 3.0|Antitumor effects of CD4+ and CD8+ antigen-specific T-cells|Duration of in vivo persistence of adoptively transferred CD8+ antigen-specific T cell clones in the presence or absence of transferred CD4+ T cells|In vivo antitumor efficacy of the infused autologous antigen-specific CD4+ T cells,https://ClinicalTrials.gov/show/NCT00553306
64,NCT00469729,"Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy",Completed,No Results Available,Hematologic Malignancies|Acute Myeloid Leukemia|Lymphoid Leukemia|Chronic Myeloid Leukemia|Hodgkin's Disease|Non-Hodgkin's Lymphoma|Myelodysplastic Syndromes,Drug: StemEx®,Gamida Cell -Teva Joint Venture Ltd.,Both,"12 Years to 55 Years   (Child, Adult)",Phase 2|Phase 3,101,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,GC P#02.01.001,3-May-07,10/1/2007,6/1/2015,7/9/2015,Mar-13,No Study Results Posted,ExCell,Feb-13,"Overall 100-day mortality|180 day mortality, acute Graft versus Host Disease (GvHD) grades III-IV, engraftment failure|Safety and tolerability measures: The incidence and frequency of adverse experiences, acute toxicity, laboratory data and vital signs follow-up.|Proportion of overall mortality at 1 year|Proportion of overall mortality at 2 years",https://ClinicalTrials.gov/show/NCT00469729
424,NCT01276730,Advanced Cervical Cancer Trial in India,"Active, not recruiting",No Results Available,Cervical Cancer,"Drug: Interferon, Retinoic Acid and radiation|Drug: Cisplatin and radiation",James Graham Brown Cancer Center|University of Louisville,Female,"18 Years and older   (Adult, Senior)",Phase 2,200,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,464.05,2-Nov-10,10/1/2007,null,4/23/2014,Apr-14,No Study Results Posted,null,Sep-15,Survival|Response rate|Overall toxicity|Determine immune response to Human Papillomavirus HPV,https://ClinicalTrials.gov/show/NCT01276730
573,NCT01445379,Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer,Completed,No Results Available,Sarcoma|Wilm's Tumor|Lymphoma|Neuroblastoma,Drug: Ipilimumab,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"3 Years to 21 Years   (Child, Adult)",Phase 1,29,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,080007|08-C-0007,30-Sep-11,10/1/2007,11/1/2015,11/14/2015,Nov-15,No Study Results Posted,null,Apr-14,To determine the tolerance and toxicity profile|Pharmacokinetics|Evaluate immunomodulatory activity.|Quantify antitumor effects,https://ClinicalTrials.gov/show/NCT01445379
1228,NCT00906841,Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma,Terminated,No Results Available,B-cell Lymphoma,Drug: 90Y-DOTA-hLL2,French Innovative Leukemia Organisation,Both,"60 Years to 80 Years   (Adult, Senior)",Phase 2,75,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,RIT90Y-DOTA-hLL2,18-May-09,10/1/2007,7/1/2018,3/15/2016,Mar-16,No Study Results Posted,null,Mar-16,"Event free survival (EFS)|Objective disease response (CR, CRu and PR), SD and disease progression|Duration of response|Time to disease progression",https://ClinicalTrials.gov/show/NCT00906841
1232,NCT00772655,Zevalin® First Line in Follicular Lymphoma,"Active, not recruiting",No Results Available,Follicular Lymphoma,Drug: 90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab|Drug: Rituximab,"Charite University, Berlin, Germany",Both,"50 Years and older   (Adult, Senior)",Phase 2,60,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,EudraCT-No.:2006-005778-34|PEI-No.: 364/01|BFS-No.: 22461/2-2007-001,14-Oct-08,10/1/2007,6/1/2015,7/31/2012,Jul-12,No Study Results Posted,null,Jun-10,Clinical and molecular remission rate after primary therapy with 90Y-Ibritumomab Tiuxetan|Time to progression after treatment with 90Y-Ibritumomab Tiuxetan|Ability of consolidation therapy with Rituximab to induce molecular remission for CR patients not achieving molecular remission within 6 months after 90Y-Ibritumomab Tiuxetan|Safety and tolerability of 90Y-Ibritumomab Tiuxetan with particular respect to further therapy strategies in relapsed patients,https://ClinicalTrials.gov/show/NCT00772655
437,NCT00566098,Activated White Blood Cells in Treating Patients Undergoing an Autologous Stem Cell Transplant for Newly Diagnosed Stage II or Stage III Multiple Myeloma,Completed,No Results Available,Multiple Myeloma and Plasma Cell Neoplasm,Biological: therapeutic autologous lymphocytes|Biological: therapeutic tumor infiltrating lymphocytes|Drug: melphalan|Procedure: autologous hematopoietic stem cell transplantation,Sidney Kimmel Comprehensive Cancer Center|National Cancer Institute (NCI),Both,"18 Years to 120 Years   (Adult, Senior)",Phase 1|Phase 2,25,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,J0770|P30CA006973|JHOC-J0770,30-Nov-07,11/1/2007,6/1/2014,10/30/2015,Oct-15,No Study Results Posted,null,Jun-14,"Toxicity|Hematopoietic engraftment|Response rates utilizing the Blade criteria, including complete response (CR) rate, near complete response (nCR) rate, very good partial response (VGPR) rate, partial response (PR) rate, minimal response (MR) rate, overall response rate (CR, VGPR, ...|Generation of activated marrow infiltrating lymphocytes (aMILs)|T-cell reconstitution, including absolute lymphocyte counts, CD3+/ CD4+/ CD8+ T-cell counts|Progression-free survival and overall survival|Pneumococcal-specific vaccine responses|Anti-tumor immune responses|Delayed-type hypersensitivity (DTH) responses",https://ClinicalTrials.gov/show/NCT00566098
632,NCT00621036,Vaccine Therapy and GM-CSF in Treating Patients With CNS Lymphoma,Recruiting,No Results Available,Brain and Central Nervous System Tumors|Lymphoma|Lymphoproliferative Disorder|Small Intestine Cancer,Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine|Biological: sargramostim|Drug: methotrexate|Drug: thiotepa|Radiation: radiation therapy,Simmons Cancer Center|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 2,30,Other,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000587504|SCCC-102007-035|SCCC-02F07,21-Feb-08,11/1/2007,null,4/1/2010,Aug-08,No Study Results Posted,null,Jun-09,Anti-idiotype (Id) and anti-keyhole limpet hemocyanin (KLH) immune response rate in the CSF|Safety and tolerability|Progression-free survival (PFS)|Time to receipt of first subsequent anti-lymphoma therapy after initiating immunization with the Id-KLH conjugate vaccine|Correlation of anti-Id immune response in the CSF and/or serum with PFS and overall survival|Kinetics of humoral immune response development,https://ClinicalTrials.gov/show/NCT00621036
737,NCT00569296,"Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer",Terminated,No Results Available,Lung Cancer,Biological: EGFRBi-armed autologous activated T cells|Biological: aldesleukin|Biological: sargramostim,Roger Williams Medical Center,Both,"18 Years and older   (Adult, Senior)",Phase 1,5,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000577502|349-32|3422,6-Dec-07,11/1/2007,3/1/2015,3/24/2015,Mar-15,No Study Results Posted,null,Dec-14,Safety|Maximum tolerated dose of EGFRBi-armed autologous activated T-cells|Determination of immunologic changes by evaluation of cytokine profiles obtained before and after stimulation with OKT3 in vitro|Overall survival|Progression-free survival|Evaluation of tumor markers and human anti-mouse antibody responses as assessed by carcinoembryonic antigen (CEA) levels in serum samples and development of IgG and IgM anti-mouse antibody responses to the Bi-antibodies|Determination of immunologic changes by evaluation of peripheral blood lymphocytes|Determination of immunologic changes by evaluation of cytotoxic T-lymphocytes as measured by interferon gamma ELISPOTS directed at autologous tumor or lung cancer cell lines|Determination of immunologic changes by evaluation of phenotypes of peripheral blood mononuclear cells before and after immunotherapy,https://ClinicalTrials.gov/show/NCT00569296
1173,NCT00547066,Study of Veltuzumab (hA20) at Different Doses in Patients With ITP,"Active, not recruiting",No Results Available,"Purpura, Thrombocytopenic, Idiopathic|Autoimmune Thrombocytopenic Purpura|Purpura, Thrombocytopenic, Autoimmune",Biological: veltuzumab,"Immunomedics, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,66,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IM-T-hA20-07,17-Oct-07,11/1/2007,12/1/2016,3/18/2016,Mar-16,No Study Results Posted,null,Dec-16,Safety|Efficacy,https://ClinicalTrials.gov/show/NCT00547066
65,NCT00645606,"Fludarabine, Cyclophosphamide, and Rituximab Followed by Rituximab or Observation in Older Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia",Completed,No Results Available,Leukemia,Biological: Rituximab,"University Hospital, Tours|FCGCLL-WM|Roche Pharma AG|French Innovative Leukemia Organisation",Both,66 Years and older   (Senior),Phase 3,542,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000589684|CHRUT-LLC-2007-SA|CHRUT-PHRN05-CD|INCA-RECF0497|2007-001015-28,26-Mar-08,12/1/2007,10/1/2015,10/16/2015,Oct-15,No Study Results Posted,LLC2007SA,Feb-14,"Three-year progression-free survival|Event-free survival|Disease-free survival|Overall survival|Time to next treatment|Overall response rate, complete response, and partial response according to NCI criteria|Rates of phenotypic response (minimal residual disease)|Rates of treatment-related adverse events|Pharmacokinetics of rituximab during induction and maintenance|Quality of life",https://ClinicalTrials.gov/show/NCT00645606
653,NCT00583752,Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21,"Active, not recruiting",No Results Available,Recurrent Prostate Cancer,Biological: Adenovirus/PSA Vaccine,University of Iowa|United States Department of Defense,Male,"18 Years to 90 Years   (Adult, Senior)",Phase 2,70,Other|U.S. Fed,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,200605706|PC061667/1,20-Dec-07,12/1/2007,7/1/2017,9/11/2015,Sep-15,No Study Results Posted,APP21,Jul-16,PSA doubling-time response|Serum PSA levels and immune response,https://ClinicalTrials.gov/show/NCT00583752
654,NCT00583024,Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer,"Active, not recruiting",No Results Available,Hormone Refractory Prostate Cancer,Biological: ADENOVIRUS/PSA VACCINE,University of Iowa|United States Department of Defense,Male,"18 Years to 90 Years   (Adult, Senior)",Phase 2,66,Other|U.S. Fed,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,200605710|PC061667/2,20-Dec-07,12/1/2007,7/1/2017,9/11/2015,Sep-15,No Study Results Posted,APP22,Jul-16,PSA doubling-time response|Serum PSA levels and Immune response,https://ClinicalTrials.gov/show/NCT00583024
689,NCT00585845,Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment,Terminated,No Results Available,"Malignant Epithelial Mesothelioma|Adenocarcinoma of the Pancreas|Carcinoma, Non-Small-Cell Lung|Adenocarcinoma of the Ovaries","Biological: CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin","Anza Therapeutics, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1,17,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,VAC07001,22-Dec-07,12/1/2007,2/1/2009,2/19/2009,Feb-09,No Study Results Posted,null,Feb-09,Dose-limiting toxicities related to the investigational agent,https://ClinicalTrials.gov/show/NCT00585845
948,NCT00569309,Vaccine Therapy in Treating Patients Who Have Undergone Autologous Stem Cell Transplant for High-Risk Lymphoma or Multiple Myeloma,"Active, not recruiting",No Results Available,Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Small Intestine Cancer,Biological: Streptococcus pneumoniae|Other: laboratory biomarker analysis|Other: quality-of-life assessment,Craig Hofmeister|Ohio State University Comprehensive Cancer Center,Both,"18 Years and older   (Adult, Senior)",,31,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,OSU-07044,6-Dec-07,12/1/2007,null,6/10/2012,Jun-12,No Study Results Posted,null,Nov-12,"Immune reconstitution|Serial assessment of the absolute number of circulating regulatory T-cells and the function of these cells as measured by their expression of TGFβ and interleukin-10 (IL-10)|Quality of life, including functional status, fatigue, and depression|Correlation of quality of life with inflammatory cytokine production of peripheral blood monocytes|Collection of baseline immune reconstitution and quality of life pilot data for comparison in future post-transplant immunotherapy trials",https://ClinicalTrials.gov/show/NCT00569309
223,NCT00672542,Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells,Completed,No Results Available,Metastatic Melanoma|Absence of CNS Metastases,Biological: Proteasome siRNA and tumor antigen RNA-transfected dendritic cells,Scott Pruitt|Duke University,Both,"18 Years and older   (Adult, Senior)",Phase 1,12,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,Pro00000806|IND # BB-13545|NIH OBA # 0708-874,3-Feb-08,1/1/2008,7/1/2013,1/21/2014,Jan-14,No Study Results Posted,null,Mar-13,"For this Phase I study, subjects will be evaluated both clinically and with laboratory testing for any signs of toxicity associated with vaccination.|For each subject, the induction of anti-melanoma immune responses will be assessed by in vitro testing.|For each subject, clinical responses to vaccination will also be assessed.",https://ClinicalTrials.gov/show/NCT00672542
299,NCT02627144,Bevacizumab in Metastatic Renal Cancer,Completed,Has Results,Renal Cell Cancer,Drug: Bevacizumab|Drug: Interferon alpha-2a,Hoffmann-La Roche,Both,"18 Years and older   (Adult, Senior)",,365,Industry,Observational,Observational Model: Cohort|Time Perspective: Cross-Sectional,ML21519,8-Dec-15,1/1/2008,9/1/2014,6/2/2016,Jun-16,2-Jun-16,null,Sep-14,Percentage of Participants With Best Overall Tumor Response|Percentage of Participants With Disease Control|Progression-free Survival (PFS) Time|Overall Survival (OS) Time|Cumulative Dose of Immunotherapy (Interferon Alpha-2a) in Daily Routine,https://ClinicalTrials.gov/show/NCT02627144
410,NCT00923910,Wilm's Tumor 1 Protein Vaccine to Treat Cancers of the Blood,Completed,Has Results,"Leukemia, Acute Myelogenous (AML)|Leukemia, Acute Lymphocytic (ALL)|Leukemia, Chronic Myelogenous (CML)|Myelodysplastic Syndrome (MDS)|Non-Hodgkin's Lymphoma (NHL)",Drug: WT1 Peptide-Pulsed Dendritic Cells|Drug: Donor Lymphocytes|Drug: IL-4|Drug: KLH|Drug: WT1 Peptides|Drug: Endotoxin|Drug: Diphenhydramine|Drug: Acetaminophen,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"1 Year to 74 Years   (Child, Adult, Senior)",Phase 1|Phase 2,10,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,080051|08-C-0051,17-Jun-09,1/1/2008,7/1/2013,5/2/2016,Apr-16,7-Apr-14,null,Jul-13,Toxicity|Number of Participants With Graft Versus Host Disease (GVHD) Greater Than or Equal to Grade 3,https://ClinicalTrials.gov/show/NCT00923910
495,NCT00837135,GI-4000 With Adoptive Transfer in Pancreatic Cancer,Withdrawn,No Results Available,Pancreatic Cancer,Other: Screening|Biological: GI-4000 Vaccine|Biological: GI-4000 Vaccine + Activated T Cells|Biological: Surgical Evaluation after Vaccine #4,University of Pennsylvania,Both,"18 Years and older   (Adult, Senior)",Phase 1,32,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,806693|UPCC 03207,4-Feb-09,1/1/2008,10/1/2009,9/21/2010,Sep-10,No Study Results Posted,null,Oct-09,"To evaluate the feasibility of incorporating GI-4000 vaccine and activated T-cell infusion into a regimen of chemotherapy, radiation, and surgical resection to treat locally advanced pancreatic cancer.",https://ClinicalTrials.gov/show/NCT00837135
557,NCT00522457,Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy,Terminated,Has Results,Metastatic Breast Cancer|Advanced Breast Cancer,Drug: ertumaxomab,Neovii Biotech|Fresenius Biotech North America,Female,"18 Years and older   (Adult, Senior)",Phase 2,19,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IV-ERT-BC-04,28-Aug-07,1/1/2008,12/1/2009,4/28/2011,Apr-11,1-Mar-11,null,Dec-09,Clinical Efficacy Measured by Objective Response Rate (Best Response During the Course of the Study)|Duration of Response|Clinical Benefit Rate,https://ClinicalTrials.gov/show/NCT00522457
670,NCT00610311,Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma,Terminated,Has Results,Metastatic Melanoma|Skin Cancer,Drug: cyclophosphamide|Drug: fludarabine phosphate|Biological: Aldesleukin|Biological: ALVAC gp100 Vaccine|Biological: anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL),National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years and older   (Adult, Senior)",Phase 2,3,NIH,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,080055|08-C-0055,6-Feb-08,1/1/2008,2/1/2011,10/6/2015,Sep-15,14-Mar-12,null,Feb-11,Number of Participants With Metastatic Melanoma Who Develop Clinical Tumor Regression (CR or PR)|Number of Participants With in Vivo Survival of T-cell Receptor (TCR) Gene-engineered Cells.|Number of Participants With Adverse Events|Number of Participants Who Develop Anti-mouse T Cell Receptor (TCR) Antibodies,https://ClinicalTrials.gov/show/NCT00610311
678,NCT00612222,Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma,Terminated,Has Results,Metastatic Melanoma|Skin Cancer,Biological: autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes|Biological: ALVAC MART-1 Vaccine|Biological: aldesleukin|Drug: cyclophosphamide|Drug: fludarabine phosphate,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years and older   (Adult, Senior)",Phase 2,4,NIH,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,080056|08-C-0056,8-Feb-08,1/1/2008,3/1/2011,10/6/2015,Oct-15,13-Mar-12,null,Mar-11,Number of Participants With Metastatic Melanoma Who Develop Clinical Tumor Regression (CR or PR)|Number of Participants With in Vivo Survival of T-cell Receptor (TCR) Gene-engineered Cells|Number of Participants With Adverse Events,https://ClinicalTrials.gov/show/NCT00612222
760,NCT01153113,Human Telomerase Reverse Transcriptase Messenger RNA (hTERT mRNA) Transfected Dendritic Cell Vaccines,Withdrawn,No Results Available,Metastatic Prostate Cancer,Biological: hTERT mRNA DC|Biological: hTERT mRNA DC,University of Florida,Male,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,0,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,LAMP hTERT DC Vaccine,31-Mar-10,1/1/2008,12/1/2010,11/30/2011,Feb-11,No Study Results Posted,null,Dec-09,The primary objective of this trial is to evaluate the safety of a boosting regimen using immunizations with two distinct doses of hTERT mRNA DC.|PSA-specific T cells from pre- and post-therapy PBMC samples|Calculate progression-free survival if subject responds to therapy.|overall survival,https://ClinicalTrials.gov/show/NCT01153113
904,NCT00669591,A Safety and Efficacy Study of Bavituximab Plus Docetaxel in Patients With Advanced Breast Cancer,Completed,No Results Available,Breast Cancer,Drug: Bavituximab,Peregrine Pharmaceuticals,Female,"18 Years and older   (Adult, Senior)",Phase 2,46,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PPHM 0704,28-Apr-08,1/1/2008,8/1/2010,8/26/2010,Aug-10,No Study Results Posted,null,Jun-10,"Overall response rate (complete response + partial response) to a combination of bavituximab plus docetaxel in patients with metastatic breast cancer|Secondary objectives include time to tumor progression, duration of response, overall survival, and safety.",https://ClinicalTrials.gov/show/NCT00669591
1133,NCT00806182,Study of Cytokines in Children With Opsoclonus-Myoclonus Syndrome,Recruiting,No Results Available,Opsoclonus-myoclonus Syndrome,,National Pediatric Myoclonus Center,Both,"1 Year to 18 Years   (Child, Adult)",,400,Other,Observational,Observational Model: Case Control,Thrasher Award 02826-2,8-Dec-08,1/1/2008,12/1/2016,1/24/2014,Jan-14,No Study Results Posted,OMS,Dec-16,Reduction in inflammatory cytokines|Correlation of cytokine concentration and clinical severity score.,https://ClinicalTrials.gov/show/NCT00806182
1233,NCT00676143,Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients,Terminated,Has Results,Alzheimer Disease,Drug: bapineuzumab|Drug: placebo,Pfizer,Both,"50 Years to 88 Years   (Adult, Senior)",Phase 3,1100,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3133K1-3001|B2521002|2007-005995-14,2-May-08,1/1/2008,11/1/2012,5/3/2016,May-16,14-Oct-13,null,Oct-12,"Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog)/11 Subscale Total Score at Week 78|Change From Baseline in Disability Assessment for Dementia (DAD) Total Score at Week 78|Change From Baseline in Brain Amyloid Burden at Week 71|Change From Baseline in Cerebrospinal Fluid (CSF) Phospho-tau Levels at Week 71|Change From Baseline in Brain Volume, as Assessed by Magnetic Resonance Imaging Brain Boundary Shift Integral (MRI BBSI), at Week 71|Divergence of Effect on the ADAS-Cog/11 Total Scores From Week 39 to Week 78|Divergence of Effect on the DAD Total Scores From Week 39 to Week 78|Time to First Median Placebo Deterioration on ADAS-Cog/11 Total Score (European Union [EU] Analysis Plan)|Time to First Clinically Meaningful Deterioration on ADAS-Cog/11 Total Score (United States [US] Analysis Plan)|Time to First Median Placebo Deterioration on DAD Total Score (EU Analysis Plan)|Time to First Clinically Meaningful Deterioration on DAD Total Score (US Analysis)|Change From Baseline in Dependence Scale Total Score at Week 78|Percentage of Participants With Worsening From Baseline in ADAS-Cog/11 Total Score at Week 78 (EU Analysis Plan)|Percentage of Responders for ADAS-Cog/11 Total Score at Week 78 (US Analysis Plan)|Percentage of Participants With Worsening From Baseline in DAD Total Score at Week 78 (EU Analysis Plan)|Percentage of Responders for DAD Total Score at Week 78 (US Analysis Plan)|Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SOB) Total Score at Week 78",https://ClinicalTrials.gov/show/NCT00676143
118,NCT00799136,A Feasibility Study of Co-administering Combination Antiretroviral Therapy (cART) and R-EPOCH Chemotherapy for the Management of ARL,Completed,No Results Available,"Lymphoma, AIDS Related|HIV Infections",Drug: R-EPOCH and cART,Ontario Clinical Oncology Group (OCOG)|Hoffmann-La Roche,Both,"18 Years and older   (Adult, Senior)",Phase 2,6,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,OCOG-2007-CATCH|CIHR FRN 79390,26-Nov-08,2/1/2008,9/1/2013,9/11/2013,Sep-13,No Study Results Posted,CATCH,Dec-12,"The primary outcome for this feasibility study will be medication adherence. Acceptable adherence, defined as compliance to ≥90% of all prescribed doses of cART during the course of chemotherapy, will be measured by pill counting and patient self-report|Toxicity Lymphoma response Rate Progression -free Survival and Overall Survival Pharmacokinetics",https://ClinicalTrials.gov/show/NCT00799136
245,NCT00577356,Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer,Terminated,Has Results,Prostate Cancer,Drug: Docetaxel|Biological: CG1940/CG8711,Benaroya Research Institute|Cell Genesys|Sanofi,Male,"18 Years and older   (Adult, Senior)",Phase 2,6,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IRB07028|I-0057|IST# 16194,18-Dec-07,2/1/2008,9/1/2008,1/18/2011,Nov-10,13-Sep-10,null,Sep-08,Number of Participants With Pathological Complete Response.,https://ClinicalTrials.gov/show/NCT00577356
265,NCT00610389,Phase II Study With Immunotherapy With Dendritic Cells and Tumor Infiltrating Lymphocytes in Solid Tumors,Recruiting,No Results Available,"Renal Cell Carcinoma|Melanoma|Carcinoma, Hepatocellular",Biological: immunotherapy with dendritic cells,"Clinica Universidad de Navarra, Universidad de Navarra",Both,"18 Years and older   (Adult, Senior)",Phase 2,27,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CD-2007-01,28-Jan-08,2/1/2008,12/1/2010,5/7/2010,May-10,No Study Results Posted,null,Apr-10,Response rate|Immunological response,https://ClinicalTrials.gov/show/NCT00610389
923,NCT00562666,Immunotherapy of Hepatocellular Carcinoma With Gamma Delta T Cells,Terminated,No Results Available,Hepatocellular Carcinoma,Other: T gamma delta lymphocytes,Rennes University Hospital|Innate Pharma,Both,"18 Years and older   (Adult, Senior)",Phase 1,2,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ID RCB 2007-A00249-44|CIC 0203/074|LOC 06/07,21-Nov-07,2/1/2008,1/1/2009,6/21/2012,Jun-12,No Study Results Posted,ICAR,Jan-09,"Onset of: thrombosis of hepatic artery, grade 4 liver toxicity, or grade 3 or more allergic, neurological, dermatological, infectious, or respiratory reaction|Onset of clinical, biological signs or images evocative of lymphocyte-induced tumor cytotoxicity and/or of a persistence of gamma-delta T cells in peripheral blood. Tumor response will be evaluated with the RECIST criteria.",https://ClinicalTrials.gov/show/NCT00562666
1221,NCT00597714,Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant,Completed,Has Results,Hodgkin's Disease|Non Hodgkin's Lymphoma|Myeloma|Leukemia|Myelodysplasia,Drug: Non-myeloablative Stem Cell Transplantation,"David Rizzieri, MD|Duke University",Both,"18 Years and older   (Adult, Senior)",Phase 2,264,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,Pro00003567,14-Jan-08,2/1/2008,11/1/2013,5/2/2014,Feb-14,5-Feb-14,null,Jul-13,Disease Free Survival|Immune Recovery|Progression Free Survival|Overall Survival|Graft Failure,https://ClinicalTrials.gov/show/NCT00597714
1241,NCT00725231,Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP,Recruiting,No Results Available,"Peripheral T Cell Lymphoma, Unspecified|Angioimmunoblastic Lymphadenopathy|Extranodal NK/T-cell Lymphoma",Biological: alemtuzumab|Drug: chemotherapy,University of Göttingen|German High-Grade Non-Hodgkin's Lymphoma Study Group|Nordic Lymphoma Group,Both,"61 Years to 80 Years   (Adult, Senior)",Phase 3,274,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,DSHNHL 2006-1B / ACT-2|BMBF GFVT 01014715,25-Jul-08,2/1/2008,3/1/2014,5/4/2012,May-12,No Study Results Posted,A-CHOP-14,Mar-14,Event free survival|Rate of complete and partial remissions|treatment related deaths|Overall survival|protocol adherence|immune reconstitution after alemtuzumab CHOP,https://ClinicalTrials.gov/show/NCT00725231
920,NCT00649584,A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies,Terminated,No Results Available,"Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin",Drug: SGN-35|Drug: gemcitabine,"Seattle Genetics, Inc.",Both,"12 Years and older   (Child, Adult, Senior)",Phase 1,44,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SG035-0002,27-Mar-08,3/1/2008,2/1/2010,12/17/2014,Dec-14,No Study Results Posted,null,Feb-10,Incidence of adverse events and laboratory abnormalities|PK profile|Immunogenicity (anti-SGN-35 antibodies)|Anti-tumor activity,https://ClinicalTrials.gov/show/NCT00649584
1059,NCT01493453,A Phase I Study of CD19 Specific T Cells in CD19 Positive Malignancy,Recruiting,No Results Available,CD19 Positive Non-Hodgkin Lymphoma,"Genetic: aCD19z cells, IL2, pre conditioning Cyclophosphamide & Fludarabine",Professor Robert Hawkins|The Christie NHS Foundation Trust,Both,"18 Years and older   (Adult, Senior)",Phase 1,24,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,05_DOG05_18,14-Dec-11,3/1/2008,12/1/2014,11/25/2013,Nov-13,No Study Results Posted,CD19,May-14,"To asses aCD19z T cell survival and aCD19z T cell toxicity in patients, & The dose of aCD19z T cells required to give optimal survival of these cells in the circulation|To assess whether aCD19z T cells in the circulation are functional",https://ClinicalTrials.gov/show/NCT01493453
45,NCT00655161,"A Pilot Phase 2 Trial of the Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant S. Cerevisiae Expressing Mutant Ras Protein, as Consolidation Therapy Following Curative Treatment for Stage I-III Non-Small Cell Lung Cancer (NSCLC) With Tumor Sequence Confirmation of K-ras Mutation",Completed,No Results Available,NSCLC,Biological: GI-4000,GlobeImmune|Memorial Sloan Kettering Cancer Center,Both,"18 Years and older   (Adult, Senior)",Phase 2,24,Industry|Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,GI-4000-03,2-Apr-08,4/1/2008,11/1/2013,1/28/2014,Jan-14,No Study Results Posted,null,Nov-13,Immune response to GI-4000,https://ClinicalTrials.gov/show/NCT00655161
209,NCT00673738,Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC),Completed,Has Results,Lung Cancer,Drug: Cetuximab|Radiation: Conformal Thoracic Radiotherapy (CTRT),H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb,Both,"18 Years and older   (Adult, Senior)",Phase 2,27,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MCC-15294|106296|CA225286,5-May-08,4/1/2008,8/1/2015,9/23/2015,Sep-15,18-Sep-13,null,Dec-13,Median Progression Free Survival (PFS)|Median Overall Survival (OS)|Overall Response Rate (ORR),https://ClinicalTrials.gov/show/NCT00673738
446,NCT00670748,Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic Cancer,"Active, not recruiting",Has Results,Metastatic Melanoma|Metastatic Renal Cell Cancer|Metastatic Cancer,Biological: Anti-NY ESO-1 T-cell receptor PBL|Drug: aldesleukin|Drug: Cyclophosphamide|Drug: fludarabine phosphate|Biological: ALVAC NY ESO-1 vaccine,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 66 Years   (Adult, Senior)",Phase 2,45,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,080121|08-C-0121,1-May-08,4/1/2008,9/1/2016,6/28/2016,Jun-16,19-May-16,null,May-13,Clinical Response Per the Response Evaluation Criteria in Solid Tumors (RECIST)|Number of Participants With In Vivo Survival of T-Cell Receptor (TCR)-Engineered Cells|Number of Participants With Adverse Events,https://ClinicalTrials.gov/show/NCT00670748
669,NCT00685750,Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma,Terminated,No Results Available,"Lung Cancer, Non-Small Cell",Procedure: Collection of tumor and blood samples,GlaxoSmithKline,Both,"18 Years and older   (Adult, Senior)",,219,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Screening,109752,23-May-08,4/1/2008,12/1/2016,6/15/2015,Jun-15,No Study Results Posted,null,Oct-14,"Expression of tumor antigens|Occurrence of a pre-defined gene-expression signature to Antigen-Specific Cancer Immunotherapeutic|The serum proteome|Correlation of relevant markers of the pre-identified gene-expression signature as measured by immunohistochemical methods and by quantitative PCR.|For NSCLC patients (where possible), the consistency of the occurrence of the gene-expression signature and tumor antigens in distinct concomitant tumor lesions obtained at the same time from the same patient.|For metastatic melanoma patients treated with ipilimumab explore predictive value to clinical activity of pre-identified immune-related gene-expression signature by evaluating the patient's best clinical response to this treatment.",https://ClinicalTrials.gov/show/NCT00685750
672,NCT00665470,Chemotherapy Followed by gp100 Lymphocytes and Aldesleukin to Treat Melanoma,Completed,Has Results,Skin Cancer|Metastatic Melanoma,Drug: Aldesleukin,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years and older   (Adult, Senior)",Phase 2,10,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,080104|08-C-0104,23-Apr-08,4/1/2008,4/1/2012,9/28/2015,Sep-15,12-Dec-12,null,Apr-12,Response|Toxicity as Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) V3.0,https://ClinicalTrials.gov/show/NCT00665470
1235,NCT01207765,Fixed Dose Radioimmunotherapy (Zevalin) for Patients With Incomplete Response to Chemo Prior to Autologous Stem Cell Transplant for Multiple Myeloma,Completed,No Results Available,Multiple Myeloma,Drug: indium-111-ibritumomab tiuxetan|Drug: 90Y Zevalin,"Tufts Medical Center|Spectrum Pharmaceuticals, Inc",Both,"18 Years to 70 Years   (Adult, Senior)",Phase 2,8,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,Zevalin,21-Sep-10,4/1/2008,6/1/2013,12/8/2014,Dec-14,No Study Results Posted,null,Jan-13,"Safety (rate of occurrence of defined toxic events) and Efficacy (objective response rate)|Evaluate the kinetics of engraftment in patients who proceed to myeloablative chemotherapy after receiving 90Y Zevalin® (ibritumomab tiuxetan).|Evaluate whether the degree of CD20 expression on plasma cells and/or targeting of post-germinal center B cells correlate with toxicity, response, biodistribution and other clinical parameters.",https://ClinicalTrials.gov/show/NCT01207765
233,NCT00879489,Cellular Immunotherapy Study With Autologous Dendritic Cells Loaded With Oncofetal Antigen/iLRP in Patients With Metastatic Breast Cancer,"Active, not recruiting",No Results Available,Breast Cancer,Biological: Dendritic Cell Vaccination,"Quantum Immunologics, Inc.|University of South Alabama",Female,"18 Years to 85 Years   (Adult, Senior)",Phase 1|Phase 2,24,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,,9-Apr-09,5/1/2008,9/1/2011,2/23/2011,Apr-09,No Study Results Posted,null,Mar-11,"Toxicity|Response, Survival, Immunological Monitoring, Time to Disease Progression",https://ClinicalTrials.gov/show/NCT00879489
1058,NCT00891475,Palliative Radiofrequency Ablation in Metastatic Renal Cell Carcinoma Patients,Completed,No Results Available,"Carcinoma, Renal Cell",Procedure: Radiofrequency ablation; Interferon-alpha|Procedure: Radiofrequency ablation; Sunitinib maleate|Drug: Sunitinib maleate,Kidney Cancer Research Bureau,Both,"18 Years to 85 Years   (Adult, Senior)",Phase 1|Phase 2,114,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,KCRB-003,30-Apr-09,5/1/2008,1/1/2011,2/11/2014,Feb-14,No Study Results Posted,null,Jan-10,Progression-free survival|Overall survival|rate of complications|time from the end of ablation to start of medical treatment|Quality of life (QOL),https://ClinicalTrials.gov/show/NCT00891475
1122,NCT00718250,Lentivirus Transduced Acute Myeloid Leukaemia Blasts Expressing B7.1 (CD80) and IL-2,Recruiting,No Results Available,"Leukemia, Myeloid, Acute",Biological: RFUSIN2-AML1|Biological: Donor leukocyte infusion (DLI)|Biological: RFUSIN2-AML1 and donor leukocyte infusion|Biological: RFUSIN2-AML1 and donor leukocyte infusion,King's College Hospital NHS Trust|Department of Health|Leukemia Research Fund|Elimination of Leukaemia Fund,Both,"18 Years and older   (Adult, Senior)",Phase 1,24,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment,O5CC14|EudraCT 2005-000806-29|GTAC GTAC098,6-Jun-08,5/1/2008,2/1/2012,7/16/2008,Jul-08,No Study Results Posted,RFUSIN2-AML1,May-11,"Toxicity and safety of the 'AML Cell Vaccine'|relapse, leukaemia free survival and overall survival",https://ClinicalTrials.gov/show/NCT00718250
1265,NCT00656812,Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma,Completed,No Results Available,Lymphoma of Mucosa-Associated Lymphoid Tissue,Drug: Rituximab|Drug: 2-CdA,Arbeitsgemeinschaft medikamentoese Tumortherapie|Hoffmann-La Roche|Lipomed,Both,"18 Years and older   (Adult, Senior)",Phase 2,40,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AGMT_MALT|EudraCT 2008-000767-41,2-Apr-08,5/1/2008,9/1/2011,12/23/2013,Dec-13,No Study Results Posted,null,Sep-11,Response rate|Progression-free survival and relapse-free survival|Occurrence of adverse events,https://ClinicalTrials.gov/show/NCT00656812
282,NCT00688090,Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.,Completed,No Results Available,Advanced Melanoma|Stage III and IV Melanoma,Biological: Biological: MKC1106-MT|Biological: Biological: MKCC1106-MT,Mannkind Corporation,Both,"18 Years and older   (Adult, Senior)",Phase 1,19,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MKC1106-MT-001,28-May-08,6/1/2008,5/1/2010,8/2/2010,Aug-10,No Study Results Posted,null,Dec-09,Is to assess the safety and tolerability of MKC1106-MT regimen|To assess the immune response (by tetramer and ELISPOT analysis) of MKC1106-MT when administered to subjects with advanced melanoma|To determine pMEL-TYR plasmid level in the blood by PCR analysis|To determine target antigen expression (Melan A and tyrosinase) and beta2 microglobulin expression in the tumor tissue|To document any preliminary evidence of clinical response,https://ClinicalTrials.gov/show/NCT00688090
440,NCT00660101,"Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients With Relapsed Stage III or IV Ovarian Cancer","Active, not recruiting",No Results Available,Adenocarcinoma of the Ovary,"Biological: OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine",AVAX Technologies,Female,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,34,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",A/100/0501,16-Apr-08,6/1/2008,1/1/2016,12/2/2015,Dec-15,No Study Results Posted,null,Dec-15,Cell-mediated immunity to autologous tumor cells|Safety,https://ClinicalTrials.gov/show/NCT00660101
480,NCT00746746,A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma,"Active, not recruiting",No Results Available,Melanoma,Biological: HyperAcute vaccine|Drug: Pegylated Interferon-Alpha 2b,Ochsner Health System|NewLink Genetics Corporation,Both,"19 Years and older   (Adult, Senior)",Phase 2,30,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,USA-MCI-01|IND# 13647,3-Sep-08,6/1/2008,6/1/2011,1/12/2011,Sep-08,No Study Results Posted,null,Jun-10,"To conduct scientific studies of patient tumor and peripheral blood samples to determine the mechanism of any observed anti-tumor effect involving the immune responses to the HyperAcute® vaccine alone & combined with PEG-Intron|To determine the safety and response rate of the administration of the HyperAcute®-Melanoma Vaccine combined with PEG-Intron® into patients with recurrent, refractory, metastatic, or high risk of recurrence melanoma",https://ClinicalTrials.gov/show/NCT00746746
590,NCT00659178,Combination Study Of SB-485232 (Interleukin 18) And Doxil For Advanced Stage Epithelial Ovarian Cancer,Completed,No Results Available,"Primary Peritoneal Carcinoma|Epithelial Ovarian Carcinoma|Neoplasms, Ovarian|Fallopian Tube Cancer","Drug: SB-485232 (interleukin 18), pegylated liposomal doxorubicin",GlaxoSmithKline,Female,"18 Years and older   (Adult, Senior)",Phase 1,15,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ILI108621,10-Apr-08,6/1/2008,2/1/2011,3/15/2012,Mar-11,No Study Results Posted,null,Feb-11,"Safety and tolerability of SB-485232/Doxil combination therapy|Biological activity of SB-485232/Doxil combination therapy|Pharmacokinetic parameters for SB-485232 and Doxil: AUC(0-t), Cmax, and Cmin|Pharmacodynamic biomarker responses|Immunogenicity (anti-SB-485232 and anti-PEG antibodies)|Anti-tumor activity (Radiographic tumor assessments and serum CA-125 levels)",https://ClinicalTrials.gov/show/NCT00659178
743,NCT00711191,A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas,Completed,Has Results,Pancreatic Neoplasm,Biological: monoclonal antibody|Drug: chemotherapy,Hoffmann-La Roche|University of Pennsylvania,Both,"18 Years and older   (Adult, Senior)",Phase 1,22,Industry|Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,A5021005,26-Jun-08,6/1/2008,1/1/2011,11/26/2013,Nov-13,3-May-12,null,Jan-11,"Number of Participants With Dose Limiting Toxicities (DLTs)|Percentage of Participants With Objective Tumor Response According to Response Evaluation Criteria in Solid Tumors (RECIST)|Overall Survival (OS)|Progression Free Survival (PFS)|Time to Progression|Maximum Serum Concentration (Cmax)|Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)|Change (Pre-dose to Post-dose) in Plasma Cytokine Concentrations: Pre-dose Concentration (CYTO0), Maximum Concentration (CTYOMAX)|Change (Pre-dose to Post-dose) in Plasma Cytokine Concentrations: Time of Maximum Concentration (TCYTOMAX)|Total and Neutralizing Human Antihuman Antibody (HAHA) Titer|Change (Pre-dose to Post-dose) in Bone Marrow Derived Cells (B Cell) Surface Markers: CD54, CD23, CD40, CD86, and Human Leukocyte Antigen (HLA-DR)|18-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) Imaging (MTD Expansion Cohort)|Carbohydrate Antigen 19-9 (CA 19-9)",https://ClinicalTrials.gov/show/NCT00711191
1103,NCT00636168,Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma,"Active, not recruiting",Has Results,High Risk Stage III Melanoma,Drug: ipilimumab|Drug: Placebo,Bristol-Myers Squibb,Both,"18 Years and older   (Adult, Senior)",Phase 3,1211,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",CA184-029|EORTC 18071,7-Mar-08,6/1/2008,7/1/2016,6/20/2016,Oct-15,25-Jul-14,null,Jul-13,"Recurrence Free Survival (RFS) Per Independent Review Committee (IRC) in the Intent to Treat (ITT) Population|Number of Patients With Recurrence or Death as Per Independent Review Committee (IRC) in the Intent to Treat (ITT) Population|Recurrence-Free Survival (RFS) Rates Per IRC at 1 Year, 2 Years, and 3 Years in the ITT Population|Number of Patients With Distant Metastasis-Free Survival (DMFS)|Number of Participants With Overall Survival (OS)|Number of Patients With Adverse Events (AEs) Leading to Discontinuation of Treatment, Serious AEs (SAEs), Drug-Related SAEs, Immune-related AEs (irAEs), Immune-mediated Adverse Reactions (imARs), Deaths in Treated Population|Exposure Adjusted Incidence Rate of Adverse Events Including Multiple Occurrences of Unique Events|Mean Change From Baseline in Global Health Status Scores at Each Assessment Timepoint",https://ClinicalTrials.gov/show/NCT00636168
1234,NCT00667810,Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients,Terminated,Has Results,Alzheimer Disease,Drug: bapineuzumab|Drug: bapineuzumab|Drug: placebo,Pfizer,Both,"50 Years to 89 Years   (Adult, Senior)",Phase 3,901,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",3133K1-3000|B2521001|2007-005994-79,24-Apr-08,6/1/2008,8/1/2013,12/4/2015,Dec-15,22-Oct-13,null,Oct-12,The Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)/11 Total Score at Week 78|The Change From Baseline in the Disability Assessment for Demential (DAD) Total Score at Week 78|The Change From Baseline in Brain Amyloid Burden at Week 71.|The Change From Baseline in Phospho-tau Levels in the Cerebrospinal Fluid (CSF) at Week 71.|The Change From Baseline in Brain Volume at Week 71|Divergence of Effect on the ADAS-Cog/11 Total Scores From Week 39 to Week 78|Divergence of Effect on the DAD Total Scores From Week 39 to Week 78|Time to Median Placebo Deterioration on ADAS-Cog/11 Total Score (European Union [EU] Analysis Plan)|Time to First Clinically Meaningful Deterioration on ADAS-Cog/11 Total Score (United States [US] Analysis Plan)|Time to Median Placebo Deterioration on DAD Total Score|Time to First Clinically Meaningful Deterioration on DAD Total Score (US Analysis Plan)|Percentage of Participants With Worsening From Baseline in ADAS-Cog/11 Total Score at Week 78 (European Union Analysis Plan)|Percentage of Participants With Worsening From Baseline in ADAS-Cog/11 Total Score at Week 78 (US Analysis Plan)|Percentage of Participants With Worsening From Baseline in DAD Total Score at Week 78 (European Union Analysis Plan)|Percentage of Participants With Worsening From Baseline in DAD Total Score at Week 78 (US Analysis Plan)|Change From Baseline in Dependence Scale Total Score at Week 78|Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SOB) Total Score at Week 78,https://ClinicalTrials.gov/show/NCT00667810
1249,NCT00722098,Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients,Terminated,No Results Available,Malignant Melanoma Stage IV,Biological: DC Vaccine & Cyclophosphamide|Biological: DC Vaccine & Placebo,Baylor Research Institute,Both,"21 Years to 75 Years   (Adult, Senior)",Phase 2,9,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",Baylor IRB #006-123,23-Jul-08,6/1/2008,7/1/2012,7/5/2013,Jul-13,No Study Results Posted,null,Apr-11,Induction of melanoma-specific CD8+T Cell Immunity.|Rate of objective clinical responses.,https://ClinicalTrials.gov/show/NCT00722098
186,NCT00715104,Sipuleucel-T as Neoadjuvant Treatment in Prostate Cancer,Completed,Has Results,Prostate Cancer,Biological: Sipuleucel-T with Booster|Biological: Sipuleucel-T without Booster,"Dendreon|University of California, San Francisco",Male,"18 Years and older   (Adult, Senior)",Phase 2,42,Industry|Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,P07-1,11-Jul-08,7/1/2008,12/1/2013,4/14/2015,Apr-15,27-Feb-15,NeoACT,Dec-12,Change in the Number of Infiltrating CD3+ T Cells Within the Prostate Tissue Between the Biopsy and the Post-RP Tissue Specimens in Each Subject|Change in the Number of Infiltrating CD4+ T Cells Within the Prostate Tissue Between the Biopsy and the Post-RP Tissue Specimens in Each Subject|Change in the Number of Infiltrating CD8+ T Cells Within the Prostate Tissue Between the Biopsy and the Post-RP Tissue Specimens in Each Subject|Change in Antigen PA2024-specific T Cell Immunity in Peripheral Blood|Change in Antigen PAP-specific T Cell Immunity in Peripheral Blood|Effect of a Post-RP Booster Infusion of Sipuleucel-T Over Time of Antigen PA2024-Specific T Cell Immunity in the Peripheral Blood.|Effect of a Post-RP Booster Infusion of Sipuleucel-T Over Time of Antigen PAP-Specific T Cell Immunity in the Peripheral Blood.|Comparison of Booster Effect in Antigen PA2024-Specific T Cell Immunity Over Time Between the Two Randomized Groups|Comparison of Booster Effect in Antigen PAP-Specific T Cell Immunity Over Time Between the Two Randomized Groups,https://ClinicalTrials.gov/show/NCT00715104
334,NCT00771017,Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer,Withdrawn,No Results Available,Prostate Cancer,Biological: GVAX prostate cancer vaccine|Drug: bicalutamide|Drug: goserelin|Drug: leuprolide acetate,Eastern Cooperative Oncology Group|National Cancer Institute (NCI),Male,"18 Years and older   (Adult, Senior)",Phase 2,0,Other|NIH,Interventional,Allocation: Randomized|Masking: Open Label|Primary Purpose: Treatment,CDR0000616570|ECOG-E3806,9-Oct-08,7/1/2008,null,8/16/2013,Aug-13,No Study Results Posted,null,Apr-10,Median PSA recurrence-free survival in patients in patients responding to the study treatments|Safety|Effects of 6-month androgen ablation on thymic production of naïve T cells|Median time to metastatic disease development,https://ClinicalTrials.gov/show/NCT00771017
651,NCT00690872,Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer,Recruiting,No Results Available,Head and Neck Cancer,Biological: autologous Epstein-Barr virus-specific cytotoxic T lymphocytes|Drug: carboplatin|Drug: gemcitabine hydrochloride|Genetic: polymerase chain reaction|Other: fluorescence activated cell sorting|Other: immunoenzyme technique,"National Cancer Centre, Singapore|National Cancer Institute (NCI)",Both,"21 Years and older   (Adult, Senior)",Phase 2,35,Other,Interventional,Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment,CDR0000577971|SINGAPORE-07-27-NPC,4-Jun-08,7/1/2008,null,6/26/2009,Jun-09,No Study Results Posted,null,Dec-14,"Median progression-free survival (PFS 1), defined as the time from study enrollment to the time of radiological disease progression or death from any cause|Median PFS 2, defined as the time from the start of induction immunotherapy to radiological disease progression or death from any cause|Response rate, defined as the proportion of patients who achieve a complete response (CR) or partial response (PR) after 4 courses of chemotherapy and the proportion of patients who achieve a further response after immunotherapy|Clinical benefit rate of immunotherapy, defined as the proportion of patients who achieve CR, PR, or stable disease",https://ClinicalTrials.gov/show/NCT00690872
987,NCT00699816,Efficacy and Safety of Immuncell-LC Group and Non-treatment Group in Hepatocelluar Carcinoma Patients,Completed,Has Results,Hepatocellular Carcinoma,Biological: Immuncell-LC,Green Cross Cell Corporation,Both,"20 Years to 80 Years   (Adult, Senior)",Phase 3,230,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,IIC-I01,17-Jun-08,7/1/2008,11/1/2012,8/23/2015,Aug-15,18-Jun-15,null,Nov-12,Recurrence Free Survival(RFS)|Recurrence Free Survival(RFS) Rate|Overall Survival(OS)|Cancer-specific Survivals|Overall Survival(OS) Rate|Cancer-specific Survival Rate,https://ClinicalTrials.gov/show/NCT00699816
224,NCT00715078,To Evaluate Sipuleucel-T Manufactured With Different Concentrations of Prostate Adenocarcinoma (PA2024) Antigen,Completed,Has Results,Prostate Cancer,Biological: Sipuleucel-T,Dendreon,Male,"18 Years and older   (Adult, Senior)",Phase 2,122,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment,P07-2,11-Jul-08,8/1/2008,4/1/2015,4/21/2016,Apr-16,19-Feb-14,ProACT,May-12,Compare the Cumulative CD54 Upregulation Ratio Between Each of the Cohorts.|Evaluate the Magnitude of the Immune Response in Each of the Cohorts.|Evaluate the Overall Survival in Each of the Cohorts.,https://ClinicalTrials.gov/show/NCT00715078
249,NCT00638612,AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01),Completed,No Results Available,Pancreatic Adenocarcinoma|Pancreatic Cancer,Biological: AdV-tk|Drug: Valacyclovir,"Advantagene, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1,27,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PaTK01,6-Mar-08,8/1/2008,6/1/2015,10/28/2015,Oct-15,No Study Results Posted,PaTK01,May-13,Safety based on symptoms and laboratory abnormalities not expected from standard of care treatments or natural history of the disease process. Toxicity grading uses NCI CTC version 3. Dose limiting toxicity is specifically defined in the protocol.|Overall survival|Progression free survival|Tumor response including pathologic response|Quality of life|Resectability|CA 19-9 response,https://ClinicalTrials.gov/show/NCT00638612
357,NCT00735345,Chemotherapy Induction and Chemoradiotherapy in Patients With Esophageal Carcinoma,Terminated,No Results Available,Esophageal Cancer,Drug: 5-FU|Drug: Cisplatin|Drug: Taxotere|Biological: Cetuximab|Radiation: Radiation during chemoradio-immunotherapy,Arbeitsgemeinschaft medikamentoese Tumortherapie|Merck Sharp & Dohme Corp.|Sanofi,Both,"18 Years and older   (Adult, Senior)",Phase 2,50,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AGMT_ECa|EudraCT Nr. 2008-001016-21,13-Aug-08,8/1/2008,12/1/2012,3/6/2015,Mar-15,No Study Results Posted,null,Dec-12,Response rate|Percentage of complete remissions and resection rate|Occurrence of toxicities|Evaluation of Quality of Life,https://ClinicalTrials.gov/show/NCT00735345
893,NCT02372708,Clinical Research on the Treatments on Advanced Malignant Melanoma by Combining in Situ Immunotherapy and Laser Therapy,Completed,No Results Available,Melanoma,Drug: dinitrophenyl(DNP)|Radiation: Radiation,Chinese PLA General Hospital,Both,"18 Years to 70 Years   (Adult, Senior)",Phase 2,72,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,ML125396,13-Feb-15,8/1/2008,5/1/2014,2/25/2015,Feb-15,No Study Results Posted,null,May-12,"ORR|PFS|OS|biomarker (peripheral blood CD4+CD25+Treg regulatory T cells (Treg), CD8+T, CD4+ T effector cells, IL-10, TGF-β)",https://ClinicalTrials.gov/show/NCT02372708
1123,NCT00603668,Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL,Completed,No Results Available,Chronic Lymphocytic Lymphoma,Biological: milatuzumab,"Immunomedics, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,19,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IM-T-hLL1-02,8-Jan-08,8/1/2008,2/1/2013,3/25/2013,Mar-13,No Study Results Posted,null,Jan-13,"Safety of the anti-CD74 antibody will be evaluated based upon physical examinations, hematology and chemistry laboratory evaluations and toxicity events|Efficacy (to see if the study drug works) in patients with NHL and CLL|Pharmacokinetics (how the drug is processed by the body)|Pharmacodynamics (how the study drug is absorbed by the body)`|Immunogenicity|optimal dose",https://ClinicalTrials.gov/show/NCT00603668
1224,NCT01073839,Adjuvant Cisplatin Plus Gemcitabine in Operable Cholangiocellular Carcinoma.,Completed,No Results Available,Cholangiocellular Carcinoma,Drug: Cisplatin and Gemcitabine,University of Zurich,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,33,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ONK USZ 001-2008,25-Jun-09,8/1/2008,8/1/2015,9/17/2015,Sep-15,No Study Results Posted,null,Aug-15,Occurence of Grade 3 or 4 toxicities according to NCI-common terminology criteria for adverse events v3.0|Disease-free survival,https://ClinicalTrials.gov/show/NCT01073839
59,NCT00769522,FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia,"Active, not recruiting",No Results Available,Leukemia,Biological: rituximab|Drug: bendamustine hydrochloride|Drug: cyclophosphamide|Drug: fludarabine phosphate,German CLL Study Group|Roche Pharma AG|Mundipharma Pte Ltd.,Both,"18 Years and older   (Adult, Senior)",Phase 3,564,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000616169|GCLLSG-CLL10|2007-007587-21,8-Oct-08,9/1/2008,1/1/2018,3/14/2012,Mar-12,No Study Results Posted,CLL10,Jul-11,"Progression-free survival rate after 24 months|Minimal residual disease, complete response rates, and partial response rates|Duration of remission|Event-free survival|Overall survival|Overall response rate|Response rates in and survival times in biological subgroups|Toxicity rates|Quality of life|Standard safety analysis",https://ClinicalTrials.gov/show/NCT00769522
782,NCT00640796,"Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors",Completed,No Results Available,"Leukemia, Myeloid, Acute|Leukemia, Lymphocytic, Acute, T-Cell|Juvenile Myelomonocytic Leukemia Lymphoblastic|T-cell Lymphoblastic Lymphoma|Myelodysplastic Syndrome",Procedure: Haploidentical donor derived natural killer cell infusion|Drug: Chemotherapy|Device: CliniMACS,St. Jude Children's Research Hospital|National Cancer Institute (NCI)|Assisi Foundation,Both,"up to 18 Years   (Child, Adult)",Phase 1,22,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NKEXP|R01CA113482,14-Mar-08,9/1/2008,4/1/2014,4/23/2014,Apr-14,No Study Results Posted,null,Apr-14,To determine the maximum tolerated dose of expanded NK cells in research participants with relapsed or refractory hematologic malignancies and sarcomas.,https://ClinicalTrials.gov/show/NCT00640796
980,NCT00866970,"Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia",Completed,No Results Available,NSCLC|Fatigue|Cachexia,Biological: ALD518|Biological: ALD518|Biological: ALD518|Biological: Infusion of 0.9% Saline without ALD518,"Alder Biopharmaceuticals, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 2,124,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ALD518-CLIN-004,20-Mar-09,9/1/2008,12/1/2009,9/10/2010,Sep-10,No Study Results Posted,null,Aug-09,Change in Safety parameters.|Time to symptomatic progressions at Weeks 12 and 24,https://ClinicalTrials.gov/show/NCT00866970
984,NCT00762255,A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma,Completed,No Results Available,Glioblastoma,Drug: Vorinostat|Drug: Bevacizumab|Drug: Irinotecan,H. Lee Moffitt Cancer Center and Research Institute|Merck Sharp & Dohme Corp.,Both,"18 Years and older   (Adult, Senior)",Phase 1,19,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MCC-15629|33726,29-Sep-08,9/1/2008,7/1/2013,7/24/2013,Jul-13,No Study Results Posted,null,Jul-13,Maximum Tolerated Dose (MTD)|Number of Participants With Progression Free Survival (PFS) at 6 Months|Number of Participants With Adverse Events (AEs),https://ClinicalTrials.gov/show/NCT00762255
1201,NCT00693095,Evaluation of Recovery From Drug-Induced Lymphopenia Using Cytomegalovirus-specific T-cell Adoptive Transfer,Completed,No Results Available,Glioblastoma,Biological: CMV-ALT + CMV-DCs|Biological: CMV-ALT + Saline,John Sampson|Duke University,Both,"18 Years and older   (Adult, Senior)",Phase 1,23,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment,Pro00000580|SPORE Project 3,3-Jun-08,9/1/2008,4/1/2015,1/20/2016,Jan-16,No Study Results Posted,ERaDICATe,Dec-13,To evaluate if vaccinating adult patients with newly-diagnosed GBMs using CMV-DCs during recovery from therapeutic TMZ-induced lymphopenia with ALT in patients that are seropositive for CMV enhances the T-cell response.|To evaluate the safety of ALT with CMV pp65-activated T-cells in adult patients with newly-diagnosed GBMs during recovery from therapeutic TMZ-induced lymphopenia.,https://ClinicalTrials.gov/show/NCT00693095
29,NCT00725283,Evaluation of a New Anti-cancer Immunotherapy After Chemotherapy in Adult Patients With Acute Myeloid Leukemia (AML),Completed,No Results Available,"Leukaemia, Myelocytic, Acute",Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A,GlaxoSmithKline,Both,"18 Years and older   (Adult, Senior)",Phase 1,34,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,111444|2010-023886-24,29-Jul-08,10/1/2008,6/1/2016,7/28/2016,Jul-16,No Study Results Posted,null,Jun-16,Occurrence of severe toxicities as defined in the protocol|Humoral and cellular Immunogenicity of the WT1 ASCI|Occurrence of adverse events and serious adverse events|Occurrence of serious adverse events related to study treatment,https://ClinicalTrials.gov/show/NCT00725283
472,NCT00694551,PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment,"Active, not recruiting",Has Results,Prostate Cancer,Biological: Peptide Vaccine|Drug: Poly IC-LC,H. Lee Moffitt Cancer Center and Research Institute|National Institutes of Health (NIH),Male,"18 Years and older   (Adult, Senior)",,29,Other|NIH,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MCC-15262|106346|20-14555-05-01,4-Jun-08,10/1/2008,4/1/2017,6/10/2016,Jun-16,6-Jan-14,null,Feb-13,Occurrence of Related Adverse Events - Grade 3 or Higher|Number of Participants With Prostatic Specific Antigen (PSA) Doubling|Number of Participants Who Did Not Have PSA Doubling,https://ClinicalTrials.gov/show/NCT00694551
1203,NCT00779337,Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas,Completed,No Results Available,Lymphoma,Biological: Autologous AdE1- Latent Membrane Protein CTLs,"Queensland Institute of Medical Research|The Atlantic Philanthropies|Australian Department of Industry, Tourism and Resources|British Society for Haematology|National Health and Medical Research Council, Australia",Both,"18 Years and older   (Adult, Senior)",Phase 1,8,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,QIMR P1167|ANZCTR12608000521325,22-Oct-08,10/1/2008,5/1/2012,5/21/2012,May-12,No Study Results Posted,EPL,Jan-12,"Feasibility (generation of autologous clinical grade AdE1-LMP-specific CTL from the blood of EBV-positive lymphoma patients)|Safety as assessed by adverse event monitoring. Patients will be questioned and toxicities recorded according to the International Common Toxicity Criteria.|Reconstitution of EBV-specific CTL immunity with anti-viral efficacy measured by immunological & virological assessment of blood samples including immunophenotyping, intracellular cytokine assays, CD107 cytotoxicity assays and EBV DNA load analysis.|Optimal dose intensity of the intervention. Clinical efficacy (radiological assessment by CT), biological efficacy (reconstitution of EBV-specific CTL immunity & anti-viral efficacy), safety & efficacy of the 1st treatment schedule vs the 2nd schedule|Clinical efficacy",https://ClinicalTrials.gov/show/NCT00779337
1216,NCT01749865,CIK Treatment for HCC Patient Underwent Radical Resection,Completed,No Results Available,"Carcinoma, Hepatocellular",Biological: Cytokine-Induced Killer Cells,Sun Yat-sen University,Both,"18 Years to 100 Years   (Adult, Senior)",Phase 3,200,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,2007043-HCC012,12-Dec-12,10/1/2008,12/1/2014,4/13/2016,Apr-16,No Study Results Posted,null,Sep-14,Time to recurrence|Disease Free Survival,https://ClinicalTrials.gov/show/NCT01749865
316,NCT00734773,Pilot Study of MGd + High-dose MTX-Based Chemoimmunotherapy + RT for Newly Dx PCNSL,Withdrawn,No Results Available,Brain and Central Nervous System Tumors|Lymphoma|Neurotoxicity,Biological: Rituximab|Drug: Cytarabine|Drug: Methotrexate|Drug: Motexafin gadolinium|Drug: Procarbazine hydrochloride|Drug: Vincristine sulfate|Radiation: Radiation therapy,Northwestern University|Pharmacyclics,Both,"18 Years and older   (Adult, Senior)",Phase 0,0,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NU 05H7|STU00002443,13-Aug-08,11/1/2008,null,5/16/2012,May-12,No Study Results Posted,null,null,"Toxicity of motexafin gadolinium (MGd) and rituximab added to high-dose methotrexate, procarbazine hydrochloride, and vincristine (MPV) chemotherapy|Toxicity of MGd added to whole-brain radiotherapy (WBRT)|Tumor-selective uptake of MGd|Overall response rate (complete remission [CR] and partial remission [CR]) to pre-radiation chemo-immunotherapy (R-MPV with MGd)|Complete response rate to pre-radiation chemo-immunotherapy (R-MPV with MGd)|Overall survival at 1 year|Event-free survival at 1 year|Progression-free survival at 1 year|Neurotoxicity of R-MVP + MGd based on pre- and post-treatment neuropsychologic testing",https://ClinicalTrials.gov/show/NCT00734773
405,NCT00924287,Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic Cancer,Terminated,Has Results,Metastatic Cancer,"Drug: in vitro tumor reactive, chimeric T cell receptor (CAR ) gene-transduced PBL plus IV aldesleukin|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Mesna",National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,1,NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,090041|09-C-0041,17-Jun-09,11/1/2008,12/1/2010,10/6/2015,Oct-15,5-Jan-12,null,Dec-10,Number of Participants With an Objective Clinical Tumor Regression Response|Number of Participants With Adverse Events|Number of Participants With In Vivo Survival of Transfused Cells,https://ClinicalTrials.gov/show/NCT00924287
983,NCT00911196,Analysis of Expression of Specific Markers and Their Prognostic Significance in Hepatocellular Carcinoma,Completed,No Results Available,Hepatocellular Carcinoma,Other: Retrospective analysis of already archived samples,GlaxoSmithKline,Both,"Child, Adult, Senior",,200,Industry,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,111726,28-May-09,11/1/2008,3/1/2009,9/29/2011,Sep-11,No Study Results Posted,null,Mar-09,The proportion of hepatocellular carcinoma patients whose tumor tissue expresses specific tumor antigens.|The prognostic character of the expression of the tumor antigens|Expression of c-MET in the same hepatocellular carcinoma tumor samples,https://ClinicalTrials.gov/show/NCT00911196
507,NCT00923806,Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer,Terminated,No Results Available,Metastatic Cancer,Biological: PG13-CEA_TCR (Anti-CEA TCR PBL)|Drug: Aldesleukin,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years and older   (Adult, Senior)",Phase 1,3,NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,090047|09-C-0047,17-Jun-09,12/1/2008,11/1/2011,10/18/2015,Oct-15,No Study Results Posted,null,Nov-11,clinical response of the administration of anti-CEA TCR engineered peripheral blood lymphocytes in patients receiving the non-myeloablative conditioning regimen and aldesleukin in patients with metastatic cancer.|Safety,https://ClinicalTrials.gov/show/NCT00923806
603,NCT00822809,CASIMAS: Catumaxomab Safety Phase IIIb Study With Intraperitoneal Infusion in Patients With Malignant Ascites Due to Epithelial Cancers,Completed,No Results Available,Cancer|Neoplasms|Carcinoma|Malignant Ascites,Drug: Catumaxomab|Drug: Prednisolone,Neovii Biotech,Both,"18 Years and older   (Adult, Senior)",Phase 3,230,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,IP-CAT-AC-03,23-Dec-08,12/1/2008,4/1/2011,10/2/2012,Aug-12,No Study Results Posted,CASIMAS,Nov-10,"Influence of prednisolone on the safety of 3 hours i.p. infusion of catumaxomab measured by a composite safety score|Puncture-free survival defined as the time from clock start to first need for therapeutic ascites puncture or death, whichever occurs first.|Safety measured by • Incidence of all AEs, • Changes in clinically relevant laboratory values (hematology, clinical chemistry, coagulation, and urinalysis), • Physical examination, • Vital signs.|Time to next ascites puncture, number of ascites punctures until end of lifetime, overall survival, anti-cancer treatment|immune monitoring",https://ClinicalTrials.gov/show/NCT00822809
759,NCT00960115,Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy,Completed,Has Results,Non-small Cell Lung Cancer,Biological: Tecemotide (L-BLP25)|Drug: Single low dose cyclophosphamide|Biological: Placebo|Other: Saline,"Merck KGaA|Merck Serono Co., Ltd., Japan",Both,"20 Years and older   (Adult, Senior)",Phase 1|Phase 2,178,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",EMR063325_009,5-Aug-09,12/1/2008,6/1/2015,9/21/2015,Sep-15,21-Sep-15,null,May-14,Overall Survival (OS) Time|Time To Progression (TTP) - Investigator Read|Progression Free Survival (PFS) Time - Investigator Read|Time to Treatment Failure (TTF),https://ClinicalTrials.gov/show/NCT00960115
787,NCT00923195,"Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma",Completed,Has Results,Melanoma|Skin Cancer,Drug: MART-1: 26-35(27L) Peptide|Drug: Montanide ISA 51 VG|Drug: gp100:154-162 Peptide|Procedure: Radiation|Drug: Aldesleukin|Drug: Fludarabine|Drug: Cyclophosphamide|Genetic: Anti-gp 100:154 TCR PBL|Genetic: Anti-MART-1 F5 TCR PBL,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years and older   (Adult, Senior)",Phase 2,4,NIH,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,090051|09-C-0051,17-Jun-09,12/1/2008,8/1/2011,10/6/2015,Oct-15,4-Oct-12,null,Aug-11,Complete Response Rates for Patients With Metastatic Melanoma|Toxicity Profile,https://ClinicalTrials.gov/show/NCT00923195
1120,NCT00815321,Autologous Cytokine Induced Killer Cells (CIK) for Chronic Myeloid Leukemia (CML) Patients on Standard Drug Therapy,Completed,No Results Available,Chronic Myeloid Leukemia,Biological: Autologous CIK cell infusion,Singapore General Hospital,Both,"12 Years to 80 Years   (Child, Adult, Senior)",Phase 2,11,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CIK#3/2008,28-Dec-08,12/1/2008,11/1/2011,5/14/2012,May-12,No Study Results Posted,null,Nov-11,response of CML to Cytokine induced killer cell therapy|Sustainability of the response,https://ClinicalTrials.gov/show/NCT00815321
58,NCT00829205,"Se-Methyl-Seleno-L-Cysteine, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment",Withdrawn,No Results Available,Lymphoma,Biological: filgrastim|Biological: rituximab|Dietary Supplement: Se-methyl-seleno-L-cysteine|Drug: carboplatin|Drug: etoposide|Drug: ifosfamide|Other: laboratory biomarker analysis|Other: pharmacological study,Cancer Research UK|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,0,Other,Interventional,Allocation: Non-Randomized|Masking: Open Label|Primary Purpose: Treatment,CDR0000632722|CRUK-UCL-SelRICE|EUDRACT-2008-002678-36|EU-20902,23-Jan-09,1/1/2009,null,8/23/2013,Jul-09,No Study Results Posted,null,null,Dose-limiting toxicity and maximum tolerated dose of Se-methyl-seleno-L-cysteine (MSC) (Phase I)|Overall response rate (Phase II)|Toxicity as assessed by NCI CTCAE v 3.0|Serum and intracellular Se and Se species|Pharmacokinetics of MSC|Protein markers of selenium activity,https://ClinicalTrials.gov/show/NCT00829205
210,NCT00834093,A Phase II Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma,"Active, not recruiting",No Results Available,Nasopharyngeal Carcinoma,Biological: Epstein-Barr Virus Specific Immunotherapy,Dana-Farber Cancer Institute|Brigham and Women's Hospital|Massachusetts General Hospital|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 2,20,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,08-292|R21CA132279-01A1,2-Feb-09,1/1/2009,12/1/2016,3/8/2016,Mar-16,No Study Results Posted,null,Jun-16,"To determine the overall response rate (ORR) with 90% confidence intervals (CIs) of EBV-specific immunotherapy in patients with recurrent and/or metastatic EBV-associated NPC using modified RECIST|To estimate the one-year progression free survival, time to progression, median duration of response and overall survival with the EBV-specific immunotherapy|To evaluate the safety of EBV-specific immunotherapy",https://ClinicalTrials.gov/show/NCT00834093
695,NCT01019798,"Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer",Recruiting,No Results Available,Non Small Cell Lung Cancer,"Drug: sunitinib, docetaxel, cisplatin",Taipei Medical University Hospital|Pfizer|TTY Biopharm,Both,18 Years to 59 Years   (Adult),Phase 2,16,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CRC-01-08-03,24-Nov-09,1/1/2009,12/1/2011,11/24/2009,Nov-09,No Study Results Posted,null,Dec-10,response rate by RECIST criteria|Time to disease progression at the end of study|Duration of survival|Safety profile: cardiac toxicity assessed in accordance with National Cancer Institute Common Toxicity Criteria. NCI-CTCAE criteria (version 3.0) will be used.,https://ClinicalTrials.gov/show/NCT01019798
828,NCT00855452,Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors,Completed,No Results Available,Metastatic Breast Cancer|Malignant Melanoma|Renal Cell Cancer|Gastrointestinal Cancer,Procedure: one - three cycles of cell therapy during 4-6 weeks (3-5x10^7 cells/kg will be given through IV systemically,Hadassah Medical Organization,Both,"12 Years to 70 Years   (Child, Adult, Senior)",Phase 2,20,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,0457-08-HMO-CTIL,19-Feb-09,1/1/2009,5/1/2014,6/10/2015,Oct-08,No Study Results Posted,rIL-2(LAK),May-14,CR:disappearance of disease.PR:<50% decrease in the total tumor load of the lesions SD:<50% reduction and 25% increase in the sum of the products of the longest perpendicular diameters of the measured lesions.PD:>25% increase in the size of lesion.,https://ClinicalTrials.gov/show/NCT00855452
1000,NCT00846456,Safe Study of Dendritic Cell (DC) Based Therapy Targeting Tumor Stem Cells in Glioblastoma,Completed,No Results Available,Glioblastoma|Brain Tumor,Biological: Dendritic cell vaccine with mRNA from tumor stem cells,Oslo University Hospital,Both,"18 Years to 70 Years   (Adult, Senior)",Phase 1|Phase 2,20,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,DC-CAST-GBM,15-Feb-09,1/1/2009,2/1/2013,10/19/2015,Oct-15,No Study Results Posted,null,Feb-13,"Adverse events|Evaluation of immunological response, time to disease progression and survival time",https://ClinicalTrials.gov/show/NCT00846456
321,NCT00924326,CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma,"Active, not recruiting",No Results Available,"Primary Mediastinal B-cell Lymphoma|Diffuse, Large B-cell Lymphoma|Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma|Mantle Cell",Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Anti-CD19-CAR PBL,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 70 Years   (Adult, Senior)",Phase 1,43,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,090082|09-C-0082,17-Jun-09,2/1/2009,12/1/2020,7/30/2016,Jul-16,No Study Results Posted,null,Dec-19,Determine the safety and feasibility of the administration of anti-CD19-CAR engineered peripheral blood lymphocytes with a nonmyeloablative conditioning regimen in patients with B-cell malignancies.|Determine the in vivo survival of the cryopreserved anti-CD19- CAR-transduced T cells.|Determine if the treatment regimen can cause regression of B-cell malignancies.,https://ClinicalTrials.gov/show/NCT00924326
383,NCT00836407,"Ipilimumab +/- Vaccine Therapy in Treating Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer",Completed,Has Results,Pancreatic Cancer,Drug: Ipilimumab|Biological: Pancreatic Cancer Vaccine,Sidney Kimmel Comprehensive Cancer Center,Both,"18 Years and older   (Adult, Senior)",Phase 1,30,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,J0834|BMS # CA184-081,3-Feb-09,2/1/2009,7/1/2012,10/16/2013,Oct-13,16-Oct-13,null,Jul-12,"Determine if Ipilimumab Alone or in Combination With Pancreatic Tumor Vaccine Has an Acceptable Safety Profile (Less Than 33% Unacceptable Toxicity) in Subjects With Locally Advanced, Unresectable or Metastatic Pancreatic Adenocarcinoma|Overall Survival (OS)|To Estimate Overall Response Rate (ORR), Immune Related Best Overall Response Rate (irBOR), Progression Free Survival (PFS), and Duration of Response in Patients Receiving Treatment.|To Explore an Association Between Immune-related Adverse Events (IRAEs) and ORR.|To Measure Tumor Marker Kinetics (CA 19-9) in Patients Receiving Treatment.",https://ClinicalTrials.gov/show/NCT00836407
488,NCT00924040,Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia,Terminated,Has Results,Hairy Cell Leukemia,Drug: BL22 (CAT-3888),National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years and older   (Adult, Senior)",Phase 2,1,NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,090076|09-C-0076,17-Jun-09,2/1/2009,8/1/2010,10/7/2015,Oct-15,20-Sep-11,null,Aug-10,"Number of Months to Response to Treatment|Number of Participants With Adverse Events|Number of Participants With Complete Response (CR) Who Resolve the Bone Marrow Abnormality by Magnetic Resonance Imaging (MRI)|Number of Patients Who Developed Neutralizing Antibodies After One or More Cycles of BL22|Number of Patients With ex Vivo Sensitivity Who Respond Clinically|Percentage of Patients Who Respond Clinically, Who Also Have Normalization in sCD22 or sCD25|Correlation Between Number of Prior Cycles of BL22 With Immunogenicity on This Protocol|Percentage of Patients Who Make Antibodies|Percentage of Patients Who Have Dose Limiting Toxicity (DLT)",https://ClinicalTrials.gov/show/NCT00924040
566,NCT00840931,Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS),"Active, not recruiting",No Results Available,Leukemia,Drug: lenalidomide|Biological: bystander vaccine,H. Lee Moffitt Cancer Center and Research Institute|Celgene,Both,"18 Years and older   (Adult, Senior)",Phase 1,22,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MCC-14998|105861|RV-MDS-PI-202|BB-IND 13478|0803-907,4-Feb-09,2/1/2009,11/1/2016,3/25/2016,Mar-16,No Study Results Posted,null,Feb-14,Maximum Tolerated Dose (MTD)|Number of Participants with Toxicities|Number of Participants with Augmentation of Specific T Cell Immunological Functions|Number of Participants with Reduction of Bone Marrow Myeloblast|Number of Participants with Improvement of Hemoglobin and/or red blood cell (RBC) Transfusion Independence|Number of Participants with Resolution of Karyotypic Changes|Number of Participants with Augmentation of Other T Cell Parameters|Duration of Response,https://ClinicalTrials.gov/show/NCT00840931
703,NCT00871481,Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma,Completed,No Results Available,Recurrent Melanoma|Stage IV Melanoma,Biological: ipilimumab|Drug: cyclophosphamide|Procedure: biopsy|Biological: aldesleukin|Other: immunohistochemistry staining method|Genetic: polymerase chain reaction|Other: immunoenzyme technique|Biological: therapeutic allogeneic cytotoxic T lymphocytes,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,10,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind|Primary Purpose: Treatment,2225.00|NCI-2010-00108|K12CA076930,27-Mar-09,2/1/2009,10/1/2013,12/17/2013,Dec-13,No Study Results Posted,null,Sep-13,"Numeric frequency and functional persistence of transferred CTL|Toxicity assessment of study treatment, assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0|Responses to non-targeted T cell antigens",https://ClinicalTrials.gov/show/NCT00871481
1151,NCT00848926,A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma,Completed,Has Results,"Disease, Hodgkin",Drug: brentuximab vedotin,"Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc.",Both,"12 Years and older   (Child, Adult, Senior)",Phase 2,102,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SG035-0003|2008-006034-10,18-Feb-09,2/1/2009,5/1/2015,11/6/2015,Jun-15,15-Sep-11,null,Aug-10,"Objective Response Rate by Independent Review Group|Complete Remission Rate by Independent Review Group|Duration of Objective Response by Kaplan-Meier Analysis|Duration of Objective Response in Participants With Complete Remission by Kaplan-Meier Analysis|Progression-free Survival by Kaplan-Meier Analysis|Overall Survival|Adverse Events by Severity, Seriousness, and Relationship to Treatment|Hematology Laboratory Abnormalities >/= Grade 3|Chemistry Laboratory Abnormalities >/= Grade 3|Area Under the Curve|Maximum Serum Concentration|Time of Maximum Serum Concentration",https://ClinicalTrials.gov/show/NCT00848926
1244,NCT00994643,Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma,"Active, not recruiting",No Results Available,High Risk Non-Hodgkin's Lymphoma,Biological: Rituximab|Biological: Interleukin-2,Thomas Jefferson University,Both,"18 Years and older   (Adult, Senior)",Phase 2,61,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,08S.461|2008-40,12-Oct-09,2/1/2009,12/1/2015,7/14/2015,Jul-15,No Study Results Posted,null,Dec-15,Potential efficacy of IL-2 with rituximab for NHL by evaluating time to progression,https://ClinicalTrials.gov/show/NCT00994643
520,NCT00924092,"An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...",Completed,No Results Available,Prostate Cancer|Breast Cancer|Lung Cancer|Colorectal Cancer|Head and Neck Cancer,Biological: GI-6207 [Recombinant Saccharomyces Cerevisia|Drug: (Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)]),National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years and older   (Adult, Senior)",Phase 1,25,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,090101|09-C-0101,17-Jun-09,3/1/2009,8/1/2012,5/21/2014,May-14,No Study Results Posted,null,null,"To determine the safety and tolerability of escalating doses of a heated-killed yeast-based vaccine that targets tumors that express CEA.|To evaluate CD4 and CD8 immunologic response. To evaluate humoral immune response to yeast antigen. To evaluate evidence of clinical benefit such as PFS, OR, & amp; decreases in circulating tumor cells & amp; tumor markers.",https://ClinicalTrials.gov/show/NCT00924092
523,NCT00923390,Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor,Terminated,No Results Available,Renal Cancer|Kidney Cancer,Genetic: 2G-1 TCR Retroviral Vector-Transduced lyn|Drug: Aldesleukin|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: (PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years and older   (Adult, Senior)",Phase 1,5,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,090092|09-C-0092,17-Jun-09,3/1/2009,8/1/2012,2/19/2014,Aug-12,No Study Results Posted,null,Aug-12,"Determine if the administration of T-cells retrovirally transduced with the 2G-1 TCR, with preparative chemotherapy and IL-2, can cause the regression of metastatic RCC, and to identify the maximum tolerated dose for the 2G-1 TCr transduced cell...|Determine the toxicities of these T-cells administered in the above fashion, and to determine TCR and vector presence in the post treatment phase.",https://ClinicalTrials.gov/show/NCT00923390
724,NCT01013441,CD3/CD28 Bead Activated T-Cells Following Chemo-Immunotherapy in Patients With Chronic Lymphocytic Leukemia,"Active, not recruiting",No Results Available,Chronic Lymphocytic Leukemia,Biological: Infusion of CD3/CD28 stimulated T cells,University of Pennsylvania|M.D. Anderson Cancer Center,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,20,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,UPCC 15408,5-Nov-09,3/1/2009,3/1/2014,1/10/2012,Jan-12,No Study Results Posted,null,Dec-13,"The occurrence of treatment-related adverse events or treatment related trial discontinuations, defined as NCI CTC ≥ grade 3 and clinical events that are possible, likely, or definitely related to study treatment at any time|The ability to complete the outlined course of therapy|The ability to harvest, expand, and reinfuse autologous T cells in this target population of patients",https://ClinicalTrials.gov/show/NCT01013441
1154,NCT00866047,A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma,"Active, not recruiting",Has Results,"Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin",Drug: brentuximab vedotin,"Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc.",Both,"12 Years and older   (Child, Adult, Senior)",Phase 2,58,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SG035-0004|2008-006035-12,19-Mar-09,3/1/2009,6/1/2016,1/26/2016,Jan-16,15-Sep-11,null,Aug-10,"Objective Response Rate by Independent Review Group|Complete Remission Rate by Independent Review Group|Duration of Objective Response by Kaplan-Meier Analysis|Duration of Objective Response in Participants With Complete Remission by Kaplan-Meier Analysis|Progression-free Survival by Kaplan-Meier Analysis|Overall Survival|Adverse Events by Severity, Seriousness, and Relationship to Treatment|Hematology Laboratory Abnormalities >/= Grade 3|Chemistry Laboratory Abnormalities >/= Grade 3|Area Under the Curve|Maximum Serum Concentration|Time of Maximum Serum Concentration",https://ClinicalTrials.gov/show/NCT00866047
285,NCT01868490,The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous Cytokine-induced Killer Cells,Recruiting,No Results Available,Cholangiocarcinoma,Drug: cytokine induced killer cells,Siriraj Hospital|Mahidol University,Both,"8 Years to 60 Years   (Child, Adult)",Phase 1|Phase 2,13,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,215-3-2552,30-May-13,4/1/2009,5/1/2016,4/8/2015,Apr-15,No Study Results Posted,null,May-16,"MRI scan for monitoring of tumor size and CIK cell-homing, Fluorescence-activated cell sorting (FACS) analysis|Survival rate",https://ClinicalTrials.gov/show/NCT01868490
548,NCT00879866,EMD 521873 Plus Radiotherapy in Non Small Cell Lung Cancer (NSCLC),Completed,No Results Available,Lung Cancer|Non Small Cell Lung Cancer,Biological: EMD 521873,Merck KGaA,Both,"18 Years and older   (Adult, Senior)",Phase 1,15,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,EMR 62235-002,10-Apr-09,4/1/2009,9/1/2012,6/20/2014,Jun-14,No Study Results Posted,null,Feb-11,"To assess the safety and tolerability of EMD 521873 given in combination with local irradiation of pulmonary primary tumor/metastases and to determine whether the maximum tolerated dose (MTD) is reached with EMD 521873 doses of up to 0.45 mg/kg.|Evaluate the pharmacokinetics (PK) of EMD 521873 in combination with local tumor irradiation|Evaluate the immunogenicity of EMD 521873 in combination with local tumor irradiation by measuring the induction of anti-EMD 521873 antibodies|Collect evidence of best overall response, changes in tumor marker levels and circulating tumor cell numbers after treatment with EMD 521873 in combination with local tumor irradiation|Collect evidence of best overall response after second-line therapy and duration of the response when it is shown|Evaluate progression-free survival and overall survival|Evaluate biological/immune responses following treatment with EMD 521873 by assessing changes in relevant parameters including leukocyte subset analysis|Evaluate biological/immune responses following treatment with EMD 521873 by assessing changes in relevant parameters including: molecular markers of immune activation (e.g. cytokines/chemokines, IL-2 receptor and neopterin)",https://ClinicalTrials.gov/show/NCT00879866
605,NCT00891345,Safety Study of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy,Completed,No Results Available,Hormone-refractory Prostate Cancer,Biological: ALECSAT,CytoVac A/S,Male,"18 Years and older   (Adult, Senior)",Phase 1,13,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CV001,30-Apr-09,4/1/2009,7/1/2010,4/26/2012,Apr-12,No Study Results Posted,ALECSAT,Jul-10,The primary endpoint is to show safety and tolerability for the administration of ALECSAT to enable further clinical development of the ALECSAT therapy.|The secondary endpoint for this study is to establish if any indications of a positive therapeutic effect on the prostate cancer may be observed.,https://ClinicalTrials.gov/show/NCT00891345
622,NCT00815607,Trial of an Intratumoral Injections of INXN-3001 in Subjects With Stage III or IV Melanoma,Completed,No Results Available,Melanoma,Drug: INXN-1001|Biological: INXN-3001,Ziopharm,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1,12,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,RTS-M101B'|NIH OBA 0710-881,19-Dec-08,4/1/2009,1/1/2013,7/17/2013,Jul-13,No Study Results Posted,null,Jan-13,"Physical examinations, vital signs, serum chemistry, urinalysis, hematology, adverse events, and objective response rate, as assessed by diagnostic CT scans|PK of oral Activator Ligand, Immunologic responses, particularly frequency of CTLs and Tregs and hIL-12 and other cytokine levels in injected target tumor(s) and in peripheral blood, Efficacy.",https://ClinicalTrials.gov/show/NCT00815607
151,NCT00909558,Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer,Suspended,No Results Available,Breast Cancer|Glioma|Hepatocellular Cancer|Squamous Cell Lung Cancer|Pancreatic Cancer|Colon Cancer|Prostate Cancer,Biological: Autologous Natural Killer / Natural Killer T Cell Immunotherapy,"Envita Medical Center, Inc.",Both,"18 Years to 80 Years   (Adult, Senior)",Phase 1,24,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,E001-08,27-May-09,5/1/2009,null,2/23/2010,Feb-10,No Study Results Posted,null,Jun-10,"Is there any measurable effect upon the underlying cancer as assessed by an increase or decrease in the tumor as measured from baseline using established criteria?|Are the dosages administered during the study safe, as measured by the number of unexpected and serious adverse events associated with the study drug, as defined by FDA regulations and as measured by established criteria?",https://ClinicalTrials.gov/show/NCT00909558
427,NCT00861614,Study of Immunotherapy to Treat Advanced Prostate Cancer,Completed,Has Results,Prostate Cancer,Drug: Ipilimumab|Drug: Placebo,Bristol-Myers Squibb,Male,"18 Years and older   (Adult, Senior)",Phase 3,988,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CA184-043|2008-003314-97,12-Mar-09,5/1/2009,8/1/2015,3/16/2016,Mar-16,15-Mar-16,null,Nov-12,"Overall Survival (OS)|Progression Free Survival (PFS)|Pain Response|Duration of Pain Response|Number of Participants With Severe Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-Related AEs, Deaths, Discontinuation of Study Drug Due to AEs, Immune-Related Adverse Events (irAE) and Immune-Mediated Adverse Reaction (imAR)|Time to Onset of Grade 3 or 4 Immune-Related Adverse Event (irAE)|Time to Resolution of Grade 3 or 4 Immune-Related Adverse Event (irAE)|Time to Onset of Grade 3 to 5 Immune-Mediated Adverse Reaction (imAR)|Time to Resolution of Grade 3 to 5 to Grade 0 Immune-Mediated Adverse Reactions (imARs) to Grade 0|Number of Participants With Worst On-Study Hematology Common Toxicity Criteria (CTC) Grade and Shift From Baseline|Number of Participants With Worst On-Study Liver Common Toxicity Criteria (CTC) Grade and Shift From Baseline|Number of Participants With Worst On-Study Serum Chemistry Common Toxicity Criteria (CTC) Grade and Shift From Baseline|Number of Participants With Worst On-Study Renal Function Common Toxicity Criteria (CTC) Grade and Shift From Baseline",https://ClinicalTrials.gov/show/NCT00861614
562,NCT00892567,Evaluating the T Cell Response to a Peptide-based Vaccine in Patients With Breast Cancer,Completed,No Results Available,Breast Neoplasms,"Biological: 9 Peptides from Her-2/neu, CEA, & CTA","Craig L Slingluff, Jr|National Cancer Institute (NCI)|University of Virginia",Both,"18 Years and older   (Adult, Senior)",,9,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,12911|R21CA130340,30-Apr-09,5/1/2009,2/1/2012,4/26/2016,Apr-16,No Study Results Posted,Breast 37,Dec-11,"To evaluate whether a multi-peptide vaccine induces T cells that traffic to and penetrate into human primary breast cancers.|To characterize the T cell response to a peptide-based vaccine in terms of antigen specificity and the induction of differentiated effector cells, both in the peripheral blood and within the tumor microenvironment.",https://ClinicalTrials.gov/show/NCT00892567
868,NCT00849875,A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients,Terminated,No Results Available,Melanoma,Biological: Immunotherapeutic GSK2132231A|Drug: Dacarbazine,GlaxoSmithKline,Both,"18 Years and older   (Adult, Senior)",Phase 2,48,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,111714,2-Feb-09,5/1/2009,11/1/2014,9/24/2015,Mar-15,No Study Results Posted,null,Nov-14,The occurrence of treatment related adverse events of Grade 3 or 4|Occurrence of serious adverse events (SAEs)|Evaluation of immunogenicity|The rate of objective response (complete and partial)|The rate of stable disease|The rate of mixed response|Time to study treatment failure|Progression free survival time|Progression free survival time after initial Slow Progressive Disease|Occurrence of any adverse events (including abnormal laboratory values for haematology and biochemistry)|Overall survival,https://ClinicalTrials.gov/show/NCT00849875
1017,NCT01649024,A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma,"Active, not recruiting",No Results Available,Malignant Mesothelioma,Drug: Tremelimumab,Azienda Ospedaliera Universitaria Senese,Both,"18 Years and older   (Adult, Senior)",Phase 2,29,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MESOT-TREM-2008|2008-005171-95,18-Jul-12,5/1/2009,6/1/2013,7/20/2012,Jul-12,No Study Results Posted,null,Jun-12,Objective tumor response by modified Response Evaluation Criteria in Solid Tumor (RECIST)|Disease control rate|Progression free survival|Safety,https://ClinicalTrials.gov/show/NCT01649024
1115,NCT00964080,"Study of MBP-426 in Patients With Second Line Gastric, Gastroesophageal, or Esophageal Adenocarcinoma","Active, not recruiting",No Results Available,Gastric Adenocarcinoma|Gastroesophageal Junction Adenocarcinoma|Esophageal Adenocarcinoma,Drug: MBP-426/Leucovorin/5-FU,"Mebiopharm Co., Ltd",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,62,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MBP-426 201,17-Aug-09,5/1/2009,4/1/2015,11/28/2014,Apr-12,No Study Results Posted,null,Oct-12,To determine the dose of MBP-426 for use in the Phase II portion of this study of MBP-426 administered every 21 days in combination with leucovorin (folinic acid or FA) and fluorouracil (5-FU)|To characterize the safety profile of the combination therapy|To determine the plasma and urine pharmacokinetics of MBP-426 when given in combination with leucovorin and 5-FU|To undertake a preliminary exploration of anti-tumor activity of the combination therapy,https://ClinicalTrials.gov/show/NCT00964080
17,NCT00992134,Immunochemotherapy With Rituximab-Bendamustine-Cytarabine (R-BAC) for Patients With Mantle Cell Lymphoma,Completed,No Results Available,"Lymphoma, Mantle-Cell","Drug: Rituximab, Bendamustine, Cytarabine",St. Bortolo Hospital,Both,"18 Years and older   (Adult, Senior)",Phase 2,41,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,VI-1903|EudraCT 2009-009912-34,7-Oct-09,6/1/2009,6/1/2012,9/25/2012,Sep-10,No Study Results Posted,null,Jun-11,The safety and tolerability of R-BAC treatment will be tested to determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of Ara-C when combined with Bendamustine and Rituximab.|Overall response and freedom from progression after R-BAC treatment,https://ClinicalTrials.gov/show/NCT00992134
248,NCT00937300,T-cell Based Immunotherapy for Head and Neck Cancer,Withdrawn,No Results Available,Squamous Cell Carcinoma|Head and Neck Cancer,"Biological: cyclophosphamide, fludarabine, T-cell infusion, and Interleukin-2",Inge Marie Svane|Herlev Hospital,Both,"18 Years to 70 Years   (Adult, Senior)",Phase 1,0,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,HH0908,10-Jul-09,6/1/2009,6/1/2011,11/22/2011,Nov-11,No Study Results Posted,null,Jun-11,toxicity|immune response,https://ClinicalTrials.gov/show/NCT00937300
362,NCT00937625,T-cell Based Immunotherapy for of Melanoma,Completed,No Results Available,Melanoma,"Biological: cyclophosphamide, fludarabine, T-cells, Interleukin-2",Inge Marie Svane|Herlev Hospital,Both,"18 Years to 70 Years   (Adult, Senior)",Phase 1|Phase 2,31,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MM0909,10-Jul-09,6/1/2009,1/1/2015,8/17/2015,Aug-15,No Study Results Posted,null,Jan-15,toxicity|immune response|tumor response,https://ClinicalTrials.gov/show/NCT00937625
587,NCT00912327,Efficacy and Safety Study of Imprime PGG With Cetuximab in Subjects With Stage IV KRAS-Mutated Colorectal Cancer,Completed,No Results Available,Colorectal Cancer,Biological: Imprime PGG,Biothera,Both,"18 Years and older   (Adult, Senior)",,18,Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,BT-CL-PGG-CRC0821,1-Jun-09,6/1/2009,2/1/2012,2/14/2012,Feb-12,No Study Results Posted,null,Feb-12,"Objective response rate (ORR)|Disease control rate (DCR) and duration of disease control|Complete response (CR), partial response (PR), and stable disease (SD) rates|Duration of objective tumor response|Duration of stable disease|Time to progression (TTP)|Progression-free survival (PFS)|Safety of the dosing regimen|Overall survival",https://ClinicalTrials.gov/show/NCT00912327
705,NCT00942058,Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell Cancer,Terminated,No Results Available,Metastatic Kidney Cancer|Metastatic Renal Cell Carcinoma,Other: Serum and urinary CA9 level,Centre Hospitalier Universitaire de Saint Etienne,Both,"18 Years and older   (Adult, Senior)",,16,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,0808071|2008-A01125-50,17-Jun-09,6/1/2009,11/1/2013,1/28/2014,Jan-14,No Study Results Posted,CA9CRM,Nov-13,"serum protein CA9 and mRNA CA9 level under medical treatment|Correlation clinical response (complete response, partial response, stabilization, progression)-evolution serum CA9 level in blood and urine|The type and duration of clinical response based on the initial rate and the slope of decline|serum CA9 level basis and during the following treatment groups of the MSKCC prognostic",https://ClinicalTrials.gov/show/NCT00942058
708,NCT01005537,"Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma",No longer available,No Results Available,Melanoma (Skin),Biological: aldesleukin|Biological: therapeutic autologous lymphocytes|Drug: cyclophosphamide,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),Both,"18 Years to 75 Years   (Adult, Senior)",,null,Other|NIH,Expanded Access,,2355.00|P30CA015704|FHCRC-2355.00|IR-6984|CDR0000648071,30-Oct-09,6/1/2009,null,8/4/2010,Aug-10,No Study Results Posted,null,Oct-10,,https://ClinicalTrials.gov/show/NCT01005537
934,NCT00929019,Messenger Ribonucleic Acid (mRNA) Transfected Dendritic Cell Vaccination in High Risk Uveal Melanoma Patients,"Active, not recruiting",No Results Available,Uveal Melanoma,Biological: autologous dendritic cells electroporated with mRNA,Radboud University|Rotterdam Eye Hospital,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1|Phase 2,30,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NL22553.000.08|KUN2008-035,25-Jun-09,6/1/2009,10/1/2016,9/24/2015,Sep-15,No Study Results Posted,null,Oct-16,immunological response|clinical response (progression free survival),https://ClinicalTrials.gov/show/NCT00929019
81,NCT01029366,Genetically Engineered Lymphocyte Therapy in Treating Patients With B-Cell Leukemia or Lymphoma That is Resistant or Refractory to Chemotherapy,Completed,No Results Available,Hematopoietic/Lymphoid Cancer|Adult Acute Lymphoblastic Leukemia in Remission|B-cell Adult Acute Lymphoblastic Leukemia|B-cell Chronic Lymphocytic Leukemia|Prolymphocytic Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Chronic Lymphocytic Leukemia|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage III Grade 3 Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Chronic Lymphocytic Leukemia|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma|Stage IV Grade 3 Follicular Lymphoma|Stage IV Mantle Cell Lymphoma,Other: laboratory biomarker analysis|Genetic: polymerase chain reaction|Genetic: reverse transcriptase-polymerase chain reaction|Biological: anti-CD19-CAR retroviral vector-transduced autologous T cells|Biological: genetically engineered lymphocyte therapy,Abramson Cancer Center of the University of Pennsylvania,Both,"18 Years and older   (Adult, Senior)",,110,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,UPCC 04409|NCI-2009-01357,9-Dec-09,7/1/2009,null,7/31/2015,Jul-15,No Study Results Posted,null,Jul-15,Number of Adverse Events,https://ClinicalTrials.gov/show/NCT01029366
96,NCT01133158,R-BMD GELTAMO Relapsed Lymphoma,"Active, not recruiting",No Results Available,Non-Hodgkin's Lymphoma,"Drug: Rituximab, Bendamustine, Mitoxantrone, Dexamethasone",Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 2,60,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,R-BMD GELTAMO 08,11-Feb-10,7/1/2009,4/1/2016,4/16/2015,Apr-15,No Study Results Posted,null,Dec-13,"The primary endpoint is the complete response and unconfirmed complete response according to the criteria of the International Workshop to Standardize Response Criteria for NHL|Secondary endpoints included an assessment of the following parameters:Global Survival, Progression-Free Survival, Disease-Free Survival,Duration of the Response.|Security of bendamustine in combination with dexamethasone,Mitoxantrone and Rituximab.",https://ClinicalTrials.gov/show/NCT01133158
616,NCT00945269,"Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma",Terminated,No Results Available,Recurrent Melanoma|Stage III Melanoma|Stage IV Melanoma,Biological: therapeutic autologous lymphocytes|Biological: aldesleukin|Biological: denileukin diftitox|Procedure: biopsy|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Genetic: polymerase chain reaction,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1|Phase 2,3,Other|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2271.00|NCI-2010-00738|K12CA076930|R21CA137647,23-Jul-09,7/1/2009,1/1/2011,12/2/2011,Dec-11,No Study Results Posted,null,Jan-11,In vivo survival of CD8+ transferred T-clones,https://ClinicalTrials.gov/show/NCT00945269
903,NCT00962052,Biomarker Discovery and Application in Bladder Cancer,Recruiting,No Results Available,Bladder Cancer,,"Wolfson Medical Center|Medical Diagnostic Laboratories, LLC",Both,"18 Years and older   (Adult, Senior)",,250,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Prospective,MDL0806,18-Aug-09,7/1/2009,12/1/2011,9/12/2010,Sep-10,No Study Results Posted,null,Dec-10,,https://ClinicalTrials.gov/show/NCT00962052
963,NCT02061332,DC Vaccine for Patients With Ductal Carcinoma In Situ,Recruiting,No Results Available,Breast Cancer|DCIS,Biological: HER-2 Pulsed Dendritic cell Vaccine,University of Pennsylvania,Female,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,54,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,807010|15107,10-Feb-14,7/1/2009,7/1/2019,2/11/2014,Feb-14,No Study Results Posted,DCIS6,Jul-14,Blood Pressure|Temperature|Pulse|Immune Response|Mammogram|MRI,https://ClinicalTrials.gov/show/NCT02061332
972,NCT00858000,Analysis of Expression of Specific Markers in Hepatocellular Carcinoma,Completed,No Results Available,Hepatocellular Carcinoma,Other: Retrospective analysis of already archived samples,GlaxoSmithKline,Both,"Child, Adult, Senior",,30,Industry,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,111722,5-Mar-09,7/1/2009,12/1/2009,12/23/2009,Dec-09,No Study Results Posted,null,Dec-09,This study will also analyze whether this gene-expression signature is present in matched cirrhotic tissue and the interface tissue with the tumor.|Proportion of hepatocellular carcinoma cancer patients whose tumor tissue -expresses any one or more of specific target antigens -overexpresses c-MET -expresses a pre-defied gene-expression signature,https://ClinicalTrials.gov/show/NCT00858000
990,NCT00952003,Oxaliplatin/Irinotecan/Bevacizumab Followed by Docetaxel/Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients,"Active, not recruiting",No Results Available,Gastric Cancer|Unresectable,"Drug: Bevacvizumab, Irinotecan, Oxaliplatin, Docetaxel",Arbeitsgemeinschaft medikamentoese Tumortherapie|Pfizer|Sanofi|Roche Pharma AG,Both,"18 Years and older   (Adult, Senior)",Phase 2,40,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AGMT GASTRIC-3,3-Aug-09,7/1/2009,4/1/2015,9/9/2014,Sep-14,No Study Results Posted,null,Apr-15,To determine efficacy in terms of response rate according to RECIST criteria|Safety|To determine median progression-free survival times following treatment with a chemoimmune therapy|To determine overall survival time following treatment with a chemoimmune therapy,https://ClinicalTrials.gov/show/NCT00952003
1055,NCT00947856,A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study,Completed,Has Results,"Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin",Drug: brentuximab vedotin,"Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc.",Both,"6 Years and older   (Child, Adult, Senior)",Phase 2,110,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,SGN35-006|2010-019932-11,24-Jul-09,7/1/2009,3/1/2013,11/17/2015,May-14,21-Mar-14,null,Mar-13,"Objective Response Rate by Investigator|Adverse Events by Severity, Seriousness, and Relationship to Treatment|Laboratory Abnormalities >/= Grade 3|Duration of Objective Response by Kaplan-Meier Analysis|Progression-free Survival by Kaplan-Meier Analysis|Overall Survival|Incidence of Antitherapeutic Antibodies",https://ClinicalTrials.gov/show/NCT00947856
1085,NCT00902044,Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma,Recruiting,No Results Available,Sarcoma,Genetic: Autologous HER2-specific T cells|Drug: Fludarabine|Drug: Cyclophosphamide,"Baylor College of Medicine|Texas Children's Hospital|The Methodist Hospital System|Center for Cell and Gene Therapy, Baylor College of Medicine",Both,"Child, Adult, Senior",Phase 1,36,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,24489-HEROS|HEROS,13-May-09,7/1/2009,7/1/2030,6/2/2016,Jun-16,No Study Results Posted,null,Jul-16,Number of patients with dose limiting toxicity after one injection of HER2-specific T cells|Number of patients with dose limiting toxicity after one injection of HER2-specific T cells after receiving lymphodepleting chemotherapy|Frequency of HER2-specific T cells pre and post injection|Change in tumor size from pre to post injection,https://ClinicalTrials.gov/show/NCT00902044
219,NCT00901342,Open Label Study of Sipuleucel-T,Completed,No Results Available,Prostate Cancer,Drug: Sipuleucel-T,Dendreon,Male,"18 Years and older   (Adult, Senior)",Phase 2,91,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,P09-1,7-May-09,8/1/2009,4/1/2015,10/5/2015,Oct-15,No Study Results Posted,null,Dec-14,Evaluate the magnitude of immune responses to treatment with sipuleucel-T|Obtain additional safety data for sipuleucel-T,https://ClinicalTrials.gov/show/NCT00901342
307,NCT00753220,Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer,Terminated,Has Results,Prostate Cancer,Biological: VDC2008|Drug: Cyclophosphamide,Bostwick Laboratories|Prostate Institute of America|Community Memorial HealthCenter|HemaCare Corporation,Male,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,7,Industry|Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CRITICAL001,12-Sep-08,8/1/2009,12/1/2011,11/3/2014,Nov-14,25-Jul-13,CRITICAL,May-11,Maximum Tolerated Dose (MTD),https://ClinicalTrials.gov/show/NCT00753220
498,NCT01007058,Markers of Response to Intravesical Bladder Cancer Therapy,"Active, not recruiting",No Results Available,Bladder Cancer,,M.D. Anderson Cancer Center|Flight Attendant Medical Research Institute,Both,"18 Years and older   (Adult, Senior)",,300,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,LAB05-0326,2-Nov-09,8/1/2009,null,12/2/2015,Dec-15,No Study Results Posted,null,Aug-17,Number of Patients with Clinical tumor recurrence or progression by 24 months after initiation of intravesical immunotherapy,https://ClinicalTrials.gov/show/NCT01007058
880,NCT00961844,Trial for Vaccine Therapy With Dendritic Cells in Patients With Metastatic Malignant Melanoma,Terminated,No Results Available,Metastatic Malignant Melanoma,"Biological: Dendritic cells - transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion|Drug: Temozolomide",Oslo University Hospital,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,15,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,DC-004|2008-006253-41,12-Aug-09,8/1/2009,6/1/2012,8/22/2014,Aug-14,No Study Results Posted,null,Jun-12,"Safety and toxicity of vaccination with DC transfected h-TERT mRNA, survivin mRNA and tumor cell mRNA, lymphodepletion treatment and T cell expansion and reinfusion in patients with metastatic malignant melanoma.|Evaluation of immunological responses, time to disease progression and survival time.",https://ClinicalTrials.gov/show/NCT00961844
902,NCT00861107,In-Situ Therapeutic Cancer Vaccine for Metastatic Cancer Combining AlloStim With Tumor Cryoablation,Completed,No Results Available,Metastatic Cancer,Biological: AlloStim-7|Procedure: percutaneous tumor cryoablation|Biological: AlloStim-7|Biological: AlloStim8 or AlloStim-9,"Immunovative Therapies, Ltd.",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,50,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ITL-002-CRYO,12-Mar-09,8/1/2009,5/1/2011,6/6/2011,Jun-11,No Study Results Posted,null,Mar-11,evaluation of any drug-related toxicity associated with AlloStim administration as well as the reversibility of such toxicity.|evaluation of the anti-tumor effect of AlloStim administration|evaluation of the immunological response to AlloStim administration,https://ClinicalTrials.gov/show/NCT00861107
182,NCT01240447,Immunotherapy With Racotumomab Versus Support Treatment in Advanced Non-small Cell Lung Cancer Patients,Completed,No Results Available,Advanced Non-small Cell Lung Cancer,Biological: racotumomab|Other: Best support treatment,Laboratorio Elea S.A.C.I.F. y A.,Both,"21 Years and older   (Adult, Senior)",Phase 2,7,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,AR-RACO-02-08|ISRCTN47153584,23-Sep-10,9/1/2009,6/1/2014,7/9/2014,Jul-14,No Study Results Posted,null,Aug-12,Number of Participants with Adverse events as a measure of safety and tolerability|Evaluation of the reactivity if the antibodies against X63 tumor line|Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry.|Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available)|Determination of gamma interferon by ELISPOT (enzyme-linked immunosorbent spot) assay.|Measurement of pro-inflammatory and anti-inflammatory cytokines|Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside|Measurement of pro-inflammatory and anti-inflammatory cytokines.|Survival|Progression free survival,https://ClinicalTrials.gov/show/NCT01240447
555,NCT00925548,STRIDE - STimulating Immune Response In aDvanced brEast Cancer,Terminated,Has Results,Breast Cancer,Biological: Tecemotide (L-BLP25) and Hormonal Treatment|Biological: Placebo of tecemotide (L-BLP25) and Hormonal Treatment|Drug: cyclophosphamide|Drug: sodium chloride (NaCl),EMD Serono,Female,"18 Years and older   (Adult, Senior)",Phase 3,16,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EMR 200038-010|2008-005544-17,17-Jun-09,9/1/2009,8/1/2010,7/23/2014,Jul-14,24-Jun-14,STRIDE,Aug-10,Progression-Free Survival (PFS)|Overall Survival (OS) Time|Percentage of Participants With Objective Tumor Response|Duration of Response|Percentage of Participants With Clinical Benefit|Time to Progression (TTP)|Time to Chemotherapy|Functional Assessment of Cancer Therapy-Breast (FACT-B) Questionnaire|European Questionnaire-5 Dimensions (EQ-5D) Questionnaire|Number of Participant Utilizing Healthcare Resources|Serum Carcinoma Antigen (CA) 15-3 Levels,https://ClinicalTrials.gov/show/NCT00925548
664,NCT00948961,A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1,Completed,No Results Available,Advanced Malignancies,Biological: CDX-1401 in combination with Resiquimod and/or Poly-ICLC|Biological: CDX-1401|Biological: Resiquimod|Biological: poly-ICLC,Celldex Therapeutics,Both,"18 Years to 99 Years   (Adult, Senior)",Phase 1|Phase 2,70,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDX1401-01,28-Jul-09,9/1/2009,2/1/2014,6/22/2016,Jun-16,No Study Results Posted,null,Jun-12,"Occurrence of adverse events (side effects)|Objective response rate (CR/PR), disease control rate (CR/PR/SD) and time to progression, based on disease-appropriate response criteria.",https://ClinicalTrials.gov/show/NCT00948961
691,NCT00890032,Vaccine Therapy in Treating Patients Undergoing Surgery for Recurrent Glioblastoma Multiforme,"Active, not recruiting",No Results Available,Recurrent Central Nervous System Neoplasm,Biological: BTSC mRNA-loaded DCs,John Sampson|National Cancer Institute (NCI)|Duke University,Both,"18 Years and older   (Adult, Senior)",Phase 1,50,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,Pro00006677|R01CA135272|P30CA014236|CDR0000630701,28-Apr-09,9/1/2009,1/1/2017,10/15/2015,Oct-15,No Study Results Posted,null,Jul-16,Feasibility and safety|Humoral and cellular immune responses,https://ClinicalTrials.gov/show/NCT00890032
1036,NCT00989352,Methotrexate-based Chemo-immunotherapy Followed by Maintenance Therapy for Patients > 65 Years With Central Nervous System (CNS)-Lymphoma,Recruiting,No Results Available,Primary Non Hodgkin Lymphoma of the Central Nervous System,Drug: Methotrexate|Drug: Lomustine|Drug: Procarbazine|Drug: Rituximab,University Hospital Freiburg|Universitätsklinikum Köln|Ludwig-Maximilians - University of Munich|University Hospital Heidelberg|University Hospital Ulm,Both,"65 Years and older   (Adult, Senior)",Phase 2,56,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,00591|Eudract: 2008-007645-31,2-Oct-09,9/1/2009,9/1/2011,10/2/2009,Oct-09,No Study Results Posted,PRIMAIN,Jun-11,Complete remission rate|Duration of response|Overall survival time|Neuropsychological state (according to Mini-Mental State and IPCG testing)|(Serious) adverse events ([S]AEs),https://ClinicalTrials.gov/show/NCT00989352
56,NCT01303887,A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients,Recruiting,No Results Available,Follicular Lymphoma,Drug: Rituximab|Drug: Cyclophosphamide|Drug: Vincristine|Drug: Prednisolone|Drug: Fludarabine,University of Liverpool|Royal Liverpool and Broadgreen University Hospitals NHS Trust|Cancer Research UK|Roche Pharma AG,Both,"60 Years and older   (Adult, Senior)",Phase 3,680,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ISRCTN99217456|2008-004759-31,24-Feb-11,10/1/2009,9/1/2016,5/4/2011,Oct-10,No Study Results Posted,PACIFICO,Sep-16,"Toxicity|Progression-free survival|Response rates (overall, complete and partial) following initial therapy|Response rates following maintenance therapy|Response duration|Overall survival|Time to next treatment|Rate of large cell transformation|Response to second-line therapy|Number of treatment cycles delivered|Cumulative dose of individual drugs administered|Quality of life|Cost effectiveness",https://ClinicalTrials.gov/show/NCT01303887
330,NCT01241682,Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma,Completed,No Results Available,Malignant (Pleural) Mesothelioma,Biological: DC + CTX,Erasmus Medical Center,Both,"Child, Adult, Senior",Phase 1,10,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NL24050.000.08,1-Jun-10,10/1/2009,10/1/2012,2/26/2014,Feb-14,No Study Results Posted,PMR-MM-002,Oct-11,number of cytotoxic T cells and regulatory T cells in the blood of patients|safety and toxicity,https://ClinicalTrials.gov/show/NCT01241682
332,NCT01081808,"Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors",Terminated,No Results Available,Neoplasms|Tumors|Solid Tumors|Metastatic Cancer,Biological: EGFRBi-armed autologous activated T cells,Roger Williams Medical Center,Both,"18 Years and older   (Adult, Senior)",Phase 1,2,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,RWH 111-32,28-Jan-10,10/1/2009,2/1/2015,3/24/2015,Mar-15,No Study Results Posted,null,Dec-14,Maximum tolerated dose of EGFRBi-armed autologous activated T-cells|Determine potential side effects of treating patients with Armed Activated T Cells (ATC)|Determination of immunologic changes by evaluation of cytokine profiles obtained before and after stimulation with OKT3 in vitro|Determination of immunologic changes by evaluation of phenotypes of peripheral blood mononuclear cells before and after immunotherapy|Overall survival|Progression-free survival|Determination of immunologic changes by evaluation of peripheral blood lymphocytes,https://ClinicalTrials.gov/show/NCT01081808
633,NCT00938626,Treated T Cells Followed by a Stem Cell Transplant in Treating Patients With Multiple Myeloma,Completed,No Results Available,Multiple Myeloma and Plasma Cell Neoplasm,Biological: anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells|Procedure: autologous hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation,Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,12,Other|NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000646891|P30CA022453|WSU-2008-106,11-Jul-09,10/1/2009,3/1/2013,9/20/2013,Sep-13,No Study Results Posted,null,Oct-11,"Cell-based toxicities according to NCI CTCAE v3.0 criteria|Ability to mobilize the number of stem cells required for autologous peripheral blood stem cell transplantation (PBSCT)|Engraftment of neutrophils|Functional changes in immune cell populations|Assess proportion of erythroid blast-forming unit (BFU)-E, colony forming unit-granulocyte-macrophage (CFU)-GM, CFU-GEMM (granulocyte, erythrocyte, monocyte, megakaryocyte) & erythroid colony forming (CFU-E)",https://ClinicalTrials.gov/show/NCT00938626
706,NCT01022346,A Study of RO5217790 (HPV Targeted Immunotherapy) in Patients With High Grade Cervical Intraepithelial Neoplasia Associated With High Risk HPV Infection,Completed,No Results Available,Cervical Intraepithelial Neoplasia,Drug: Placebo|Drug: RO5217790,Hoffmann-La Roche,Female,"18 Years and older   (Adult, Senior)",Phase 2,209,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",NV25025|2008-006946-24,20-Nov-09,10/1/2009,9/1/2013,7/7/2016,Jul-16,No Study Results Posted,null,Sep-13,Histologic resolution|Viral clearance by Roche HPV genomic testing|Immunological response to HPV antigens|Incidence of adverse events (AEs)|Abnormal laboratory values,https://ClinicalTrials.gov/show/NCT01022346
911,NCT01128803,Immunotherapy of Hepatocellular Carcinoma by Induction of Anti-alpha Fetoprotein Response,Terminated,No Results Available,Hepatocellular Carcinoma,Procedure: injection of the cell therapy product,Nantes University Hospital,Both,"18 Years to 80 Years   (Adult, Senior)",Phase 1|Phase 2,1,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,06/9-P,21-May-10,10/1/2009,10/1/2010,11/6/2013,Nov-13,No Study Results Posted,null,Oct-10,Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Analysis of T lymphocytes,https://ClinicalTrials.gov/show/NCT01128803
947,NCT01008527,Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100,Completed,No Results Available,Melanoma,"Drug: CP 870,893|Biological: Peptides|Biological: Oncovir poly IC:LC","H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)|Oncovir, Inc.|Pfizer",Both,"18 Years and older   (Adult, Senior)",Phase 1,22,Other|NIH|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MCC-15383|106566|NCI-P-8215,2-Nov-09,10/1/2009,9/1/2015,9/23/2015,Sep-15,No Study Results Posted,null,Sep-13,Maximum Tolerated Dose (MTD)|Number of Participants With Immunologic Response|Number of Participants With Progression Free Survival (PFS),https://ClinicalTrials.gov/show/NCT01008527
1271,NCT00799513,Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma,Recruiting,No Results Available,Diffuse Large B-cell Lymphoma,Drug: Lenalidomide,IRCCS San Raffaele|Celgene Corporation,Both,"65 Years and older   (Adult, Senior)",Phase 2,47,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2008-003729-18,20-Nov-08,10/1/2009,11/1/2013,3/21/2012,Mar-12,No Study Results Posted,null,Oct-13,"1-year progression-free survival|Median overall survival, response rate, response duration",https://ClinicalTrials.gov/show/NCT00799513
203,NCT02845999,Allogenic Immunotherapy Based on Natural Killer (NK) Cell Adoptive Transfer in Metastatic Gastrointestinal Carcinoma Treated With Cetuximab,Completed,No Results Available,Gastrointestinal Metastatic Cancer,Biological: allogenic immunotherapy based on Natural Killer cells adoptive transfer|Biological: cetuximab|Drug: Cyclophosphamide|Drug: fludarabine|Drug: interleukin-2,"Centre Hospitalier Universitaire de Besancon|National Cancer Institute, France",Both,18 Years to 65 Years   (Adult),Phase 1,9,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,N2005/48-A,1-Dec-11,11/1/2009,null,7/22/2016,Mar-16,No Study Results Posted,NK-EGFR01,Jan-13,number of patients with clinical or biological grade 3 or 4 treatment-related adverse events as assessed by CTCAE v4.0,https://ClinicalTrials.gov/show/NCT02845999
450,NCT00953849,Vitamin D - Celecoxib Therapy,Completed,No Results Available,Mouth Neoplasms,"Drug: celecoxib|Drug: 1,25-dihydroxyvitamin D3 + celecoxib|Drug: 1,25-dihydroxyvitamin D3",VA Office of Research and Development,Both,"18 Years to 85 Years   (Adult, Senior)",Phase 1|Phase 2,26,U.S. Fed,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Basic Science,CLIN-003-09S,4-Aug-09,11/1/2009,12/1/2015,1/4/2016,Jan-16,No Study Results Posted,null,Dec-15,"Immunological - increased dendritic cell levels, increased T-cell activity",https://ClinicalTrials.gov/show/NCT00953849
790,NCT00953420,Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes,Completed,No Results Available,Nasopharyngeal Carcinoma,Drug: Docetaxel|Drug: Carboplatin|Drug: Dexamethasone|Biological: EBV-specific cytotoxic T lymphocytes,"Baylor College of Medicine|Texas Children's Hospital|The Methodist Hospital System|Center for Cell and Gene Therapy, Baylor College of Medicine|M.D. Anderson Cancer Center",Both,"10 Years and older   (Child, Adult, Senior)",Phase 2,20,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,25145-CADEN|CADEN,4-Aug-09,11/1/2009,7/1/2015,8/26/2015,Aug-15,No Study Results Posted,CADEN,Jun-14,"The primary endpoint of the study is to evaluate the overall response rate for patients with advanced-stage, relapsed/refractory, EBV positive nasopharyngeal carcinoma after re-induction chemotherapy and immunotherapy.|Response to re-induction chemotherapy|Evaluation of immune response by measuring EBV-DNA levels",https://ClinicalTrials.gov/show/NCT00953420
950,NCT00977145,Evaluating the Safety and the Biological Effects of Intratumoral Interferon Gamma and a Peptide-Based Vaccine in Patients With Melanoma,Terminated,No Results Available,Melanoma,Biological: A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1,"Craig L Slingluff, Jr|University of Virginia",Both,"18 Years and older   (Adult, Senior)",,11,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,14215,14-Sep-09,11/1/2009,null,12/19/2014,Dec-14,No Study Results Posted,Mel 51,Oct-12,"Safety: To determine the safety of administration of intratumoral interferon gamma with a peptide-based vaccine in patients with cutaneous or subcutaneous metastases of melanoma.|Biologic effect: To evaluate the biological effects of vaccine plus IFN-gamma at the tumor site, to include expression of CXCR3 ligands (CXCL9, CXCL10 & CXCL11) and the magnitude of infiltration of CD8+ CXCR3+ T cells and vaccine-specific T cells.|To estimate the effects of vaccine on CXCR3 expression by circulating antigen-experienced CD4 and CD8 T cells.|To estimate the effects of vaccine plus IFN-gamma on changes in the percentage of FoxP3+ CD25hi CD4+ (putative regulatory T cells, T regulatory cells) among tumor infiltrating T cells.|To obtain preliminary data on the variability of immunologic parameters among multiple biopsies of subcutaneous or cutaneous metastases of melanoma.|To obtain preliminary data on the clinical response of cutaneous or subcutaneous metastases of melanoma to the proposed combination regimen.",https://ClinicalTrials.gov/show/NCT00977145
1062,NCT01037127,Study to Determine the Effectiveness of GSK1120212 in BRAF Mutation-positive Melanoma Previously Treated With or Without a BRAF Inhibitor,Completed,Has Results,Cancer,Drug: GSK1120212,GlaxoSmithKline,Both,"18 Years and older   (Adult, Senior)",Phase 2,97,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,113583,25-Nov-09,11/1/2009,1/1/2013,2/13/2014,Jan-14,12-Jun-13,null,Jul-11,"Number of Participants With Best Confirmed Response|Number of Participants With Best Confirmed Response in the Indicated Subgroups of Participants Previously Treated With Standard Therapy But Not BRAF Inhibitors|Number of Participants With Best Unconfirmed Response at the Time of the Interim Analysis (Week 8)|Mean Plasma Concentrations|Number of Participants With Any Adverse Event (AE)|Duration of Tumor Response|Progression-free Survival (PFS)|PFS in the Indicated Subgroups of Participants Previously Treated With Standard Therapy But Not BRAF Inhibitors|Overall Survival|Number of Participants Who Survived Until 6 Months, 12 Months and 24 Months From Baseline|Number of Participants With Tumor Progression",https://ClinicalTrials.gov/show/NCT01037127
1081,NCT01013623,Stage IV Surgery Versus Best Medical Therapy,Terminated,No Results Available,Stage IV Resectable Melanoma,Procedure: Surgery|Procedure: Surgery plus 2 adjuvant doses of BCG|Other: best medical therapy,John Wayne Cancer Institute|Melanoma Research Alliance,Both,"18 Years and older   (Adult, Senior)",Phase 3,12,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MORD-STG4SURG-0409|3P01CA012582-35S1,12-Nov-09,11/1/2009,9/1/2012,9/24/2012,Sep-12,No Study Results Posted,STG4SURG,Sep-12,Overall survival|Time to progression of initial metastatic sites (progression-free survival)|Melanoma-specific survival|Time to development of new metastatic sites.,https://ClinicalTrials.gov/show/NCT01013623
1146,NCT01015911,A Phase 1 Dose-escalation Trial of SGN-75 in CD70-positive Non-Hodgkin Lymphoma or Renal Cell Carcinoma,Completed,No Results Available,"Carcinoma, Renal Cell|Lymphoma, Non-Hodgkin",Drug: SGN-75,"Seattle Genetics, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1,58,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SGN75-001,13-Nov-09,11/1/2009,3/1/2012,12/17/2014,Dec-14,No Study Results Posted,null,Nov-11,"Incidence of adverse events and laboratory abnormalities|Best clinical response|Duration of response, progression-free survival|Blood concentrations of SGN-75 and metabolites|Incidence of antitherapeutic antibodies",https://ClinicalTrials.gov/show/NCT01015911
32,NCT01051063,Evaluation of a New Anti-cancer Immunotherapy in Adult Acute Myeloid Leukemia Patients With a Suboptimal Clinical Response to Induction Chemotherapy,Completed,No Results Available,"Leukaemia, Myelocytic, Acute",Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A,GlaxoSmithKline,Both,"18 Years and older   (Adult, Senior)",Phase 1,17,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,111727|2008-005348-17,8-Dec-09,12/1/2009,4/1/2016,5/5/2016,May-16,No Study Results Posted,null,Apr-16,"Occurrence of severe toxicities (according to the Common Terminology Criteria for Adverse Events [CTCAE], Version 3.0) as defined in the protocol|Evaluation of clinical activity in terms of induction of Complete Response, Partial Response or Stable Disease (SD) in both cohorts|immunogenicity of the WT1 ASCI|Occurrence of adverse events (AEs) and serious adverse events (SAEs)|Occurrence of SAEs related to study treatment|Evaluation of clinical activity in terms of time to study treatment failure|Evaluation of clinical activity in terms of progression-free survival|Evaluation of clinical activity in terms of Induction of molecular CR (for patients with molecular abnormality detected before starting ASCI treatment)|Evaluation of clinical activity in terms of Induction of cytogenetic CR (for patients with aberrant cytogenetics detected before starting ASCI treatment)",https://ClinicalTrials.gov/show/NCT01051063
103,NCT01066429,DA-EDOCH14-R in Poor-prognosis Diffuse Large B-cell Lymphoma,Recruiting,No Results Available,Diffuse Large B-Cell Lymphoma (DLBCL),Drug: Dexamethasone and dose-dense immunochemoterapy,Hospital Universitario Principe de Asturias,Both,"18 Years to 70 Years   (Adult, Senior)",Phase 2,30,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,DA-EDOCH14-R/07,8-Feb-10,12/1/2009,12/1/2012,2/11/2010,Dec-09,No Study Results Posted,null,Dec-10,efficacy of the EDOCH14-R scheme at an adjusted dose|hematological and extra-hematological toxicity of the EDOCH14-R scheme,https://ClinicalTrials.gov/show/NCT01066429
380,NCT01159288,Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes,Recruiting,No Results Available,Non Small Cell Lung Cancer,Biological: Dex2,"Gustave Roussy, Cancer Campus, Grand Paris",Both,"18 Years to 70 Years   (Adult, Senior)",Phase 2,47,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IGR Dex2,8-Jul-10,12/1/2009,12/1/2014,4/3/2012,Jul-10,No Study Results Posted,CSET 1437,Dec-14,Progression free survival,https://ClinicalTrials.gov/show/NCT01159288
443,NCT00558675,A Phase I/II Study of Mis-Matched Immune Cells (AlloStim) in Patients With Advanced Hematological Malignancy,Completed,No Results Available,Hematological Malignancy|Leukemia|Lymphoma|Multiple Myeloma,Biological: AlloStim|Biological: AlloStim|Biological: AlloStim|Biological: AlloStim,"Immunovative Therapies, Ltd.|Hadassah Medical Organization",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,25,Industry|Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ITL-001-HMC,13-Nov-07,12/1/2009,3/1/2013,2/19/2015,Nov-12,No Study Results Posted,null,Dec-12,Determination of toxicity related to AlloStim infusion in accordance with NCI Common Toxicity Criteria v.3|Evaluation and reporting of anti-tumor response will be conducted in accordance with internationally accepted criteria for the disease indication being evaluated|Immunological Response,https://ClinicalTrials.gov/show/NCT00558675
899,NCT01026415,Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35),Completed,No Results Available,"Carcinomas|Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin|Neoplasms",Drug: brentuximab vedotin|Drug: rifampin|Drug: midazolam|Drug: ketoconazole|Drug: brentuximab vedotin,"Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1,73,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,SGN35-008,2-Dec-09,12/1/2009,5/1/2012,12/17/2014,Dec-14,No Study Results Posted,null,May-12,"Midazolam blood concentrations +/- brentuximab vedotin|Brentuximab vedotin blood concentrations +/- rifampin|Brentuximab vedotin in urine, feces, and blood|Brentuximab vedotin blood concentrations in special populations|Brentuximab vedotin blood concentrations +/- ketoconazole|Incidence of adverse events and laboratory abnormalities",https://ClinicalTrials.gov/show/NCT01026415
159,NCT01481259,Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Nonsquamous Non-small Cell Lung Cancer,Recruiting,No Results Available,Non-small Cell Lung Cancer,Biological: Autologous cytokine-induced killer cell|Other: Pemetrexed,People's Hospital of Guangxi,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 2|Phase 3,120,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CIKLC-201004,16-Nov-11,1/1/2010,7/1/2013,7/2/2012,Jul-12,No Study Results Posted,null,Jan-13,Progression-free survival|Overall survival|Toxicities|Quality-of-life,https://ClinicalTrials.gov/show/NCT01481259
302,NCT01082887,A Study of Immunotherapy With TIL (Tumor Infiltrating Lymphocytes) in Combination With Intra-tumoral Injections of Interferon Gamma-adenovirus (Ad-IFNg) in Patients With Stage IIIc or Stage IV Metastatic Melanoma (AJCC)(Protocol TIL-Ad-INFg),Terminated,No Results Available,Metastatic Melanoma,Other: TIL-Ad-INFg,Nantes University Hospital,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1|Phase 2,18,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,09/5-R|2009-013087-38,8-Mar-10,1/1/2010,10/1/2012,6/11/2013,Jun-13,No Study Results Posted,null,Oct-12,"Clinical and biological toxicity of combined treatment TIL, IL2 et Ad-INFg|Objective response rate|Tumoral response|Progression-free survival|Overall survival|Immunological response",https://ClinicalTrials.gov/show/NCT01082887
364,NCT01050790,Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma,"Active, not recruiting",Has Results,Multiple Myeloma,Drug: Azacitidine,Virginia Commonwealth University|National Cancer Institute (NCI)|Celgene Corporation,Both,"18 Years to 70 Years   (Adult, Senior)",,17,Other|NIH|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000663409|P30CA016059|MCC-12430,14-Jan-10,1/1/2010,8/1/2017,3/31/2016,Mar-16,16-Jul-15,null,Aug-14,Feasibility to Mobilize and Infuse Autologous Lymphocytes (ALI) After Immunomodulatory Therapy and After Stem Cell Transplant Engraftment|Complete Response Rate at 6 Months|Toxicity as Assessed by NCI CTCAE v3.0|Time to Progression Post Transplant|Progression-free and Overall Survival|Pre- and Post-ALI Immune Response to Cancer Testis Antigens (CTA)|CTA Expression Before and After Azacitidine Therapy,https://ClinicalTrials.gov/show/NCT01050790
526,NCT01034787,Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma,"Active, not recruiting",No Results Available,Uveal Melanoma,"Drug: CP-675,206",Alberta Health Services|AHS Cancer Control Alberta,Both,"18 Years and older   (Adult, Senior)",Phase 2,32,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,TBCC 905001,15-Dec-09,1/1/2010,null,1/18/2012,Sep-11,No Study Results Posted,null,Jan-13,"Progression-free survival at 6 months after initiation of CP-675,206|Objective tumor response|Durable response, defined as an objective tumor response that last 6 or more months|Median survival and overall survival|Adverse events and tolerability",https://ClinicalTrials.gov/show/NCT01034787
631,NCT01284205,First Line Comparative Study of EN3348 (MCC) vs BCG in NMIBC,Withdrawn,No Results Available,Bladder Cancer,Biological: Mycobacterial Cell-Wall DNA Complex|Biological: Bacillus Calmette-Guerin,Bioniche Life Sciences Inc.,Both,"18 Years and older   (Adult, Senior)",Phase 3,0,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",EN3348-302,25-Jan-11,1/1/2010,2/1/2017,8/28/2014,Aug-14,No Study Results Posted,null,Feb-14,"Duration of disease-free survival (time to recurrence, progression or death) in all patients|Percent of patients who due to study drug-related AEs experience 2 consecutive treatment delays or discontinue due to drug related AEs|Disease-free survival rate at 2 years|Frequency, severity, and nature of drug-related AEs|Duration of progression-free survival (time to progression or death) in all patients|Frequency, severity, and nature of drug-related SAEs|Number of treatment delays and their reason|Frequency, severity and nature of all AEs|Number of treatment discontinuations and their reason|Duration of Survival (time to death from any cause) in all patients",https://ClinicalTrials.gov/show/NCT01284205
726,NCT00861965,Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match Alternative to Allogeneic Transplant for Blood Cancers,Withdrawn,No Results Available,"Advanced or Refractory Leukemia, Lymphoma, Multiple Myeloma",Biological: AlloStim-8|Biological: AlloStim-8|Biological: AlloStim-8|Biological: AlloStim-8,"Immunovative Therapies, Ltd.",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,0,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ITL-001-HM,12-Mar-09,1/1/2010,null,4/1/2015,Apr-15,No Study Results Posted,null,Nov-12,To evaluate the safety of administration of an intravenous AlloStim-9 infusion and to define any drug-related toxicity and reversibility of such toxicity|evaluate the safety of administration of up to three consecutive daily intravenous AlloStim-8 booster infusions in patients that previously received a infusion of AlloStim-9 and to define any drug-related toxicity and reversibility of such toxicity|evaluate the anti-tumor effect of AlloStim infusions by evaluating the objective response rates,https://ClinicalTrials.gov/show/NCT00861965
773,NCT00904722,Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma,Completed,Has Results,Lymphoma,Drug: CT-011|Drug: Rituximab,M.D. Anderson Cancer Center|CureTech Ltd,Both,"18 Years and older   (Adult, Senior)",Phase 2,32,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2009-0163|NCI-2011-03225,18-May-09,1/1/2010,4/1/2015,4/27/2016,Apr-16,27-Apr-16,null,Apr-15,Overall Response Rate|Progression-Free Survival,https://ClinicalTrials.gov/show/NCT00904722
802,NCT01042847,How Our Immune System Can Help Fight Cancer,Not yet recruiting,No Results Available,Ovarian Cancer,,Winthrop University Hospital,Female,"20 Years to 90 Years   (Adult, Senior)",,100,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,9316,4-Jan-10,1/1/2010,1/1/2011,1/5/2010,Jan-10,No Study Results Posted,null,Jan-11,"To examine the association of indoleamine 2,3-dioxygenase (IDO) genetic polymorphisms with clinical outcomes of ovarian cancer.|To correlate IDO activity with gene polymorphisms by measuring tryptophan/kynurenine ratios in the ascites of epithelial ovarian cancer patients.",https://ClinicalTrials.gov/show/NCT01042847
938,NCT00965224,Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma,Enrolling by invitation,No Results Available,Acute Myeloid Leukemia|Chronic Myeloid Leukemia|Multiple Myeloma,Biological: dendritic cell vaccination (active specific immunotherapy),"University Hospital, Antwerp",Both,"18 Years and older   (Adult, Senior)",Phase 2,50,Other,Interventional,Endpoint Classification: Efficacy Study|Primary Purpose: Treatment,CCRG 09-003,24-Aug-09,1/1/2010,null,7/11/2013,Jul-13,No Study Results Posted,null,Dec-14,"Immunogenicity of WT1 mRNA-transfected DC vaccination|Induction/maintenance of molecular remission as evidenced by molecular MRD monitoring of WT1 (AML, CML and MM) and BCR/ABL RNA (CML) copies in peripheral blood|Time to relapse (TTR)|progression-free survival|overall survival (OS)",https://ClinicalTrials.gov/show/NCT00965224
991,NCT01026233,Cardiac Safety Study of Brentuximab Vedotin (SGN-35),Completed,No Results Available,"Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin",Drug: brentuximab vedotin,"Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1,52,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SGN35-007,2-Dec-09,1/1/2010,8/1/2011,12/11/2014,Dec-14,No Study Results Posted,null,Aug-10,QTc interval|ECG parameters|Blood MMAE levels|Incidence of proarrhythmic adverse events|Incidence of adverse events and laboratory abnormalities,https://ClinicalTrials.gov/show/NCT01026233
1035,NCT01216436,Local Modulation of Immune Receptors to Enhance the Response to Dendritic Cell Vaccination in Metastatic Melanoma,Terminated,No Results Available,Metastatic Melanoma,Biological: Vaccination with RNA-transfected mature autologous DC,Duke University,Both,"18 Years and older   (Adult, Senior)",Phase 1,2,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Factorial Assignment|Masking: Open Label,Pro00019239,1-Feb-10,1/1/2010,10/1/2013,5/22/2015,Apr-14,No Study Results Posted,null,Oct-13,Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Cellular anti-melanoma immune responses will be assessed,https://ClinicalTrials.gov/show/NCT01216436
1105,NCT01060904,A Phase 1 Study of Brentuximab Vedotin Combined With Multi-Agent Chemotherapy for Hodgkin Lymphoma,Completed,No Results Available,"Disease, Hodgkin",Drug: brentuximab vedotin|Drug: doxorubicin|Drug: vinblastine|Drug: dacarbazine|Drug: bleomycin|Drug: brentuximab vedotin,"Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc.",Both,18 Years to 60 Years   (Adult),Phase 1,51,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SGN35-009,29-Jan-10,1/1/2010,9/1/2012,12/17/2014,Dec-14,No Study Results Posted,null,Sep-12,Incidence of adverse events and laboratory abnormalities|Brentuximab vedotin concentration in blood|Antitherapeutic antibodies in blood|Best clinical response,https://ClinicalTrials.gov/show/NCT01060904
1281,NCT01066494,A Pharmacokinetic and Efficacy Study of Amonafide L-malate (AS1413) in Combination With Cytarabine in Patients With Acute Myeloid Leukemia (AML),"Active, not recruiting",No Results Available,Acute Myeloid Leukemia,Drug: Amonafide + cytarabine,Antisoma Research,Both,"18 Years and older   (Adult, Senior)",Phase 2,20,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AS1413-C-101,9-Feb-10,1/1/2010,1/1/2011,1/14/2011,Jan-11,No Study Results Posted,null,Sep-10,To define the plasma PK Profile of amonafide and metabolite(s)|To deine the urniary excretion of amonafide and metabolite(s)|To investigate the fecal excretion of amonafide and metabolite(s) in selected patients|To evaluate the safety and tolerability of amonafide in combination with cytarabine|To evaluate the remission rate|All outcomes are of equal weighting,https://ClinicalTrials.gov/show/NCT01066494
387,NCT00669734,Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery,"Active, not recruiting",No Results Available,Pancreatic Acinar Cell Carcinoma|Pancreatic Ductal Adenocarcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer,Biological: Falimarev|Biological: Inalimarev|Other: Laboratory Biomarker Analysis|Biological: Sargramostim,National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,18,NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NCI-2012-03111|070602|7606|P30CA072720|U01CA132194,29-Apr-08,2/1/2010,null,4/5/2016,Apr-16,No Study Results Posted,null,Nov-13,"MTD of falimarev, defined as the dose level that 0/6 or 1/6 patients experience dose-limiting toxicity (DLT) and that at least 2/3 or 2/6 patients treated with the next higher dose have had DLT|Cytokine production|Mean number of positive cells per high power field in the pancreas biopsy specimen|T cell proliferation",https://ClinicalTrials.gov/show/NCT00669734
471,NCT01158248,"Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer",Recruiting,No Results Available,Cervical Cancer,Biological: panitumumab|Drug: cisplatin|Radiation: brachytherapy|Radiation: external beam radiation therapy,Medical University Innsbruck|National Cancer Institute (NCI),Female,"Child, Adult, Senior",Phase 2,50,Other,Interventional,Masking: Open Label|Primary Purpose: Treatment,CDR0000675699|MUI-AGO-20|EUDRACT-2009-012453-38|EU-21043,7-Jul-10,2/1/2010,null,7/8/2010,Jul-10,No Study Results Posted,null,Mar-13,Progression-free survival at 4 months by MRI according to RECIST criteria|Rate of skin and/or gastrointestinal toxicity CTCAE grade 4 at 4 months|Overall response rate at 4 months according to RECIST criteria|Progression-free survival at 12 and 24 months according to RECIST criteria|Overall survival at 12 and 24 months|Rate of severe adverse events according to CTCAE at 4 months|Rate of post-treatment severe adverse events according to CTCAE at 12 and 24 months|Rate of severe adverse events according to CTCAE of panitumumab monotherapy at day 14,https://ClinicalTrials.gov/show/NCT01158248
909,NCT01029873,Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma,Completed,No Results Available,Metastatic Melanoma,Drug: Cisplatin|Biological: ALT-801,Altor Bioscience Corporation|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,25,Industry|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CA-ALT-801-02-09|R44CA097550,9-Dec-09,2/1/2010,9/1/2013,1/12/2015,Jan-15,No Study Results Posted,null,Nov-11,"To evaluate the safety of the ALT-801-Cisplatin regimen.|To assess the objective response (OR) which includes CR and PR.|To assess the clinical benefit (CB) of the ALT-801-Cisplatin regimen which includes CR, PR and SD.|To determine the MTD of the ALT-801-Cisplatin regimen.|To assess the six-month and one-year survival rates.|To evaluate the immunogenicity and pharmacokinetic profile of ALT-801.",https://ClinicalTrials.gov/show/NCT01029873
919,NCT01086735,Suicide Gene Therapy for Donor Lymphocytes Infusion After Allogeneic Hematopoietic Stem Cell Transplantation,Completed,No Results Available,Hematological Malignancy,Biological: donor lymphocyte infusion,Assistance Publique - Hôpitaux de Paris|Paris 12 Val de Marne University|Pierre and Marie Curie University,Both,"18 Years to 70 Years   (Adult, Senior)",Phase 1|Phase 2,11,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,P010506,12-Mar-10,2/1/2010,11/1/2012,1/11/2013,Jan-13,No Study Results Posted,ILD-TK01,Nov-12,"Incidence of ""severe"" GHVD (acute grade >II or chronic extensive) following DLI-TK and treatment with GCV|The incidence of GVHD of any grade after DLI-TK|The anti-tumoral efficiency of DLI-TK to treat the relapse of the hematological malignancy|The survival and the survival without disease after DLI-TK",https://ClinicalTrials.gov/show/NCT01086735
943,NCT01087294,Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation,Suspended,No Results Available,"Leukemia, B-cell|Lymphoma, Hodgkins|Lymphoma, Non-hodgkins|Lymphoma, B-Cell",Procedure: Allogeneic stem cell transplant|Biological: Anti-CD19-chimeric-antigen-receptor- transduced T cell|Drug: Cyclophosphamide|Drug: Pentostatin,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1,42,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,100054|10-C-0054,13-Mar-10,2/1/2010,3/1/2018,5/13/2016,May-16,No Study Results Posted,null,Mar-17,To assess the safety of allogeneic anti-CD19-CAR,https://ClinicalTrials.gov/show/NCT01087294
1037,NCT01287923,Assessment of Biomarkers Initially Identified in Whole Blood by DNA Microarrays in Patients With Aggressive Lymphoma BMS_LyTrans,Recruiting,No Results Available,DLBCL,,"Rennes University Hospital|French Innovative Leukemia Organisation|National Cancer Institute, France",Both,"18 Years to 70 Years   (Adult, Senior)",,400,Other,Observational,Observational Model: Cohort,2010-A00812-37|TRANS/10-01|B101038-10,31-Jan-11,2/1/2010,8/1/2017,6/10/2016,Jun-16,No Study Results Posted,BMS-LyTrans,Aug-17,Research for cancer-related biomarkers|Sensitivity & specificity of the identified molecular signature in the DLBCL diagnosis context|Identify a prognostic whole blood RNA signature related to aggressive DLBCL|Proportion and phenotypic characteristics of circulating cells expressing the previously identified biomarkers at the time of diagnosis of DLBCL|Immune functions of these circulating cells expressing the previously identified biomarkers at the time of diagnosis of DLBCL,https://ClinicalTrials.gov/show/NCT01287923
464,NCT01095848,"A Phase I Safety Study of a Cancer Vaccine to Treat HLA-A2 Positive Advanced Stage Ovarian, Breast and Prostate Cancer",Completed,No Results Available,Ovarian Neoplasms|Breast Neoplasms|Prostatic Neoplasms,"Biological: DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG","ImmunoVaccine Technologies, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1,23,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ONC-DPX-0907-01,26-Mar-10,3/1/2010,11/1/2011,12/14/2015,Dec-15,No Study Results Posted,null,Apr-11,"To determine the safety profile of two different doses of subcutaneously administered DPX-0907. Safety assessments will be based on reported adverse events and the results of vital sign measurements, physical examinations, and clinical laboratory tests.|To determine the levels of CMI (cell mediated immunity) to the 7 cancer epitopes induced by vaccination with DPX-0907|To establish a recommended dose based on safety and immune response for phase 2 studies.",https://ClinicalTrials.gov/show/NCT01095848
865,NCT01191632,Effect of Neoadjuvant Radiation on Tumor Infiltrating T-cells by Low Dose Radiation in Colorectal Liver Metastases,Recruiting,No Results Available,Colorectal Liver Metastases,Radiation: one time radiation|Radiation: No Radiation,Heidelberg University,Both,"50 Years to 90 Years   (Adult, Senior)",Phase 1|Phase 2,40,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,S081/2008,20-Aug-10,3/1/2010,3/1/2012,10/21/2010,Oct-10,No Study Results Posted,null,Mar-12,"Purpose of the study is the determination of an active local external beam radiotherapy dose leading to a maximal number of tumor infiltrating T-cells. The total T-cell activity serves as primary surrogate parameters for anti- tumor activity|To determine local control and recurrence patterns of colorectal liver metastases in a CT|To determine the progression-free survival in patients treated with low dose photon beam radiation therapy|• To determine the surgical morbidity in patients undergoing liver resection who received this protocol treatment|• To determine 30-day post-operative mortality after liver resection in patients who received this protocol treatment|• To determine the T-cell activity in the resected liver tissue|• To determine quality of life according to the EORTC QoL questionnaire after 6 months.|To determine the number of regulatory T-cells in the resected liver tissue|To determine the frequencies of tumor-reactive T-cells in the blood and bone marrow of the patients|To determine quality of life according to the EORTC QoL questionnaire after 12 months.|To determine the number of patients with adverse events as a measure of safety and tolerability according to CTCAE, Version 4.0 criteria",https://ClinicalTrials.gov/show/NCT01191632
1277,NCT01164267,Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL),Completed,No Results Available,Marginal Zone B-cell Lymphoma,Drug: Everolimus,International Extranodal Lymphoma Study Group (IELSG),Both,"18 Years and older   (Adult, Senior)",Phase 2,30,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IELSG 34|2009-011725-14,15-Jul-10,3/1/2010,null,11/21/2013,May-12,No Study Results Posted,null,Dec-12,Total Body CT-Scan,https://ClinicalTrials.gov/show/NCT01164267
131,NCT01072981,Immunotherapy Study for Surgically Resected Pancreatic Cancer,"Active, not recruiting",No Results Available,Pancreatic Cancer,Biological: HyperAcute-Pancreas Immunotherapy|Drug: Gemcitabine|Radiation: 5FU Chemoradiation,NewLink Genetics Corporation,Both,"18 Years and older   (Adult, Senior)",Phase 3,722,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,NLG0405|OBA# 0912-1013,18-Feb-10,4/1/2010,null,8/5/2015,Aug-15,No Study Results Posted,null,Jun-16,The primary objective is to assess overall survival|The secondary objective is to assess disease free survival and to conduct correlative scientific studies of subject samples to determine the mechanism of any observed anti-tumor effect.,https://ClinicalTrials.gov/show/NCT01072981
257,NCT01326104,Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor,Recruiting,No Results Available,Medulloblastoma|Neuroectodermal Tumor,Biological: TTRNA-xALT|Biological: TTRNA-DCs,University of Florida|United States Department of Defense,Both,"up to 30 Years   (Child, Adult)",Phase 1|Phase 2,50,Other|U.S. Fed,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,Re-MATCH|W81XWH-10-1-0089|CDMRP-PRO93877,22-Jul-10,4/1/2010,3/1/2018,5/31/2016,May-16,No Study Results Posted,Re-MATCH,Mar-17,"Evaluate safety of TTRNA-DCs and TTRNA-xALT|Determine progression-free survival|Determine Objective Radiographic Response Rate|Correlate magnitude and persistence of anti-tumor humoral or cellular immunity with clinical outcome|Evaluate changes in cytokine profile and Toll-Like Receptor activation status|Characterize the immunologic phenotype of lymphocyte subsets (naïve, effector, memory, regulatory) and natural killer cells|Identify potential tumor specific antigens as vaccine candidates|Determine the progression-free survival and overall survival rate",https://ClinicalTrials.gov/show/NCT01326104
286,NCT01107639,"Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery","Active, not recruiting",No Results Available,Adenocarcinoma of the Gastroesophageal Junction|Esophageal Cancer,Biological: cetuximab|Drug: cisplatin|Drug: docetaxel|Procedure: adjuvant therapy|Procedure: neoadjuvant therapy,Swiss Group for Clinical Cancer Research,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 3,297,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment,SAKK 75/08|SWS-SAKK-75/08|EUDRACT-2009-016584-10|EU-21024|CDR0000669249,20-Apr-10,4/1/2010,6/1/2019,11/2/2015,Nov-15,No Study Results Posted,null,Dec-13,Progression-free survival (PFS)|Progression-free survival after surgery|Adverse events according to CTCAE version 4.0 and major postoperative complications|Pathological remission|Overall survival|Time to locoregional failure after R0 resection|Time to systemic failure after R0 resection|In-hospital mortality|Time to progression (TTP),https://ClinicalTrials.gov/show/NCT01107639
525,NCT01094496,"A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The ""N-ABLE"" Study)",Terminated,No Results Available,Bladder Cancer,Biological: CDX-1307 Vaccine Regimen|Drug: Chemotherapy,Celldex Therapeutics,Both,"18 Years and older   (Adult, Senior)",Phase 2,30,Industry,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDX1307-03,25-Mar-10,4/1/2010,10/1/2017,2/16/2016,Feb-16,No Study Results Posted,null,Jul-11,2 year Recurrence-Free Survival Rate|Duration of Recurrence-Free Survival|Tumor response to neoadjuvant chemotherapy|Overall survival|Safety / Tolerability,https://ClinicalTrials.gov/show/NCT01094496
550,NCT01118091,Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...,Completed,Has Results,Skin Cancer|Melanoma|Metastatic Melanoma,Biological: Aldesleukin|Biological: CD8 enriched Young TIL,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years and older   (Adult, Senior)",Phase 2,12,NIH,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,100117|10-C-0117,5-May-10,4/1/2010,4/1/2012,10/6/2015,Sep-15,9-Nov-12,null,Apr-12,Response Rate|Progression Free Survival|Toxicity,https://ClinicalTrials.gov/show/NCT01118091
584,NCT01081223,Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma,Completed,No Results Available,Glioma|High Grade Astrocytoma|Glioblastoma Multiforme,"Biological: Cancer vaccine plus immune adjuvant, plus activated white blood cells",TVAX Biomedical,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,14,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,TVI-AST-002,3-Mar-10,4/1/2010,3/1/2011,6/4/2013,Jun-13,No Study Results Posted,null,Mar-11,Relative toxicity|Progression free survival|Immunogenicity|Overall survival,https://ClinicalTrials.gov/show/NCT01081223
624,NCT01088789,A Trial of Boost Vaccinations of Pancreatic Tumor Cell Vaccine,Recruiting,No Results Available,Pancreatic Cancer,Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine.,Sidney Kimmel Comprehensive Cancer Center,Both,"18 Years and older   (Adult, Senior)",Phase 2,72,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,"J09100, NA_00031401|NA_00031401",1-Mar-10,4/1/2010,4/1/2023,3/8/2016,Mar-16,No Study Results Posted,null,Apr-23,Disease free overall survival.,https://ClinicalTrials.gov/show/NCT01088789
640,NCT01106235,"Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma",Terminated,No Results Available,Stage IV Melanoma,Biological: therapeutic autologous lymphocytes|Biological: aldesleukin|Drug: cyclophosphamide|Procedure: biopsy,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1,12,Other|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2390.00|NCI-2010-00146,8-Apr-10,4/1/2010,null,12/20/2011,Dec-11,No Study Results Posted,null,Nov-11,Safety and toxicity as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v 3.0|Functional and numeric in vivo persistence of adoptively transferred IL-21 modulated CTL and factors contributing to immunopotentiation in patients receiving IL-21 modulated CTL following cyclophosphamide conditioning|In vivo persistence and anti-tumor effect of the infused IL-21 modulated CTL,https://ClinicalTrials.gov/show/NCT01106235
806,NCT00634231,A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors,"Active, not recruiting",No Results Available,Malignant Glioma|Recurrent Ependymoma,Biological: AdV-tk|Drug: valacyclovir|Radiation: Radiation,"Advantagene, Inc.|Children's Hospital Boston",Both,"3 Years to 21 Years   (Child, Adult)",Phase 1,12,Industry|Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,07-098,5-Mar-08,4/1/2010,12/1/2020,10/28/2015,Oct-15,No Study Results Posted,null,Dec-16,Safety based on standard laboratory and clinical adverse event monitoring|Overall survival|Progression-free survival|Objective tumor response|Immunologic function,https://ClinicalTrials.gov/show/NCT00634231
822,NCT01103323,Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy,Completed,Has Results,Metastatic Colorectal Cancer,"Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Placebo|Other: Best Supportive Care (BSC)",Bayer,Both,"18 Years and older   (Adult, Senior)",Phase 3,760,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",14387|2009-012787-14,8-Apr-10,4/1/2010,1/1/2014,5/28/2015,May-15,19-Oct-12,null,Jul-11,Overall Survival|Progression-free Survival (Based on Investigator's Assessment)|Objective Tumor Response|Disease Control|Tumor Response,https://ClinicalTrials.gov/show/NCT01103323
1143,NCT01104025,Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis,Completed,No Results Available,Hemophagocytic Lymphohistiocytosis,"Drug: ATG, rabbit|Drug: Etoposide|Drug: Methotrexate|Drug: hydrocortisone|Drug: Dexamethasone","Children's Hospital Medical Center, Cincinnati",Both,"up to 18 Years   (Child, Adult)",Phase 2,31,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,HIT-HLH,13-Apr-10,4/1/2010,4/1/2016,6/9/2016,Jun-16,No Study Results Posted,null,Nov-15,Complete Response Rate|Time to Response|Overall Survival|Incidence of Infection|Incidence and Time to Relapse|Overall Survival to day +100|Gather Biologic Samples,https://ClinicalTrials.gov/show/NCT01104025
1148,NCT01100502,A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial),"Active, not recruiting",Has Results,"Disease, Hodgkin",Drug: brentuximab vedotin|Drug: placebo,"Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 3,329,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",SGN35-005|2009-016947-20,6-Apr-10,4/1/2010,4/1/2020,4/12/2016,Apr-16,31-Jul-15,null,Aug-14,Progression-free Survival by Independent Review|Overall Survival|Incidence of Adverse Events or Laboratory Abnormalities|Incidence of Anti-therapeutic Antibodies (ATA) to Brentuximab Vedotin,https://ClinicalTrials.gov/show/NCT01100502
278,NCT01138410,Study of a DNA Immunotherapy to Treat Melanoma,"Active, not recruiting",No Results Available,Malignant Melanoma,Biological: SCIB1,Scancell Ltd,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,35,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SCIB1-001,24-May-10,5/1/2010,12/1/2017,4/12/2016,Apr-16,No Study Results Posted,null,Dec-17,"Safety & Tolerability|Safety, tolerability, biological and clinical effects",https://ClinicalTrials.gov/show/NCT01138410
298,NCT01082926,"Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2",Completed,No Results Available,Anaplastic Astrocytoma|Anaplastic Ependymoma|Anaplastic Meningioma|Anaplastic Oligodendroglioma|Brain Stem Glioma|Ependymoblastoma|Giant Cell Glioblastoma|Glioblastoma|Gliosarcoma|Grade III Meningioma|Meningeal Hemangiopericytoma|Mixed Glioma|Pineal Gland Astrocytoma|Brain Tumor,Biological: therapeutic allogeneic lymphocytes|Biological: aldesleukin|Other: laboratory biomarker analysis|Procedure: positron emission tomography,City of Hope Medical Center,Both,"18 Years to 70 Years   (Adult, Senior)",Phase 1,6,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,07082|NCI-2010-00303,5-Mar-10,5/1/2010,9/1/2013,6/3/2015,Jun-15,No Study Results Posted,null,Sep-13,Safety of GRm13Z40-2 CTL CNS loco-regional cellular immunotherapy|Safety of convection enhanced delivery (CED) of recombinant human Interleukin-2 (rhuIL-2) used in conjunction with GRm13Z40-2 CTL adoptive transfer|Toxicity as assessed by NCI CTCAE version 4.0|Ability of 9-(4-fluoro-3-hydroxy-methyl-butyl) guanine (18FHBG) positron emission tomography PET to image GRm13Z40-2 CTLs|Impact of concurrent dexamethasone on the tempo and magnitude of T cell allograft rejection responses by tracking the frequency of anti-GRm13Z40-2 immune responses in serially acquired peripheral blood samples|Evaluation of ganciclovir administration for ablating transferred GRm13Z40-2 in vivo should significant graft-mediated toxicities be encountered,https://ClinicalTrials.gov/show/NCT01082926
363,NCT01057810,Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer,Completed,No Results Available,Prostate Cancer,Drug: Ipilimumab|Drug: Placebo,Bristol-Myers Squibb,Male,"18 Years and older   (Adult, Senior)",Phase 3,602,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CA184-095|2009-016217-23,26-Jan-10,5/1/2010,7/1/2015,9/2/2015,Sep-15,No Study Results Posted,null,Apr-15,"To compare overall survival (OS) of subjects, defined as the time from the date of randomization until the date of death. For those subjects who have not died OS will be censored at the last date the subject was known to be alive|Compare Progression Free Survival (PFS) by collecting tumor assessments every 12 weeks until protocol defined progression or initiation of subsequent therapy for prostate cancer|Compare time to pain progression by collection of a Patient Pain Diary prior to each treatment visit and every 12 weeks during follow up until progression of disease or initiation of subsequent therapy for prostate cancer|Compare time to subsequent non-hormonal systemic therapy by collection of subsequent prostate cancer therapies during follow up|Characterize Safety Profile by collection of adverse event information and review of laboratory values at every study visit",https://ClinicalTrials.gov/show/NCT01057810
419,NCT01143545,"Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas",Completed,No Results Available,Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma,Biological: Allogeneic Tumor Cell Vaccine (K562)|Drug: Celecoxib|Drug: cyclophosphamide,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 120 Years   (Adult, Senior)",Phase 1,10,NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,100138|10-C-0138,11-Jun-10,5/1/2010,3/1/2015,5/11/2016,Mar-16,No Study Results Posted,null,Feb-15,"Tabulation of toxicity type and grade|To ascertain if K526-GM vaccines induce immunity to CT antigens commonly expressed in thoracic malignancies.|To determine if metronomic oral CP and celecoxib reduce the number, percentage and function of CD4+ CD25+ Fox P3+ regulatory T cells (T reg) in peripheral blood of thoracic oncology patients.",https://ClinicalTrials.gov/show/NCT01143545
858,NCT01103375,Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma,Terminated,No Results Available,Adult Anaplastic Astrocytoma|Adult Anaplastic Oligodendroglioma|Adult Diffuse Astrocytoma|Adult Giant Cell Glioblastoma|Adult Glioblastoma|Adult Gliosarcoma|Adult Mixed Glioma|Adult Oligodendroglioma|Recurrent Adult Brain Tumor,Drug: erlotinib hydrochloride|Drug: isotretinoin|Other: laboratory biomarker analysis|Genetic: protein expression analysis,Comprehensive Cancer Center of Wake Forest University|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,5,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CCCWFU 91209|NCI-2010-00132,13-Apr-10,5/1/2010,3/1/2013,7/27/2015,Jul-15,No Study Results Posted,null,Jan-13,"Recommended phase II doses of erlotinib hydrochloride and isotretinoin|Toxicity as assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0|Progression-free survival|Overall survival|Response rates (complete or partial response)|EGFRvIII, PTEN, cyclin D1, cyclin E, and RARbeta1 expression in tumor samples",https://ClinicalTrials.gov/show/NCT01103375
1130,NCT01096602,Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission,Recruiting,No Results Available,Acute Myelogenous Leukemia|AML,Biological: DC AML Vaccine|Drug: CT-011,"Beth Israel Deaconess Medical Center|National Institutes of Health (NIH)|Medivation, Inc.|The Leukemia and Lymphoma Society|Dana-Farber Cancer Institute",Both,"18 Years and older   (Adult, Senior)",Phase 2,75,Other|NIH|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,09-412,29-Mar-10,5/1/2010,null,2/26/2016,Feb-16,No Study Results Posted,null,Sep-16,Toxicity|Immune response|Tumor regression|Time to disease progression,https://ClinicalTrials.gov/show/NCT01096602
1185,NCT01101581,"Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL","Active, not recruiting",No Results Available,Non Hodgkin's Lymphoma|NHL|Aggressive NHL|Diffuse Large B-cell Lymphoma,Drug: Veltuzumab and 90Y-Epratuzumab Tetraxetan|Drug: 90Y-epratuzumab tetraxetan|Drug: veltuzumab,"Immunomedics, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,70,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,IM-T-hA20/90Y-hLL2-01,16-Mar-10,5/1/2010,3/1/2017,3/2/2015,Mar-15,No Study Results Posted,null,Dec-16,Safety/dose limiting toxicity|Efficacy,https://ClinicalTrials.gov/show/NCT01101581
14,NCT01186640,Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL),Completed,No Results Available,T-cell-prolymphocytic Leukemia,"Drug: Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab|Drug: Alemtuzumab","German CLL Study Group|Genzyme, a Sanofi Company|University of Cologne",Both,"18 Years and older   (Adult, Senior)",Phase 2,16,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,TPLL2|2008-001421-34,20-Aug-10,6/1/2010,5/1/2014,10/21/2015,Oct-15,No Study Results Posted,null,May-14,Remission Rate|Overall Survival Time,https://ClinicalTrials.gov/show/NCT01186640
137,NCT01174368,"Efficacy Trial of the Implantation of Mouse Renal Adenocarcinoma Macrobeads in Subjects With Castration-Resistant Prostate Cancer Resistant to Taxanes (Docetaxel, Cabazitaxel) and Evidence of Disease Progression on Androgen-axis Inhibition and/or Immunotherapy in the Form of Sipuleucel-T",Recruiting,No Results Available,Prostate Cancer,Biological: Cancer Macrobead placement in abdominal cavity,The Rogosin Institute,Male,"18 Years and older   (Adult, Senior)",Phase 2,38,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,1003010955,1-Aug-10,6/1/2010,12/1/2017,5/23/2016,Feb-16,No Study Results Posted,null,Dec-16,Tumor volume|Number of metastases|Progression-free survival,https://ClinicalTrials.gov/show/NCT01174368
169,NCT01147965,Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA,Completed,No Results Available,Colon Cancer|Lung Cancer|Breast Cancer,Biological: AD5 CEA Vaccine,Etubics Corporation|Duke University,Both,"21 Years to 75 Years   (Adult, Senior)",Phase 1|Phase 2,35,Industry|Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ETBX-011,15-Jun-10,6/1/2010,3/1/2013,3/21/2013,Mar-13,No Study Results Posted,null,Mar-13,"The primary objective of this protocol is to determine the safety of immunization with Ad5 [E1-, E2B-]-CEA(6D), in patients with advanced or metastatic CEA-expressing malignancies, including Maximum Tolerated Dose (MTD).|The secondary objectives of this protocol are to evaluate CEA-specific immune responses to the immunizations and to obtain preliminary data on clinical response rate.",https://ClinicalTrials.gov/show/NCT01147965
279,NCT01308294,Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients,Terminated,No Results Available,Melanoma,"Biological: 2 vaccine injections in 1 limb|Biological: 2 vaccine injections in different limbs|Biological: 2 vaccine injections in different limbs, the vaccine does not contain the MHC class II peptide MAGE-A3-DP4",Centre Hospitalier Universitaire Vaudois|Immutep S.A.,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,16,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,P009-2010DR1082,3-Mar-11,6/1/2010,4/1/2014,10/14/2014,Oct-14,No Study Results Posted,LAG-3/IMP321,Apr-14,Safety of vaccination will be assessed according to NCI CTC scale|Immunological response (tumor antigen specific CD4 and CD8 T cell reactivity) will be measured by Tetramer analysis and ELISpot assays|Tumor response will be assessed by radiology in patients with measurable disease,https://ClinicalTrials.gov/show/NCT01308294
489,NCT01140373,Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC),Recruiting,No Results Available,Prostate Cancer,Biological: engineered autologous T cells|Drug: cyclophosphamide,Memorial Sloan Kettering Cancer Center|United States Department of Defense,Male,"18 Years and older   (Adult, Senior)",Phase 1,18,Other|U.S. Fed,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,09-036,7-Jun-10,6/1/2010,6/1/2017,7/14/2016,Jul-16,No Study Results Posted,null,Jun-17,"The safety and tolerability of immunotherapy|Changes in bone metastases|Changes in biomarkers of bone metastasis and metabolism|Changes in circulating tumor cells|Humoral and cell-mediated immunity to PSMA and other known prostate cancer antigens|To assess patterns of change in PSA.|To track the persistence, accumulation, and migration of genetically retargeted anti-PSMA autologous T cells",https://ClinicalTrials.gov/show/NCT01140373
675,NCT01219348,IDO Peptid Vaccination for Stage III-IV Non Small-cell Lung Cancer Patients.,Completed,No Results Available,NSCLC|Lung Cancer,Biological: IDO peptide vaccination,Inge Marie Svane|Herlev Hospital,Both,"18 Years and older   (Adult, Senior)",Phase 1,14,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,LU 1006 - IDO,10-May-10,6/1/2010,8/1/2012,8/17/2015,Aug-15,No Study Results Posted,IDOvaccine,Aug-12,evidence of toxicity|evaluation of immunological and clinical responses,https://ClinicalTrials.gov/show/NCT01219348
905,NCT01654692,A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma,Completed,No Results Available,Metastatic Malignant Melanoma,Drug: Ipilimumab and Fotemustine,Italian Network for Tumor Biotherapy|Bristol-Myers Squibb,Both,"18 Years and older   (Adult, Senior)",Phase 2,86,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NIBIT-M1|2010-019356-50,18-Jul-12,6/1/2010,9/1/2014,5/12/2015,May-15,No Study Results Posted,NIBIT-M1,May-12,The immune response disease control rate (irDCR) using the immune-related (ir) tumor response criteria of the combination of ipilimumab and fotemustine in patients with unresectable locally advanced or metastatic melanoma.|safety and feasibility of the combination of ipilimumab and fotemustine|Immune-related Major Durable Disease Control Rate (irMDDCR)|Immune-related Objective Response Rate (irORR)|Immune-related Time to Response (irTTR)|Immune-related Progression-Free Survival (irPFS)|Brain Progression-free Survival (Brain-PFS)|Overall Survival (OS),https://ClinicalTrials.gov/show/NCT01654692
928,NCT01138163,Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer,Completed,No Results Available,Non-small-cell Lung Cancer,Drug: Docetaxel plus bavituximab or placebo,Peregrine Pharmaceuticals,Both,"18 Years and older   (Adult, Senior)",Phase 2,121,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PPHM 0902,3-Jun-10,6/1/2010,5/1/2013,5/3/2013,May-13,No Study Results Posted,null,Oct-12,Objective Response Rate,https://ClinicalTrials.gov/show/NCT01138163
929,NCT01160601,Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer,Completed,No Results Available,Non-Squamous Non-Small Cell Lung Cancer,Drug: Paclitaxel / Carboplatin|Drug: bavituximab,Peregrine Pharmaceuticals,Both,"18 Years and older   (Adult, Senior)",Phase 2,86,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,PPHM 1001,8-Jul-10,6/1/2010,9/1/2013,3/31/2014,Mar-14,No Study Results Posted,null,Jun-13,Objective Response Rate,https://ClinicalTrials.gov/show/NCT01160601
1083,NCT01145209,A Phase II Study of Ofatumumab-Based Induction Chemoimmunotheraphy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,"Active, not recruiting",No Results Available,Small Lymphocytic Lymphoma|CLL (Chronic Lymphocytic Leukemia),Drug: Fludarabine Phosphate|Biological: Ofatumumab|Drug: Cyclophosphamide,"National Heart, Lung, and Blood Institute (NHLBI)|University of Virginia|GlasoSmithKline|National Institutes of Health Clinical Center (CC)",Both,"18 Years to 99 Years   (Adult, Senior)",Phase 2,32,NIH|Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,100141|10-H-0141,15-Jun-10,6/1/2010,12/1/2016,6/29/2016,Jun-16,No Study Results Posted,null,Oct-16,2-year progression -free survival rate|response rate (complete response and partial response); toxicity profile; rate of minimal residual disease positivity after completion of induction therapy; rate of conversion to minimal residual disease negativity after consolidation therapy,https://ClinicalTrials.gov/show/NCT01145209
1100,NCT01147380,Safety Study of Liver Natural Killer Cell Therapy for Hepatoma Liver Transplantation,Completed,Has Results,Liver Cirrhosis|Hepatocellular Carcinoma|Evidence of Liver Transplantation,Biological: Liver NK cell inoculation,Seigo Nishida|Florida Department of Health|University of Miami,Both,"18 Years and older   (Adult, Senior)",Phase 1,18,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,20100344,17-Jun-10,6/1/2010,12/1/2014,2/11/2016,Feb-16,26-May-15,MIAMINK,Dec-14,Side Effect of Cadaveric Donor Liver NK Cell Infusion|NK Cell Infusion-related Toxicity|Anti-HCC Effect of This Treatment|Anti-HCV Effect of This Treatment (If Applicable),https://ClinicalTrials.gov/show/NCT01147380
1237,NCT01137006,"An Open-Label, Dose-Escalation Study of IMC-20D7S In Patients With Malignant Melanoma",Completed,No Results Available,Malignant Melanoma,Biological: IMC-20D7S (Cohort 1A)|Biological: IMC-20D7S (Cohort 2A )|Biological: IMC-20D7S (Cohort 3A )|Biological: IMC-20D7S (Cohort 4A )|Biological: IMC-20D7S (Cohort 1B)|Biological: IMC-20D7S (Cohort 2B )|Biological: Biological/Vaccine: IMC-20D7S (Cohort 3B ),ImClone LLC,Both,"18 Years and older   (Adult, Senior)",Phase 1,27,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,13945|CP22-0901|I4Z-IE-JDEA,2-Jun-10,6/1/2010,8/1/2012,9/26/2012,Sep-12,No Study Results Posted,null,Aug-12,"Maximum tolerated dose (MTD)|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Maximum concentration (Cmax) cycle 1|Minimal concentration (Cmin) cycle 1|Halflife (t½), cycle 1|Clearance (Cl), cycle 1|Area under the curve (AUC), cycle 1|Volume of distribution at steady state (Vd), cycle 1|Maximum concentration (Cmax) cycle 3 (Arm A)|Minimal concentration (Cmin) cycle 3, (Arm A)|Halflife (t½), cycle 3, (Arm A)|Clearance (Cl), cycle 3, (Arm A)|Area under the curve (AUC), cycle 3, (Arm A)|Volume of distribution at steady state (Vd), cycle 3, (Arm A)|Maximum concentration (Cmax) cycle 3 (Arm B)|Minimal concentration (Cmin) cycle 3, (Arm B)|Halflife (t½), cycle 3, (Arm B)|Clearance (Cl), cycle 3, (Arm B)|Area under the curve (AUC), cycle 3, (Arm B)|Volume of distribution at steady state (Vd), cycle 3, (Arm B)|Maximum concentration (Cmax) cycles 2 and 4|Minimal concentration (Cmin) cycles 2 and 4|Halflife (t½), cycles 2 and 4|Clearance (Cl), cycles 2 and 4|Area under the curve (AUC), cycles 2 and 4|Volume of distribution at steady state (Vd), cycles 2 and 4|Development of antibodies (immunogenicity)|Measure the progression-free survival (PFS)|Recommend doses for Phase 2/3 studies based on MTD",https://ClinicalTrials.gov/show/NCT01137006
280,NCT01174121,Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer,Recruiting,No Results Available,Metastatic Colorectal Cancer|Metastatic Gastric Cancer|Metastatic Pancreatic Cancer|Metastatic Hepatocellular Carcinoma|Metastatic Cholangiocarcinoma,Biological: Young TIL|Drug: Aldesleukin|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Pembrolizumab,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 70 Years   (Adult, Senior)",Phase 2,290,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,100166|10-C-0166,31-Jul-10,7/1/2010,12/1/2019,6/30/2016,Jun-16,No Study Results Posted,null,Dec-18,"To determine the rate of tumor regression in patients in cohort 3 with metastatic digestive tract, urothelial, breast, and ovarian/endometrial cancers who receive autologous, minimally cultured tumor infiltrating lymphocytes (TIL) plus aldesleuk...|To determine the toxicity of this treatment regimen.|To evaluate the safety and efficacy of pembrolizumab in combination with the TIL therapy",https://ClinicalTrials.gov/show/NCT01174121
296,NCT01149902,Study of Chemo-Immunotherapy in Head and Neck Cancer Patients,Recruiting,No Results Available,Head and Neck Cancer,"Biological: Cyclophosphamide, Docetaxel, Dendritic cells, OK-432",University of Yamanashi,Both,"20 Years and older   (Adult, Senior)",Phase 1,10,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,631,22-Jun-10,7/1/2010,null,8/23/2011,Jun-10,No Study Results Posted,null,Mar-12,The safety and feasibility of chemo-immunotherapy|The number and function of immune effector cells in treated patients,https://ClinicalTrials.gov/show/NCT01149902
327,NCT01144247,Cellular Immunotherapy Study for Brain Cancer,Completed,No Results Available,Gliomas|Anaplastic Astrocytoma|Anaplastic Oligodendroglioma|Anaplastic Mixed Glioma|Glioblastoma Multiforme|Malignant Meningioma,Drug: alloreactive CTL,Jonsson Comprehensive Cancer Center|National Institutes of Health (NIH)|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,10,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,UCLA 07-09-008|R01CA125244,11-Jun-10,7/1/2010,7/1/2015,5/26/2016,May-16,No Study Results Posted,alloCTL,Jul-15,Number of patients with adverse events as a measure of safety and tolerability|Maximum tolerated dose,https://ClinicalTrials.gov/show/NCT01144247
598,NCT01147016,Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery,Suspended,No Results Available,Breast Cancer,Biological: HER2Bi-armed activated T cells|Drug: cyclophosphamide|Drug: doxorubicin hydrochloride|Drug: paclitaxel|Other: laboratory biomarker analysis|Procedure: neoadjuvant therapy|Procedure: therapeutic conventional surgery,Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI),Both,"18 Years to 120 Years   (Adult, Senior)",Phase 2,32,Other|NIH,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000675211|P30CA022453|WSU-2010-056,17-Jun-10,7/1/2010,6/1/2017,7/18/2016,Jul-16,No Study Results Posted,null,Jun-17,Pathologic complete response|Recurrence-free survival|Overall survival,https://ClinicalTrials.gov/show/NCT01147016
825,NCT01166490,A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma,Completed,No Results Available,Gastric Neoplasms|Pancreatic Neoplasms,Drug: ASG-5ME,"Seattle Genetics, Inc.|Agensys, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1,51,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ASG5ME-002,19-Jul-10,7/1/2010,7/1/2013,8/23/2013,Aug-13,No Study Results Posted,null,Jul-13,Incidence of adverse events and laboratory abnormalities|Best clinical response|Overall and progression-free survival|Concentrations of ASG-5ME and metabolites in blood|Incidence of antitherapeutic antibodies in blood,https://ClinicalTrials.gov/show/NCT01166490
874,NCT01176474,Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody Nivolumab or Ipilimumab With Nivolumab For Patients With Resected Stages IIIC/ IV Melanoma,"Active, not recruiting",No Results Available,Melanoma (Skin),Biological: NY-ESO-1 157-165 (165V)|Drug: Nivolumab|Biological: gp100:280-288 (288V)|Drug: Montanide ISA 51 vegetable grade (VG)|Drug: Ipilimumab|Procedure: Apheresis Procedure,H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)|Medarex|Bristol-Myers Squibb,Both,"16 Years and older   (Child, Adult, Senior)",Phase 1,73,Other|NIH|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MCC-15651|NCI-8316,5-Aug-10,7/1/2010,2/1/2017,7/5/2016,Jul-16,No Study Results Posted,null,Feb-17,Time to Relapse|Overall Survival (OS),https://ClinicalTrials.gov/show/NCT01176474
16,NCT01279902,Abbreviated R-CHOP in Completely Excised Stage I or II DLBCL,"Active, not recruiting",No Results Available,Diffuse Large B-cell Lymphoma,Drug: Rituximab plus CHOP Immunochemotherapy,Asan Medical Center,Both,"18 Years to 80 Years   (Adult, Senior)",Phase 2,32,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AMC_NHL01,3-Aug-10,8/1/2010,1/1/2017,7/25/2016,Jul-16,No Study Results Posted,null,Aug-16,Disease-free survival|Overall survival|any adverse events as a measure of safety and tolerability,https://ClinicalTrials.gov/show/NCT01279902
326,NCT01183897,3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow,"Active, not recruiting",No Results Available,Neuroblastoma,Biological: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic,Memorial Sloan Kettering Cancer Center,Both,"18 Months and older   (Child, Adult, Senior)",Phase 2,53,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,09-161,16-Aug-10,8/1/2010,8/1/2016,9/18/2015,Sep-15,No Study Results Posted,null,Aug-16,Assess the activity of high-dose 3F8/GM-CSF|Apply real-time quantitative RT-PCR|Monitor safety of the high-dose antibody treatment,https://ClinicalTrials.gov/show/NCT01183897
328,NCT01183884,3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma,"Active, not recruiting",No Results Available,Neuroblastoma,Biological: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid,Memorial Sloan Kettering Cancer Center,Both,"18 Months and older   (Child, Adult, Senior)",Phase 2,63,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,09-160,16-Aug-10,8/1/2010,8/1/2016,9/21/2015,Sep-15,No Study Results Posted,null,Aug-16,Assess the impact of high-dose 3F8/GM-CSF on relapse-free survival|Apply real-time quantitative RT-PCR to test the hypothesis that the minimal residual disease content of bone marrow|Monitor safety of the high-dose antibody treatment,https://ClinicalTrials.gov/show/NCT01183884
486,NCT01183429,3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Non-Myeloablative Therapy in Patients With High-Risk Neuroblastoma,"Active, not recruiting",No Results Available,Neuroblastoma,Drug: 3F8 and 13-cis-retinoic acid,Memorial Sloan Kettering Cancer Center,Both,"18 Months and older   (Child, Adult, Senior)",Phase 2,58,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,09-159,16-Aug-10,8/1/2010,8/1/2017,3/28/2016,Mar-16,No Study Results Posted,null,Aug-17,Assess the impact of high-dose 3F8/GM-CSF|Apply real-time quantitative RT-PCR|Monitor safety of the high-dose antibody treatment,https://ClinicalTrials.gov/show/NCT01183429
553,NCT01183416,High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation,"Active, not recruiting",No Results Available,Neuroblastoma,Drug: 3F8 monoclonal antibody and 13-cis-Retinoic Acid,Memorial Sloan Kettering Cancer Center,Both,"18 Months and older   (Child, Adult, Senior)",Phase 2,43,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,09-158,16-Aug-10,8/1/2010,8/1/2016,9/21/2015,Sep-15,No Study Results Posted,null,Aug-16,Assess the impact of high-dose 3F8/GM-CSF on relapse-free survival|Apply real-time quantitative RT-PCR to test the hypothesis that the minimal residual disease content of bone marrow|Monitor safety of the high-dose antibody treatment,https://ClinicalTrials.gov/show/NCT01183416
643,NCT01198808,Tumorspecific T-cell Immunity in Bladder Cancer as Prognostic Marker,"Active, not recruiting",No Results Available,Bladder Cancer,,Technische Universität München,Both,"18 Years to 90 Years   (Adult, Senior)",,50,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,IBT-1,8-Sep-10,8/1/2010,null,1/16/2012,Jan-12,No Study Results Posted,null,Dec-11,,https://ClinicalTrials.gov/show/NCT01198808
736,NCT01176461,Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558,"Active, not recruiting",No Results Available,Melanoma (Skin),Biological: MART-1|Biological: NY-ESO-1|Biological: gp100:209-217(210M)|Biological: gp100:280-288(288V)|Drug: Montanide ISA 51 VG|Biological: BMS-936558,H. Lee Moffitt Cancer Center and Research Institute|National Cancer Institute (NCI)|Bristol-Myers Squibb|Medarex,Both,"16 Years and older   (Child, Adult, Senior)",Phase 1,127,Other|NIH|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MCC-15400|NCI-P-7997|CA209-006/007|10-15526-99-01,5-Aug-10,8/1/2010,11/1/2016,3/25/2016,Mar-16,No Study Results Posted,null,Nov-16,Best Overall Response Rate (BORR)|Time to Response|Duration of Response,https://ClinicalTrials.gov/show/NCT01176461
1251,NCT01186913,Natural History Study of SCID Disorders,Recruiting,No Results Available,SCID|Leaky SCID|Omenn Syndrome|Reticular Dysgenesis|ADA Deficiency|XSCID,,National Institute of Allergy and Infectious Diseases (NIAID)|Office of Rare Diseases (ORD),Both,"Child, Adult, Senior",,265,NIH,Observational,Observational Model: Cohort|Time Perspective: Prospective,DAIT RDCRN PIDTC-6901,20-Aug-10,8/1/2010,8/1/2019,3/16/2016,Mar-16,No Study Results Posted,null,Aug-19,Overall survival following HCT|Full T cell reconstitution|Full B cell reconstitution|Engraftment|Infections|Growth and Nutrition|Graft versus Host Disease|Occurrence of autoimmunity requiring treatment|Neurodevelopment/Neurocognition|Other complications of HCT needing treatment|Quality of Life,https://ClinicalTrials.gov/show/NCT01186913
5,NCT02657785,Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy,Recruiting,No Results Available,Primary Central Nervous System Lymphoma,Drug: R-IDARAM plus intrathecal chemotherapy,"Navy General Hospital, Beijing",Both,"18 Years to 75 Years   (Adult, Senior)",Phase 2|Phase 3,100,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NavyGHB-001|001,23-Apr-14,9/1/2010,12/1/2024,2/1/2016,Feb-16,No Study Results Posted,null,Dec-18,Overall survival,https://ClinicalTrials.gov/show/NCT02657785
92,NCT02520895,Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia,Completed,No Results Available,LYMPHOMA,Biological: blood samplings,Hospices Civils de Lyon,Both,"18 Years and older   (Adult, Senior)",,98,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2009.548|2010-A00591-38,15-Sep-14,9/1/2010,10/1/2013,8/7/2015,Jul-15,No Study Results Posted,RIPAL,Oct-13,change in variations of the T and B cell repertoire in patients with lymphoid blood disease under treatment|performance of the mapping of the immune repertoire to predict treatment response|performance of the mapping of the immune repertoire to predict progression free survival|performance of the mapping of the immune repertoire to predict the risk of infection|sensitivity of detection of the circulating clones,https://ClinicalTrials.gov/show/NCT02520895
164,NCT01460472,Immunotherapy With Racotumomab in Advanced Lung Cancer,"Active, not recruiting",No Results Available,"NSCLC|Lung Cancer, Non-small Cell",Biological: Racotumomab|Other: Best Support Treatment,Recombio SL|CIMAB (Cuba)|Laboratorio Elea S.A.C.I.F. y A.|Innogene Kalbiotech Pte. Ltd|Eurofarma Laboratorios S.A.,Both,"18 Years and older   (Adult, Senior)",Phase 3,1082,Industry|Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,EC-AR-1E10 MAb-301|ISRCTN47153584,23-Oct-11,9/1/2010,9/1/2016,7/28/2016,Jul-16,No Study Results Posted,null,Sep-16,Overall Survival|Number of Participants with Adverse events as a measure of safety and tolerability|Progression Free Survival|Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside|Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside for Racotumomab Group|Determination of gamma interferon by ELISPOT (enzyme-linked immunosorbent spot) assay.|Determination of gamma interferon by ELISPOT (enzyme-linked immunosorbent spot) assay for Racotumomab Group.|Evaluation of the reactivity if the antibodies against X63 tumor line (mouse myeloma) for Racotumomab Group|Evaluation of the reactivity if the antibodies against X63 tumor line (mouse yeloma) for Racotumomab Group|Evaluation of the reactivity if the antibodies against X63 tumor line (mouse myeloma) for Best Support Treatment Group|Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside for Best Support Treatment Group|Determination of gamma interferon by ELISPOT (enzyme-linked immunosorbent spot) assay for Best Support Treatment Group.|Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry.|Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry in the Racotumomab Group.|Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry in the Best Support Treatment Group.|Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available)|Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available) in the Racotumomab Group.|Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available) in the Best Support Treatment Group.|Measurement of pro-inflammatory and anti-inflammatory cytokines|Measurement of pro-inflammatory and anti-inflammatory cytokines in the Racotumomab Group|Measurement of pro-inflammatory and anti-inflammatory cytokines in the Best Support Treatment Group|Determination of anti-idiotypic IgG response|Determination of anti-idiotypic IgG response in the Racotumomab Group.|Determination of anti-idiotypic IgG response in the Best Support Treatment Group.,https://ClinicalTrials.gov/show/NCT01460472
215,NCT01456065,Safety of Active Immunotherapy in Subjects With Ovarian Cancer,"Active, not recruiting",No Results Available,Ovarian Epithelial Cancer,Biological: Procure|Biological: Procure,Life Research Technologies GmbH,Female,"18 Years to 75 Years   (Adult, Senior)",Phase 1,15,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,LRT-I-L01 Ovar,14-Sep-11,9/1/2010,4/1/2013,2/28/2013,Feb-13,No Study Results Posted,null,Apr-13,Incidence of Adverse Events and clinical relevant deviations from Laboratory parameters|Number of circulating tumor cells in peripheral blood|Immune monitoring - Number of autologous dendritic cells loaded with tumor specific antigens|time to progression (CA (Cancer Antigen)-125 and CT (Computer tomography)|Overall survival,https://ClinicalTrials.gov/show/NCT01456065
300,NCT01171469,Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor,Completed,No Results Available,Brain Tumor|Glioblastoma|Medulloblastoma|Ependymoma|Anaplastic Astrocytoma,Biological: Dendritic Cells|Drug: Imiquimod,"Masonic Cancer Center, University of Minnesota",Both,"Child, Adult, Senior",Phase 1,8,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2008LS053|0809M48641,27-Jul-10,9/1/2010,6/1/2012,6/11/2013,Jun-13,No Study Results Posted,null,May-12,Maximum Tolerated Dose|Time to Tumor Progression,https://ClinicalTrials.gov/show/NCT01171469
392,NCT01079741,Safety Study of Adjuvant Vaccine to Treat Melanoma Patients,Completed,No Results Available,Melanoma,Biological: NY-ESO-1 protein; Poly-ICLC; Montanide,"Nina Bhardwaj|Ludwig Institute for Cancer Research|Oncovir, Inc.|Cancer Research Institute, New York City|Icahn School of Medicine at Mount Sinai",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,35,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,GCO 13-1391,2-Mar-10,9/1/2010,3/1/2013,1/6/2015,Dec-14,No Study Results Posted,null,Mar-13,"Phase I, to define the safety of subcutaneous vaccination with NY-ESO-1 protein, Montanide and escalating doses of Poly-ICLC|To evaluate the induction of humoral and T cell (CD4+ and CD8+) immunity to subcutaneous vaccination with NY-ESO-1 protein in combination with Poly-ICLC when given with or without Montanide.",https://ClinicalTrials.gov/show/NCT01079741
702,NCT01204684,Dendritic Cell Vaccine for Patients With Brain Tumors,"Active, not recruiting",No Results Available,Glioma|Anaplastic Astrocytoma|Anaplastic Astro-oligodendroglioma|Glioblastoma,Biological: autologous tumor lysate-pulsed DC vaccination|Biological: Tumor lysate-pulsed DC vaccination+0.2% resiquimod|Biological: Tumor-lysate pulsed DC vaccination +adjuvant polyICLC,Jonsson Comprehensive Cancer Center,Both,"18 Years to 70 Years   (Adult, Senior)",Phase 2,60,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,10-000202,16-Sep-10,9/1/2010,null,2/1/2016,Jan-16,No Study Results Posted,null,Sep-16,Most effective combination of DC vaccine components|Time to tumor progression and overall survival,https://ClinicalTrials.gov/show/NCT01204684
823,NCT00932152,Fulvestrant and Anastrozole as Consolidation Therapy in Postmenopausal Women With Advanced Non-small Cell Lung Cancer,Terminated,No Results Available,Non-small Cell Lung Cancer|Postmenopausal Women,Drug: fulvestrant (Faslodex)|Drug: anastrozole (Arimidex)|Drug: Bevacizumab (Avastin)|Drug: Best supportive care,University of Pittsburgh,Female,"18 Years and older   (Adult, Senior)",Phase 2,3,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,UPCI 08-131,1-Jul-09,9/1/2010,1/1/2013,2/12/2014,Feb-14,No Study Results Posted,null,Jan-13,"To evaluate the progression-free survival.|To evaluate the time to overall survival, time to progression, and toxicities|To evaluate the levels of 17b-estradiol, VEGF, E-selectin, thrombospondin-1 and IGF-1, and other biomarkers in the plasma.|To evaluate biomarkers (ERa, ERb, PR, VEGF and aromatase expression) in baseline, archival tumor tissue and correlate their expression with progression-free survival, time to progression, and overall survival.",https://ClinicalTrials.gov/show/NCT00932152
954,NCT01192555,Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma,"Active, not recruiting",No Results Available,Neuroblastoma,Biological: Neuroblastoma Vaccine|Drug: Cytoxan,"Baylor College of Medicine|Texas Children's Hospital|Center for Cell and Gene Therapy, Baylor College of Medicine",Both,"Child, Adult, Senior",Phase 1|Phase 2,11,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,H-26652-ATOMIC,16-Aug-10,9/1/2010,9/1/2026,3/28/2016,Mar-16,No Study Results Posted,ATOMIC,Jul-12,Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Number of Participants with Disease Progression as a Measure of Efficacy|Participants with T-cell changes as a Measure of Immune Response|Analysis of Immunologic Measurements,https://ClinicalTrials.gov/show/NCT01192555
98,NCT01210287,Incidence of Hepatitis B Virus (HBV) Reactivation in HBsAg Negative/HBcAb Positive Lymphoma Patients Treated With RCHOP,"Active, not recruiting",No Results Available,Lymphoma,Drug: nucleoside analog reverse transcriptase inhibitor,Fudan University,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 2|Phase 3,110,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label,201010HBV,27-Sep-10,10/1/2010,8/1/2014,1/7/2014,Jan-14,No Study Results Posted,IHBVRL,Aug-14,incidence of HBV reactivation|the outcome of antiviral therapy in HBV-DNA abnormal patients,https://ClinicalTrials.gov/show/NCT01210287
107,NCT01203930,A Study of Idelalisib and Rituximab in Elderly Patients With Untreated CLL or SLL,Terminated,No Results Available,Chronic Lymphocytic Leukemia (CLL)|Small Lymphocytic Lymphoma (SLL),Drug: Idelalisib|Drug: Rituximab,Gilead Sciences,Both,"65 Years and older   (Adult, Senior)",Phase 2,105,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,101-08,15-Sep-10,10/1/2010,5/1/2016,6/1/2016,Jun-16,No Study Results Posted,null,Aug-15,"Overall response rate|Type, frequency, severity, and relationship to study therapy of any adverse events (AEs) or abnormalities of physical findings, laboratory tests, drug discontinuations due to AEs or serious adverse events (SAEs)|Lymphadenopathy response rate|Change from baseline in the sum of the perpendicular diameters of all measurable lesions|Duration of response|Progression-free survival|Overall survival|Trough and 1.5 hour postdose plasma concentrations of idelalisib|Changes in potential pharmacodynamic markers of drug activity in plasma and whole blood",https://ClinicalTrials.gov/show/NCT01203930
205,NCT01218867,CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic Cancer,Completed,Has Results,Metastatic Cancer|Metastatic Melanoma|Renal Cancer,Biological: Anti-VEGFR2 CAR CD8 plus PBL|Drug: Cyclophosphamide|Biological: Aldesleukin|Drug: Fludarabine,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 70 Years   (Adult, Senior)",Phase 1|Phase 2,24,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,110013|11-C-0013,8-Oct-10,10/1/2010,2/1/2016,6/9/2016,Jun-16,15-Apr-16,null,Feb-16,Response to Therapy|Number of Participants With Adverse Events|In Vivo Survival of Chimeric T Cell Receptor (CAR) Gene-engineered Cells,https://ClinicalTrials.gov/show/NCT01218867
312,NCT01239368,Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma,Recruiting,No Results Available,Multiple Myeloma,Procedure: Adoptive Immunotherapy|Biological: Rapamycin-Generated Autologous Th1/Tc1 Cells,National Cancer Institute (NCI)|Hackensack University Medical Center|Georgetown University|National Institutes of Health Clinical Center (CC),Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1,86,NIH|Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,110016|11-C-0016,10-Nov-10,10/1/2010,8/1/2019,5/11/2016,Mar-16,No Study Results Posted,null,Nov-18,Evaluate feasibility and toxicity|Overall Survival|Disease-free survival,https://ClinicalTrials.gov/show/NCT01239368
320,NCT01026051,"Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma",Terminated,No Results Available,Stage III Melanoma|Stage IV Melanoma,Biological: MKC1106-MT,Mannkind Corporation,Both,"18 Years and older   (Adult, Senior)",Phase 2,5,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MKC1106-MT-002,3-Dec-09,10/1/2010,7/1/2012,5/10/2012,May-12,No Study Results Posted,null,Sep-11,"To evaluate the objective response, where response is defined as either complete response (CR), partial response (PR), or stable disease (SD) for 12 weeks or longer (CR, PR, and SD are defined according to RECIST 1.1 criteria)|To assess clinical efficacy of MKC1106-MT in subjects with advanced melanoma measured at 6 months and 1 year by (1) time to progression, progression-free survival|To identify and characterize correlations between biological activity (immune response), target antigen expression and clinical efficacy.|To further assess the safety profile and tolerability",https://ClinicalTrials.gov/show/NCT01026051
645,NCT01885702,Dendritic Cell Vaccination in Patients With Lynch Syndrome or Colorectal Cancer With MSI,"Active, not recruiting",No Results Available,Colorectal Cancer,Biological: DC vaccination,Radboud University,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1|Phase 2,25,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,EudraCT 2008-005584-33,18-Jun-13,10/1/2010,6/1/2016,4/6/2016,Apr-16,No Study Results Posted,null,Apr-16,"Safety and feasibility of vaccination with frameshift-derived neoantigen-loaded DC of CRC patients|To evaluate whether peptide-loaded DC can induce or enhance an immune response to tumor-associated antigen CEA and specific frameshift-derived neoantigens in the study population|Pathological responses|Clinical responses, e.g. disease-free survival, determined according to the standard protocol.",https://ClinicalTrials.gov/show/NCT01885702
682,NCT01236573,Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes,Terminated,Has Results,Skin Cancer|Metastatic Melanoma,Drug: Fludarabine|Drug: Cyclophosphamide|Biological: IL-12 transduced TIL,National Institutes of Health Clinical Center (CC)|National Cancer Institute (NCI),Both,"18 Years to 66 Years   (Adult, Senior)",Phase 1|Phase 2,34,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,110011|11-C-0011,5-Nov-10,10/1/2010,3/1/2015,10/26/2015,Oct-15,20-Aug-15,null,Mar-15,Maximum Tolerated Dose (MTD)|Response (Complete Response (CR) + Partial Response (PR)) to Therapy|Number of Participants With Adverse Events,https://ClinicalTrials.gov/show/NCT01236573
130,NCT01256801,Gene Expression Profiling of Breast Cancer Cells Predict the Response of Malignant Pleural Effusion,Completed,No Results Available,Breast Neoplasms|Neoplasm Metastasis|Gene Expression Profiling|Immunotherapy,Biological: cytokine,Beijing Cancer Hospital,Female,"18 Years to 75 Years   (Adult, Senior)",Phase 3,36,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,GMPE,1-Dec-10,11/1/2010,12/1/2013,7/27/2015,Jul-15,No Study Results Posted,GMPE,Jan-13,immunotherapy response|immunological status,https://ClinicalTrials.gov/show/NCT01256801
521,NCT01245673,Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma,"Active, not recruiting",No Results Available,Advanced Myeloma.,"Biological: Prevnar- Pneumococcal Conjugate Vaccine (PCV)|Other: Activated/costimulated autologous T-cell|Drug: Lenalidomide|Biological: MAGE-A3, Hiltonol® (Poly-ICLC)",Abramson Cancer Center of the University of Pennsylvania|University of Pennsylvania,Both,"18 Years to 80 Years   (Adult, Senior)",Phase 2,28,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,UPCC 02710|UMGCC 0955,19-Nov-10,11/1/2010,null,12/14/2015,Dec-15,No Study Results Posted,null,Nov-13,T-Cell responses against the MAGE-3 vaccine|Change in Paraprotein Levels|MAGE-A3 Immune Responses,https://ClinicalTrials.gov/show/NCT01245673
807,NCT01348256,Study With Dendritic Cell Immunotherapy in Resected Hepatic Metastasis of Colorectal Carcinoma,Recruiting,No Results Available,Colorectal Carcinoma|Hepatic Metastasis,Drug: Dendritic cells vaccine,"Clinica Universidad de Navarra, Universidad de Navarra",Both,"18 Years and older   (Adult, Senior)",Phase 2,58,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CD-2009-01|2008-007795-23,3-May-11,11/1/2010,6/1/2014,5/6/2013,Nov-12,No Study Results Posted,null,Dec-13,Progression Free survival|Overall survival,https://ClinicalTrials.gov/show/NCT01348256
1209,NCT01354457,Safety and Efficacy of Radio-immunotherapy (RIT) for Patients With Relapse or Refractory Acute Lymphoblastic Leukaemia (ALL) B CD22+,"Active, not recruiting",No Results Available,Acute Lymphoblastic Leukemia,Drug: Epratuzumab and 90Y-Epratuzumab,Nantes University Hospital,Both,"18 Years to 70 Years   (Adult, Senior)",Phase 1|Phase 2,21,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,BRD 08/12-H,17-Jul-09,11/1/2010,6/1/2016,6/24/2014,May-11,No Study Results Posted,RIT 90YEpra,Jun-16,Determination of MTD by evaluation of hematological and non hematoligical toxicity|rate of haematological response,https://ClinicalTrials.gov/show/NCT01354457
1239,NCT01206023,Applications of Nanotechnology in Multiple Sclerosis by Respiratory Samples,Completed,No Results Available,Multiple Sclerosis,Other: NA-NOSE artificial olfactory system,"Carmel Medical Center|Technion, Israel Institute of Technology",Both,18 Years to 60 Years   (Adult),Phase 1,71,Other,Observational,Observational Model: Case-Only|Time Perspective: Cross-Sectional,Nano-MS-10,19-Sep-10,11/1/2010,11/1/2012,6/26/2016,Jun-16,No Study Results Posted,MS-NANOSE,Nov-11,Successful discrimination between healthy and MS,https://ClinicalTrials.gov/show/NCT01206023
106,NCT01285765,"Study Evaluating the Non-inferiority of a Treatment Adapted to the Early Response Evaluated With 18F-FDG PET Compared to a Standard Treatment, for Patients Aged From 18 to 80 Years With Low Risk (aa IPI = 0) Diffuse Large B-cells Non Hodgkin's Lymphoma CD 20+",Recruiting,No Results Available,DLBCL,Drug: RCHOP21,The Lymphoma Academic Research Organisation|CHU de Nancy,Both,"18 Years to 80 Years   (Adult, Senior)",Phase 3,650,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,LNH 2009-1B,14-Jan-11,12/1/2010,12/1/2020,7/6/2016,Jul-16,No Study Results Posted,null,Dec-20,"Progression Free Survival|DELTA SUV|Overall Survival, EFS, response duration, DFS|prognostic impact of the existence of a high tumor burden at diagnosis (> 10 cm) on PFS|biological factors|Overall Response Rate|Rate of good responders according to results at PET after C2",https://ClinicalTrials.gov/show/NCT01285765
442,NCT01273181,MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered Lymphocytes,Terminated,Has Results,Metastatic Cancer|Metastatic Renal Cancer|Metastatic Melanoma,Biological: PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes|Drug: Aldesleukin|Drug: Cyclophosphamide|Drug: Fludarabine,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,9,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,110062|11-C-0062,7-Jan-11,12/1/2010,12/1/2012,10/6/2015,Oct-15,14-Feb-13,null,Dec-12,Toxicity Profile|Clinical Tumor Regression (Complete Response (CR) + Partial Response (PR)) in Patients With Metastatic Cancer,https://ClinicalTrials.gov/show/NCT01273181
855,NCT01271907,Drosophila-generated CTL,Terminated,Has Results,Metastatic Cutaneous Melanoma,Drug: fludarabine|Drug: cyclophosphamide|Drug: Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ PBL|Drug: Aldesleukin,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years and older   (Adult, Senior)",Phase 2,3,NIH,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,110052|11-C-0052,6-Jan-11,12/1/2010,4/1/2012,10/13/2015,Oct-15,7-Nov-12,null,Apr-12,Clinical Response|Safety of Drosophila Generated PBL Administered in Combination With a Lymphodepleting Preparative Regimen and Supportive Systemic Aldesleukin,https://ClinicalTrials.gov/show/NCT01271907
1003,NCT01265433,Randomized Study of Adjuvant WT-1 Analog Peptide Vaccine in Patients With Malignant Pleural Mesothelioma (MPM) After Completion of Combined Modality Therapy,"Active, not recruiting",No Results Available,Malignant Pleural Mesothelioma,Biological: WT-1-vaccine Montanide + GM-CSF|Biological: Montanide adjuvant + GM-CSF (This arm is closed),Memorial Sloan Kettering Cancer Center|United States Department of Defense,Both,"18 Years and older   (Adult, Senior)",Phase 2,31,Other|U.S. Fed,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",10-134,21-Dec-10,12/1/2010,12/1/2016,2/10/2016,Feb-16,No Study Results Posted,null,Dec-16,To assess the 1-year progression free survival in patients|To confirm the immunogenicity of the WT-1 analog peptide vaccine|To assess the utility of using the serum marker|overall survival,https://ClinicalTrials.gov/show/NCT01265433
28,NCT01213472,Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma,"Active, not recruiting",No Results Available,Melanoma,Biological: GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI),GlaxoSmithKline,Both,"18 Years and older   (Adult, Senior)",Phase 1,34,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,112406|2010-020663-20,1-Oct-10,1/1/2011,4/1/2018,4/28/2016,Feb-16,No Study Results Posted,null,Apr-18,"Occurrence of severe toxicities.|The induction of objective clinical response (Complete Response (CR) or Partial Response (PR)) in the overall population.|Occurrence of objective clinical response (CR or PR) in the population of patients who present the predictive Melanoma Antigen A3 (MAGE-A3) gene signature.|Occurrence of adverse events (AEs) and serious adverse events (SAEs).|Immunogenicity of the NY-ESO-1 ASCI treatment.|In the overall population and in the population of patients presenting the predictive MAGE-A3 gene signature: Occurrence of stable disease (SD).|In the overall population and in the population of patients presenting the predictive MAGE-A3 gene signature: Occurrence of mixed response (MR).|In the overall population and in the population of patients presenting the predictive MAGE-A3 gene signature: Time to Treatment Failure (TTF).|In the overall population and in the population of patients presenting the predictive MAGE-A3 gene signature: Progression-free survival (PFS).|In the overall population and in the population of patients presenting the predictive MAGE-A3 gene signature: Overall survival (OS).|In the overall population and in the population of patients presenting the predictive MAGE-A3 gene signature: The duration of response for patients with CR, PR or Stable Disease (SD) status.",https://ClinicalTrials.gov/show/NCT01213472
509,NCT01347034,Radiation Therapy and Intratumoral Autologous Dendritic Cells in Soft Tissue Sarcomas (STS),Completed,Has Results,Soft Tissue Sarcoma,Procedure: External Beam Radiation Therapy (RT)|Biological: Autologous Dendritic Cells,H. Lee Moffitt Cancer Center and Research Institute|University of Florida,Both,"18 Years and older   (Adult, Senior)",Phase 2,20,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MCC-16441,2-May-11,1/1/2011,4/1/2016,4/21/2016,Apr-16,14-Jul-14,null,Aug-13,Number of Participants With Enhanced T Lymphocyte Immune Response Specific for Soft Tissue Sarcoma Tumor Associated Antigens(STS-TAAs)|Number of Participants With Treatment Emergent Serious Adverse Events (SAEs) and Adverse Events (AEs),https://ClinicalTrials.gov/show/NCT01347034
674,NCT01280552,A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM),Completed,Has Results,Glioblastoma Multiforme,Biological: ICT-107|Biological: Placebo DC,"ImmunoCellular Therapeutics, Ltd.",Both,"18 Years to 80 Years   (Adult, Senior)",Phase 2,124,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",ICT-107-201,19-Jan-11,1/1/2011,12/1/2015,2/2/2016,Oct-14,2-Oct-14,null,Dec-13,Overall Survival (OS)|Overall Survival in HLA-A2 Patients|PFS|Progression Free Survival in HLA- A2 Patients,https://ClinicalTrials.gov/show/NCT01280552
788,NCT01240005,Cytokine Induced Killer Cells Stimulated by DC Immunotherapy for Renal Cell Carcinoma,Not yet recruiting,No Results Available,Renal Cell Carcinoma,Biological: DCIK,Qingdao University,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1|Phase 2,30,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,DCCIK002,12-Nov-10,1/1/2011,9/1/2013,11/12/2010,Nov-10,No Study Results Posted,null,Dec-12,"overall survival|Objective tumor response, Time to recurrence, Progression-free, Cellular immunity.",https://ClinicalTrials.gov/show/NCT01240005
877,NCT01342224,"Radiation Therapy, Tadalafil, Sargramostim, Gemcitabine, and Telomerase Vaccine (GV1001) in Patients With Pancreatic Cancer","Active, not recruiting",No Results Available,Locally Advanced Pancreatic Adenocarcinoma,Biological: tadalafil and vaccination,"Providence Health & Services|Providence Cancer Center, Earle A. Chiles Research Institute|Robert W. Franz Cancer Research Center",Both,"18 Years and older   (Adult, Senior)",Phase 1,11,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label,PHS 10-141B,21-Apr-11,1/1/2011,4/1/2017,3/28/2016,Mar-16,No Study Results Posted,null,Jun-12,Safety|Immune Response|Tumor Response,https://ClinicalTrials.gov/show/NCT01342224
1094,NCT01245556,Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma,Completed,No Results Available,Melanoma,Drug: BMS-908662|Drug: BMS-908662|Drug: Ipilimumab|Drug: Ipilimumab,Bristol-Myers Squibb,Both,"18 Years and older   (Adult, Senior)",Phase 1,8,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CA206-005,19-Nov-10,1/1/2011,11/1/2012,6/11/2013,Jun-13,No Study Results Posted,null,Nov-12,"Toxicity will be evaluated according to the NCI Common Toxicity Criteria for Adverse Events (CTCAE) version 3|Efficacy as determined by estimates of objective response rates and response duration|PK for BMS-908662 as determined by minimum and maximum observed concentrations, time of maximum observed concentration, area under the concentration curve for one dosing interval and the accumulation index|PD will be assessed by evaluating markers of RAS/RAF pathway activity",https://ClinicalTrials.gov/show/NCT01245556
1248,NCT01264731,Combination Therapy of Topical Imiquimod Plus Multipeptide Vaccination for Cutaneous Metastases of Melanoma,Suspended,No Results Available,Melanoma,Biological: MELITAC 12.1|Drug: Imiquimod,University of Virginia,Both,"18 Years and older   (Adult, Senior)",,24,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,15168,20-Dec-10,1/1/2011,6/1/2015,9/19/2013,Sep-13,No Study Results Posted,MEL53,Jan-15,"Safety: To determine the safety of administration of topical 5% imiquimod cream with or without administration of a peptide-based vaccine in patients with cutaneous metastases of melanoma.|Biologic: To evaluate whether topical imiquimod at sites of melanoma metastasis, with or without vaccine, increases a) endothelial expression of E-selectin and b) T cell infiltration.",https://ClinicalTrials.gov/show/NCT01264731
26,NCT02285413,Platin-based Chemotherapeutics to Enhance Dendritic Cell Vaccine Efficacy in Melanoma Patients,Completed,No Results Available,Melanoma,Biological: DC vaccination|Biological: DC vaccination with cisplatinum,Radboud University,Both,"18 Years to 70 Years   (Adult, Senior)",Phase 2,54,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NL32381.000.10,11-May-13,2/1/2011,4/1/2016,5/3/2016,May-16,No Study Results Posted,null,Oct-15,Immunogenicity: number of participants with KLH and/or tumor-specific antigens immune responses.|Feasibility: % of vaccines meeting the release criteria.|Toxicity: number of Participants with Adverse Events.|Progression-free survival|Overall survival|Best objective response (only in stage IV),https://ClinicalTrials.gov/show/NCT02285413
229,NCT01637532,Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer,Completed,No Results Available,Recurrent Ovarian Cancer,Drug: tocilizumab and interferon alpha 2-b|Drug: Carboplatin and Caelyx or doxorubicin,Leiden University Medical Center|University Medical Center Groningen,Female,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,21,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,PITCH trial,15-Apr-12,2/1/2011,9/1/2013,1/25/2016,Jan-16,No Study Results Posted,PITCH,Sep-13,The feasibility (NCI-CTCv4.0) to combine carboplatin and PLD or doxorubicin with tocilizumab as well as with tocilizumab and Peg-Intron|The effect of chemo-immunotherapy on the immune system|The relation between anti-tumor immunity and clinical outcome,https://ClinicalTrials.gov/show/NCT01637532
463,NCT01313429,"Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum",Completed,No Results Available,Sarcoma|Melanoma|Epithelial Malignancies|Pleural Malignancies,Drug: Cyclophosphamide|Biological: Allogenic tumor Cell Vaccine (K562)|Drug: Celecoxib,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 99 Years   (Adult, Senior)",Phase 1,19,NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,110111|11-C-0111,10-Mar-11,2/1/2011,6/1/2014,4/27/2016,Apr-16,No Study Results Posted,null,Jun-14,Summary of adverse events|Number and description of immunologic responses to a panel of CT antigens in vaccinated patients|Paired t test analysis of difference between number and percentage of T reg cells at baseline and at treatment conclusion,https://ClinicalTrials.gov/show/NCT01313429
579,NCT01309230,Trial of Adjuvant FANG™ Vaccine for High Risk Stage III/IV Ovarian Cancer,"Active, not recruiting",No Results Available,Ovarian Cancer,Biological: Vigil™,"Gradalis, Inc.",Female,"18 Years and older   (Adult, Senior)",Phase 2,44,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CL-PTL 105,25-Feb-11,2/1/2011,1/1/2018,3/30/2016,Mar-16,No Study Results Posted,FANG Ovarian,Jan-17,To determine and compare time to recurrence (TTR)|Immune Function,https://ClinicalTrials.gov/show/NCT01309230
586,NCT01022138,Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Women With HER2/Neu-Negative Metastatic Breast Cancer,"Active, not recruiting",No Results Available,Breast Cancer,Biological: HER2Bi-armed activated T cells|Drug: Cyclophosphamide|Other: Laboratory biomarker analysis,Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI),Female,"18 Years to 120 Years   (Adult, Senior)",Phase 2,63,Other|NIH,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CDR0000657998|P30CA022453|WSU-2009-085,26-Nov-09,2/1/2011,8/1/2016,3/17/2016,Mar-16,No Study Results Posted,null,Aug-16,"Progression-free survival|Overall survival|Toxicity|Cytokine responses, phenotypic markers of differentiation, specificity, and antitumor cytotoxicity in blood and tumor samples (if accessible)|Correlation between immunotherapy-induced changes in immune functions and clinical endpoints",https://ClinicalTrials.gov/show/NCT01022138
1280,NCT01227564,Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease,Completed,Has Results,Alzheimer's Disease,Biological: ACC-001 3 μg/ QS-21 50 μg|Biological: ACC-001 10 μg/ QS-21 50 μg|Other: Placebo- Phosphate buffered saline (PBS),"Pfizer|JANSSEN Alzheimer Immunotherapy Research & Development, LLC",Both,"50 Years to 80 Years   (Adult, Senior)",Phase 2,63,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",B2571010|3134K1-2208,22-Oct-10,2/1/2011,2/1/2014,1/28/2016,Jan-16,9-Feb-15,null,Feb-14,Change From Baseline in Brain Fibrillar Beta-Amyloid Protein (Aβ) at Week 104 as Measured by Standard Uptake Value Ratios (SUVRs) Over the Composite Regions of Interest (ROIs),https://ClinicalTrials.gov/show/NCT01227564
522,NCT01319565,Prospective Randomized Study of Cell Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction w/1200 TBI,"Active, not recruiting",No Results Available,Metastatic Melanoma|Skin Cancer,Drug: Aldesleukin|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Young Tumor Infiltrating Lymphocytes|Procedure: 1200 Gy Irradiation,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 66 Years   (Adult, Senior)",Phase 2,102,NIH,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,110123|11-C-0123,18-Mar-11,3/1/2011,6/1/2020,7/30/2016,Jul-16,No Study Results Posted,null,Jun-19,Determine the objective response rate and survival of melanoma patients receiving young TL plus aldesleukin treatment following either chemo preparative regimen alon or the same chemotherapy preparative regimen plus total body radiation,https://ClinicalTrials.gov/show/NCT01319565
975,NCT01328691,Prognostic Factor for Renal Cell Carcinoma (RCC) With Venous Tumor Thrombus,Completed,No Results Available,"Carcinoma, Renal Cell|Thrombus",,Seoul National University Hospital,Both,"18 Years and older   (Adult, Senior)",,118,Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,MCCho5,1-Apr-11,3/1/2011,3/1/2011,5/9/2011,May-11,No Study Results Posted,null,Mar-11,Cancer-specific survival|Recurrence-free survival,https://ClinicalTrials.gov/show/NCT01328691
1072,NCT01323400,Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST),Completed,No Results Available,GIST,Drug: Pazopanib|Other: Best supportive care,Centre Leon Berard|GlaxoSmithKline,Both,"18 Years to 90 Years   (Adult, Senior)",Phase 2,81,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,PAZOGIST,10-Mar-11,3/1/2011,2/1/2016,2/24/2016,Feb-16,No Study Results Posted,PAZOGIST,Apr-14,"Progression-free survival|Overall survival|Objective tumour response rate (RECIST v.1.1) at 4 months|Best response (RECIST v.1.1) obtained during the study|Tolerance profile (NCI-CTCAE v.4.0)|Pattern of progression-free survival in the different molecular subtypes|Intra and inter-patient variability of the Cmin of pazopanib|Progression-free survival in patients not randomly assigned to pazopanib, but receiving pazopanib on a compassionate basis after progression|Overall survival in patients not randomly assigned to pazopanib, but receiving pazopanib on a compassionate basis after progression",https://ClinicalTrials.gov/show/NCT01323400
1131,NCT01343043,A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma,Recruiting,No Results Available,Synovial Sarcoma,Biological: NY-ESO-1(c259)T Cells,Adaptimmune,Both,"4 Years and older   (Child, Adult, Senior)",Phase 1|Phase 2,65,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ADP 04511,26-Apr-11,3/1/2011,3/1/2028,7/29/2016,Jul-16,No Study Results Posted,NY-ESO-1,Mar-17,"Proportion of subjects with a confirmed Complete Response (CR) or Partial Response (PR) in each cohort|Number of subjects with dose-limiting toxicity (DLT) and adverse events (AE), including serious adverse events (SAE)|Evaluation of the persistence of genetically modified T cells|Percentage of total gene modified T cells with memory subtype|After progressing and after receiving a 2nd dose of NY-ESO-1ᶜ²⁵⁹T, proportion of subjects with a confirmed Complete Response (CR)",https://ClinicalTrials.gov/show/NCT01343043
1180,NCT01319838,Aflac ST1001 Prolonged Isotretinoin,Withdrawn,No Results Available,Neuroblastoma,Drug: Isotretinoin,Emory University|Children's Healthcare of Atlanta,Both,"up to 30 Years   (Child, Adult)",Phase 1,0,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IRB00047148|Aflac ST1001,18-Mar-11,3/1/2011,12/1/2013,12/9/2013,Dec-13,No Study Results Posted,Aflac ST1001,Dec-13,Progression free survival|Isotretinoin toxicity|Bone growth effect|Isotretinoin pharmacokinetic profile|Neurologic or psychologic sequelae,https://ClinicalTrials.gov/show/NCT01319838
1253,NCT01329354,Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy,"Active, not recruiting",No Results Available,Follicular Lymphoma|Follicular Non-Hodgkin´s Lymphoma|Autologous Effector Lymphocytes,Biological: Autologous effector lymphocytes expanded ex-vivo,"Clinica Universidad de Navarra, Universidad de Navarra|Spanish National Health System",Both,"18 Years to 75 Years   (Adult, Senior)",Phase 2,38,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,LFNK|2009-017829-19,1-Apr-11,3/1/2011,11/1/2017,7/16/2015,May-15,No Study Results Posted,null,Nov-15,Progression free survival (PFS) from the entry in the study.|Event free survival from the entry in the study|Time to the next anti-lymphoma treatment|Disease free survival|Safety,https://ClinicalTrials.gov/show/NCT01329354
12,NCT01220128,Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer,Terminated,No Results Available,"Neoplasms, Breast",Biological: GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A|Drug: Placebo|Drug: Aromatase inhibitor|Drug: 5-Fluorouracil|Drug: Carboplatin AUC|Drug: Cyclophosphamide|Drug: Docetaxel|Drug: Doxorubicin|Drug: Epirubicin|Drug: Paclitaxel|Drug: Trastuzumab,GlaxoSmithKline,Both,"18 Years and older   (Adult, Senior)",Phase 2,60,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",113172|2010-019909-42,7-Oct-10,4/1/2011,11/1/2014,2/18/2016,Feb-16,No Study Results Posted,INDUCT,Nov-14,Phase I segment of the study: occurrence of severe toxicities.|Phase I segment of the study: immunogenicity to constituent of the investigational immunotherapy.|Phase II segment of the study: occurrence of severe toxicities.|Phase II segment of the study: occurrence of adverse events and serious adverse events.|Phase II segment of the study: occurrence of serious adverse events related to study treatment.|Phase II segment of the study: Immunogenicity to constituent of the investigational immunotherapy.|Phase II segment of the study: clinical activity (The pathological response in the breast and axillary nodes at the definitive surgery).|Phase II segment of the study: other indicators of clinical activity (Disease free survival and Overall survival).,https://ClinicalTrials.gov/show/NCT01220128
441,NCT01341496,Tumor Cell Vaccines and ISCOMATRIX With Chemotherapy After Tumor Removal,Terminated,No Results Available,Sarcoma|Melanoma|Epithelial Malignancies|Pleural Malignancy,Biological: Epigenetically Modified Autologous Tumor|Drug: Cyclophosphamide|Drug: Celecoxib,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 99 Years   (Adult, Senior)",Phase 1,41,NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,110148|11-C-0148,22-Apr-11,4/1/2011,7/1/2016,7/23/2016,Jul-16,No Study Results Posted,null,May-16,"tabulation and grade of observed patient toxicities attributed to the vaccine, and report of the fractions of patients who encounter these toxicities at the various grades|Determine if 5 or greater of the first 20 vaccinated patients undergoing thoracic metastasectomy have successful tumor cell line development|Number and characteristics of immunologic responses to a panel of CT antigens in vaccinated patients",https://ClinicalTrials.gov/show/NCT01341496
836,NCT01334047,Trial of Vaccine Therapy in Recurrent Platinum Sensitive Ovarian Cancer Patients,Terminated,No Results Available,Recurrent Epithelial Ovarian Cancer,Biological: DC-006 vaccine,Oslo University Hospital,Female,"18 Years to 75 Years   (Adult, Senior)",Phase 1|Phase 2,5,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,DC-006,30-Mar-11,4/1/2011,4/1/2022,8/22/2014,Aug-14,No Study Results Posted,null,Aug-13,Frequency and severity of adverse events|Determine immunological response to the vaccine (induction of specific T-cell response)|Determine time of disease progression and survival time.|Treatment free interval,https://ClinicalTrials.gov/show/NCT01334047
875,NCT01336478,CD56+CD3- NK Cells Following Allogeneic Stem Cell Transplantation,Withdrawn,No Results Available,Haematological Malignancies|Allogeneic Stem Cell Transplant|CD56+CD3- NK Cells,Procedure: Infusion of donor derived ex-vivo selected NK cells to patients after transplant|Procedure: Haematology / Blood chemistry sampling,Imperial College London,Both,"18 Years and older   (Adult, Senior)",Phase 1,0,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,JROHH0203,22-Mar-11,4/1/2011,6/1/2014,6/3/2015,Mar-12,No Study Results Posted,null,Jun-14,Safety and toxicity donor CD56+CD3- NK cells|Donor neutrophil and platelet engraftment|Rates of acute GVHD (grade 2-4)|Relapse rate,https://ClinicalTrials.gov/show/NCT01336478
1215,NCT01339962,Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2.,Completed,No Results Available,Renal Cell Carcinoma,Other: Non-interventional,"Pfizer|Copenhagen University Hospital at Herlev|Rigshospitalet, Denmark|Aarhus University Hospital|Odense University Hospital|Danish Renal Cancer Study Group",Both,"18 Years and older   (Adult, Senior)",Phase 4,1073,Industry|Other,Observational,Observational Model: Cohort|Time Perspective: Retrospective,A6181203|DARENCA STUDY 2,15-Apr-11,4/1/2011,4/1/2012,8/15/2014,Aug-14,No Study Results Posted,null,Apr-12,"Overall survival from initiation of first systemic anticancer therapy|Progression free survival from initiation of each systemic anticancer therapy separately|Time to treatment failure from initiation of each systemic anticancer therapy separately|Prognostic factors at baseline associated with efficacy (PFS) of each systemic anticancer therapy and overall survival|Serious Adverse Events: Defined as AEs leading to dose adjustment, treatment interruption/ cessation or death.|Predictive factors|Co-morbidity assessed by Charlson Comorbidity Index|Combined PFS and OS on sequential treatment|Assessment of first line immunotherapy´s effect on second line targeted therapy|Assessment of prognostic factors and overall survival for patients not receiving systemic therapy",https://ClinicalTrials.gov/show/NCT01339962
309,NCT01295762,Immunomonitoring of Children With Neuroblastoma,Recruiting,No Results Available,Neuroblastoma,Other: Immunological analyses,Centre Leon Berard,Both,"up to 21 Years   (Child, Adult)",,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Screening,IMMUNEURO,11-Feb-11,5/1/2011,7/1/2019,7/1/2015,Jul-15,No Study Results Posted,Immuneuro,Jul-15,"Description of immune effectors in the blood, marrow and tumor diagnosis.",https://ClinicalTrials.gov/show/NCT01295762
461,NCT01369875,Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma,Completed,Has Results,Metastatic Melanoma|Skin Cancer,Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Aldesleukin|Biological: Tumor Infiltrating Lymphocytes,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years and older   (Adult, Senior)",Phase 2,2,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,110163|11-C-0163,8-Jun-11,5/1/2011,11/1/2012,10/6/2015,Sep-15,14-Feb-13,null,Nov-12,Clinical Tumor Regression.|Toxicity,https://ClinicalTrials.gov/show/NCT01369875
628,NCT01369888,Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma,Terminated,Has Results,Metastatic Melanoma|Skin Cancer,Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Tumor Infiltrating Lymphocytes|Drug: IL-15,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 66 Years   (Adult, Senior)",Phase 1|Phase 2,3,NIH,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,110170|11-C-0170,8-Jun-11,5/1/2011,5/1/2014,1/26/2015,Jan-15,15-Jan-15,null,May-14,Phase 1: Maximum Tolerated Dose (MTD) of Intravenous Recombinant IL-15 as a Daily Intravenous Bolus for 10 Consecutive Days in Patients With Metastatic Melanoma Who Have Received a Lymphodepleting Chemotherapy and ACT TIL.|Number of Participants With Adverse Events,https://ClinicalTrials.gov/show/NCT01369888
1212,NCT01346150,Patients Treated for SCID (1968-2010),Recruiting,No Results Available,SCID|ADA-SCID|XSCID|Leaky SCID|Omenn Syndrome|Reticular Dysgenesis,,National Institute of Allergy and Infectious Diseases (NIAID)|Office of Rare Diseases (ORD),Both,"Child, Adult, Senior",,1146,NIH,Observational,Observational Model: Cohort|Time Perspective: Retrospective,DAIT RDCRN PIDTC-6902,29-Apr-11,5/1/2011,8/1/2019,3/17/2016,Mar-16,No Study Results Posted,null,Aug-19,Retrospective Study - Part 1|Cross-Sectional Study - Part 2|Retrospective Study Part 1,https://ClinicalTrials.gov/show/NCT01346150
1276,NCT01947322,Haploidentical NK-cell Infusion in Acute Myeloid Leukemia,"Active, not recruiting",No Results Available,Acute Myeloid Leukemia,Drug: Allogenic NK cells infusion,Assistance Publique - Hôpitaux de Paris,Both,18 Years to 65 Years   (Adult),Phase 1|Phase 2,11,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,P070505,26-Mar-13,5/1/2011,9/1/2015,9/4/2015,Sep-15,No Study Results Posted,NK,Dec-12,duration of neutropenia inferior to 500 neutrophils /mm3,https://ClinicalTrials.gov/show/NCT01947322
76,NCT01326871,A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer,"Active, not recruiting",No Results Available,Transitional Cell Carcinoma of Bladder|Urethra Cancer|Ureter Cancer|Malignant Tumor of Renal Pelvis,Drug: Cisplatin|Drug: Gemcitabine|Biological: ALT-801,Altor Bioscience Corporation|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,90,Industry|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CA-ALT-801-01-10,30-Mar-11,6/1/2011,10/1/2017,4/11/2016,Apr-16,No Study Results Posted,null,Jul-17,Maximum Tolerated Dose (MTD) and/or the recommended dose (RD) for dose expansion of ALT-801 in combination with cisplatin and gemcitabine or ALT-801 in combination with gemcitabine alone|Safety Profile|Clinical Benefit|Progression Free Survival|Overall survival|Pharmacokinetics and immunogenicity|Tumor Typing,https://ClinicalTrials.gov/show/NCT01326871
275,NCT01368107,"Study Evaluating Impact of IL-7 on CD4 Lymphopenia, Risks of Severe Haematological Toxicity and Tumor Progression in Metastatic Breast Cancer Patients",Completed,No Results Available,Metastatic Breast Cancer,Drug: placebo|Drug: interleukin 7|Drug: interleukin 7|Drug: interleukin 7,"Centre Leon Berard|Ministry of Health, France|Cytheris, Inc.",Female,"18 Years and older   (Adult, Senior)",Phase 2,24,Other|Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",ELYPSE 7|2011-000226-30,6-Jun-11,6/1/2011,6/1/2014,2/6/2015,Dec-13,No Study Results Posted,null,Sep-13,"to determine the optimal schedule to deliver CYT107 during chemotherapy based on restoration of CD4 count|to determine if CYT107 treatment enables to reduce the incidence of severe haematological toxicity (any type of haematological toxicity Grade ≥ 3) post-chemotherapy|To assess the impact of CYT107 on progression-free survival|To assess the impact of CYT107 on compliance to chemotherapy regimen (dose intensity, number of chemotherapy cycles).|To assess the impact of CYT107 on CD4 lymphopenia over the study period|to evaluate if CYT107 treatment will selectively stimulate the proliferation and activation of peripheral immune subsets (analysis of phenotype and activation status of peripheral immune e sub-populations)|to evaluate if CYT107 treatment will selectively improve the functional response of T cells, DC subsets and NK cells|to evaluate if CYT107 treatment will is able to revert tolerogenic immune burden to increase specific anti-tumor response (measure of antigen specific CD8 response, measure of cytokine plasmatic levels)|to evaluate if CYT107 treatment will enable to increase TCR diversity (analysis of combinatorial diversity).|To assess the impact of CYT107 treatment on overall incidence of side effects",https://ClinicalTrials.gov/show/NCT01368107
291,NCT01221675,TF2- Small Cell Lung Cancer Radio Immunotherapy,"Active, not recruiting",No Results Available,Small Cell Lung Cancer|CEA-expressing Non Small Cell Lung Carcinoma (NSCLC),Drug: Antibody TF2|Radiation: IMP-288-Lutetium|Radiation: IMP-288-Indium,Centre René Gauducheau,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,33,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,BRD 08/9-O,11-Oct-10,6/1/2011,6/1/2017,4/8/2016,Apr-16,No Study Results Posted,null,Jun-17,Primary endpoint of study plan I: To determine the optimal TF2 protein dose for pretargeting IMP-288.|Primary endpoint of study plan II • the maximum tolerated dose (MTD) for the TF2-pretargeted 177Lu-IMP-288 under optimal pretargeting conditions.,https://ClinicalTrials.gov/show/NCT01221675
475,NCT01331525,The Addition of Ipilimumab to Carboplatin and Etoposide Chemotherapy for Extensive Stage Small Cell Lung Cancer,Completed,No Results Available,Extensive Stage Small Cell Lung Cancer,Biological: Ipilimumab,"University Hospital Southampton NHS Foundation Trust.|Cancer Research UK|Institute of Cancer Research, United Kingdom|Bristol-Myers Squibb",Both,"18 Years and older   (Adult, Senior)",Phase 2,42,Other|Industry,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,RHM CAN0739,4-Apr-11,6/1/2011,6/1/2015,4/13/2016,Apr-16,No Study Results Posted,ICE,Jun-15,"To establish the progression free survival at 1 year in patients with extensive stage small cell lung cancer treated with ipilimumab, carboplatin and etoposide.|Assess tumour response and toxicity of ICE combination. Response measured by RECIST and immune related response criteria. Toxicity via physical exam, adverse event review, assessing signs and symptoms, quality of life assessment and blood testing.",https://ClinicalTrials.gov/show/NCT01331525
534,NCT01353222,DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma,Completed,No Results Available,Urothelial Carcinoma,Biological: DN24-02|Other: Standard of Care,Dendreon,Both,"18 Years and older   (Adult, Senior)",Phase 2,142,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,N10-1,4-May-11,6/1/2011,7/1/2015,4/21/2016,Apr-16,No Study Results Posted,null,Jul-15,Evaluate overall survival following administration of DN24-02|Evaluate disease-free survival following administration of DN24-02|Evaluate the safety of DN24-02|Evaluate the magnitude of immune response induced by administration of DN24-02|Evaluate the magnitude of cumulative CD54 upregulation following administration of DN24-02,https://ClinicalTrials.gov/show/NCT01353222
575,NCT01290692,Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma,"Active, not recruiting",No Results Available,Grade IV Glioma|Grade IV Astrocytoma|Glioblastoma Multiforme,Biological: TVI-Brain-1,TVAX Biomedical,Both,"18 Years and older   (Adult, Senior)",Phase 2,86,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,TVI-AST-005,3-Feb-11,6/1/2011,2/1/2014,9/16/2012,Sep-12,No Study Results Posted,null,Dec-13,Progression Free Survival|Overall Survival|Quality of life|Toxicity|Time to progression|Objective response rate|Cancer immunogenicity,https://ClinicalTrials.gov/show/NCT01290692
604,NCT01376505,Vaccine Therapy in Treating Patients With Metastatic Solid Tumors,Recruiting,No Results Available,Malignant Solid Tumour|Breast Cancer|Malignant Tumor of Colon|GIST|Ovarian Cancer,Biological: HER-2 vaccine,Pravin Kaumaya|Ohio State University Comprehensive Cancer Center,Both,"18 Years and older   (Adult, Senior)",Phase 1,36,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,OSU-09138|NCI-2011-00920,9-Jun-11,6/1/2011,null,3/1/2016,Mar-16,No Study Results Posted,null,Dec-16,Type and duration of immune response measured over time to repeat vaccine administration|Clinical benefit will be assessed|Evaluation of safety and toxicity at regular intervals by NCI common toxicity criteria (CTCAE v 4.0),https://ClinicalTrials.gov/show/NCT01376505
768,NCT01334177,"TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck",Completed,No Results Available,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma|Recurrent Metastatic Squamous Neck Cancer With Occult Primary|Recurrent Salivary Gland Cancer|Recurrent Squamous Cell Carcinoma of the Hypopharynx|Recurrent Squamous Cell Carcinoma of the Larynx|Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity|Recurrent Squamous Cell Carcinoma of the Nasopharynx|Recurrent Squamous Cell Carcinoma of the Oropharynx|Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Recurrent Verrucous Carcinoma of the Larynx|Recurrent Verrucous Carcinoma of the Oral Cavity|Salivary Gland Squamous Cell Carcinoma|Stage III Salivary Gland Cancer|Stage III Squamous Cell Carcinoma of the Hypopharynx|Stage III Squamous Cell Carcinoma of the Larynx|Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage III Squamous Cell Carcinoma of the Nasopharynx|Stage III Squamous Cell Carcinoma of the Oropharynx|Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage III Verrucous Carcinoma of the Larynx|Stage III Verrucous Carcinoma of the Oral Cavity|Stage IV Salivary Gland Cancer|Stage IVA Squamous Cell Carcinoma of the Larynx|Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVA Squamous Cell Carcinoma of the Oropharynx|Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVA Verrucous Carcinoma of the Larynx|Stage IVA Verrucous Carcinoma of the Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Larynx|Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVB Squamous Cell Carcinoma of the Oropharynx|Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVB Verrucous Carcinoma of the Larynx|Stage IVB Verrucous Carcinoma of the Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Larynx|Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity|Stage IVC Squamous Cell Carcinoma of the Oropharynx|Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity|Stage IVC Verrucous Carcinoma of the Larynx|Stage IVC Verrucous Carcinoma of the Oral Cavity|Tongue Cancer,Drug: TLR8 agonist VTX-2337|Biological: cetuximab|Other: laboratory biomarker analysis|Other: pharmacogenomic studies,University of Washington|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,13,Other|NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,7406|NCI-2011-00240|P30CA015704,21-Mar-11,6/1/2011,null,3/3/2015,Mar-15,No Study Results Posted,null,Jun-14,Maximum tolerated dose and the toxicities of TLR8 agonist VTX-2337 in combination with cetuximab|Pharmacodynamic immune response to TLR8 agonist VTX-2337 in combination with cetuximab,https://ClinicalTrials.gov/show/NCT01334177
1015,NCT01373047,CEA-Expressing Liver Metastases Safety Study of Intrahepatic Infusions of Anti-CEA Designer T Cells,Completed,No Results Available,Liver Metastases,Biological: anti-CEA 2nd generation designer T cells,Roger Williams Medical Center,Both,"18 Years and older   (Adult, Senior)",Phase 1,8,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,RWH 335-99,9-Jun-11,6/1/2011,7/1/2013,7/29/2013,Jul-13,No Study Results Posted,HITM,Jul-13,Determine the safety of modified T cells delivered into the hepatic artery by documenting the type and severity of any side effects and establishing the Maximum Tolerated Dose (MTD).|Tumor Response by CT or MRI and PET scan|Designer T cell distribution following infusion|Designer T cell survival and phenotype following infusion,https://ClinicalTrials.gov/show/NCT01373047
1048,NCT01425749,Study to Assess Safety and Immune Response of Stage IIB-IV Resected Melanoma After Treatment With MAGE-A3 ASCI,Completed,Has Results,Melanoma,Biological: recMAGE-A3 + AS15 ASCI,"Craig L Slingluff, Jr|GlaxoSmithKline|University of Virginia",Both,"18 Years and older   (Adult, Senior)",Phase 0,25,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CSlingluff,19-Jul-11,6/1/2011,10/1/2015,3/2/2016,Mar-16,13-Dec-15,Mel55,Jul-13,"Number of Participants With Treatment-related Adverse Events as a Measure of Safety and Tolerability|Enumeration of CD4 and CD8 T Cell Responses to MAGE-A3 Epitopes in the Injection Site-draining Lymph Node (Sentinel Immunized Node, SIN) as a Measure of Immunogenicity.|Enumeration of CD4+ and CD8+ T Cells Reactive to MAGE-A3 Epitopes in Peripheral Blood as a Measure of Immunogenicity.|Identification of Antibody Responses to MAGE-A3 After MAGE-A3 ASCI Administration as a Measure of Immunogenicity.|Characterization of the Maturation and Activation of Dendritic Cell (DC) Populations in the Sentinel Immunized Node (SIN) After Treatment With MAGE-A3 ASCI.|A Preliminary Evaluation of Cellular Components of the Injection Site Microenvironment for Cutaneous Immunization With MAGE-A3 ASCI (Activated T Cells, Th1,Th2, Th17 Infiltrating CD4 Cells, Regulatory T Cells, and Myeloid-derived Suppressor Cells).",https://ClinicalTrials.gov/show/NCT01425749
221,NCT01384253,Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy,"Active, not recruiting",No Results Available,Breast Neoplasms|Peritoneal Neoplasms|Ovarian Neoplasms|Pancreatic Neoplasms|Stomach Neoplasms,Other: ²¹²Pb-TCMC-Trastuzumab|Biological: trastuzumab,Areva Med LLC,Both,"19 Years and older   (Adult, Senior)",Phase 1,36,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AREVAMED01,27-Jun-11,7/1/2011,12/1/2015,6/22/2015,Jun-15,No Study Results Posted,null,Dec-15,"Safety and tolerability: To measure the number of participants who experience adverse events after intraperitoneal (IP) administration of ²¹²Pb-TCMC-Trastuzumab.|Immunogenicity: To characterize the human immune response against ²¹²Pb-TCMC-Trastuzumab given via IP infusion.|Anti-tumor effects: To monitor for anti-tumor effects as assessed by physical examination, radiographic imaging, and tumor marker studies.|Pharmacokinetics: To determine the plasma pharmacokinetics and assess the extent of exit of radioactivity from the peritoneal cavity by γ-camera imaging.",https://ClinicalTrials.gov/show/NCT01384253
347,NCT02366884,Clinical Evaluation of a New Form of Cancer Therapy Based on the Principles of Atavistic Metamorphosis,Recruiting,No Results Available,Neoplasms,Drug: Anti-Bacterial Agents|Drug: Anti-Fungal Agents|Drug: Anti-Protozoal Agents,Dr. Frank Arguello Cancer Clinic|Instituto de Ciencia y Medicina Genomica,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 2,100,Industry|Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment,ACI/2015,9-Feb-15,7/1/2011,12/1/2016,8/18/2015,Aug-15,No Study Results Posted,null,Dec-16,Clinical efficacy as measured by the number of participants with an objective clinical tumor regression response|Clinical safety as measured by the incidence of adverse events in each intervention group,https://ClinicalTrials.gov/show/NCT02366884
1101,NCT01389076,"Trial of Low-Dose Methotrexate and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma",Terminated,Has Results,Follicular Lymphoma,Drug: Low dose methotrexate and Bexxar,University of Michigan Cancer Center|GlaxoSmithKline,Both,"18 Years and older   (Adult, Senior)",Phase 2,22,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,UMCC 2010.098|HUM00043235,5-Jul-11,7/1/2011,7/1/2017,6/2/2016,Jun-16,2-Jun-16,null,Feb-14,Rate of Early Onset HAMA (Human Anti-mouse Antibody) Conversion Following Treatment|Percentage of Participants That Respond to Treatment|The Percentage of Participants Alive at 2 Years,https://ClinicalTrials.gov/show/NCT01389076
1191,NCT01416831,Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.,Recruiting,No Results Available,Metastatic Melanoma,Other: Radiation therapy and high-dose IL-2|Drug: High-dose IL-2,Providence Health & Services|Prometheus Laboratories,Both,"18 Years and older   (Adult, Senior)",Phase 2,44,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,11-062A,12-Aug-11,7/1/2011,10/1/2018,6/23/2016,Jun-16,No Study Results Posted,SBRT/IL-2,Oct-17,Change in diameter of target lesions|Response rate in crossover patients,https://ClinicalTrials.gov/show/NCT01416831
60,NCT01406782,DNA Analysis in Influencing Response to Rituximab in Samples From Patients With Follicular Lymphoma Treated on ECOG-E4402,Not yet recruiting,No Results Available,Lymphoma,Biological: rituximab|Genetic: DNA analysis|Genetic: gene expression analysis|Genetic: polymerase chain reaction|Other: laboratory biomarker analysis,Eastern Cooperative Oncology Group|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",,200,Other|NIH,Observational,,CDR0000706811|ECOG-E4402T3,29-Jul-11,8/1/2011,null,7/29/2011,Jul-11,No Study Results Posted,null,Sep-11,KIR-HLA genotype predictive of antibody-dependent cell-mediated cytotoxicity (ADCC)-based cancer immunotherapy,https://ClinicalTrials.gov/show/NCT01406782
260,NCT01639885,"Chemo-immunotherapy (Gemcitabine, Interferon-alpha 2b and p53 SLP) in Patients With Platinum-resistant Ovarian Cancer",Completed,No Results Available,Recurrent Ovarian Cancer,Drug: Interferon Alfa-2b|Drug: Interferon Alfa-2b|Biological: p53 SLP,Leiden University Medical Center|University Medical Center Groningen,Female,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,15,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CHIP trial|2010-023124-24,16-Apr-12,8/1/2011,null,1/6/2014,Jan-14,No Study Results Posted,CHIP,Jan-14,"Feasibility (change in grade III and IV toxicity) and change in immunogenicity of the triple combination of gemcitabine, Peg-Intron and p53 SLP vaccination|Clinical outcome (response (RECIST 1.1)|The effect of this new treatment combination on the immune system|progression free survival|overall survival",https://ClinicalTrials.gov/show/NCT01639885
317,NCT01588769,A Phase I Study to Investigate Tolerability and Efficacy of ALECSAT Administered to Glioblastoma Multiforme Patients,Completed,No Results Available,Glioblastoma Multiforme,Biological: ALECSAT cell based immunotherapy,CytoVac A/S,Both,"18 Years and older   (Adult, Senior)",Phase 1,23,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CV003|2011-002180-22,27-Apr-12,8/1/2011,4/1/2013,6/3/2016,Jun-16,No Study Results Posted,ALECSAT-GBM,Nov-12,"Observation of tolerability and sideeffects of treatment monitored by objective medical examinations, Karnofsky score and QOL interviews.|Potential clinical effect will be monitored by PET-MRI and SPECT scanning of the brain.",https://ClinicalTrials.gov/show/NCT01588769
377,NCT01420874,Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer),"Active, not recruiting",No Results Available,Colorectal Cancer|Cancer of Pancreas|Pancreatic Neoplasm|Malignant Neoplasm of Large Intestine|Malignant Tumor of Colon|Colon Carcinoma|Cancer of Colon|Pancreatic Cancer,Drug: FOLFOX6|Biological: EGFRBi armed ATC Infusions,Barbara Ann Karmanos Cancer Institute,Both,"18 Years and older   (Adult, Senior)",Phase 1,30,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2011-025,17-Aug-11,8/1/2011,7/1/2016,2/3/2016,Feb-16,No Study Results Posted,null,Jul-16,"Determining in a dose-escalation phase Ib trial the safety of 3 infusions of EGFR2Bi aATC, and a booster infusion after 3 months, for patients with advanced colorectal or pancreatic cancer.|Determining whether IMT enhances anti-tumor immunity;Cytokine resp., phenotypic markers, anti-tumor cytotoxicity, in vivo and in vitro specific anti-tumor antibody prod. & molecular signaling markers of T-cell activation assessed before chemo & after IMT|Determining the tumor response rate|Overall Survival",https://ClinicalTrials.gov/show/NCT01420874
556,NCT01421017,"Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases",Recruiting,No Results Available,Breast Cancer|Metastatic Breast Cancer|Recurrent Breast Cancer,Radiation: Radiation|Drug: Imiquimod|Drug: Cyclophosphamide,New York University School of Medicine|National Cancer Institute (NCI),Female,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,55,Other|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,NYU 11-00598|1R01CA161891-01,17-Aug-11,8/1/2011,12/1/2016,7/7/2016,Jul-16,No Study Results Posted,null,Dec-16,systemic tumor response rates (Complete Response+Partial Response)|Local tumor response rates (Clinical Complete Response+Partial Response),https://ClinicalTrials.gov/show/NCT01421017
591,NCT01422850,Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy,Completed,Has Results,Hormone-refractory Prostate Cancer,Biological: ALECSAT,CytoVac A/S,Male,"18 Years and older   (Adult, Senior)",Phase 1,21,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CV002,23-Aug-11,8/1/2011,10/1/2012,3/26/2014,Mar-14,5-Aug-13,ALECSAT,Sep-12,"Adverse Events|Blood Pressure, Pulse and Temperature|The Secondary Endpoint for This Study is to Establish if Any Indications of a Positive Therapeutic Effect on the Prostate Cancer May be Observed.",https://ClinicalTrials.gov/show/NCT01422850
892,NCT01533727,CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC),Withdrawn,No Results Available,Non-small Cell Lung Cancer,Drug: Autologous CIK Transfusion plus Chemotherapy|Drug: chemotherapy alone,Sun Yat-sen University,Both,"18 Years to 70 Years   (Adult, Senior)",Phase 2,0,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,2010014,12-Feb-12,8/1/2011,12/1/2020,12/5/2013,Feb-12,No Study Results Posted,null,Dec-17,the relapse rate,https://ClinicalTrials.gov/show/NCT01533727
946,NCT01404702,Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma,Terminated,No Results Available,Neuroblastoma,Drug: Zoledronic Acid|Biological: Aldesleukin,University of Alabama at Birmingham,Both,"2 Years to 21 Years   (Child, Adult)",Phase 1,4,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,UAB 1051|F101013003,13-Jul-11,8/1/2011,8/1/2014,12/1/2014,Dec-14,No Study Results Posted,null,Aug-14,Evaluate the safety and toxicity of zoledronic acid and aldesleukin|Evaluate the biologic function of autologous expanded/activated gamma delta T cells in neuroblastoma patients receiving therapy with zoledronic acid and aldesleukin|Evaluate immune phenotype of in vivo expanded/activated autologous gamma delta T cells|To document tumor response in patients with measurable disease.|Determine the ability of in vivo expanded/activated gamma delta T cells to infiltrate neuroblastoma tissue using immunohistochemical techniques when post-therapy specimens are available.,https://ClinicalTrials.gov/show/NCT01404702
1026,NCT01403285,Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma,Terminated,No Results Available,Glioblastoma,Drug: Cyclophosphamide|Biological: IMA950 plus GM-CSF|Biological: IMA950|Drug: Imiquimod,immatics Biotechnologies GmbH|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,6,Industry|NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IMA950-102|11C0192,21-Jul-11,8/1/2011,4/1/2014,5/16/2014,May-14,No Study Results Posted,null,Apr-14,"Safety and tolerability of IMA950 administered with granulocyte macrophage colony stimulating factor (GM-CSF) and topical imiquimod together following a single low-dose application of cyclophosphamide.|Immunogenicity of IMA950|Immune status parameters|Biomarker assessment and correlation to clinical and immunological response|Clinical anti-tumor activity (response rate, 6-month progression-free survival)|Influence of corticosteroids on immunogenicity of IMA950|Health-related quality of life",https://ClinicalTrials.gov/show/NCT01403285
1149,NCT01421667,A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma,Completed,No Results Available,"Lymphoma, B-Cell|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Non-Hodgkin|Lymphoma, T-Cell",Drug: brentuximab vedotin|Drug: rituximab,"Seattle Genetics, Inc.",Both,"6 Years and older   (Child, Adult, Senior)",Phase 2,176,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,SGN35-012,19-Aug-11,8/1/2011,6/1/2015,6/22/2015,Jun-15,No Study Results Posted,null,Jun-15,Objective response rate with brentuximab vedotin|Incidence of adverse events with brentuximab vedotin + rituximab|Incidence of laboratory abnormalities with brentuximab vedotin + rituximab|Incidence of adverse events with brentuximab vedotin|Incidence of laboratory abnormalities with brentuximab vedotin|Correlation between CD30 expression and antitumor activity with brentuximab vedotin|Duration of response|Progression-free survival|Area under the plasma concentration versus time curve (AUC)|Peak plasma concentration (Cmax)|Plasma concentration at end of infusion (Ceoi)|Pharmacodynamic (PD) biomarkers|Objective response rate with brentuximab vedotin + rituximab|Complete remission (CR) rate,https://ClinicalTrials.gov/show/NCT01421667
1258,NCT01760616,Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy,Enrolling by invitation,No Results Available,Hepatic Carcinoma,Drug: Huaier Granule,"Qidong Gaitianli Medicines Co., Ltd|Huazhong University of Science and Technology",Both,"18 Years to 75 Years   (Adult, Senior)",Phase 4,1680,Industry|Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,HE-201102,1-Jan-13,8/1/2011,6/1/2019,4/7/2016,Apr-16,No Study Results Posted,null,Dec-18,Time to significant progression after surgery|ECOG and QLQ-C30 scores|Iconography assessment|Alpha-fetoprotein quantitation and related biochemical indicators,https://ClinicalTrials.gov/show/NCT01760616
49,NCT01462903,A Study of Adoptive Immunotherapy With Autologous Tumor Infiltrating Lymphocytes in Solid Tumors,Recruiting,No Results Available,Nasopharyngeal Carcinoma|Hepatocellular Carcinoma|Breast Carcinoma,"Biological: tumor infiltrating lymphocytes, IL-2",Sun Yat-sen University,Both,"18 Years to 70 Years   (Adult, Senior)",Phase 1,20,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SenU-200902002-2,29-Sep-11,9/1/2011,12/1/2014,11/21/2014,Nov-14,No Study Results Posted,null,Nov-14,• the safety and tolerability of autologous tumor infiltrating lymphocytes (TIL) in combination with Interleukin-2(IL-2) in patients with nasopharyngeal carcinoma (NPC).|• immune efficacy and anti-tumor effects of autologous tumor infiltrating lymphocytes (TIL) in combination with Interleukin-2(IL-2) in patients with nasopharyngeal carcinoma (NPC).,https://ClinicalTrials.gov/show/NCT01462903
162,NCT01436968,Phase 3 Study of ProstAtak™ Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer,Recruiting,No Results Available,Prostate Cancer,Biological: ProstAtak™(AdV-tk) + valacyclovir|Biological: Placebo + valacyclovir,"Advantagene, Inc.",Male,"18 Years and older   (Adult, Senior)",Phase 3,711,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PrTK03,19-Sep-11,9/1/2011,null,7/29/2016,Jul-16,No Study Results Posted,PrTK03,Dec-19,Disease free survival defined as the time from randomization until the date of the first failure event will be compared for the ProstAtak™ arm versus the placebo control arm. The analyses will be based on the intent to treat population.|Prostate cancer specific survival and overall survival will be compared for the ProstAtak™ arm versus the placebo control arm.|PSA nadir will be compared for the ProstAtak™ arm versus the placebo control arm.|Patient reported Health Related Quality of Life outcomes will be collected using the Expanded Prostate Cancer Index Composite (EPIC-26) questionnaire. The change in QOL over time will be compared for the ProstAtak™ arm versus the placebo control arm.|The safety profile will be characterized by collection of adverse event information and laboratory values during the treatment phase (until the completion of radiation). Data on late effects will be collected after radiation completion.,https://ClinicalTrials.gov/show/NCT01436968
204,NCT01468818,Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma,Terminated,Has Results,Metastatic Melanoma|Skin Cancer,Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Young Tumor Infiltrating Lymphocytes (TIL),National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 70 Years   (Adult, Senior)",Phase 2,18,NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,110260|11-C-0260,6-Oct-11,9/1/2011,8/1/2013,5/19/2016,May-16,19-May-16,null,Aug-13,Objective Response in Patients With Metastatic Melanoma|Level of Persistence of the Transferred Cells in Blood,https://ClinicalTrials.gov/show/NCT01468818
244,NCT01417000,Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer,"Active, not recruiting",No Results Available,Pancreatic Cancer,Biological: GVAX Pancreas|Biological: CRS-207|Drug: Cyclophosphamide,"Aduro Biotech, Inc.|Johns Hopkins University",Both,"18 Years and older   (Adult, Senior)",Phase 2,93,Industry|Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ADU-CL-01,10-Aug-11,9/1/2011,11/1/2016,7/11/2016,Jul-16,No Study Results Posted,null,Nov-16,"Overall survival in subjects receiving test treatments|To assess safety of the cyclophosphamide, GVAX Pancreas vaccine, and CRS-207 treatment regimen|To assess the immune response",https://ClinicalTrials.gov/show/NCT01417000
304,NCT01454596,CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII,Suspended,No Results Available,Malignant Glioma|Glioblastoma|Brain Cancer,Biological: Anti-EGFRvIII CAR transduced PBL|Drug: Aldesleukin|Drug: Fludarabine|Drug: Cyclophosphamide,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 70 Years   (Adult, Senior)",Phase 1|Phase 2,18,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,110266|11-C-0266,6-Oct-11,9/1/2011,12/1/2019,7/7/2016,Jun-16,No Study Results Posted,null,Dec-18,"To evaluate the safety of the administration of anti- EGFRvIII CAR engineered peripheral blood lymphocytes in patients receiving the non-myeloablative conditioning regimen, and aldesleukin and todetermine the six month progression free surviv...",https://ClinicalTrials.gov/show/NCT01454596
462,NCT01437709,Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant,"Active, not recruiting",No Results Available,Mantle Cell Lymphoma,Biological: Ofatumumab (This arm is closed)|Other: Ofatumumab + Bendamustine,Memorial Sloan Kettering Cancer Center|GlaxoSmithKline,Both,"18 Years and older   (Adult, Senior)",Phase 2,30,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,11-050,19-Sep-11,9/1/2011,9/1/2017,4/25/2016,Apr-16,No Study Results Posted,null,Sep-17,single agent efficacy (as determined by response rate)|the efficacy (as determined by response rate) of the combination ofatumumab + Bendamustine|Overall Survival (OS)|progression free survival (PFS)|Remission duration|Response duration,https://ClinicalTrials.gov/show/NCT01437709
577,NCT01431391,Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer,Completed,No Results Available,Prostatic Neoplasm|Prostate Cancer|Prostatic Adenocarcinoma,Biological: sipuleucel-T|Drug: leuprolide acetate,Dendreon,Male,"18 Years and older   (Adult, Senior)",Phase 2,68,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,P10-2,5-Aug-11,9/1/2011,12/1/2014,2/11/2015,Feb-15,No Study Results Posted,null,Dec-14,"Measure change in immune response to PA2024 by IFN-gamma production ELISPOT following sipuleucel-T/ADT treatment regimens.|Number of Participants with Adverse Events as a Measure of Safety|Measure changes in immune responses over time|Measure changes in sipuleucel-T product parameters: CD54 upregulation, number of CD54+ cells, and total nucleated cell number|Measure changes in PSA over time",https://ClinicalTrials.gov/show/NCT01431391
967,NCT01318317,"Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma","Active, not recruiting",No Results Available,Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma,Procedure: peripheral blood stem cell transplantation (PBSCT)|Biological: filgrastim|Genetic: polymerase chain reaction|Biological: rituximab|Biological: genetically engineered lymphocyte therapy|Other: laboratory biomarker analysis|Drug: plerixafor|Procedure: autologous hematopoietic stem cell transplantation,City of Hope Medical Center|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,57,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,09174|NCI-2011-00344|P50CA107399,16-Mar-11,9/1/2011,null,2/10/2016,Feb-16,No Study Results Posted,null,Aug-22,MTD based on DLTs and defining the full toxicity profile (Phase I)|Woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) detection above background (Phase II)|Rates of engraftment and persistence|Failure to engraft|Progression-free survival|Overall survival,https://ClinicalTrials.gov/show/NCT01318317
1032,NCT01482949,A Rollover Protocol for Subjects Previously Treated With AGS-003,"Active, not recruiting",No Results Available,Renal Cell Carcinoma,Drug: AGS-003,Argos Therapeutics,Both,"18 Years and older   (Adult, Senior)",Phase 2,2,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AGS-003-005,17-Nov-11,9/1/2011,12/1/2016,5/24/2016,May-16,No Study Results Posted,null,Dec-16,"Tumor response|Clinical benefit (stable disease or response)|Immune function|Progression Free Survival (PFS)|Overall Survival (OS)|Treatment-emergent Adverse Events|Monitor clinical chemistry, hematology, and urinalysis for treatment-emergent changes from baseline|Physical Examinations|Vital Signs|Monitor signs and symptoms indicating treatment-emergent autoimmunity|Monitor for lymph node adenopathy|Injection Site Reaction",https://ClinicalTrials.gov/show/NCT01482949
1056,NCT01435499,Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma,Completed,No Results Available,Melanoma,Biological: melanoma GVAX|Drug: Cyclophosphamide,Sidney Kimmel Comprehensive Cancer Center|The John P. Hussman Foundation,Both,"18 Years and older   (Adult, Senior)",Phase 1,21,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,J1112,8-Sep-11,9/1/2011,3/1/2016,5/23/2016,May-16,No Study Results Posted,null,Jan-13,Number of Participants with Adverse Events as a Measure of Safety and Tolerability of Administering Melanoma GVAX With and Without Cyclophosphamide|In vitro correlates of anti-melanoma immunization,https://ClinicalTrials.gov/show/NCT01435499
1108,NCT01440283,A Phase II Study of Intensity Modulated Radiation Therapy (IMRT) in High Risk Abdominal Neuroblastoma,Terminated,Has Results,Abdominal Neuroblastoma,Radiation: Intensity Modulated Radiation Therapy (IMRT),St. Jude Children's Research Hospital|Mayo Clinic,Both,"6 Months to 18 Years   (Child, Adult)",Phase 2,14,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NBIMRT,20-Sep-11,9/1/2011,3/1/2015,2/3/2016,Nov-15,9-Nov-15,null,Mar-15,Percentage of Participants Who Failed to Reach Local-regional Control|Pattern of Local-regional Failure.|Quantify the Range of Organ Movement During the Breathing Phase Measured by 4-dimensional MRI (4DMRI) and 4DCT.|Quantify (in mm/cm) the Range of Target Movement During the Breathing Phase Measured by 4DMRI and 4DCT.,https://ClinicalTrials.gov/show/NCT01440283
1116,NCT01156350,Haplo-identical Hematopoietic Stem Cell Transplantation Following Reduced-intensity Conditioning in Children With Neuroblastoma,Not yet recruiting,No Results Available,Neuroblastoma,Drug: Busulfan - Fludarabine - TBI,"University Hospital, Clermont-Ferrand",Both,"1 Year to 18 Years   (Child, Adult)",Phase 2,10,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CHU-0075,28-Jun-10,9/1/2011,9/1/2014,1/18/2011,Jan-11,No Study Results Posted,Rice NK,Sep-13,Evaluation of the feasibility of the CD3 / CD19 selected haplo identical hematopoietic stem cell transplant after conditioning with reduced intensity in children with neuroblastoma in failure of reference treatments|Study of the overall survival Study of graft versus tumor effect at day + 100,https://ClinicalTrials.gov/show/NCT01156350
1196,NCT01657734,Multimodal MR Imaging in Patients With Glioblastoma Treated With Dendritic Cell Therapy,Recruiting,No Results Available,Malignant Gliomas,Other: MR imaging,Universitaire Ziekenhuizen Leuven,Both,"18 Years and older   (Adult, Senior)",,30,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,S53303,7-Sep-11,9/1/2011,null,8/1/2012,May-11,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT01657734
31,NCT01829373,Lung Cancer Vaccine Plus Oral Dietary Supplement,Completed,No Results Available,Lung Cancer,Biological: vaccine 1650-G,Edward Hirschowitz|University of Louisville|University of Kentucky,Both,"21 Years and older   (Adult, Senior)",Phase 1,5,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,BG1006,8-Apr-13,10/1/2011,2/1/2013,4/10/2013,Apr-13,No Study Results Posted,null,Jun-12,Immunologic response to vaccine,https://ClinicalTrials.gov/show/NCT01829373
478,NCT01457131,Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic Cancer,Terminated,No Results Available,Metastatic Cancer|Metastatic Melanoma|Metastatic Renal Cancer,Drug: Fludarabine|Drug: Cyclophosphamide|Other: IL-12 & amp; Anti-NY ESO1 TCR PBL,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years and older   (Adult, Senior)",Phase 1,2,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,120006|12-C-0006,12-Oct-11,10/1/2011,8/1/2013,2/19/2014,Aug-13,No Study Results Posted,null,Aug-13,"To evaluate the safety of the IL-12 and anti-NY-ESO-1 engineered PBL in patients receiving a non-myeloablative conditioning regimen, and to determine if patients with metastatic cancer will have clinical tumor regression following this regimen.|To determine the in vivo survival of cotransduced gene-engineered cells.",https://ClinicalTrials.gov/show/NCT01457131
746,NCT01461538,Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies,Completed,Has Results,"Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Anemia, Refractory, With Excess of Blasts|Solid Tumors",Drug: brentuximab vedotin|Drug: brentuximab vedotin|Drug: brentuximab vedotin,"Seattle Genetics, Inc.",Both,"6 Years and older   (Child, Adult, Senior)",Phase 2,84,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,SGN35-013,24-Oct-11,10/1/2011,12/1/2014,2/5/2016,Feb-16,18-Dec-15,null,Dec-14,"Objective Response Rate (ORR) by Investigator|Complete Remission (CR) Rate by Investigator|Duration of Objective Response by Kaplan-Meier Analysis|Duration of Complete Response by Kaplan-Meier Analysis|Progression-Free Survival by Kaplan-Meier Analysis|Adverse Events by Severity, Seriousness, and Relationship to Treatment|Laboratory Abnormalities >/= Grade 3|Brentuximab Vedotin Antibody-Drug Conjugate (ADC) Concentration at End of Infusion (Ceoi)|Brentuximab Vedotin Antibody-Drug Conjugate (ADC) Trough Concentration (Ctrough)|Maximum Concentration (Cmax) of Brentuximab Vedotin Monomethyl Auristatin E (MMAE)|Brentuximab Vedotin Monomethyl Auristatin E (MMAE) Trough Concentration (Ctrough)|Incidence of Anti-therapeutic Antibodies (ATA)",https://ClinicalTrials.gov/show/NCT01461538
981,NCT01460901,"Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma",Completed,No Results Available,Neuroblastoma,Biological: Tri-virus specific cytotoxic t-cells,"Children's Mercy Hospital Kansas City|National Heart, Lung, and Blood Institute (NHLBI)",Both,18 Months to 17 Years   (Child),Phase 1,5,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,STALLONe|00038,25-Oct-11,10/1/2011,1/1/2015,2/4/2015,Feb-15,No Study Results Posted,STALLONe,Jan-15,"Infusional and long term safety and persistence of tumor redirected, genetically modified, donor derived, allogeneic multi-virus specific cytotoxic T-cells (tV-CTL) after allogeneic hematopoietic stem cell transplant in patients with neuroblastoma|Evaluating the survival, expansion, anti-viral and anti-tumor function of infused tV-CTL after allogeneic transplant in patients with neuroblastoma|Comparing the frequency and expansion of allogeneic, tumor redirected, multi-virus cytotoxic T-cells to that of identically transduced, autologous EBV-specific T-cells infused in prior studies.|Comparing anti-viral immunity after infusion of gene modified, multi-virus specific T-cells to that of patients receiving viral-specific T-cells without gene modification following allogeneic transplant",https://ClinicalTrials.gov/show/NCT01460901
1041,NCT01468311,Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin s Lymphoma,Suspended,No Results Available,Hodgkin Disease|Hodgkin Lymphoma,Procedure: Auto stem cell transplant|Drug: BEAM|Radiation: 111In-daclizumab|Radiation: 90Y-daclizumab,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 99 Years   (Adult, Senior)",Phase 1|Phase 2,6,NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,120003|12-C-0003,5-Nov-11,10/1/2011,9/1/2021,5/11/2016,Mar-16,No Study Results Posted,null,Sep-20,safe tolerated dose of 90Y-daclizumab w BEAM and ASCT,https://ClinicalTrials.gov/show/NCT01468311
18,NCT02221310,Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS,Recruiting,No Results Available,Acute Myelogenous Leukemia|Myelodysplastic Syndrome,Drug: Gemtuzumab Ozogamicin,New York Medical College,Both,"up to 30 Years   (Child, Adult)",Phase 2,25,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,"NYMC-515|L-10,349",31-Jul-14,11/1/2011,12/1/2018,3/10/2016,Mar-16,No Study Results Posted,null,Dec-17,Response rate,https://ClinicalTrials.gov/show/NCT02221310
42,NCT01516593,Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma,Recruiting,No Results Available,HIV|Burkitt's Lymphoma,Drug: Induction Phase|Drug: Consolidation Phase (on day +50)|Drug: Intensification phase|Drug: BEAM conditioning|Radiation: Consolidation radiotherapy,Andres J. M. Ferreri|IRCCS San Raffaele,Both,18 Years to 60 Years   (Adult),Phase 2,19,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CARMEN,6-Jan-12,11/1/2011,8/1/2015,1/24/2012,Jan-12,No Study Results Posted,CARMEN,Apr-13,evaluation of activity of the induction phase in terms of complete remission rate|Feasibility and tolerability of the investigational intensive chemotherapy in terms of grade ≥4 adverse events|Feasibility and tolerability of the consolidation phase followed by BEAM conditioning and autologous stem cell transplantation in terms of prevalence of grade ≥4 adverse events|Feasibility and tolerability of intensification phase in terms of prevalence of grade ≥4 adverse events|Activity of the whole investigational program in terms of complete remission rate,https://ClinicalTrials.gov/show/NCT01516593
101,NCT01478542,"OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine",Recruiting,No Results Available,CD20+ Aggressive B-Cell Lymphoma,Drug: Conventional Vincristine|Drug: Liposomal Vincristine|Drug: Ricover-scheme rituximab|Drug: optimised rituximab-schedule,"University Hospital, Saarland|German High-Grade Non-Hodgkin's Lymphoma Study Group",Both,"61 Years to 80 Years   (Adult, Senior)",Phase 3,1152,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment,DSHNHL 2009-1,18-Nov-11,11/1/2011,10/1/2019,5/3/2016,Oct-15,No Study Results Posted,OPTIMAL>60,Oct-16,"Progression-free survival|for efficacy: CR-rate, PR-rate, rate of primary progressions, relapse rate, EFS and OS; rate and CTC grades of PNP. Prognostic value of the FDG-PET derived imaging biomarkers for lymphoma load: SUV, MTV, TLG.",https://ClinicalTrials.gov/show/NCT01478542
687,NCT01338012,Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer (CRPC) Patients Previously Treated on Dendreon Study P-11 (NCT00779402),Completed,No Results Available,Prostate Cancer,Drug: sipuleucel-T,Dendreon,Male,"18 Years and older   (Adult, Senior)",Phase 2,8,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,P10-1,2-Mar-11,11/1/2011,4/1/2015,2/29/2016,Feb-16,No Study Results Posted,null,Apr-15,To evaluate the immune response generated by sipuleucel-T|To evaluate the safety of sipuleucel-T|To explore the correlation between sipuleucel-T immune response and overall survival.,https://ClinicalTrials.gov/show/NCT01338012
1065,NCT01408004,Rotating Pazopanib and Everolimus to Avoid Resistance,Completed,No Results Available,Clear Cell Renal Carcinoma,Drug: Pazopanib|Drug: Everolimus|Drug: Pazopanib|Drug: Everolimus|Drug: Everolimus|Drug: Pazopanib,Netherlands Working Group on Immunotherapy of Oncology,Both,"18 Years and older   (Adult, Senior)",Phase 2,101,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,NL35303.041.11,7-Apr-11,11/1/2011,4/1/2014,7/15/2014,Jul-14,No Study Results Posted,ROPETAR,Apr-14,Progression free survival|Time to second progression|Change in Quality of life assessed by the FKSI-DRS and EORTC QLQ-C30 questionnaires compared to baseline|Toxicity reported as number/percentage of patients with adverse events|Overall survival,https://ClinicalTrials.gov/show/NCT01408004
1082,NCT01478074,ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia,Withdrawn,No Results Available,Acute Myeloid Leukemia,Drug: G-CSF|Drug: Cytarabine|Drug: Fludarabine|Biological: Donor Natural Killer (NK) cells|Biological: ALT-801,Altor Bioscience Corporation|M.D. Anderson Cancer Center,Both,"2 Years to 59 Years   (Child, Adult)",Phase 1,0,Industry|Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CA-ALT-801-02-08,17-Nov-11,11/1/2011,11/1/2013,1/2/2014,Jan-14,No Study Results Posted,null,Oct-13,Maximum tolerated dose of NK cells|Safety of delivering NK cells and ALT-801 in combination with FLAG|Activation status of NK cells following activation with ALT-801|In vivo persistence and function of haploidentical NK cells activated with ALT-801.|Overall response to this regimen|Rate of stem cell transplantation and the time-to-transplantation|ALT-801 immunogenicity,https://ClinicalTrials.gov/show/NCT01478074
1140,NCT01599559,"Randomized, Open-label, Two-arms, Phase III Comparative Study Assessing the Role of Involved Mediastinal Radiotherapy After Rituximab Containing Chemotherapy Regimens to Patients With Newly Diagnosed Primary Mediastinal Large B-Cell Lymphoma",Recruiting,No Results Available,Primary Mediastinal B-cell Lymphoma,Other: observation|Radiation: 3D-Conformal Radiotherapy (3D-CRT),International Extranodal Lymphoma Study Group (IELSG),Both,"18 Years and older   (Adult, Senior)",Phase 3,540,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,IELSG37,10-May-12,11/1/2011,5/1/2025,7/26/2016,Jul-16,No Study Results Posted,null,May-17,Progression free survival (PFS)|Overall survival (OS),https://ClinicalTrials.gov/show/NCT01599559
1274,NCT01541280,VIDAZA-DLI Pre-emptive Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome,Completed,No Results Available,Acute Myeloid Leukemia|Myelodysplastic Syndrome,Drug: Azacitidine|Other: DLI,Nantes University Hospital,Both,"18 Years to 70 Years   (Adult, Senior)",Phase 2,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,BRD 10/07-H,13-Dec-11,11/1/2011,7/1/2015,3/17/2016,Feb-16,No Study Results Posted,VIDAZA-DLI,Jul-15,"Evaluation of the cumulative incidence of relapse rate|Evaluation of disease-free survival (DFS) at 2 years from transplantation|Measure the overall survival rate at 2 years|Cumulative incidence death from leukemia, and non relapse mortality (NRM)|Feasibility and safety of administrating maintenance azacitidine following allogenic transplantaton|Feasibility and safety of performing prophylactic donor lymphocytes infusion|Incidence and severity of acute and chronic graft-versus-host disease",https://ClinicalTrials.gov/show/NCT01541280
53,NCT01461928,A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera,Recruiting,No Results Available,Non-Hodgkin's Lymphoma,Drug: chemotherapy|Drug: rituximab [MabThera/Rituxan]|Drug: rituximab [MabThera/Rituxan]|Drug: rituximab [MabThera/Rituxan],Hoffmann-La Roche,Both,"18 Years and older   (Adult, Senior)",Phase 4,700,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MO25455|2010-023407-95,19-Oct-11,12/1/2011,3/1/2019,8/1/2016,Aug-16,No Study Results Posted,null,Mar-19,"Progression-free survival (Maintenance II phase): from randomization to disease progression or death; tumour assessments according to the 1999 International Working Group response (Cheson) criteria for lymphoma|Safety: Incidence of adverse events|Event-free survival (time to treatment failure): from day of first rituximab induction dose to day of any treatment failure, including disease progression, or discontinuation of treatment for any reason|Time to next lymphoma treatment: from day of first rituximab induction dose to any new lymphoma treatment|Overall survival (from 1st induction dose/from time to randomization)|Overall Response Rate|Partial Response to Complete Response conversion rate (at end of Maintenance I phase)|Progression-free survival: from day of first induction dose until disease progression or death by any cause",https://ClinicalTrials.gov/show/NCT01461928
192,NCT01516307,Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects,"Active, not recruiting",No Results Available,Metastatic Breast Cancer,Biological: OPT-822/OPT-821(30 μg/100 μg) + Cyclophosphamide|Biological: Phosphate Buffer Saline (PBS) + Cyclophosphamide,"OBI Pharma, Inc",Female,"21 Years and older   (Adult, Senior)",Phase 2,349,Industry,Interventional,"Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",OPT-822-001,19-Jan-12,12/1/2011,12/1/2016,1/5/2016,Jan-16,No Study Results Posted,null,Mar-16,Progression Free Survival (PFS)|Overall Survival (OS),https://ClinicalTrials.gov/show/NCT01516307
281,NCT01416038,"Phase 1-2 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer","Active, not recruiting",No Results Available,Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer,Biological: DPX-Survivac|Drug: low dose cyclophosphamide (oral),"ImmunoVaccine Technologies, Inc.",Female,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,19,Industry,Interventional,Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ONC-DPX-Survivac-01,9-Aug-11,12/1/2011,null,12/14/2015,Dec-15,No Study Results Posted,null,May-13,PHASE 1: Number of reported adverse events|PHASE 2: Progression free survival as per RECIST 1.1 criteria|PHASE 1-2: Levels of cell mediated immunity targeting the survivin epitopes|PHASE 2: Repeated CA-125 measurements|PHASE 2: Progression free survival as per immune response criteria (irRC),https://ClinicalTrials.gov/show/NCT01416038
322,NCT01513109,Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia,Recruiting,No Results Available,Acute Myelogenous Leukemia|Myeloid Leukemia in Remission|Effects of Immunotherapy,Biological: Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI),Jules Bordet Institute,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,20,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,BORLEUWT01,16-Jan-12,12/1/2011,12/1/2014,1/19/2012,Jan-12,No Study Results Posted,ASCI,Dec-13,Occurence of severe toxicities|Immunogenicity of the WT1 ASCI,https://ClinicalTrials.gov/show/NCT01513109
552,NCT01487863,Concurrent Versus Sequential Treatment With Sipuleucel-T and Abiraterone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC),"Active, not recruiting",No Results Available,Prostate Cancer Metastatic|Hormone Refractory Prostate Cancer,Biological: sipuleucel-T|Drug: abiraterone acetate,Dendreon,Male,"18 Years and older   (Adult, Senior)",Phase 2,69,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Basic Science,P11-3,6-Dec-11,12/1/2011,4/1/2016,4/21/2016,Apr-16,No Study Results Posted,null,Apr-16,Evaluate cumulative sipuleucel-T CD54 upregulation|Evaluate sipuleucel-T product parameters|Evaluate the peripheral immune response to sipuleucel-T|Evaluate safety of sipuleucel-T therapy with concurrent or sequential administration of abiraterone acetate plus prednisone,https://ClinicalTrials.gov/show/NCT01487863
569,NCT01322490,"A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer","Active, not recruiting",No Results Available,Prostate Cancer Metastatic,Biological: PROSTVAC-V|Biological: PROSTVAC-F|Drug: GM-CSF|Other: GM-CSF Placebo|Biological: Placebo,"Bavarian Nordic, Inc.",Male,"18 Years and older   (Adult, Senior)",Phase 3,1298,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",BNIT-PRV-301,23-Mar-11,12/1/2011,6/1/2018,6/10/2016,Jun-16,No Study Results Posted,Prospect,Jun-17,Overall survival|Proportion of event-free patients compared with placebo,https://ClinicalTrials.gov/show/NCT01322490
617,NCT01495572,Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells,Terminated,Has Results,Metastatic Melanoma|Skin Cancer,Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Aldesleukin|Drug: MART-1 Reactive CD8+ PBL,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years and older   (Adult, Senior)",Phase 2,5,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,120045|12-C-0045,16-Dec-11,12/1/2011,2/1/2014,10/13/2015,Oct-15,8-May-14,null,Feb-14,Clinical Tumor Response|Number of Participants With Adverse Events,https://ClinicalTrials.gov/show/NCT01495572
625,NCT01504542,Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer,Withdrawn,No Results Available,Non-small Cell Lung Cancer,Biological: HS110 vaccine|Biological: Placebo|Biological: HS110 vaccine,Heat Biologics,Both,"18 Years and older   (Adult, Senior)",Phase 2,0,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",HS110-10-01,20-Dec-11,12/1/2011,12/1/2013,11/20/2013,Nov-13,No Study Results Posted,null,Dec-13,Immunologic Response (defined as production of IFNƴ from CD8+ T cells as evaluated by ELISPOT assay)|Safety of the combination of HS110 vaccine and erlotinib|Tumor assessment by immunologic response criteria (irRC)|Exploratory Immunologic endpoint - evaluation of circulating tumor cells|Exploratory immunologic endpoint - immune function|Exploratory immunologic endpoint - proteomic profile,https://ClinicalTrials.gov/show/NCT01504542
1242,NCT01465087,Nanotechnology for Detection of Multiple Sclerosis Compared to Autoimmune and Neurological Diseases by Exhaled Samples,Completed,No Results Available,Multiple Sclerosis,Other: NA-NOSE artificial olfactory system,"Carmel Medical Center|Technion, Israel Institute of Technology",Both,"18 Years to 70 Years   (Adult, Senior)",,314,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic,CMC-11-0083-CTIL|Nano-MS-2011,24-Oct-11,12/1/2011,1/1/2015,6/26/2016,Jun-16,No Study Results Posted,null,Feb-14,Volatile organic compounds in the exhaled breath|Markers in exhaled breath,https://ClinicalTrials.gov/show/NCT01465087
612,NCT01550523,Pilot Immunotherapy Trial for Recurrent Malignant Gliomas,Completed,No Results Available,Malignant Glioma of Brain,Drug: IGF-1R/AS ODN|Device: biodiffusion chamber,Thomas Jefferson University,Both,"18 Years and older   (Adult, Senior)",Phase 1,12,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,DWA-11G.532,14-Feb-12,1/1/2012,6/1/2013,12/2/2013,Dec-13,No Study Results Posted,null,Jun-13,To establish the safety profile of a combination product with an optimized Good Manufacturing Practices AS ODN in the treatment of patients with recurrent malignant glioma with concomitant assessment of any therapeutic impact.|MRI based radiographic responses to treatment,https://ClinicalTrials.gov/show/NCT01550523
945,NCT01477021,Autologous T Cells and Cyclophosphamide in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery,Completed,No Results Available,Adult Liposarcoma|Adult Synovial Sarcoma|Recurrent Adult Soft Tissue Sarcoma|Stage III Adult Soft Tissue Sarcoma|Stage IV Adult Soft Tissue Sarcoma,Drug: cyclophosphamide|Biological: NY-ESO-1-specific T cells|Other: laboratory biomarker analysis,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,6,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2537.00|NCI-2011-03549|P30CA015704,17-Nov-11,1/1/2012,null,12/9/2014,Dec-14,No Study Results Posted,null,Sep-13,"Incidence of treatment-related toxicity, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Antitumor efficacy as determined by CT scan",https://ClinicalTrials.gov/show/NCT01477021
1071,NCT01423760,Collect Long-term Data on Subjects Following Participation in Previous EMD 531444 (L-BLP25 or BLP25 Liposome Vaccine) Clinical Trials,Terminated,No Results Available,Non-Small Cell Lung Cancer|Multiple Myeloma,Biological: Tecemotide|Other: No intervention,Merck KGaA,Both,"18 Years and older   (Adult, Senior)",,20,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,EMR 63325-011,23-Aug-11,1/1/2012,7/1/2015,7/31/2015,Jul-15,No Study Results Posted,null,Jun-15,Long Term Safety - number of patients experiencing any adverse event|Long Term Efficacy: Overall Survival (OS),https://ClinicalTrials.gov/show/NCT01423760
1091,NCT01497496,Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL),"Active, not recruiting",No Results Available,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Drug: High Dose Methylprednisolone (HDMP)|Drug: Ofatumumab|Drug: Lenalidomide,H. Lee Moffitt Cancer Center and Research Institute|Novartis|Celgene Corporation,Both,"18 Years and older   (Adult, Senior)",Phase 2,29,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MCC-16631|COMB157AUS08T|RV-CLL-PI-0560,20-Dec-11,1/1/2012,11/1/2016,4/26/2016,Apr-16,No Study Results Posted,null,Nov-16,Number of Participants With Complete Response (CR)|Number of Participants With Partial Response (PR)|Number of Participants With Progression/Relapse Free Survival (PFS)|Number of Participants With Overall Survival (OS),https://ClinicalTrials.gov/show/NCT01497496
1092,NCT01496976,Phase II Ofatumumab/Methylprednisolone Followed by Ofatumumab/Lenalidomide for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL),"Active, not recruiting",No Results Available,Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Drug: High Dose Methylprednisolone (HDMP)|Drug: Ofatumumab|Drug: Lenalidomide,H. Lee Moffitt Cancer Center and Research Institute|Novartis|Celgene Corporation,Both,"18 Years and older   (Adult, Senior)",Phase 2,45,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MCC-16622|COMB157BUS21T|RV-CLL-PI-0560,16-Dec-11,1/1/2012,12/1/2016,5/2/2016,Apr-16,No Study Results Posted,null,Dec-16,Number of Participants With Complete Response (CR)|Number of Participants With Partial Response (PR)|Number of Participants With Progression/Relapse Free Survival (PFS)|Number of Participants With Overall Survival (OS),https://ClinicalTrials.gov/show/NCT01496976
235,NCT02105675,Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer,"Active, not recruiting",No Results Available,Prostate Cancer|Prostate Cancer Metastatic,Biological: Dendritic Cells DCVAC/PCa|Drug: Docetaxel,Sotio a.s.,Male,"18 Years and older   (Adult, Senior)",Phase 2,60,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,SP001|2011-004735-32,24-Mar-14,2/1/2012,3/1/2017,6/29/2015,Jun-15,No Study Results Posted,null,Mar-14,Survival rate|Radiographic Progression Free Survival|Duration to Prostate Specific Antigen (PSA) Progression|Changes in Quality of Life (QOL) assessed by European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30|Changes in Pain assessed by EORTC QLQ-C30|Incidence of Adverse Events,https://ClinicalTrials.gov/show/NCT02105675
817,NCT01392586,Systemic Therapy With or Without Upfront Surgery in Metastatic Breast Cancer,Terminated,No Results Available,Metastatic Breast Cancer,Procedure: upfront breast surgery|Other: systemic therapy,Jeroen Bosch Ziekenhuis|Borstkanker Onderzoek Groep|Comprehensive Cancer Centre The Netherlands,Both,"18 Years and older   (Adult, Senior)",Phase 3,10,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,BOOG 2010-05,5-Jul-11,2/1/2012,1/1/2014,2/2/2014,Feb-14,No Study Results Posted,SUBMIT,Jan-14,Survival|Quality of Life|Two year survival|Number of unplanned local therapies|Difference in systemic therapy given|Determination of pathological resection margin|Number of treatments of the axillary lymph nodes,https://ClinicalTrials.gov/show/NCT01392586
885,NCT01526473,A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901,"Active, not recruiting",No Results Available,HER2+ Cancer,Biological: AVX901,H. Kim Lyerly|Susan G. Komen Breast Cancer Foundation|Duke University,Both,"18 Years and older   (Adult, Senior)",Phase 1,22,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label,Pro00034612,24-Jan-12,2/1/2012,12/1/2017,8/1/2016,May-16,No Study Results Posted,null,Mar-16,Safety|Immune response,https://ClinicalTrials.gov/show/NCT01526473
916,NCT01611506,"Combination Chemotherapy, Cetuximab and Radiation for Patients With Localized Gastric Cancer",Terminated,No Results Available,Gastric Cancer,Biological: Cetuximab|Drug: Capecitabine|Drug: Cisplatin,Dr Anna Dorothea Wagner|Centre Hospitalier Universitaire Vaudois,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1|Phase 2,1,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CHUV-CePO-B354re (gastric),15-May-12,2/1/2012,12/1/2012,1/8/2013,Jan-13,No Study Results Posted,null,Dec-12,"Dose limiting toxicity|Metabolic response|Secondary resectability|Major histopathological response rate|R-0 resection rate|Surgical morbidity|Overall survival|Time to local and systemic progression after R0-resection|Feasibility|Toxicity (according to NCI-CTCAE, Version 4.0)",https://ClinicalTrials.gov/show/NCT01611506
177,NCT01583686,CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer,Suspended,No Results Available,Cervical Cancer|Pancreatic Cancer|Ovarian Cancer|Ovarian|Lung Cancer,Drug: Fludarabine|Biological: Anti-mesothelin CAR|Drug: Cycolphosphamide|Drug: Aldesleukin,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 70 Years   (Adult, Senior)",Phase 1|Phase 2,15,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,120111|12-C-0111,20-Apr-12,3/1/2012,12/1/2019,6/3/2016,Jun-16,No Study Results Posted,null,Dec-18,Determine a safe dose of administration and determine if this approach will result in an objective tumor regression.|Determine the in vivo survival of CAR gene-engineered cells.,https://ClinicalTrials.gov/show/NCT01583686
211,NCT02133079,Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96,"Active, not recruiting",No Results Available,Liver Cancer|Pancreatic Adenocarcinoma,Biological: autologous gp96 vaccination,"Cure&Sure Biotech Co., LTD|Chinese Academy of Medical Sciences",Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1|Phase 2,20,Industry|Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CS-CIH-Li-01,3-May-14,3/1/2012,11/1/2019,12/10/2015,Dec-15,No Study Results Posted,null,Nov-16,blood count|blood chemistries|electrocardiogram|Disease-free survival|overall survive|changes in antigen specific T cells,https://ClinicalTrials.gov/show/NCT02133079
266,NCT02107391,Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer,"Active, not recruiting",No Results Available,Prostate Cancer,Biological: Dendritic Cells DCVAC/PCa|Drug: Leuprolide acetate|Drug: Goserelin Acetate,Sotio a.s.,Male,"18 Years and older   (Adult, Senior)",Phase 2,63,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,SP002|2011-004986-34,4-Apr-14,3/1/2012,9/1/2016,1/5/2016,Jun-15,No Study Results Posted,null,Dec-15,Proportion of patients with PSA Progression|Proportion of patients with Progression of Disease|Frequency of Adverse Events|Frequency of Skeletal Related Events|Changes in Quality of Life (QOL) assessed by EORTC QLQ-C30|Changes in Pain assessed by EORTC QLQ-C30,https://ClinicalTrials.gov/show/NCT02107391
268,NCT02107430,Phase II Study of DCVAC/PCa After Primary Radiotherapy for Patients With High Risk Localized Prostate Cancer,"Active, not recruiting",No Results Available,Prostate Cancer,Biological: Dendritic Cells DCVAC/PCa|Radiation: Standard radiotherapy,Sotio a.s.,Male,"18 Years and older   (Adult, Senior)",Phase 2,62,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,SP004|2011-004967-65,4-Apr-14,3/1/2012,9/1/2018,6/29/2015,Jun-15,No Study Results Posted,null,Sep-13,Number of Prostate Specific Antigen (PSA) failures in 5 years|Proportion of Patients without use of salvage therapy within 5 years|Frequency of Adverse Events|Proportion of Patients without Objective disease progression within 5 years,https://ClinicalTrials.gov/show/NCT02107430
452,NCT01522820,Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors,"Active, not recruiting",No Results Available,Anaplastic Astrocytoma|Anaplastic Oligoastrocytoma|Anaplastic Oligodendroglioma|Estrogen Receptor Negative|Estrogen Receptor Positive|Glioblastoma|Hormone-Resistant Prostate Cancer|Metastatic Prostate Carcinoma|Metastatic Renal Cell Cancer|Recurrent Adult Brain Neoplasm|Recurrent Bladder Carcinoma|Recurrent Breast Carcinoma|Recurrent Colorectal Carcinoma|Recurrent Esophageal Carcinoma|Recurrent Gastric Carcinoma|Recurrent Hepatocellular Carcinoma|Recurrent Lung Carcinoma|Recurrent Melanoma|Recurrent Ovarian Carcinoma|Recurrent Prostate Carcinoma|Recurrent Renal Cell Carcinoma|Recurrent Uterine Corpus Carcinoma|Resectable Hepatocellular Carcinoma|Sarcoma|Stage IA Breast Cancer|Stage IA Ovarian Cancer|Stage IA Uterine Corpus Cancer|Stage IB Breast Cancer|Stage IB Ovarian Cancer|Stage IB Uterine Corpus Cancer|Stage IC Ovarian Cancer|Stage II Uterine Corpus Cancer|Stage IIA Breast Cancer|Stage IIA Lung Carcinoma|Stage IIA Ovarian Cancer|Stage IIB Breast Cancer|Stage IIB Esophageal Cancer|Stage IIB Lung Carcinoma|Stage IIB Ovarian Cancer|Stage IIB Skin Melanoma|Stage IIC Ovarian Cancer|Stage IIC Skin Melanoma|Stage IIIA Breast Cancer|Stage IIIA Esophageal Cancer|Stage IIIA Lung Carcinoma|Stage IIIA Ovarian Cancer|Stage IIIA Skin Melanoma|Stage IIIA Uterine Corpus Cancer|Stage IIIB Breast Cancer|Stage IIIB Esophageal Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Skin Melanoma|Stage IIIB Uterine Corpus Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Skin Melanoma|Stage IIIC Uterine Corpus Cancer|Stage IV Bladder Urothelial Carcinoma|Stage IV Esophageal Cancer|Stage IV Ovarian Cancer|Stage IV Prostate Cancer|Stage IV Skin Melanoma|Stage IVA Uterine Corpus Cancer|Stage IVB Uterine Corpus Cancer,Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Drug: Sirolimus,Roswell Park Cancer Institute|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,30,Other|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,I 191511|NCI-2011-03568|071614|P30CA016056|R01CA158318,25-Jan-12,3/1/2012,null,7/25/2016,Jul-16,No Study Results Posted,null,Sep-16,"Incidence of adverse events in patients receiving the DEC-205/NY-ESO-1 fusion protein CDX-1401 with and without sirolimus, as evaluated according to the NCI CTCAE scale version 4.0|NY-ESO-1 specific cellular immunity|NY-ESO-1 specific humoral immunity",https://ClinicalTrials.gov/show/NCT01522820
749,NCT02055846,Analysis of the Mechanisms of Actions of Heat Shock Protein (Hsp27) Responsible of the Androgen-independent Evolution in Prostate Cancer,Terminated,No Results Available,Androgen-independent Prostate Cancer,"Procedure: Realisation of blood sample, urinary sample and tumor biopsy",Institut Paoli-Calmettes,Male,"18 Years and older   (Adult, Senior)",,59,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Basic Science,PPPR / IPC 2012-002,26-Oct-12,3/1/2012,6/1/2015,6/24/2015,Dec-12,No Study Results Posted,null,Jun-15,Level of Hsp27 protein|Targets for OGX-427,https://ClinicalTrials.gov/show/NCT02055846
814,NCT01567202,Study of DC Vaccination Against Glioblastoma,Recruiting,No Results Available,Glioma|Glioblastoma Multiforme|Neoplasms,Procedure: Surgery|Drug: Chemotherapy|Radiation: Radiotherapy|Biological: DC vaccination|Drug: blank placebo,Huashan Hospital|Fudan University,Both,"18 Years to 70 Years   (Adult, Senior)",Phase 2,100,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",DC81001115,26-Mar-12,3/1/2012,12/1/2016,5/19/2015,May-15,No Study Results Posted,null,Dec-16,Overall survival|Progression free survival|To correlate and characterize the immune response to the clinical response|To explore the association of GBM molecular subtype with immune response|To evaluate the effect of residual tumor volume on the immune response.,https://ClinicalTrials.gov/show/NCT01567202
852,NCT01540175,Immune Reconstitution in Oncology Patients Following Autologous Stem Cell Transplant,Completed,No Results Available,Solid Tumor|Brain Tumor|Lymphoma,Other: Blood samples obtained,St. Jude Children's Research Hospital,Both,"up to 21 Years   (Child, Adult)",,31,Other,Observational,Observational Model: Case-Only|Time Perspective: Prospective,XPD12-013 IROPAST,17-Feb-12,3/1/2012,6/1/2015,7/13/2015,Jul-15,No Study Results Posted,IROPAST,Jun-15,"Change in the immune reconstitution of T cell, B cell, and NK cell compartment.",https://ClinicalTrials.gov/show/NCT01540175
172,NCT01585428,Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers,"Active, not recruiting",No Results Available,Cervical Cancer|Oropharyngeal Cancer|Vaginal Cancer|Anal Cancer|Penile Cancer,Drug: Fludarabine|Drug: Cycolphosphamide|Biological: Young TIL|Drug: Aldesleukin,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 70 Years   (Adult, Senior)",Phase 2,29,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,120116|12-C-0116,24-Apr-12,4/1/2012,4/1/2017,6/10/2016,Jun-16,No Study Results Posted,null,Apr-16,To determine if autologous Young TIL infused in conjunction with high dose aldesleukin following a non-myeloablative lymphodepleting preparative regimen can mediate tumor regression in patients with metastatic or locally advanced refractory/recu...,https://ClinicalTrials.gov/show/NCT01585428
213,NCT02107404,Phase II Study of DCVAC/PCa Added After Radical Primary Prostatectomy for Patients With Localized Prostate Cancer,"Active, not recruiting",No Results Available,Prostate Cancer,Biological: Dendritic Cells DCVAC/PCa,Sotio a.s.,Male,"18 Years and older   (Adult, Senior)",Phase 2,150,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,SP003,4-Apr-14,4/1/2012,6/1/2017,6/30/2015,Jun-15,No Study Results Posted,null,Jun-15,Change in Prostate Specific Antigen (PSA) Doubling Time from randomization to week 40|Change in PSA Doubling Time during Follow-up from week 40 to 2 years after randomization|Frequency of Adverse Events|Proportion of Patients with Objective disease progression within 2 years|Number of Patients requiring further therapy at 2 years|Comparison of PSA Doubling Time in Treatment Phase with Immunotherapy with the Value Prior to Randomization|Proportion of patients after RPE with biochemical relapse within 2 years of randomization|Proportion of patients with progressive increase in PSA within 2 years of randomization|Overall survival,https://ClinicalTrials.gov/show/NCT02107404
246,NCT01383148,Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer,"Active, not recruiting",No Results Available,Non-Small-Cell Lung Carcinoma,Biological: TG4010|Drug: placebo,Transgene,Both,"18 Years and older   (Adult, Senior)",Phase 2|Phase 3,1000,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",TG4010.14/TIME|8559,23-Jun-11,4/1/2012,3/1/2019,11/3/2015,Nov-15,No Study Results Posted,TIME,Jan-19,Phase 2: Progression-free Survival (PFS)|Phase 3: Overall Survival (OS)|Phase 2 : Overall Survival (OS)|Phase 2 : Overall Response Rate (ORR)|Phase 3: Progression-free Survival (PFS)|Phase 3 : Overall Response Rate (ORR)|Phase 2 : Duration of response|Phase 2: Safety|Phase 3: Duration of response|Phase 3: Safety,https://ClinicalTrials.gov/show/NCT01383148
530,NCT01625260,A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer,"Active, not recruiting",No Results Available,Non-muscle Invasive Bladder Cancer,Biological: ALT-801|Drug: Gemcitabine,Altor Bioscience Corporation|James and Esther King Biomedical Research Program,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,52,Industry|Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CA-ALT-801-01-12,19-Jun-12,4/1/2012,12/1/2016,4/11/2016,Apr-16,No Study Results Posted,null,Sep-16,Safety Profile|Tolerability of ALT-801 combined with gemcitabine and designation of the Recommended Dose level (RD)|Clinical Benefit|Duration of response|Progression-free survival|Event free survival|Overall survival|Immunogenicity of ALT-801|Tumor Typing,https://ClinicalTrials.gov/show/NCT01625260
563,NCT01493154,Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients,Terminated,No Results Available,Head and Neck Cancer,Biological: DNA Vaccine|Drug: Cyclophosphamide,Sidney Kimmel Comprehensive Cancer Center|National Institute of Dental and Craniofacial Research (NIDCR)|Ichor Medical Systems Incorporated,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1,2,Other|NIH|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,J11129|P50DE019032|NA_00023916,21-Nov-11,4/1/2012,null,9/5/2014,Sep-14,No Study Results Posted,null,Apr-15,Number of participants with adverse events after administration of pNGVL4a-CRT/E7 (detox) DNA vaccine using the intramuscular TriGridTM Delivery System (TDS-IM) in combination with cyclophosphamide|Number of participants with measurable HPV-specific immune responses after vaccination,https://ClinicalTrials.gov/show/NCT01493154
600,NCT01475058,CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant,Completed,No Results Available,Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia|Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Chronic Lymphocytic Leukemia,Biological: allogeneic cytomegalovirus-specific cytotoxic T lymphocytes,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1|Phase 2,1,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2494.00|NCI-2011-01819|P30CA015704|R01CA136551,10-Nov-11,4/1/2012,null,8/4/2015,Aug-15,No Study Results Posted,null,Apr-14,"Safety and toxicity assessment of study treatment|Feasibility assessment of study treatment|Anti-tumor efficacy and duration of persistence, migration, and function of adoptively transferred bi-specific effector cells",https://ClinicalTrials.gov/show/NCT01475058
623,NCT01666353,PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy,"Active, not recruiting",No Results Available,Melanoma|Renal Cell Carcinoma (RCC)|Non-small Cell Lung Cancer (NSCLC),Radiation: PET/CT imaging with [18F] 2-deoxy-2-(18F)fluoro-D-glucose (FDG),Sidney Kimmel Comprehensive Cancer Center,Both,"18 Years and older   (Adult, Senior)",Phase 0,20,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic,J1208|NA_00049919,18-May-12,4/1/2012,12/1/2015,3/17/2015,Mar-15,No Study Results Posted,null,Dec-15,Compare FDG PET-based qualitative and quantitative tumor response assessment with standard CT immune RECIST criteria|Assess the use of FDG PET as a non-invasive imaging method to detect early evidence of organ inflammation,https://ClinicalTrials.gov/show/NCT01666353
741,NCT01723813,Peptide Vaccinations Plus GM-CT-01 in Melanoma,Recruiting,No Results Available,Metastatic Melanoma,Biological: Tumor specific peptides: MAGE-3.A1 and / or NA17.A2|Biological: Galectin-3 inhibitor: GM-CT-01 systemic injections|Biological: Galectin-3 inhibitor: GM-CT-01 Peri-tumoral administration,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,12,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,LUC 10-001,28-Sep-12,4/1/2012,4/1/2015,11/7/2012,Nov-12,No Study Results Posted,null,Apr-14,Number of participants with adverse events|Response rate in both arms|Response rate in group 2 versus group 1|Time to Progression|Overall Survival|Immunogenicity of the treatment,https://ClinicalTrials.gov/show/NCT01723813
777,NCT01585415,Vemurafenib and White Blood Cell Therapy for Advanced Melanoma,Terminated,No Results Available,Metastatic Cancer|Melanoma,Drug: Vemurafenib|Biological: Young TIL|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldesleukin,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 66 Years   (Adult, Senior)",Phase 1,12,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,120114|12-C-0114,24-Apr-12,4/1/2012,6/1/2017,7/22/2016,Jul-16,No Study Results Posted,null,Jun-17,Determine the safety of the administration of vemurafenib in conjunction with ACT consisting of autologous TIL infused along with high dose aldesleukin following a non-myeloablative lymphodepleting preparative regimen.,https://ClinicalTrials.gov/show/NCT01585415
783,NCT01572493,Continuous Infusion of rhIL-15 for Adults With Advanced Cancer,Suspended,No Results Available,Lymphoma|Carcinoma,Biological: rh IL-15,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 99 Years   (Adult, Senior)",Phase 1,25,NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,120113|12-C-0113,5-Apr-12,4/1/2012,4/1/2020,7/28/2016,Jul-16,No Study Results Posted,null,Apr-18,MTD and DLT,https://ClinicalTrials.gov/show/NCT01572493
926,NCT01593696,Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma,"Active, not recruiting",No Results Available,ALL|B Cell Lymphoma|Leukemia|Large Cell Lymphoma|Non-Hodgkin Lymphoma,Biological: Anti-CD19- CAR,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"1 Year to 30 Years   (Child, Adult)",Phase 1,52,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,120112|12-C-0112,5-May-12,4/1/2012,12/1/2025,5/18/2016,May-16,No Study Results Posted,null,Jan-20,Safety & amp; Feasibility|Persistence of Anti-CD19-CAR Tcells|Antitumor Effects|Ability to reduce grade 4 CRS to,https://ClinicalTrials.gov/show/NCT01593696
979,NCT01530269,C11-Sodium Acetate PET/CT Imaging for Metastatic Disease in Intermediate-to-high Risk Prostate Adenocarcinoma,Recruiting,No Results Available,Prostate Cancer|Prostate Adenocarcinoma,Drug: C11-Sodium Acetate,Phoenix Molecular Imaging,Male,"18 Years to 90 Years   (Adult, Senior)",Phase 2,300,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic,AMIC-AC-002,4-Feb-12,4/1/2012,4/1/2018,4/1/2016,Apr-16,No Study Results Posted,null,Apr-17,Tissue Biopsy of metastatic site(s)|PSA (prostate specific antigen),https://ClinicalTrials.gov/show/NCT01530269
119,NCT01543464,Peptide Vaccine and Temozolomide for Metastatic Melanoma Patients,Terminated,No Results Available,Malignant Melanoma,Drug: Chemotherapy: Temozolomide,Inge Marie Svane|Copenhagen University Hospital at Herlev|Herlev Hospital,Both,"18 Years and older   (Adult, Senior)",Phase 2,41,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MM1120,8-Feb-12,5/1/2012,9/1/2016,8/17/2015,Aug-15,No Study Results Posted,null,Sep-16,Clinical benefit rate (CBR),https://ClinicalTrials.gov/show/NCT01543464
1184,NCT01195480,CD19-CAR Immunotherapy for Childhood Acute Lymphoblastic Leukemia (ALL),Terminated,No Results Available,Acute Lymphoblastic Leukemia,Genetic: donor-derived EBV-specific cytotoxic T-cells (EBV-CTL) transduced with the retroviral vector SFGalpha-CD19-CD3zeta|Biological: Irradiated donor-derived Lymphoblastoid Cell Line,"University College, London|European Union|The Leukemia and Lymphoma Society|Children with Leukaemia|Department of Health, United Kingdom|JP Moulton Charitable Foundation|Deutsche Krebshilfe e.V., Bonn (Germany)",Both,"up to 18 Years   (Child, Adult)",Phase 1|Phase 2,29,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,UCL/09/0050|2007-007612-29,3-Sep-10,5/1/2012,1/1/2021,12/7/2015,Aug-13,No Study Results Posted,CD19TPALL,Nov-15,"Toxicity attributable to transfer of CD19-zeta transduced CTL|Biological efficacy as assessed by effect of CD19-zeta transduced CTL on Minimal Residual Disease levels in the bone marrow in the first year post- transduced CTL infusion|Persistence and frequency of circulating CD19-zeta transduced CTL in the peripheral blood of recipients after adoptive transfer as assessed by flow cytometry and quantitative real-time PCR.|In vitro anti-leukaemic response of circulating PBMC post adoptive transfer of CD19-zeta transduced CTL using interferon-gamma ELISPOT assays after stimulation with CD19+ve targets|Relapse rate, disease-free survival and overall survival at 1 and 2 years after adoptive immunotherapy with CD19ζ-transduced EBV-CTL",https://ClinicalTrials.gov/show/NCT01195480
109,NCT01703364,Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL,Completed,No Results Available,CLL|Chronic Lymphocytic Leukemia,Drug: Lenalidomide,Arbeitsgemeinschaft medikamentoese Tumortherapie|Celgene,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,12,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AGMT_CLL-9|2011-004912-43,4-Oct-12,6/1/2012,10/1/2015,5/25/2016,May-16,No Study Results Posted,null,Mar-15,"Tolerability of escalated starting dose|Establishment of maximal tolerated dose (MTD) of Lenalidomide in combination with FR|Time to MTD|Safety profile of the FRL combination|Response rates in all phases by 4-colour flow cytometric and ASO-PCR MRD analysis|Risk factor analysis (FISH cytogenetics, CD38/ZAP-70 expression, mutation status)|Longitudinal definition of T cell subsets (including prognostic EM T cells and Treg cells)+/- PD1",https://ClinicalTrials.gov/show/NCT01703364
341,NCT01219907,Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer,Withdrawn,No Results Available,HER2-positive Breast Cancer|Male Breast Cancer|Stage IV Breast Cancer,Biological: HER-2/neu peptide vaccine|Drug: cyclophosphamide|Biological: ex vivo-expanded HER2-specific T cells|Other: laboratory biomarker analysis|Other: flow cytometry|Other: immunoenzyme technique,University of Washington|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,0,Other|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,7266|NCI-2010-01792,22-Sep-10,6/1/2012,null,5/15/2013,May-13,No Study Results Posted,null,Jun-14,"Ability to expand HER-2-specific T cells ex vivo from memory T cell subsets which are derived from patients with advanced HER-2 expressing cancer|Safety and systemic toxicity as assessed at regular time points by NCI common toxicity criteria (CTCAE v 4.0). Stopping rules for the study protect patients against therapy with a rate of severe toxicity of 20% or greater.|Extent to which to HER-2-specific T cell immunity can be boosted successfully with adoptive immunotherapy will be defined by quantitative assessment of HER-2-specific CD8+ T cells assessed by cytokine flow cytometry (CFC), Elispot, and tetramer staining|Persistence of T cell immune augmentation in vivo after adoptive transfer of HER-2-specific T cells as assessed by presence of HER-2-specific central memory T cells and effector memory T cells|Anti-tumor effects of HER-2-specific T cells as assessed by RECIST criteria",https://ClinicalTrials.gov/show/NCT01219907
477,NCT01616303,A Controlled Study of the Effectiveness of Oregovomab (Antibody) Plus Chemotherapy in Advanced Ovarian Cancer,"Active, not recruiting",No Results Available,Ovarian Neoplasms,Drug: Carboplatin & paclitaxel|Biological: Carboplatin & paclitaxel & oregovomab,Quest PharmaTech Inc.,Female,"18 Years to 75 Years   (Adult, Senior)",Phase 2,80,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,QPT-ORE-002|2010-024305-13,30-May-12,6/1/2012,6/1/2018,3/29/2016,Mar-16,No Study Results Posted,null,Jun-14,Change in CA125 ELISPOT assay response for cytotoxic T cell antigen specific immunity induction to end of first-line chemotherapy|Time to clinical relapse|Immune parameters: HAMA (human anti-mouse antibody) titers and DTH (delayed type hypersensitivity)|Clinical response|Survival|Change in vital signs from baseline to end of study|Change in clinical laboratory results from baseline to end of chemotherapy,https://ClinicalTrials.gov/show/NCT01616303
607,NCT01477749,Sipuleucel-T Manufacturing Demonstration Study,Completed,Has Results,"Cancer of Prostate|Cancer of the Prostate|Neoplasms, Prostate|Neoplasms, Prostatic|Prostate Cancer|Prostate Neoplasms|Prostatic Cancer",Biological: sipuleucel-T,Dendreon,Male,"18 Years and older   (Adult, Senior)",Phase 2,47,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label,P11-1|2011-001192-39,19-Nov-11,6/1/2012,6/1/2014,11/4/2015,Nov-15,10-Jun-15,null,Jun-14,Cumulative CD54+ Cell Count|Cumulative CD54 Upregulation|Cumulative Total Nucleated Cell (TNC) Count|Product Viability (Percentage),https://ClinicalTrials.gov/show/NCT01477749
638,NCT01684241,RBL001/RBL002 Phase I Clinical Trial,Completed,No Results Available,Melanoma,Biological: RBL001/RBL002,Biontech RNA Pharmaceuticals GmbH,Both,"18 Years and older   (Adult, Senior)",Phase 1,29,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,RB_0001-01,10-Sep-12,6/1/2012,7/1/2015,7/21/2015,Jul-15,No Study Results Posted,MERIT,May-15,Number of adverse events|Determination of antitumoral immune responses|Clinical Monitoring of Tumor Lesions,https://ClinicalTrials.gov/show/NCT01684241
1167,NCT01192087,"Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy",Recruiting,No Results Available,Adenoid Cystic Carcinoma,Drug: Cetuximab,"Heidelberg University|Dept. of Radiation Oncology, INF 400, 69120 Heidelberg, Germany|University Hospital Heidelberg|Merck KGaA",Both,"18 Years to 70 Years   (Adult, Senior)",Phase 1|Phase 2,49,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ACCEPT,30-Aug-10,6/1/2012,7/1/2017,4/23/2013,Apr-13,No Study Results Posted,ACCEPT,Jul-15,Number of Participants with acute adverse effects as a Measure of toxicity|Number of Participants with late adverse effects as a Measure of toxicity|local relapse-free survival|distant relapse-free survival|overall disease-free survival|overall survival,https://ClinicalTrials.gov/show/NCT01192087
19,NCT01625741,Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy,Terminated,No Results Available,Chronic Lymphocytic Leukemia,Drug: Rituximab,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,Both,"19 Years and older   (Adult, Senior)",Phase 2,6,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,HYDRIC,6-Jun-12,7/1/2012,5/1/2015,9/28/2015,Sep-15,No Study Results Posted,HYDRIC,May-15,rate of conversion into Minimal Residual Disease negativity|toxicity of the consolidation treatment by rituximab|Pharmacokinetic/Pharmacodynamic correlation|quality of life study,https://ClinicalTrials.gov/show/NCT01625741
167,NCT01592422,Maintenance Therapy With Autologous Cytokine-induced Killer Cells for Small Cell Lung Cancer,Recruiting,No Results Available,Small Cell Lung Cancer,Biological: Autologous cytokine-induced killer cell|Other: Best Supportive Care,People's Hospital of Guangxi,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 2,60,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CIKSCLC-2012,26-Apr-12,7/1/2012,9/1/2015,7/2/2012,Jul-12,No Study Results Posted,null,Jul-15,Progression-free survival|Overall survival|Quality-of-life,https://ClinicalTrials.gov/show/NCT01592422
277,NCT01532960,Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer,Suspended,No Results Available,Breast Cancer,"Biological: poly-ICLC|Biological: 9 Peptides from Her-2/neu, CEA, & CTA|Biological: Peptide-tet","Craig L Slingluff, Jr|University of Virginia",Both,"18 Years and older   (Adult, Senior)",Phase 1,24,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,15881,8-Feb-12,7/1/2012,null,8/24/2015,Aug-15,No Study Results Posted,Breast 41,Jul-16,Safety (Frequency of dose limiting adverse events)|Immune response rate|Safety (adverse event profile)|Immunogenicity- CD8+ T cell specificity|Immunogenicity- CD8+ cytokine production|Immunogenicity- immue responses among subjects treated with anti-estrogen therapies,https://ClinicalTrials.gov/show/NCT01532960
449,NCT01400672,Imiquimod/Brain Tumor Initiating Cell (BTIC) Vaccine in Brain Stem Glioma,"Active, not recruiting",No Results Available,Diffuse Intrinsic Pontine Glioma,Biological: Tumor Lysate Vaccine|Drug: Imiquimod|Radiation: Radiation therapy,"Masonic Cancer Center, University of Minnesota",Both,"3 Years and older   (Child, Adult, Senior)",Phase 1,8,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2009LS136|1004M81213,19-Jul-11,7/1/2012,8/1/2017,4/8/2016,Apr-16,No Study Results Posted,null,Aug-17,Dose-limiting toxicity|Time to Tumor Progression|Drop-out rate,https://ClinicalTrials.gov/show/NCT01400672
482,NCT01659151,Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma,Recruiting,No Results Available,Metastatic Melanoma,Drug: High Dose Interleukin-2 (IL-2)|Procedure: ACT with TIL Infusion|Drug: Vemurafenib|Drug: Lymphodepletion,H. Lee Moffitt Cancer Center and Research Institute,Both,"18 Years and older   (Adult, Senior)",Phase 2,30,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MCC-16992,3-Aug-12,7/1/2012,12/1/2016,5/6/2016,May-16,No Study Results Posted,null,Dec-16,Overall Response (OR)|Drop Out Rate|Number of Participants with Progression Free Survival (PFS),https://ClinicalTrials.gov/show/NCT01659151
1078,NCT01655888,The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma,Recruiting,No Results Available,Malignant Mesothelioma,Drug: Tremelimumab,Azienda Ospedaliera Universitaria Senese|MedImmune LLC,Both,"18 Years and older   (Adult, Senior)",Phase 2,29,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MESOT-TREM-2012|2012-002762-12,31-Jul-12,7/1/2012,1/1/2015,7/31/2012,Jul-12,No Study Results Posted,null,Jan-14,To determine the objective response|Disease control rate (DCR)|Safety|Progression free survival,https://ClinicalTrials.gov/show/NCT01655888
83,NCT01670994,A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma,Terminated,No Results Available,Relapsed or Refractory Multiple Myeloma,Biological: ALT-801,Altor Bioscience Corporation|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,6,Industry|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CA-ALT-801-01-11,20-Aug-12,8/1/2012,9/1/2015,7/13/2016,Jul-16,No Study Results Posted,null,Aug-13,Safety Profile|Tolerability and MTD designation|Clinical Benefit|Immunogenicity and Pharmacokinetics|Tumor Typing|Overall and progression-free survival|Duration of Response,https://ClinicalTrials.gov/show/NCT01670994
190,NCT01795313,Immunotherapy for Recurrent Ependymomas in Children Treatment for Recurrent Ependymomas Using HLA-A2 Restricted Tumor Antigen Peptides in Combination With Imiquimod,Recruiting,No Results Available,Ependymoma,Biological: HLA-A2 restricted synthetic tumor antigen|Drug: Imiquimod|Other: enzyme-linked immunosorbent assay|Other: flow cytometry|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis,University of Pittsburgh|Solving Kids’ Cancer|National Cancer Institute (NCI),Both,"12 Months to 21 Years   (Child, Adult)",,24,Other|NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PRO12050422|R01CA174858,12-Feb-13,8/1/2012,null,7/10/2016,Jul-16,No Study Results Posted,null,Feb-17,Number of Participants with unacceptable toxicity|Tumor-associated antigen-specific T-cell,https://ClinicalTrials.gov/show/NCT01795313
207,NCT01675765,Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma,"Active, not recruiting",No Results Available,Malignant Pleural Mesothelioma,Biological: Immunotherapy plus chemotherapy|Biological: Immunotherapy with cyclophosphamide plus chemotherapy,"Aduro Biotech, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1,60,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ADU-CL-02,23-Aug-12,8/1/2012,12/1/2016,6/16/2016,Jun-16,No Study Results Posted,null,Dec-16,Number of subjects reporting adverse events|Induction of immune response to mesothelin by enzyme-linked immunosorbent spot (ELISPOT) assay|Objective tumor response|Time to progression|Serum mesothelin as correlate of therapeutic response,https://ClinicalTrials.gov/show/NCT01675765
517,NCT01595321,"Pancreatic Tumor Cell Vaccine (GVAX), Low Dose Cyclophosphamide, Fractionated Stereotactic Body Radiation Therapy (SBRT), and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas","Active, not recruiting",No Results Available,Pancreatic Cancer,Drug: Cyclophosphamide|Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1/GM-Neo vaccine|Radiation: Stereotactic Body Radiation (SBRT)|Drug: FOLFIRINOX,Sidney Kimmel Comprehensive Cancer Center,Both,"18 Years to 76 Years   (Adult, Senior)",,19,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,J1179|NA_00050233,27-Apr-12,8/1/2012,8/1/2018,5/12/2016,May-16,No Study Results Posted,null,Jul-17,Number of participants with adverse events as a measure of toxicity|Survival|Time to disease progression using immune correlates,https://ClinicalTrials.gov/show/NCT01595321
1087,NCT01683188,HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma,Terminated,No Results Available,Metastatic Melanoma,Drug: vemurafenib + HD IL-2,Prometheus Laboratories,Both,"18 Years and older   (Adult, Senior)",Phase 4,53,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label,12PLK01,7-Sep-12,8/1/2012,11/1/2014,2/3/2015,Feb-15,No Study Results Posted,PROCLIVITY 01,Nov-14,Assess Complete Response (CR) rate in BRAFV600 mutation positive metastatic melanoma patients who have received vemurafenib plus HD IL-2 at 10 (±3) weeks and 26 (±3) weeks from the start of HD IL-2 dosing.,https://ClinicalTrials.gov/show/NCT01683188
1125,NCT01585688,Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL,"Active, not recruiting",No Results Available,Non-Hodgkin's Lymphoma|Chronic Lymphocytic Leukemia,Drug: hLL1-DOX (IMMU-115),"Immunomedics, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,30,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IM-T-hLL1-DOX-02,23-Apr-12,8/1/2012,2/1/2017,9/3/2015,Sep-15,No Study Results Posted,null,Nov-16,Safety|Efficacy,https://ClinicalTrials.gov/show/NCT01585688
1182,NCT01684761,Study of Tcelna (Imilecleucel-T) in Secondary Progressive Multiple Sclerosis,"Active, not recruiting",No Results Available,Autoimmune Diseases of the Nervous System|Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Disease Progression|Brain Atrophy,Biological: Tcelna|Biological: Placebo,"Opexa Therapeutics, Inc.",Both,18 Years to 60 Years   (Adult),Phase 2,180,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",Protocol Number 2012-00,11-Sep-12,8/1/2012,8/1/2016,7/15/2016,Jul-15,No Study Results Posted,Abili-T,Aug-16,Brain Atrophy|Disease Progression,https://ClinicalTrials.gov/show/NCT01684761
140,NCT01688492,Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer,"Active, not recruiting",No Results Available,Prostate Cancer,Drug: Ipilimumab,Memorial Sloan Kettering Cancer Center|Bristol-Myers Squibb|Northwestern University|Oregon Health and Science University,Male,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,57,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,12-120,14-Sep-12,9/1/2012,9/1/2016,9/18/2015,Sep-15,No Study Results Posted,null,Sep-16,safety (Phase I)|progression-free survival (PFS) Phase II|Changes in PSA kinetics|Measurable disease when present|Evaluate changes in radionuclide bone scan,https://ClinicalTrials.gov/show/NCT01688492
170,NCT01691625,Concurrent Chemoradiation With or Without DC-CIK Immunotherapy in Treating Locally Advanced Esophageal Cancer,Recruiting,No Results Available,Esophageal Carcinoma,Other: concurrent chemoradiotherapy plus DC-CIK immunotherapy|Other: Concurrent chemoradiation only,Capital Medical University,Both,"18 Years and older   (Adult, Senior)",,50,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,JR-01,17-Sep-12,9/1/2012,9/1/2017,1/27/2016,Jan-16,No Study Results Posted,null,Sep-16,the quality of life|progression-free survival,https://ClinicalTrials.gov/show/NCT01691625
253,NCT01696877,A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer,"Active, not recruiting",No Results Available,Prostate Cancer Adenocarcinoma in Situ,Drug: degarelix acetate|Drug: Cyclophosphamide|Drug: GVAX,Sidney Kimmel Comprehensive Cancer Center,Male,"21 Years and older   (Adult, Senior)",Phase 1|Phase 2,29,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,J1265|NA_00073453,14-Sep-12,9/1/2012,4/1/2018,6/28/2016,Jun-16,No Study Results Posted,null,Apr-18,Intraprostatic CD8+ T cell infiltration|Number of participants with adverse events|Intraprostatic CD4+ T cell and Treg infiltration|Quantification of tissue androgen concentrations|Quantification of markers of apoptosis|Pathological complete responses|Serum antibodies to prostate-associated antigens|PSA response rate and time-to-PSA-recurrence,https://ClinicalTrials.gov/show/NCT01696877
378,NCT01420965,"Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer",Suspended,No Results Available,Prostatic Neoplasms,Drug: CT-011 (Anti-PD1 Antibody)|Other: Sipuleucel-T (Provenge)|Drug: Cyclophosphamide,Georgia Regents University,Male,"18 Years and older   (Adult, Senior)",Phase 2,57,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,11C0231|11-C-0231,19-Aug-11,9/1/2012,12/1/2018,6/28/2016,Jun-16,No Study Results Posted,null,Dec-16,"Determine feasibility of Provenge plus low-dose Cyclophosphamide as well as the immune efficacy of Provenge alone versus Provenge plus low-dose Cyclophosphamide and anti PD1 monoclonal antibodies (CT011) on the change in specific immune response...|Determine whether the combination of low dose-Cyclophosphamide and anti PD1 monoclonal antibodies (CT-011) with Provenge(tm) lead to improvement in increase progression free survival (PFS) and Overall Survival (OS) in patients with advanced, min...",https://ClinicalTrials.gov/show/NCT01420965
642,NCT01691664,Adoptive Cellular Therapy and Radiation Therapy After Surgery in Treating Patients With Esophageal Cancer,Recruiting,No Results Available,Esophageal Cancer,Radiation: Only radiation therapy|Other: Radiation therapy plus DC-CIK cellular therapy,Capital Medical University,Both,"18 Years and older   (Adult, Senior)",,40,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,JR-02,18-Sep-12,9/1/2012,6/1/2017,1/27/2016,Jan-16,No Study Results Posted,null,Dec-16,Disease free survival|quality of life,https://ClinicalTrials.gov/show/NCT01691664
1063,NCT01719341,Study of Non-Myeloablative Haplo-identical Haematopoietic Stem Cell Transplantation in Patients With Haematological Malignancies or Acquired Aplastic Anaemia,Recruiting,No Results Available,Haematological Malignancies|Acquired Aplastic Anaemia,,"National University Hospital, Singapore",Both,"18 Years to 70 Years   (Adult, Senior)",,21,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2012/00465,30-Oct-12,9/1/2012,null,12/10/2013,Dec-13,No Study Results Posted,null,Jun-14,1 year overall survival after HLA-Haploidentical transplantation|Progression free survival one and 2 years post-transplantation|Cumulative incidence of relapse/progression at one and 2 years post-transplant,https://ClinicalTrials.gov/show/NCT01719341
1106,NCT01697800,A Phase II Trial of Tadalafil in Patients With Squamous Cell Carcinoma of the Upper Aero Digestive Tract,Recruiting,No Results Available,Head and Neck Squamous Cell Carcinoma,Drug: Tadalafil|Drug: Placebo,Sidney Kimmel Comprehensive Cancer Center|National Institute of Dental and Craniofacial Research (NIDCR),Both,"21 Years and older   (Adult, Senior)",Phase 2,40,Other|NIH,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Investigator, Outcomes Assessor)|Primary Purpose: Treatment",J1247|2P50DE019032|NA_00073880,28-Sep-12,9/1/2012,9/1/2016,5/12/2014,May-14,No Study Results Posted,null,Sep-14,Increase in immune response after tadalafil administration,https://ClinicalTrials.gov/show/NCT01697800
1263,NCT01793025,Mismatched Donor Cells to Treat Acute Myeloid Leukemia,Recruiting,No Results Available,Acute Myeloid Leukemia,Biological: ATAC Therapy,Maisonneuve-Rosemont Hospital,Both,"18 Years and older   (Adult, Senior)",Phase 1,12,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ATAC-AML-01,10-Feb-13,9/1/2012,3/1/2017,4/8/2015,Apr-15,No Study Results Posted,ATAC-AML-01,Dec-16,"Safety|Treatment-related mortality|Non-relapse mortality|Incidence of graft-versus-host disease|Duration of cytopenias|Overall survival|Complete and incomplete remissions (CR, CRi)|Relapse-free survival",https://ClinicalTrials.gov/show/NCT01793025
141,NCT00986518,T Regulatory Lymphocytes (Treg) Depletion for Cancer Treatment Efficacy and Safety Study,Completed,No Results Available,Colorectal Cancer,Biological: Adaptive autologous cell immunotherapy,Assistance Publique - Hôpitaux de Paris,Both,18 Years to 65 Years   (Adult),Phase 1|Phase 2,5,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,P080601,29-Sep-09,10/1/2012,2/1/2013,11/21/2013,Sep-13,No Study Results Posted,STARTREK,Feb-13,"Tumor size of hepatic and/or lung metastases, as measured with tomodensitometry (RECIST 1.1 criteria)|MRI : Assessment of tumor necrosis, cellularity and morphological criteria RECIST 1.1 (functional criteria following injection : DCEMRI and diffusion MRI)|Sonography : assessment of vascular micro-circulation with contrast injection,|Immune cell reconstitution will be assessed through measuring rate of regulatory T-cell reconstitution,|Clinical Exam (WHO-CTC), Vital Signs, Adverse events|Laboratory test: hepatic function, immune function, haematology",https://ClinicalTrials.gov/show/NCT00986518
198,NCT01678352,Imiquimod and Tumor Lysate Vaccine Immunotherapy in Adults With High Risk or Recurrent Grade II Gliomas,Recruiting,No Results Available,High Risk WHO Grade II Glioma|Recurrent/Post-Chemotherapy WHO Grade II Glioma,Biological: Tumor Lysate Vaccine|Drug: Imiquimod,University of Pittsburgh|University of Minnesota - Clinical and Translational Science Institute,Both,"18 Years and older   (Adult, Senior)",Phase 0,27,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,11-136,30-Aug-12,10/1/2012,9/1/2017,1/12/2016,Jan-16,No Study Results Posted,null,Sep-16,Safety|Induction of BTIC Lysate-specific T-cell response,https://ClinicalTrials.gov/show/NCT01678352
365,NCT01433172,Combination Immunotherapy of GM.CD40L Vaccine With CCL21 in Lung Cancer,"Active, not recruiting",No Results Available,Lung Cancer|Adenocarcinoma,Biological: GM.CD40L.CCL21 Vaccinations|Biological: GM.CD40L cells Vaccinations,H. Lee Moffitt Cancer Center and Research Institute|Bankhead-Coley Florida Biomedical Research Program|James and Esther King Biomedical Research Program,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,73,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MCC-16439,12-Sep-11,10/1/2012,11/1/2016,4/25/2016,Apr-16,No Study Results Posted,null,Nov-16,Number of Participants With Progressive Free Survival (PFS)|Number of Participants With Adverse Events,https://ClinicalTrials.gov/show/NCT01433172
775,NCT01701674,Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts,"Active, not recruiting",No Results Available,Metastatic Melanoma,Drug: Ipilimumab|Procedure: Tumor Infiltrating Lymphocytes (TIL)|Drug: Administration of Lymphodepletion|Drug: Cyclophosphamide as Part of Lymphodepletion|Drug: Fludarabine as Part of Lymphodepletion|Drug: High Dose IL-2|Biological: Adoptive Cell Therapy with TIL,H. Lee Moffitt Cancer Center and Research Institute|Bristol-Myers Squibb,Both,"18 Years and older   (Adult, Senior)",,13,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MCC-17057|CA184-213,3-Oct-12,10/1/2012,11/1/2016,4/8/2016,Apr-16,No Study Results Posted,null,Nov-16,Safety and Feasibility of Administering Ipilimumab with adoptive cell transfer (ACT) Using TIL|Overall Response Rate (ORR)|Progression Free Survival (PFS),https://ClinicalTrials.gov/show/NCT01701674
784,NCT01723306,Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas,Suspended,No Results Available,Metastatic Cancers,Genetic: Gene Modified T Cells,Roger Williams Medical Center,Both,"18 Years to 80 Years   (Adult, Senior)",Phase 2,48,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,306-04,1-Nov-12,10/1/2012,8/1/2017,6/10/2016,Jun-16,No Study Results Posted,null,Oct-16,Efficacy|Safety,https://ClinicalTrials.gov/show/NCT01723306
952,NCT01740401,CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma,Completed,No Results Available,Melanoma,"Drug: Cyclophosphamide, Ipilimumab",Icahn School of Medicine at Mount Sinai|Bristol-Myers Squibb,Both,"18 Years and older   (Adult, Senior)",Phase 2,11,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,GCO 14-0677|114660,29-Nov-12,10/1/2012,12/1/2014,1/6/2015,Dec-14,No Study Results Posted,null,Dec-13,The primary objective of this study is: Evaluate the anti-tumor activity of the combination of low dose Cyclophosphamide and CTLA-4 blockade using Objective Response Rate (ORR) by 12 weeks following mWHO RC.|The secondary objectives are: 1. Progression-free survival 2. T regulatory cell profile in peripheral blood,https://ClinicalTrials.gov/show/NCT01740401
1202,NCT01585350,A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients,"Active, not recruiting",No Results Available,Melanoma,Biological: MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS)|Biological: MELITAC 12.1 + Montanide ISA-51 + polyICLC,"Craig L Slingluff, Jr|University of Virginia|National Cancer Institute (NCI)|Oncovir, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1,51,Other|NIH|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,15781,24-Apr-12,10/1/2012,null,7/30/2015,Jul-15,No Study Results Posted,MEL58,Jul-14,"Safety, with measures of adverse events, locally and systemically|CD8+ and CD4+ peptide-reactive T cell responses among lymphocytes in the peripheral blood and in sentinel immunized nodes (SIN)|Toll-like receptor signaling in the replicate immunization site|CCR and integrin expression on vaccine induced T cells in the peripheral blood and at the replicate immunization site|Th1, Th2, and Th17 profiles of T cells in the vaccination site and SIN as measured by cytokine expression (IFNγ, IL-2, TNFα, IL-4, IL-5, IL-10, IL-17, IL-23), and nuclear expression of transcription factors (T-bet, GATA3, RORγt) by immunohistochemistry.|Chemokines CXCL9, 10, and 11; CCL19, CCL21, CXCL12, CXCL13 in the vaccine site microenvironment|Markers of activation, regulation, and apoptosis on CD4 and CD8 T cells in the vaccine site and SIN: CD69, Ki67, FoxP3, and TUNEL staining|Homing receptors expressed by antigen-reactive (tetramer-positive) T cells induced by vaccination, in the circulation and SIN|MyD88 expression in the VSME and SIN|Regulatory processes in the immunization site and SIN",https://ClinicalTrials.gov/show/NCT01585350
1227,NCT01700946,Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma,Recruiting,No Results Available,Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia|Recurrent Childhood B-Lymphoblastic Lymphoma,Drug: dexamethasone|Drug: vincristine sulfate|Biological: rituximab|Drug: clofarabine|Drug: cyclophosphamide|Drug: etoposide|Biological: aldesleukin|Drug: pegaspargase|Drug: methotrexate|Drug: mercaptopurine|Drug: cytarabine|Drug: mitoxantrone|Drug: teniposide|Drug: vinblastine|Biological: natural killer cell infusion|Other: laboratory biomarker analysis|Drug: therapeutic hydrocortisone|Procedure: allogeneic hematopoietic stem cell transplantation,St. Jude Children's Research Hospital|Cookies for Kids' Cancer|Assisi Foundation,Both,"up to 21 Years   (Child, Adult)",Phase 2,40,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ALLR18,1-Oct-12,10/1/2012,10/1/2021,5/24/2016,May-16,No Study Results Posted,null,Oct-21,3-year overall survival rate of patients with relapsed ALL|3-year event-free survival rates in patients with relapsed ALL|Proportion of participants with positive minimal residual disease|Mean of CD20 expression levels|Median CD20 expression levels,https://ClinicalTrials.gov/show/NCT01700946
515,NCT01582672,Phase 3 Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (RCC),"Active, not recruiting",No Results Available,Advanced Renal Cell Carcinoma|Renal Cell Carcinoma|Metastatic Renal Cell Carcinoma,Drug: Standard Treatment|Biological: AGS-003,Argos Therapeutics,Both,"18 Years and older   (Adult, Senior)",Phase 3,450,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,AGS-003-007|2012-000871-17,19-Apr-12,11/1/2012,4/1/2017,1/21/2016,Jan-16,No Study Results Posted,ADAPT,Apr-17,Overall Survival|Progression Free Survival|Tumor Response|Monitor treatment emergent adverse events between both arms,https://ClinicalTrials.gov/show/NCT01582672
971,NCT01784900,Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab,Terminated,No Results Available,Patients With Gastric Peritoneal Carcinomatosis,Drug: Catumaxomab 100µg|Drug: Catumaxomab 140µg,"Gustave Roussy, Cancer Campus, Grand Paris",Both,"18 Years and older   (Adult, Senior)",Phase 2,26,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,2012-000475-17|2011/1793,4-Feb-13,11/1/2012,1/1/2016,2/10/2016,Feb-16,No Study Results Posted,IIPOP,Jan-16,Progression Free Survival,https://ClinicalTrials.gov/show/NCT01784900
1264,NCT01712490,Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma,"Active, not recruiting",No Results Available,Hodgkin Lymphoma,Drug: brentuximab vedotin|Drug: doxorubicin|Drug: bleomycin|Drug: vinblastine|Drug: dacarbazine,"Millennium Pharmaceuticals, Inc.|Seattle Genetics, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 3,1334,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,C25003|2011-005450-60|U1111-1161-4937|12/LO/1950|JapicCTI-142491|REec-2013-0114|1025002760|C25003CTID,19-Oct-12,11/1/2012,3/1/2020,7/19/2016,Jul-16,No Study Results Posted,null,Dec-19,Modified progression free survival (mPFS) per independent review facility (IRF)|Overall survival rate,https://ClinicalTrials.gov/show/NCT01712490
27,NCT02261714,Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer,"Active, not recruiting",No Results Available,"Pancreatic Cancer, Resected",Biological: TG01|Biological: TG01,Targovax ASA,Both,"18 Years to 99 Years   (Adult, Senior)",Phase 1|Phase 2,32,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CT TG01-01,24-Mar-14,12/1/2012,6/1/2018,7/13/2016,Jul-16,No Study Results Posted,null,Jun-18,Patients' safety during study|Patients' Immune response|Clinical Efficacy,https://ClinicalTrials.gov/show/NCT02261714
185,NCT01782287,Proteome-based Immunotherapy of Lung Cancer Brain Metastases,Enrolling by invitation,No Results Available,Neoplasm Metastasis,"Biological: Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|Biological: Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes",NeuroVita Clinic|Blokhin's Russian Cancer Research Center|Russian Foundation of Technological Development|The Serbsky State Scientific Center for Social and Forensic Psychiatry|National Institute of Regenerative Medicine|SRC Bioclinicum,Both,"18 Years to 70 Years   (Adult, Senior)",Phase 2|Phase 3,60,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MCL/2012,30-Jan-13,12/1/2012,12/1/2017,4/21/2015,Apr-15,No Study Results Posted,null,Dec-15,All cause mortality|Complete disappearance of all tumor foci,https://ClinicalTrials.gov/show/NCT01782287
187,NCT01782274,Proteome-based Immunotherapy of Brain Metastases From Breast Cancer,Enrolling by invitation,No Results Available,Neoplasm Metastasis,"Biological: Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|Biological: Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes",NeuroVita Clinic|Blokhin's Russian Cancer Research Center|Russian Foundation of Technological Development|The Serbsky State Scientific Center for Social and Forensic Psychiatry|National Institute of Regenerative Medicine|SRC Bioclinicum,Both,"18 Years to 70 Years   (Adult, Senior)",Phase 2|Phase 3,60,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,BrCr/2012,30-Jan-13,12/1/2012,12/1/2017,4/21/2015,Dec-12,No Study Results Posted,null,Dec-15,All cause mortality|Complete disappearance of all tumor foci,https://ClinicalTrials.gov/show/NCT01782274
414,NCT01640301,"Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant",Recruiting,No Results Available,"Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome|Adult Myelodysplastic Syndrome|Childhood Myelodysplastic Syndrome|Previously Treated Myelodysplastic Syndrome|Recurrent Adult Acute Myeloid Leukemia|Recurrent Childhood Acute Myeloid Leukemia|Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia",Biological: Aldesleukin|Other: Laboratory Biomarker Analysis|Biological: WT1-Sensitized Allogeneic T-Lymphocytes,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),Both,"Child, Adult, Senior",Phase 1|Phase 2,55,Other|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,2498.00|NCI-2011-03362|2498|P01CA018029|P30CA015704,29-Nov-11,12/1/2012,null,3/28/2016,Mar-16,No Study Results Posted,null,Mar-17,"Anti-leukemic potential efficacy, in terms of duration of response (Arm II)|Efficacy, in terms of relapse rate (Arm I)|Incidence of chronic GVHD (Arm I)|Incidence of chronic GVHD (Arm II)|Incidence of grade III-IV acute graft-versus-host disease (GVHD) (Arm I)|Incidence of grade III-IV acute GVHD (Arm II)|Treatment-related toxicity rate, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 4.0 (Arm I)|Treatment-related toxicity rate, graded according to the NCI CTCAE 4.0 (Arm II)|Disease-free survival after T cell therapy|Incidence of relapse after T cell therapy|Maintenance of TCR expression and function of transduced T cells|Persistence and migration of transferred T cells to bone marrow|Time to progression after T cell therapy",https://ClinicalTrials.gov/show/NCT01640301
434,NCT01759810,Proteome-based Personalized Immunotherapy of Glioblastoma,Enrolling by invitation,No Results Available,Glioblastoma,"Biological: Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|Biological: Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes",NeuroVita Clinic|Blokhin's Russian Cancer Research Center|Russian Foundation of Technological Development|The Serbsky State Scientific Center for Social and Forensic Psychiatry|National Institute of Regenerative Medicine|SRC Bioclinicum,Both,"18 Years to 70 Years   (Adult, Senior)",Phase 2|Phase 3,60,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,GBM/2012,28-Dec-12,12/1/2012,12/1/2017,4/21/2015,Apr-15,No Study Results Posted,null,Dec-15,All cause mortality|Complete disappearance of all tumor foci,https://ClinicalTrials.gov/show/NCT01759810
944,NCT02460068,A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis,Recruiting,No Results Available,Brain Metastases,Drug: Fotemustine|Drug: Fotemustine and Ipilimumab|Drug: Ipilimumab and nivolumab,Italian Network for Tumor Biotherapy Foundation|Bristol-Myers Squibb,Both,"18 Years and older   (Adult, Senior)",Phase 3,168,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,NIBIT-M2,22-May-15,12/1/2012,1/1/2020,6/1/2015,May-15,No Study Results Posted,NIBIT-M2,Jan-18,Overall Survival (OS)|safety (adverse events)|m-WHO and immune-related Disease Control Rate (DCR) in and outside the brain|Immune-related Progression-free Survival (irPFS)|m-WHO Progression-free Survival (irPFS)|Objective Response Rate (ORR)|Immune-related Objective Response Rate (irORR)|Time to Response (TTR)|Immune-related Time to Response (irTTR)|Duration of Response (DoR)|Immune-related Duration of Response (irDoR)|Brain progression-free survival (Brain-PFS),https://ClinicalTrials.gov/show/NCT02460068
1053,NCT02525250,Pilot Study Immunomonitoring Natural Killers Cells in Patients With Myeloid Malignancies Treated With Lenalidomide,Completed,No Results Available,Acute Myeloid Leukemia or Myelodysplasic Syndrome,Procedure: Realization of 3 Blood samples during study during treatment with lenalidomide,Institut Paoli-Calmettes,Both,"18 Years and older   (Adult, Senior)",,14,Other,Interventional,Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label,MDS-AML-NK / IPC-2012-007,3-Apr-13,12/1/2012,1/1/2015,8/13/2015,Jul-15,No Study Results Posted,null,Jan-15,Evaluation of NK functions|cytotoxic response therapy,https://ClinicalTrials.gov/show/NCT02525250
1163,NCT01828762,Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy,Completed,No Results Available,Primary Hepatocellular Carcinoma,Biological: DC-TC+GM-CSF,"Cellular Biomedicine Group Ltd.|No.85 Hospital, Changning, Shanghai, China|China Cell Technology Ltd. licensed CBMG to conduct the clinical trial as the sponsor in China",Both,"18 Years to 80 Years   (Adult, Senior)",,8,Industry|Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,40420100005,2-Apr-13,12/1/2012,null,12/20/2013,Apr-13,No Study Results Posted,DC-TC,Dec-13,Vital signs，physical examinations and adverse events,https://ClinicalTrials.gov/show/NCT01828762
1170,NCT01656135,Reference Group Trial for The ONE Study,Completed,No Results Available,End-stage Renal Failure|Kidney Graft Rejection,Other: Blood drawing for immune monitoring and questionnaires,University of Regensburg|European Commission,Both,"18 Years and older   (Adult, Senior)",Phase 4,70,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Basic Science,ONErgt11|260687|2011-004301-24,31-Jul-12,12/1/2012,12/1/2015,3/8/2016,Mar-16,No Study Results Posted,null,Dec-15,biopsy-confirmed acute rejection incidence|time to first acute rejection episode|severity of acute rejection episodes|total immunosuppressive burden|incidence of chronic graft dysfunction|incidence of graft loss through rejection|incidence of adverse drug reactions|incidence of major infections|incidence of neoplasia|incidence of patients treated for subclinical acute rejection,https://ClinicalTrials.gov/show/NCT01656135
1256,NCT01683279,A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia,"Active, not recruiting",No Results Available,B Cell Leukemia,Biological: Autologous CD19 CAR+ EGFTt + T cells,Seattle Children's Hospital,Both,"1 Year to 26 Years   (Child, Adult)",Phase 1,18,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PLAT-01,7-Sep-12,12/1/2012,1/1/2031,4/21/2016,Apr-16,No Study Results Posted,null,Jan-31,Number of Participant with Adverse Events|Persistence of the CD19 CAR+ T cells|Determine if there is anti-leukemic activity of the CD19 CAR+ T cells,https://ClinicalTrials.gov/show/NCT01683279
6,NCT01768195,Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy,Recruiting,No Results Available,Hepatitis B,Drug: Entecavir prophylaxis,Peking University,Both,"18 Years and older   (Adult, Senior)",Phase 4,80,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PKU-2012111304,9-Jan-13,1/1/2013,12/1/2016,1/21/2015,Jan-15,No Study Results Posted,null,Dec-15,the incidence of hepatitis B virus reactivation and hepatitis B virus reactivation related hepatitis|the incidence of hepatitis B virus virological response|the incidence of hepatitis B virus serological response|the incidence of hepatitis B virus maintained response|the incidence of hepatitis B virus sustained response|the incidence of hepatitis B virus relapse and relapse related hepatitis,https://ClinicalTrials.gov/show/NCT01768195
68,NCT01777802,Monitoring Anti-Prostate Cancer Immunity Following Stereotactic Body Radiotherapy (SBRT),"Active, not recruiting",No Results Available,Oligometastatic Prostate Cancer,,Mayo Clinic,Male,"18 Years and older   (Adult, Senior)",,20,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,12-008383,24-Jan-13,1/1/2013,6/1/2017,6/25/2016,Mar-16,No Study Results Posted,SBRT,Jan-17,Induction of anti-prostate cancer immunity,https://ClinicalTrials.gov/show/NCT01777802
78,NCT01689974,Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma,Terminated,No Results Available,Metastatic Melanoma,Drug: Ipilimumab|Other: Radiation Therapy and Ipilimumab,New York University School of Medicine,Both,"19 Years to 80 Years   (Adult, Senior)",Phase 2,10,Other,Interventional,Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,S12-02746|NYU S12-02746,18-Sep-12,1/1/2013,3/1/2015,7/30/2015,Jul-15,No Study Results Posted,null,Mar-15,response rates of ipilimumab alone and of ipilimumab with radiation therapy and to estimate the difference between response rates with ipilimumab alone and ipilimumab with radiation therapy,https://ClinicalTrials.gov/show/NCT01689974
102,NCT01859819,Treatment for Advanced B-Cell Lymphoma,Recruiting,No Results Available,Diffuse Large Cell Lymphoma|Burkitt's Lymphoma|High Grade B-cell Lymphoma,Drug: Rituximab|Drug: IT Cytarabine,New York Medical College,Both,"3 Years to 31 Years   (Child, Adult)",Phase 2,24,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,"NYMC-157|L 10,753",16-Apr-13,1/1/2013,12/1/2018,7/29/2016,Jul-16,No Study Results Posted,REBOOT,Dec-17,"To determine if disease response rate will improve with this combination of therapy.|To determine if the combination of IT Depocyte®, Rituximab and FAB Chemotherapy is safe.",https://ClinicalTrials.gov/show/NCT01859819
197,NCT01570036,Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax,Recruiting,No Results Available,Breast Cancer,Drug: Herceptin|Drug: NeuVax vaccine|Drug: GM-CSF,"George E. Peoples|Genentech, Inc.|Galena Biopharma, Inc.|Cancer Insight, LLC",Female,"18 Years and older   (Adult, Senior)",Phase 2,300,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention,368255|1137008 / 20130058,25-Mar-12,1/1/2013,12/1/2018,12/1/2015,Dec-15,No Study Results Posted,null,Dec-16,Disease-free survival (DFS)|Cardiac toxicity|Local and systemic toxicities,https://ClinicalTrials.gov/show/NCT01570036
694,NCT01754376,Combined BRAF-Targeted Therapy & Immunotherapy for Melanoma,"Active, not recruiting",No Results Available,Melanoma,Drug: Aldesleukin|Drug: Vemurafenib,Massachusetts General Hospital,Both,"18 Years and older   (Adult, Senior)",Phase 2,49,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,12-343,16-Dec-12,1/1/2013,null,3/20/2016,Mar-16,No Study Results Posted,null,Feb-15,"Efficacy of Vemurafenib + Aldesleukin|Determine Response Rates (Complete, Partial and Durable)|Overall Survival|Toxicity and Safety of Aldesleukin and Vemurafenib|Confirm Pre-Clinical Data|Exploration of Biomarkers",https://ClinicalTrials.gov/show/NCT01754376
771,NCT01801852,Autologous Natural Killer T Cells Infusion for the Treatment of Cancer,Recruiting,No Results Available,Breast Cancer|Glioma|Hepatocellular Cancer|Squamous Cell Lung Cancer|Pancreatic Cancer|Colon Cancer|Prostate Cancer,Biological: NKT cells,Chinese PLA General Hospital|Tsinghua University,Both,"18 Years to 90 Years   (Adult, Senior)",,300,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CHN-PLAGH-BT-003,22-Feb-13,1/1/2013,6/1/2017,1/26/2016,Jan-16,No Study Results Posted,null,May-16,Occurrence of study related adverse events|Anti-tumor responses to NKT cells infusions,https://ClinicalTrials.gov/show/NCT01801852
808,NCT01760499,"Detection of Immune Cell Infiltration Into Melanomas Treated by PV-10, a Feasibility Study","Active, not recruiting",No Results Available,Melanoma,Drug: PV-10|Procedure: Surgery,H. Lee Moffitt Cancer Center and Research Institute|Provectus Pharmaceuticals,Both,"18 Years and older   (Adult, Senior)",Phase 1,15,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MCC-17183,21-Dec-12,1/1/2013,12/1/2016,5/6/2016,May-16,No Study Results Posted,null,Dec-16,Occurrence of Change in Infiltration of Immune Cells|Frequency and Phenotype of Circulating Immune Cells in Peripheral Blood Mononuclear Cells (PBMC)|Titer of Anti-tumor IgG in the Serum|Occurrence of Adverse Events (AEs),https://ClinicalTrials.gov/show/NCT01760499
976,NCT01781520,Study of S-1 Plus DC-CIK for Patients With Unresectable Locally Advanced Pancreatic Cancer,Recruiting,No Results Available,Pancreatic Cancer,Other: S-1 plus DC-CIK,Capital Medical University,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,30,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,S1+DC CIK-P,30-Jan-13,1/1/2013,12/1/2017,1/27/2016,Jan-16,No Study Results Posted,null,Dec-16,Progression free survival（PFS）|Two year survival rate|Adverse events|Response rate|Quality of life,https://ClinicalTrials.gov/show/NCT01781520
1027,NCT01724866,Phase 2 Study of HM10460A or Pegfilgrastim Use for the Management of Neutropenia in Breast Cancer Patients,Completed,No Results Available,Neutropenia,Drug: HM10460A (45 μg/kg)|Drug: HM10460A (135 μg/kg)|Drug: HM10460A (270 μg/kg)|Drug: Pegfilgrastim 6mg,"Spectrum Pharmaceuticals, Inc",Both,"18 Years and older   (Adult, Senior)",Phase 2,148,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,SPI-GCF-12-201,24-Oct-12,1/1/2013,12/1/2014,5/26/2015,May-15,No Study Results Posted,null,Dec-14,Duration of severe neutropenia (DSN) in Cycle 1|Effect of Test Doses of HM10460A,https://ClinicalTrials.gov/show/NCT01724866
1069,NCT01636388,Allogeneic Stem Cell Transplantation With Adoptive Immunotherapy in Epstein-Barr Virus Positive Recurrent/Refractory Hodgkins Lymphoma,Recruiting,No Results Available,Hodgkins Lymphoma,Biological: allogeneic donor derived LMP specific cytotoxic T-lymphocyte,New York Medical College|Children's Research Institute|Baylor College of Medicine|M.D. Anderson Cancer Center|Beckman Research Institute|Johns Hopkins University|Ohio State University|University of Utah|University of Michigan,Both,"up to 45 Years   (Child, Adult)",Phase 2,45,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NYMC-553,26-Jun-12,1/1/2013,12/1/2017,3/23/2016,Mar-16,No Study Results Posted,null,Dec-16,Safety|Toxicity|Feasibility,https://ClinicalTrials.gov/show/NCT01636388
1134,NCT02209857,The Symphony Triple A Study: Using Symphony in Treatment Decisions Concerning Adjuvant Systemic Therapy,Recruiting,No Results Available,Breastcancer|Invasive Breast Carcinoma by Gene Expression Profile,,"Diakonessenhuis, Utrecht|Agendia",Female,"18 Years and older   (Adult, Senior)",,600,Other|Industry,Observational,Observational Model: Case Control|Time Perspective: Prospective,DIAK-TrA-20121,24-Jul-14,1/1/2013,12/1/2015,8/24/2015,May-15,No Study Results Posted,Symphony,Oct-15,"Frequency of adjuvant chemotherapy|Changes in adjuvant systemic treatment decisions due to MammaPrint use|Influence of BluePrint and TargetPrint on adjuvant systemic treatment decisions|Clinical utility of MammaPrint in multicentric/contralateral disease.|Concordance of TargetPrint results with locally assessed ICH/FISH ER, PR and Her2 results|Comparison of clinical subtype with BluePrint molecular subtype",https://ClinicalTrials.gov/show/NCT02209857
1238,NCT01714817,Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis,"Active, not recruiting",No Results Available,Lupus Nephritis,Biological: BMS-188667|Drug: Mycophenolate mofetil|Drug: Prednisone|Biological: Placebo matching with BMS-188667,Bristol-Myers Squibb,Both,"18 Years and older   (Adult, Senior)",Phase 3,400,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",IM101-291|2012-000714-11,24-Oct-12,1/1/2013,5/1/2019,7/26/2016,Jan-16,No Study Results Posted,null,Mar-17,"Proportion of subjects achieving Complete Response of renal disease following 52 weeks of treatment, where complete response is a composite endpoint based on renal function, proteinuria, urine sediment, and corticosteroid dose|Proportion of nephrotic subjects in complete renal response of lupus glomerulonephritis|Mean change in Urine Protein Creatinine ratio (UPCR) from baseline in nephrotic subjects|Mean change in UPCR from baseline in overall population|Proportion of subjects with complete renal response of lupus glomerulonephritis in overall population|Proportion of subjects with ranked outcome of complete renal response, partial renal response and no response|Time to achieving first complete renal response during the double-blind period|Time to achieving first partial renal response during the double-blind period|Proportion of subjects meeting each of the components of PR and CR over time during the double-blind period|Mean change from baseline in disease activity as measured by BILAG 2004 over time during the double-blind period|Time to and proportion of subjects with sustained change to lower level of response, ie, CR to PR or NR, PR to NR during the double-blind period|Time to first lupus treatment failure and proportion of subjects in lupus treatment failures overall, and after achievement of CR or PR during the double-blind period|Time to first overall treatment failure and proportion of subjects in lupus treatment failure overall, and after achievement of CR or PR during the double-blind period|Safety assessments based on All adverse events (AEs/SAEs)|Safety assessments based on AEs of interest (infections, malignancies, autoimmune disorders, and infusional reactions)|Safety assessments based on AEs of interest (injection site reactions)|Safety assessments based on Vital signs|Safety assessments based on Laboratory test abnormalities|Immunogenicity assessment based on Proportion of subjects with abatacept induced antibody response over time in the double blind period|Cmin (µg/mL): Trough level serum concentration of abatacept prior to the administration of the intravenous infusion|Cmax (µg/mL): Maximum observed serum concentration following subjects receiving active abatacept IV|AUC (TAU) (µg•h/mL): Area under the serum concentration time curve over a dosing interval",https://ClinicalTrials.gov/show/NCT01714817
11,NCT01809600,Retrospective Analysis of Rituximab-containing Immunochemotherapy for Burkitt's or Burkitt-like Lymphoma in Adults,Recruiting,No Results Available,Burkitt's Lymphoma|High-grade B-cell Lymphoma,Other: No intervention (observational study),Gachon University Gil Medical Center,Both,"20 Years and older   (Adult, Senior)",,55,Other,Observational,Observational Model: Case-Only|Time Perspective: Retrospective,CISL-1203,8-Mar-13,2/1/2013,8/1/2013,3/11/2013,Mar-13,No Study Results Posted,RBL,May-13,Event-free survival|complete response rate|overall survival|Grade 4 hematologic toxicities,https://ClinicalTrials.gov/show/NCT01809600
112,NCT01727076,"Recombinant Interleukin-15 in Treating Patients With Advanced Melanoma, Kidney Cancer, Non-small Cell Lung Cancer, or Squamous Cell Head and Neck Cancer","Active, not recruiting",No Results Available,Head and Neck Squamous Cell Carcinoma|Recurrent Head and Neck Carcinoma|Recurrent Non-Small Cell Lung Carcinoma|Recurrent Renal Cell Carcinoma|Recurrent Skin Carcinoma|Stage III Renal Cell Cancer|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIA Skin Melanoma|Stage IIIB Non-Small Cell Lung Cancer|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Non-Small Cell Lung Cancer|Stage IV Renal Cell Cancer|Stage IV Skin Melanoma,Other: Laboratory Biomarker Analysis|Other: Pharmacological Study|Biological: Recombinant Human Interleukin-15,National Cancer Institute (NCI),Both,"19 Years and older   (Adult, Senior)",Phase 1,30,NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NCI-2012-02205|CITN11-02|U01CA154967,12-Nov-12,2/1/2013,null,5/5/2016,May-16,No Study Results Posted,null,Jun-16,"MTD defined as the next lower dose in which 1 or more patients experiences a dose limiting toxicity defined as grade 3 or 4 toxicity graded according to the NCI Common Terminology Criteria for Adverse Events version 4.0|ALC, monitored daily during treatment|Change in NK cell function measured using flow cytometric analysis of cytokine (IFN-y) secretion and expression of degranulation marker CD107a|Change in presence of auto-antibodies, assessed by ELISA|Change in T cell responses to non- physiologic stimuli including PMA|Change in T cell subset response to recall viral antigens including CMV and influenza A virus, determined by enzyme-linked immunosorbent spot assay|Change in total number of T cells and NK cells, as well as activated T cells, T cell subsets, and NK cell subsets, assessed by flow cytometric analysis of peripheral blood mononuclear cells|ORR based on RECIST criteria|Serum PK of IL15 and IL15 receptor-alpha, assessed by enzyme linked immunosorbent assay (ELISA)|Total white blood cell count, monitored daily during treatment",https://ClinicalTrials.gov/show/NCT01727076
125,NCT01774578,Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer,"Active, not recruiting",No Results Available,Non-small Cell Lung Cancer|Progression of Non-small Cell Lung Cancer|Non-small Cell Lung Cancer Recurrent,Drug: Docetaxel|Biological: HyperAcute®-Lung Immunotherapy|Drug: Gemcitabine|Drug: Pemetrexed,NewLink Genetics Corporation,Both,"18 Years and older   (Adult, Senior)",Phase 2|Phase 3,135,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,NLG0301|1209-1184,7-Jan-13,2/1/2013,null,5/11/2016,May-16,No Study Results Posted,null,Dec-16,Overall survival|Dosing schedule|Tumor response rate|Immunologic Response,https://ClinicalTrials.gov/show/NCT01774578
236,NCT01758458,Viral Oncoprotein Targeted Autologous T Cell Therapy for Merkel Cell Carcinoma,Terminated,No Results Available,Recurrent Merkel Cell Carcinoma|Stage IV Merkel Cell Carcinoma,Biological: Aldesleukin|Other: Laboratory Biomarker Analysis|Biological: MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells|Radiation: Radiation Therapy|Biological: Recombinant Interferon Beta,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,4,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2586.00|NCI-2012-02779|2586|P30CA015704,27-Dec-12,2/1/2013,null,6/7/2016,Jun-16,No Study Results Posted,null,May-16,"Evidence and nature of toxicity related to the study treatment assessed using National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0|Evidence of response based on ""median time to new metastasis""|Disease response by RECIST criteria|Functional capacity of transferred T cells|MCC-specific survival|Persistence of transferred T cells in blood and in tumor",https://ClinicalTrials.gov/show/NCT01758458
395,NCT01738139,Ipilimumab and Imatinib Mesylate in Advanced Cancer,Recruiting,No Results Available,Advanced Cancers,Drug: Ipilimumab|Drug: Imatinib Mesylate,M.D. Anderson Cancer Center,Both,"15 Years and older   (Child, Adult, Senior)",Phase 1,96,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2012-0784|NCI-2013-00030,28-Nov-12,2/1/2013,null,2/10/2016,Feb-16,No Study Results Posted,null,Feb-18,Maximum Tolerated Dose (MTD) of Ipilimumab and Imatinib Mesylate,https://ClinicalTrials.gov/show/NCT01738139
481,NCT01862900,Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions,Recruiting,No Results Available,Metastatic Breast Cancer|Lung Metastases|Liver Metastases,Biological: MEDI6469,"Providence Health & Services|Robert W. Franz Cancer Center|Providence Cancer Center|Providence Cancer Center, Earle A. Chiles Research Institute|MedImmune LLC",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,40,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,12-017A,22-May-13,2/1/2013,2/1/2023,6/23/2016,Jun-16,No Study Results Posted,OX40 Breast,Feb-18,Determine the maximum tolerated dose and safety profile of radiation administered in combination with anti-OX40 in patients with metastatic breast cancer.|Estimate the response rate of combined modality treatment in both irradiated and non-irradiated tumors.,https://ClinicalTrials.gov/show/NCT01862900
710,NCT01774409,Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer,Recruiting,No Results Available,Neoplasms,Genetic: Blood and tumor samples,Centre Leon Berard,Both,"Child, Adult, Senior",,2000,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic,PROFILER|ET12-082,16-Jan-13,2/1/2013,7/1/2020,4/4/2016,Apr-16,No Study Results Posted,PROFILER,Jul-17,"Establish a map of genetic profiles (for the pre-identified target genes) for all types of advanced malignant tumors.|Establish a map of immunologic profiles for all types of advanced malignant tumors.|Determine for each histological type of tumor, characteristic profiles of genetic and/or immunologic disorders and disorders that might be common to several histological types.|Identify genetic and/or immunologic biomarkers (or molecular profiles) with a potential predictive value on response to treatments.|Identify biomarkers (constitutional or somatic alterations in tumor cells) that might be correlated with systemic or local alterations of the immunity status observed in some patients with advanced cancers|Assess the changes of genetic and/or immunologic profiles in case of progressive disease",https://ClinicalTrials.gov/show/NCT01774409
779,NCT01769222,"Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer",Suspended,No Results Available,Adult Nasal Type Extranodal NK/T-cell Lymphoma|Anaplastic Large Cell Lymphoma|Angioimmunoblastic T-cell Lymphoma|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Hepatosplenic T-cell Lymphoma|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Peripheral T-cell Lymphoma|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Adult T-cell Leukemia/Lymphoma|Recurrent Colon Cancer|Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Melanoma|Recurrent Mycosis Fungoides/Sezary Syndrome|Recurrent Rectal Cancer|Recurrent Small Lymphocytic Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|T-cell Large Granular Lymphocyte Leukemia|Testicular Lymphoma|Waldenström Macroglobulinemia,Biological: ipilimumab|Radiation: radiation therapy|Other: laboratory biomarker analysis,Stanford University|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,69,Other|NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,VAR0090|NCI-2012-02988,14-Jan-13,2/1/2013,null,11/19/2013,Nov-13,No Study Results Posted,null,Mar-15,"Safety as the percentage of patients experiencing dose limiting toxicities (DLTs) or serious adverse events using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I)|Immune response (Phase II)|Response rate (complete response [CR], partial response [PR], stable disease [SD]) calculated based on the Response Evaluation Criteria in Solid Tumors (RECIST)/RECIST Immunotherapy and Cheson criteria (Phase II)|Overall survival (Phase II)|Duration of response (Phase II)",https://ClinicalTrials.gov/show/NCT01769222
974,NCT01783951,Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer,Recruiting,No Results Available,Gastric Cancer,Other: S-1 plus DC-CIK,Capital Medical University,Both,"18 Years to 80 Years   (Adult, Senior)",Phase 1|Phase 2,30,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,S1+DC CIK- G,1-Feb-13,2/1/2013,12/1/2017,1/27/2016,Jan-16,No Study Results Posted,null,Dec-16,Progression free survival（PFS）|Overall survival|Response rate|Adverse Events|Quality of life,https://ClinicalTrials.gov/show/NCT01783951
1132,NCT01740297,Ipilimumab With or Without Talimogene Laherparepvec in Unresected Melanoma,"Active, not recruiting",No Results Available,Melanoma,Drug: Talimogene laherparepvec plus ipilimumab|Drug: Ipilimumab,Amgen,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,217,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,20110264,14-Nov-12,2/1/2013,2/1/2019,3/28/2016,Mar-16,No Study Results Posted,null,Aug-16,Safety and Tolerability|Efficacy|Safety,https://ClinicalTrials.gov/show/NCT01740297
287,NCT01884168,Study of Gene Expression Profiling and Immunological Mechanism Affects the Response of Immunotherapy,Recruiting,No Results Available,Malignant Tumor,Biological: Dc-CIK immunotherapy,Capital Medical University,Both,"18 Years to 80 Years   (Adult, Senior)",,30,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,GIMCEI,19-Jun-13,3/1/2013,5/1/2017,1/27/2016,Jan-16,No Study Results Posted,null,Dec-16,Immunotherapy response,https://ClinicalTrials.gov/show/NCT01884168
506,NCT01685606,Study of Infusion of Blood Cells (Lymphocytes) to Stimulate the Immune System to Fight Leukemia/Lymphoma,Terminated,Has Results,Mantle Cell Lymphoma|Diffuse Large Cell Lymphoma|Burkitts Lymphoma|T Cell Lymphomas|Acute Myeloid Leukemia/Acute Lymphoblastic Leukemia,Biological: cellular immunotherapy,Brown University,Both,"18 Years and older   (Adult, Senior)",Phase 2,6,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,BrUOG 273,12-Sep-12,3/1/2013,6/1/2015,7/17/2015,Jul-15,4-Jun-15,273,Jun-15,Overall Response Rate of Cellular Immune Therapy With HLA Haploidentical Peripheral Blood Pheresed Cells in Patients With Relapsed/Refractory Hematological Malignancies.|To Evaluate the Rate of Dose Limiting Toxicities of HLA Haploidentical Peripheral Blood Pheresed Cellular Infusions.,https://ClinicalTrials.gov/show/NCT01685606
519,NCT01814046,Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma,Recruiting,No Results Available,Metastatic Ocular Melanoma|Metastatic Uveal Melanoma,Drug: Aldesleukin|Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Young TIL,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"16 Years to 75 Years   (Child, Adult, Senior)",Phase 2,57,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,130093|13-C-0093,15-Mar-13,3/1/2013,5/1/2019,6/17/2016,Jun-16,No Study Results Posted,null,May-17,Determine whether objective reponses can be mediated in patients with ocular melonoma treated with young TIL with or without high dose aldesleukin,https://ClinicalTrials.gov/show/NCT01814046
713,NCT01810016,NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma,Terminated,No Results Available,Unresectable or Metastatic Melanoma,Biological: Ipilimumab|Biological: NY-ESO-1 Protein Vaccine|Biological: NY-ESO-1 OLP4 Vaccine,"Ludwig Institute for Cancer Research|Institute of Cancer Research, United Kingdom",Both,"18 Years and older   (Adult, Senior)",Phase 1,27,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,LUD2012-004,8-Mar-13,3/1/2013,12/1/2016,6/16/2016,Jun-16,No Study Results Posted,null,Mar-16,Safety and tolerability according to the National Cancer Institute CTCAE v4.0|Immune Response|Tumor Response by the immune-related Response Criteria (irRC)|Tumor Microenvironment,https://ClinicalTrials.gov/show/NCT01810016
813,NCT01813214,The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma,Recruiting,No Results Available,Melanoma,Drug: Vemurafenib,"Georgetown University|Genentech, Inc.|Melanoma Research Alliance",Both,"18 Years and older   (Adult, Senior)",Phase 2,15,Other|Industry,Interventional,Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MLN28305,12-Mar-13,3/1/2013,12/1/2016,7/28/2016,Jul-16,No Study Results Posted,null,Dec-16,Time course by which vemurafenib increases T cell infiltration|Activation state tumor-infiltrating T cells|Expression of immunoinhibitory proteins|Lysis of tumor cells|Presence of tumor associated immune signatures|Changes in endothelial homing receptor ligands and tumor associated chemokines|Presence of immune/inflammatory expression pattern|Presence of tissue-specific destruction and IFN-gamma upregulation|IFN-gamma upregulation and TSD expression patterns relative to baseline,https://ClinicalTrials.gov/show/NCT01813214
1034,NCT01728207,Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL,Recruiting,No Results Available,Non-hodgkin's Lymphoma|Follicular Lymphoma|Mantle Cell Lymphoma|Marginal Zone Lymphoma|Chronic Lymphocytic Leukemia|Small Lymphocytic Lymphoma,Drug: IMMU-114,"Immunomedics, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1,100,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IMMU-114-01,13-Nov-12,3/1/2013,8/1/2017,1/28/2016,Jan-16,No Study Results Posted,null,Mar-17,Safety|Efficacy,https://ClinicalTrials.gov/show/NCT01728207
820,NCT01890980,Phase II Study of Adjuvant WT-1 Analog Peptide Vaccine in MPM Patients After MSK10-134,"Active, not recruiting",No Results Available,Malignant Pleural Mesothelioma,Biological: WT-1-vaccine Montanide + GM-CSF|Biological: Montanide adjuvant + GM-CSF,M.D. Anderson Cancer Center|U.S. Army Medical Research and Materiel Command|Memorial Sloan Kettering Cancer Center|Sellas Life Sciences Group,Both,"18 Years and older   (Adult, Senior)",Phase 2,60,Other|U.S. Fed|Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",2011-0289|HRPO Log Number A-15872|NCI-2010-02375|W81XWH-10-1-0699,27-Jun-13,4/1/2013,null,3/30/2016,Mar-16,No Study Results Posted,null,Dec-17,1-Year Progression Free Survival,https://ClinicalTrials.gov/show/NCT01890980
1275,NCT01586455,Human Placental-Derived Stem Cell Transplantation,Recruiting,No Results Available,Mucopolysaccharidosis I|Mucopolysaccharidosis VI|Adrenoleukodystrophy|Niemann-Pick Disease|Metachromatic Leukodystrophy|Wolman Disease|Krabbe's Disease|Gaucher's Disease|Fucosidosis|Batten Disease|Severe Aplastic Anemia|Diamond-Blackfan Anemia|Amegakaryocytic Thrombocytopenia|Myelodysplastic Syndrome|Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia,Drug: Human Placental Derived Stem Cell,New York Medical College,Both,"up to 55 Years   (Child, Adult)",Phase 1,30,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,"NYMC 550|NYMC IRB L-10,733",25-Apr-12,4/1/2013,12/1/2019,7/29/2016,Jul-16,No Study Results Posted,HPDSC,Dec-18,Safety|donor chimerism|engraftment|Survival|Relapse|Mortality,https://ClinicalTrials.gov/show/NCT01586455
71,NCT01836432,Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer,"Active, not recruiting",No Results Available,Pancreatic Cancer|Pancreatic Carcinoma Non-resectable|Locally Advanced Malignant Neoplasm,Drug: FOLFIRINOX|Biological: Algenpantucel-L Immunotherapy|Radiation: 5-FU Chemoradiation|Drug: Gemcitabine|Drug: Capecitabine|Drug: Nab-Paclitaxel,NewLink Genetics Corporation,Both,"18 Years and older   (Adult, Senior)",Phase 3,302,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,NLG0505|1210-1195,17-Apr-13,5/1/2013,6/1/2017,12/21/2015,Dec-15,No Study Results Posted,PILLAR,Dec-16,Overall Survival|Progression Free Survival|Frequency and grade of adverse events of FOLFIRINOX or gemcitabine/nab-paclitaxel in combination with algenpantucel-L Immunotherapy versus FOLFIRINOX or gemcitabine/nab-paclitaxel alone|Immune Response,https://ClinicalTrials.gov/show/NCT01836432
251,NCT01871480,CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer,Terminated,No Results Available,Non-Small Cell Lung Cancer,Drug: Group A:cytokine-induced killer cell +gefitinib|Drug: Group B:Gefitinib,Kunming Medical University,Both,"18 Years to 80 Years   (Adult, Senior)",Phase 2,50,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CIK plus gefitinib,4-Jun-13,5/1/2013,5/1/2016,12/26/2013,Dec-13,No Study Results Posted,null,Nov-15,Progression-free survival|Overall survival,https://ClinicalTrials.gov/show/NCT01871480
337,NCT01906632,Gene Expression Profiling of Malignant Tumor Predict the Therapeutic Response of DC-CIK Immunotherapy,Recruiting,No Results Available,Malignant Tumor,Biological: DC-CIK Immunotherapy,Capital Medical University,Both,"18 Years to 80 Years   (Adult, Senior)",,50,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,GIMC,21-Jul-13,5/1/2013,12/1/2016,10/13/2015,Oct-15,No Study Results Posted,null,Jun-16,T-Cell Receptor/B-Cell Receptor gene expression,https://ClinicalTrials.gov/show/NCT01906632
567,NCT01685489,A Phase 1b Dose Escalation Trial of PSK®/Placebo With Docetaxel to Treat Metastatic Castration-resistant Prostate Cancer,Withdrawn,No Results Available,Prostatic Neoplasms,"Drug: Docetaxel, PSK®|Drug: Docetaxel, Placebo",Bastyr University|University of Washington|Fred Hutchinson Cancer Research Center,Male,"18 Years and older   (Adult, Senior)",Phase 1,0,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",1U19AT006028-01A1,6-Sep-12,5/1/2013,null,10/23/2015,Oct-15,No Study Results Posted,null,null,Determine tolerability dose of PSK alone and in combination with docetaxel|Determine maximum tolerated dose and recommended phase 2 dose of PSK in combination with docetaxel|Pharmacokinetics of docetaxel when combined with oral PSK|Pharmacokinetics of oral PSK dosing and in combination with docetaxel|Immunological laboratory analysis|Clinical tumor markers|Prostatic acid phosphatase,https://ClinicalTrials.gov/show/NCT01685489
593,NCT01875250,Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer,"Active, not recruiting",No Results Available,Prostate Cancer,Biological: PROSTVAC-F/TRICOM|Biological: PROSTVAC-V/TRICOM|Drug: Enzalutamide (Xtandi),National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Male,"18 Years to 100 Years   (Adult, Senior)",Phase 2,38,NIH,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,130153|13-C-0153,7-Jun-13,5/1/2013,10/1/2017,5/11/2016,Mar-16,No Study Results Posted,null,Oct-16,Decrease in tumor re-growth rate|Immune response|Determine impact on PSA,https://ClinicalTrials.gov/show/NCT01875250
647,NCT01867333,Enzalutamide With or Without Vaccine Therapy for Advanced Prostate Cancer,Recruiting,No Results Available,Prostate Cancer,Biological: PROSTVAC-F/TRICOM|Biological: PROSTVAC-V/TRICOM|Drug: Enzalutamide (Xtandi),National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Male,"18 Years to 100 Years   (Adult, Senior)",Phase 2,76,NIH,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,130146|13-C-0146,30-May-13,5/1/2013,1/1/2018,5/11/2016,Mar-16,No Study Results Posted,null,Jan-17,Increase in time to progression|Increase in overall survival|Delay in PSA progression|Immune response,https://ClinicalTrials.gov/show/NCT01867333
667,NCT01875601,NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors,Completed,No Results Available,Solid Tumors|Brain Tumors|Sarcoma|Pediatric Cancers|Neuroblastoma,Biological: Recombinant human interleukin-15 (rhIL-15)|Biological: NK Cell Infusion,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"2 Years to 25 Years   (Child, Adult)",Phase 1,16,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,130152|13-C-0152,11-Jun-13,5/1/2013,9/1/2015,6/4/2016,Jun-16,No Study Results Posted,null,Sep-15,Toxicity|Feasibility|Antitumor activity,https://ClinicalTrials.gov/show/NCT01875601
870,NCT01865617,"Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia",Recruiting,No Results Available,Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Non-Hodgkin Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Non-Hodgkin Lymphoma|Refractory Small Lymphocytic Lymphoma,Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes|Other: Laboratory Biomarker Analysis,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,145,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2639.00|NCI-2013-00073|2639|P30CA015704|R01CA136551,28-May-13,5/1/2013,null,4/29/2016,Apr-16,No Study Results Posted,null,Apr-29,"Death within 8 weeks of the study cell infusion thought to be definitely or probably related to CAR T cell therapy|Duration of persistence of adoptively transferred CD19 CAR-T cells|Highest dose of T cells that is estimated to result in grade 3 or greater toxicity, using Common Terminology Criteria for Adverse Events version 4.0, in less than or equal to 1/3 patients|Migration of adoptively transferred CD19 CAR-T cells|Objective response rate of complete remission and partial remission|Overall survival|Progression free survival",https://ClinicalTrials.gov/show/NCT01865617
1009,NCT01860937,T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia,Recruiting,No Results Available,Relapsed B-Cell Acute Lymphoblastic Leukemia,Procedure: leukapheresis or collection of PBMCs|Drug: cyclophosphamide based chemotherapy regimens|Biological: modified T cells,Memorial Sloan Kettering Cancer Center|Dana-Farber Cancer Institute:Dana- Farber/Children's Hospital,Both,"up to 26 Years   (Child, Adult)",Phase 1,24,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,13-052,21-May-13,5/1/2013,5/1/2017,2/8/2016,Feb-16,No Study Results Posted,null,May-17,safety|assess the persistence of modified T cells|the development of B cell aplasia,https://ClinicalTrials.gov/show/NCT01860937
10,NCT01936961,Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors,Withdrawn,No Results Available,Metastatic Non-Small Cell Lung Cancer|Metastatic Colon Cancer|Metastatic Triple Negative Breast Cancer,Drug: CTLA-4 Antibody|Radiation: Hypofractionated Radiotherapy,Western Regional Medical Center,Both,"18 Years and older   (Adult, Senior)",,0,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,13-03,3-Sep-13,6/1/2013,4/1/2014,12/8/2015,Dec-15,No Study Results Posted,I-CREST,Apr-14,Complete Response,https://ClinicalTrials.gov/show/NCT01936961
166,NCT01853878,"A Study to Demonstrate the Benefit of a New Kind of Anti-cancer Treatment [PReferentially Expressed Antigen of MElanoma (PRAME) Immunotherapy] for Patients With Non-Small Cell Lung Cancer (NSCLC), After Removal of Their Tumor","Active, not recruiting",No Results Available,"Lung Cancer, Non-Small Cell",Biological: Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A|Biological: Placebo,GlaxoSmithKline,Both,"18 Years and older   (Adult, Senior)",Phase 2,220,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",116389|2012-002790-55,18-Apr-13,6/1/2013,9/1/2016,7/28/2016,Jul-16,No Study Results Posted,PEARL,Sep-16,"Disease Free Survival (DFS)|Overall Survival (OS)|Lung-cancer-specific survival|Disease Free Survival (DFS) at 2, 3, 4 and 5 years after randomization|Disease-free specific survival (DFSS)|anti-PRAME antibody concentrations at protocol defined timepoints|Occurrence of Adverse Events|Occurrence of abnormal hematological parameters|Occurrence of abnormal biochemical parameters|Occurrence of Serious Adverse Events (SAEs)",https://ClinicalTrials.gov/show/NCT01853878
230,NCT01807065,Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer,"Active, not recruiting",No Results Available,Adenocarcinoma of the Prostate|Bone Metastases|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Soft Tissue Metastases|Stage IV Prostate Cancer,Biological: sipuleucel-T|Radiation: external beam radiation therapy|Other: laboratory biomarker analysis,City of Hope Medical Center|National Cancer Institute (NCI),Male,"18 Years and older   (Adult, Senior)",Phase 2,50,Other|NIH,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,12367|NCI-2013-00542,6-Mar-13,6/1/2013,null,7/29/2016,Jul-16,No Study Results Posted,null,Jun-17,"Percent able, or willing to receive all three infusions of sipuleucel-T immunotherapy, when combining sipuleucel-T with radiation therapy to a single site of metastasis delivered one week prior to beginning of sipuleucel-T therapy|Incidence of toxicities, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0|Measurements of immune responses to PAP, PA2024 and PSA and radiologic responses to therapy",https://ClinicalTrials.gov/show/NCT01807065
310,NCT01863108,Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma,Recruiting,No Results Available,Melanoma|Tumor Vaccines|Effects of Immunotherapy,Biological: GeniusVac-Mel4,"University Hospital, Grenoble|Etablissement Français du Sang|Institut National de la Santé Et de la Recherche Médicale, France|Université Joseph Fourier",Both,"18 Years and older   (Adult, Senior)",Phase 1,15,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,DCIC 11 19|2012-003124-20,22-May-13,6/1/2013,11/1/2017,6/28/2016,Jun-16,No Study Results Posted,GeniusVac-Mel4,Jun-17,Tolerability and safety of a multiple sub-cutaneous injections of GeniusVac-Mel4.|Evaluation of the immune response|Evaluation of the clinical response,https://ClinicalTrials.gov/show/NCT01863108
315,NCT01902875,Preconditioning Chemotherapy Combination With Cytokine Induced Killer Cell (CIK) Immunotherapy,Recruiting,No Results Available,Non Small Cell Lung Cancer,Drug: Paclitaxel + Cisplatin|Biological: CIK cell therapy,"Jinling Hospital, China",Both,"40 Years to 70 Years   (Adult, Senior)",,100,Other,Observational,Observational Model: Case Control|Time Perspective: Prospective,NJ0001,14-Jul-13,6/1/2013,null,7/16/2013,Jul-13,No Study Results Posted,null,Dec-14,Disease Control Rate(DCR) and Disease Progression-Free Survival(PFS)|safety and tolerance of patient,https://ClinicalTrials.gov/show/NCT01902875
456,NCT01883518,Autologous Dendritic Cell Vaccine Loaded With Allogeneic Tumor Lysate Expression of Cancer Testis Antigens in Patients With Soft Tissue Sarcoma,Recruiting,No Results Available,"Sarcoma|Neoplasms, Connective and Soft Tissue",Biological: Autologous dendritic cell vaccine,Petrov Research Institute of Oncology,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,48,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MC-01-2013,17-Jun-13,6/1/2013,null,2/3/2015,Feb-15,No Study Results Posted,ADCVCTAST,Sep-15,Achieving a six-month progression free survival (PFS) of patients receiving ADKV with soft tissue sarcomas|Median progression-free survival|Median overall survival|Objective response rate|Toxicity|Assess biological response of tumors,https://ClinicalTrials.gov/show/NCT01883518
513,NCT01891357,Phase II Trial to Validate Markers for a Response Evaluation of a Combined Therapy in Patients With HER2+ Breast Cancer,Recruiting,No Results Available,"Carcinoma, Ductal, Breast",Procedure: Biopsy before and after three weeks of study treatment|Drug: Paclitaxel|Drug: lapatinib|Drug: trastuzumab,West German Study Group|GlaxoSmithKline,Female,"18 Years to 75 Years   (Adult, Senior)",Phase 2,80,Other|Industry,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,WSG-AM07 (Neo-PREDICT-HER2)|2012-003679-21,14-May-13,6/1/2013,12/1/2016,8/6/2015,Aug-15,No Study Results Posted,null,Dec-15,Pathological complete response (pCR)|Event free survival (EFS)|Overall Survival (OS),https://ClinicalTrials.gov/show/NCT01891357
968,NCT01753089,Dendritic Cell Activating Scaffold in Melanoma,Recruiting,No Results Available,Melanoma,Biological: WDVAX,Dana-Farber Cancer Institute,Both,"18 Years and older   (Adult, Senior)",Phase 1,25,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,12-306,17-Dec-12,6/1/2013,6/1/2017,1/19/2016,Jan-16,No Study Results Posted,null,Jun-16,"Feasibility of WDVAX for Metastatic Melanoma|Safety and Biologic Activity of WDVAX|Immune Response|Tumor Response|Survival|Response to subsequent immunotherapy (E.G., anit-CTLA-4 or anti_PD-1mAbs",https://ClinicalTrials.gov/show/NCT01753089
1010,NCT01847274,A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer,Completed,No Results Available,Platinum Sensitive Ovarian Cancer,Drug: Active comparator: Niraparib|Drug: placebo,"Tesaro, Inc.|European Network of Gynaecological Oncological Trial Groups (ENGOT)|Myriad Genetics, Inc.|US Oncology Research|Sarah Cannon|Cooperative Ovarian Cancer Group for Immunotherapy (COGI) Network|Facing Our Risk of Cancer Empowered",Female,"18 Years and older   (Adult, Senior)",Phase 3,597,Industry|Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",PR-30-5011-C,11-Apr-13,6/1/2013,6/1/2016,7/1/2016,Jul-16,No Study Results Posted,null,Jun-16,Progression free survival of ovarian cancer patients|Patient Reported Outcomes|Progression Free Survival Two|Chemotherapy Free Interval|Overall Survival of Ovarian Cancer Patients|Evaluate the safety and tolerability of niraparib in ovarian cancer patients|BRACA diagnostic test|HRD diagnostic test,https://ClinicalTrials.gov/show/NCT01847274
1157,NCT01874054,Study of Brentuximab Vedotin Combined With Bendamustine in Patients With Hodgkin Lymphoma,"Active, not recruiting",No Results Available,Hodgkin Disease,Drug: brentuximab vedotin|Drug: bendamustine,"Seattle Genetics, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,55,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SGN35-016,6-Jun-13,6/1/2013,12/1/2017,6/6/2016,Jun-16,No Study Results Posted,null,Dec-15,Complete remission rate|Incidence of adverse events|Incidence of laboratory abnormalities|Incidence of dose-limiting toxicities|Objective response rate|Duration of response|Progression-free survival,https://ClinicalTrials.gov/show/NCT01874054
1169,NCT01898663,DCs Vaccine Combined With Cytokine-induced Killer Cells in Patients With High-risk Soft Tissue Sarcoma,"Active, not recruiting",No Results Available,High-risk Soft Tissue Sarcoma,Biological: Adenovirus-transfected DC + CIK,Affiliated Hospital to Academy of Military Medical Sciences,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,30,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,307-CTC-DC/CIK,9-Jul-13,6/1/2013,12/1/2016,2/18/2016,Feb-16,No Study Results Posted,null,Dec-16,Objective tumor response (CR+PR) as measured by RECIST criteria|Number of participants with adverse events,https://ClinicalTrials.gov/show/NCT01898663
338,NCT01903083,Chemoimmunotherapy and Radiation in Pancreatic Cancer,"Active, not recruiting",No Results Available,Locally Advanced Malignant Neoplasm,Drug: Tadalafil|Drug: Gemcitabine|Radiation: Radiation|Procedure: Pancreaticoduodenectomy,Providence Health & Services|Eli Lilly and Company,Both,"18 Years and older   (Adult, Senior)",Phase 1,10,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,13-026A,2-Jul-13,7/1/2013,3/1/2017,3/28/2016,Mar-16,No Study Results Posted,CRIT,Dec-16,Safety|Immune Infiltration in pancreaticoduodenectomy tissue|Quantification of T cells in peripheral blood pre- and post-treatment,https://ClinicalTrials.gov/show/NCT01903083
340,NCT01807182,Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma,Recruiting,No Results Available,Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma,Biological: Aldesleukin|Drug: Cyclophosphamide|Drug: Fludarabine Phosphate|Other: Laboratory Biomarker Analysis|Biological: Therapeutic Tumor Infiltrating Lymphocytes,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 2,40,Other|NIH,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2643.00|NCI-2013-00486|2643|P30CA015704,6-Mar-13,7/1/2013,null,6/27/2016,Jun-16,No Study Results Posted,null,Apr-17,"Clinical response, assessed using Response Evaluation Criteria in Solid Tumors 1.1 definitions for complete response, partial response, stable disease, and progressive disease|In vivo persistence of adoptively transferred T cells following TIL infusion|Incidence of adverse events, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Percent expression of biomarkers",https://ClinicalTrials.gov/show/NCT01807182
428,NCT01909752,Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer,Recruiting,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: Cyclophosphamide|Biological: DRibble vaccine|Drug: Imiquimod|Drug: GM-CSF|Biological: HPV vaccine,"UbiVac|National Cancer Institute (NCI)|Providence Cancer Center, Earle A. Chiles Research Institute|Providence Health & Services|Mayo Clinic|Louisiana State University Health Sciences Center in New Orleans",Both,"18 Years and older   (Adult, Senior)",Phase 2,48,Industry|NIH|Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,UbiVac DPV-001|R44CA121612,24-Jul-13,7/1/2013,12/1/2016,5/26/2015,May-15,No Study Results Posted,null,Jul-16,Identify the regimen that produces the strongest antibody response|Safety|Progression free survival|Immune response and progression-free survival correlation.,https://ClinicalTrials.gov/show/NCT01909752
564,NCT02122822,Research for Immunotherapy of Glioblastoma With Autologous Heat Shock Protein gp96,"Active, not recruiting",No Results Available,Glioma,Biological: gp96,"Cure&Sure Biotech Co., LTD|Beijing Tiantan Hospital",Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1,20,Industry|Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CS-TT-G-01,23-Apr-14,7/1/2013,1/1/2018,12/10/2015,Dec-15,No Study Results Posted,null,Jul-15,blood count|blood chemistries|electrocardiogram|progression-free survival rate of six month|tumor control rate|progress free survive|overall survive|quality of life|changes in antigen specific T cells,https://ClinicalTrials.gov/show/NCT02122822
918,NCT01913691,Study of the Drug Ipilimumab for Metastatic Merkel Cell Carcinoma,Withdrawn,No Results Available,Merkel Cell Carcinoma,Drug: Ipilimumab,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years and older   (Adult, Senior)",Phase 2,0,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,130173|13-C-0173,28-Jul-13,7/1/2013,2/1/2014,10/9/2014,Feb-14,No Study Results Posted,null,Feb-14,"Overall survival at 12 months with ipilimumab treatment.|Determine the best overall response rate, median survival, disease-specific survival, and progression free survival.|Determine median survival, disease-specific survival, and progressionfree survival",https://ClinicalTrials.gov/show/NCT01913691
1004,NCT01763164,Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma,"Active, not recruiting",No Results Available,Metastatic or Unresectable Cutaneous Melanoma,Drug: MEK162|Drug: Dacarbazine,Array BioPharma,Both,"18 Years and older   (Adult, Senior)",Phase 3,402,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CMEK162A2301|2012-003593-51,4-Jan-13,7/1/2013,3/1/2017,7/13/2016,Jul-16,No Study Results Posted,null,Dec-15,Progression free survival (PFS)|Overall Survival (OS)|Overall Response Rate (ORR)|Time to Objective Response (TTR)|Duration of objective response (DOR)|Disease control rate (DCR)|Number of patients with adverse events|Number of patients with serious adverse events|Time to definitive 10% deterioration in the global health status score of the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Core 30 (QLQ-C30)|Change from baseline in the global health status score of the EORTC QLQ-C30|Change from baseline in the EQ-5D-5L (EuroQol Group standardised instrument for use as a measure of health outcome),https://ClinicalTrials.gov/show/NCT01763164
1090,NCT01944982,Salvage Therapy With Chemotherapy and Natural Killer Cells in Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma,Recruiting,No Results Available,Relapsed/Refractory Paediatric T Cell Lymphoblastic Leukaemia and Lymphoma,Biological: Expanded haploidentical natural killer cells (NKAEs),"Hospital Infantil Universitario Niño Jesús, Madrid, Spain",Both,"up to 21 Years   (Child, Adult)",Phase 1|Phase 2,10,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,HNJ-NKAES-2012|2012-000054-63,13-Sep-13,7/1/2013,3/1/2017,2/23/2016,Feb-16,No Study Results Posted,HNJ-NKAES-2012,Dec-16,"Safety profile (number of AEs per patient)|Incidence of episodes of febrile neutropenia, bacteriemia or viral or fungal infections|time to hematological recovery (days)|days of hospitalization in each cycle|Objective response rate|days of isolation",https://ClinicalTrials.gov/show/NCT01944982
1156,NCT01902329,A Safety Study of SGN-CD33A in AML Patients,"Active, not recruiting",No Results Available,Acute Myelogenous Leukemia|Acute Myeloid Leukemia|Acute Promyelocytic Leukemia,Drug: HMA|Drug: SGN-CD33A,"Seattle Genetics, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1,195,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,SGN33A-001,15-Jul-13,7/1/2013,12/1/2017,7/22/2016,Mar-16,No Study Results Posted,null,Jun-17,Incidence of adverse events|Incidence of laboratory abnormalities|Blood concentrations of SGN-CD33A and metabolites|Incidence of antitherapeutic antibodies|Rate of complete remission|Duration of complete remission|Relapse-free survival|Overall survival,https://ClinicalTrials.gov/show/NCT01902329
1164,NCT01924156,DC Vaccine Combined With CIK Cells in Patients With Renal Cell Carcinoma,"Active, not recruiting",No Results Available,Renal Cell Carcinoma,Biological: adenovirus-transfected DC + CIK,Affiliated Hospital to Academy of Military Medical Sciences,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,30,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,307-CTC-DC/CIK-RCC,14-Aug-13,7/1/2013,12/1/2016,2/18/2016,Feb-16,No Study Results Posted,null,Dec-16,objective tumor response (CR+PR) as measured by RECIST criteria|number of participants with adverse events,https://ClinicalTrials.gov/show/NCT01924156
876,NCT01818986,Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC),Recruiting,No Results Available,Metastatic Castrate-resistant Prostate Cancer|mCRPC,Drug: Sipuleucel-T|Radiation: Stereotactic Ablative Body Radiation,University of Texas Southwestern Medical Center,Both,"18 Years to 99 Years   (Adult, Senior)",Phase 2,41,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,STU 102012-026,6-Mar-13,8/1/2013,12/1/2018,4/11/2016,Apr-16,No Study Results Posted,null,Dec-16,Time to progression|Immune response,https://ClinicalTrials.gov/show/NCT01818986
1018,NCT01822652,"3rd Generation GD-2 Chimeric Antigen Receptor and iCaspase Suicide Safety Switch, Neuroblastoma, GRAIN","Active, not recruiting",No Results Available,Neuroblastoma,Genetic: iC9-GD2 T Cell Lymphocytes-frozen cells|Genetic: iC9-GD2 T Cell Lymphocytes-fresh cells|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: pembrolizumab|Genetic: iC9-GD2 T Cell Lymphocytes-fresh cells,"Baylor College of Medicine|Center for Cell and Gene Therapy, Baylor College of Medicine|Texas Children's Hospital|The Methodist Hospital System|Solving Kids’ Cancer|The EVAN Foundation|National Cancer Institute (NCI)|Kids' Cancer Research Foundation",Both,"Child, Adult, Senior",Phase 1,11,Other|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,H-31493 GRAIN|P01CA094237,28-Mar-13,8/1/2013,10/1/2030,5/28/2016,May-16,No Study Results Posted,GRAIN,Dec-15,Dose limiting toxicities at 6 weeks post T cell infusion|To evaluate the expansion and persistence of 3rd generation iC9-GD2 T cells|Time to progression of disease|Change in serum cytokine and chemokine levels,https://ClinicalTrials.gov/show/NCT01822652
1099,NCT01920191,Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma,Completed,No Results Available,"CNS Tumor, Adult",Biological: IMA 950|Biological: Poly ICLC|Other: Immunomonitoring,"University Hospital, Geneva|immatics Biotechnologies GmbH|Oncovir, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,19,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IMA950 Poly ICLC,31-Jul-13,8/1/2013,3/1/2016,4/19/2016,Apr-16,No Study Results Posted,null,Mar-16,"Tolerability and safety of IMA950 adjuvanted with Poly-ICLC when given together with temozolomide, using CTCAE V 4.0|6, 9 month progression free survival (PFS) using gadolinium enhanced MRI and clinical assessment according to revised RANO criteria|Overall survival (OS)|Immunologic endpoints",https://ClinicalTrials.gov/show/NCT01920191
1159,NCT02600143,Identification of Predictive Parameters for Colitis in Melanoma Patients Treated With Immunotherapy.,Recruiting,No Results Available,Melanoma|Colitis,,University Medical Center Groningen,Both,"18 Years and older   (Adult, Senior)",,300,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,METc 2012/085,3-Nov-15,8/1/2013,11/1/2017,4/19/2016,Apr-16,No Study Results Posted,COLIPI,Nov-17,Genetic predisposition for immunotherapy-induced colitis|Predictive biomarkers for immunotherapy-induced colitis in stool and serum|Clinical scoring system of colitis|Histological assessment of colon biopsies in patients that develop colitis|Analysis of the gut microbiome in stool samples,https://ClinicalTrials.gov/show/NCT02600143
1254,NCT01369368,Treatment of Acute Leukemia Relapse After Allotransplantation,Recruiting,No Results Available,Acute Myeloid Leukemia,"Drug: Combined use of azacitidine, valproic acid, hydroxurea and eventually donor leukocyte infusions.",University of Bergen,Both,"18 Years to 90 Years   (Adult, Senior)",Phase 1|Phase 2,20,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,Allo-Relapse-2011,7-Jun-11,8/1/2013,10/1/2020,6/23/2015,Jun-15,No Study Results Posted,null,Oct-17,Disease stabilization|Survival,https://ClinicalTrials.gov/show/NCT01369368
70,NCT01881867,CYT107 After Vaccine Treatment (Provenge) in Patients With Metastatic Hormone-Resistant Prostate Cancer,Recruiting,No Results Available,Hormone-Resistant Prostate Cancer|Metastatic Prostate Carcinoma|Recurrent Prostate Carcinoma|Stage IV Prostate Cancer,Biological: Glycosylated Recombinant Human Interleukin-7|Other: Laboratory Biomarker Analysis,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)|Cancer Immunotherapy Trials Network,Male,"18 Years and older   (Adult, Senior)",Phase 2,80,Other|NIH,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CITN12-03|NCI-2013-00998|CITN12-03 IL7|U01CA154967,18-Jun-13,9/1/2013,null,6/6/2016,Jun-16,No Study Results Posted,null,Jan-17,"Quantification of T-cell responses to PAP-GM-CSF, assessed by quantification of interferon gamma levels measured using enzyme-linked immunospot (ELISPOT)|Change in bystander antigen specific immune responses, measured by interferon gamma production in response to various antigens as quantified by ELISPOT|Change in circulating tumor cells|Change in number and percentage of peripheral blood mononuclear cell (PBMC) subsets and T lymphocyte subsets|Change in PSA kinetics evaluated according to the recommendations from PSA Working Group (PSAWG)|Change in T-cell response to PAP-GM-CSF, as measured using interferon-gamma levels quantified by ELISPOT|Change in thymic function, as measured by levels of T-cell receptor rearrangement deoxyribonucleic acid (DNA) excision circles|Change in vaccine-induced antigen-specific antibody immune response to PAP, as measured by change in immunoglobulin G (IgG) and immunoglobulin M (IgM) levels quantified by standard enzyme-linked immunosorbent assay (ELISA)|Change in vaccine-induced antigen-specific antibody immune response to PAP-GM-CSF, as measured by change in IgG and IgM levels quantified by standard ELISA|Incidence of adverse events graded and reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Overall survival|Progression free survival assessed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria for measurable disease by bone scans and radiographic criteria for non-measurable bony metastasis|T-cell diversity, measured by T-cell repertoire characterized by T-cell receptor (TCR) deep sequencing",https://ClinicalTrials.gov/show/NCT01881867
110,NCT01939327,Safety and Efficacy of Revlimid® (Lenalidomide) With Mabthera® (Rituximab) in Non-Hodgkin's Lymphoma,Recruiting,No Results Available,Non-Hodgkin Lymphoma,Drug: Lenalidomide/Rituximab,Institut Paoli-Calmettes,Both,"18 Years and older   (Adult, Senior)",Phase 2,38,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,R2/IPC-2012-004,29-Aug-13,9/1/2013,9/1/2020,2/25/2016,Feb-16,No Study Results Posted,R2,Sep-16,Response Rate|Progression|safety,https://ClinicalTrials.gov/show/NCT01939327
113,NCT01961115,Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma,Recruiting,No Results Available,Mucosal Melanoma|Recurrent Melanoma|Recurrent Uveal Melanoma|Stage IIIA Skin Melanoma|Stage IIIA Uveal Melanoma|Stage IIIB Skin Melanoma|Stage IIIB Uveal Melanoma|Stage IIIC Skin Melanoma|Stage IIIC Uveal Melanoma|Stage IV Skin Melanoma|Stage IV Uveal Melanoma,Drug: Epacadostat|Other: Laboratory Biomarker Analysis|Biological: MELITAC 12.1 Peptide Vaccine,Fred Hutchinson Cancer Research Center|Incyte Corporation|National Cancer Institute (NCI)|University of Virginia,Both,"18 Years and older   (Adult, Senior)",Phase 2,12,Other|Industry|NIH,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CITN-04|NCI-2013-01605|U01CA154967,8-Oct-13,9/1/2013,null,5/12/2016,May-16,No Study Results Posted,null,Oct-16,"Changes in the concentration and number of CD8+ cells infiltrating tumor by IHC|Change in PBMC transcriptome|Change in the number and character of PBMC populations, including T and NK cells, as evaluated by multiparameter flow cytometry|Changes in expression of IDO1 protein by IHC in tumor or tumor-infiltrating cells|Changes in the level or character of the vaccine-induced CD8+ and CD4+ specific T-cell immune responses by IFN-gamma ELISPOT|Incidence of adverse events using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Overall response rate using the RECIST or Immune-Related Response Criteria (irRC)|Overall survival|Time to tumor progression using RECIST or irRC",https://ClinicalTrials.gov/show/NCT01961115
179,NCT01967823,T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer,Suspended,No Results Available,Synovial Sarcoma|Breast Cancer|Non-Small Cell Lung Cancer|Hepatocellular Cancer,Biological: Anti-NY ESO-1 mTCR PBL|Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Aldesleukin,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 70 Years   (Adult, Senior)",Phase 2,7,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,130214|13-C-0214,18-Oct-13,9/1/2013,7/1/2018,5/11/2016,Apr-16,No Study Results Posted,null,Jul-17,Determine whether objective tumor regression can be mediated in patients with metastatic cancers whose tumors express the NY-ESO-1 Antigen who aer treated with anti-NY ESO-1 Antigen who are treated with anti-NY ESO-1 transduced mTCR PBL|Determine the in vivo survival of TCR gene-engineered cells|Determine the toxicity profile of this treatment regimen,https://ClinicalTrials.gov/show/NCT01967823
201,NCT01929499,Efficacy of Adjuvant Cytokine-induced Killer Cells in Colon Cancer,Not yet recruiting,No Results Available,Colonic Neoplasms,Biological: cytokine-induced killer cells,Yanjuan Zhu|Guangdong Provincial Hospital of Traditional Chinese Medicine,Both,"18 Years to 80 Years   (Adult, Senior)",Phase 2,210,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CIKCC,20-Aug-13,9/1/2013,8/1/2019,8/27/2013,Aug-13,No Study Results Posted,CIKCC,Aug-16,DFS (Disease free survival)|OS (overall survival)|Side effect|T lymphocyte subset|QoL (quality of life),https://ClinicalTrials.gov/show/NCT01929499
273,NCT01959672,Combination Chemotherapy With or Without Oregovomab Followed by Stereotactic Body Radiation Therapy and Nelfinavir Mesylate in Treating Patients With Locally Advanced Pancreatic Cancer,Recruiting,No Results Available,Pancreatic Adenocarcinoma|Resectable Pancreatic Cancer|Stage IA Pancreatic Cancer|Stage IB Pancreatic Cancer|Stage IIA Pancreatic Cancer|Stage IIB Pancreatic Cancer|Stage III Pancreatic Cancer,Procedure: 4-Dimensional Computed Tomography|Drug: Fluorouracil|Drug: Gemcitabine Hydrochloride|Other: Laboratory Biomarker Analysis|Drug: Leucovorin Calcium|Drug: Nelfinavir Mesylate|Biological: Oregovomab|Radiation: Stereotactic Body Radiation Therapy|Procedure: Therapeutic Conventional Surgery,University of Nebraska|National Cancer Institute (NCI),Both,"19 Years and older   (Adult, Senior)",Phase 2,66,Other|NIH,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,441-13|NCI-2013-02273|NCI-2013-02118|NCI-2012-00835|P30CA036727,8-Oct-13,9/1/2013,null,5/27/2015,May-15,No Study Results Posted,null,Dec-18,"Rate of progressive disease, defined as at least a 25% increase in the longest diameter of a lesion, taking as reference the longest diameter recorded since the treatment started|Dosimetry|Failure-free survival|Incidence of toxicity, graded by the National Cancer Institute Common Toxicity Criteria version 4.0, reported by frequency and severity|Local control|Organ motion, assessed with 4D CT|Organ motion, assessed with respiratory gating data|Overall survival|Surgical complete resection (negative margin) rate|Survival|Tumor motion, assessed with 4D CT|Tumor motion, assessed with respiratory gating data|Tumor response rate, evaluated on CT/magnetic resonance imaging (MRI) using Response Evaluation Criteria in Solid Tumors|Tumor response rate, evaluated on the pathology specimen",https://ClinicalTrials.gov/show/NCT01959672
733,NCT01963481,Exemestane and Cyclophosphamide for Metastatic Breast Cancer,"Active, not recruiting",No Results Available,Metastatic Beast Cancer,Drug: Exemestane|Drug: Cyclophosphamide,New York University School of Medicine,Both,"18 Years and older   (Adult, Senior)",Phase 2,23,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,S13-00761,11-Oct-13,9/1/2013,9/1/2016,12/11/2015,Dec-15,No Study Results Posted,null,Jul-15,Progression-free survival (PFS) rate at 3 months|Response rate (complete response and partial response)|Clinical benefit rate,https://ClinicalTrials.gov/show/NCT01963481
801,NCT01950273,Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Lymphoma,Completed,No Results Available,"Lymphoma, Follicular",Drug: BI 695500|Drug: MabThera,Boehringer Ingelheim,Both,"18 Years and older   (Adult, Senior)",Phase 1,null,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment,1301.5|2013-001904-12,23-Sep-13,9/1/2013,12/1/2015,1/6/2016,Jan-16,No Study Results Posted,null,Dec-15,Area under the curve (AUC) for BI 695500 and rituximab concentrations|Comparison of AEs between the two study arms|AUC for BI 695500 and rituximab concentrations|Maximum observed concentration of the BI 695500 and rituximab|AUC 0-7 days (area under the depletion-time curve) of the CD19+ B-cells depletion (change from baseline)|Change from baseline of CD19+ B-cells|Tumor response evaluation based on revised International Working Group (IWG) criteria 2007,https://ClinicalTrials.gov/show/NCT01950273
816,NCT01896271,High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer,Recruiting,No Results Available,Metastatic Clear Cell Renal Cell Carcinoma,Drug: IL-2|Radiation: Stereotactic Ablative Body Radiation Therapy,University of Texas Southwestern Medical Center|Prometheus Therapeutics and Diagnostics,Both,"18 Years and older   (Adult, Senior)",Phase 2,26,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,STU 012013-041,5-Jul-13,9/1/2013,12/1/2017,3/19/2015,Mar-15,No Study Results Posted,null,Aug-16,Response rate|Overall survival|Progression free survival|Time to progression|Median response duration|Local control rate|Tumor-specific immune response|Toxicity|Health-related quality of life (HRQoL).,https://ClinicalTrials.gov/show/NCT01896271
913,NCT01815749,Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma,"Active, not recruiting",No Results Available,Adult Grade III Lymphomatoid Granulomatosis|Cutaneous B-cell Non-Hodgkin Lymphoma|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Post-transplant Lymphoproliferative Disorder|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia,Biological: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Procedure: autologous hematopoietic stem cell transplantation|Other: laboratory biomarker analysis,City of Hope Medical Center|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,30,Other|NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,12224|NCI-2013-00590|P50CA107399,19-Mar-13,9/1/2013,null,7/29/2016,Jul-16,No Study Results Posted,null,Sep-18,Adverse events attributed to Tcm adoptive transfer as reported using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|MTD of CD19-CAR-specific/truncated EGFR lentiviral vector-transduced autologous T cells based on dose limiting toxicities|Engraftment of the transferred T cell products|CD19+ B cell precursors in the peripheral blood as a surrogate for the in vivo effector function of transferred CD19-specific T cells,https://ClinicalTrials.gov/show/NCT01815749
960,NCT01955408,Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment,Recruiting,No Results Available,Overactive Bladder|Bladder Cancer|Synergo,"Other: Questionnaires, anticholinergic treatment, urodynamic study",Meir Medical Center,Both,"18 Years and older   (Adult, Senior)",,335,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,SYNERGO-OAB,24-Sep-13,9/1/2013,12/1/2016,3/15/2016,Mar-16,No Study Results Posted,OABSYNERGO,Dec-16,OAB symptoms severity and urodynamic variables in failed medical treatment patients|Synergo treatment variables and OAB severity|OAB severity of symptoms and urodynamic variables in failed medical treatment patients|OAB treatment satisfaction and urodynamic variables in failed medical treatment patients,https://ClinicalTrials.gov/show/NCT01955408
965,NCT01909453,Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma,"Active, not recruiting",No Results Available,Melanoma,Drug: LGX818|Drug: MEK162|Drug: vemurafenib,Array BioPharma,Both,"18 Years and older   (Adult, Senior)",Phase 3,900,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CMEK162B2301,24-Jul-13,9/1/2013,null,7/27/2016,Jul-16,No Study Results Posted,COLUMBUS,Sep-16,Progression free survival (PFS)|Overall Survival (OS)|Progression Free Survival (PFS)|Objective Response Rate (ORR)|Time To Response (TTR)|Disease Control Rate (DCR)|Duration of objective response (DOR)|Safety and tolerability of combination and LGX818|ECOG Performance status (PS)|Time to definitive 1 point deterioration in ECOG performance status|Pharmacokinetics of LGX818 and MEK162|Time to definitive 10% deteriortaion in global health status (EORTC QLQC30)|Global health status (EORTC QLQC30)|Time to definitive 10% deterioration in the FACT-M melanoma subscale|Global health status (EQ-5D),https://ClinicalTrials.gov/show/NCT01909453
1068,NCT01956734,Virus DNX2401 and Temozolomide in Recurrent Glioblastoma,"Active, not recruiting",No Results Available,Glioblastoma Multiforme|Recurrent Tumor,Procedure: DNX2401 and Temozolomide,"Clinica Universidad de Navarra, Universidad de Navarra|DNAtrix, Inc.",Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1,31,Other|Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,D24GBM EudraCT: 2011-005935-21,27-Sep-13,9/1/2013,3/1/2017,11/12/2015,Nov-15,No Study Results Posted,D24GBM,Dec-15,Number of participans with adverse events|Efficacy of the combination: PFS6 and OS12|Tumor response|Quality of life|Biological response,https://ClinicalTrials.gov/show/NCT01956734
1187,NCT01956630,Clinical Study of DC Plus CIK for Patients With Relapse Acute Leukemia After Allo-HSCT,"Active, not recruiting",No Results Available,Acute Leukemia,Biological: Genetically modified DCs plus CIK cells|Biological: Donor leukocyte infusions (DLI),Affiliated Hospital to Academy of Military Medical Sciences,Both,"8 Years to 61 Years   (Child, Adult)",Phase 1|Phase 2,25,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,307-CTC-DC/CIK-Leukemia,23-Sep-13,9/1/2013,12/1/2016,2/18/2016,Feb-16,No Study Results Posted,null,Sep-16,Overall survival|Gvhd incidence,https://ClinicalTrials.gov/show/NCT01956630
1226,NCT01734304,DC Vaccination for Postremission Therapy in AML,Recruiting,No Results Available,Acute Myeloid Leukemia,Biological: DC vaccination for postremission therapy in AML,Ludwig-Maximilians - University of Munich,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1|Phase 2,20,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2010-022446-24,17-Oct-12,9/1/2013,4/1/2019,3/5/2016,Mar-16,No Study Results Posted,null,Apr-17,% of grade I/II and grade III/IV toxicities|Immune responses to applied antigens|Control of minimal residual disease|Time to progression of disease|ECOG performance status,https://ClinicalTrials.gov/show/NCT01734304
561,NCT01924689,Safety Study of Intratumoral Injection of Clostridium Novyi-NT Spores to Treat Patients With Solid Tumors That Have Not Responded to Standard Therapies,Recruiting,No Results Available,Solid Tumor Malignancies,Biological: Clostridium novyi-NT spores,"BioMed Valley Discoveries, Inc",Both,"18 Years and older   (Adult, Senior)",Phase 1,18,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,BVDCNV2,14-Aug-13,10/1/2013,null,3/30/2016,Mar-16,No Study Results Posted,null,Jun-17,"Safety and tolerability of C. novyi-NT spore administration in patients with advanced solid tumor malignancies will be measured over a 8-day inpatient admission with routine labs, imaging (CT or MRI) assessments and continuous adverse event assessments.|Anti-tumor activity of C. novyi-NT spores will be assessed with serial imaging studies such as CT scans, MRI and blood-based tumor markers.|Pharmacokinetics of the C. novyi-NT spores will be measured in routine blood sampling over the course of the study.|The host immune and inflammatory response to C. novyi-NT spores will be measured in routine blood sampling over the course of the study.",https://ClinicalTrials.gov/show/NCT01924689
657,NCT02000947,A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer,Recruiting,No Results Available,NSCLC|Non-small Cell Lung Cancer|Lung Cancer,Drug: MEDI4736|Drug: Tremelimumab|Drug: MEDI4736|Drug: MEDI4736|Drug: MEDI4736|Drug: Tremelimumab|Drug: tremelimumab|Drug: tremelimumab,MedImmune LLC,Both,"18 Years to 99 Years   (Adult, Senior)",Phase 1,446,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,D4190C00006|2015-003715-38,27-Nov-13,10/1/2013,10/1/2018,6/2/2016,Jun-16,No Study Results Posted,D4190C00006,Oct-18,Number of subjects reporting adverse events|Objective response|Number of subjects experiencing dose-limiting toxicities (DLTs)|Immunogenicity of tremelimumab in combination with MEDI4736|Antitumor activity of tremelimumab in combination with MEDI4736|Pharmacokinetic parameters,https://ClinicalTrials.gov/show/NCT02000947
699,NCT01967758,Phase I Study of Safety and Immunogenicity of ADU-623,Recruiting,No Results Available,Astrocytic Tumors|Glioblastoma Multiforme|Anaplastic Astrocytoma|Brain Tumor,Biological: Cohort 1|Biological: Cohort 2|Biological: Cohort 3|Drug: Antibiotics,"Providence Health & Services|Aduro Biotech, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1,38,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,13-012A,18-Oct-13,10/1/2013,4/1/2017,6/23/2016,Jun-16,No Study Results Posted,null,Oct-16,Maximum Tolerated Dose|Tumor response based on magnetic resonance imaging (MRI) exam|Immune Response,https://ClinicalTrials.gov/show/NCT01967758
936,NCT01997190,Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion,"Active, not recruiting",No Results Available,Malignant Pleural Effusion|Lung Cancer|Mesothelioma|Breast Cancer|Ovarian Cancer,Biological: AdV-tk + valacyclovir,"Advantagene, Inc.|University of Pennsylvania",Both,"18 Years and older   (Adult, Senior)",Phase 1,19,Industry|Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MpeTK01,19-Nov-13,10/1/2013,10/1/2020,10/28/2015,Oct-15,No Study Results Posted,MpeTK01,Oct-16,Safety|Progression-free survival|Overall survival,https://ClinicalTrials.gov/show/NCT01997190
1230,NCT02248402,Autologous Dendritic Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma,Recruiting,No Results Available,Multiple Myeloma,Biological: Vax-DC/MM,Chonnam National University Hospital,Both,"18 Years to 70 Years   (Adult, Senior)",Phase 1|Phase 2,15,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,13-038,17-Sep-14,10/1/2013,null,9/24/2014,Sep-14,No Study Results Posted,Vax-DC/MM,Oct-15,Number of participants with adverse events|Clinical response after completion of Vax-DC/MM injection|Progression free survival,https://ClinicalTrials.gov/show/NCT02248402
1231,NCT02423291,A Study of SGN-35 (Brentuximab Vedotin) of Patients With Relapsed or Refractory PMLBCL,Completed,No Results Available,Primary Mediastinal Large B-cell Lymphoma.,Drug: Brentuximab Vedotin,Fondazione Italiana Linfomi ONLUS,Both,"18 Years and older   (Adult, Senior)",Phase 2,15,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,FIL_SGN01,30-Sep-13,10/1/2013,7/1/2016,8/3/2016,Aug-16,No Study Results Posted,FIL_SGN01,Jul-16,To determine the antitumor efficacy of single-agent Brentuximab vedotin as measured by the overall objective response rate in patients with relapsed or refractory PMLBCL,https://ClinicalTrials.gov/show/NCT02423291
1262,NCT01909934,Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma,Recruiting,No Results Available,Anaplastic Large-cell Lymphoma,Drug: brentuximab vedotin,"Millennium Pharmaceuticals, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 4,45,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,C25006|2012-004128-39|U1111-1154-9784|REec-2014-0649|13/NI/0072,1-Jul-13,10/1/2013,5/1/2020,2/23/2015,Feb-15,No Study Results Posted,null,Oct-15,Objective Response Rate (ORR) as assessed by an independent review facility (IRF) according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma|Duration of response|Progression-free survival (PFS)|Complete remission rate (CR)|Overall Survival,https://ClinicalTrials.gov/show/NCT01909934
57,NCT01865110,R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL,Recruiting,No Results Available,Mantle Cell Lymphoma,Drug: R-CHOP|Drug: R-CHOP / R-HAD|Drug: Rituximab|Drug: Lenalidomide,The Lymphoma Academic Research Organisation,Both,"60 Years and older   (Adult, Senior)",Phase 3,633,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MCL R2 Elderly,24-May-13,11/1/2013,3/1/2024,11/12/2015,Nov-15,No Study Results Posted,null,Jun-21,Progression free survival,https://ClinicalTrials.gov/show/NCT01865110
104,NCT01788020,Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia,Recruiting,No Results Available,Waldenström's Macroglobulinemia,"Drug: Dexamethasone, Rituximab, Cyclophosphamide|Drug: Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib",University of Ulm,Both,"18 Years and older   (Adult, Senior)",Phase 3,380,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ECWM-1|2013-000506-37,1-Feb-13,11/1/2013,12/1/2022,5/27/2015,May-15,No Study Results Posted,null,Dec-17,Progression Free Survival|Complete Response rate|Time to treatment failure|Remission duration|Overall survival|Overall response rate,https://ClinicalTrials.gov/show/NCT01788020
222,NCT01890213,Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer,Recruiting,No Results Available,Stage III Colon Cancer,Biological: AVX701,"Duke University|AlphaVax, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1,12,Other|Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,Pro00045976|IND13372,26-Jun-13,11/1/2013,11/1/2017,12/17/2015,Dec-15,No Study Results Posted,null,Jun-16,Number of participants with adverse events,https://ClinicalTrials.gov/show/NCT01890213
270,NCT02132988,Trial of Active Immunotherapy With Globo H-KLH (OPT-822/821) in Women Who Have Non-Progressive Ovarian Cancer,Recruiting,No Results Available,Ovarian Cancer,Biological: OPT-822/OPT-821,"Mackay Memorial Hospital|OBI Pharma, Inc",Female,"21 Years and older   (Adult, Senior)",Phase 2,110,Other|Industry,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MMH-OPT822-OC001,6-May-14,11/1/2013,11/1/2018,5/6/2014,May-14,No Study Results Posted,null,Nov-17,Progression Free Survival (PFS)|Disease Recurrence Rate,https://ClinicalTrials.gov/show/NCT02132988
415,NCT01993719,Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma,Recruiting,No Results Available,Metastatic Melanoma,Drug: Aldesleukin|Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Young Tumor Infiltrating Lymphocytes (Young TIL)|Drug: Keytruda (pembrolizumab) - ONLY FOR RETREATMENT,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 70 Years   (Adult, Senior)",Phase 2,64,NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,140022|14-C-0022,22-Nov-13,11/1/2013,9/1/2019,7/27/2016,Jul-16,No Study Results Posted,null,Oct-18,Determine if there is a difference in the rate of response between patients who have received prior anti-PD1 and those who have not.|Evaluate progression free and overall survival.|Evaluate the safety and efficacy of pembrolizumab in combination with TIL therapy.,https://ClinicalTrials.gov/show/NCT01993719
492,NCT01896869,"A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer",Recruiting,No Results Available,Metastatic Pancreatic Adenocarcinoma,Drug: Ipilimumab|Biological: Vaccine|Drug: FOLFIRINOX,Sidney Kimmel Comprehensive Cancer Center,Both,"18 Years and older   (Adult, Senior)",Phase 2,92,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,J13108|NA_00086350|FD-R-004819-01,8-Jul-13,11/1/2013,null,7/19/2016,Jul-16,No Study Results Posted,null,Nov-18,Overall Survival|Number of adverse events as a measure of toxicity|Progression Free Survival (PFS)|immune-related Progression Free Survival (irPFS)|Objective Response Rate|Duration of Response|Tumor Marker (CA19-9) Kinetics,https://ClinicalTrials.gov/show/NCT01896869
497,NCT02343211,Immunotherapy and Paraneoplastic Neurological Syndromes,Recruiting,No Results Available,Paraneoplastic Neurological Syndromes,Drug: Immunoglobulin,Assistance Publique - Hôpitaux de Paris,Both,"18 Years and older   (Adult, Senior)",Phase 2,17,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,P120101,15-Jan-15,11/1/2013,11/1/2016,5/9/2016,May-16,No Study Results Posted,IaSON,Jun-16,"percentage of patients with neurological improvement after 3 months of immunotherapy with IVIg|percentage of patients with neurological improvement after 6 months of immunotherapy with IVIg|percentage of patients with improvement in Barthel Index (BI)|percentage of patients with improvement in International Cooperative Ataxia Rating Scale (ICARS),|percentage of patients with improvement in Overall Neuropathy Limitations Scale (ONLS)|Progression-free survival",https://ClinicalTrials.gov/show/NCT02343211
613,NCT01556841,The Activity of TroVax® Versus Placebo in Relapsed Asymptomatic Ovarian Cancer,Recruiting,No Results Available,Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Cancer,Biological: TroVax®|Biological: Placebo,"University College, London|Oxford BioMedica|Cancer Research UK",Female,"18 Years and older   (Adult, Senior)",Phase 2,75,Other|Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",UCL/11/0119,14-Mar-12,11/1/2013,10/1/2018,6/3/2016,Jun-16,No Study Results Posted,TRIOC,May-17,Progression|Immune-related response criteria (irRC)|Progression-free survival|Time to clinical intervention|Incidence of clinical intervention|CA-125 doubling time|Overall survival|Quality of Life,https://ClinicalTrials.gov/show/NCT01556841
648,NCT01984892,Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC),Terminated,No Results Available,Melanoma|Squamous Cell Carcinoma of the Head and Neck|Squamous Cell Carcinoma of the Skin|Sarcoma of the Skin|Basal Cell Cancer of the Skin|Breast Cancer,Drug: Poly-ICLC,"Nina Bhardwaj|Oncovir, Inc.|Icahn School of Medicine at Mount Sinai",Both,"14 Years and older   (Child, Adult, Senior)",Phase 2,8,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,GCO 13-1687|BB-43984,5-Nov-13,11/1/2013,8/1/2014,2/16/2016,Oct-14,No Study Results Posted,Hiltonol,Aug-14,Progression-free survival|Therapeutic effect in treated patients,https://ClinicalTrials.gov/show/NCT01984892
680,NCT02009449,A Phase 1 Study of AM0010 in Patients With Advanced Solid Tumors,Recruiting,No Results Available,Melanoma|Prostate Cancer|Ovarian Cancer|Renal Cell Carcinoma|Colorectal Carcinoma|Pancreatic Carcinoma|Non-small Cell Lung Carcinoma|Solid Tumors|Breast Cancer,Drug: AM0010|Drug: Paclitaxel or Docetaxel and Carboplatin or Cisplatin|Drug: FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)|Drug: gemcitabine/nab-paclitaxel|Drug: Capecitabine|Drug: Pazopanib|Drug: Pembrolizumab|Drug: Paclitaxel|Drug: nivolumab|Drug: Gemcitabine/carboplatin,ARMO BioSciences,Both,"18 Years and older   (Adult, Senior)",Phase 1,300,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,AM0010-001,2-Dec-13,11/1/2013,12/1/2016,1/11/2016,Jan-16,No Study Results Posted,null,Dec-16,Safety and tolerability as measured by incidence of adverse events|Pharmacokinetic (PK) parameters|Change in tumor burden measured by volumetric Computer Tomography (CT) or Magnetic Resonance Imaging (MRI) according to immune-related response criteria (irRC)|Progression in bone by bone scintigraphy according to Prostate Cancer Working Group 2 (PCWG2) for patients with metastatic castration resistant prostate cancer (CRPC)|Anti-AM0010 antibody formation,https://ClinicalTrials.gov/show/NCT02009449
717,NCT02015416,A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer,"Active, not recruiting",No Results Available,Melanoma|Ovarian Cancer|Sarcoma|Non-small Cell Lung Cancer|Breast Cancer,Biological: IDC-G305,Immune Design,Both,"18 Years to 80 Years   (Adult, Senior)",Phase 1,30,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IDC-G305-2013-001,13-Dec-13,11/1/2013,8/1/2015,2/2/2015,Feb-15,No Study Results Posted,null,Nov-14,Safety and tolerability|Immunogenicity,https://ClinicalTrials.gov/show/NCT02015416
748,NCT01923233,In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer,Withdrawn,No Results Available,Hepatocellular Carcinoma,Biological: AlloStim,"Immunovative Therapies, Ltd.",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,0,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ITL-017-HCC,12-Aug-13,11/1/2013,6/1/2015,12/7/2015,Dec-15,No Study Results Posted,null,Nov-14,Safety|Tumor-Specific Immunity|Anti-Tumor Response,https://ClinicalTrials.gov/show/NCT01923233
853,NCT01876212,Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma,Recruiting,No Results Available,Metastatic Melanoma,Biological: DC vaccine|Drug: Dasatinib,Walter J. Storkus|National Cancer Institute (NCI)|University of Pittsburgh,Both,"18 Years and older   (Adult, Senior)",Phase 2,28,Other|NIH,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,12-048|R01CA169118|UPCI 12-048,10-Jun-13,11/1/2013,7/1/2018,3/24/2016,Mar-16,No Study Results Posted,null,Jul-17,Increase of CD8+ T cell response from addition of dasatinib|Number of participants with adverse events|Tumor response|PF and overall survival|Number of CD8+ T cells infiltrating into melanoma lesions|Number of suppressor cell populations and blood vessels in melanoma tumor biopsies|Number of suppressor cell populations in patients peripheral blood|Level of EphA2 protein expression in tumor biopsies|Serum concentration of the T cell-recruiting chemokine CXCL10/IP-10,https://ClinicalTrials.gov/show/NCT01876212
1261,NCT01950364,A Phase 1 Study in Patients With Relapsed or Refractory Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma,Completed,Has Results,Hodgkin Lymphoma|Anaplastic Large-cell Lymphoma,Drug: brentuximab vedotin|Drug: Brentuximab vedotin and rifampicin,"Millennium Pharmaceuticals, Inc.",Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1,20,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,C25005|2013-000193-29|U1111-1174-1958,23-Sep-13,11/1/2013,6/1/2015,3/30/2016,Mar-16,30-Oct-15,null,Oct-14,"Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, Predose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 2, Predose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, Predose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 0.5 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 2, 0.5 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 0.5 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 4 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 4 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 24 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 24 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 48 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 48 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 72 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 72 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 96 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 96 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 144 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 144 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 1, 336 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 336 Hour Postdose|Plasma Concentration of Monomethylauristatin E (MMAE) and Its Metabolites at Cycle 3, 480 Hour Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, Predose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 0-24 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 24-48 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 48-72 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 72-96 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 96-120 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 120-144 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 144-168 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 336-360 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 1, 480-504 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, Predose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 0-24 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 24-48 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 48-72 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 72-96 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 96-120 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 120-144 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 144-168 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 336-360 Hours Postdose|Amount of Monomethylauristatin E (MMAE) and Its Metabolites Excreted in Urine at Cycle 3, 480-504 Hours Postdose|Serum Concentrations of Antibody-drug Conjugate (ADC)|Serum Concentration of Total Antibody (TAb)|Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)|Number of Participants With Anti-therapeutic Antibodies (ATA) to Brentuximab Vedotin|Number of Participants With Markedly Abnormal Laboratory Values|Number of Participants With Clinically Significant Change From Baseline in Vital Signs",https://ClinicalTrials.gov/show/NCT01950364
63,NCT02007239,Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH),Recruiting,No Results Available,Hemophagocytic Lymphohistiocytosis,Drug: tocilizumab,Children's Hospital of Philadelphia,Both,"3 Months to 25 Years   (Child, Adult)",Phase 2,10,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,13-010459,5-Dec-13,12/1/2013,7/1/2017,4/28/2016,Apr-16,No Study Results Posted,null,Jan-17,"Reduction in serum interferon-gamma levels after tocilizumab (TCZ) administration|Change in other cytokine levels (interleukin-6, interleukin-10, tumor necrosis factor-alpha, etc.)|Presence of HLH disease activity for each subject following TCZ administration|Degree of hepatic function, cytopenias and infection in subjects following administration of TCZ|Overall survival of subjects",https://ClinicalTrials.gov/show/NCT02007239
483,NCT01998542,Safety and Tolerability Study of AlloVax(TM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck,"Active, not recruiting",No Results Available,Cancer of Head and Neck|Squamous Cell Carcinoma of the Head and Neck,Biological: AlloVax|Biological: CRCL|Biological: AlloStim|Other: PlasmaLyteA with 1% human serum albumin,"Immunovative Therapies, Ltd.",Both,"18 Years to 70 Years   (Adult, Senior)",Phase 1|Phase 2,52,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",ITL-010-HNC,21-Nov-13,12/1/2013,9/1/2016,12/7/2015,Dec-15,No Study Results Posted,HNC,Jul-16,To compare the safety and tolerability of AlloVax to the placebo|Anti-tumor specific immune response|Anti-Tumor Response,https://ClinicalTrials.gov/show/NCT01998542
524,NCT02010203,A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT,"Active, not recruiting",No Results Available,Bladder Cancer,Biological: HS-410|Biological: Placebo|Biological: BCG,Heat Biologics,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,110,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",HS410-101,5-Dec-13,12/1/2013,5/1/2017,3/7/2016,Mar-16,No Study Results Posted,null,Jun-16,"Phase 1: Safety and tolerability|Phase 2: 1-year Disease-Free Survival|Proportion of patients with recurrence at 3, 6, 12, 18, and 24 months|Proportion of patients with progressive disease at 3, 6, 12, 18, and 24 months|Disease-free survival at 3, 6, 18, and 24 months|Overall disease-free survival|Overall survival|Proportion of patients undergoing repeat transurethral resection of bladder tumor (TURBT) by 12 and 24 months|Proportion of patients undergoing cystectomy by 12 and 24 months|Immunologic response of PBMCs via intracellular cytokine staining (ICS) by flow cytometry and/or enzyme-linked immunosorbent spot (ELISPOT) on CD8+ cells after HS-410 vaccination as compared to baseline.|Immunologic response of peripheral blood mononuclear cells (PBMCs) and stimulation analysis via ICS in baseline and post-treatment biopsies, if clinically indicated|Total PBMC counts by flow cytometry|Tumor antigen expression|Tumor Infiltrating Lymphocytes (TILs)|T cell receptor sequencing of peripheral blood T cells before and during treatment|Safety of the combination of the HS-410 and BCG|Safety of the high dose HS-410 monotherapy",https://ClinicalTrials.gov/show/NCT02010203
551,NCT01995227,An Individualized Anti-Cancer Vaccine Study in Patients With HCC,Withdrawn,No Results Available,Hepatocellular Carcinoma,Biological: AlloVax|Biological: CRCL|Biological: AlloStim,"Immunovative Therapies, Ltd.",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,0,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ITL-019-HCC-VAX,18-Nov-13,12/1/2013,7/1/2018,4/1/2015,Apr-15,No Study Results Posted,null,Feb-18,Safety|Tumor-Specific Immunity|Tumor Biomarker Status,https://ClinicalTrials.gov/show/NCT01995227
578,NCT02015104,Study of Bacillus Calmette-Guerin (BCG) Combined With PANVAC Versus BCG Alone in Adults With High Grade Non-Muscle Invasive Bladder Cancer Who Failed At Least 1 Course of BCG,Recruiting,No Results Available,Bladder Cancer,Biological: TICE Bacillus Calmette-Guerin (BCG)|Biological: PANVAC,National Cancer Institute (NCI)|Rutgers Cancer Institute of New Jersey|National Institutes of Health Clinical Center (CC),Both,"18 Years to 100 Years   (Adult, Senior)",Phase 2,54,NIH|Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,140036|14-C-0036,18-Dec-13,12/1/2013,1/1/2019,5/11/2016,Mar-16,No Study Results Posted,null,Jan-19,Improvement in disease-free survival (DFS) with BCG + PANVAC compared with BCG alone.|Estimate the probability distribution of progression-free survival and the time to recurrence.,https://ClinicalTrials.gov/show/NCT02015104
609,NCT02137746,Study to Allow for Second Treatment Cycle of DCVAC in Patients With Localized Prostate Cancer,"Active, not recruiting",No Results Available,Prostate Cancer,Biological: Dendritic Cells DCVAC/PCa,Sotio a.s.,Male,"18 Years and older   (Adult, Senior)",Phase 2,24,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SP010|2013-003809-26,12-May-14,12/1/2013,4/1/2017,6/30/2015,Jun-15,No Study Results Posted,null,Apr-15,Safety evaluation of the second cycle of DCVAC|Time to Prostate Specific Antigen (PSA) Doubling Time,https://ClinicalTrials.gov/show/NCT02137746
681,NCT02010606,Phase I Study of a Dendritic Cell Vaccine for Patients With Either Newly Diagnosed or Recurrent Glioblastoma,Recruiting,No Results Available,Glioblastoma|Glioblastoma Multiforme|Glioma|Astrocytoma|Brain Tumor,"Biological: Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy|Biological: Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab",Cedars-Sinai Medical Center,Both,"18 Years and older   (Adult, Senior)",Phase 1,40,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,33203,2-Dec-13,12/1/2013,null,3/29/2016,Mar-16,No Study Results Posted,null,Oct-18,"Assess safety and tolerability according to National Cancer Institute Common Toxicity Criteria for Adverse Events (NCI CTCAEs) Version 4.03|Assess the number of serious adverse events|Assess treatment-related toxicities|Evaluate Overall Survival (OS) and Progression-Free Survival (PFS)|Evaluate health-related quality of life parameters|Assess the overall response rate, defined as the percentage of patients showing either partial response or complete response, in patients with subtotal resection|Evaluate immune response by assessing cytotoxic T cell activity in vitro pre- vs post-vaccination|Assess tumor stem cell antigen expression",https://ClinicalTrials.gov/show/NCT02010606
811,NCT02020070,"Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy",Recruiting,No Results Available,Metastatic Castration Sensitive Prostate Cancer,Drug: Degarelix|Drug: Ipilimumab|Procedure: Radical Prostatectomy,Memorial Sloan Kettering Cancer Center|Ferring Pharmaceuticals,Male,"18 Years and older   (Adult, Senior)",Phase 2,53,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,13-134,18-Dec-13,12/1/2013,null,3/10/2016,Mar-16,No Study Results Posted,null,Dec-17,undetectable PSA|progression-free survival (PFS)|overall survival (OS)|Toxicity,https://ClinicalTrials.gov/show/NCT02020070
830,NCT02035956,IVAC MUTANOME Phase I Clinical Trial,"Active, not recruiting",No Results Available,Melanoma,"Biological: IVAC MUTANOME, RBL001/RBL002",Biontech RNA Pharmaceuticals GmbH,Both,"18 Years and older   (Adult, Senior)",Phase 1,15,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,RB_0004-01,10-Jan-14,12/1/2013,12/1/2016,1/18/2016,Jan-16,No Study Results Posted,null,May-16,"Safety and tolerability of repetitive doses|Monitoring of vaccine-induced cellular immune response,",https://ClinicalTrials.gov/show/NCT02035956
912,NCT02002182,"ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer",Recruiting,No Results Available,Head and Neck Cancer|Squamous Cell Carcinoma of the Head and Neck|Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma,Biological: ADXS11-001 (ADXS-HPV),"Andrew Sikora|Advaxis, Inc.|Baylor College of Medicine",Both,"18 Years and older   (Adult, Senior)",Phase 2,30,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,GCO 13-1411,29-Nov-13,12/1/2013,8/1/2019,4/20/2016,Apr-16,No Study Results Posted,null,Aug-18,change in HPV E6/E7-specific CD8+ cytotoxic lymphocyte (CTL) responses|Toxicity|Vaccine induced HPV E6/E7specific CD8+ CTL responses,https://ClinicalTrials.gov/show/NCT02002182
933,NCT02049489,A Study of ICT-121 Dendritic Cell Vaccine in Recurrent Glioblastoma,Recruiting,No Results Available,Glioblastoma Multiforme,Biological: ICT-121 DC vaccine,"ImmunoCellular Therapeutics, Ltd.",Both,"18 Years and older   (Adult, Senior)",Phase 1,20,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ICT-121 DC-01,28-Jan-14,12/1/2013,11/1/2017,2/2/2016,Apr-15,No Study Results Posted,null,Nov-17,Safety and tolerability of an autologous ICT-121 DC vaccine|Response rate and immune response to autologous ICT-121 DC vaccine,https://ClinicalTrials.gov/show/NCT02049489
39,NCT01804465,A Randomized Phase 2 Trial of Combining Sipuleucel-T With Immediate vs. Delayed CTLA-4 Blockade for Prostate Cancer,Recruiting,No Results Available,Prostate Cancer,Drug: SipT Treatment|Drug: Ipilimumab,"University of California, San Francisco|M.D. Anderson Cancer Center|Bristol-Myers Squibb|Dendreon",Male,"18 Years and older   (Adult, Senior)",Phase 2,54,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CC#12557,27-Feb-13,1/1/2014,12/1/2018,5/22/2016,May-16,No Study Results Posted,null,Dec-17,Impact of the timing of ipilimumab administration on PAP/PA2024specific immune responses by SipT|Prostate Specific Antigen (PSA) Measurements (patient response to therapy)|Radiographic Clinical Responses|Modulation of Effector and Regulatory T Cells|Safety assessment of combining ipilimumab with SipT,https://ClinicalTrials.gov/show/NCT01804465
75,NCT02054104,"Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum",Suspended,No Results Available,Lung Cancer|Esophageal Cancer|Malignant Pleural Mesothelioma|Sarcoma|Thymic Carcinoma,Biological: H1299 Lysate Vaccine|Drug: Cyclophosphamide|Drug: Celecoxib,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 99 Years   (Adult, Senior)",Phase 1|Phase 2,60,NIH,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,140053|14-C-0053,1-Feb-14,1/1/2014,11/1/2018,7/29/2016,Jul-16,No Study Results Posted,null,Sep-18,Comparison of immune response rates in patients taking vaccine alone versus those taking vaccine plus metronomic chemotherapy.|Determine whether oral metronomic cyclophosphamide andcelecoxib therapy diminishes the percentage and number of Tregulatory cells and diminishes activity of these cells in patientswith thoracic malignancies|Determine whether H1299 cell lysate/Iscomatrix vaccinationenhances immunologic response to autologous tumor orepigenetically modified autologous EBV-transformed lymphocytes(B cells),https://ClinicalTrials.gov/show/NCT02054104
189,NCT02111850,T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 Positive,Suspended,No Results Available,Metastatic Cancer That Express the MAGE-A3-DP4 Antigen,Biological: Anti-MAGE-A3-DP4 TCR|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldesleukin,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 70 Years   (Adult, Senior)",Phase 1|Phase 2,18,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,140052|14-C-0052,9-Apr-14,1/1/2014,12/1/2018,7/13/2016,Jul-16,No Study Results Posted,null,Dec-17,Determine a safe dose of administration and determine if this approach will result in an objective tumor regression|Determine the in vivo survival of TCR gene-engineered cells.,https://ClinicalTrials.gov/show/NCT02111850
499,NCT01702792,Derivation of Tumor Specific Hybridomas,Terminated,No Results Available,Glioblastoma,Biological: Tumor Vaccine,Dartmouth-Hitchcock Medical Center|University of Vermont,Both,"18 Years and older   (Adult, Senior)",Phase 1,1,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,W12209,3-Oct-12,1/1/2014,null,3/22/2016,Mar-16,No Study Results Posted,null,May-15,number of hybridoma clones that produce anti-glioma antibodies|Production of Antibodies|Toxicity of Vaccine|Clone Production Rate|Lymph Node Biopsy,https://ClinicalTrials.gov/show/NCT01702792
542,NCT02061423,HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer Post Neoadjuvant Chemotherapy,"Active, not recruiting",No Results Available,Breast Cancer,Biological: HER-2 pulsed Dendritic Cell Vaccine,H. Lee Moffitt Cancer Center and Research Institute,Female,"18 Years and older   (Adult, Senior)",Phase 1,6,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention,MCC-18776|26113,10-Feb-14,1/1/2014,6/1/2018,6/7/2016,Feb-16,No Study Results Posted,Neoadjuvant,Feb-16,Blood Pressure|Temperature|Pulse|Immune Response|Mammogram,https://ClinicalTrials.gov/show/NCT02061423
543,NCT02063724,HER-2 Pulsed DC Vaccine to Prevent Recurrence of Invasive Breast Cancer,"Active, not recruiting",No Results Available,Breast Cancer,Biological: HER-2 pulsed Dendritic Cell Vaccine,H. Lee Moffitt Cancer Center and Research Institute,Female,"18 Years and older   (Adult, Senior)",Phase 1,11,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention,MCC-18777|25113,6-Feb-14,1/1/2014,6/1/2018,6/7/2016,Jun-16,No Study Results Posted,Adjuvant,Feb-16,Change in Blood Pressure|Change in Temperature|Change in Pulse|Immune Response|Mammogram,https://ClinicalTrials.gov/show/NCT02063724
583,NCT02030561,NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer,Recruiting,No Results Available,Breast Cancer|Gastric Cancer,Drug: Trastuzumab + NK cells,"National University Hospital, Singapore|National University, Singapore",Both,"21 Years to 99 Years   (Adult, Senior)",Phase 1|Phase 2,29,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MC01/21/13|2013/00566,7-Jan-14,1/1/2014,8/1/2018,6/21/2016,Jun-16,No Study Results Posted,null,Aug-17,Number of Participants with Serious and Non-Serious Adverse Events|Duration of Tumor Response Measure|Time-to-Event Outcome Measure,https://ClinicalTrials.gov/show/NCT02030561
619,NCT02042053,PET/MR Assessment of Sipuleucel T Treatment for Metastatic Castration Resistant Prostate Cancer,Terminated,No Results Available,Prostate Cancer,Device: PET/CT|Device: PET/MRI,New York University School of Medicine|Dendreon,Male,"18 Years and older   (Adult, Senior)",,10,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label,NYU S12-03902,17-Jan-14,1/1/2014,10/1/2015,3/10/2016,Mar-16,No Study Results Posted,null,May-15,Percentage of patients with imaging parameter change(s) among the patients with immunological response|Percentage of patients with imaging parameter change(s) among the patients who respond per Response Evaluation Criteria In Solid Tumors (RECIST),https://ClinicalTrials.gov/show/NCT02042053
727,NCT02004262,Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting,"Active, not recruiting",No Results Available,"2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer","Biological: GVAX Pancreas Vaccine|Biological: CRS-207|Drug: gemcitabine, capecitabine, 5-FU, irinotecan or erlotinib|Drug: cyclophosphamide","Aduro Biotech, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 2,240,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ADU-CL-04,23-Oct-13,1/1/2014,null,8/17/2015,Aug-15,No Study Results Posted,ECLIPSE,Dec-16,Overall survival in subjects receiving test treatments|Adverse events in each treatment arm treatment regimen,https://ClinicalTrials.gov/show/NCT02004262
962,NCT02107378,Efficacy of DCVAC/OvCa Plus Standard of Care in Relapsed Platinum Resistant Epithelial Ovarian Carcinoma,"Active, not recruiting",No Results Available,Epithelial Ovarian Carcinoma,Biological: DCVAC/OvCa|Drug: Standard of Care (Paclitaxel or topotecan or doxorubicin),Sotio a.s.,Female,"18 Years and older   (Adult, Senior)",Phase 2,60,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,SOV03,4-Apr-14,1/1/2014,1/1/2017,1/12/2016,Jan-16,No Study Results Posted,null,Oct-16,Overall survival (all cause mortality)|Progression Free Survival|Objective Response Rate|Biological Progression Free Interval|Immunological Response|Frequency of Adverse Events|Evaluation of Quality of Life via Functional Assessment of Cancer Therapy-Ovarian,https://ClinicalTrials.gov/show/NCT02107378
1229,NCT02028455,A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD19 for Relapsed/Refractory CD19+ Leukemia,Recruiting,No Results Available,CD19+ Acute Leukemia,Biological: Patient Derived CD19 specific CAR T cells also expressing an EGFRt,Seattle Children's Hospital,Both,"1 Year to 26 Years   (Child, Adult)",Phase 1|Phase 2,80,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PLAT-02,3-Jan-14,1/1/2014,1/1/2032,7/22/2016,Jul-16,No Study Results Posted,null,Jan-17,Number of Participants With Adverse Events|Number of participants with an MRD negative complete remission after T cells infusion|Number of Participants who have a Releasable Cell Product Generated|Persistence of functional CD19 CAR+ T cells|Number of participants with recrudescence or development of acute GVHD|Number of participants who have T cells ablated with cetuximab,https://ClinicalTrials.gov/show/NCT02028455
220,NCT02062359,T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Melanoma,Terminated,Has Results,Metastatic Cancer|Metastatic Melanoma,Biological: Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells|Drug: Aldesleukin|Drug: Cyclophosphamide|Drug: Fludarabine,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 70 Years   (Adult, Senior)",Phase 2,2,NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,140058|14-C-0058,12-Feb-14,2/1/2014,2/1/2016,5/19/2016,May-16,11-Apr-16,null,Feb-16,"Objective Response (Complete Response (CR) + Partial Response (PR)) of Melanoma Tumors|Persistence of Genetically Engineered, Adoptively Transferred Cluster of Differentiation 62L (CD62L) + Derived Lymphocytes|Number of Participants With Adverse Events",https://ClinicalTrials.gov/show/NCT02062359
234,NCT02111863,Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma,Terminated,No Results Available,Melanoma|Skin Cancer,Drug: Aldesleukin|Drug: Fludarabine|Drug: Cylcophosphamide|Biological: 4-1BB Selected TIL,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 70 Years   (Adult, Senior)",Phase 2,6,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,140062|14-C-0062,9-Apr-14,2/1/2014,12/1/2018,7/22/2016,Jul-16,No Study Results Posted,null,Dec-17,To determine the safety and objective response rate of patients with metastatic melanoma receiving ACT using 4-1BB selected TIL plus aldesleukin treatment following a chemotherapy preparative regimen.|To determine the survival of patients receiving this treatment regimen.,https://ClinicalTrials.gov/show/NCT02111863
333,NCT02039674,A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Lung Cancer (MK-3475-021/KEYNOTE-021),Recruiting,No Results Available,Non-small Cell Lung Carcinoma,Biological: Pembrolizumab|Drug: Paclitaxel|Drug: Carboplatin|Biological: Bevacizumab|Drug: Pemetrexed|Biological: Ipilimumab|Drug: Erlotinib|Drug: Gefitinib,Merck Sharp & Dohme Corp.,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,308,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,3475-021,16-Jan-14,2/1/2014,6/1/2019,5/26/2016,May-16,No Study Results Posted,null,Nov-16,"Part II, Cohort G: Objective Response Rate|Part II, Cohort H: Objective Response Rate|Part I, All Cohorts: the recommended Phase II dose for pembrolizumab in combination with chemotherapy or immunotherapy|Part II, Cohort G: Overall survival (OS)|Part II, Cohort G: Progression-Free Survival (PFS)|Part II, Cohort G: Duration of Response (DOR)",https://ClinicalTrials.gov/show/NCT02039674
439,NCT01922921,Vaccine Therapy With or Without Polysaccharide-K in Treating Patients With Stage IV HER2 Positive Breast Cancer Receiving HER2-Targeted Monoclonal Antibody Therapy,Suspended,No Results Available,HER2/Neu Positive|Recurrent Breast Carcinoma|Stage IV Breast Cancer,Biological: HER-2/neu Intracellular Domain Protein|Other: Laboratory Biomarker Analysis|Biological: Pertuzumab|Other: Placebo|Biological: Polysaccharide-K|Biological: Trastuzumab,University of Washington|National Cancer Institute (NCI)|Office of Cancer Complementary and Alternative Medicine,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,30,Other|NIH,Interventional,"Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",7866|NCI-2013-01377|135|7866/135|P30CA015704|U19AT006028,1-Aug-13,2/1/2014,null,3/9/2016,Mar-16,No Study Results Posted,null,Sep-16,"Incidence of grade 3 or higher toxicity (including systemic and local injection site reactions) graded per Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events 4.0|Induction of interferon (IFN)-gamma production and cluster of differentiation (CD)107a expression in NK cells, via flow cytometry",https://ClinicalTrials.gov/show/NCT01922921
720,NCT02107963,A Phase I Trial of T Cells Expressing an Anti-GD2 Chimeric Antigen Receptor in Children and Young Adults With GD2+ Solid Tumors,Recruiting,No Results Available,Sarcoma|Osteosarcoma|Neuroblastoma|Melanoma,Biological: Anti-GD2-CAR engineered T cells|Drug: AP1903|Drug: Cyclophosphamide,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"1 Year to 35 Years   (Child, Adult)",Phase 1,72,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,140059|14-C-0059,5-Apr-14,2/1/2014,12/1/2018,6/4/2016,Apr-16,No Study Results Posted,null,Mar-17,Determine the feasibility of producing anti-GD2-CAR cells meeting the established release criteria and to assess the safety of administering escalating doses of autologous anti-GD2-CAR (anti-GD2.28.z.OX40.ICD9) engineered T cells in children and...|Determine antitumr effects|Persistence of anti-GD2 CAR T cells and correlate with anti-tumor effects|Evaluate prevalencew of GD2 expression|Evaluate effectiveness of AP1903 to mediate clearance of anti-GD2 CAR T cells|Assess toxicity of AP1903,https://ClinicalTrials.gov/show/NCT02107963
970,NCT02060955,Randomized Phase 2 Study to Investigate Efficacy of ALECSAT in Patients With GBM Measured Compared to Avastin/Irinotecan,Terminated,No Results Available,Glioblastoma Multiforme,Biological: ALECSAT|Drug: Bevacizumab/Irinotecan,CytoVac A/S,Both,"18 Years and older   (Adult, Senior)",Phase 2,25,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CV-005,10-Feb-14,2/1/2014,7/1/2015,6/3/2016,Jun-16,No Study Results Posted,null,Jun-15,Progression-free survival (PFS)|Overall survival (OS)|Time to progression (TTP)|Quality of Life by European Organization for Research and Treatment of Cancer (EORTC) questionnaire|Overall Response Rate (ORR),https://ClinicalTrials.gov/show/NCT02060955
37,NCT01789827,Aldesleukin Imaging in Viewing Tumor Growth in Patients With Stage IV Melanoma Receiving Ipilimumab or Pembrolizumab Therapy,"Active, not recruiting",No Results Available,Stage IV Skin Melanoma,Other: Laboratory Biomarker Analysis|Procedure: Radionuclide Imaging|Biological: Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2,Mayo Clinic|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",,12,Other|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic,MC1274|NCI-2013-00297|Mod12-003605-14|P30CA015083,8-Feb-13,3/1/2014,null,4/19/2016,Oct-15,No Study Results Posted,null,Mar-17,"Proportion of patients who develop scintigraphy limiting toxicities (SLTs)|Incidence of adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Target-to-background (T/B) ratio as determined by technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphy|TIL invasion as determined by technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphy",https://ClinicalTrials.gov/show/NCT01789827
55,NCT02061449,"Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma",Recruiting,No Results Available,Cutaneous T-cell Lymphoma,Drug: Romidepsin|Drug: Poly ICLC|Radiation: Focal lesional radiation,New York University School of Medicine|Ludwig Institute for Cancer Research,Both,"18 Years and older   (Adult, Senior)",Phase 1,24,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,13-00686,11-Feb-14,3/1/2014,12/1/2017,6/15/2016,Jun-16,No Study Results Posted,null,Dec-17,Maximum tolerated dose (MTD)|Overall response rate|Median progression-free survival|Median overall survival,https://ClinicalTrials.gov/show/NCT02061449
84,NCT02316028,Phase I:Decitabine by Hepatic Arterial Infusion(HAI) in Unresectable Liver Metastases Colorectal Cancer (CRC),Recruiting,No Results Available,Liver Metastasis|Colorectal Cancer,Drug: Decitabine,"Universitair Ziekenhuis Brussel|Janssen, LP",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,6,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,UZB-BN-2013-002,3-Dec-14,3/1/2014,7/1/2016,1/12/2016,Dec-15,No Study Results Posted,DECIT,Jun-16,toxicity of escalating doses of decitabine administered by HAI|overall survival|progression free survival|best objective tumor response|measuring Global DNA methylation of tumoral DNA|measuring Global DNA methylation of cell free DNA,https://ClinicalTrials.gov/show/NCT02316028
218,NCT02100891,Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors,Recruiting,No Results Available,Ewing Sarcoma|Neuroblastoma|Rhabdomyosarcoma|Osteosarcoma|CNS Tumors,Procedure: Allogeneic HCT|Drug: Donor NK Cell Infusion,Monica Thakar|Medical College of Wisconsin,Both,"Child, Adult, Senior",Phase 2,20,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,STIR Trial,27-Mar-14,3/1/2014,12/1/2019,2/25/2016,Feb-16,No Study Results Posted,STIR,Dec-19,Disease-control rate|Overall survival,https://ClinicalTrials.gov/show/NCT02100891
262,NCT02118415,Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT),Recruiting,No Results Available,NSCLC Stage IIIA/B,"Other: Hsp70-peptide TKD/IL-2 activated, autologous NK cells",Technische Universität München,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 2,90,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,NSCLC-TKD/IL-2|2008-002130-30,25-Feb-14,3/1/2014,2/1/2018,4/28/2016,Apr-16,No Study Results Posted,null,Sep-17,"Progress free survival|overall survival (OS)|toxicity (AE and SAE)|quality of life (QoLQ-30, LC-13)|biological parameters (NK cell activation)",https://ClinicalTrials.gov/show/NCT02118415
271,NCT02115958,The Immunotherapy of Nasopharyngeal Cancer Using Cancer Stem Cells Vaccine,Completed,No Results Available,"Neoplasms, Lung",Biological: cancer stem cell vaccine,"Fuda Cancer Hospital, Guangzhou|University of Michigan",Both,"18 Years to 80 Years   (Adult, Senior)",Phase 1|Phase 2,40,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment,CLN-001|201401,14-Apr-14,3/1/2014,5/1/2015,6/1/2015,Apr-14,No Study Results Posted,null,May-15,The primary study purpose to determine the safety of immunization with cancer stem cells vaccine by the number of participants with adverse events|The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements,https://ClinicalTrials.gov/show/NCT02115958
679,NCT02018419,Increased Frequency of AlloStim(TM) Dosing in Combination With Cryoablation in Metastatic Breast Cancer Patients,Withdrawn,No Results Available,Metastatic Breast Cancer,Biological: AlloStim|Procedure: Cryoablation,"Immunovative Therapies, Ltd.",Female,"18 Years to 70 Years   (Adult, Senior)",Phase 1|Phase 2,0,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ITL-014-TACT-MBC,17-Dec-13,3/1/2014,3/1/2017,4/1/2015,Apr-15,No Study Results Posted,MBC,Mar-16,To determine the safety of increased frequency of dosing|Health-Related Quality of Life|Evaluate the anti-tumor effect of Allostim combined with cryoablation at the new proposed dose and frequency schedule.,https://ClinicalTrials.gov/show/NCT02018419
762,NCT02036918,Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer,Recruiting,No Results Available,Prostate Cancer,Drug: Sipuleucel-T|Procedure: Lymph Node Biopsy,Duke University,Male,"18 Years and older   (Adult, Senior)",Phase 1,20,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label,Pro00047231,13-Jan-14,3/1/2014,12/1/2018,7/18/2016,Jul-16,No Study Results Posted,null,Dec-17,anti-PA2024 and anti-PAP immune response|Serum anti-PA2024 antibody level|serum anti-PAP antibody level,https://ClinicalTrials.gov/show/NCT02036918
864,NCT02200081,Randomized Study of Maintenance Therapy With MGN1703 in Patients With SCLC,"Active, not recruiting",No Results Available,Small Cell Lung Cancer,Drug: MGN1703|Other: Standard of care,Mologen AG,Both,"18 Years and older   (Adult, Senior)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MGN1703-C03,9-Jan-14,3/1/2014,3/1/2017,11/5/2015,Jul-14,No Study Results Posted,IMPULSE,Mar-17,Overall survival (OS)|OS1,https://ClinicalTrials.gov/show/NCT02200081
921,NCT02081937,CART-19 Immunotherapy in Mantle Cell Lymphoma,Recruiting,No Results Available,"Hematopoietic/Lymphoid Cancer|Non-hodgkin Lymphoma,B Cell|Mantle Cell Lymphoma",Biological: anti-CD19-CAR vector-transduced T cells,Chinese PLA General Hospital,Both,"50 Years to 80 Years   (Adult, Senior)",Phase 1|Phase 2,2,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CN301-XYK-CAR001,6-Mar-14,3/1/2014,12/1/2019,3/10/2014,Mar-14,No Study Results Posted,null,Dec-18,Occurrence of study related adverse events|Clinical responses to CART-19 cell therapy,https://ClinicalTrials.gov/show/NCT02081937
1079,NCT02117362,Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma,Recruiting,No Results Available,Metastatic Melanoma,Biological: 1 mg/kg GR-MD-02|Biological: 2 mg/kg GR-MD-02|Biological: 4 mg/kg GR-MD-02|Biological: 8 mg/kg GR-MD-02|Biological: Ipilimumab,"Providence Health & Services|Providence Cancer Center, Earle A. Chiles Research Institute|Galectin Therapeutics Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1,22,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,14-004A,14-Apr-14,3/1/2014,3/1/2020,6/23/2016,Jun-16,No Study Results Posted,null,Mar-18,Determine a safe dose of GR-MD-02 used in combination with the approved dose of ipilimumab (3 mg/kg)|Response rate to combined therapy,https://ClinicalTrials.gov/show/NCT02117362
1114,NCT01990534,A Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma,"Active, not recruiting",No Results Available,Hodgkin Lymphoma,Drug: Brentuximab vedotin,"Millennium Pharmaceuticals, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 4,60,Industry,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,C25007|2013-000232-10|U1111-1154-2250|NMRR-13-1246-18099|REec-2014-0619,15-Nov-13,3/1/2014,12/1/2019,5/3/2016,Jan-16,No Study Results Posted,null,Dec-15,"Objective response rate (ORR, complete remission (CR) + partial remission (PR)) as assessed by an independent review facility (IRF) according to the International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma|Duration of response, PFS, CR rate, and duration of CR, by IRF assessment|Proportion of patients who receive SCT after treatment with brentuximab vedotin|Overall survival",https://ClinicalTrials.gov/show/NCT01990534
1138,NCT02100930,Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma,Recruiting,No Results Available,Neuroblastoma,Biological: Anti-GD2 3F8 Monoclonal Antibody|Drug: GM-CSF (granulocyte-macrophage colony-stimulating factor)|Drug: oral isotretinoin,Memorial Sloan Kettering Cancer Center,Both,"Child, Adult, Senior",,125,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,13-260,27-Mar-14,3/1/2014,null,7/5/2016,Jul-16,No Study Results Posted,null,Mar-19,relapse-free survival|complete remission,https://ClinicalTrials.gov/show/NCT02100930
1158,NCT02017249,Efficacy Study of Oral Arginine to Improve Immune Function in Glioblastoma Multiforme,Completed,No Results Available,Glioblastoma Multiforme,Drug: arginine in powder form,Inova Health Care Services,Both,"18 Years and older   (Adult, Senior)",Phase 1,1,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",13-1364,7-Nov-13,3/1/2014,null,9/10/2015,Sep-15,No Study Results Posted,ArginineGBM,Sep-15,Change in GBM patients immune function through arginine supplementation|Change in control group immune function through arginine supplementation,https://ClinicalTrials.gov/show/NCT02017249
1186,NCT02098512,Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients,Recruiting,No Results Available,Hodgkin Lymphoma,Drug: Brentuximab Vedotin|Procedure: Allogeneic Stem Cell Transplantation|Drug: Reduced Intensity Conditioning,New York Medical College|St. Baldrick's Foundation,Both,"up to 45 Years   (Child, Adult)",Phase 1|Phase 2,20,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NYMC 564,17-Mar-14,3/1/2014,12/1/2018,7/29/2016,Jul-16,No Study Results Posted,null,Dec-17,Safety|Overall Survival|To assess feasibility of developing a bank of LMP-specific CTLs from healthy donors,https://ClinicalTrials.gov/show/NCT02098512
258,NCT02299999,SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer,Recruiting,No Results Available,Metastatic Breast Cancer,Drug: AZD2014|Drug: AZD4547|Drug: AZD5363|Drug: AZD8931|Drug: Selumetinib|Drug: Vandetanib|Drug: Bicalutamide|Drug: Olaparib|Drug: Anthracyclines|Drug: Taxanes|Drug: cyclophosphamide|Drug: DNA intercalators|Drug: Methotrexate|Drug: vinca alkaloids|Drug: Platinum based chemotherapies|Drug: Bevacizumab|Drug: Mitomycine C|Drug: Eribuline|Drug: MEDI4736,UNICANCER|Fondation ARC|AstraZeneca,Both,"18 Years and older   (Adult, Senior)",Phase 2,460,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,UC-0105/1304|2013-001652-36,1-Oct-14,4/1/2014,10/1/2018,2/19/2016,Feb-16,No Study Results Posted,SAFIR02_Breast,Oct-16,"Progression-free survival in the targeted drug arm compared to standard maintenance therapy arm|progression-free survival in patients treated with anti-PDL1 antibody (MEDI4736) compared to standard maintenance therapy arm|overall survival in each substudy|overall response rates and changes in tumor size in each substudy|evaluate safety, in each substudy|efficacy (response rate, change in tumor size, progression-free survival, overall survival) and safety of each individual targeted agent (substudy 1)|correlate molecular characteristics in patients with the efficacy endpoints (response rate, progression-free and overall survival) in each substudy",https://ClinicalTrials.gov/show/NCT02299999
331,NCT02133196,T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer,Recruiting,No Results Available,Metastatic Non-Small Cell Lung Cancer|Squamous Cell Carcinoma|Advanced NSCLC|Adenosquamous Carcinoma|Adenocarcinomas,Drug: Aldesleukin|Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Young TIL,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 70 Years   (Adult, Senior)",Phase 2,85,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,140104|14-C-0104,6-May-14,4/1/2014,2/1/2020,6/17/2016,Jun-16,No Study Results Posted,null,Feb-19,Determine the rate of tumor regression|To determine the phenotypic and functional characteristics of TIL derived from NSCLC.|To determine the toxicity of this treatment regimen.|To determine the feasibility of generating TIL from patients with NSCLC,https://ClinicalTrials.gov/show/NCT02133196
344,NCT02117167,SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profils in Metastatic NSCLC Patients,Recruiting,No Results Available,Non-small Cell Lung Cancer Metastatic,Drug: AZD2014|Drug: AZD4547|Drug: AZD5363|Drug: AZD8931|Drug: Selumetinib|Drug: Vandetanib|Drug: Erlotinib|Drug: Pemetrexed|Drug: MEDI4736,UNICANCER|IFCT|Fondation ARC|AstraZeneca,Both,"18 Years and older   (Adult, Senior)",Phase 2,650,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,UC 0105-1305 / IFCT 1301|2013-001653-27,8-Apr-14,4/1/2014,10/1/2018,2/19/2016,Feb-16,No Study Results Posted,SAFIR02_Lung,Oct-17,"progression-free survival in the targeted drug arm compared to standard maintenance therapy arm|progression-free survival in patients treated with anti-PDL1 antibody (MEDI4736) compared to standard maintenance therapy arm|overall survival in each substudy|overall response rates and changes in tumor size in each substudy|evaluate safety, in each substudy|efficacy (response rate, change in tumor size, progression-free survival, overall survival) and safety of each individual targeted agent (substudy 1)|correlate molecular characteristics in patients with the efficacy endpoints (response rate, progression-free and overall survival) in each substudy",https://ClinicalTrials.gov/show/NCT02117167
639,NCT02111577,Phase III Study of DCVAC Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer,Recruiting,No Results Available,Metastatic Castrate Resistant Prostate Cancer,Biological: Dendritic Cells DCVAC|Biological: Placebo|Drug: Docetaxel|Drug: Taxotere,Sotio a.s.,Male,"18 Years and older   (Adult, Senior)",Phase 3,1170,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",SP005|2012-002814-38,9-Apr-14,4/1/2014,6/1/2018,7/13/2016,Jul-16,No Study Results Posted,VIABLE,Dec-17,Overall survival (all cause mortality)|Radiographic Progression Free Survival|Duration to Prostate Specific Antigen (PSA) Progression|Duration to Skeletal Related Events,https://ClinicalTrials.gov/show/NCT02111577
840,NCT02096614,Investigator Initiated Phase 1 Study of TBI-1201,Recruiting,No Results Available,Solid Tumors,Drug: TBI-1201|Drug: Cyclophosphamide|Drug: Fludarabine,"Mie University|Takara Bio Inc.|Shionogi|Fiverings Co., Ltd.|Statcom Co. Ltd.",Both,"20 Years and older   (Adult, Senior)",Phase 1,12,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,1201-01,19-Mar-14,4/1/2014,null,3/23/2016,Mar-16,No Study Results Posted,null,Feb-17,Incidence and grade of adverse events (CTCAE)|Appearance of replication competent retrovirus by PCR|Appearance of clonality by LAM-PCR|Kinetics of TBI-1201 in blood by realtime-PCR and flow cytometry,https://ClinicalTrials.gov/show/NCT02096614
1111,NCT02129881,The ONE Study UK Treg Trial,Recruiting,No Results Available,End-stage Renal Failure,Biological: Autologous regulatory T Cell Product,Guy's and St Thomas' NHS Foundation Trust|King's College London,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,12,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ONETreg1,1-May-14,4/1/2014,3/1/2017,6/19/2014,Jun-14,No Study Results Posted,ONETreg1,Dec-16,Incidence of biopsy‐confirmed acute rejection.|Time to first acute rejection episode|Severity of acute rejection episodes|Total immunosuppressive burden|Incidence of chronic graft dysfunction|Incidence of graft loss through rejection|Incidence of adverse drug reactions|Incidence of major and/or opportunistic infections|Incidence of neoplasia.,https://ClinicalTrials.gov/show/NCT02129881
1179,NCT02074657,"""LANK-2"": Activated and Expanded NK Cell Immunotherapy Together With Salvage Chemotherapy in Children, Adolescents and Young Adults With Relapsed or Refractary Acute Leukemia",Recruiting,No Results Available,Relapsed/Refractory Paediatric Acute Leukaemia,Biological: Activated and expanded natural killer cells (NKAEs),Hospital Universitario La Paz,Both,"up to 23 Years   (Child, Adult)",Phase 2,10,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2012-005146-38,26-Feb-14,4/1/2014,4/1/2017,2/23/2016,Feb-16,No Study Results Posted,LYDIA,Dec-16,"To assess the safety of activated and expanded NK cell (NKAE) immunotherapy after salvage chemotherapy in patients with relapsed or refractary acute leukemia|Incidence of episodes of febrile neutropenia, bacteriemia or viral or fungal infections|Days of hematological recovery (neutrophils >500/microL, lymphocytes >250/microL and platelets >50.000/microL), days of hospitalization, in each cycle Immune|Objective response rate according to cytomorphic and by ""minimal residual disease"" criteria (cytometry and/or real time PCR) at the end of the treatment|Immune reconstitution: Median of T-cell , B, NK, Natural Killer T cell (NKT) and dendritic cells count and subpopulations of T and NK lymphocytes (cel/microL) during posttreatment follow-up period.",https://ClinicalTrials.gov/show/NCT02074657
1257,NCT02056756,Carfilzomib In Combination With Bendamustine And Dexamethasone In Refractory Or Relapsed Multiple Myeloma,Recruiting,No Results Available,Multiple Myeloma,Drug: Carfilzomib,Stichting Hemato-Oncologie voor Volwassenen Nederland|Fondazione Neoplasie Sangue Onlus,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,68,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,EMN09|2012-003938-17,5-Feb-14,4/1/2014,2/1/2019,5/9/2016,May-16,No Study Results Posted,null,Sep-15,Identification of dose-limiting toxicity (DLT)|Determine the rate of very good partial response (VGPR) or more with the CBd association:,https://ClinicalTrials.gov/show/NCT02056756
13,NCT02055924,Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas,Recruiting,No Results Available,B-cell Lymphoma,Drug: Ibrutinib and immunochemotherapies,"The Lymphoma Academic Research Organisation|Janssen Pharmaceutica N.V., Belgium",Both,"18 Years to 70 Years   (Adult, Senior)",Phase 1,84,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,BIBLOS,31-Jan-14,5/1/2014,11/1/2019,3/14/2016,Mar-16,No Study Results Posted,BIBLOS,Oct-18,The primary endpoint is the incidence rate of DLTs at each dose level on cycle 1|Secondary safety endpoints|Response Rate|Duration of response (DoR)|Progression-Free Survival (PFS)|Time to Next Anti-Lymphoma Treatment (TTNLT)|Overall Survival (OS)|Pharmacokinetics profile of ibrutinib in Groups A bis and B bis,https://ClinicalTrials.gov/show/NCT02055924
88,NCT02052492,Safety Study of EF-022 ( Modified Vitamin D Binding Protein Macrophage Activator) in Subjects With Advanced Solid Tumors,Recruiting,No Results Available,Solid Tumors,Drug: EF-022 (Modified Vitamin D Binding Protein Macrophage Activator),Efranat Ltd.,Both,"18 Years to 80 Years   (Adult, Senior)",Phase 1,46,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,PR-001,30-Jan-14,5/1/2014,5/1/2017,10/11/2015,Oct-15,No Study Results Posted,null,May-16,Number of Adverse Events that meets the DLT definition|Percentage of participants with Adverse Events grade 3-4,https://ClinicalTrials.gov/show/NCT02052492
240,NCT02241369,Immunotherapy in Subjects With HPV6 (Human Papillomavirus) Associated Aerodigestive Malignancies,Recruiting,No Results Available,Aerodigestive Malignancies (e.g Squamous Cell Carcinoma),"Biological: INO-3106, INO-9012",Inovio Pharmaceuticals|University of Pennsylvania,Both,"18 Years and older   (Adult, Senior)",Phase 1,6,Industry|Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,HPV-006,11-Sep-14,5/1/2014,12/1/2018,2/22/2016,Feb-16,No Study Results Posted,null,Jun-18,"Adverse events measured and graded in accordance with ""Common Terminology Criteria for Adverse Events (CTCAE)"", NCI version 4.03|Injection site reactions including skin erythema, induration pain and tenderness at administration site|HPV6 specific Ig levels|Number of antigen-specific IFN-γ-secreting cells in response to stimulation with HPV6 by antigen-specific IFN-γ ELISpot assays|Cytotoxic T cells in response to HPV6 specific immunotherapy by flow cytometry",https://ClinicalTrials.gov/show/NCT02241369
339,NCT02153905,T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive,Suspended,No Results Available,Metastatic Cancer That Express the MAGE-A3-HLA A01 Antigen|Metastatic Melanoma That Express the MAGE-A3-HLA A01 Antigen|Metastatic Cancer,Drug: Aldesleukin|Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Anti-MAGE-A3 HLAA* 01-restricted TCR,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 70 Years   (Adult, Senior)",Phase 1|Phase 2,3,NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,140110|14-C-0110,31-May-14,5/1/2014,11/1/2018,6/7/2016,May-16,No Study Results Posted,null,Jun-17,Determine objective response rate of administration of autologous T cells transduced with an anti-MAGE-A3 HLA-A*01-restricted TCR (MAGE-A3-01) TCR and aldesleukin|Determine a safe dose of administration of anti-MAGE-A3 HLA-A*01 restricted TCR T cells and IL2 following a nonmyeloblative but lymphodepleting preparative regimen|Determine the toxicity profile of the treatment regimen|Determine the in vivo survival of TCR gen-engineered cells,https://ClinicalTrials.gov/show/NCT02153905
835,NCT02122861,"Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1",Recruiting,No Results Available,Melanoma - Currently Enrolling|Non-small Cell Lung Cancer - Enrollment Completed|Ovarian Candcer - Enrollment Completed|Sarcoma - Enrollment Completed,Biological: ID-LV305,Immune Design|Merck Sharp & Dohme Corp.,Both,"18 Years to 80 Years   (Adult, Senior)",Phase 1,59,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ID-LV305-2013-001,22-Apr-14,5/1/2014,12/1/2018,5/25/2016,Mar-16,No Study Results Posted,null,Dec-18,Safety and tolerability|Immunogenicity,https://ClinicalTrials.gov/show/NCT02122861
982,NCT02051257,Memory Enriched T Cells Following Stem Cell Transplant in Treating Patients With Recurrent B-Cell Non-Hodgkin Lymphoma,Recruiting,No Results Available,Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Mantle Cell Lymphoma|Refractory Diffuse Large B-Cell Lymphoma|Refractory Mantle Cell Lymphoma|Transformed Recurrent Non-Hodgkin Lymphoma,Biological: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Biological: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Other: Laboratory Biomarker Analysis,City of Hope Medical Center|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,51,Other|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,13277|NCI-2014-00133|P50CA107399,29-Jan-14,5/1/2014,null,8/1/2016,Aug-16,No Study Results Posted,null,Jun-21,"Incidence of dose limiting toxicities (DLTs), defined as any grade 3 or higher toxicity, any grade 3 or greater autoimmune toxicity, or failure for a research participant with documented T cell persistence to engraft by day 21 post HSCT|Incidence of adverse events attributable to the cellular immunotherapy product|MTD of autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells based on DLTs|MTD of autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing TN/MEM-enriched T cells based on DLTs|Engraftment of the transferred T cell product|Levels of CD19+ B-cell precursors in the bone marrow, used as a surrogate for the in vivo effector function of transferred CD19-specific T-cells",https://ClinicalTrials.gov/show/NCT02051257
992,NCT02094872,Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic,Recruiting,No Results Available,Recurrent Melanoma|Stage IIIA Melanoma|Stage IIIB Melanoma|Stage IIIC Melanoma|Stage IV Melanoma,Other: cytology specimen collection procedure|Drug: MEK 162 therapy or molecularly targeted therapy|Procedure: therapeutic procedure|Other: laboratory biomarker analysis|Other: quality-of-life assessment,Yale University|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 2,47,Other|NIH,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,HIC # 1408014446|NCI-2014-00670|WIRB Pro #20140190|WO #1-822810-1|Invest #161467|Study #1144561|2013-184|P30CA022453,18-Mar-14,5/1/2014,4/1/2017,7/25/2016,Jul-16,No Study Results Posted,null,Apr-17,BORR|PFS,https://ClinicalTrials.gov/show/NCT02094872
996,NCT00900809,Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia,"Active, not recruiting",No Results Available,Acute Myeloid Leukemia,Biological: Neukoplast™ (NK-92),"NantKwest, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1,18,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,UPCI 12-151,11-May-09,5/1/2014,5/1/2016,12/22/2015,Dec-15,No Study Results Posted,null,May-16,"Determine the safety / maximum tolerated dose of Neukoplast™ (NK-92 cell line for clinical use) in patients with refractory or relapsed acute myeloid leukemia|Evaluate the therapeutic efficacy of Neukoplast™ in patients with refractory or relapsed acute myeloid leukemia|Determine the Neukoplast™ cell phenotype and cytotoxic activity at different time intervals after the Neukoplast™ cell infusion|Determine the presence of Neukoplast™ in the bone marrow|Determine the effects of Neukoplast™ on the host immune system, using flow cytometry and the LUMINEX multianalytic profiling system, at different time intervals after the Neukoplast™ infusion.",https://ClinicalTrials.gov/show/NCT00900809
1024,NCT02134262,Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes,Recruiting,No Results Available,Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma,Drug: Cyclophosphamide or Bendamustine|Genetic: Dose Level -1|Genetic: Dose Level 1|Genetic: Dose Level 2|Genetic: Dose Level 3,Jichi Medical University|Takara Bio Inc.,Both,"20 Years to 70 Years   (Adult, Senior)",Phase 1|Phase 2,18,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,JMU-CD19CAR,16-Apr-14,5/1/2014,3/1/2017,11/4/2014,Nov-14,No Study Results Posted,null,Mar-17,Toxicity Profile|Quality test of CD19-CAR-T|Tumor shrinkage effect|Lymphocyte subset analysis of CD19-CAR-T|Human anti-mouse antibody (HAMA) test,https://ClinicalTrials.gov/show/NCT02134262
1150,NCT02078648,"Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme",Recruiting,No Results Available,Adult Brain Glioblastoma|Glioblastoma Multiforme,Biological: SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)|Drug: Bevacizumab,"Stemline Therapeutics, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,76,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,STML-701-0114,20-Feb-14,5/1/2014,10/1/2017,7/6/2016,Jul-16,No Study Results Posted,null,Jul-17,Characterize the safety and tolerability of SL-701|Estimate the percent of patients alive 12 months after the initiation of SL-701 (OS-12)|Estimate the objective response rate (ORR)|Estimate duration of response|Estimate the percent of patients alive and progression-free survival at 6 months (PFS-6) after the initiation of SL-701.|Estimate the distributions of progression-free survival (PFS) and overall survival (OS).,https://ClinicalTrials.gov/show/NCT02078648
90,NCT02179515,Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM),"Active, not recruiting",No Results Available,Lung Cancer|Breast Cancer|Prostate Cancer|Tumors (Others)|Ovarian Cancer,Biological: MVA-brachyury- TRICOM,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 100 Years   (Adult, Senior)",Phase 1,38,NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,140142|14-C-0142,28-Jun-14,6/1/2014,5/1/2017,6/2/2016,Apr-16,No Study Results Posted,null,May-17,"Safety and tolerability of escalating doses of MVA-brachyury-TRICOM vaccine.|CD8 and CD4 immunologic response as measured by an increase in brachyury-specific T cells.|Evidence of clinical benefit, such as progression-free survival, RECIST criteria, reduction in serum markers, and/or reduction in circulating tumor cells.|Frequency of immune cell subsets in peripheral blood and changes in serum levels of cytokines and antibodies to brachyury.|Correlation of brachyury expression in tissue samples with clinical outcomes.",https://ClinicalTrials.gov/show/NCT02179515
303,NCT02176746,A Phase I/II Study of Active Immunotherapy With Cancer Stem Cells Vaccine for Colorectal Cancer,Completed,No Results Available,"Neoplasms,Colorectal",Biological: cancer stem cell vaccine,"Fuda Cancer Hospital, Guangzhou|University of Michigan",Both,"18 Years to 80 Years   (Adult, Senior)",Phase 1|Phase 2,40,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment,CLC-001,25-Jun-14,6/1/2014,5/1/2015,6/1/2015,Jun-14,No Study Results Posted,CSC,May-15,The number of participants with adverse events|The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements,https://ClinicalTrials.gov/show/NCT02176746
305,NCT02163057,Study of HPV Specific Immunotherapy in Patients With HPV Associated Head and Neck Squamous Cell Carcinoma,"Active, not recruiting",No Results Available,Head and Neck Squamous Cell Cancer,Biological: 1.1 mL of INO-3112 (VGX-3100 + INO-9012) delivered IM via EP with CELLECTRA-5P device,Inovio Pharmaceuticals|University of Pennsylvania,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,22,Industry|Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,HPV-005,10-Jun-14,6/1/2014,3/1/2017,6/3/2016,Jun-16,No Study Results Posted,null,Dec-16,Safety and Tolerability of INO-3112 (VGX-3100 and INO-9012) delivered via IM+EP|Immunogenicity of INO-3112 (VGX-3100 and INO-9012) delivered via IM+EP,https://ClinicalTrials.gov/show/NCT02163057
319,NCT02054520,Immunotherapy Study for Patients With Stage IV Melanoma,Recruiting,No Results Available,Stage IV Melanoma|Metastatic Melanoma,Drug: HyperAcute®-Melanoma (HAM) Immunotherapy|Drug: Ipilimumab|Drug: Pembrolizumab|Drug: Nivolumab,NewLink Genetics Corporation,Both,"18 Years and older   (Adult, Senior)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NLG0304|1303-1217,3-Feb-14,6/1/2014,null,10/28/2015,Oct-15,No Study Results Posted,null,Dec-16,Safety|Clinical Response Rate|Clinical Activity|Anti-tumor Immune Response|Immune Activation|Anti-Tumor Mechanism,https://ClinicalTrials.gov/show/NCT02054520
329,NCT02178670,Safety and Effectivity Immunotherapy to Treat Ovarian Cancer With Cancer Stem Cells Vaccine,Completed,No Results Available,"Neoplasms,Ovarian",Biological: CSC-DC,"Fuda Cancer Hospital, Guangzhou|University of Michigan",Female,"18 Years to 75 Years   (Adult, Senior)",Phase 1|Phase 2,40,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment,CLO-001|201401,27-Jun-14,6/1/2014,4/1/2015,6/1/2015,Jun-14,No Study Results Posted,null,Apr-15,The primary study purpose to determine the safety of immunization with cancer stem cells vaccine by the number of participants with adverse events|The secondary objectives are to evaluate vaccine immune responses to the immunizations by the data of body measurements,https://ClinicalTrials.gov/show/NCT02178670
505,NCT02169609,Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma,Not yet recruiting,No Results Available,"Neuroblastoma|Neoplasm, Residual|Effects of Immunotherapy",Drug: Dinutuximab. Immunotherapy,Fundació Sant Joan de Déu,Both,"up to 18 Years   (Child, Adult)",Phase 2,10,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,HSJD-HR-NB-Ch14.18,12-Jun-14,6/1/2014,5/1/2017,6/18/2014,Jun-14,No Study Results Posted,null,May-17,Number of Participants with Serious and Non-Serious Adverse Events|Relapse-free survival,https://ClinicalTrials.gov/show/NCT02169609
558,NCT02221739,Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC),"Active, not recruiting",No Results Available,Non-small Cell Lung Cancer (NSCLC),Drug: Ipilimumab|Radiation: Radiotherapy (IMRT or 3-D CRT),New York University School of Medicine|Bristol-Myers Squibb,Both,"18 Years to 99 Years   (Adult, Senior)",Phase 2,39,Other|Industry,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,S14-00208,24-Jun-14,6/1/2014,12/1/2018,12/11/2015,Dec-15,No Study Results Posted,null,Jul-15,Therapeutic efficacy of anti-CTLA-4 mAb and concurrent local RT in NSCLC patients with metastatic disease.|The effects of RT and anti-CTLA-4 mAb on development of anti-tumor immunity.,https://ClinicalTrials.gov/show/NCT02221739
793,NCT02232230,A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T,"Active, not recruiting",No Results Available,Castrate Refractory Metastatic Prostate Cancer (mCRPC),Drug: Provenge,21st Century Oncology|Dendreon,Male,"18 Years and older   (Adult, Senior)",Phase 2,20,Other|Industry,Observational,Observational Model: Cohort|Time Perspective: Retrospective,21C-2013-02,18-Jul-14,6/1/2014,null,7/13/2016,Jul-16,No Study Results Posted,null,Jun-17,Change in immune stimulation,https://ClinicalTrials.gov/show/NCT02232230
1250,NCT02082353,Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995,Recruiting,No Results Available,"Granulomatous Disease, Chronic",,National Institute of Allergy and Infectious Diseases (NIAID)|Primary Immune Deficiency Treatment Consortium|Rare Diseases Clinical Research Network|Pediatric Blood and Marrow Transplant Consortium,Both,"Child, Adult, Senior",,1480,NIH|Other,Observational,Observational Model: Case Control,DAIT RDCRN PIDTC-6903,6-Mar-14,6/1/2014,8/1/2019,3/24/2016,Mar-16,No Study Results Posted,null,Aug-19,Death|Engraftment|Quality of Life Measures|Infections|Autoimmune or inflammatory complications,https://ClinicalTrials.gov/show/NCT02082353
15,NCT02203526,"Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Dose-Adjusted-Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (DA-TEDDI-R) in Primary CNS Lymphoma",Suspended,No Results Available,Primary Central Nervious System Lymphoma,Drug: TEDDI|Biological: Rituximab|Drug: Cytarabine|Drug: TEDD|Drug: Ibrutinib,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 100 Years   (Adult, Senior)",Phase 1,17,NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,140157|14-C-0157,29-Jul-14,7/1/2014,6/1/2023,6/7/2016,Jun-16,No Study Results Posted,null,Jun-22,MTD of ibrutinib when given with TEDD-R,https://ClinicalTrials.gov/show/NCT02203526
610,NCT02138734,A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer,Recruiting,No Results Available,Non-muscle Invasive Bladder Cancer,Biological: BCG+ALT-803|Biological: BCG,Altor Bioscience Corporation,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,115,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Factorial Assignment|Masking: Open Label|Primary Purpose: Treatment,CA-ALT-803-01-14,13-May-14,7/1/2014,10/1/2018,6/7/2016,Jun-16,No Study Results Posted,null,Jul-18,Safety Profile|MTD Determination and RD Designation|Clinical Benefit|Pharmacokinetics|Biomarkers|Molecular Alterations|Immune Cell Assessment|Immunogenicity|Overall Survival,https://ClinicalTrials.gov/show/NCT02138734
644,NCT02117024,A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,"Active, not recruiting",No Results Available,Non Small Cell Lung Cancer,"Drug: Viagenpumatucel-L|Drug: Metronomic Cyclophosphamide|Drug: Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)",Heat Biologics,Both,"18 Years and older   (Adult, Senior)",Phase 2,123,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,HS110-201,15-Apr-14,7/1/2014,6/1/2018,9/1/2015,Jun-15,No Study Results Posted,null,Jun-17,Overall survival (OS)|Safety|Disease Control Rate (DCR)|6-Month Disease Control Rate (6mDCR)|Overall Response Rate (ORR)|Progression-Free Survival (PFS)|Time to Progression (TTP)|Survival at 6 months|Survival at 12 months|Immune Response,https://ClinicalTrials.gov/show/NCT02117024
843,NCT02202928,Adoptive Cell Therapy Plus Chemotherapy and Radiation After Surgery in Treating Patients With Colorectal Cancer,"Active, not recruiting",No Results Available,Colorectal Cancer|Neoplasms|Intestinal Neoplasms|Digestive System Neoplasms|Gastrointestinal Diseases,Biological: DC-CIK|Radiation: Radiotherapy|Drug: Chemotherapy,"Shenzhen Hornetcorn Bio-technology Company, LTD|Jingzhou Central Hospital",Both,"18 Years to 80 Years   (Adult, Senior)",Phase 2,60,Industry|Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,HYK-Colorectal Cancer,25-Jul-14,7/1/2014,12/1/2017,12/23/2015,Jul-15,No Study Results Posted,null,Dec-17,Progress-free survival|Overall survival|Quality of life (QOL)|Phenotypic analysis of T cells,https://ClinicalTrials.gov/show/NCT02202928
989,NCT01827579,Infusion of Depleted T Cells Following Unrelated Donor Stem Cell Transplant (ICAT),Recruiting,No Results Available,Haematological Malignancies,Biological: CD25/71 allodepleted donor T-cells,"University College, London|Medical Research Council",Both,"16 Years and older   (Child, Adult, Senior)",Phase 1|Phase 2,24,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Prevention,UCL/11/0519|2013-000872-14|MR/K007491/1,4-Apr-13,7/1/2014,7/1/2018,11/30/2015,Nov-15,No Study Results Posted,ICAT,Jan-18,Circulating CD3+ve T cell count at 4 months post-SCT|Incidence of grade II-IV acute and chronic GVHD|Time to recovery of normal T-cell (>700/uL) and CD4 (>300/uL) counts and normal TCR diversity as assessed by Vb spectratyping|In vitro anti-viral responses of circulating PBMC|Transplant related mortality at 1 year post-SCT|Disease-free survival at 1 year post-SCT,https://ClinicalTrials.gov/show/NCT01827579
1061,NCT02578641,"Multicentre, Randomized, Open-Label, Phase III Clinical Trial for Advanced Nasopharyngeal Carcinoma Patients",Recruiting,No Results Available,Nasopharyngeal Cancer,Biological: autologous EBV specific Cytotoxic T Lymphocytes|Drug: combination IV gemcitabine and IV carboplatin (AUC2),Tessa Therapeutics,Both,"21 Years and older   (Adult, Senior)",Phase 3,330,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,FF01,12-Oct-15,7/1/2014,12/1/2021,7/7/2016,May-16,No Study Results Posted,null,Dec-18,Prolonging Overall Survival|Disease Progression|Overall Response Rate|Clinical Benefit Rate|Quality of Life of patients,https://ClinicalTrials.gov/show/NCT02578641
1077,NCT02085629,The ONE Study M Reg Trial,Recruiting,No Results Available,"Renal Failure, End Stage",Biological: Donor M reg (Mreg_UKR),University of Regensburg,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,16,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ONEmreg12|2013-000999-15|grant number 260687,10-Mar-14,7/1/2014,7/1/2017,7/11/2016,Jul-16,No Study Results Posted,ONEmreg12,Jul-17,"biopsy-confirmed acute rejection incidence|time to first acute rejection episode|severity of acute rejection episodes|total immunosuppressive burden|incidence of patients treated for subclinical acute rejection|prevention of chronic graft dysfunction (chronic rejection or IF/TA)|incidence of post-transplant dialysis, inclusion on the transplant waiting list or re-transplantation following graft loss through rejection|avoidance of drug-related complications by immunosuppressant reduction|incidence of embolic pulmonary complications and other embolic events|incidence of immunological reactions resulting in anaphylactoid reactions, immediate cardiovascular compromise or other acute organ failure|biochemical disturbances caused by cell infusion|over-suppression of the immune system assessed by the incidence of major and/or opportunistic infections, especially CMV, EBV and polyoma virus|over-suppression of the immune system assessed by the incidence of neoplasia|immunological condition of study patients",https://ClinicalTrials.gov/show/NCT02085629
1107,NCT02158091,"A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL",Recruiting,No Results Available,Chronic Lymphocytic Leukemia,Drug: IPI-145|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Rituximab,"Dana-Farber Cancer Institute|Infinity Pharmaceuticals, Inc.",Both,18 Years to 65 Years   (Adult),Phase 1|Phase 2,32,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,14-193,4-Jun-14,7/1/2014,7/1/2021,6/29/2016,Jun-16,No Study Results Posted,null,Oct-17,Rate of minimal residual disease negative complete response (MRD-negative CR) in the bone marrow|Determination of the maximum tolerated dose (MTD) of IPI-145 with FCR|Duration of Response|Number of Participants with Serious and Non-Serious Adverse Events|Overall Response Rate|Complete response rate|Partial response rate|Rate of minimal residual disease (MRD) in the peripheral blood|Established CLL prognostic factors,https://ClinicalTrials.gov/show/NCT02158091
1214,NCT02073123,Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma,Recruiting,No Results Available,Metastatic Melanoma|Stage III Melanoma|Stage IV Melanoma,Drug: Indoximod|Drug: Ipilimumab|Drug: Nivolumab|Drug: Pembrolizumab,NewLink Genetics Corporation,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,56,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NLG2103,25-Feb-14,7/1/2014,null,3/22/2016,Mar-16,No Study Results Posted,null,Dec-16,Overall Incidence of Adverse Events as a Measure of Safety and Tolerability|Phase 2 Dosing|Overall Response Rate|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Overall Survival|Mechanisms of activity/resistance to IDO/CTLA-4 inhibitor therapy|Progression Free Survival|Disease control rate,https://ClinicalTrials.gov/show/NCT02073123
367,NCT02215837,Study of Autologous Tumor Lysate-pulsed D-CIK Combined With Chemotherapy for Gastric Cancer,"Active, not recruiting",No Results Available,Gastric Cancer|Neoplasms|Gastrointestinal Neoplasms|Digestive System Neoplasms|Gastrointestinal Diseases,Drug: Chemotherapy|Biological: Ag-D-CIK,"Shenzhen Hornetcorn Bio-technology Company, LTD|Affiliated Tumor Hospital of Guangzhou Medical University|Jingzhou Central Hospital",Both,"18 Years to 80 Years   (Adult, Senior)",Phase 2,40,Industry|Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,HYK-Gastric Cancer,12-Aug-14,8/1/2014,5/1/2018,5/23/2016,Nov-15,No Study Results Posted,null,May-18,Progress-free survival|Overall survival|Quality of life (QOL)|Phenotypic analysis of T cells|Severity of adverse events,https://ClinicalTrials.gov/show/NCT02215837
411,NCT02197169,DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors,Recruiting,No Results Available,Glioblastoma or Gliosarcoma,Drug: Single intratumoral injection of DNX-2401|Drug: Interferon-gamma,"DNAtrix, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1,36,Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,2401BT-IFN-001,20-Jul-14,8/1/2014,null,8/1/2016,Aug-16,No Study Results Posted,TARGET-I,Aug-17,"Objective response rate (ORR) determined by MRI scan review|Incidence and severity of adverse events, including changes in laboratory test results and neurological examination findings|Number of subjects with immunological and biological effects after DNX-2401 with Interferon gamma|Changes in steroid use (dose and frequency) and clinical and KPS status overall and per study arm assignment|Overall survival (OS), progression-free survival (PFS), and clinical benefit rate (CBR).|Changes in responses to quality of life questionnaires",https://ClinicalTrials.gov/show/NCT02197169
426,NCT02239900,Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid Tumors,Recruiting,No Results Available,Liver Cancer|Lung Cancer,Drug: Ipilimumab|Radiation: Stereotactic Body Radiation Therapy (SBRT),M.D. Anderson Cancer Center|Bristol-Myers Squibb,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,120,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,2013-0882|NCI-2015-00042,11-Sep-14,8/1/2014,null,6/1/2016,Jun-16,No Study Results Posted,null,Aug-18,Maximum Tolerated Dose (MTD) of Ipilimumab and Stereotactic Body Radiation Therapy (SBRT)|Response Rate of Ipilimumab and Stereotactic Body Radiation Therapy (SBRT),https://ClinicalTrials.gov/show/NCT02239900
707,NCT02476734,FDG-PET/CT Imaging as Early Predictor of DP,"Active, not recruiting",No Results Available,Lymphoma,Biological: CART-19 autologous T-cells|Radiation: FDG-PET/CT,Abramson Cancer Center of the University of Pennsylvania,Both,"18 Years and older   (Adult, Senior)",Phase 0,9,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment,UPCC 12914,16-Jun-15,8/1/2014,null,2/23/2016,Feb-16,No Study Results Posted,null,Feb-16,NUmber of Adverse Events,https://ClinicalTrials.gov/show/NCT02476734
883,NCT02215967,Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma,Recruiting,No Results Available,"Myeloma, Plasma-Cell|Myeloma-Multiple",Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Anti-BCMA CAR T cells,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 73 Years   (Adult, Senior)",Phase 1,38,NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,140168|14-C-0168,12-Aug-14,8/1/2014,10/1/2018,7/6/2016,Jul-16,No Study Results Posted,null,Oct-17,Determine the safety of administering T cells expressing an BCMA CAR,https://ClinicalTrials.gov/show/NCT02215967
85,NCT02099539,A Study of ALT-803 in Patients With Relapsed or Refractory Multiple Myeloma,Recruiting,No Results Available,Relapsed or Refractory Multiple Myeloma,Biological: ALT-803,Altor Bioscience Corporation|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,57,Industry|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CA-ALT-803-02-13|CA167925,26-Feb-14,9/1/2014,1/1/2020,7/13/2016,Jul-16,No Study Results Posted,null,Oct-16,"Safety Profile|MTD or MED Determination, Phase II Dose Level Designation|Clinical Benefit|Blood Cell Counts|Pharmacokinetics|Biomarkers|Immunogenicity|Overall Survival",https://ClinicalTrials.gov/show/NCT02099539
99,NCT02320383,CLLR3: FC + GA101 and B + GA101 in Relapsed or Refractory CLL Followed by GA101 Maintenance for Responding Patients,Recruiting,No Results Available,Chronic Lymphocytic Leucemia,Drug: FC+ GA101|Drug: B+ GA101,Munich Municipal Hospital|German CLL Study Group,Both,"18 Years and older   (Adult, Senior)",Phase 2,100,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CLLR3,1-Sep-14,9/1/2014,9/1/2022,3/18/2016,Mar-16,No Study Results Posted,null,Sep-21,"Evaluate the efficacy of two regimens of immunochemotherapy, i.e. Response rates of Fludarabine, Cyclophosphamide plus GA101 (FCG) and Bendamustine plus GA101 (BG), in patients with relapsed or refractory CLL.|MRD levels|Progression free survival (PFS)|Event-free survival (EFS)|Overall survival (OS)|Duration of response in patients with CR/ CRi, clinical CR / clinical CRi or nPR/ PR|Time to next anti-leukemia treatment|Overall response rate in biological defined risk groups|Complete response rate|Safety parameters during induction and maintenance phase",https://ClinicalTrials.gov/show/NCT02320383
143,NCT02496520,Dendritic Cell-based Immunotherapy for Advanced Solid Tumours of Children and Young Adults,Recruiting,No Results Available,Sarcoma|Central Nervous System Tumor,Biological: dendritic cells|Procedure: Surgery as needed by the patient´s tumor and stage|Drug: Chemotherapy as needed by the patient´s tumor and stage|Radiation: Radiation therapy as needed by the patient´s tumor and stage,"Clinica Universidad de Navarra, Universidad de Navarra",Both,"3 Years to 40 Years   (Child, Adult)",Phase 1|Phase 2,10,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,DEND/TIA|2013-003632-71,15-Jun-15,9/1/2014,9/1/2021,7/16/2015,Jun-15,No Study Results Posted,DEND/TIA,Sep-17,"Number and type of adverse events detected in the follow up as a measure of safety and tolerability|Event free progression, overall survival, time to progression and number and size of existent tumoral lesions as measures of clinical efficacy|Humoral and cellular immune response as a measure of the immunogenicity of the vaccine.|Quality of life measured with QLQ-C30, QLQ-BN20 questionnaires.",https://ClinicalTrials.gov/show/NCT02496520
158,NCT02140996,Safety Study of Human MUC-1 (Mucin-1) Adenoviral Vector Vaccine for Immunotherapy of Epithelial Cancers,Recruiting,No Results Available,"Epithelial Cancers of the Lung, Breast, Ovary, Prostate and Colon",Drug: Ad-sig-hMUC-1/ecdCD40L vector vaccine,"Singapore Clinical Research Institute|MicroVAX, LLC|ClinDatrix, Inc.",Both,"21 Years and older   (Adult, Senior)",Phase 1,24,Other|Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MUC-1,8-May-14,9/1/2014,2/1/2017,2/11/2016,Feb-16,No Study Results Posted,MUC-1,Nov-16,"Assessment of a safe, tolerable, and immunologically active dose level of the Ad-sig-hMUC-1/ecdCD40L vector vaccine",https://ClinicalTrials.gov/show/NCT02140996
232,NCT02130869,A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas,Recruiting,No Results Available,Neuroblastoma|Lymphoma|High-risk Tumor,Device: CD133+ selected autologous stem cell infusion|Biological: IL-2|Biological: hu14.18K322A|Drug: Busulfan|Drug: Melphalan|Biological: GM-CSF|Drug: Bendamustine|Drug: Etoposide|Drug: Cytarabine|Drug: Carboplatin|Device: Haploidentical natural killer cell infusion|Biological: G-CSF|Drug: Etoposide phosphate,St. Jude Children's Research Hospital,Both,"up to 21 Years   (Child, Adult)",Phase 1,36,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ASCIST|NCI-2014-00275,1-May-14,9/1/2014,9/1/2020,4/18/2016,Apr-16,No Study Results Posted,null,Sep-20,Percent of participants with positive ANC engraftment|Overall survival|Disease-free survival|Incidence of relapse|Lymphocyte and hematopoietic reconstitution|Characteristics of the stem cell grafts|Characteristics of the natural killer cell grafts.|Overall survival of patients treated without stem cell manipulation or NK cell infusion due to off therapy criteria,https://ClinicalTrials.gov/show/NCT02130869
301,NCT02256514,Open Label Trial of Immunotherapy for Advanced Liver Cancer,Enrolling by invitation,No Results Available,HCC|Liver Cirrhosis,Biological: Daily oral dose of hepcortespenlisimut-L,Immunitor LLC|Immunitor Inc.,Both,"18 Years and older   (Adult, Senior)",Phase 2,120,Industry,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IMMV5,24-Sep-14,9/1/2014,12/1/2016,3/31/2016,Mar-16,No Study Results Posted,HCC,Sep-16,Effect of hepcortespenlisimut-L (V5) immunotherapy on serum levels of AFP (IU/ml) compared to baseline|Effect of hepcortespenlisimut-L (V5) immunotherapy on tumor size or clearance|Effect of hepcortespenlisimut-L (V5) immunotherapy in patients with advanced HCC on blood biochemistry parameters|Effect of hepcortespenlisimut-L (V5) immunotherapy on patients' performance,https://ClinicalTrials.gov/show/NCT02256514
406,NCT02153580,"Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia or B-Cell Prolymphocytic Leukemia","Active, not recruiting",No Results Available,"Post-transplant Lymphoproliferative Disorder|B-Cell Prolymphocytic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Hairy Cell Leukemia|B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma|B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma|Recurrent Lymphoplasmacytic Lymphoma",Drug: cyclophosphamide|Biological: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Other: laboratory biomarker analysis|Drug: Bendamustine Hydrochloride|Drug: Etoposide|Drug: Fludarabine Phosphate,City of Hope Medical Center|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,48,Other|NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,13351|NCI-2014-01168,30-May-14,9/1/2014,null,7/29/2016,Jul-16,No Study Results Posted,null,Sep-17,"Toxicity profile of T-cell infusion as defined by all toxicities associated with T cells at the probably or definite levels|Dose-limiting toxicity rate at the recommended phase II dose assessed using CTCAE v4.0|Detection of transferred T cells in the circulation for at least 28 days by quantitative-polymerase chain reaction|Disease response by physical exam, lab data, radiographic imaging and, in the case of stratum 2 (CLL/PLL) and leukemic phase NHL patients by flow cytometry and bone marrow biopsy|CD19 B cell aplasia/immunoglobulin G levels",https://ClinicalTrials.gov/show/NCT02153580
429,NCT02146924,Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia,Recruiting,No Results Available,B-cell Adult Acute Lymphoblastic Leukemia|Recurrent Adult Acute Lymphoblastic Leukemia,Biological: autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Other: laboratory biomarker analysis|Biological: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes,City of Hope Medical Center|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,48,Other|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,13447|NCI-2014-01060,19-May-14,9/1/2014,null,3/14/2016,Mar-16,No Study Results Posted,null,Sep-17,Toxicity profile of T-cell infusion as defined by all toxicities associated with T cells at the probably or definite levels assessed using Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (v4.0)|Dose-limiting toxicity rate at the RP2D assessed using CTCAE v4.0 for Arm I (CD19R(EQ)28zeta/EGFRt+ TCM)|Dose-limiting toxicity rate at the RP2D assessed using CTCAE v4.0 for Arm II (CD19R(EQ)28zeta/EGFRt+ TN/NEM)|Detection of transferred T cells in the circulation for at least 28 days by quantitative-PCR|Complete response (CR) or complete response with incomplete bone marrow recovery (CRi) with the exception of participants in CR or CRi that go from MRD negative to MRD positive or progress as determined by the Principal Investigator (PI)|No MRD|CD19 B cell aplasia/immunoglobulin G levels|Proof of elimination of T cell product by cetuximab,https://ClinicalTrials.gov/show/NCT02146924
662,NCT02077868,Evaluation of MGN1703 Maintenance Treatment in Patients With mCRC With Tumor Reduction During Induction Treatment,Recruiting,No Results Available,Metastatic Colorectal Cancer,Other: Usual Maintenance|Drug: MGN1703 treatment,Mologen AG,Both,"18 Years and older   (Adult, Senior)",Phase 3,540,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MGN1703-C06,28-Feb-14,9/1/2014,6/1/2019,10/5/2015,Oct-15,No Study Results Posted,IMPALA,Oct-17,Overall survival|Progression Free Survival (PFS)|Safety|Overall Response rate|Quality of life (QoL),https://ClinicalTrials.gov/show/NCT02077868
711,NCT02234921,Pilot Study of DRibble Vaccine for Prostate Cancer Patients,Recruiting,No Results Available,Adenocarcinoma of the Prostate,Drug: Cyclophosphamide|Biological: DRibble Vaccine|Biological: HPV Vaccinations|Drug: Imiquimod,"UbiVac|Providence Health & Services|Providence Cancer Center|Providence Cancer Center, Earle A. Chiles Research Institute",Male,"Child, Adult, Senior",Phase 1,6,Industry|Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,14-116B,4-Sep-14,9/1/2014,9/1/2019,5/26/2015,May-15,No Study Results Posted,DRibble,Sep-18,Safety Assessment|Immune Response|Prostate Cancer Response to DRibble vaccine,https://ClinicalTrials.gov/show/NCT02234921
1084,NCT02213263,"A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)",Recruiting,No Results Available,Follicular Lymphoma,Biological: PF-05280586|Biological: MabThera®,Pfizer,Both,"18 Years and older   (Adult, Senior)",Phase 3,394,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",B3281006|2014-000132-41|REFLECTIONS,7-Aug-14,9/1/2014,1/1/2018,7/5/2016,Jul-16,No Study Results Posted,null,Jul-17,Objective Response Rate (ORR) according to the revised response criteria for malignant lymphoma|Time to Treatment Failure (TTF)|Progression-Free Survival (PFS)|Complete Remission (CR) rate|Duration of response|Overall survival|Maximum observed plasma concentration (Cmax)|Minimum observed plasma concentration (Cmin)|CD19-positive B-cell counts|Incidence of anti-drug antibodies (ADA) and safety associated with immune response,https://ClinicalTrials.gov/show/NCT02213263
1096,NCT01948180,Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma,Recruiting,No Results Available,"Lymphoma, Extranodal NK-T-Cell|EBV",Biological: CMD-003,Cell Medica Ltd,Both,"18 Years and older   (Adult, Senior)",Phase 2,30,Industry,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CM-2013-01,13-Sep-13,9/1/2014,6/1/2018,7/18/2016,Feb-16,No Study Results Posted,CITADEL,Jun-17,Assess overall response rate (ORR = CR + PR)|Response duration|Overall survival,https://ClinicalTrials.gov/show/NCT01948180
93,NCT02259231,RTA 408 Capsules in Patients With Melanoma - REVEAL,Recruiting,No Results Available,Melanoma|Unresectable (Stage III) Melanoma|Metastatic (Stage IV) Melanoma,Drug: Omaveloxolone Capsules (2.5 mg/capsule)|Drug: Ipilimumab (3 mg/kg)|Drug: Nivolumab (3 mg/kg),"Reata Pharmaceuticals, Inc.|AbbVie",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,84,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,RTA 408-C-1401,3-Oct-14,10/1/2014,4/1/2017,2/22/2016,Feb-16,No Study Results Posted,null,Mar-17,Measure of overall response rate using RECIST (Response Evaluation Criteria in Solid Tumors),https://ClinicalTrials.gov/show/NCT02259231
115,NCT02243579,Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome,"Active, not recruiting",No Results Available,Recurrent Mycosis Fungoides and Sezary Syndrome|Stage IB Mycosis Fungoides and Sezary Syndrome|Stage IIA Mycosis Fungoides and Sezary Syndrome|Stage IIB Mycosis Fungoides and Sezary Syndrome|Stage IIIA Mycosis Fungoides and Sezary Syndrome|Stage IIIB Mycosis Fungoides and Sezary Syndrome|Stage IVA Mycosis Fungoides and Sezary Syndrome|Stage IVB Mycosis Fungoides and Sezary Syndrome,Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab,National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 2,24,NIH,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NCI-2014-00709|CITN-10|U01CA154967,16-Sep-14,10/1/2014,null,7/29/2016,Jul-16,No Study Results Posted,null,Jan-18,"Objective response rate (ORR), defined as a confirmed partial response (PR) or CR using global assessment standard response criteria for MF and SS|DOR|Incidence of adverse events graded using the Common Terminology Criteria for Adverse Events version 4.0|OS|PFS",https://ClinicalTrials.gov/show/NCT02243579
133,NCT01875653,Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma,Terminated,No Results Available,Stage IV Melanoma|Stage III Melanoma,Biological: Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)|Biological: Autologous PBMCs in GM-CSF (MC),"Caladrius Biosciences, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 3,250,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CL-CA-P01|2015-001984-38,7-Jun-13,10/1/2014,6/1/2022,4/25/2016,Jan-16,No Study Results Posted,null,Jan-17,Overall survival|Adverse Events as a Measure of Safety and Tolerability,https://ClinicalTrials.gov/show/NCT01875653
134,NCT02280278,Cytokine-induced Killer Cell Immunotherapy for Surgical Resected Stage III Colorectal Cancer Patients After Chemotherapy,Recruiting,No Results Available,Stage III Colon Cancer,Procedure: Radical surgery|Drug: Adjuvant chemotherapy|Biological: Cytokine-induced killer cell immunotherapy,Sun Yat-sen University,Both,"18 Years to 70 Years   (Adult, Senior)",Phase 3,550,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,5010010,29-Oct-14,10/1/2014,null,11/3/2014,Nov-14,No Study Results Posted,null,Oct-19,Disease free survival|survival rate|toxin-side effect,https://ClinicalTrials.gov/show/NCT02280278
175,NCT02280811,T Cell Receptor Immunotherapy Targeting HPV-16 E6 for HPV-Associated Cancers,Completed,No Results Available,Vaginal Cancer|Cervical Cancer|Anal Cancer|Penile Cancer|Oropharyngeal Cancer,Drug: Fludarabine|Drug: Cyclophosphamide|Biological: E6 TCR|Drug: Aldesleukin,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 70 Years   (Adult, Senior)",Phase 2,12,NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,150005|15-C-0005,30-Oct-14,10/1/2014,6/1/2016,6/30/2016,Jun-16,No Study Results Posted,null,Jun-16,To determine the objective tumor response rate and duration in patients with metastatic or recurrent/refractory HPV-16+ cancers treated with autologous T cells expressing the E6 TCR plus aldesleukin following a lymphocyte-depleting preparative r...,https://ClinicalTrials.gov/show/NCT02280811
193,NCT02297698,Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients,Recruiting,No Results Available,Breast Cancer,Biological: NeuVax vaccine|Drug: Trastuzumab|Drug: GM-CSF,"Cancer Insight, LLC|Genentech, Inc.|Galena Biopharma, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Prevention,2014-0443,14-Nov-14,10/1/2014,10/1/2019,12/21/2015,Dec-15,No Study Results Posted,HER3+,Oct-16,Invasive Disease-free survival (DFS)|Distant recurrence-free survival (DRFS)|Local and systemic toxicities|Evaluate in vivo and in vitro immune responses,https://ClinicalTrials.gov/show/NCT02297698
241,NCT02170389,Vaccine Therapy Before Surgery in Treating Patients With Localized Kidney Cancer,Recruiting,No Results Available,Recurrent Renal Cell Carcinoma|Stage I Renal Cell Cancer|Stage II Renal Cell Cancer,Other: Laboratory Biomarker Analysis|Procedure: Nephrectomy|Biological: Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003,Roswell Park Cancer Institute|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",,10,Other|NIH,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,I 250113|NCI-2014-01254|AGS-003-012|P30CA016056,19-Jun-14,10/1/2014,null,7/29/2016,Jul-16,No Study Results Posted,null,Apr-17,Change in immune marker expression levels|Adverse event rates as graded by the Common Terminology Criteria for Adverse Events version 4.0,https://ClinicalTrials.gov/show/NCT02170389
531,NCT02621151,"Pembrolizumab (MK3475), Gemcitabine, and Concurrent Hypofractionated Radiation Therapy for Muscle-Invasive Urothelial Cancer of the Bladder",Recruiting,No Results Available,Muscle-invasive Urothelial Cancer of the Bladder,Biological: Pembrolizumab|Procedure: Transurethral Resection of Bladder Tumor|Drug: Gemcitabine|Radiation: External Beam Radiation Therapy,New York University School of Medicine|Merck Sharp & Dohme Corp.,Both,"18 Years and older   (Adult, Senior)",Phase 2,54,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,S15-00220,1-Dec-15,10/1/2014,5/1/2024,6/23/2016,Jun-16,No Study Results Posted,null,May-21,Two-year bladder-intact disease-free survival rate|Safety (adverse events) of the protocol therapy|Complete response (CR) rate|Overall survival|Metastasis-free survival,https://ClinicalTrials.gov/show/NCT02621151
725,NCT02274155,Anti-OX40 Antibody in Head and Neck Cancer Patients,Recruiting,No Results Available,Head and Neck Cancer,Drug: Anti-OX40 antibody administration|Procedure: Surgical Resection,Providence Health & Services|MedImmune LLC,Both,"18 Years and older   (Adult, Senior)",Phase 1,55,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,14-042A,14-Oct-14,10/1/2014,10/1/2019,6/23/2016,Jun-16,No Study Results Posted,null,Oct-18,Safety and feasibility of definitive surgical resection for locoregionally advanced OHNSCC following MEDI6469 administration|Immunologic phenotypes of lymphocyte subsets,https://ClinicalTrials.gov/show/NCT02274155
761,NCT02273375,Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC,Recruiting,No Results Available,Non-Small Cell Lung Cancer,Drug: MEDI4736|Drug: Placebo,"Canadian Cancer Trials Group|Intergroupe Francophone de Cancerologie Thoracique (IFCT)|Australasian Lung Cancer Trials Group|National Health and Medical Research Council, Australia|National Cancer Institute (NCI), Naples|Central and Eastern European Oncology Group|Dutch Society of Physicians for Pulmonology and Tuberculosis|Korean Cancer Study Group|Spanish Lung Cancer Group|West Japan Oncology Group (WJOG)",Both,"18 Years and older   (Adult, Senior)",Phase 3,1100,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",BR31|IFCT1401|ACTRN12615000323527,22-Oct-14,10/1/2014,null,7/12/2016,Mar-16,No Study Results Posted,null,Jan-25,"Compare Disease free survival (DFS) for patients with NSCLC that is PD-L1 positive|Compare Disease Free Survival in all randomized patients|Compare overall survival (OS) for patients with NSCLC that is PD-L1 positive|Compare overall survival for all randomized patients|Compare Lung cancer specific survival for patients with NSCLC that is PD-L1 positive and all randomized patients|Evaluate the nature, severity and frequency of adverse effects and tolerability of MEDI4736|Evaluate the Quality of life between the two treatment arms in PD-L1+ patients and in all randomized patients.|Determine survival benefits participants judge necessary to make adjuvant immunotherapy worthwhile|Determine the incremental cost effectiveness and cost utility ratios for MEDI4736|Evaluate the predictive/prognostic significance of PD-L1 expression|Evaluation of changes in plasma/serum cytokines and other blood and tissue based biomarkers after treatment with MEDI4736 and at disease event|Explore polymorphisms that may be associated with outcomes",https://ClinicalTrials.gov/show/NCT02273375
803,NCT01795976,NY-ESO-1 T Cells in OG Cancer,"Active, not recruiting",No Results Available,Oesophageal Cancer,Genetic: NY-ESO-1 T cells|Drug: cyclophosphamide|Drug: Fludarabine|Biological: Interleukin 2,Fiona Thistlethwaite|The Christie NHS Foundation Trust|Erasmus Medical Center|Ospedale San Raffaele|University College London Hospitals|Karolinska University Hospital|The Netherlands Cancer Institute,Both,"18 Years and older   (Adult, Senior)",Phase 2,28,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,12_DOG14_22,10-Jan-13,10/1/2014,8/1/2018,2/12/2016,Feb-16,No Study Results Posted,ATTACK-OG,Dec-16,Response rate to New York esophageal squamous cell carcinoma (NYESO) T cells|Response rate to NYESO T cells|Feasibility and tolerability of NY-ESO-1 targeted cell therapy|Evaluation of the progression free survival,https://ClinicalTrials.gov/show/NCT01795976
114,NCT02267603,Pembrolizumab in Treating Patients With Advanced Merkel Cell Cancer,Recruiting,No Results Available,Recurrent Merkel Cell Carcinoma|Stage IIIA Merkel Cell Carcinoma|Stage IIIB Merkel Cell Carcinoma|Stage IV Merkel Cell Carcinoma,Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab,National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 2,50,NIH,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NCI-2014-00848|MK-3475|CITN-09|U01CA154967,14-Oct-14,11/1/2014,null,8/3/2016,Jul-16,No Study Results Posted,null,Jan-18,Objective response rate (ORR) defined as the proportion of patients who have achieved complete response (CR) or partial response (PR) according to RECIST version 1.1|Duration of response (DOR)|Incidence of adverse events (AEs) graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Overall survival (OS)|Progression-free survival (PFS) using RECIST 1.1,https://ClinicalTrials.gov/show/NCT02267603
183,NCT02317471,Immunotherapy of Gastric Cancer With Autologous Tumor Derived Heat Shock Protein gp96,Recruiting,No Results Available,Gastric Carcinoma,Biological: autologous gp96 vaccination|Drug: Oxaliplatin+S-1,"Chinese PLA General Hospital|Cure&Sure Biotech Co., LTD",Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1|Phase 2,45,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,PLAG-CS-Ga-01,10-Dec-14,11/1/2014,12/1/2017,6/2/2016,Jun-16,No Study Results Posted,null,Dec-17,Disease free survival|Number of participants with adverse events related to gp96 immunotherapy|Changes in antigen specific T cells|Overall survival,https://ClinicalTrials.gov/show/NCT02317471
352,NCT02173093,Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma,Suspended,No Results Available,Desmoplastic Small Round Cell Tumor|Disseminated Neuroblastoma|Metastatic Osteosarcoma|Recurrent Neuroblastoma|Recurrent Osteosarcoma,Biological: IL-2|Biological: GD2Bi-aATC|Biological: GM-CSF|Other: laboratory evaluations of immune responses,Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI),Both,"13 Months to 29 Years   (Child, Adult)",Phase 1|Phase 2,40,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2013-171|NCI-2014-01149|P30CA022453,22-Jun-14,11/1/2014,5/1/2018,2/15/2016,Feb-16,No Study Results Posted,null,May-18,Maximum tolerated dose (MTD) of GD2Bi-aATC|Anti-tumor activity|Immune responses after GD2Bi-aATC infusions,https://ClinicalTrials.gov/show/NCT02173093
501,NCT02301754,INVAC-1 Anti-Cancer hTERT DNA Immunotherapy,Recruiting,No Results Available,Solid Tumors,Biological: INVAC-1,Invectys|Keyrus,Both,"18 Years and older   (Adult, Senior)",Phase 1,18,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,INVAC1-CT-101,18-Nov-14,11/1/2014,12/1/2017,5/9/2016,May-16,No Study Results Posted,null,Aug-16,"Dose Limiting Toxicities (DLTs) of INVAC-1 as single agent in combination with electroporation|Adverse Events as characterized by type, frequency, severity (as graded by NCI Common Toxicity Criteria for Adverse Effects (CTCAE) v.4.03), timing, seriousness and relationship to study therapy INVAC-1 + electroporation;|Routine laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE v.4.03) and timing|Tumor Necrosis Factor-α, Interleukine (IL)-17, IL-8, IL-6, IL-1β measured in serum|anti-nuclear antibodies (ANA), anti-DNA, anti-TPO measured in serum|Elispot Interferon gamma|Absolute cell counts and phenotype for circulating T and Natural Killer cells|circulating tumor DNA assessed by quantification of the allelic fraction of the DNA mutations; circulating DNA is extracted from plasma|Objective response assessed by immune-related Response Criteria (ir-RC);|Duration of response|Progression free survival|Overall survival",https://ClinicalTrials.gov/show/NCT02301754
765,NCT02315612,Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies,Recruiting,No Results Available,Follicular Lymphoma|ALL|NHL|Large Cell Lymphoma,Biological: CD22-CAR,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"1 Year to 30 Years   (Child, Adult)",Phase 1,57,NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,150029|15-C-0029,11-Dec-14,11/1/2014,1/1/2020,8/3/2016,Apr-16,No Study Results Posted,null,Jan-18,"Feasibility|Safety|Explore administration of cells & amp; mediating antitumor effects|Measure persistence of T-cells|Assess cognitive effects|Safety, feasibility, clinical impact of cryo-cells following chemo regimen post-initial infusion|Explore cog. test score & amp; cytokine level relationships",https://ClinicalTrials.gov/show/NCT02315612
985,NCT02311621,Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01,Recruiting,No Results Available,Neuroblastoma|Ganglioneuroblastoma,Biological: Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells)|Biological: Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells),Seattle Children's Hospital,Both,"up to 18 Years   (Child, Adult)",Phase 1,80,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ENCIT-01,4-Dec-14,11/1/2014,null,4/12/2016,Apr-16,No Study Results Posted,null,Nov-17,Dose Limiting Toxicity|Response (Tumor response will be evaluated by the revised International Neuroblastoma Response Criteria),https://ClinicalTrials.gov/show/NCT02311621
1013,NCT02291614,A Phase 1 Study of AMG 211 in Subjects With Advanced Gastrointestinal Cancer,Recruiting,No Results Available,GI Adenocarcinoma,Drug: AMG 211,Amgen|MedImmune LLC,Both,"18 Years and older   (Adult, Senior)",Phase 1,78,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,20130354|2014-000201-12,6-Nov-14,11/1/2014,10/1/2017,7/29/2016,Jul-16,No Study Results Posted,null,Apr-17,"Subject incidence of treatment emergent adverse events (TEAEs) as a Measure of Safety|Subject incidence of dose-limiting toxicities (DLTs) as a Measure of Safety|Subject incidence of clinically significant changes in vital signs, electrocardiograms, physical examination findings, and clinical laboratory tests as a Measure of Safety|Determination of serum concentrations of AMG 211 after continuous intravenous (cIV) infusion as PK Measure|Incidence of anti-AMG 211 antibody formation|Time to progression (TTP)|Progression-free rate|Efficacy parameters: overall response rate (ORR; per modified irRC), duration of response, time to response",https://ClinicalTrials.gov/show/NCT02291614
1070,NCT02185781,Phase I Study of Adoptive Immunotherapy With Enriched and Expanded Autologous Natural Killer (NK) Cells for Patients With Ph+ Acute Lymphoblastic Leukemia (ALL),Recruiting,No Results Available,Acute Lymphoblastic Leukemia|Complete Hematologic Remission (CHR)|Persistent/Recurrent Minimal Residual Disease (MRD),Other: Autologous NK cells infusions,Gruppo Italiano Malattie EMatologiche dell'Adulto,Both,"60 Years and older   (Adult, Senior)",Phase 1,6,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,LAL 2013,7-Jul-14,11/1/2014,9/1/2017,4/28/2015,Apr-15,No Study Results Posted,null,Sep-17,To determine the MTD and the recommended final dose (RD) to be used for further investigations.|Number of adverse events.|Number of patients able to complete the study.|Time to complete enrolment.|Number and characteristics of immunologic modifications.|Number of patients who respond to treatment.|Number of patients alive after treatment conclusion.|Number of patients alive without progression.,https://ClinicalTrials.gov/show/NCT02185781
1127,NCT02138786,Selinexor in Initial or Relapsed/Refractory Richter's Transformation,Recruiting,No Results Available,Richter's Transformation,Drug: selinexor,"Karyopharm Therapeutics, Inc",Both,"18 Years and older   (Adult, Senior)",Phase 2,50,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,KCP-330-010,13-May-14,11/1/2014,5/1/2017,4/4/2016,Apr-16,No Study Results Posted,SIRRT,Nov-16,Overall Response Rate (ORR),https://ClinicalTrials.gov/show/NCT02138786
35,NCT02042391,Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy,Recruiting,No Results Available,Posttransplant Lymphoproliferative Disorder,Drug: Rituximab sc|Drug: Rituximab sc consolidation|Drug: Rituximab sc combined with CHOP chemotherapy|Drug: Rituximab sc combined with alternating chemotherapy with CHOP and DHAOx,Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH,Both,"18 Years and older   (Adult, Senior)",Phase 2,90,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,DPTLDSG-IIT-PTLD-2,20-Jan-14,12/1/2014,9/1/2019,8/3/2015,Aug-15,No Study Results Posted,PTLD-2,Sep-19,Event free survival (EFS) of low-risk patients in the intention to treat population with following definitions for low-risk and event:|Overall survival|Time to progression|Progression-free survival|Response at interim staging|Response after full treatment|Duration of response|Treatment-related mortality,https://ClinicalTrials.gov/show/NCT02042391
178,NCT02327468,"Inovio TRT-001: Telomerase DNA Immunotherapy in Breast, Lung, and Pancreatic Cancers",Recruiting,No Results Available,Breast Cancer|Lung Cancer|Pancreatic Cancer|Head and Neck Squamous Cell Cancer|Ovarian Cancer|Colorectal Cancer|Gastric Cancer|Esophageal Cancer|Hepatocellular Cancer,Biological: INO-1400|Biological: INO-9012,Inovio Pharmaceuticals|Abramson Cancer Center of the University of Pennsylvania|University of North Carolina|Thomas Jefferson University|Wayne State University,Both,"18 Years and older   (Adult, Senior)",Phase 1,54,Industry|Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,UPCC 22913,23-Dec-14,12/1/2014,4/1/2018,8/3/2016,Aug-16,No Study Results Posted,null,Dec-17,"Adverse events graded in accordance with ""Common Terminology Criteria for Adverse Events (CTCAE)"", NCI version 4.03|Injection site reactions including, but not necessarily limited to, local skin erythema, induration, pain and tenderness at administration site [|Changes in safety laboratory parameters from baseline|Time to progression|Antigen specific cellular immune responses|Antigen specific ELISA|H&E stain; immunohistochemistry for CD45, CD3, CD8, FoxP3; and TCRbeta molecular analysis of baseline/archival tumor tissue and relapsed tumor tissue, when possible.",https://ClinicalTrials.gov/show/NCT02327468
356,NCT02470468,Evaluation of Safety and Efficacy of DCVAC/LuCa (Immunotherapy of Lung Cancer) in Patients With Metastatic Lung Cancer,Recruiting,No Results Available,Stage IV Non-small Cell Lung Cancer,Biological: DCVAC add on to SOC|Biological: DCVAC and immune enhancers add on to SOC|Other: Standard of Care Chemotherapy,Sotio a.s.,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,105,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,SLU01|2014-003084-37,3-Jun-15,12/1/2014,4/1/2018,12/16/2015,Dec-15,No Study Results Posted,null,Nov-17,"Comparison efficacy of DCVAC/LuCa + chemotherapy +/- immune enhancers vs. chemotherapy alone in patients with stage IV NSCLC, as measured by progression free survival (PFS).|Comparison of safety in patients treated with DCVAC/LuCa + chemotherapy +/- immune enhancers vs. chemotherapy alone. (AEs, SAEs, laboratory abnormalities, vital signs)|Further comparison of efficacy of DCVAC/LuCa + chemotherapy +/- immune enhancers vs. chemotherapy alone, as measured by objective response rate and duration of response (per RECIST 1.1).|Further comparison of efficacy of DCVAC/LuCa + chemotherapy +/- immune enhancers vs. chemotherapy alone, as measured by overall survival.",https://ClinicalTrials.gov/show/NCT02470468
540,NCT01799161,"Combination of gp96-Ig Vaccine, Theophylline and Oxygen for the Treatment of Patients With Advanced, Relapsed or Metastatic Non-Small Cell Lung Cancer",Withdrawn,No Results Available,Non-Small Cell Lung Cancer|Non-small-cell Lung Carcinoma|Lung Cancer|NSCLC,Biological: gp96-Ig Vaccine|Drug: Theophylline|Other: Oxygen|Procedure: Immunologic Evaluation,Eckhard Podack|University of Miami,Both,"18 Years and older   (Adult, Senior)",Phase 1,0,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,20110847,22-Feb-13,12/1/2014,null,11/14/2014,Nov-14,No Study Results Posted,null,Apr-18,Number of Adverse Events Experienced by Patients Receiving Study Treatment|Immune response to vaccination|Clinical Response to gp96-Ig Vaccination|Recommended Dose-schedule Combination for further testing,https://ClinicalTrials.gov/show/NCT01799161
752,NCT02289222,Anti-PD-1 (MK-3475) and IMiD (Pomalidomide) Combination Immunotherapy in Relapsed/Refractory Multiple Myeloma,Recruiting,No Results Available,Multiple Myeloma,Drug: MK-3475|Drug: Pomalidomide|Drug: Dexamethasone,Ashraf Badros|Merck Sharp & Dohme Corp.|University of Maryland,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,48,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,GCC1454,17-Oct-14,12/1/2014,12/1/2016,1/22/2015,Jan-15,No Study Results Posted,null,Dec-16,The number of Participants with Adverse Events|The Identification of biomarker PD-LI & Correlate Positive Expression|Time to Progression Free Survival (PFS),https://ClinicalTrials.gov/show/NCT02289222
827,NCT02129556,"Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer",Recruiting,No Results Available,Metastatic Breast Cancer,Drug: MK-3475,International Breast Cancer Study Group,Female,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,61,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IBCSG 45-13/BIG 4-13|2013-004770-10,24-Apr-14,12/1/2014,12/1/2023,4/11/2016,Apr-16,No Study Results Posted,PANACEA,Dec-17,Recommended dose of MK-3475 in combination with trastuzumab|Efficacy and safety profile of MK-3475 combined with trastuzumab|Safety and Tolerability|Disease control (DC)|Duration of Response (DoR)|Time to Progression (TTP)|Progression-free survival (PFS)|Overall survival (OS)|Efficacy and safety of the drug combination in PD-L1 negative pts,https://ClinicalTrials.gov/show/NCT02129556
940,NCT02414750,Vemurafenib Plus Cobimetinib in Metastatic Melanoma,Recruiting,No Results Available,Metastatic Melanoma,Drug: Vemurafenib plus cobimetinib|Device: Positron Emission Tomography|Procedure: Tissue sampling|Procedure: Blood sampling,Netherlands Working Group on Immunotherapy of Oncology|Hoffmann-La Roche|VU University Medical Center|The Netherlands Cancer Institute,Both,"18 Years and older   (Adult, Senior)",Phase 2,90,Other|Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label,M14REP,11-Feb-15,12/1/2014,12/1/2018,11/6/2015,Nov-15,No Study Results Posted,REPOSIT,Dec-17,"Progression Free survival (PFS)|Standardized Uptake Value (SUV) of 18F-FDG and 18F-FLT as measured by PET.|RECIST 1.1 tumor size measurement on diagnostic CT.|Cut-off values of metabolic tracer uptake of 18F-FDG/FLT on PET as a measure of response.|Diagnostic accuracy of metabolic tracer uptake on PET in responders and non-responders.|Glycolytic Index, Metabolic Tumor Volume and % Injected Dose of 18F-FDG/FLT on PET.|Immunohistochemical analysis of tumor tissue in responders and non-responders.|Changes of DNA in tumor tissue as measured by DNA deep sequencing analysis.|Changes of RNA in tumor tissue as measured by RNA expression analysis.|Changes of phosphoproteomic profiles in tumor tissue measured by nano-liquid chromatography coupled to tandem mass spectrometry (nanoLC-MS/MS).|Changes in vemurafenib and cobimetinib drug concentrations in plasma as measured by a validated Liquid Chromotography tandem Mass Spectrometry assay|Overall Survival (OS)|ECOG Performance status",https://ClinicalTrials.gov/show/NCT02414750
24,NCT02232490,Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimu (V5),Recruiting,No Results Available,Hepatocellular Carcinoma|HCC|Liver Cancer,Biological: hepcortespenlisimut-L|Biological: Placebo,Lisichansk Regional Tuberculosis Dispensary|National Cancer Center,Both,"18 Years and older   (Adult, Senior)",Phase 3,100,Other,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",Immunitor IMM05|IMM05,3-Sep-14,1/1/2015,12/1/2015,4/17/2015,Apr-15,No Study Results Posted,IMM05,Nov-15,changes in plasma AFP|CT scan,https://ClinicalTrials.gov/show/NCT02232490
142,NCT02240537,Phase I Study of an Oncofetal Antigen Multi-Peptide Immunotherapy in Subjects With Hematologic Cancer,"Active, not recruiting",No Results Available,Acute Myelogenous Leukemia (AML)|Multiple Myeloma (MM)|Myelodysplastic Syndrome (MDS)|Smoldering Multiple Myeloma (sMM),Drug: Sargramostim|Drug: BB-MPI-03|Drug: Montanide,"Benovus Bio, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1,4,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,BBMPI03-Hem-01,9-Sep-14,1/1/2015,6/1/2017,4/18/2016,Apr-16,No Study Results Posted,BBMPI03,Dec-16,"Determine the safety, dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and optimal biologic dose (OBD) of BB-MPI-03 and adjuvants in subjects with hematologic cancers who are off treatment and with stable disease (SD) or better.|Determine the in vivo cellular immune response profile of BB-MPI-03 and adjuvants in subjects who receive 5 and 6 intradermal (ID) injections over a 6- month period.|Evaluate any anti-tumor activity of BB-MPI-03 and adjuvants as assessed by disease reduction and lack of disease progression during and after treatment.",https://ClinicalTrials.gov/show/NCT02240537
348,NCT02164461,ADXS11-001 High Dose HPV+ Cervical Cancer,"Active, not recruiting",No Results Available,Effects of Immunotherapy|Metastatic/Recurrent Cervical Cancer|Cervical Adenocarcinoma|Cervical Adenosquamous Cell Carcinoma|Cervical Squamous Cell Carcinoma|Cervical Small Cell Carcinoma|Stage III Cervical Cancer|Stage IVA Cervical Cancer|Stage IVB Cervical Cancer,Biological: ADXS11-001,"Advaxis, Inc.",Female,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,25,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,Lm-LLO-E7-1401,13-Jun-14,1/1/2015,null,6/17/2016,Jun-16,No Study Results Posted,null,Dec-18,"Number of patients with dose-limiting toxicities, as assessed by CTCAE v 4.0|Frequency and severity of adverse effects as assessed by CTCAE v 4.0|Changes in clinical immunology based upon serum|Proportion of patients who have objective tumor response (complete or partial)",https://ClinicalTrials.gov/show/NCT02164461
397,NCT02027935,Cellular Adoptive Immunotherapy Using Autologous CD8+ Antigen-Specific T Cells and Anti-CTLA4,Recruiting,No Results Available,Melanoma,Drug: Cyclophosphamide|Procedure: CD8+ T Cells|Drug: Interleukin-2|Drug: Ipilimumab,M.D. Anderson Cancer Center|Cancer Prevention Research Institute of Texas|American Association for Cancer Research,Both,"18 Years and older   (Adult, Senior)",Phase 2,20,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2012-1055|R1301|SU2C-AACR-OT 1012|NCI-2014-01040,2-Jan-14,1/1/2015,null,3/30/2016,Mar-16,No Study Results Posted,null,Jan-19,Overall Response,https://ClinicalTrials.gov/show/NCT02027935
576,NCT02250326,Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 and Nab®-Paclitaxel Monotherapy as Second Line Treatment for Advanced Nonsquamous Non-small Cell Lung Cancer,Recruiting,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: nab-paclitaxel IV|Drug: CC-486,Celgene Corporation,Both,"18 Years and older   (Adult, Senior)",Phase 2,160,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ABI-007-NSCL-006|2014-001105-41,24-Sep-14,1/1/2015,9/1/2017,7/8/2016,Jul-16,No Study Results Posted,abound2L,May-17,Progression free survival|Adverse Events|Disease Control Rate|Overall Survival|Overall Response Rate|Discontinuation rate|Median dose intensity|Incidence of dose reduction,https://ClinicalTrials.gov/show/NCT02250326
655,NCT02338778,Safety and Efficacy Study of Mix Vaccine in Hepatocyte Carcinoma Patient,Completed,No Results Available,Liver Neoplasms,Biological: MV|Other: Standard Treatment,"Fuda Cancer Hospital, Guangzhou",Both,"18 Years to 80 Years   (Adult, Senior)",Phase 1|Phase 2,20,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,liver cancer MV,11-Jan-15,1/1/2015,8/1/2015,9/8/2015,Jan-15,No Study Results Posted,null,Aug-15,efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1|safety as measured by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 criteria|immunology index,https://ClinicalTrials.gov/show/NCT02338778
659,NCT02338804,Safety and Efficacy Study of Mix Vaccine in Breast Carcinoma Patient,Completed,No Results Available,Breast Neoplasms,Biological: MV|Other: standard treatment,"Fuda Cancer Hospital, Guangzhou",Both,"18 Years to 80 Years   (Adult, Senior)",Phase 1|Phase 2,20,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,breast cancer MV,11-Jan-15,1/1/2015,8/1/2015,9/8/2015,Jan-15,No Study Results Posted,null,Aug-15,efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1|safety as measured by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 criteria|immunology index,https://ClinicalTrials.gov/show/NCT02338804
660,NCT02338752,Safety and Efficacy Study of Mix Vaccine in Pancreatic Carcinoma Patient,Completed,No Results Available,Pancreatic Neoplasms,Biological: MV|Other: Standard Treatment,"Fuda Cancer Hospital, Guangzhou",Both,18 Years to 18 Years   (Adult),Phase 1|Phase 2,20,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,pancreatic cancer MV,11-Jan-15,1/1/2015,8/1/2015,9/8/2015,Jan-15,No Study Results Posted,null,Aug-15,efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1|safety as measured by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 criteria|immunology index,https://ClinicalTrials.gov/show/NCT02338752
690,NCT02338700,Safety and Efficacy Study of Mix Vaccine in Prostate Carcinoma Patient,Completed,No Results Available,Prostatic Neoplasms,Biological: MV|Other: standard treatment,"Fuda Cancer Hospital, Guangzhou",Both,"18 Years to 80 Years   (Adult, Senior)",Phase 1|Phase 2,20,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,prostate cancer MV,11-Jan-15,1/1/2015,8/1/2015,9/8/2015,Jan-15,No Study Results Posted,null,Aug-15,efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1|safety as measured by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 criteria|immunology index,https://ClinicalTrials.gov/show/NCT02338700
721,NCT02333474,Safety and Efficacy of Mix Vaccine in Lung Carcinoma Patient,Completed,No Results Available,Lung Neoplasms,Biological: MV mix vaccine|Other: standard treatment,"Fuda Cancer Hospital, Guangzhou",Both,"18 Years to 80 Years   (Adult, Senior)",Phase 1|Phase 2,20,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,FudaCH,3-Jan-15,1/1/2015,8/1/2015,9/8/2015,Jan-15,No Study Results Posted,null,Aug-15,efficacy as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) criteria version 1.1|Safety as measured by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0 criteria|immunology index,https://ClinicalTrials.gov/show/NCT02333474
869,NCT02395679,Dendritic Cells Loaded With Allogeneous Cell Lysate in Mesothelioma Patients,Recruiting,No Results Available,Mesothelioma,Biological: MesoCancerVac,Erasmus Medical Center,Both,"18 Years and older   (Adult, Senior)",Phase 1,9,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NL44330.000.14,30-Jan-15,1/1/2015,12/1/2016,3/17/2015,Mar-15,No Study Results Posted,MesoCancerVa,Dec-15,The primary objective is to establish a tolerable dose of MesoCancerVac in patients with malignant mesothelioma|The secondary objective is the evaluation of an immune response after MesoCancerVac,https://ClinicalTrials.gov/show/NCT02395679
995,NCT02306850,Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma,Recruiting,No Results Available,Unresectable Malignant Neoplasm|Melanoma|Metastatic Melanoma|Stage IV Melanoma|Stage III Melanoma,Drug: Pembrolizumab,St. Louis University,Both,"18 Years to 90 Years   (Adult, Senior)",Phase 2,15,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SLU IRB 25007|51604,1-Dec-14,1/1/2015,2/1/2018,2/5/2016,Feb-16,No Study Results Posted,NeoPembroMel,Feb-17,Resectability rate|Response by RECIST criteria,https://ClinicalTrials.gov/show/NCT02306850
1119,NCT02144623,Pretreatment With Valproate Prior to Immunotherapy Targeting Cluster of Differentiation Antigen 20 in Chronic Lymphocytic Leukemia,Recruiting,No Results Available,Chronic Lymphocytic Leukemia,Drug: Valproate,Lund University Hospital,Both,"18 Years to 80 Years   (Adult, Senior)",Phase 0,10,Other,Interventional,Endpoint Classification: Pharmacokinetics/Dynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,Version 1.2,15-May-14,1/1/2015,null,2/16/2016,Feb-16,No Study Results Posted,PREVAIL,May-16,Levels of CD20 protein and messengerRNA in response to treatment with valproate in patients with chronic lymphatic leukemia.|Translational blood samples.,https://ClinicalTrials.gov/show/NCT02144623
1161,NCT02371434,The ONE Study nTreg Trial (ONEnTreg13),Enrolling by invitation,No Results Available,Immunosuppressive Treatment of Living-donor Renal Transplantation,Biological: autologous CD4+CD25+FoxP3+ natural regulat. T cells (nTregs),"Prof. Dr. Petra Reinke|Charite University, Berlin, Germany",Both,18 Years to 65 Years   (Adult),Phase 1|Phase 2,9,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ONEnTreg13,18-Feb-15,1/1/2015,12/1/2017,9/1/2015,Sep-15,No Study Results Posted,ONEnTreg13,Apr-17,"Incidence of biopsy-confirmed acute rejection (BCAR) within 60 weeks of organ transplantation|Incidence of infectious complications associated with cell administration.|Incidence of embolic pulmonary complications and other embolic events.|Incidence of immune responses resulting in anaphylactic reactions, cardiovascular compromise or other acute organ failure.|Biochemical disturbances associated with the cell infusion.|Over-suppression of the immune system assessed by the incidence of opportunistic infections, especially, CMV, EBV and polyoma virus.|Over-suppression of the immune system assessed by the incidence of neoplasia.|Prevention of acute rejection will be secondarily assessed by measuring|Incidence of patients treated for subclinical acute rejection on the basis of histopathological findings|Prevention of chronic graft dysfunction (chronic rejection or IF/TA) will be assessed by clinical (impairment of GFR) and histopathological (Banff staging) measures.|Incidence of post-transplant dialysis, inclusion on the transplant waiting list or retransplantation following graft loss through rejection (acute or chronic).|Avoidance of drug-related complications by immunosuppressant reduction will be assessed by the incidence of reported adverse drug reactions.",https://ClinicalTrials.gov/show/NCT02371434
1183,NCT02672527,Trial Comparing Trabectedin to the Best Supportive Care in Patients With Sarcoma,Recruiting,No Results Available,Soft Tissue Sarcoma,Drug: Trabectedin|Drug: Dexamethasone,"Gustave Roussy, Cancer Campus, Grand Paris",Both,"18 Years and older   (Adult, Senior)",Phase 3,100,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,2014-003176-23|2014/2154,6-May-15,1/1/2015,1/1/2018,6/8/2016,Jun-16,No Study Results Posted,TSAR,Jan-18,Progression Free Survival,https://ClinicalTrials.gov/show/NCT02672527
48,NCT02323893,"Study of the Kinetics, Dosimetry and Safety of [18F]F-AraG, a Positron Emission Tomography Imaging Tracer",Recruiting,No Results Available,Cancer,Drug: [18F]F-AraG,"CellSight Technology, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1,30,Industry,Interventional,Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic,2.61201E+11,16-Dec-14,2/1/2015,12/1/2016,7/27/2016,Jul-16,No Study Results Posted,null,Dec-16,Visualize biodistribution of the PET tracer [18F]F-AraG|Analyze human dosimetry of [18F]F-AraG|Assess acute safety of intravenously injected trace dose of [18F]F-AraG,https://ClinicalTrials.gov/show/NCT02323893
124,NCT02346747,Phase II/III Trial of Maintenance Vigil™ for High Risk Stage III/IV Ovarian Cancer,Recruiting,No Results Available,Ovarian Cancer|Ovarian Neoplasms,Biological: Vigil|Biological: Placebo,"Gradalis, Inc.",Female,"18 Years and older   (Adult, Senior)",Phase 2|Phase 3,574,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CL-PTL-119,21-Jan-15,2/1/2015,12/1/2019,6/28/2016,Jun-16,No Study Results Posted,VITAL,Dec-17,Recurrence Free Survival|Overall Survival,https://ClinicalTrials.gov/show/NCT02346747
267,NCT02342613,Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation,Recruiting,No Results Available,Hematologic Malignancies|Graft-Versus-Host Disease,Biological: Activated PTCy-MILs,Sidney Kimmel Comprehensive Cancer Center,Both,"18 Years and older   (Adult, Senior)",Phase 1,27,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,J1484|IRB00039074,15-Jan-15,2/1/2015,2/1/2020,8/21/2015,Aug-15,No Study Results Posted,null,Feb-20,Feasibility of generating activated marrow infiltrating lymphocytes (MILs) from patients previously treated with PTCy (PTCy-MILs) who have relapsed disease involving the bone marrow,https://ClinicalTrials.gov/show/NCT02342613
508,NCT01209871,Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma,Recruiting,No Results Available,Lymphoma|Lymphoplasmacytic Lymphoma|Waldenström Macroglobulinemia,Biological: DNA Vaccine,M.D. Anderson Cancer Center,Both,"18 Years and older   (Adult, Senior)",Phase 1,12,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,2009-0465|NCI-2012-01897,24-Sep-10,2/1/2015,null,7/15/2016,Jul-16,No Study Results Posted,null,Feb-18,Maximum Tolerated Dose (MTD) of a Novel Lymphoma DNA Vaccine Encoding a MIP3a-Fused Lymphoma Idiotype|Immune Response,https://ClinicalTrials.gov/show/NCT01209871
544,NCT02376699,Safety Study of SEA-CD40 in Cancer Patients,Recruiting,No Results Available,"Cancer|Carcinoma|Neoplasms|Neoplasm Metastasis|Hematologic Malignancies|Hodgkin Disease|Lymphoma|Lymphoma, B-Cell|Lymphoma, Follicular|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Non-Hodgkin",Drug: SEA-CD40,"Seattle Genetics, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1,186,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,SGNS40-001,17-Feb-15,2/1/2015,3/1/2019,7/20/2016,Jul-16,No Study Results Posted,null,Jan-18,Incidence of adverse events|Incidence of chemistry and hematology laboratory abnormalities|Blood concentrations of SEA-CD40|Incidence of antitherapeutic antibodies against SEA-CD40|Mean absolute and percent change from baseline over time of selected pharmacodynamic markers|Objective response rate|Disease control rate|Duration of response|Progression-free survival|Overall survival,https://ClinicalTrials.gov/show/NCT02376699
856,NCT02361346,"PK, PD, Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Non-Hodgkin's B-Cell Lymphoma and B-Cell Chronic Lymphocytic Leukemia",Recruiting,No Results Available,"Non-Hodgkin's B-cell Lymphoma|Leukemia, Lymphocytic, Chronic, B-Cell|Small Lymphocytic Leukemia",Drug: MT-3724,"Molecular Templates, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1,40,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MT-3724_NHL_001,3-Feb-15,2/1/2015,3/1/2017,3/16/2016,Mar-16,No Study Results Posted,MT-3724NHL001,Dec-16,"Tolerability as measured by number of subjects with dose limiting toxicities|Safety as measured by number of subjects with Adverse Events using CTCAE|Tolerability as measured by adverse events using CTCAE and clinical laboratory parameters|PK as measured by concentrations of free MT-3724 (Cmax, AUC, tmax, Cinf)|PD as measured by clinical symptoms, tumor response, immunogenicity|Tumor Response as measured by PET or CT scan",https://ClinicalTrials.gov/show/NCT02361346
872,NCT02320292,Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma,Recruiting,No Results Available,Stage I Grade 1 Follicular Lymphoma|Stage I Grade 2 Follicular Lymphoma|Stage II Grade 1 Contiguous Follicular Lymphoma|Stage II Grade 1 Non-Contiguous Follicular Lymphoma|Stage II Grade 2 Contiguous Follicular Lymphoma|Stage II Grade 2 Non-Contiguous Follicular Lymphoma|Stage III Grade 1 Follicular Lymphoma|Stage III Grade 2 Follicular Lymphoma|Stage IV Grade 1 Follicular Lymphoma|Stage IV Grade 2 Follicular Lymphoma,Other: Laboratory Biomarker Analysis|Other: Quality-of-Life Assessment|Biological: Rituximab|Radiation: Yttrium Y-90 Ibritumomab Tiuxetan,Mayo Clinic|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 3,128,Other|NIH,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,LS138D|NCI-2014-02476|P30CA015083,15-Dec-14,2/1/2015,null,6/15/2016,Feb-16,No Study Results Posted,null,Jan-26,Complete response (CR) rate at the 6-month disease assessment|Incidence of adverse events assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Progression-free survival (PFS)|Time to any therapy (TTNT)|Time to chemotherapy (TTC),https://ClinicalTrials.gov/show/NCT02320292
1039,NCT02336165,Phase 2 Study of MEDI4736 in Patients With Glioblastoma,Recruiting,No Results Available,Glioblastoma,Drug: MEDI4736|Radiation: Radiotherapy|Biological: Bevacizumab,"Ludwig Institute for Cancer Research|MedImmune LLC|Cancer Research Institute, New York City|Cure Brain Cancer Foundation, Australia",Both,"18 Years and older   (Adult, Senior)",Phase 2,108,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,LUD2013-006,23-Dec-14,2/1/2015,null,6/16/2016,Jun-16,No Study Results Posted,null,Jul-17,"Clinical Efficacy, as judged by survival, is the primary objective of the study for all cohorts but the primary endpoints differ by cohort due to the difference in patient populations.|Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Evaluation of Clinical Efficacy by median Progression-Free Survival, and Overall Survival as well as overall response rate (ORR).|Pharmacokinetic profile of MEDI4736, including half-life, Tmax, Cmax and other parameters.|Quality of Life (EORTC QLQ-30/BN20).",https://ClinicalTrials.gov/show/NCT02336165
1129,NCT02065362,TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC,Recruiting,No Results Available,EBV-positive Nasopharyngeal Carcinoma,Genetic: DNR.NPC-specific T cells|Genetic: DNR.NPC-specific T cells + cyclophosphamide + fludarabine,"Baylor College of Medicine|National Cancer Institute (NCI)|Center for Cell and Gene Therapy, Baylor College of Medicine|The Methodist Hospital System|Texas Children's Hospital",Both,"Child, Adult, Senior",Phase 1,14,Other|NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,33954: RESIST-NPC|P01CA094237,14-Feb-14,2/1/2015,2/1/2033,6/8/2016,Jun-16,No Study Results Posted,null,Feb-18,Number of subjects with a dose limiting toxicity|Amount of T cells in the blood after the infusions,https://ClinicalTrials.gov/show/NCT02065362
86,NCT02274753,Personalizing Colorectal Cancer Medicine (ImmuCol2),Recruiting,No Results Available,Colon Cancer,,"Assistance Publique - Hôpitaux de Paris|Ministry of Health, France",Both,"18 Years and older   (Adult, Senior)",,200,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,NI13017,20-Oct-14,3/1/2015,3/1/2020,1/22/2016,Jan-16,No Study Results Posted,ImmuCol2,Mar-20,Relapse in relation with the immunoscore determined on a tumor section and criteria defined in the monitoring of patients|Relapse in relation with the immune component cancers beyond immunoscore|Relapse in relation with the immunoscore on biopsies,https://ClinicalTrials.gov/show/NCT02274753
399,NCT02403271,A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors,Recruiting,No Results Available,Breast Cancer|Non-Small Cell Lung Cancer,Drug: Ibrutinib|Drug: Durvalumab (MEDI4736),Pharmacyclics,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,160,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PCYC-1135-CA,27-Feb-15,3/1/2015,6/1/2019,7/12/2016,Jul-16,No Study Results Posted,null,Jun-17,Phase 1b: Number of participants with adverse events as a measure of safety and tolerability of ibrutinib and MEDI4736 and to find the recommended Phase II dose.|Phase 2: Efficacy of ibrutinib in combination with MEDI4736 in subjects with relapsed or refractory solid tumors by assessing the ORR per RECIST 1.1.|Phase 1b: Pharmacokinetics of ibrutinib.|Phase 1b: Pharmacokinetics of MEDI4736|Phase 1b: Pharmacodynamics|Phase 2: Number of participants with adverse events as a measure of safety and tolerability of ibrutinib and MEDI4736|Phase 2: Pharmacokinetics of ibrutinib|Phase 2: Pharmacokinetics of MEDI4736|Phase 2: Pharmacodynamics,https://ClinicalTrials.gov/show/NCT02403271
421,NCT02296684,Immunotherapy With MK-3475 in Surgically Resectable Head and Neck Squamous Cell Carcinoma,Recruiting,No Results Available,"Cancer of Head and Neck|Head and Neck Cancer|Neoplasms, Head and Neck|Carcinoma, Squamous Cell of Head and Neck|Squamous Cell Carcinoma of the Head and Neck|Squamous Cell Carcinoma, Head and Neck",Biological: MK-3475|Procedure: Surgery|Radiation: Intensity modulated radiation therapy|Radiation: Image-guided radiation therapy|Drug: Cisplatin,Washington University School of Medicine|Merck Sharp & Dohme Corp.,Both,"18 Years and older   (Adult, Senior)",Phase 2,46,Other|Industry,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,201412118,17-Nov-14,3/1/2015,3/1/2022,7/11/2016,Jul-16,No Study Results Posted,null,Mar-19,Locoregional recurrence rates|Distant failure rate|Occurrence of adverse events|Surgical complications and/or delays,https://ClinicalTrials.gov/show/NCT02296684
458,NCT02423863,"In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®",Recruiting,No Results Available,Melanoma|Head and Neck Cancer|Sarcoma|Non-Melanoma Skin Cancers,Biological: Hiltonol,"Oncovir, Inc.|National Institutes of Health (NIH)|Icahn School of Medicine at Mount Sinai|Bay Hematology Oncology|Emory University|University of Pittsburgh|National Cancer Institute (NCI)",Both,"18 Years and older   (Adult, Senior)",Phase 2,100,Industry|NIH|Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ONC2014-001|1R44CA183075-01A1,13-Apr-15,3/1/2015,12/1/2020,3/28/2016,Mar-16,No Study Results Posted,Poly-ICLC,Dec-18,"Evaluate safety of sequential intratumoral, plus intramuscular injections of Poly-ICLC, Hiltonol® for treatment of study subjects with advanced accessible solid tumors (response determined using the irRC criteria)|To evaluate therapeutic efficacy in treated study subjects as assessed by Disease Control (CR, PR, or SD) as defined by the Immune-related Response Criteria (irRC) and recorded at the 6-month time point only, compared to baseline.|Determine if the study regimen of Poly-ICLC will induce an innate and/or an adaptive, specific anti-tumor T cell immune response in the injected tumor lesion and systemically.|Determine if the treatments will lead to regression of injected tumor lesions as defined by change in size at 8 weeks and 26 weeks as assessed by bi-dimensional measurement.|Determine if the treatments will lead to regression of non-injected tumor lesions, both visceral and non-visceral as defined by change in size at 8 weeks and 26 weeks as assessed by bidimensional measurement, using irRC criteria.|Determine long-term progression free survival at 12, 24 and 36 months in treated study subjects.|Determine overall survival (OS) in treated study subjects.",https://ClinicalTrials.gov/show/NCT02423863
541,NCT02390739,Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing Human Thyroglobulin to People With Thyroglobulin Expressing Thyroid Cancer,Suspended,No Results Available,Metastatic Thyroid Cancer,Drug: Aldesleukin|Drug: Fludarabine|Drug: Cyclophosphamide|Biological: Anti-Thyroglobulin mTCR PBL,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 70 Years   (Adult, Senior)",Phase 1|Phase 2,68,NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,150090|15-C-0090,17-Mar-15,3/1/2015,9/1/2019,7/7/2016,Jun-16,No Study Results Posted,null,Sep-18,Determine a safe dose of administration and determine if this approach will result in an objective tumor regression.,https://ClinicalTrials.gov/show/NCT02390739
630,NCT02305186,Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer,Recruiting,No Results Available,Pancreatic Cancer,Drug: Pembrolizumab|Radiation: Neoadjuvant Chemoradiation,"Osama Rahma, MD|M.D. Anderson Cancer Center|University of Virginia",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,56,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,17801,21-Nov-14,3/1/2015,6/1/2019,3/23/2016,Mar-16,No Study Results Posted,UVA-PC-PD101,Jun-17,Number of Tumor Infiltrating Lymphocytes (TILs) per high powered field (hpf) in pancreatic tissue (resected tissue).|Safety: Incidence of Dose-Limiting Toxicities (DLTs)|Disease-free survival (DFS)|Overall survival (OS)|Response Rate (RR),https://ClinicalTrials.gov/show/NCT02305186
831,NCT02318394,A Phase 1 Study of MEDI0562 in Adult Subjects With Selected Advanced Solid Tumors,Recruiting,No Results Available,Advanced Solid Tumors,Biological: MEDI0562,MedImmune LLC,Both,"18 Years to 99 Years   (Adult, Senior)",Phase 1,196,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,D6060C00001,3-Dec-14,3/1/2015,5/1/2020,3/15/2016,Mar-16,No Study Results Posted,null,Sep-17,"Number and percentage of subjects with adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)|Objective response rate (ORR)|Maximum observed concentration (Cmax), area under the curve (AUC), clearance (CL) and terminal half-life of MEDI0562|Number and percentage of subjects who develop detectable anti-drug antibodies (ADAs)|Induction of proliferation markers on various lymphocyte subsets, immunohistochemistry of tumor biopsies and assessment of programmed death ligand 1 (PD-L1) and tumor-infiltrating lymphocyte phenotypic markers|Disease control rate (DCR)|Duration of response (DoR)|Progression-free survival (PFS)|Overall survival (OS)",https://ClinicalTrials.gov/show/NCT02318394
841,NCT02366546,Investigator Initiated Phase 1 Study of TBI-1301,Recruiting,No Results Available,Solid Tumors,Drug: TBI-1301|Drug: Cyclophosphamide|Drug: Fludarabine,"Mie University|Takara Bio Inc.|Shionogi|Fiverings Co., Ltd.|Statcom Co. Ltd.",Both,"20 Years and older   (Adult, Senior)",Phase 1,12,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,1301-01,12-Feb-15,3/1/2015,null,3/23/2016,Mar-16,No Study Results Posted,null,Mar-17,Incidence and grade of adverse events (CTCAE)|Appearance of replication competent retrovirus by PCR|Appearance of clonality by LAM-PCR|Kinetics of TBI-1301 in blood by realtime-PCR,https://ClinicalTrials.gov/show/NCT02366546
861,NCT02327390,Ex Vivo-Activated Lymph Node Lymphocytes in Treating Patients With Stage IIIC-IV Melanoma,Recruiting,No Results Available,Stage IIIC Skin Melanoma|Stage IV Melanoma,Procedure: lymph node|Biological: X-ACT,Julian Kim|National Cancer Institute (NCI)|Case Comprehensive Cancer Center,Both,"18 Years and older   (Adult, Senior)",Phase 1,24,Other|NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CASE3612|NCI-2014-00761|CASE 3612|P30CA043703,17-Dec-14,3/1/2015,11/1/2017,7/26/2016,Jul-16,No Study Results Posted,null,May-17,Incidence of dose-limiting toxicity|Prevalence of each biomarker in peripheral blood over time|Clinical response defined by Response Evaluation Criteria In Solid Tumors 1.1,https://ClinicalTrials.gov/show/NCT02327390
887,NCT02421640,Phase II Trial of TIL Following CCRT in Patients With Locoregionally Advanced NPC,Recruiting,No Results Available,Nasopharyngeal Carcinoma,Drug: Cisplatin+TIL|Drug: Cisplatin,Sun Yat-sen University,Both,18 Years to 65 Years   (Adult),Phase 2,150,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,NPC and TIL,11-Apr-15,3/1/2015,3/1/2020,4/15/2015,Apr-15,No Study Results Posted,TIL,Mar-17,Progress-free survival|Overall Survival (OS)|Locoregional Relapse-Free Survival (LRRF)|Distant Metastasis-Free Survival (DMFS)|Complete Response (CR)|Determine the toxic effects in these patients.|Determine the molecular expression of EBV DNA.|Determine the quality of life (QoL) of these regimens in these patients.,https://ClinicalTrials.gov/show/NCT02421640
937,NCT02280525,Cord Blood Natural Killer (NK) Cells in Chronic Lymphocytic Leukemia (CLL),Recruiting,No Results Available,Leukemia,Drug: Lenalidomide|Drug: Rituximab|Drug: Fludarabine|Drug: Cyclophosphamide|Procedure: NK Cells,M.D. Anderson Cancer Center|The Leukemia and Lymphoma Society|Celgene Corporation,Both,"18 Years to 80 Years   (Adult, Senior)",Phase 1,44,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2014-0297|P-TRP-1996-14|NCI-2014-02678,29-Oct-14,3/1/2015,null,6/22/2016,Jun-16,No Study Results Posted,null,Mar-21,Maximum Tolerated Dose (MTD) of Natural Killer (NK) Cells with Lenalidomide and Lymphodepleting Chemotherapy,https://ClinicalTrials.gov/show/NCT02280525
1008,NCT02406183,Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma,Recruiting,No Results Available,Melanoma|Effects of Immunotherapy|Adverse Effect of Radiation Therapy,Radiation: Stereotactic body radiotherapy (SBRT)|Drug: Ipilimumab,"Radiotherapie|University Hospital, Ghent",Both,"18 Years and older   (Adult, Senior)",Phase 1,21,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,EC 2015/0025,17-Mar-15,3/1/2015,7/1/2017,4/1/2015,Mar-15,No Study Results Posted,null,Jul-17,Maximal tolerated dose (MDT) that is associated with dose-limiting toxicity (DLT) in 25% of patients.|Preliminary anti-tumor activity following escalating doses of radiation combined to ipilimumab using the immune related response criteria irRC|Overall survival|Progression-free survival|Immunomonitoring (absolute lymphocyte count)|Immunomonitoring (frequencies of Foxp3+ Treg-cells)|Immunomonitoring (functional analysis looking at shifts in Th1/Th2/Th17)|Immunomonitoring (plasmacytoid dendritic cells and myeloid derived suppressor cells and their IDO expression),https://ClinicalTrials.gov/show/NCT02406183
1086,NCT02384954,ALT-803 in Patients With Relapse/Refractory Indolent B Cell Non-Hodgkin Lymphoma (iNHL) in Conjunction With Rituximab,Recruiting,No Results Available,Relapsed/Refractory Indolent B Cell Non-Hodgkin Lymphoma,Biological: Rituximab|Biological: ALT-803,Altor Bioscience Corporation,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,86,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CA-ALT-803-02-14,19-Feb-15,3/1/2015,6/1/2023,7/13/2016,Jul-16,No Study Results Posted,null,Mar-18,"Determination of MTD or MED, Phase II Dose Level Designation|Number of treatment related adverse events as a measure of safety|Overall Response Rate|Progression-free Survival|Overall Survival|Duration of Response|Blood Cell Counts|Levels of specific biomarkers as a predictive measure of efficacy|Immunogenicity|Pharmacokinetics as a measure of drug persistence|Polymorphism|Mutations|Lymph node biopsies",https://ClinicalTrials.gov/show/NCT02384954
1097,NCT02340975,"A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma",Recruiting,No Results Available,Gastric or Gastroesophageal Junction Adenocarcinoma,Biological: MEDI4736 + tremelimumab|Biological: MEDI4736|Biological: Tremelimumab|Biological: MEDI4736 + tremelimumab,MedImmune LLC,Both,"18 Years to 99 Years   (Adult, Senior)",Phase 1|Phase 2,236,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,D4190C00021,14-Jan-15,3/1/2015,11/1/2017,7/15/2016,Jul-16,No Study Results Posted,null,Nov-17,Number (percentage) of subjects reporting adverse events and number (percentage) of subjects reporting serious adverse events.|Number of subjects experiencing dose-limiting toxicities|Phase 2: Objective Response Rate|Phase 2: Progression Free Survival at 6 months|Phase 1: Objective Response Rate|Phase 1: Progression Free Survival at 6 months|Disease Control Rate|PD-L1 expression|Overall Survival|Duration of Response,https://ClinicalTrials.gov/show/NCT02340975
1110,NCT02388906,Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238),"Active, not recruiting",No Results Available,Melanoma,Drug: Ipilimumab|Drug: Nivolumab|Other: Placebo matching Ipilimumab|Other: Placebo matching Nivolumab,Bristol-Myers Squibb|Ono Pharmaceutical Co. Ltd,Both,"15 Years and older   (Child, Adult, Senior)",Phase 3,800,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CA209-238|2014-002351-26,10-Mar-15,3/1/2015,11/1/2019,7/26/2016,Aug-15,No Study Results Posted,null,Nov-18,Recurrence -free-survival|Overall survival,https://ClinicalTrials.gov/show/NCT02388906
1128,NCT02252055,The ONE Study ATDC Trial,Recruiting,No Results Available,"Renal Failure, End Stage",Biological: ATDC_Nantes,Nantes University Hospital,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,16,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,RC13_0441,25-Sep-14,3/1/2015,10/1/2018,4/21/2016,Mar-16,No Study Results Posted,ONEatDC,Jun-18,"Incidence of biopsy-confirmed acute rejection (BCAR)|Time to first acute rejection episode|Severity of acute rejection episodes|Total immunosuppressive burden|Incidence of patients treated for subclinical acute rejection on the basis of histopathological findings|Prevention of chronic graft dysfunction (chronic rejection or IF/TA)|Incidence of post-transplant dialysis, inclusion on the transplant waiting list or re-transplantation following graft loss through rejection (acute or chronic).|Avoidance of drug-related complications by immunosuppressant reduction|Incidence of embolic pulmonary complications and other embolic events|Incidence of immunological reactions resulting in anaphylactoid reactions, immediate cardiovascular compromise or other acute organ failure|Biochemical disturbances caused by cell infusion|Over-suppression of the immune system assessed by the incidence of major and/or opportunistic infections, especially CMV, EBV and polyoma virus|Over-suppression of the immune system assessed by the incidence of neoplasia.|Immunological condition of study patients w",https://ClinicalTrials.gov/show/NCT02252055
1195,NCT02405338,DC Vaccination for Post-remission Therapy in AML,Recruiting,No Results Available,Acute Myeloid Leukemia,Biological: WT1/PRAME vaccination,Medigene AG,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1|Phase 2,20,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label,CD-FDC-001,24-Mar-15,3/1/2015,null,4/25/2016,Apr-16,No Study Results Posted,null,Nov-18,Percentage of patients in whom treatment with the scheduled number of immunotherapies is feasible|Percentage of grade I/II and grade III/IV toxicities in patients having received at least 1 immunotherapy|Induction of immune responses in patients having received at least 1 immunotherapy|Control of minimal residual disease (MRD)|Time to progression (TTP).|ECOG performance status (Grades 0-5),https://ClinicalTrials.gov/show/NCT02405338
126,NCT02405585,Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer,Terminated,No Results Available,Pancreatic Cancer|Pancreatic Carcinoma Non-resectable,Drug: mFOLFIRINOX|Biological: Algenpantucel-L Immunotherapy|Radiation: SBRT|Drug: Gemcitabine,NewLink Genetics Corporation,Both,"18 Years and older   (Adult, Senior)",Phase 2,10,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NLG0605|1409-1350,25-Mar-15,4/1/2015,null,6/30/2016,Jun-16,No Study Results Posted,null,Dec-16,Progression Free Survival|Overall Survival|Frequency and grade of adverse events of FOLFIRINOX in combination with algenpantucel-L Immunotherapy|Immune Response|Tumor Response|Resection Rate,https://ClinicalTrials.gov/show/NCT02405585
184,NCT02425735,Safety and Efficiency of γδ T Cell Against Hepatocellular Liver Cancer,Completed,No Results Available,Liver Cancer,Biological: DC-CIK cells|Biological: γδ T cells|Biological: γδ T/DC-CIK cells,"Fuda Cancer Hospital, Guangzhou|Jinan University Guangzhou",Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1|Phase 2,40,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment,Gd T cell and Hepatocellular,21-Apr-15,4/1/2015,6/1/2016,7/17/2016,Apr-15,No Study Results Posted,null,Jun-16,Reduced size of the tumors,https://ClinicalTrials.gov/show/NCT02425735
200,NCT02423902,A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Breast Cancer,Recruiting,No Results Available,Metastatic Breast Cancer,Biological: Ad-RTS-hIL-12|Drug: Veledimex,Ziopharm,Female,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,40,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ATI001-203,6-Apr-15,4/1/2015,10/1/2017,8/4/2015,Apr-15,No Study Results Posted,null,Aug-17,"Composite measure of safety and tolerability of Ad-RTS-hIL-12 immunotherapy following a first-or second-line standard treatment in HER2-negative subjects, or together with a first- or second-line anti-HER2 antibody therapy in HER2-positive subjects|Progression rate at 12 weeks after the start of one cycle of Ad-RTS-hIL-12 immunotherapy|Overall response rate (ORR), defined as the rate of complete response (CR) plus the rate of partial response (PR) at 12 weeks following the start of Ad-RTS-hIL-12 immunotherapy|Disease control rate (DCR), defined as the proportion of subjects who have a complete response (CR), partial response (PR), or stable disease (SD) at 12 weeks following the start of one cycle of Ad-RTS-hIL-12 immunotherapy|Number of subjects whose baseline tumor status (stable disease or partial response) improves to partial response or better at 12 weeks following the start of Ad-RTS-hIL-12 immunotherapy|Comparison of radiographic tumor responses by irRC with RECIST|Impact of treatment on serum immune biomarkers such as cytokines, chemokines, soluble receptors and antibodies to tumor antigens",https://ClinicalTrials.gov/show/NCT02423902
308,NCT02425748,Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation),Completed,No Results Available,Lung Cancer,Biological: DC-CIK|Biological: γδ T Cell|Biological: γδ T/DC-CIK cells,"Fuda Cancer Hospital, Guangzhou|Jinan University Guangzhou",Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1|Phase 2,40,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment,Gd T cell and lung cancer,21-Apr-15,4/1/2015,6/1/2016,7/17/2016,Apr-15,No Study Results Posted,null,Jun-16,Reduced size of the tumor.,https://ClinicalTrials.gov/show/NCT02425748
314,NCT02418481,"Safety and Efficiency of γδ T Cell Against Breast Cancer(Her-, er-, and pr-)",Completed,No Results Available,Breast Cancer,Biological: DC-CIK|Biological: γδ T Cell|Biological: Combination,"Fuda Cancer Hospital, Guangzhou|Jinan University Guangzhou",Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1|Phase 2,40,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment,Gd T cell,13-Apr-15,4/1/2015,6/1/2016,7/17/2016,Apr-15,No Study Results Posted,null,Jun-16,Reduced size of the tumors,https://ClinicalTrials.gov/show/NCT02418481
529,NCT02439450,A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer,"Active, not recruiting",No Results Available,Non-small Cell Lung Cancer,Biological: Viagenpumatucel-L|Drug: Nivolumab,Heat Biologics,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,8,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,HS110-102,4-May-15,4/1/2015,3/1/2019,3/17/2016,Mar-16,No Study Results Posted,null,Mar-18,Phase 1b: Safety and Tolerability by physical and laboratory examinations|Phase 2: Objective Response Rate (ORR)|Phase 1b: Objective Response Rate (ORR)|Phase 2: Safety and Tolerability by physical and laboratory examinations|Immune Response by intracellular cytokine staining (ICS) by flow cytometry|Overall Survival (OS)|Progression-Free Survival (PFS),https://ClinicalTrials.gov/show/NCT02439450
698,NCT02422381,MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC),Recruiting,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: MK-3475|Drug: Gemcitabine,"Providence Health & Services|Merck Sharp & Dohme Corp.|Providence Cancer Center, Earle A. Chiles Research Institute",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,46,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,15-011A,20-Mar-15,4/1/2015,4/1/2021,6/23/2016,Jun-16,No Study Results Posted,null,Apr-20,Frequency of Toxicities (determine any changes in signs or symptoms that may represent drug toxicity)|Progression Free Survival|Overall Survival|Disease Response,https://ClinicalTrials.gov/show/NCT02422381
767,NCT02315066,Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566,Recruiting,No Results Available,Neoplasms,Drug: PF-04518600|Drug: PF-04518600|Drug: PF-04518600 plus PF-05082566|Drug: PF-04518600 plus PF-05082566,Pfizer,Both,"18 Years and older   (Adult, Senior)",Phase 1,190,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Masking: Open Label|Primary Purpose: Treatment,B0601002|2014-004107-75,4-Dec-14,4/1/2015,5/1/2018,7/26/2016,Jul-16,No Study Results Posted,null,May-18,Number of participants with Dose-limiting toxicities (DLT) [Dose Escalation]|Overall safety profile [Dose Expansion]|Time to Reach Maximum Observed Plasma Concentration (Tmax)|Incidence of anti-drug antibodies|Number of participants with objective response|Unbound (free) cell surface OX40 in peripheral blood|Maximum Observed Plasma Concentration (Cmax)|Area under the concentration versus time curve (AUCt),https://ClinicalTrials.gov/show/NCT02315066
781,NCT02724488,Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies,Recruiting,No Results Available,Head and Neck Cancer|Melanoma,,"University Health Network, Toronto|Princess Margaret Hospital, Canada",Both,"18 Years and older   (Adult, Senior)",,40,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,SPECIAL-001,19-Nov-15,4/1/2015,12/1/2020,3/24/2016,Mar-16,No Study Results Posted,SPECIAL,Dec-20,Part 1: The detection of new mutations from circulating tumor DNA (ctDNA) analyses or change in the frequency of mutations found in archival tumor Whole Exome Sequencing (WES) analyses.|Part 2: Concordance between WES analyses of serial tumor biopsies.|Part 1: Concordance between DNA analyses of archival tumor and ctDNA analyses.|Part 2: Concordance between WES analyses of serial tumor biopsies and ctDNA analyses of serial blood samples.|Part 2: Changes in radiomic signatures of tumors between commencement of immune targeted therapies and disease progression assessed from serial CT scans.|Part 2: Correlation between tumor radiomic signatures from serial CT scans and genomic profiles (WES and gene expression analyses of serial tumor biopsies and ctDNA samples).|Part 2: Changes in levels of immune cells repertoire in peripheral circulation of patients using flow cytometry and related assays.,https://ClinicalTrials.gov/show/NCT02724488
792,NCT02416466,CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases,Recruiting,No Results Available,Liver Metastases,Biological: anti-CEA CAR-T cells|Device: Sir-Spheres,Roger Williams Medical Center|Sirtex Medical,Both,"18 Years and older   (Adult, Senior)",Phase 1,6,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,383-74,30-Mar-15,4/1/2015,12/1/2016,3/31/2016,Mar-16,No Study Results Posted,HITM-SIR,Sep-16,"Safety of CAR-T cell hepatic artery infusions in combination with Sir-Spheres as Measured by Number of Participants with Adverse Events|Treatment response (Liver tumor response by MRI, PET, CEA level, and biopsy)|Serum cytokine levels|CAR-T detection in liver tumors, normal liver, and extrahepatic sites",https://ClinicalTrials.gov/show/NCT02416466
799,NCT02379741,ADC-1013 First-in-Human Study,Recruiting,No Results Available,Neoplasms|Solid Tumors,Biological: ADC-1013,Alligator Bioscience AB,Both,"18 Years and older   (Adult, Senior)",Phase 1,50,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,A-14-1013-C-01,16-Feb-15,4/1/2015,10/1/2017,4/5/2016,Apr-16,No Study Results Posted,null,Oct-17,"Safety and tolerability of increasing doses of ADC-1013, assessed by medical review of AE reports and vital signs measurements (blood pressure, pulse rate, body temperature), physical examinations, ECGs and clinical laboratory tests.|Pharmacokinetics of ADC-1013 after single and repeated administrations assessed by the following parameters: Cmax, Tmax, elimination half-life, AUC0-∞, total serum clearance (CL) and the volume of distribution at steady state (Vss).|Immunogenicity of ADC-1013 after repeated administrations assessed by anti-drug antibody (ADA) titers in serum|Clinical efficacy (i.e. anti-tumor activity) of ADC-1013 assessed by immune-related RECIST (irRECIST) and RECIST 1.1.",https://ClinicalTrials.gov/show/NCT02379741
819,NCT02417129,BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma,Completed,No Results Available,"Lymphoma, Non-Hodgkin",Drug: Rituximab|Drug: BI 695500,Boehringer Ingelheim,Both,"18 Years to 99 Years   (Adult, Senior)",Phase 3,2,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment,1301.6|2014-004544-36,10-Apr-15,4/1/2015,12/1/2015,12/16/2015,Dec-15,No Study Results Posted,null,Dec-15,"Overall Response (measured as Overall Response Rate {ORR}), which is Completed Response (CR) + Partial Response (PR) at Week 30, approximately 26 weeks after the completion of study treatment, as defined by IWG criteria|Extraporated AUC 0-T, SS establised by PPK from plasma concentrations of BI 695500 or rituximab sampled during the trial period|Immunogenicity at Week 30",https://ClinicalTrials.gov/show/NCT02417129
897,NCT02351739,Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer,"Active, not recruiting",No Results Available,Metastatic Urothelial Carcinoma,Drug: pembrolizumab|Drug: ACP-196 in combination with pembrolizumab,Acerta Pharma BV|Merck Sharp & Dohme Corp.,Both,"18 Years and older   (Adult, Senior)",Phase 2,74,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ACE-ST-005,28-Jan-15,4/1/2015,9/1/2017,1/6/2016,Jan-16,No Study Results Posted,KEYNOTE143,May-17,To determine the overall response rate (ORR) of pembrolizumab monotherapy and the combination of ACP-196 and pembrolizumab in subjects,https://ClinicalTrials.gov/show/NCT02351739
910,NCT02457650,T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies,Recruiting,No Results Available,Bladder Carcinoma|Breast Cancer|Esophagus Carcinoma|Lung Cancer|Melanoma|Multiple Myeloma|Neuroblastoma|Ovarian Cancer|Synovial Sarcoma|Other Metastatic Solid Cancers,Drug: Cyclophosphamide|Drug: Fludarabine|Biological: Anti-NY ESO-1 TCR-transduced T cells,Shenzhen Second People's Hospital|Shenzhen institute for innovation and translational medicine,Both,"1 Year and older   (Child, Adult, Senior)",Phase 1,36,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,201504002,12-May-15,4/1/2015,12/1/2019,8/1/2016,Aug-16,No Study Results Posted,null,Dec-19,Number of participants with Adverse Events|Number of participants with Clinical responses,https://ClinicalTrials.gov/show/NCT02457650
25,NCT02431572,A Pilot Study to Evaluate PBR PET in Brain Tumor Patients Treated With Chemoradiation or Immunotherapy,Not yet recruiting,No Results Available,Intracranial Tumors|Glioblastoma|Melanoma,Other: PBR PET|Biological: Cancer Immunotherapy|Radiation: Radiation and chemotherapy,Massachusetts General Hospital,Both,"18 Years and older   (Adult, Senior)",,40,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Diagnostic,14-421,15-Apr-15,5/1/2015,3/1/2020,4/30/2015,Apr-15,No Study Results Posted,null,Jul-18,Change in PBR uptake (changes in PBR uptake by PET),https://ClinicalTrials.gov/show/NCT02431572
132,NCT02035358,Immunotherapy Study for Metastatic Renal Cell Cancer,Recruiting,No Results Available,Metastatic Renal Cell Carcinoma|Metastatic Clear-cell Renal Cancer|Recurrent Renal Cell Carcinoma|Refractory Renal Cell Carcinoma|Metastatic Kidney Cancer,Biological: HyperAcute®-Renal (HAR) Immunotherapy,NewLink Genetics Corporation,Both,"18 Years and older   (Adult, Senior)",Phase 1,20,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NLG0106,10-Jan-14,5/1/2015,null,2/2/2016,Feb-16,No Study Results Posted,null,Apr-16,Toxicity|Immunological Correlative Studies|Progression-Free Survival,https://ClinicalTrials.gov/show/NCT02035358
155,NCT02448173,A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer,Recruiting,No Results Available,Stage II Colon Cancer,Biological: OncoVAX and Surgery|Procedure: Surgery,Vaccinogen Inc,Both,"18 Years and older   (Adult, Senior)",Phase 3,550,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ASI-2005-04,6-May-15,5/1/2015,7/1/2022,7/24/2015,Jul-15,No Study Results Posted,null,Jul-20,Disease-Free Survival|Overall Survival|Recurrence-Free Interval,https://ClinicalTrials.gov/show/NCT02448173
161,NCT02423928,Phase I Clinical Trial of Cryoimmunotherapy Against Prostate Cancer,Recruiting,No Results Available,Prostate Cancer,Biological: Dendritic cell based cryoimmunotherapy|Drug: Cyclophosphamide|Drug: ipilimumab,Alden Cancer Therapy II|Haukeland University Hospital|Norwegian Radium Hospital,Male,"18 Years and older   (Adult, Senior)",Phase 1,20,Industry|Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ACT2001|2014-001898-14,15-Apr-15,5/1/2015,12/1/2017,7/19/2016,Jul-16,No Study Results Posted,CryoIT,May-17,"Composite measure of the safety and toxicity profile, including definition of the Maximum Tolerated Dose.",https://ClinicalTrials.gov/show/NCT02423928
342,NCT02208362,Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma,Recruiting,No Results Available,Malignant Glioma|Refractory Brain Neoplasm|Recurrent Brain Neoplasm,"Biological: IL13Rα2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing T lymphocytes|Other: laboratory biomarker analysis|Other: quality-of-life assessment|Procedure: Magnetic Resonance Imaging|Procedure: Magnetic Resonance Spectroscopic Imaging",City of Hope Medical Center|National Cancer Institute (NCI),Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1,75,Other|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,13384|NCI-2014-01488,1-Aug-14,5/1/2015,null,7/1/2016,Jul-16,No Study Results Posted,null,Dec-18,"Incidence of grade 3 toxicity, graded using the National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 4.0, the revised cytokine release syndrome grading system as well as the modified neurological grading system|Incidence of DLT, graded using NCI CTCAE version 4.0|Incidence of toxicities, graded using NCI CTCAE version 4.0 as well as the modified neurological grading system|Changes in largest length of tumor|Changes in cytokine levels|Progression free survival|Disease response by MacDonald criteria|Overall survival|Changes in quality of life|T cell detection in tumor|IL13Ra2 antigen expression levels|Disease response from intraventricular infusion following progression after intracranial infusion (stratum 1 and 2)",https://ClinicalTrials.gov/show/NCT02208362
370,NCT02408016,Genetically Modified T Cells in Treating Patients With Stage III-IV Non-small Cell Lung Cancer or Mesothelioma,Recruiting,No Results Available,Advanced Pleural Malignant Mesothelioma|HLA-A*0201 Positive Cells Present|Recurrent Non-Small Cell Lung Carcinoma|Recurrent Pleural Malignant Mesothelioma|Stage III Pleural Mesothelioma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIB Non-Small Cell Lung Cancer|Stage IV Non-Small Cell Lung Cancer|Stage IV Pleural Mesothelioma,Biological: Aldesleukin|Biological: Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes|Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Procedure: Therapeutic Conventional Surgery,Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,20,Other|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,2727.00|NCI-2015-00329|2727|P30CA015704,31-Mar-15,5/1/2015,null,5/2/2016,May-16,No Study Results Posted,null,Dec-16,"Evidence and nature of toxicity based on the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0|Feasibility of naive T cell (TN) and central memory T cell (TCM) subsets, measured as the proportion of patients for which T cells are successfully generated and infused and whether only TN or TCM could be generated|Persistence of transduced T cells|Frequency of transferred T cells at biopsied tumor sites between the Tn and Tcm groups|Functional capacity of transferred cells, measured by production of intracellular cytokines|TTP based on RECIST criteria and immune-related response criteria",https://ClinicalTrials.gov/show/NCT02408016
602,NCT02465983,Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer,"Active, not recruiting",No Results Available,Pancreatic Cancer,Biological: CART-meso-19 T cells|Drug: Cyclophosphamide,"University of Pennsylvania|University of California, San Francisco",Both,"18 Years and older   (Adult, Senior)",Phase 1,12,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CART-meso-19|UPCC 19214|UCSF CC144520,28-May-15,5/1/2015,1/1/2017,3/9/2016,Mar-16,No Study Results Posted,null,Jul-16,Safety of IV administration of CART-meso-19 with cyclophosphamide as lymphodepleting chemotherapy in patients with pancreatic cancer using the NCI CTCAE v4.03 criteria,https://ClinicalTrials.gov/show/NCT02465983
637,NCT02414269,Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin,Recruiting,No Results Available,Malignant Pleural Disease|Mesothelioma|Metastases|Lung Cancer|Breast Cancer,Genetic: iCasp9M28z T cell infusions|Drug: cyclophosphamide,Memorial Sloan Kettering Cancer Center,Both,"18 Years and older   (Adult, Senior)",Phase 1,24,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,15-007,2-Apr-15,5/1/2015,null,6/17/2016,Jun-16,No Study Results Posted,null,Apr-18,Composite measure of severity and number of adverse events (AEs); changes in clinical laboratory test findings (hematologic and chemistry); and physical examination.|Changes in serum levels of the biomarker soluble mesothelin related peptide (SMRP),https://ClinicalTrials.gov/show/NCT02414269
753,NCT02482168,Study of the CD40 Agonistic Monoclonal Antibody APX005M,Recruiting,No Results Available,Cancer|Carcinoma|Neoplasms|Neoplasm Metastasis,Drug: APX005M,"Apexigen, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1,32,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,APX005M-001,11-Jun-15,5/1/2015,12/1/2017,7/11/2016,Jul-16,No Study Results Posted,null,Apr-17,Incidence of dose limiting toxicities|Incidence of adverse events|Blood concentrations of APX005M|Presence and titer of anti-APX005M antibodies|Objective response rate according to Response Evaluation Criteria in Solid Tumors (RECIST),https://ClinicalTrials.gov/show/NCT02482168
955,NCT02452216,Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS,Recruiting,No Results Available,Brain Injury|Central Nervous System Degenerative Disorder|Central Nervous System Infectious Disorder|Central Nervous System Vascular Malformation|Hemorrhagic Cerebrovascular Accident|Ischemic Cerebrovascular Accident|Primary Brain Neoplasm|Brain Cancer|Brain Tumors,Drug: Ferumoxytol|Other: Tissue Analysis|Procedure: Magnetic Resonance Imaging,Michael Iv|National Cancer Institute (NCI)|Stanford University,Both,"2 Years and older   (Child, Adult, Senior)",,120,Other|NIH,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic,BRNCNS0007|NCI-2015-00435|P30CA124435,20-May-15,5/1/2015,5/1/2019,7/8/2016,Jul-16,No Study Results Posted,null,May-19,Obtain measurements of iron concentration (indicative of ferumoxytol uptake) on T2*-weighted MR images.|Determine the number of macrophages in resected/biopsied samples at histopathology.,https://ClinicalTrials.gov/show/NCT02452216
1029,NCT02424916,Adoptive Transfer of Specific Melanoma Antigens CD8+ T Cells in Metastatic Melanoma Patients: a Phase I/II Study,Recruiting,No Results Available,Metastatic Melanoma|Brain Metastases,Biological: Melanoma antigens-specific CD8+ T lymphocytes,Nantes University Hospital|UMR892,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1|Phase 2,17,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,RC12_0261,3-Apr-15,5/1/2015,4/1/2018,6/9/2015,Jun-15,No Study Results Posted,MelSort,Apr-18,"Clinical and biological safety defined by the NCI (Common Toxicity Criteria - Version 4.0, may 2009, http:// ctep.cancer.gov)|Progression-free survival|Overall survival|Overall tumor response (complete response, partial response, stable disease) evaluated according to Response Evaluation Criteria in Solid Tumor (RECIST) and immune-related Response Criteria (irRC)|Duration of clinical responses defined as the time interval between the evaluation of the first objective response or stable disease and the first evaluation of disease progression|Persistence of injected specific T cells evaluated by immunomonitoring",https://ClinicalTrials.gov/show/NCT02424916
1168,NCT02487017,DC-CIK Combined With TACE in the Treatment of Hepatocellular Carcinoma,Recruiting,No Results Available,Hepatocellular Carcinoma|Neoplasms|Digestive System Neoplasms,Procedure: Transcatheter Arterial Chemoembolization (TACE)|Biological: DC-CIK,"Shenzhen Hornetcorn Bio-technology Company, LTD|Yantai City Hospital for Infectious Diseases",Both,"18 Years to 80 Years   (Adult, Senior)",Phase 2,60,Industry|Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,HYK-Hepatocellular Carcinoma,29-Jun-15,5/1/2015,12/1/2018,5/23/2016,Dec-15,No Study Results Posted,null,Dec-18,Overall survival|Progress-free survival|Quality of life (QOL)|Phenotypic analysis of T cells,https://ClinicalTrials.gov/show/NCT02487017
1188,NCT02315755,Observational Study Evaluating The Efficacy And Effects On Quality Of Life Of Targeted Treatments Following TKIs In mRCC,Recruiting,No Results Available,Renal Cell Carcinoma (RCC),,Pfizer,Both,"18 Years and older   (Adult, Senior)",,152,Industry,Observational,Time Perspective: Prospective,A4061086,9-Dec-14,5/1/2015,10/1/2017,7/13/2016,Jul-16,No Study Results Posted,null,Dec-16,Measurement of health-related quality of life with targeted therapy used as 3rd line treatment|Overall response rate at the end of follow up|Median progression free survival according to RECIST version 1.1|Overall survival rate|Effect of quality of life on prognosis|Adverse events during 3rd line targeted treatment according to CTCAE.4.03|Dose modifications due to adverse events|Correlation between efficacy (overall response rate at month 12 and median PFS) and dose modifications due to adverse events|Correlation between efficacy (overall response rate at month 12 and median PFS) and blood pressure,https://ClinicalTrials.gov/show/NCT02315755
34,NCT01530984,Ipilimumab and GMCSF Immunotherapy for Prostate Cancer,Withdrawn,No Results Available,Prostate Cancer,Drug: Ipilimumab|Drug: GM-CSF,"Lawrence Fong|Bristol-Myers Squibb|Sanofi|University of California, San Francisco",Male,"18 Years and older   (Adult, Senior)",Phase 2,0,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CC# 12552,7-Feb-12,6/1/2015,12/1/2018,10/1/2015,Oct-15,No Study Results Posted,null,Dec-17,"To assess for clinical activity by PSA response, of both single agent ipilimumab and the combination of GM-CSF and ipilimumab in chemotherapy-naïve patients with metastatic castrate resistant prostate cancer.|To evaluate the duration of PSA response and time to PSA progression. To quantify the frequency of immune toxicities. To evaluate T cell activation. To assess for clinical activity by objective response.",https://ClinicalTrials.gov/show/NCT01530984
128,NCT01818323,Phase I Trial: T4 Immunotherapy of Head and Neck Cancer,Recruiting,No Results Available,Head and Neck Cancer,Other: Intra-tumoral T4 immunotherapy,King's College London|Guy's and St Thomas' NHS Foundation Trust,Both,"18 Years and older   (Adult, Senior)",Phase 1,30,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label,2012-001654-25,19-Mar-13,6/1/2015,12/1/2017,2/22/2016,Feb-16,No Study Results Posted,null,Jun-17,"Dose limiting toxicities for T4 immunotherapy in SCCHN and determine a safe and feasible recommended dose for phase II testing of intra-tumoral T4 immunotherapy.|To investigate serum cytokine levels after administration of T4 immunotherapy|To investigate persistence of T4+ T-cells at the site of administration and in the peripheral circulation|To achieve preliminary assessment of anti-tumour activity, using cross-sectional imaging to quantify objective responses|To investigate tumour ErbB receptor phenotype, before and after administration of T4 immunotherapy|To investigate immunomodulatory effects of metronomic cyclophosphamide on T4 immunotherapy|To investigate effect of T4 immunotherapy upon immune reactivity against endogenous tumour antigens",https://ClinicalTrials.gov/show/NCT01818323
146,NCT02466906,RhGM-CSF as Adjuvant Immunotherapy in Treating Stage III Colon Cancer,Recruiting,No Results Available,Colon Cancer,Drug: rhGM-CSF|Drug: placebo,The Affiliated Hospital of the Chinese Academy of Military Medical Sciences,Both,"18 Years to 70 Years   (Adult, Senior)",Phase 2,60,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment,L-15-01,5-Jun-15,6/1/2015,7/1/2020,1/18/2016,Dec-15,No Study Results Posted,null,Jun-20,"Disease-free survival（DFS）|Immune anti-tumor effect: DC cells, CD4+ cells, CD8+ cells, Treg cells|Overall survival (OS)|Incidence of liver metastasis|Adverse effects (AE)",https://ClinicalTrials.gov/show/NCT02466906
401,NCT02529579,Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer,Recruiting,No Results Available,"Carcinoma, Pancreatic Ductal",Other: iAPA-DC/CTL adoptive cellular immunotherapy|Drug: Gemcitabine,"Changhai Hospital|ImmunoGene Biotechology Co.,Ltd",Both,"18 Years to 70 Years   (Adult, Senior)",Phase 1|Phase 2,187,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Outcomes Assessor)|Primary Purpose: Treatment,cellular immunotherapy,18-Aug-15,6/1/2015,12/1/2019,8/19/2015,Jan-15,No Study Results Posted,null,Dec-18,6-month SR|PFS|OS|ORR|QOL,https://ClinicalTrials.gov/show/NCT02529579
469,NCT01966809,Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas,"Active, not recruiting",No Results Available,"Brain Tumor, Recurrent",Drug: Photofrin photodynamic therapy.,"Harry T Whelan, MD|Pinnacle Biologics Inc.|Medical College of Wisconsin",Both,"18 Years and older   (Adult, Senior)",Phase 2,30,Other|Industry,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PRO00023580,17-Oct-13,6/1/2015,6/1/2021,2/10/2016,Feb-16,No Study Results Posted,null,Dec-18,Six month relapse-free survival (RFS).|Remission rate.|Progression-free survival and overall survival.|Tumor response.,https://ClinicalTrials.gov/show/NCT01966809
646,NCT02470559,"Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent",Withdrawn,No Results Available,Malignant Ovarian Clear Cell Tumor|Malignant Ovarian Serous Tumor|Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer,Biological: Aldesleukin|Biological: HER2Bi-Armed Activated T Cells|Other: Laboratory Biomarker Analysis|Biological: Sargramostim,Barbara Ann Karmanos Cancer Institute|National Cancer Institute (NCI),Female,"18 Years and older   (Adult, Senior)",Phase 1,0,Other|NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2014-129|NCI-2015-00180|P30CA022453,10-Jun-15,6/1/2015,2/1/2017,2/15/2016,Feb-16,No Study Results Posted,null,Feb-17,"MTD of IP injections in combination with the IV fixed dose of aATC determined by the incidence of dose-limiting toxicity (DLT) defined using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0|Toxicity profile of IP and IV HER2Bi-aATC at the MTD or technically feasible dose graded using NCI CTCAE version 4.0|Changes in cytokine profiles|Changes in HAMA levels in serum samples|Changes in phenotyping induced by immunotherapy in peripheral blood mononuclear cells (PBMC)|Clinical response rate (including complete response, partial response, progressive disease, and stable disease) measured on the basis of CA-125 or RECIST-defined tumor measurements|Increases in IFN-gamma ELISPOTS|Increases in the immunoglobulin G titer against selected ovarian cancer cell lines in serum samples|Overall survival|Progression free survival",https://ClinicalTrials.gov/show/NCT02470559
845,NCT02489266,In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma,Withdrawn,No Results Available,Metastatic Melanoma,Biological: AKTi-treated TIL|Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldesleukin,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 70 Years   (Adult, Senior)",Phase 1,0,NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,150153|15-C-0153,2-Jul-15,6/1/2015,11/1/2019,6/30/2016,Jun-16,No Study Results Posted,null,Nov-18,Determine whether ACT using TIL cultured in a pharmacologic inhibitor of AktKT (during ex vivo expansion) results in enhanced in vivo persistence of TIL after adoptive transfer into autologous patients with advanced melanoma.|Determine whether ACT using a combination of conventional and AKTi-treated TIL can mediate tumor regression by RECIST guidelines in patients with advanced melanoma|Determine the toxicity profile of this treatment regimen.,https://ClinicalTrials.gov/show/NCT02489266
1109,NCT02454634,Phase I Trial of IDH1 Peptide Vaccine in IDH1R132H-mutated Grade III-IV Gliomas,Recruiting,No Results Available,Glioma,Drug: IDH1 peptide vaccine,"National Center for Tumor Diseases, Heidelberg|University Hospital Heidelberg|German Cancer Research Center|Neuro-Oncology Working Group of the German Cancer Society",Both,"18 Years and older   (Adult, Senior)",Phase 1,39,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NCT-2013-0216|2014-000503-27,12-May-15,6/1/2015,8/1/2018,6/13/2016,May-15,No Study Results Posted,NOA-16,Aug-18,"safety and tolerability of repeated fixed dose vaccinations of the IDH1 peptide vaccine administered with topical imiquimod (Aldara®) assessed by Regime Limiting Toxicity (RLT).|immunogenicity of the IDH1 peptide vaccine|immunogenicity by assessing the IDH1R132H-specific T-cell and antibody response|progression-free survival (PFS)|overall response rate (ORR)|association between immunogenicity (IDH1R132H-specific T-cell and antibody response) and the clinical outcome parameters (ORR, PFS)",https://ClinicalTrials.gov/show/NCT02454634
1269,NCT02497053,Four Versus Six Cycles of Pemetrexed/Platinum for MPM,Recruiting,No Results Available,Malignant Pleural Mesothelioma,Drug: pemetrexed/platinum chemotherapy|Drug: Pemetrexed/platinum chemotherapy,Ain Shams University,Both,"18 Years and older   (Adult, Senior)",Phase 2,70,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,Meso-01,10-Jul-15,6/1/2015,null,7/13/2015,Jul-15,No Study Results Posted,null,Jun-16,Progression free survival|Overall survival,https://ClinicalTrials.gov/show/NCT02497053
74,NCT02537977,CD19-directed CAR T Cells Therapy in Relapsed/Refractory B Cell Malignancy,Recruiting,No Results Available,Leukemia|Lymphoma,Biological: CD19-directed CAR-T cells,"Shanghai Tongji Hospital, Tongji University School of Medicine",Both,"12 Years to 70 Years   (Child, Adult, Senior)",Phase 1|Phase 2,40,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,TJ1537,26-Aug-15,7/1/2015,12/1/2018,8/28/2015,Aug-15,No Study Results Posted,null,Jun-18,Occurrence of study related adverse events|Response rates to CAR-T cells|Survival time of the patients treated with CAR-T cells,https://ClinicalTrials.gov/show/NCT02537977
181,NCT02494206,Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL),"Active, not recruiting",No Results Available,Breast Cancer|Upper Extremity Lymphedema,Drug: QBX258,Memorial Sloan Kettering Cancer Center|Novartis,Female,"18 Years to 70 Years   (Adult, Senior)",,9,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,15-085,7-Jul-15,7/1/2015,null,5/24/2016,May-16,No Study Results Posted,null,Jul-17,volume changes as measured by perometry,https://ClinicalTrials.gov/show/NCT02494206
272,NCT02511132,Randomized Phase IIb Trial of Vigil™ Versus Gemcitabine + Docetaxel for Ewing's Sarcoma,Recruiting,No Results Available,Ewing's Sarcoma,Biological: Vigil|Drug: gemcitabine and docetaxel,"Gradalis, Inc.",Both,"2 Years and older   (Child, Adult, Senior)",Phase 2,62,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CL-PTL-121,28-Jul-15,7/1/2015,12/1/2018,6/6/2016,Jun-16,No Study Results Posted,null,Dec-17,Overall Survival|γIFN ELISPOT conversion rate,https://ClinicalTrials.gov/show/NCT02511132
537,NCT02654938,Safety and Tolerability Clinical Trial of Different Doses of the Immunotherapeutic Drug Mobilan (M-VM3) and Placebo in Patients With Prostate Cancer,Recruiting,No Results Available,Prostate Cancer,Drug: Mobilan (M-VM3)|Drug: Placebo,Panacela Labs LLC,Male,"45 Years to 75 Years   (Adult, Senior)",Phase 1,44,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Treatment,PNC-M-VM3-01,7-Dec-15,7/1/2015,3/1/2017,7/14/2016,Jul-16,No Study Results Posted,null,Mar-17,"Frequency and intensity of adverse events (according to CTCAE v 4.03 classification)|Exposure of Mobilan DNA vector in patient's peripheral blood|Prostate-specific antigen (PSA) measure|Immune cell count in whole blood of patients assessed with flow cytometry|Histopathological assessment of prostate tissue using Gleason grading system (if prostatectomy is made in the study period, and material is available for analysis)|Presence of protein 502s in blood plasma|Titer of 502 antibodies (AB) in peripheral blood serum|Histopathological assessment of prostate tissue using Irani scale (if prostatectomy is made in the study period, and material is available for analysis)",https://ClinicalTrials.gov/show/NCT02654938
595,NCT02224781,Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma,Recruiting,No Results Available,Recurrent Melanoma|Stage IIIA Skin Melanoma|Stage IIIB Skin Melanoma|Stage IIIC Skin Melanoma|Stage IV Skin Melanoma,Drug: Dabrafenib|Biological: Ipilimumab|Other: Laboratory Biomarker Analysis|Biological: Nivolumab|Other: Quality-of-Life Assessment|Drug: Trametinib,National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 3,300,NIH,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment,NCI-2014-01747|EA6134|U10CA180820,22-Aug-14,7/1/2015,null,8/3/2016,Jun-16,No Study Results Posted,null,Jul-19,"OS rate, defined as the proportion of patients alive after 2 years of follow-up time|PFS, evaluated based on RECIST version 1.1|Response rate according to RECIST version 1.1|Toxicity rate for categorized AEs|Toxicity rate for individual adverse events (AEs)|Toxicity rate for worst degree AEs",https://ClinicalTrials.gov/show/NCT02224781
809,NCT02362594,Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/KEYNOTE-054),Recruiting,No Results Available,Melanoma,Biological: pembrolizumab|Other: placebo,Merck Sharp & Dohme Corp.|European Organisation for Research and Treatment of Cancer,Both,"18 Years and older   (Adult, Senior)",Phase 3,900,Industry|Other,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",3475-054|1325-MG|2014-004944-37,9-Feb-15,7/1/2015,1/1/2024,5/20/2016,May-16,No Study Results Posted,null,Apr-18,Recurrence-free survival (RFS) for All Participants|RFS for Participants with PD-L1-positive Tumor Expression|Distant Metastases-free Survival (DMFS) in All Participants|DMFS for Participants with PD-L1-positive Tumor Expression|Overall Survival (OS) in All Participants|OS in for Participants with PD-L1-positive Tumor Expression,https://ClinicalTrials.gov/show/NCT02362594
873,NCT02508324,IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia,Recruiting,No Results Available,Acute Myeloid Leukemia|Myelodysplastic Syndrome,Biological: haplo-identical cells (donor)|Biological: umbilical cord blood unit (CBU),Weill Medical College of Cornell University,Both,"18 Years and older   (Adult, Senior)",Phase 2,40,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,1403014939,7-Apr-15,7/1/2015,12/1/2018,7/22/2015,Jul-15,No Study Results Posted,null,Dec-17,Safety of cellular immunotherapy|Incidence of Graft Versus Host Disease (GVHD) <10%|Detection of graft chimerism after infusion|Detection of HLA-antibodies after after infusion <10%|The response rate of leukemia,https://ClinicalTrials.gov/show/NCT02508324
1118,NCT02497508,Nivolumab in Patients With Recurrent Malignant Mesothelioma,Not yet recruiting,No Results Available,Malignant Pleural Mesothelioma,Drug: nivolumab,The Netherlands Cancer Institute|Bristol-Myers Squibb,Both,"18 Years and older   (Adult, Senior)",Phase 2,33,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,N14MPN,6-Jul-15,7/1/2015,7/1/2017,7/13/2015,Jul-15,No Study Results Posted,NivoMes,Jul-17,DCR|PFS|OS|TTP|ORR|Safety and tolerability (The incidence of (serious) adverse events),https://ClinicalTrials.gov/show/NCT02497508
1160,NCT02523313,Immunotherapy With Nivolumab or Nivolumab Plus Ipilimumab vs. Double Placebo for Stage IV Melanoma w. NED,Recruiting,No Results Available,Malignant Melanoma,Drug: Nivolumab + Placebo|Drug: Nivolumab + Ipilimumab|Drug: Double Placebo Control,"Prof. Dr. med. Dirk Schadendorf|University Hospital, Essen",Both,"18 Years and older   (Adult, Senior)",Phase 2,312,Other,Interventional,"Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",IMMUNED,5-Aug-15,7/1/2015,6/1/2021,12/1/2015,Dec-15,No Study Results Posted,null,Jun-21,Efficacy of adjuvant immunotherapy with Nivolumab alone or in combination with Ipilimumab (Progression-free survival)|Overall survival,https://ClinicalTrials.gov/show/NCT02523313
1176,NCT02334735,A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence,Recruiting,No Results Available,Melanoma,Biological: DC Vaccine|Biological: Montanide Vaccine|Biological: Poly-ICLC,"Nina Bhardwaj|New York University School of Medicine|Memorial Sloan Kettering Cancer Center|Ludwig Institute for Cancer Research|Melanoma Research Alliance|Oncovir, Inc.|Icahn School of Medicine at Mount Sinai",Both,"18 Years and older   (Adult, Senior)",Phase 2,50,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,GCO 14-0780,6-Jan-15,7/1/2015,6/1/2018,2/16/2016,Feb-16,No Study Results Posted,null,Jan-17,Humoral immune response|Cytokine secretion,https://ClinicalTrials.gov/show/NCT02334735
149,NCT02415699,DC-CIK Immunotherapy Plus Chemotherapy vs Chemotherapy Alone in the Adjuvant Treatment of Stage III Colorectal Cancer,Not yet recruiting,No Results Available,Colorectal Cancer,Drug: Fluorouracil|Drug: Oxaliplatin|Drug: Leucovorin|Biological: DC-CIK,"Sixth Affiliated Hospital, Sun Yat-sen University",Both,"18 Years to 75 Years   (Adult, Senior)",Phase 2|Phase 3,100,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2015045010,9-Apr-15,8/1/2015,7/1/2020,4/13/2015,Apr-15,No Study Results Posted,null,Jul-17,Disease free survival|Overall survival|Side Effect,https://ClinicalTrials.gov/show/NCT02415699
254,NCT02529930,An Exploratory Safety and Immunogenicity Study of HPV16+ Immunotherapy VB10.16 in Women With HSIL; CIN 2/3),Recruiting,No Results Available,High Grade Cervical Intraepithelial Neoplasia,Biological: VB10.16 Immunotherapy (DNA vaccine),Vaccibody AS|Theradex,Female,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,40,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,VB C-01,19-Aug-15,8/1/2015,2/1/2017,11/27/2015,Nov-15,No Study Results Posted,null,Aug-16,Safety/tolerability|Immunogenicity|Preliminary assessment of efficacy,https://ClinicalTrials.gov/show/NCT02529930
722,NCT02507583,Antisense102: Pilot Immunotherapy for Newly Diagnosed Malignant Glioma,Recruiting,No Results Available,Malignant Glioma|Neoplasms,"Drug: IGF-1R/AS ODN; Surgery with tissue harvest and implantation 10 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 24 hours.|Drug: IGF-1R/AS ODN; Surgery with tissue harvest and implantation 10 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 48 hours.|Drug: IGF-1R/AS ODN; Surgery with tissue harvest and implantation of 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 24 hours.|Drug: IGF-1R/AS ODN; Surgery with tissue harvest and implantation of 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 48 hours.",Thomas Jefferson University,Both,"18 Years and older   (Adult, Senior)",Phase 1,32,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,TJU-14379-102,29-Jun-15,8/1/2015,12/1/2018,4/19/2016,Apr-16,No Study Results Posted,null,Dec-18,Collect adverse events as a measure of safety and tolerability of IG-1R/ AS ODN|Document any T-1 weighted MRI-based radiographic responses to treatment.|Document any T-2 weighted MRI-based radiographic abnormalities or responses to treatment.|MRI measure of tumor response,https://ClinicalTrials.gov/show/NCT02507583
747,NCT02403193,Trial of PBF-509 in Patients With Advanced NSCLC,Recruiting,No Results Available,Non-small Cell Lung Cancer (NSCLC),Drug: PBF-509|Drug: PBF-509|Drug: PBF-509|Drug: PBF-509,Palobiofarma SL|H. Lee Moffitt Cancer Center and Research Institute,Both,"18 Years and older   (Adult, Senior)",Phase 1,15,Industry|Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PBFCC07,17-Mar-15,8/1/2015,10/1/2017,3/29/2016,Mar-16,No Study Results Posted,AdenONCO,Aug-17,"Maximum Tolerated Dose (MTD)|Time to PBF-509 peak concentration in plasma ""Tmax""|Time to PBF-509 peak concentration in plasma at steady state ""Tmax,ss""|PBF-509 peak concentration in plasma ""Cmax""|PBF-509 peak concentration in plasma at steady state""Cmax,ss""|The area under PBF-509 plasma concentration-time curve to infinite time ""AUC(0-inf)""|The area under PBF-509 plasma concentration-time curve up to time 't' ""AUC(0-t)""|The area under PBF-509 plasma concentration-time curve over the dosing interval ""AUC(0-τ)""|PBF-509 half-life in plasma "" t½""|PBF-509 apparent volume of distribution following extravascular administration""Vd/F""|PBF-509 total body clearance following extravascular administration ""Cl/F""|The PBF 509 accumulation index ""Rac""|Efficacy as measured by Objective response rate (ORR)|Efficacy as measured by Disease control rate (DCR)|Efficacy as measured by duration of response (DoR)|Efficacy as measured by progression-free survival (PFS)|Efficacy as measured by overall survival (OS)",https://ClinicalTrials.gov/show/NCT02403193
770,NCT02467361,A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers,Recruiting,No Results Available,Cancer,Drug: BBI608|Drug: Ipilimumab|Drug: Nivolumab|Drug: Pembrolizumab,"Boston Biomedical, Inc",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,120,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,BBI608-201CIT,4-Jun-15,8/1/2015,null,7/5/2016,Jul-16,No Study Results Posted,null,Aug-17,Determination of the safety and tolerability of BBI608 administered in combination with selected immunotherapeutic agent by assessing dose-limiting toxicities (DLTs)|Determination of the Recommended Phase 2 Dose (RP2D) by assessing dose-limiting toxicities (DLTs)|Assessment of the preliminary anti-tumor activity by performing tumor assessments every 8 weeks (Phase 2 portion)|Pharmacokinetic profile of BBI608 administered in combination with the selected immunotherapeutic agent as assessed by maximum plasma concentration and area under the curve|Pharmacodynamic activity of BBI608 administered in combination with the selected immunotherapeutic agent as assessed by biomarker analysis,https://ClinicalTrials.gov/show/NCT02467361
978,NCT02427893,Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma,Recruiting,No Results Available,Melanoma,Drug: Cobimetinib|Drug: Vemurafenib,"Sidney Kimmel Comprehensive Cancer Center|Genentech, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 3,20,Other|Industry,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,J1517|IRB00051085,27-Mar-15,8/1/2015,null,4/5/2016,Apr-16,No Study Results Posted,null,Apr-17,Safety and tolerability of cobimetinib monotherapy and combination vemurafenib/cobimetinib in subjects with advanced melanoma.|Anti-tumor activity of cobimetinib monotherapy and combination vemurafenib/cobimetinib in subjects with advanced melanoma.,https://ClinicalTrials.gov/show/NCT02427893
1102,NCT02498756,Cytokine-induced Killer Study for Patients With Stage II Melanoma,Not yet recruiting,No Results Available,Melanoma,Biological: Cytokine-induced killer cells|Drug: Ipilimumab,The First People's Hospital of Changzhou,Both,"18 Years to 80 Years   (Adult, Senior)",Phase 2,300,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,Melanoma001,30-Jun-15,8/1/2015,8/1/2040,7/14/2015,Jul-15,No Study Results Posted,null,Aug-38,Overall survival (OS)|Progression Free Survival (PFS),https://ClinicalTrials.gov/show/NCT02498756
1141,NCT02503800,The Significance of Blood-tryptase and c-Kit Mutation in Insect Venom Immunotherapy,Not yet recruiting,No Results Available,"Hypersensitivity, Immediate|Insect Bites and Stings|Mastocytosis",,Meir Medical Center,Both,"4 Years to 75 Years   (Child, Adult, Senior)",,200,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,MMC150100-15CTIL,16-Jul-15,8/1/2015,8/1/2016,7/20/2015,Jul-15,No Study Results Posted,null,Aug-16,The association between tryptase values/c-Kit mutation and immunotherapy adverse events will be evaluated using blood sample analysis and patient medical records.|The association between tryptase values/c-Kit mutation and severity of index sting event will be evaluated using blood sample analysis and patient medical records.,https://ClinicalTrials.gov/show/NCT02503800
1162,NCT02520427,A Phase 1 Study of AMG 330 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia,Recruiting,No Results Available,Relapsed/Refractory AML,Drug: AMG 330,Amgen,Both,"18 Years and older   (Adult, Senior)",Phase 1,50,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,20120252|2014-004462-20,17-Jun-15,8/1/2015,6/1/2018,4/13/2016,Apr-16,No Study Results Posted,null,Jun-18,Subject incidence of adverse events as a Measure of Safety|Subject incidence of dose-limiting toxicities (DLTs) as a Measure of Safety|Incidence of anti-AMG 330 antibody formation|Efficacy parameter: Response rate|Efficacy parameter: duration of response|Efficacy parameter: time to progression|Efficacy parameter: time to response|Pharmacokinetic parameter: Half-life of AMG330|Pharmacokinetic parameter: Steady state concentration of AMG330|Pharmacokinetic parameter: Volume of distribution of AMG330|Pharmacokinetic parameter: Clearance of AMG330,https://ClinicalTrials.gov/show/NCT02520427
44,NCT02546921,"Phase I Study of MOv18 IgE, a First in Class Chimeric IgE Antibody in Patients With Advanced Solid Tumours",Recruiting,No Results Available,Human Cancers,Drug: MOv18 IgE,Cancer Research UK,Both,"16 Years and older   (Child, Adult, Senior)",Phase 1,25,Other,Interventional,Primary Purpose: Treatment,CRUKD14/001,19-Aug-15,9/1/2015,3/1/2018,7/6/2016,Jul-16,No Study Results Posted,null,Mar-18,Reported safety information (adverse events graded for severity using the NCI CTCAE version 4.02)|Antitumour activity measured according to the Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1|Assessment of Disease Response using CA 125 Tumour Marker,https://ClinicalTrials.gov/show/NCT02546921
61,NCT02316457,RNA-Immunotherapy of IVAC_W_bre1_uID and IVAC_M_uID,Not yet recruiting,No Results Available,Breast Cancer (Triple Negative Breast Cancer (TNBC)),Biological: IVAC_W_bre1_uID|Biological: IVAC_W_bre1_uID/IVAC_M_uID,Biontech AG|Seventh Framework Programme,Female,"18 Years and older   (Adult, Senior)",Phase 1,30,Industry|Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,BN_0002-01,21-Nov-14,9/1/2015,12/1/2016,7/21/2015,Jul-15,No Study Results Posted,TNBC-MERIT,Dec-16,Number of Adverse Events as a Measure of Safety and Tolerability of IVAC_W_bre1_uID|Maximal Tolerated Dose (MTD)|Number of Adverse Events as a Measure of Safety and Tolerability of IVAC_W_bre1_uID plus IVAC_M_uID|Change of induced T-cell responses for IVAC_W_bre_uID change from Visit 1 to V9|Change of induced T-cell responses for IVAC_M_uID change from Visit 12 to V18,https://ClinicalTrials.gov/show/NCT02316457
108,NCT02535286,Study of Pembrolizumab in Combination With Ublituximab and TGR-1202 in Patients With Relapsed-refractory CLL,Recruiting,No Results Available,Chronic Lymphocytic Leukemia,Drug: Pembrolizumab|Drug: TGR-1202|Biological: ublituximab,"TG Therapeutics, Inc.|Abramson Cancer Center of the University of Pennsylvania",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,12,Industry|Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,TG-UPCC-108,24-Aug-15,9/1/2015,12/1/2016,4/13/2016,Apr-16,No Study Results Posted,null,Nov-16,Determine Acceptable Adverse Events That Are Related to Treatment|Overall Response Rate,https://ClinicalTrials.gov/show/NCT02535286
129,NCT02692976,Natural Dendritic Cells for Immunotherapy of Chemo-naive Metastatic Castration-resistant Prostate Cancer Patients,Recruiting,No Results Available,Prostatic Neoplasms|Immunotherapy|Dendritic Cells|Vaccines,Biological: mDC vaccination|Biological: pDC vaccination|Biological: mDC and pDC vaccination,Radboud University,Male,"18 Years and older   (Adult, Senior)",Phase 2,21,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,EudraCT 2012-002531-29,30-Sep-15,9/1/2015,6/1/2017,4/1/2016,Apr-16,No Study Results Posted,null,Jan-17,"The immunogenicity of tumor-peptide loaded natural blood dendritic cells (myeloid DC, plasmacytoid DC and the combination of mDC/pDC) in metastatic castration-resistant prostate cancer (mCRPC) patients|Treatment-related adverse events assessment by Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Quality of life|Prostate-specific antigen (PSA)-progression|Progression Free Survival (PFS)|Overall Survival (OS)|Time to opiate use|Time to skeletal-related event (SRE)|World Health Organization (WHO) performance score decline|Time to chemotherapy initiation after mDC/pDC vaccinations|Radiologic profression-free survival|Feasibility of the natural DC vaccination trial",https://ClinicalTrials.gov/show/NCT02692976
225,NCT02632201,Immunotherapy Using Pluripotent Killer-Human Epidermal Growth Factor Receptor-2 (PIK-HER2) Cells for the Treatment of Advanced Gastric Cancer With Liver Metastasis,Recruiting,No Results Available,Liver Metastasis|Gastric Cancer,Biological: PIK-HER2|Biological: DC-PMAT,Second Military Medical University,Both,18 Years to 65 Years   (Adult),Phase 1|Phase 2,40,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,EHBHKY2015-02-008,13-Dec-15,9/1/2015,9/1/2017,12/30/2015,Sep-15,No Study Results Posted,null,Mar-17,Overall survival|Progress-free survival|Quality of life,https://ClinicalTrials.gov/show/NCT02632201
256,NCT02632188,Radical Surgery Followed by Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen for the Treatment of Hepatocellular Carcinoma,Recruiting,No Results Available,Liver Cancer,Procedure: Postoperative routine treatment|Biological: DC-PMAT treatment,Second Military Medical University,Both,18 Years to 65 Years   (Adult),Phase 1|Phase 2,60,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,EHBHKY2015-02-005,10-Dec-15,9/1/2015,9/1/2017,12/30/2015,Sep-15,No Study Results Posted,null,Mar-17,Progress-free survival|Overall survival|Quality of life,https://ClinicalTrials.gov/show/NCT02632188
290,NCT02632019,Immunotherapy Using Precision T Cells Specific to Personalized Neo-antigen for the Treatment of Advanced Malignant Tumor of Biliary Tract,Recruiting,No Results Available,Advanced Biliary Tract Malignant Tumor,Drug: Gemcitabine|Biological: Dendritic cell-precision T cell for neo-antigen combined with gemcitabine treatment,Second Military Medical University,Both,18 Years to 65 Years   (Adult),Phase 1|Phase 2,40,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,EHBHKY2015-02-006,12-Dec-15,9/1/2015,9/1/2017,12/30/2015,Sep-15,No Study Results Posted,null,Mar-17,Overall survival|Progress-free survival|Quality of life,https://ClinicalTrials.gov/show/NCT02632019
353,NCT02575261,CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients,Recruiting,No Results Available,EphA2 Positive Malignant Glioma|CAR-T Cell Immunotherapy,Biological: CAR-T cell immunotherapy,"Fuda Cancer Hospital, Guangzhou",Both,"18 Years to 80 Years   (Adult, Senior)",Phase 1|Phase 2,60,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CAR-T for malignant glioma,29-Sep-15,9/1/2015,9/1/2020,10/13/2015,Oct-15,No Study Results Posted,null,Sep-16,The effectiveness of CAR-T cell immunotherapy|The safety of CAR-T cell immunotherapy (adverse events),https://ClinicalTrials.gov/show/NCT02575261
423,NCT02638857,Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma,Recruiting,No Results Available,Recurrence Hepatocellular Carcinoma|Advanced Hepatocellular Carcinoma,Procedure: TACE|Biological: Dendritic Cell|Drug: lipiodol|Drug: Mitomycin (MMC)|Drug: Epirubicin(EADM)|Biological: Precision Multiple Antigen T Cell,Second Military Medical University,Both,18 Years to 65 Years   (Adult),Phase 1|Phase 2,60,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,EHBHKY2015-02-004,9-Dec-15,9/1/2015,9/1/2017,12/30/2015,Sep-15,No Study Results Posted,null,Mar-17,Overall survival|Progress-free survival|Quality of life,https://ClinicalTrials.gov/show/NCT02638857
571,NCT02644655,Immunotherapy Using Autologous T Cell-Engineered With CD19-specific Chimeric Antigen Receptor for the Treatment of Recurrent /Refractory B Cell Leukemia,Recruiting,No Results Available,Recurrent B-Cell Tumor|Refractory B-Cell Tumor,Biological: CD19-specific chimeric antigen receptor,Second Military Medical University,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,20,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,EHBHKY2015-02-007,12-Dec-15,9/1/2015,9/1/2017,12/31/2015,Sep-15,No Study Results Posted,null,Mar-17,Occurrence of adverse events and tumor response rate related to study drug,https://ClinicalTrials.gov/show/NCT02644655
704,NCT02559024,Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer,Recruiting,No Results Available,Colorectal Neoplasms,Drug: MEDI6469,Providence Health & Services|MedImmune LLC,Both,"18 Years and older   (Adult, Senior)",Phase 1,44,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,14-102A,22-Sep-15,9/1/2015,9/1/2021,6/23/2016,Jun-16,No Study Results Posted,null,Sep-20,Safety (side-effects or complications related to the study drug)|Immune Score,https://ClinicalTrials.gov/show/NCT02559024
718,NCT02492789,A Trial to Evaluate Safety and Tolerability of INCSHR01210 in Cancer Patients,Recruiting,No Results Available,Neoplasm,Biological: INCSHR01210 injection,Incyte Corporation,Both,"18 Years and older   (Adult, Senior)",Phase 1,27,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,INCSHR1210-101,26-Jun-15,9/1/2015,12/1/2016,7/1/2016,Jul-16,No Study Results Posted,null,Jul-16,Number of Participants with Adverse Events as a Measure of Safety and Tolerability|Pharmacokinetics (PK) profile of INCSHR01210 (Tmax)|Maximum tolerated dose (MTD) of INCSHR01210|Incidence of anti-INCSHR01210 antibody in serum|PD-1 receptor occupancy|Duration of response|Objective response rate|Time to progression|Pharmacokinetics (PK) profile of INCSHR01210 (Cmax)|Pharmacokinetics (PK) profile of INCSHR01210 (AUC0-28day)|Pharmacokinetics (PK) profile of INCSHR01210 (accumulation ratio R),https://ClinicalTrials.gov/show/NCT02492789
797,NCT02528357,GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors (ENGAGE-1),Recruiting,No Results Available,Cancer,Drug: GSK3174998|Drug: Pembrolizumab,GlaxoSmithKline|Merck Sharp & Dohme Corp.,Both,"18 Years and older   (Adult, Senior)",Phase 1,264,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,201212,17-Aug-15,9/1/2015,1/1/2020,6/29/2016,Jun-16,No Study Results Posted,null,Jan-20,"Part 1 and 2: Number of subjects with adverse events (AEs) and serious adverse events (SAEs)|Part 1A and 2A: Dose limiting toxicities (DLT)|Part 1 and 2: Number of withdrawals due to AEs|Part 1 and 2: Number of dose reductions or delays|Part 1 and 2: Change in composite of clinical laboratory assessments as a measure of safety, including hematology, clinical chemistry, thyroid functions and urinalysis parameters|Part 1 and 2: Change in composite of vital signs as a measure of safety, including temperature, systolic and diastolic blood pressure, and pulse rate|Part 1 and 2: Changes in electrocardiogram (ECG) as a measure of safety|Part 1 and 2: Objective response rate (ORR)|Part 1 and 2: Disease Control Rate (DCR)|Part 1 and 2: Time to response|Part 1 and 2: Overall survival (OS)|Part 1 and 2: Duration of Response (DoR)|Part 1 and 2: Progression Free Survival (PFS)|Part 1: Pharmacodynamic activity of GSK3174998 in tissue and periphery|Part 2: Pharmacodynamic activity of GSK3174998 in combination with pembrolizumab in tissue and periphery|Part 1 and 2: Number and percentage of subjects who develop detectable antidrug antibodies (ADA) against GSK3174998|Part 2 only: Number and percentage of subjects who develop detectable ADA against Pembrolizumab|Part 1 and 2: GSK3174998 and Part 2: Pembrolizumab PK parameters - tmax, terminal phase half life|Part 1 and 2: GSK3174998 and Part 2: Pembrolizumab PK parameter - AUC|Part 1 and 2: GSK3174998 and Part 2: Pembrolizumab PK parameter - terminal phase rate constant|Part 1 and 2: GSK3174998 and Part 2: Pembrolizumab PK parameter - clearance|Part 1 and 2: GSK3174998 and Part 2: Pembrolizumab PK parameters - Cmax and Cmin",https://ClinicalTrials.gov/show/NCT02528357
829,NCT02439008,Early Biomarkers of Tumor Response in High Dose Hypofractionated Radiotherapy Word Package 3 : Immune Response,Recruiting,No Results Available,"Carcinoma, Hepatocellular|Colorectal Neoplasms|Melanoma|Kidney Neoplasms",Procedure: Blood samples collection before radiotherapy|Procedure: Blood samples collection during radiotherapy|Procedure: Blood samples collection after radiotherapy|Radiation: Radiotherapy,Centre Oscar Lambret|Institut de Biologie de Lille,Both,"18 Years and older   (Adult, Senior)",,30,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Basic Science,EarlyBio-HypoRT-WP3-1504,27-Apr-15,9/1/2015,6/1/2018,9/17/2015,Sep-15,No Study Results Posted,null,Nov-16,"Number of immune cells|Presence of activation markers|Number of secreted exosomes|Cell viability, determined by number of live/dead cells present|Progression-free rate|Number of Participants with Adverse Events related to radiotherapy",https://ClinicalTrials.gov/show/NCT02439008
871,NCT02608528,Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy,Recruiting,No Results Available,Non-Small Cell Lung Cancer (NSCLC),Radiation: [18F]fluoroglucose(FDG),Abramson Cancer Center of the University of Pennsylvania,Both,"18 Years and older   (Adult, Senior)",Phase 0,40,Other,Interventional,Intervention Model: Single Group Assignment|Primary Purpose: Basic Science,UPCC 15515,17-Nov-15,9/1/2015,null,6/7/2016,Jun-16,No Study Results Posted,null,Sep-17,Number of inflammatory changes within the tumor,https://ClinicalTrials.gov/show/NCT02608528
951,NCT02559778,Pediatric Precision Laboratory Advanced Neuroblastoma Therapy,Recruiting,No Results Available,Neuroblastoma,Drug: bortezomib|Drug: crizotinib|Drug: dasatinib|Drug: lapatinib|Drug: sorafenib|Drug: vorinostat|Drug: DFMO,"Giselle Sholler|Dell, Inc.|Beat NB Cancer Foundation|Because of Ezra|Spectrum Health Hospitals",Both,"12 Months to 21 Years   (Child, Adult)",Phase 1,24,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NMTRC012,22-Sep-15,9/1/2015,9/1/2025,2/16/2016,Feb-16,No Study Results Posted,PEDS-PLAN,Sep-20,Number of subjects that have a targeted agent chosen for treatment.|Number of subjects that receive 75% of dosing of medications while on study protocol during cycles 3-6.|Number of subjects required to go off therapy due to treatment-related adverse events as assessed by CTCAE v4.0.|Number of subjects that are able to complete 2 years of DFMO therapy.|Number of participants with treatment-related adverse events as assessed by CTCAE v4.0|Overall Response Rate (ORR) of Participants by the presence of radiologically assessable disease by cross-sectional CT or MRI imaging and/or by MIBG or PET scans.|Number of days that subjects remain disease free,https://ClinicalTrials.gov/show/NCT02559778
1067,NCT02574377,myDC/pDC in Stage III Melanoma Patients,Recruiting,No Results Available,Melanoma,Drug: A: myDC vaccination|Drug: B: pDC vaccination|Drug: C: combined myDC/pDC vaccination,Radboud University,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 1|Phase 2,30,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,NL49528.000.14,30-Sep-15,9/1/2015,12/1/2017,1/25/2016,Jan-16,No Study Results Posted,null,May-17,"immunogenicity - type I IFN|immunogenicity - response to KLH|immunogenicity - T cells in DTH|biodistribution/localization of pDC and myDC in the lymph node|safety - Toxicity will be assessed according to the NCI Common Toxicity Criteria, CTC version 4.0|quality of life|progression-free survival|overall survival",https://ClinicalTrials.gov/show/NCT02574377
1192,NCT02229266,Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML,Recruiting,No Results Available,Acute Myeloid Leukemia,Biological: NK cells|Drug: Cytarabine,Technische Universität Dresden|German Research Foundation,Both,"60 Years to 99 Years   (Adult, Senior)",Phase 2,56,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,TUD-HINKL1-059,28-Aug-14,9/1/2015,9/1/2020,1/15/2016,Jan-16,No Study Results Posted,HINKL,Sep-19,2-year overall survival|Time to relapse|Relapse-free survival|Yield and purity of NK cells (CD3-CD56+) after CD3 depletion and CD56 enrichment|NK cell analysis|Clinical performance (ECOG score)|Incidence and severity of GVHD|Incidence of (S)AEs,https://ClinicalTrials.gov/show/NCT02229266
1194,NCT02632006,Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma,Recruiting,No Results Available,Advanced Hepatocellular Carcinoma,Biological: PIK-PD-1 cells|Biological: DC-PMAT,Second Military Medical University,Both,"20 Years to 70 Years   (Adult, Senior)",Phase 1|Phase 2,40,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,EHBHKY2015-02-009,13-Dec-15,9/1/2015,9/1/2017,12/30/2015,Sep-15,No Study Results Posted,null,Mar-17,Overall survival|Progress-free survival|Quality of life,https://ClinicalTrials.gov/show/NCT02632006
30,NCT02405078,Pilot Project for Creation of the Diffuse Large B-cell Lymphoma (DLBCL) Response Prediction Model,Recruiting,No Results Available,Lymphoma,Drug: 18F-fluorodeoxyglucose|Procedure: FDG PET/CT Imaging|Procedure: Blood Draws,M.D. Anderson Cancer Center|Sequenta,Both,"18 Years and older   (Adult, Senior)",,50,Other,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic,2015-0022|NCI-2015-01946,27-Mar-15,10/1/2015,null,6/24/2016,Jun-16,No Study Results Posted,null,Oct-18,Response to Standard Immunochemotherapy,https://ClinicalTrials.gov/show/NCT02405078
105,NCT02568748,Evaluation of Cytokine-induced Killer (CIK) Cells as Therapy or Adjuvant Treatment for Advanced HCC,Recruiting,No Results Available,Liver Cancer,Biological: CIK|Procedure: TACE,Sherief Abd-Elsalam|Tanta University,Both,"Child, Adult, Senior",Phase 3,20,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CIK Tanta university,4-Oct-15,10/1/2015,10/1/2017,4/19/2016,Apr-16,No Study Results Posted,null,Jun-17,Number of patients with ablated HCC,https://ClinicalTrials.gov/show/NCT02568748
120,NCT02529839,Safety and Efficacy of an Immunoablative Nonmyeloablative Conditioning Protocol for Autologous Bone Marrow Transplantation (BMT) in Patients With Multiple Sclerosis (MS),Not yet recruiting,No Results Available,Multiple Sclerosis,Procedure: Autologous bone marrow transplantation|Drug: Fludarabine|Drug: Cyclophosphamide|Drug: Alemtuzumab,Hadassah Medical Organization,Both,18 Years to 65 Years   (Adult),,20,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,0105-15-HMO-CTIL,10-Jun-15,10/1/2015,10/1/2017,8/19/2015,Apr-15,No Study Results Posted,null,Oct-17,"Engraftment parameters of Neutrophils and Platelets|Transplant related mortality by Day 100|Changes in the Expanded Disability Status Scale (EDSS score, as compared to baseline)|Overall survival (OS) at 1 year|Progression-free survival (PFS) at 1 year|Changes in MRI activity",https://ClinicalTrials.gov/show/NCT02529839
217,NCT02574533,Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma,Recruiting,No Results Available,Melanoma Recurrent|Malignant Melanoma|Melanoma,Biological: Vigil|Drug: Pembrolizumab,"Gradalis, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1,15,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CL-PTL-123,9-Oct-15,10/1/2015,9/1/2017,7/22/2016,Jul-16,No Study Results Posted,null,Mar-17,Tumor Immune-Related Response to Vigil and Vigil + Pembrolizumab|Best Overall Response Rate (ORR) to Vigil and Vigil + Pembrolizumab|Toxicities and AEs for Vigil + Pembrolizumab according to the Common Toxicity Criteria for Adverse Events (CTCAE) Version 4.03,https://ClinicalTrials.gov/show/NCT02574533
494,NCT02649829,Autologous Dendritic Cell Vaccination in Mesothelioma,Recruiting,No Results Available,Malignant Pleural Mesothelioma,Biological: dendritic cell vaccination plus chemotherapy,"University Hospital, Antwerp",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,10,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CCRG13-002,7-Dec-15,10/1/2015,11/1/2020,1/5/2016,Jan-16,No Study Results Posted,MESODEC,Oct-18,Number of resectable MPM patients with feasible and safe DC vaccine production|Number of patients receiving investigational DC vaccine administration combined with standard of care chemotherapy within the proposed time frame|Objective clinical responses by tumor evaluation (clinical efficacy)|Overall survival (clinical efficacy)|Systemic immunogenicity|Local immunogenicity,https://ClinicalTrials.gov/show/NCT02649829
581,NCT02549833,Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma,Not yet recruiting,No Results Available,Glioma - Recurrent Grade II,Biological: GBM6-AD and poly-ICLC,"University of California, San Francisco|University of Minnesota - Clinical and Translational Science Institute",Both,"18 Years and older   (Adult, Senior)",Phase 1,30,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,15-17078,20-Aug-15,10/1/2015,9/1/2019,9/11/2015,Aug-15,No Study Results Posted,null,Mar-18,Safety - incidence and severity of adverse events|Measurement of vaccine-induced immune response in the resected tumor|Response rate and magnitude of CD4+ and CD8+ T-cell responses against the GM6-AD lysate in pre- and post-vaccine PBMC using IFN-γ-ELISPOT|Tumor tissue expression of glioma-associated antigens (GAAs) and antigen-presentation machinery (APM) molecules|Overall survival (OS)|To tabulate tumor objective response rate (ORR)|Progression-free survival (PFS),https://ClinicalTrials.gov/show/NCT02549833
677,NCT02546986,Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer,Recruiting,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: CC-486|Drug: Pembrolizumab|Drug: Placebo,Celgene Corporation,Both,"18 Years and older   (Adult, Senior)",Phase 2,90,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CC-486-NSCL-001,20-Aug-15,10/1/2015,5/1/2017,5/11/2016,May-16,No Study Results Posted,null,Jan-17,Progression-Free Survival (PFS)|Number of subjects with Stable Disease (SD) for ≥ 18 weeks measured via CT scan or MRI|Number of subjects with Complete Response (CR) measured via CT scan or MRI|Number of subjects with Partial Response (PR) measured via CT scan or MRI|Number of subjects with Disease Control Rate (DCR)|Number of subjects with Overall Survival (OS)|Number of subjects who achieved Overall Response Rate (ORR)|Pharmacokinetics ‐ Maximum Observed Concentration (Cmax) for CC-486|Pharmacokinetics - Area Under the Curve (AUC) for CC-486|Pharmacokinetics ‐Time to Maximum Concentration (Tmax) for CC-486|Pharmacokinetics ‐ Terminal Half-Life (t1/2) for CC-486|Pharmacokinetics ‐ Apparent Total Body Clearance (CL/F) for CC-486|Pharmacokinetics ‐ (Apparent Volume of Distribution (Vz/F) for CC-486|Adverse Events (AEs),https://ClinicalTrials.gov/show/NCT02546986
735,NCT02562755,Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone,Recruiting,No Results Available,Hepatocellular Carcinoma (HCC),Biological: Pexastimogene Devacirepvec (Pexa Vec)|Drug: Sorafenib,"SillaJen, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 3,600,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,JX594-HEP024,24-Sep-15,10/1/2015,10/1/2019,4/14/2016,Apr-16,No Study Results Posted,PHOCUS,Oct-17,Overall Survival|Time to Progression (TTP)|Progression Free Survival (PFS)|Overall Response Rate (ORR)|Disease Control Rate (DCR)|Incidence of Adverse Events (AE) and Serious Adverse Events (SAE)|Time to Symptomatic Progression (TSP),https://ClinicalTrials.gov/show/NCT02562755
849,NCT02463994,A Pilot Study of MPDL3280A and HIGRT in Metastatic NSCLC,Recruiting,No Results Available,Non-small Cell Lung Cancer,Drug: MPDL3280A|Radiation: Hypofractionated Radiotherapy,University of Michigan Cancer Center|University of Washington,Both,"18 Years and older   (Adult, Senior)",Phase 0,12,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,UMCC 2015.005|HUM00100387,29-May-15,10/1/2015,7/1/2020,6/24/2016,Jun-16,No Study Results Posted,null,Jul-20,The number of participants that respond to a combination of HIGRT and MPDL3280A (PD-L1),https://ClinicalTrials.gov/show/NCT02463994
884,NCT02502708,"Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors",Recruiting,No Results Available,Glioblastoma Multiforme|Glioma|Gliosarcoma|Malignant Brain Tumor|Ependymoma|Medulloblastoma,Drug: Indoximod|Drug: Temozolomide|Radiation: Conformal Radiation,NewLink Genetics Corporation,Both,"3 Years to 21 Years   (Child, Adult)",Phase 1,66,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,NLG2105,6-Jul-15,10/1/2015,7/1/2018,7/25/2016,Jul-16,No Study Results Posted,null,Jul-17,"Incidence of regimen limiting toxicities (RLTs)|Objective Response Rate|Pharmacokinetics: Serum concentrations (Cmax/Steady State)|Safety and Tolerability of Indoximod combined with Temozolomide as assessed by incidence and severity of adverse events, dose interruptions and dose reductions.|Progression Free Survival (PFS)|Time to Progression|Overall Survival|Safety and Feasibility of Indoximod combined with conformal radiation as assessed by incidence and severity of adverse events, dose interruptions and dose reductions.",https://ClinicalTrials.gov/show/NCT02502708
930,NCT02588131,A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1),Recruiting,No Results Available,Pleural Mesothelioma|Peritoneal Mesothelioma,Drug: tremelimumab plus MEDI4736,Italian Network for Tumor Biotherapy Foundation|AstraZeneca,Both,"18 Years and older   (Adult, Senior)",Phase 2,40,Other|Industry,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NIBIT-MESO-1,26-Oct-15,10/1/2015,3/1/2018,10/26/2015,Oct-15,No Study Results Posted,null,Jun-16,immune-related (ir)- objective response rate (ORR)|Immune-related-Disease control rate (ir-DCR)|Disease control rate (DCR)|Immune-related-progression-free-survival (PFS)|progression-free-survival (PFS)|Overall survival (OS)|Safety (adverse events)|Immune-related-ORR based on PD-L1 tumor expression|Immune-related-Disease control rate based on PD-L1 tumor expression|Immune-related-progression- free-survival based on PD-L1 tumor expression|Overall survival based on PD-L1 tumor expression,https://ClinicalTrials.gov/show/NCT02588131
1033,NCT02592876,Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma,Recruiting,No Results Available,"Lymphoma, B-cell|Lymphoma, Large B-Cell, Diffuse|Lymphoma, Follicular, Grade 3b|Follicular Lymphoma, Grade 3b",Drug: denintuzumab mafodotin|Drug: rituximab|Drug: ifosfamide|Drug: carboplatin|Drug: etoposide,"Seattle Genetics, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 2,150,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,SGN19A-003,29-Oct-15,10/1/2015,5/1/2020,7/28/2016,Jul-16,No Study Results Posted,null,Jun-17,Complete remission rate|Incidence of adverse events and laboratory abnormalities|Objective response rate|Duration of response|Progression-free survival|Overall survival|Proportion of patients achieving peripheral blood stem cell mobilization|Proportion of patients receiving autologous stem cell transplant,https://ClinicalTrials.gov/show/NCT02592876
1047,NCT02608437,A Study Investigating SGI-110 in Combination With Ipilimumab in Unresectable or Metastatic Melanoma Patients,Recruiting,No Results Available,Metastatic Melanoma,Drug: SGI-110|Drug: Ipilimumab,Italian Network for Tumor Biotherapy Foundation|Astex Pharmaceuticals,Both,"18 Years and older   (Adult, Senior)",Phase 1,19,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NIBIT-M4,13-Nov-15,10/1/2015,10/1/2018,11/16/2015,Nov-15,No Study Results Posted,NIBIT-M4,Oct-16,Maximum Tolerated Dose (MTD) of SGI-110 in combination with ipilimumab|Immune-related Disease Control Rate (irDCR)|Immune-related Objective Response Rate (irORR)|Immune-related Time to Response (irTTR)|Immune-related Duration of Response (irDoR)|Immune-related progression free survival (irPFS),https://ClinicalTrials.gov/show/NCT02608437
1050,NCT02581228,"Multi-Centre, Retrospective, Open Label Study, to Validate ML-PrediCare by Patients With Melanoma Under 1st and 2nd Lines of Immunotherapy",Recruiting,No Results Available,Melanoma,Device: ML-PrediCare,Optimata Ltd.,Both,"18 Years to 120 Years   (Adult, Senior)",,500,Industry,Observational,Observational Model: Cohort|Time Perspective: Retrospective,OPTI-007,19-Oct-15,10/1/2015,11/1/2018,11/2/2015,Oct-15,No Study Results Posted,null,Apr-18,The primary endpoint in this study stage is Time to Progression of disease,https://ClinicalTrials.gov/show/NCT02581228
1054,NCT02446093,Neoadjuvant GMCI Plus mFOLFIRINOX and Chemoradiation for Non-Metastatic Pancreatic Adenocarcinoma,Recruiting,No Results Available,Pancreatic Adenocarcinoma,Biological: GMCI|Drug: mFOLFIRINOX|Drug: Gemcitabine|Radiation: Radiation|Procedure: Surgery,"Advantagene, Inc.|Ohio State University",Both,"18 Years to 76 Years   (Adult, Senior)",Phase 1|Phase 2,44,Industry|Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,PaTK02,14-Apr-15,10/1/2015,12/1/2020,10/21/2015,Oct-15,No Study Results Posted,PaTK02,Dec-17,Resection rate|Safety graded by CTC ver4.0|Overall survival|Progression-free survival,https://ClinicalTrials.gov/show/NCT02446093
1073,NCT02609984,Trial of CMB305 and Atezolizumab in Patients With Sarcoma,Recruiting,No Results Available,Sarcoma|Myxoid/Round Cell Liposarcoma|Synovial Sarcoma|Metastatic Sarcoma|Recurrent Adult Soft Tissue Sarcoma|Locally Advanced Sarcoma|Liposarcoma,Biological: CMB305|Biological: atezolizumab,"Immune Design|Genentech, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 2,80,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,IMDZ-C232,14-Nov-15,10/1/2015,7/1/2019,7/25/2016,Mar-16,No Study Results Posted,IMDZ-C232,Mar-17,"Progression Free Survival|Safety as Evaluated by Adverse Events, Laboratory Findings and Patient Discontinuations|Progression Free Survival Rates|Best Overall Response Rate|Overall Survival",https://ClinicalTrials.gov/show/NCT02609984
1152,NCT02572167,A Study of Brentuximab Vedotin Combined With Nivolumab for Relapsed or Refractory Hodgkin Lymphoma,Recruiting,No Results Available,Hodgkin Lymphoma,Drug: brentuximab vedotin|Drug: nivolumab,"Seattle Genetics, Inc.|Bristol-Myers Squibb",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,60,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SGN35-025,7-Oct-15,10/1/2015,5/1/2020,7/28/2016,Jul-16,No Study Results Posted,null,May-17,Incidence of adverse events|Complete response rate|Objective response rate|Duration of complete response|Duration of objective response|Progression-free survival post-autologous stem cell transplant,https://ClinicalTrials.gov/show/NCT02572167
1172,NCT02462252,"Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome",Recruiting,No Results Available,Aplastic Anemia|Hypoplastic Myelodysplastic Syndrome,Drug: BL-8040|Drug: horse anti-thymocyte globulin (hATG)|Drug: Methylprednisolone|Drug: Cyclosporine,"BioLineRx, Ltd.",Both,"18 Years and older   (Adult, Senior)",Phase 2,25,Industry,Interventional,Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,BL-8040.06,25-May-15,10/1/2015,1/1/2018,6/28/2016,Jun-16,No Study Results Posted,null,Jul-17,Response Rate|Toxicity|general safety|tolerability|Time to response|Response duration|Overall survival|Change in blood product requirements compared to Baseline,https://ClinicalTrials.gov/show/NCT02462252
1190,NCT02575404,GR-MD-02 Plus Pembrolizumab in Melanoma Patients,Recruiting,No Results Available,Melanoma,Drug: GR-MD-02|Drug: Pembrolizumab,Providence Health & Services|Galectin Therapeutics Inc.,Both,"18 Years and older   (Adult, Senior)",Phase 1,22,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,15-166,9-Oct-15,10/1/2015,10/1/2021,6/23/2016,Jun-16,No Study Results Posted,null,Oct-20,Frequency and Severity of Treatment-Related Adverse Events Measured by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0|Measure the response rate to combined therapy with GR-MD-02 and pembrolizumab in patients with metastatic melanoma.|Assess the biological activity of GR-MD-02 in combination with pembrolizumab.,https://ClinicalTrials.gov/show/NCT02575404
1246,NCT02519348,"A Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Unresectable Hepatocellular Carcinoma",Recruiting,No Results Available,Hepatocellular Carcinoma,Biological: MEDI4736 + tremelimumab|Biological: MEDI4736|Biological: Tremelimumab,MedImmune LLC,Both,"18 Years to 99 Years   (Adult, Senior)",Phase 2,144,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,D4190C00022,30-Jul-15,10/1/2015,1/1/2018,7/20/2016,Jul-16,No Study Results Posted,null,Jan-18,Number of subjects reporting adverse events and number of subjects reporting serious adverse events.|Number of subjects experiencing dose limiting toxicities|Objective Response Rate|Duration of Response|Overall Survival|PD-L1 expression,https://ClinicalTrials.gov/show/NCT02519348
1,NCT02554812,A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley),Recruiting,No Results Available,Advanced Cancer,Drug: Avelumab|Drug: PF-05082566|Drug: PF-04518600|Drug: PF-04518600,Pfizer,Both,"18 Years and older   (Adult, Senior)",Phase 1,317,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,B9991004|2015-002552-27|JAVELIN MEDLEY,16-Sep-15,11/1/2015,6/1/2018,8/2/2016,Aug-16,No Study Results Posted,null,Jan-18,Number of participants with Dose-Limiting Toxicities (DLT)|Objective Response - Number of Participants With Objective Response|Cmax of avelumab (MSB0010718C)|Cmax of PF-05082566|Ctrough of avelumab (MSB0010718C)|Ctrough of PF-05082566|Anti-Drug Antibody (ADA) levels of avelumab (MSB0010718C)|Anti-Drug Antibody (ADA) levels of PF-05082566|Time to Tumor Response (TTR)|Duration of Response (DR)|Progression-Free Survival (PFS)|Overall Survival (OS)|Tumor tissue biomarkers|Cmax of PF-04518600|Anti-Drug Antibody (ADA) levels of PF-04518600|Ctrough of PF-04518600,https://ClinicalTrials.gov/show/NCT02554812
73,NCT02539017,The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer,Not yet recruiting,No Results Available,Triple Negative Breast Neoplasms,Drug: Chemo|Biological: Immunotherapy,First Affiliated Hospital Xi'an Jiaotong University,Female,"18 Years to 70 Years   (Adult, Senior)",Phase 2,340,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,Renyu-012,5-Aug-15,11/1/2015,null,9/1/2015,Aug-15,No Study Results Posted,null,Sep-17,"disease free survival|overall survival|percentage of participants with fever, skin rash, bone marrow suppression, allergy, gastrointestinal response, myalgia and arthralgia",https://ClinicalTrials.gov/show/NCT02539017
147,NCT02584829,Localized Radiation Therapy or Recombinant Interferon Beta and Avelumab With or Without Cellular Adoptive Immunotherapy in Treating Patients With Metastatic Merkel Cell Carcinoma,Recruiting,No Results Available,Merkel Cell Polyomavirus Infection|Stage IV Merkel Cell Carcinoma,Drug: Avelumab|Other: Laboratory Biomarker Analysis|Biological: MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells|Radiation: Radiation Therapy|Biological: Recombinant Interferon Beta,Fred Hutchinson Cancer Research Center|EMD Serono|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,20,Other|Industry|NIH,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,9245|NCI-2014-02462|FHCRC 9245|P30CA015704|R01CA176841,21-Oct-15,11/1/2015,null,4/20/2016,Apr-16,No Study Results Posted,null,Jul-19,"Evidence of response, based on median time to new metastasis|Incidence of adverse events, evaluated according to the current guidelines in NCI Common Toxicity Criteria version 4.0|Disease response, as assessed by Response Evaluation Criteria in Solid Tumors version 1.1|Evidence of epitope spreading|Functional capacity of transferred T cells (Group 2)|MCC-specific survival|Persistence of transferred T cells in blood and tumor (Group 2)",https://ClinicalTrials.gov/show/NCT02584829
237,NCT02431559,"A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects With Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated",Recruiting,No Results Available,Ovarian Cancer,Drug: Motolimod|Drug: Durvalumab|Drug: Pegylated Liposomal Doxorubicin,"Ludwig Institute for Cancer Research|MedImmune LLC|VentiRx Pharmaceuticals Inc.|Cancer Research Institute, New York City",Female,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,53,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,LUD2014-001,27-Apr-15,11/1/2015,12/1/2018,5/16/2016,May-16,No Study Results Posted,null,Jun-18,Maximum Tolerated Dose (MTD) - Phase 1|Assessment of Clinical Efficacy - Phase 2 (Progression Free Survival (PFS) rate at 6 months)|Assessment of Clinical Efficacy - Phase 1 (Progression Free Survival (PFS) rate at 6 months)|Assessment of Clinical Efficacy - Phase 1 & 2 (progression¬‐free survival rate at 12 months),https://ClinicalTrials.gov/show/NCT02431559
264,NCT02617134,CAR-T Cell Immunotherapy in MUC1 Positive Solid Tumor,Recruiting,No Results Available,Malignant Glioma of Brain|Colorectal Carcinoma|Gastric Carcinoma,Biological: anti-MUC1 CAR-T cells,"PersonGen BioTherapeutics (Suzhou) Co., Ltd.|The First People's Hospital of Hefei|Hefei Binhu Hospital",Both,"18 Years to 80 Years   (Adult, Senior)",Phase 1|Phase 2,20,Industry|Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PG-021-002,26-Nov-15,11/1/2015,11/1/2018,7/11/2016,Jul-16,No Study Results Posted,null,Nov-17,Adverse events attributed to the administration of the anti-MUC1 CAR-T cells|Objective Response Rate,https://ClinicalTrials.gov/show/NCT02617134
350,NCT02585908,Safety and Efficacy of γδ T Cell Against Gastric Cancer,Not yet recruiting,No Results Available,Gastric Cancer,Biological: CIK|Biological: γδ T|Biological: CIK and γδ T,"Beijing Doing Biomedical Co., Ltd.",Both,"30 Years to 75 Years   (Adult, Senior)",Phase 1|Phase 2,120,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Investigator)|Primary Purpose: Treatment,Doing-001,22-Oct-15,11/1/2015,7/1/2017,11/12/2015,Oct-15,No Study Results Posted,null,Jan-17,"Reduced size of the tumor.|Safety, as measured by the rate of adverse events and serious adverse events",https://ClinicalTrials.gov/show/NCT02585908
745,NCT02621021,A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab,Recruiting,No Results Available,Melanoma,Drug: Cyclophosphamide|Drug: Fludarabine|Drug: Aldeslaukin|Drug: Pembrolizumab|Biological: young TIL,National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC),Both,"18 Years to 70 Years   (Adult, Senior)",Phase 2,170,NIH,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,160027|16-C-0027,2-Dec-15,11/1/2015,9/1/2021,6/18/2016,Jun-16,No Study Results Posted,null,Sep-20,"To determine in a prospective randomized trial whether the addition of pembrolizumab to the standard nonmyeloablative conditioningregimen, TIL and high dose IL-2 (ACT TIL) can improve complete response rates in patients with metastatic melano...",https://ClinicalTrials.gov/show/NCT02621021
805,NCT02583165,A Study in Adult Subjects With Select Advanced Solid Tumors,Recruiting,No Results Available,Advanced Solid Tumors,Biological: MEDI1873,MedImmune LLC,Both,"18 Years and older   (Adult, Senior)",Phase 1,45,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,D6150C00001,19-Oct-15,11/1/2015,8/1/2020,5/4/2016,May-16,No Study Results Posted,null,Jun-19,"Number and percentage of subjects with adverse events (AEs), serious adverse events (SAEs), and dose-limiting toxicities (DLTs)|Objective response rate (ORR)|Disease control rate (DCR)|Duration of response (DoR)|Progression-free survival (PFS)|Overall survival (OS)|Maximum observed concentration (Cmax) of MEDI1873|Number of subjects who develop detectable anti-drug antibodies (ADAs)|PD biomarkers including changes from baseline levels in various lymphocyte populations|Area under the curve (AUC) of MEDI1873|Clearance (CL) of MEDI1873|Terminal half-life of MEDI1873|Percentage of subjects who develop detectable anti-drug antibodies (ADAs)",https://ClinicalTrials.gov/show/NCT02583165
839,NCT02593123,Allogeneic Stem Cell Transplantationin Relapsed Hematological Malignancy: Early GVHD Prophylaxis,Recruiting,No Results Available,Hodgkin's Lymphoma|Lymphoid Leukemia|Lymphoma|Leukemia|Myeloma,Drug: mycophenolate mofetil|Drug: Tacrolimus|Biological: Sargramostim|Biological: Filgrastim|Drug: Antithymocyte Globulin (Rabbit),Virginia Commonwealth University|Massey Cancer Center,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 2,60,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MCC-14-10739|HM20005586,29-Oct-15,11/1/2015,12/1/2025,5/16/2016,May-16,No Study Results Posted,null,Dec-25,The differences in the relapse-free/donor lymphocyte infusion(DLI)-free survival rates between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort).|The differences in the Day 60 ddCD3 rates between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort)|The differences in the Overall survival (OS) between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort)|The differences in the rates of acute GVHD between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort)|The differences in the rates of chronic GVHD between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort)|The differences in the rates of opportunistic infections between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort)|The differences in the rates of graft loss between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort)|The differences in the rates of engraftment syndrome between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort)|The differences in the rates of achieving donor chimerisms between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort).|The differences in the rates of T-cell recovery kinetics following SCT between patients randomized to MMF-30 (control cohort) and MMF-15 (investigational cohort).,https://ClinicalTrials.gov/show/NCT02593123
966,NCT02556346,"Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic Lymphoma",Withdrawn,No Results Available,Chronic B-cell Lymphocytic Leukemia|Small Lymphocytic Leukemia,Drug: MT-3724|Drug: MT-3724|Drug: MT-3724|Drug: MT-3724|Drug: MT-3724,"Molecular Templates, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 1,0,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MT-3724_CLL_SLL_001,16-Sep-15,11/1/2015,12/1/2016,2/29/2016,Feb-16,No Study Results Posted,null,Aug-16,"Tolerability as measured by number of subjects with dose limiting toxicities|Safety as measured by number of subjects with Adverse Events using CTCAE|Tolerability as measured by adverse events using CTCAE and clinical laboratory parameters|PK as measured by concentrations of free MT-3724 (Cmax, Cinf)|PK as measured by area under the curve of free MT-3724 (AUC)|PK as measured by time to maximum concentration of free MT-3724 ( tmax)|PD as measured by immunogenicity (anti-drug antibodies)|Tumor Response as measured by PET or CT scan",https://ClinicalTrials.gov/show/NCT02556346
1030,NCT02641782,NB2013-HR German (GPOH) / Dutch (DCOG) Trial,Recruiting,No Results Available,Neuroblastoma,Drug: antibody ch14.18|Drug: GM-CSF|Drug: IL-2 i.v.|Drug: IL-2 s.c.|Drug: Retinoic acid,University of Cologne,Both,"18 Months to 25 Years   (Child, Adult)",Phase 2,36,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,Uni-Koeln-1694,12-Dec-15,11/1/2015,7/1/2019,12/23/2015,Dec-15,No Study Results Posted,NB2013-HR,Jul-19,toxic death or relevant grade 4 toxicity|Reduction of key side effects|Maximum of antibody-related pain|Comparative pharmacokinetics,https://ClinicalTrials.gov/show/NCT02641782
79,NCT02652910,Memory-enriched CAR-T Cells Immunotherapy for B Cell Lymphoma,Recruiting,No Results Available,Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Stage III Adult Diffuse Large Cell Lymphoma|Stage III Follicular Lymphoma|Stage III Mantle Cell Lymphoma|Stage IV Adult Diffuse Large Cell Lymphoma|Stage IV Follicular Lymphoma|Stage IV Mantle Cell Lymphoma,Drug: CD19.CAR-T cells,Xinqiao Hospital of Chongqing|Xuzhou Medical College,Both,"18 Years to 70 Years   (Adult, Senior)",Phase 1|Phase 2,20,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,20151117,18-Nov-15,12/1/2015,12/1/2019,4/25/2016,Apr-16,No Study Results Posted,MeCAR,Dec-17,Phase 1: Safety measured by occurrence of study related adverse effects defined by NCI CTCAE 4.0|Phase 2: Overall complete remission rate defined by the standard response criteria for malignant lymphoma for each arm|Phase 2: Comparison of overall complete remission rate for the two arms|Duration of remission|Minimum residual disease negative remission rate|Duration of CAR-positive T cells in circulation|Total number of CAR-positive T cells infiltrated into lymphoma tissue|Overall survival,https://ClinicalTrials.gov/show/NCT02652910
173,NCT02616185,A Phase 1 Study To Evaluate Escalating Doses Of A Vaccine-Based Immunotherapy Regimen For Prostate Cancer (PrCa VBIR),Recruiting,No Results Available,Prostatic Neoplasms,Biological: PF-06755992|Biological: PF-06755990|Device: TDS-IM Electroporation Device|Biological: Tremelimumab|Drug: Sunitinib,Pfizer,Male,"18 Years and older   (Adult, Senior)",Phase 1,78,Industry,Interventional,Endpoint Classification: Safety Study|Masking: Open Label|Primary Purpose: Treatment,B7791001|PRCA VBIR FIP STUDY,24-Nov-15,12/1/2015,11/1/2018,7/8/2016,Jul-16,No Study Results Posted,null,Nov-18,Incidence and grade of treatment-emergent adverse events including DLTs|Immune response to the selected prostate cancer tumor-antigens|Antibody response specific to the PSMA antigen|Maximum observed plasma concentration of tremelimumab (Cmax)|Time to maximum concentration of tremelimumab (Tmax)|Area under the curve from time zero extrapolated to infinity of tremelimumab|Trough concentrations after multiple doses of tremelimumab (Ctrough)|Incidence and titers of anti-drug antibodies against tremelimumab|Maximum observed plasma concentration of sunitinib (Cmax)|Time to maximum concentration of sunitinib (Tmax)|Steady state area under the curve during one dose interval of sunitinib (AUCtau)|Incidence and titers of neutralizing antibodies against tremelimumab,https://ClinicalTrials.gov/show/NCT02616185
202,NCT02310464,"Trial of Active Immunotherapy With OBI-833 (Globo H-CRM197)in Gastric, Lung, Colorectal or Breast Cancer Subjects",Recruiting,No Results Available,Metastatic Gastric Cancer|Metastatic Breast Cancer|Metastatic Colorectal Cancer|Metastatic Lung Cancer,Drug: OBI-833/OBI-821,"OBI Pharma, Inc",Both,"21 Years and older   (Adult, Senior)",Phase 1,26,Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,OBI-833-001,2-Dec-14,12/1/2015,11/1/2017,5/2/2016,Mar-16,No Study Results Posted,null,Nov-16,"Safety and tolerability assessed by adverse events, changes in laboratory values, and changes in vital signs.",https://ClinicalTrials.gov/show/NCT02310464
252,NCT02625857,"Safety & Immunogenicity of JNJ-64041809, a Live Attenuated Double-deleted Listeria Immunotherapy, in Participants With Metastatic Castration-resistant Prostate Cancer",Recruiting,No Results Available,"Prostatic Neoplasms, Castration-Resistant",Biological: JNJ-64041809 (Cohort 1A and 1B)|Biological: JNJ-64041809 (Cohort 2A and 2B),"Janssen Research & Development, LLC",Male,"18 Years and older   (Adult, Senior)",Phase 1,50,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CR107668|64041809PCR1001,7-Dec-15,12/1/2015,3/1/2017,7/8/2016,Jul-16,No Study Results Posted,null,Aug-16,Part 1: Incidence of Dose-limiting-toxicity (DLT)|Part 2: Antigen-specific T-cell Response|Part 1 and Part 2: Incidence of Adverse Events (AEs)|Part 1 and Part 2: Objective Response Rate (ORR)|Part 1 and Part 2: Duration of Response (DOR)|Part 1 and Part 2: Progression-free Survival (PFS)|Part 1 and Part 2: Time to Prostate Specific Antigen (PSA) progression (TTPP),https://ClinicalTrials.gov/show/NCT02625857
261,NCT02614456,Combination of Interferon-gamma and Nivolumab for Advanced Solid Tumors,Recruiting,No Results Available,Advanced Solid Tumors,Drug: interferon-gamma and nivolumab,"Fox Chase Cancer Center|Horizon Pharma Ireland, Ltd., Dublin Ireland",Both,"18 Years and older   (Adult, Senior)",Phase 1,15,Other|Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,GU-084,23-Nov-15,12/1/2015,12/1/2018,12/11/2015,Dec-15,No Study Results Posted,null,Dec-17,Number of participants with treatment-related adverse events as assesses by CTCAE version 4.03.|Determine the recommended phase 2 dose (RP2D) based on Dose limiting toxicities|To evaluate the investigator assessed ORR using standard response evaluation criteria in solid tumors (RECIST) version 1.1 for metastatic renal cell carcinoma.|To evaluate the investigator assessed ORR using standard response evaluation criteria in solid tumors (RECIST) version 1.1 for metastatic urothelial cancer.|To evaluate median progression free survival (PFS) using Kaplan-Meier curves for metastatic renal cell carcinoma.|To evaluate median progression free survival (PFS) using Kaplan-Meier curves for metastatic urothelial cancer.|To evaluate median overall survival (OS) using Kaplan-Meier curves for metastatic renal cell carcinoma.|To evaluate median overall survival (OS) using Kaplan-Meier curves for metastatic urothelial cancer.|To investigate the relationship between PD-L1 expression on tumor cells and on immune cells using IHC and SMI methods.,https://ClinicalTrials.gov/show/NCT02614456
325,NCT02609386,IRX-2 Regimen in Patients With Newly Diagnosed Stage III or IVA Squamous Cell Carcinoma of the Oral Cavity,Recruiting,No Results Available,Squamous Cell Carcinoma of the Oral Cavity,Biological: IRX-2|Drug: Cyclophosphamide|Drug: Indomethacin|Dietary Supplement: Zinc-containing multivitamin|Drug: Omeprazole,IRX Therapeutics,Both,"18 Years and older   (Adult, Senior)",Phase 2,200,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,IRX-2 2015-A,10-Sep-15,12/1/2015,12/1/2019,4/27/2016,Apr-16,No Study Results Posted,INSPIRE,Feb-19,Change in Event-Free Survival from baseline|Change in Overall Survival from baseline|Change in safety from baseline in each Regimen using a pre-approved questionnaire (case report form)|Change in tumor size from baseline to surgery|Change in lymphocyte infiltrates in tumor comparing pre-treatment biopsy and surgical specimens,https://ClinicalTrials.gov/show/NCT02609386
422,NCT02614833,IMP321 as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma,Recruiting,No Results Available,Adenocarcinoma Breast Stage IV,Biological: IMP321|Drug: Placebo|Drug: Paclitaxel,Immutep S.A.|Prima BioMed Ltd,Female,"18 Years and older   (Adult, Senior)",Phase 2,211,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment",IMP321 P011,5-Nov-15,12/1/2015,6/1/2019,7/9/2016,Jul-16,No Study Results Posted,null,Jun-19,"Assessment of Progression-Free Survival (PFS)|Assessment of the safety and tolerability of IMP321 as compared to placebo (adverse events and serious adverse events, physical examinations, vital signs, safety lab, ECG)|Assessment of the overall survival (OS)|Stage 1: Evaluation of the pharmacokinetic e.g. Peak Plasma Concentration [Cmax]|Stage 1: Evaluation of the pharmacokinetic e.g. Area Under the Curve [AUC]|Stage 1: Evaluation of the pharmacokinetic e.g. time to reach Cmax [tmax]|Stage 1: Evaluation of the pharmacokinetic e.g. systemic clearance [CL]|Stage 1: Evaluation of the pharmacokinetic e.g. elimination half-life[t1/2]|Stage 1: Evaluation of the pharmacokinetic e.g. volume of distribution [VD]|Assessment of the change in quality of life (QOL)|Evaluation of the time to next treatment. This is defined as the time between the date of first study treatment administration and the start of the next anti-cancer treatment|Evaluation of objective response rate (ORR)|Evaluation of stable disease. This is defined as the time (days) from the date study administration to the date of disease progression or death (if death occured before progression)",https://ClinicalTrials.gov/show/NCT02614833
466,NCT02159495,Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,Recruiting,No Results Available,Adult Acute Myeloid Leukemia in Remission|Donor|Early Relapse of Acute Myeloid Leukemia|Late Relapse of Acute Myeloid Leukemia|Recurrent Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia,Drug: cyclophosphamide|Biological: Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes|Other: laboratory biomarker analysis|Drug: Etoposide|Drug: Fludarabine Phosphate|Biological: Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes,City of Hope Medical Center|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,30,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,13272|NCI-2014-01147,6-Jun-14,12/1/2015,null,6/24/2016,Jun-16,No Study Results Posted,null,Dec-17,Dose-limiting toxicity (DLT) defined as any grade 3 or higher toxicity as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0|Incidence of adverse events as assessed by NCI CTCAE version 4.0|Disease response (CR or CRi)|Engraftment of transferred T-cell|CAR123-specific antibody level,https://ClinicalTrials.gov/show/NCT02159495
512,NCT02592967,"Safety & Immunogenicity of JNJ-64041757, Live-attenuated Double-deleted Listeria Immunotherapy, in Subjects With Non Small Cell Lung Cancer",Recruiting,No Results Available,"Carcinoma, Non-Small-Cell Lung",Biological: JNJ-64041757 (Cohort 1A and 1B)|Biological: JNJ-64041757 (Cohort 2A and 2B),"Janssen Research & Development, LLC",Both,"18 Years and older   (Adult, Senior)",Phase 1,50,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CR107667|64041757LUC1001,29-Oct-15,12/1/2015,4/1/2017,6/2/2016,May-16,No Study Results Posted,null,Apr-17,Part 1: Incidence of Dose-limiting toxicity (DLT)|Part 2: Antigen-specific T-cell Response|Part 1 and Part 2: Incidence of Adverse Events (AEs)|Part 1 and Part 2: Objective Response Rate (ORR)|Part 1 and Part 2: Duration of Response (DOR)|Part 1 and Part 2: Progression-free Survival (PFS),https://ClinicalTrials.gov/show/NCT02592967
516,NCT02459067,ImmuniCell® in Patients With Advanced Cancers,Recruiting,No Results Available,Malignant Melanoma|Non-small Cell Lung Cancer|Renal Cell Cancer,Biological: ImmuniCell®,TC Biopharm,Both,"18 Years and older   (Adult, Senior)",Phase 2|Phase 3,60,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,TCB-101-001,20-May-15,12/1/2015,7/1/2018,7/18/2016,Jul-16,No Study Results Posted,null,Dec-17,"Proportion of patients with drug-related > grade 3 toxicity (except for nausea, vomiting or grade 3 diarrhoea without maximal supportive therapy; anaemia, alopecia, or asymptomatic grade 3 laboratory findings that last for < 7 days)|Document the clinical response (immediate or delayed CR, PR, SD or PD) of the patients following ImmuniCell® treatment and assess the data for a response signal to guide the confirmatory stage|Changes in markers of immune response (such as IFN-γ, IL-2 and TNF-α) before the first and subsequent ImmuniCell® infusions|Changes in peripheral T lymphocyte counts before the first and subsequent ImmuniCell® infusions (optional)",https://ClinicalTrials.gov/show/NCT02459067
634,NCT02649582,Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients,Recruiting,No Results Available,Glioblastoma Multiforme of Brain,Biological: Dendritic cell vaccine plus temozolomide chemotherapy,"University Hospital, Antwerp",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,20,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CCRG14-001,23-Jan-15,12/1/2015,12/1/2019,1/5/2016,Jan-16,No Study Results Posted,ADDIT-GLIO,Dec-17,Overall survival|Number of glioblastoma patients post surgical resection with feasible and safe DC vaccine production|Feasibility of DC vaccine administration to glioblastoma patients combined with chemotherapy|Number of participants with adverse events as a measure of safety and tolerability|Immunological responses to the DC vaccine|Objective clinical responses by tumor evaluation (clinical efficacy),https://ClinicalTrials.gov/show/NCT02649582
757,NCT02193347,IDH1 Peptide Vaccine for Recurrent Grade II Glioma,Recruiting,No Results Available,"Brain Cancer|Brain Neoplasm, Primary|Brain Neoplasms, Recurrent|Brain Tumor|Cancer of the Brain",Biological: PEPIDH1M vaccine,Duke University,Both,"18 Years and older   (Adult, Senior)",Phase 1,24,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,Pro00054746,2-Jul-14,12/1/2015,6/1/2019,7/26/2016,Jul-16,No Study Results Posted,RESIST,May-17,The proportion of patients with an unacceptable toxicity will be estimated.|IFNγ ELIspot Measurements,https://ClinicalTrials.gov/show/NCT02193347
766,NCT02086721,Phase I Clinical Study Combining L19-IL2 With SABR in Patients With Oligometastatic Solid Tumor,Recruiting,No Results Available,Solid Tumour,Drug: L19-IL2,Maastricht Radiation Oncology,Both,"18 Years and older   (Adult, Senior)",Phase 1,18,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,L19-IL2,3-Sep-13,12/1/2015,3/1/2017,2/29/2016,Feb-16,No Study Results Posted,L19-IL2,Mar-17,Toxicity (CTCAE 4.0)|Progression-Free survival|Local control rate|non-invasive response evaluation using PET|Quality of life|Correlation of outcome measures with PET-imaging|correlation of outcome measures with immunological markers in tumor tissue.|Overall survival,https://ClinicalTrials.gov/show/NCT02086721
804,NCT02463799,Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC,Recruiting,No Results Available,Prostate Cancer,Drug: Radium-223|Biological: Sipuleucel-T,Sidney Kimmel Comprehensive Cancer Center,Male,"18 Years and older   (Adult, Senior)",Phase 2,34,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,J1522,21-May-15,12/1/2015,12/1/2020,6/28/2016,Jun-16,No Study Results Posted,null,Dec-18,Immune responses to treatment with sipuleucel-T (with or without Radium-223) measured by peripheral PA2024 T-cell proliferation|To evaluate peripheral antigen-specific T-cell proliferation over time|To evaluate peripheral antigen-specific T-cell activation to sipuleucel-T over time|To evaluate antigen specific antibody response to sipuleucel-T over time|To evaluate sipuleucel-T induced antigen spread (epitope spread) phenomena|To evaluate the sipuleucel-T product immune parameters|To investigate safety of combined use of radium-223 and sipuleucel-T (composite measure of both arms)|To evaluate time to prostate-specific antigen (PSA) progression|To evaluate time to alkaline phosphatase (ALP) progression|To evaluate time to pain progression and first cancer-related opioid use|To evaluate time to radiographic or clinical progression|To evaluate time to first skeletal related event (SRE)|To evaluate time to first chemotherapy use,https://ClinicalTrials.gov/show/NCT02463799
973,NCT02644863,Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal Cancer,Recruiting,No Results Available,Esophageal Neoplasms|Neoplasms|Digestive System Neoplasms|Esophageal Cancer,Drug: Paclitaxel|Biological: DC-CIK|Drug: Cisplatin,"Shenzhen Hornetcorn Bio-technology Company, LTD|Affiliated Tumor Hospital of Guangzhou Medical University",Both,"18 Years to 75 Years   (Adult, Senior)",Phase 2,60,Industry|Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,HYK-esophageal cancer,28-Dec-15,12/1/2015,5/1/2019,5/23/2016,Dec-15,No Study Results Posted,null,Dec-18,Overall survival|Progress-free survival|Quality of life (QOL)|Phenotypic analysis of T cells,https://ClinicalTrials.gov/show/NCT02644863
1174,NCT02542124,NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT),Recruiting,No Results Available,Cutaneous T Cell Lymphoma (CTCL)|Mycosis Fungoides|Sézary Syndrome,Biological: NM-IL-12,Neumedicines Inc.|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 2,10,Industry|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NM-ONC-001|1R44CA192576-01,1-Sep-15,12/1/2015,8/1/2017,8/2/2016,Aug-16,No Study Results Posted,null,May-17,"Safety and tolerability will be evaluated on the basis of the following parameters (Vital signs, physical examination,Toxicity according to the NCI CTCAE, Immunogenicity evaluated by the presence of anti-drug antibody) :|Clinical Response measured by a modified severity-weighted assessment tool (mSWAT)|Progression free survival",https://ClinicalTrials.gov/show/NCT02542124
1222,NCT02617485,MabionCD20® Compared to MabThera® in Lymphoma Patients,Recruiting,No Results Available,Diffuse Large B-Cell Lymphoma,Drug: Rituximab|Drug: Doxorubicin|Drug: Vincristine|Drug: Cyclophosphamide|Drug: prednisone,Mabion SA,Both,"18 Years and older   (Adult, Senior)",Phase 3,140,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Bio-equivalence Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment",MabionCD20-002NHL,12-Nov-15,12/1/2015,6/1/2017,6/1/2016,May-16,No Study Results Posted,null,Dec-16,Area under the plasma concentration- time curve from time zero to final time point,https://ClinicalTrials.gov/show/NCT02617485
2,NCT02626455,Study of Copanlisib in Combination With Standard Immunochemotherapy in Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL),Recruiting,No Results Available,"Lymphoma, Non-Hodgkin",Drug: Copanlisib (BAY 80-6946)|Drug: Placebo|Drug: Rituximab|Drug: Cyclophosphamide|Drug: Doxorubicin|Drug: Vincristine|Drug: Bendamustine|Drug: Prednisone,Bayer,Both,"18 Years and older   (Adult, Senior)",Phase 3,724,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",17833|2015-001088-38,3-Nov-15,1/1/2016,7/1/2024,7/26/2016,Jul-16,No Study Results Posted,CHRONOS-4,Mar-21,"Evaluation whether copanlisib in combination with standard immunochemotherapy, is superior to placebo and standard immunochemotherapy assessed by the prolongation of progression free survival (PFS) - applicable to Phase III part|Determination of the recommended Phase III dose (RP3D) of copanlisib in combination with standard immunochemotherapy assessed by the occurrence of dose-limiting toxicity s (DLTs) / adverse events (AEs) - applicable to safety run-in part|Objective tumor response rate (ORR)|Duration of tumor response (DOR)|Complete tumor response rate (CRR)|Time to tumor progression (TTP)|Overall survival (OS)|Time to deterioration in disease-related physical symptoms (DRS-P) of at least 3 points as measured by by the FLymSI-18 (Lymphoma Symptom Index -18) questionnaire|Time to improvement in DRS-P of at least 3 points, as measured by the FLymSI-18 questionnaire, will be evaluated for patients with a baseline DRS-P score of 30 points or less|Time to next anti-lymphoma treatment (TTNT)|Progression free survival (PFS)|Number of participants with adverse events as a measure of safety and tolerability",https://ClinicalTrials.gov/show/NCT02626455
67,NCT02460367,Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer,Recruiting,No Results Available,Non-small Cell Lung Cancer|Progression of Non-small Cell Lung Cancer|Non-small Cell Lung Cancer Recurrent,Drug: Docetaxel|Biological: Tergenpumatucel-L|Drug: Indoximod 600mg|Drug: Indoximod 1200mg,NewLink Genetics Corporation,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,115,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NLG0401|1504-1393,21-May-15,1/1/2016,null,2/2/2016,Feb-16,No Study Results Posted,null,Jun-17,"Regimen Limiting Toxicity|Progression Free Survival (PFS)|Frequency and grade of adverse events of tergenpumatuucel-L, indoximod and docetaxel|Objective Response Rate|Overall Survival|Response rate to subsequent therapy",https://ClinicalTrials.gov/show/NCT02460367
72,NCT02575807,"Safety and Efficacy of CRS-207 With Epacadostat in Platinum Resistant Ovarian, Fallopian, or Peritoneal Cancer",Recruiting,No Results Available,Platinum-resistant Ovarian Cancer|Platinum-resistant Fallopian Cancer|Platinum-resistant Peritoneal Cancer,Biological: CRS-207|Drug: epacadostat (INCB024360),"Aduro Biotech, Inc.|Incyte Corporation",Female,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,126,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ADU-CL-11,12-Oct-15,1/1/2016,12/1/2018,6/17/2016,May-16,No Study Results Posted,SEASCAPE,Dec-18,"Part 1: Number of patients reporting treatment-related adverse events that qualify as dose-limiting toxicities|Part 1: Adverse events by CTCAE grade|Part 1: Ratio of tumor infiltrating lymphocytes CD8/Treg (FoxP3)|Part 1: Plasma kynurenine/tryptophan ratio|Part 2: ORR will be measured, defined as CR or PR as determined by mRECIST|Part 2: PFS will be measured, defined as the time from the date of first dose to PD or death due to any cause",https://ClinicalTrials.gov/show/NCT02575807
121,NCT00517907,Safety Study of Preimplantation Factor (PIF-1) to Treat Acute Steroid-Resistant Graft-Versus-Host Disease (GVHD),Not yet recruiting,No Results Available,Graft Vs Host Disease,Drug: Preimplantation factor (PIF-1),Hadassah Medical Organization|BioIncept LLC,Both,"14 Years to 70 Years   (Child, Adult, Senior)",Phase 1,6,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PIF1BMT-HMO-CTIL,16-Aug-07,1/1/2016,1/1/2018,6/10/2015,Aug-08,No Study Results Posted,PIF1GVHD,Jan-18,"Safety and tolerability of PIF-1 in steroid-resistant patients who develop acute GVHD, as evidenced by clinical and laboratory indices|Therapeutic effect of PIF-1 on participants' acute GVHD status, as determined by comparison with the clinical and laboratory indices before intervention",https://ClinicalTrials.gov/show/NCT00517907
294,NCT02635360,Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer,Recruiting,No Results Available,Cervical Cancer,Drug: Pembrolizumab|Radiation: Brachytherapy|Drug: Cisplatin,Linda R Duska|Merck Sharp & Dohme Corp.|University of Virginia,Female,"18 Years and older   (Adult, Senior)",Phase 2,88,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,18472|UVA-LACC-PD201,4-Dec-15,1/1/2016,5/1/2021,6/27/2016,Jun-16,No Study Results Posted,null,May-18,Change in immunologic markers following combination of study drug with chemoradiation|Incidence of dose limiting toxicities|Metabolic Response Rate on PET/CT imaging|Incidence of distant metastases|Progression Free Survival|Overall Survival,https://ClinicalTrials.gov/show/NCT02635360
879,NCT02546739,"Immunotherapy With CD19 CAR T-cells for B-Cell Lymphoma, ALL and CLL",Not yet recruiting,No Results Available,Leukemia|Lymphoma,Biological: Anti-CD19-CAR,"Beijing Doing Biomedical Co., Ltd.|First Hospital of Jilin University",Both,"18 Years to 70 Years   (Adult, Senior)",Phase 1,100,Industry|Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,Doing-002,8-Sep-15,1/1/2016,10/1/2019,1/12/2016,Sep-15,No Study Results Posted,null,Oct-18,Adverse events of each patient.|Survival time of Anti-CD19 CAR T cells in vivo.|Antitumor Effects|Maximum tolerated dose (MTD) of CD19 targeted CAR T cells.,https://ClinicalTrials.gov/show/NCT02546739
900,NCT02529072,Nivolumab With DC Vaccines for Recurrent Brain Tumors,Recruiting,No Results Available,Malignant Glioma|Astrocytoma|Glioblastoma,Drug: nivolumab|Biological: DC,Gary Archer Ph.D.|Bristol-Myers Squibb|Duke Cancer Institute|Duke University,Both,"18 Years to 80 Years   (Adult, Senior)",Phase 1,66,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,Pro00065241,12-Aug-15,1/1/2016,8/1/2019,6/28/2016,Jun-16,No Study Results Posted,AVERT,May-18,"The safety of administering DC vaccines with nivolumab, as measured by the percentage of patients who experience unacceptable toxicity during combination treatment|Survival of subjects treated with any protocol treatment (i.e. nivolumab or DC vaccines).|Progression Free Survival (PFS) of subjects treated with any protocol treatment (i.e. nivolumab or DC vaccines).",https://ClinicalTrials.gov/show/NCT02529072
959,NCT02619253,Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma,Recruiting,No Results Available,Renal Cell Carcinoma|Urinary Bladder Neoplasms,Drug: Pembrolizumab|Drug: Vorinostat,Roberto Pili|Indiana University,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,42,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,IUSCC-0551,16-Nov-15,1/1/2016,null,4/4/2016,Apr-16,No Study Results Posted,null,May-18,"Find Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (RP2D) of pembrolizumab in combination with vorinostat|Serious adverse events, adverse events (AEs) and discontinuations due to AEs will be summarized according to CTCAE 4.0|Objective response rate|Progression free survival",https://ClinicalTrials.gov/show/NCT02619253
1220,NCT02192021,Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL),Recruiting,No Results Available,Cutaneous T Cell Lymphoma,Drug: Micro needle array-Doxorubicin (MNA-D),University of Pittsburgh,Both,"18 Years and older   (Adult, Senior)",Phase 1,54,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,PRO14030589,10-Jul-14,1/1/2016,7/1/2017,2/12/2016,Feb-16,No Study Results Posted,MNA-D,Jul-16,"Evaluate the safety of the micro array needle doxorubicin (MNA-D) system confirmed by vital signs, hematology, comprehensive metabolic panel, assessment for skin toxicity, and adverse event evaluation.|Evaluate the clinical responses (i.e., effectiveness) by the MNA-D",https://ClinicalTrials.gov/show/NCT02192021
1245,NCT02577094,Testing a Reduced Conditioning Regimen FB2A2 Preceded by a Fractionated Radio-immunotherapy (RIT) With 90Y-Epratuzumab Before Allogeneic Stem Cell Transplantation for Patients With Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia,Not yet recruiting,No Results Available,Lymphocyte B CD22 Positive Acute Lymphoblastic Leukemia,Drug: 90Y-DOTA-Epratuzumab IgG/Epratuzumab IgG|Drug: Busulfan|Biological: allogeneic stem cell transplantation.|Drug: Fludarabine|Biological: Thymoglobulines,"Nantes University Hospital|Immunomedics, Inc.|Institut Cancerologie de l'Ouest",Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,15,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,RC14_0429,2-Oct-15,1/1/2016,2/1/2018,10/13/2015,Oct-15,No Study Results Posted,EPRALLO,Feb-18,Determination of the maximum tolerated dose (MTD)|Overall survival|Disease free survival at one year post-transplant|Incidence of relapse at 1 year post-transplant|Non relapse mortality at day 100 post-transplant|Non relapse mortality at one year post-transplant|Hematologic reconstitutions post-transplant|Immune reconstitutions post-transplant|Incidence of acute and chronic GVHD|Chimerism post-transplant|Residual disease post-transplant|Toxicity of RIT|Tolerance of RIT|Immunization analysis : detection of antibody anti epratuzumab|90Y-DOTA-Epratuzumab blood pharmacokinetics|Dosage of FLT3-ligand in plasma and correlation with efficacy and toxicity of RIT,https://ClinicalTrials.gov/show/NCT02577094
50,NCT02595866,"Pembrolizumab in Treating Patients With HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms",Recruiting,No Results Available,AIDS-Related Non-Hodgkin Lymphoma|Classical Hodgkin Lymphoma|HIV Infection|Locally Advanced Malignant Neoplasm|Metastatic Malignant Neoplasm|Recurrent Hepatocellular Carcinoma|Recurrent Hodgkin Lymphoma|Recurrent Kaposi Sarcoma|Recurrent Malignant Neoplasm|Recurrent Melanoma of the Skin|Recurrent Non-Hodgkin Lymphoma|Recurrent Non-Small Cell Lung Carcinoma|Refractory Hodgkin Lymphoma|Refractory Malignant Neoplasm|Solid Neoplasm|Stage IIIA Hepatocellular Carcinoma|Stage IIIA Non-Small Cell Lung Cancer|Stage IIIA Skin Melanoma|Stage IIIB Hepatocellular Carcinoma|Stage IIIB Non-Small Cell Lung Cancer|Stage IIIB Skin Melanoma|Stage IIIC Hepatocellular Carcinoma|Stage IIIC Skin Melanoma|Stage IV Non-Small Cell Lung Cancer|Stage IV Skin Melanoma|Stage IVA Hepatocellular Carcinoma|Stage IVB Hepatocellular Carcinoma,Other: Laboratory Biomarker Analysis|Biological: Pembrolizumab,National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,39,NIH,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NCI-2015-01906|CITN-12|U01CA154967,3-Nov-15,2/1/2016,null,7/19/2016,Jul-16,No Study Results Posted,null,Apr-18,"Frequency of observed AEs graded using CTCAE version 4.0|Incidence of cART-related ECIs of grade 2 or higher AEs using CTCAE version 4.0|Incidence of immune-related events of clinical interest (ECIs), which include the occurrence of grade 2 or higher AEs using CTCAE version 4.0|Duration of response defined in participants experiencing CR or PR using RECIST 1.1, ""Lugano Criteria"" for malignant lymphoma or other tumor-specific criteria|Objective response rate defined as the proportion of patients who have achieved completer response (CR) or partial response (PR) according to RECIST 1.1, ""Lugano Criteria"" for Malignant Lymphoma or other tumor-specific criteria|Overall survival|Progression-free survival using RECIST 1.1, ""Lugano Criteria"" for Malignant Lymphoma or other tumor-specific criteria",https://ClinicalTrials.gov/show/NCT02595866
127,NCT02491697,Immunotherapy Combined With Capecitabine Versus Capecitabine Monotherapy in Advanced Breast Cancer,"Active, not recruiting",No Results Available,Breast Cancer,Biological: DC-CIK Immunotherapy|Drug: Capecitabine Monotherapy,The First People's Hospital of Changzhou,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 2,400,Other,Interventional,Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,CZ1H-BC-001,1-Jul-15,2/1/2016,8/1/2033,2/21/2016,Jul-15,No Study Results Posted,null,Aug-30,Overall Survival(OS)|Disease-free survival,https://ClinicalTrials.gov/show/NCT02491697
402,NCT02630823,MK-3475 Immunotherapy in Endometrial Carcinoma,Recruiting,No Results Available,"Endometrial Cancer|Endometrial Carcinoma|Neoplasms, Endometrial",Drug: MK-3475|Procedure: Surgical resection (standard of care)|Drug: Paclitaxel (standard of care)|Drug: Carboplatin (standard of care)|Radiation: Radiation (standard of care)|Procedure: Endometrial biopsy|Procedure: Peripheral blood draw,Washington University School of Medicine|Merck Sharp & Dohme Corp.,Female,"18 Years and older   (Adult, Senior)",Phase 0,9,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,201601062,10-Dec-15,2/1/2016,3/1/2019,2/10/2016,Feb-16,No Study Results Posted,null,Mar-18,Safety as measured by treatment related adverse events|Progression-free survival (PFS),https://ClinicalTrials.gov/show/NCT02630823
485,NCT02571725,PARP-inhibition and CTLA-4 Blockade in BRCA-deficient Ovarian Cancer,Recruiting,No Results Available,Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Neoplasms,Drug: Olaparib|Drug: Tremelimumab,New Mexico Cancer Care Alliance,Female,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,50,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,INST 1419,6-Oct-15,2/1/2016,2/1/2022,6/7/2016,Jun-16,No Study Results Posted,null,Feb-18,Phase 1: Recommended Phase 2 Dose (RP2D)|Phase 2: Objective response rate (ORR)|Phase 2: Progression free survival (PFS),https://ClinicalTrials.gov/show/NCT02571725
866,NCT02575222,Study of Neoadjuvant Nivolumab in Patients With Non-metastatic Stage II-IV Clear Cell Renal Cell Carcinoma,Recruiting,No Results Available,Clear Cell Renal Cell Carcinoma,Drug: Nivolumab,Sidney Kimmel Comprehensive Cancer Center|Bristol-Myers Squibb,Both,"18 Years and older   (Adult, Senior)",Phase 1,30,Other|Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,J15179|IRB00068726,6-Oct-15,2/1/2016,12/1/2019,2/29/2016,Feb-16,No Study Results Posted,null,Dec-18,Safety and Tolerability (number of adverse events as a measure of toxicity)|Objective Tumor Response Rate (by RECIST)|Objective Tumor Response Rate (by irRC)|Quality of Life (Median scores on FKSI-15 questionnaire)|Metastasis-Free Survival|Overall Survival,https://ClinicalTrials.gov/show/NCT02575222
199,NCT02572843,Anti-PD-L1 in Stage IIIA(N2) NSCLC,Recruiting,No Results Available,NSCLC Non-small Cell Lung Cancer,Drug: MEDI4736 (anti-PD-L1),Swiss Group for Clinical Cancer Research,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 2,68,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SAKK 16/14|000001480,1-Oct-15,3/1/2016,12/1/2021,5/30/2016,May-16,No Study Results Posted,null,Mar-21,Event-free survival (EFS)|Overall survival (OS)|Objective response (OR) after neoadjuvant chemotherapy|OR after neoadjuvant immunotherapy|Pathological responses (pCR)|Adverse Events (AEs) (according to NCI CTCAE v4.0),https://ClinicalTrials.gov/show/NCT02572843
212,NCT02639234,Vigil™ + Nivolumab in Advanced Non-Small Cell Lung Cancer,Recruiting,No Results Available,Advanced Non-small Cell Lung Cancer|Metastatic Non-small Cell Lung Cancer|Lung Neoplasms,Biological: Vigil™|Drug: Nivolumab,"Gradalis, Inc.",Both,"18 Years and older   (Adult, Senior)",Phase 2,35,Industry,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CL-PTL-122,21-Dec-15,3/1/2016,9/1/2017,7/22/2016,Jul-16,No Study Results Posted,null,Mar-17,"Objective Response Rate (ORR) by RECIST 1.1 criteria of Vigil™ plus nivolumab in patients with NSCLC after failure of prior platinum-based chemotherapy|Tolerability and safety profile of Vigil™ combined with nivolumab (all adverse events (CTCAE 4.03), laboratory safety assessments, and physical examination findings)|Progression-Free Survival (PFS) of study patients treated with Vigil™ and nivolumab",https://ClinicalTrials.gov/show/NCT02639234
686,NCT02573896,Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells,Not yet recruiting,No Results Available,Neuroblastoma,Drug: Ch14.18|Biological: NK Cells|Drug: Lenalidomide,New Approaches to Neuroblastoma Therapy Consortium|M.D. Anderson Cancer Center|United Therapeutics,Both,"1 Month to 30 Years   (Child, Adult)",Phase 1,24,Other|Industry,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NANT 2013-01,16-Sep-15,3/1/2016,6/1/2019,12/11/2015,Dec-15,No Study Results Posted,null,Dec-18,"Feasibility of expanding NK cells from neuroblastoma patients and cryopreserving, shipping, and infusing multiple doses of NK cells.|Determination of the Maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of autologous expanded NK cells|Toxicity (Per Patient)|Evaluation of Clinical Response (Per Patient)",https://ClinicalTrials.gov/show/NCT02573896
1200,NCT02632786,"The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis",Recruiting,No Results Available,AL Amyloidosis,Drug: NEOD001|Drug: Placebo,Prothena Therapeutics Ltd.,Both,"18 Years and older   (Adult, Senior)",Phase 2,100,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",NEOD001-201,9-Dec-15,3/1/2016,1/1/2018,8/1/2016,Jun-16,No Study Results Posted,PRONTO,Jan-18,"Cardiac best response as measured by NT-proBNP|Change in Short Form-36 (SF-36) Questionnaire|Change in 6MWT|Renal best response as measured by proteinuria|Change in Neuropathy Impairment Score- Lower Limb (NIS-LL) score|Progression Free Survival|To assess the safety of single agent NEOD001 by assessing vital signs, electrocardiogram(ECG),laboratory tests and AEs",https://ClinicalTrials.gov/show/NCT02632786
1210,NCT02583477,Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma,Recruiting,No Results Available,Metastatic Pancreatic Ductal Adenocarcinoma,Drug: MEDI4736 in combination with nab-paclitaxel and gemcitabine|Drug: MEDI4736 in combination with AZD5069,AstraZeneca,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,26,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,D4198C00003,20-Oct-15,3/1/2016,7/1/2017,5/6/2016,May-16,No Study Results Posted,null,Jul-17,Occurrence of dose-limiting toxicities|Objective response rate|Duration of response|Disease control rate|Progression-free survival|Presence of antidrug antibodies(ADAs) for MEDI4736|Pharmacokinetics of MEDI4736: Peak concentration (Cmax)|Pharmacokinetics of MEDI4736: Trough concentration (Ctrough),https://ClinicalTrials.gov/show/NCT02583477
355,NCT02443831,CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies,Recruiting,No Results Available,Acute Lymphoblastic Leukemia|Burkitt Lymphoma,Procedure: Leukapheresis|Drug: Lymphodepletion with fludarabine|Drug: Lymphodepletion with cyclophosphamide|Biological: CD19 CAR T-cells,"University College, London",Both,"up to 24 Years   (Child, Adult)",Phase 1,18,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,UCL 14/0529,29-Apr-15,4/1/2016,12/1/2028,6/3/2016,Jun-16,No Study Results Posted,null,Apr-18,Toxicity evaluation following CD19CAR T-cell infusion|Molecular remission|Long term molecular remission|Frequency of circulating CD19 CAR T-cells|Incidence of hypogammaglobulinaemia|Relapse rate|Overall Survival,https://ClinicalTrials.gov/show/NCT02443831
1178,NCT02626962,Trial of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated Metastatic Uveal Melanoma,Recruiting,No Results Available,Uveal Melanoma,Drug: ipilimumab|Drug: Nivolumab,Grupo Español Multidisciplinar de Melanoma|Bristol-Myers Squibb,Both,"18 Years to 99 Years   (Adult, Senior)",Phase 2,48,Other|Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,GEM-1402|2015-004429-15,1-Dec-15,4/1/2016,2/1/2020,5/6/2016,May-16,No Study Results Posted,GEM1402,Feb-20,The primary endpoint is Overall Survival at 12 months defined as the percentage of patients alive at 1-year from first dose of treatment.|Overall survival and overall survival at 24 months.|Progression Free Survival (PFS) at 3 months according to RECIST 1.1 criteria.|Global PFS according to RECIST 1.1 criteria.|Objective Response Rate (ORR) according to RECIST 1.1 criteria.|Disease Control Rate proportion|Duration of response,https://ClinicalTrials.gov/show/NCT02626962
38,NCT02650986,Gene-Modified T Cells in Treating Patients With Locally Advanced or Stage IV Solid Tumors Expressing NY-ES0-1,Not yet recruiting,No Results Available,Adult Solid Neoplasm,Drug: Cyclophosphamide|Other: Laboratory Biomarker Analysis|Biological: NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL|Biological: TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes,Roswell Park Cancer Institute|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,24,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,I 258514|NCI-2015-02080|P30CA016056,21-Dec-15,5/1/2016,null,5/19/2016,May-16,No Study Results Posted,null,Oct-17,Dose-limiting toxicity using Common Toxicity Criteria|Feasibility based on potential problems in the manufacturing of NY-ESO-1/ dnTGFβRII engineered cells|Expression of the NY-ESO-1 TCR transgenic protein in peripheral blood mononuclear cells (PBMC)|Replication competent retrovirus (RCR)|Tumor response (complete and partial response) as determined by RECIST 1.1,https://ClinicalTrials.gov/show/NCT02650986
214,NCT02501278,A Phase II Clinical Trial of Chemo-radiotherapy in Combination With INO-3112 in Patients With Locally Advanced Cervical Cancer,Withdrawn,No Results Available,Uterine Cervical Neoplasms,Biological: INO-3112 vaccine|Radiation: Radiotherapy (Extrernal beam radiotherapy + brachytherapy)|Drug: Cisplatin chemotherapy,European Organisation for Research and Treatment of Cancer - EORTC|Inovio Pharmaceuticals|Centre Hospitalier Universitaire Vaudois,Female,"18 Years and older   (Adult, Senior)",Phase 2,0,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,EORTC-1411|2015-004602-42,7-Jul-15,5/1/2016,5/1/2021,5/12/2016,May-16,No Study Results Posted,null,May-19,Occurence of Adverse Events|Progression free survival (PFS) at 18 months assessed by RECIST,https://ClinicalTrials.gov/show/NCT02501278
393,NCT02210104,Adoptive Therapy Using Antigen-Specific CD4 T-Cells,Not yet recruiting,No Results Available,Melanoma|Sarcoma,Drug: Ipilimumab|Drug: Cyclophosphamide|Biological: CD4+ T cells,M.D. Anderson Cancer Center|National Institutes of Health (NIH)|National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,12,Other|NIH,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,2013-0669|R01CA104711-09,4-Aug-14,5/1/2016,null,2/8/2016,Feb-16,No Study Results Posted,null,May-19,Maximum Tolerated Dose (MTD) of Adoptively Transferred CD4 T Cells|Clinical Response,https://ClinicalTrials.gov/show/NCT02210104
606,NCT02457845,HSV G207 Alone or With a Single Radiation Dose in Children With Progressive or Recurrent Supratentorial Brain Tumors,Recruiting,No Results Available,"Supratentorial Neoplasms, Malignant",Biological: G207,University of Alabama at Birmingham,Both,"3 Years to 18 Years   (Child, Adult)",Phase 1,18,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,UAB 1472|R01FD005379,20-May-15,5/1/2016,null,6/28/2016,Jun-16,No Study Results Posted,null,May-19,Safety and Tolerability as Measured by Frequency of Grade 3 or Above Adverse Events|Immunologic Response|Virologic Shedding|Progression Free Survival|Overall Survival|Change in Performance (Ability to Perform Normal Activities)|Quality of Life (optional),https://ClinicalTrials.gov/show/NCT02457845
774,NCT02577588,Trial of Adoptive T Cell Therapy With Activated P53 Specific T Cells for Treatment of Advanced Colorectal Cancer,Recruiting,No Results Available,Colorectal Carcinoma,Biological: re-activated T cells,"National Center for Tumor Diseases, Heidelberg|German Cancer Research Center|University Hospital Heidelberg",Both,"18 Years and older   (Adult, Senior)",Phase 1,10,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,NCT-2009-11-03-1055,6-May-15,5/1/2016,3/1/2018,6/15/2016,Mar-16,No Study Results Posted,ATACC,Dec-17,Safety|evaluation of p53 specific T cell Responses by analysing data from EliSpot assay,https://ClinicalTrials.gov/show/NCT02577588
1040,NCT02648633,Stereotactic Radiosurgery With Nivolumab and Valproate in Patients With Recurrent Glioblastoma,Recruiting,No Results Available,Glioblastoma,Radiation: Stereotactic Radiosurgery|Drug: Nivolumab|Drug: Valproate,University of Virginia,Both,"18 Years and older   (Adult, Senior)",Phase 1,17,Other,Interventional,Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,18574|CA209-378,16-Dec-15,5/1/2016,12/1/2019,5/6/2016,May-16,No Study Results Posted,null,Feb-18,Feasibility based on number of subjects who complete 4 doses of nivolumab|Incidence of adverse events|Clinical Response Rate,https://ClinicalTrials.gov/show/NCT02648633
1076,NCT02623595,A Study of SBRT in Combination With rhGM-CSF for Stage IV NSCLC Patients Who Failed in Second-line Chemotherapy,Recruiting,No Results Available,"Carcinoma, Non-Small-Cell Lung",Radiation: Stereotactic body radiotherapy|Drug: rhGM-CSF,Wuhan University|Tongji Hospital|Hubei Cancer Hospital,Both,"18 Years to 75 Years   (Adult, Senior)",Phase 2,60,Other,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CHX-65,23-Nov-15,5/1/2016,11/1/2019,5/30/2016,May-16,No Study Results Posted,null,May-19,abscopal effect rate|overall survival|Incidence of Adverse events|progression free survival|objective response rate|Incidence of treatment-related adverse events|Incidence of immune-related adverse events,https://ClinicalTrials.gov/show/NCT02623595
343,NCT02645149,Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma,Not yet recruiting,No Results Available,Melanoma,Drug: Standard therapy or clinical trial|Drug: Matched targeted therapy|Drug: Trametinib and / or supportive care,Melanoma Institute Australia,Both,"18 Years to 100 Years   (Adult, Senior)",Phase 4,1000,Other,Interventional,Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,MIA2015/174,27-Dec-15,6/1/2016,6/1/2021,3/22/2016,Mar-16,No Study Results Posted,MatchMel,Jun-21,"Type and frequency of genetic aberrations in BRAF/NRAS wild-type metastatic melanoma|Proportion of patients with BRAS/NRAS wild-type melanoma receiving targeted therapy|Proportion of patients who have BRAF/NRAS wild type melanoma|Proportion of patients with complete (CR) or partial (PR) response.|Duration of response|Progression free survival|Overall survival|Correlation of genetic aberration detected in tumour tissue with clinical response and disease progression|Correlation of with genetic aberration detected in tumour tissue with age at diagnosis, site of primary tumour, chronic sun damaged skin.|Correlation of genetic aberration detected in tumour tissue with site of metastases, nodular or superficial spreading disease.",https://ClinicalTrials.gov/show/NCT02645149
386,NCT02559674,ALT-803 in Patients With Advanced Pancreatic Cancer Conjunction With Gemcitabine and Nab-Paclitaxel,Not yet recruiting,No Results Available,Advanced Pancreatic Cancer,Biological: Gemcitabine|Biological: Nab-paclitaxel|Biological: ALT-803,Altor Bioscience Corporation,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,66,Industry,Interventional,Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,CA-ALT-803-01-15,23-Sep-15,6/1/2016,6/1/2022,6/14/2016,Jun-16,No Study Results Posted,null,Jun-19,Determination of MTD; Phase Ib|Safety Profile (Number and severity of treatment related AEs); Phase Ib and II|Overall Survival; Phase II|Objective response rate|Duration of response|Time to progression|Progression-free survival|Biomarkers; Phase Ib|Determine the level of anti-ALT-803 antibodies in patient serum|Area under the plasma concentration-time curve from time zero to infinity (AUC); Phase Ib|Correlation between the level of circulating cell free DNA in patient plasma and response to study treatment|Correlation between the level of tumor DNA in patient plasma and response to study treatment,https://ClinicalTrials.gov/show/NCT02559674
715,NCT02551211,Association Between Circulating Immune Cells and the Tumor Immune Contexture in Resectable Non-small Cell Lung Cancer,Not yet recruiting,No Results Available,Resectable Non-small Lung Cancer,Procedure: blood drawn|Procedure: surgical resection of cancer,"University Hospital, Rouen",Both,"18 Years and older   (Adult, Senior)",,58,Other,Interventional,Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Diagnostic,2015/080/HP,14-Sep-15,6/1/2016,12/1/2017,5/10/2016,May-16,No Study Results Posted,LYMPHOLUNG,Oct-17,Level of expression of the T regulator over total lymphocytes count ratio in the blood|Level of expression of the T regulator over total lymphocytes count ratio into the tumor|Number of cell population counts as blood markers for the corresponding population in the tumor|Number of patient alive 2 years after resection,https://ClinicalTrials.gov/show/NCT02551211
772,NCT02560636,Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer,Recruiting,No Results Available,Invasive Bladder Cancer,Drug: Pembrolizumab|Radiation: Radiotherapy,"Royal Marsden NHS Foundation Trust|Merck Sharp & Dohme Corp.|Institute of Cancer Research, United Kingdom|National Institute for Health Research, United Kingdom",Both,"18 Years and older   (Adult, Senior)",Phase 1,34,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label,CCR 4255,21-Sep-15,6/1/2016,6/1/2019,6/13/2016,Jun-16,No Study Results Posted,PLUMMB,Jun-19,Establishing the maximum tolerated dose (MTD) that can be safely combined with hypofractionated radiotherapy to the bladder in the absence of dose limiting toxicity (DLT)|Measurement of the rates of toxicity rate assessed by CTCAEv4|Measurement of the percentage of patients experiencing late grade 2+ and 3+ toxicity|Determining the proportion of patients treated with the combination of Pembrolizumab and radiotherapy with local control of their bladder cancer (based on cystoscopy and/or diffusionweighted MRI)|Measurement of progression free and overall survival rate,https://ClinicalTrials.gov/show/NCT02560636
935,NCT02587455,Pembrolizumab and Palliative Radiotherapy in Lung,Recruiting,No Results Available,Thoracic Tumours,Drug: Pembrolizumab|Radiation: Radiotherapy,"Royal Marsden NHS Foundation Trust|Merck Sharp & Dohme Corp.|Institute of Cancer Research, United Kingdom|National Institute for Health Research, United Kingdom",Both,"18 Years and older   (Adult, Senior)",Phase 1,48,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label,CCR 4282,13-Oct-15,6/1/2016,6/1/2018,6/16/2016,Jun-16,No Study Results Posted,PEAR,Jun-18,"Toxicity rate of DLTs assessed by CTCAEv4|Maximum tolerated dose (MTD) of pembrolizumab that can be safely combined with radiotherapy (RT) in the absence of dose limiting toxicity (DLT) assessed by CTCAEv4|Progression free survival rates will be calculated at 6 and 12 months, respectively|Overall survival rates will be calculated at 6 and 12 months, respectively|Progression free survival rates will be calculated at 6 and 12 months for PDL-1 strong patients, respectively|Overall survival rates will be calculated at 6 and 12 months for PDL-1 strong patients, respectively|Duration of clinical benefit, as assessed by RECIST v1.1|Compare response rates, as assessed by RECIST v1.1, between squamous and non-squamous histological sub-types",https://ClinicalTrials.gov/show/NCT02587455
396,NCT02033616,Autologous Dendritic Cell-Tumor Cell Immunotherapy for Advanced Epithelial Ovarian Carcinomas,Withdrawn,No Results Available,Stage III Ovarian Carcinoma|Stage IV Ovarian Carcinoma|Fallopian Tube Carcinoma|Primary Peritoneal Carcinoma,Biological: ovapuldencel-T|Biological: MC: Autologous PBMCs in GM-CSF,"Caladrius Biosciences, Inc.",Female,"18 Years and older   (Adult, Senior)",Phase 2,0,Industry,Interventional,"Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment",CL-OVA-P00,7-Jan-14,7/1/2016,12/1/2022,4/25/2016,Sep-15,No Study Results Posted,null,Dec-17,Primary Efficacy Endpoint: Overall Survival|Secondary Efficacy Endpoints: Success rate for establishing a tumor cell line|Secondary Efficacy Endpoint: Progression Free Survival (PFS)|Secondary Efficacy Endpoint: OS and PFS for platinum-sensitive patients|Secondary Efficacy Endpoint: OS and PFS for platinum-resistant patients|Secondary Efficacy Endpoints: OS and PFS from date of debulking surgery and diagnosis,https://ClinicalTrials.gov/show/NCT02033616
1165,NCT02631447,Sequential Combo Immuno and Target Therapy (SECOMBIT) Study,Not yet recruiting,No Results Available,Metastatic Melanoma,Drug: LGX818|Drug: MEK162|Drug: Nivolumab|Drug: Ipilimumab,Fondazione Melanoma Onlus|Clinical Research Technology S.r.l.,Both,"18 Years and older   (Adult, Senior)",Phase 2,230,Other|Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,SECOMBIT|2014-004842-92,9-Dec-15,7/1/2016,12/1/2020,6/14/2016,Jun-16,No Study Results Posted,SECOMBIT,Dec-20,Overall Survival|Total Progression free survival|Percentage of patients alive at 2 and 3 years;|Best overall response rate (BORR);|Duration of response (DoR);|Toxicity of the investigational medicinal products (IMPs).|Quality of life and general health,https://ClinicalTrials.gov/show/NCT02631447
1260,NCT02549651,MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Diffuse Large B-cell Lymphoma (D4190C00023),Recruiting,No Results Available,Diffuse Large B-Cell Lymphoma,Drug: MEDI4736|Drug: tremelimumab|Drug: AZD9150,MedImmune LLC,Both,"18 Years and older   (Adult, Senior)",Phase 1,186,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,D4190C00023,27-Aug-15,7/1/2016,6/1/2021,7/20/2016,Jul-16,No Study Results Posted,null,Jun-21,Number of subjects reporting adverse events and number (percentage) of subjects reporting serious adverse events|Number of subjects experiencing dose-limiting toxicities|Number of subjects who develop anti-drug antibodies (ADA)|Programmed Cell Death Ligand 1 (PD-L1) expression|Time to Response|Duration of Response|Progression Free survival|Time to progression|Event free survival|Overall survival|MEDI4736 Maximum Plasma Concentration (Cmax)|Tremelimumab Maximum Plasma Concentration (Cmax)|AZD9150 Maximum Plasma Concentration (Cmax)|MEDI4736 Minimum Plasma Concentration (Cmin)|Tremelimumab Minimum Plasma Concentration (Cmin)|AZD9150 Minimum Plasma Concentration (Cmin)|Individual MEDI4736 Concentrations|Individual tremelimumab Concentrations|Individual AZD9150 Concentrations|Change from baseline of STAT3 RNA (signal transducer and activator of transcription)|Change from baseline of sPD-L1 (soluble programmed cell death ligand 1),https://ClinicalTrials.gov/show/NCT02549651
908,NCT02236936,Parenteral Nutrition for Patients Treated for Locally Advanced Inoperable Tumors of the Head and Neck,Not yet recruiting,No Results Available,Squamous Cell Carcinoma of the Hypopharynx Stage III|Squamous Cell Carcinoma of the Hypopharynx Stage IV|Laryngeal Squamous Cell Carcinoma Stage III|Laryngeal Squamous Cell Carcinoma Stage IV|Oropharyngeal Squamous Cell Carcinoma Stage III|Oropharyngeal Squamous Cell Carcinoma Stage IV|Squamous Cell Carcinoma of the Oral Cavity Stage III|Squamous Cell Carcinoma of the Oral Cavity Stage IV|Locally Advanced Malignant Neoplasm,Dietary Supplement: Standard care of parenteral nutrition|Dietary Supplement: Parenteral over night nutrition|Biological: Cetuximab|Drug: Cisplatin|Radiation: Radiotherapy,Arbeitsgemeinschaft medikamentoese Tumortherapie|Medical University of Graz,Both,"18 Years and older   (Adult, Senior)",Phase 3,154,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,AGMT_HNO_PN,5-Sep-14,8/1/2016,9/1/2021,6/29/2016,Jun-16,No Study Results Posted,AGMT_HNO_PN,Sep-21,Loss of body weight by more than 5% at the end of radiotherapy|Bioelectrical Impedance Analysis (BIA): reduction of phase angle by > 10% during treatment/observation,https://ClinicalTrials.gov/show/NCT02236936
259,NCT02380443,Increased Frequency of AlloStim® Dosing in Combination With Cryoablation in Metastatic Colorectal Cancer,Not yet recruiting,No Results Available,Colorectal Cancer Metastatic,Biological: AlloStim|Procedure: Cryoablation,"Immunovative Therapies, Ltd.",Both,"18 Years to 80 Years   (Adult, Senior)",Phase 2,18,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ITL-019-CORK-CRYVAC,2-Mar-15,9/1/2016,11/1/2018,7/10/2016,Apr-16,No Study Results Posted,null,May-18,To determine the safety of increased frequency of dosing (Part 1) (whether a Dose Limiting Toxicity (DLT) has occurred)|To evaluate the anti-tumor effect of AlloStim combined with cryoablation at the new proposed dose and frequency schedule (Part 2)|To assess change from baseline in Health-Related Quality of Life (HRQoL),https://ClinicalTrials.gov/show/NCT02380443
473,NCT02466568,Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung,Not yet recruiting,No Results Available,Lung Cancer|Adenocarcinoma of the Lung,Drug: Nivolumab|Biological: GM.CD40L Vaccine,H. Lee Moffitt Cancer Center and Research Institute,Both,"18 Years and older   (Adult, Senior)",Phase 1|Phase 2,100,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,MCC-18147|1504-1392,5-Jun-15,9/1/2016,null,6/9/2016,Jun-16,No Study Results Posted,null,May-17,Phase I: Recommended Phase II Dose|Phase II: Objective Response Rate (ORR)|Phase II: Overall Survival (OS)|Phase II: Progression-free Survival (PFS),https://ClinicalTrials.gov/show/NCT02466568
1074,NCT02844530,Study Evaluating the Efficacy of 90Yttrium-epratuzumab in Adults With CD22+ Relapsed/Refractory B-ALL,Not yet recruiting,No Results Available,CD22+ Relapsed/Refractory B-ALL,Drug: 90Y-epratuzumab tetraxetan|Drug: chemotherapy/ immunotherapy,Nantes University Hospital,Both,"18 Years and older   (Adult, Senior)",Phase 2,69,Other,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,RC15_0088,13-Nov-15,9/1/2016,9/1/2020,7/25/2016,Jul-16,No Study Results Posted,RITEPRALL,Sep-20,Compare the complete response rate (CR + CRp) in the two arms|Overall survival: overall and comparison between both groups|Disease free survival|time to disease progression|duration of response|CD22 expression|Safety and tolerance of fractionated RIT with 90Y-epratuzumab tetraxetan assessed by NCI Criteria|Immunization test to search for antibodies by ELISA test|Realization of a blood pharmacokinetics profile of 111In /90Y-epratuzumab tetraxetan|Tumour and organ dosimetry of 90Y-epratuzumab tetraxetan assessed using 111In-epratuzumab tetraxetan biodistribution|Correlation between FLT3-ligand serum value and efficacy and toxicity after treatment|Relapse incidence: overall and comparison between both groups|Minimal Residual Disease (MRD) (by FACS analysis),https://ClinicalTrials.gov/show/NCT02844530
153,NCT01631357,Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer,Not yet recruiting,No Results Available,Lung Cancer,Drug: Arm 1: cytokine-induced killer cell + cisplatin + paclitaxel|Drug: Arm 2: cisplatin + paclitaxel,Tianjin Medical University Cancer Institute and Hospital,Both,"18 Years to 80 Years   (Adult, Senior)",Phase 2|Phase 3,200,Other,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care,CIH-RXB-201205001,27-May-12,11/1/2016,12/1/2016,12/21/2015,Feb-13,No Study Results Posted,CIK,Nov-16,Overall survival|Progression-free survival,https://ClinicalTrials.gov/show/NCT01631357
490,NCT01741038,AlloStim® In-Situ Vaccine in Pre-Treated Metastatic Colorectal Cancer,Not yet recruiting,No Results Available,Metastatic Colorectal Cancer,Biological: AlloStim®|Procedure: cryoablation|Other: Physician's Choice (PC),"Immunovative Therapies, Ltd.",Both,"18 Years and older   (Adult, Senior)",Phase 2|Phase 3,450,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ITL-008-INSTAVAC-CRC,29-Nov-12,12/1/2016,10/1/2019,4/4/2016,Apr-16,No Study Results Posted,null,Dec-18,Overall Survival|Safety|Health-Related Quality of Life (HRQoL),https://ClinicalTrials.gov/show/NCT01741038
528,NCT02624999,Study Comparing AlloVax™ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck,Not yet recruiting,No Results Available,Squamous Cell Carcinoma Head and Neck,Biological: AlloVax™|Drug: Cisplatin,"Immunovative Therapies, Ltd.",Both,"18 Years and older   (Adult, Senior)",Phase 2,100,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,ITL-020-HENK-VAXPII,29-Nov-15,12/1/2016,5/1/2019,7/10/2016,Jul-16,No Study Results Posted,null,Dec-18,"Safety and tolerability (vital signs, physical examination, clinical laboratory profile, adverse events assessed by CTCAE v4.0 and dose limiting toxicity (DLT))|Overall Survival|Health related Quality of Life (HRQoL)",https://ClinicalTrials.gov/show/NCT02624999
626,NCT02531854,"A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients With Human Papillomavirus Positive (HPV+), NSCLC Following First-Line Induction Chemotherapy",Not yet recruiting,No Results Available,"Carcinoma, Non-Small-Cell Lung",Drug: ADXS11-001|Drug: Pemetrexed,"Advaxis, Inc.",Both,"20 Years and older   (Adult, Senior)",Phase 2,124,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment,GBP-11-201,26-Feb-15,12/1/2016,null,6/17/2016,Jun-16,No Study Results Posted,null,Mar-19,"Number of study participants with objective tumor response as assessed by Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 and Immune-Related Response Evaluation Criteria in Solid Tumors (irRECIST)|Number of study participants with progression free survival as assessed by Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 and Immune-Related Response Evaluation Criteria in Solid Tumors (irRECIST)|Distribution of overall response rate (ORR) as assessed by RECIST v1.1 and irRECIST|Distribution of duration of response (DR) as assessed by RECIST v1.1 and irRECIST|Distribution of disease stabilization (SD) as assessed by RECIST v1.1 and irRECIST|Distribution of overall survival (OS) as assessed by RECIST v1.1 and irRECIST|Frequency and severity of treatment related adverse events (AEs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.03 for study participants on the combination arm",https://ClinicalTrials.gov/show/NCT02531854
1057,NCT02314481,Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity,Not yet recruiting,No Results Available,Non-small Cell Lung Cancer,Drug: MPDL3280A|Drug: Vemurafenib|Drug: Alectinib|Drug: Trastuzumab emtansine,"University College, London|Hoffmann-La Roche",Both,"18 Years and older   (Adult, Senior)",Phase 2,119,Other|Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,14/0274,5-Dec-14,1/1/2017,1/1/2023,3/8/2016,Mar-16,No Study Results Posted,DARWIN II,Jan-23,"Progression free survival (PFS), defined as the period between the date of registration to the date of subsequent progression or death (whichever occurs first).|ORR, Investigator-assessed according to RECISTv1.1 and irRC (Arm 1 only)|Time to event outcomes - overall survival|Time to event outcomes - progression|Duration of response|Toxicity, including dose reductions, interruptions, modifications and exposure|Exploratory assessments include interrogation of recurrence and progression biopsies to decipher the molecular basis for resistance in combination with analyses of CTCs/cfDNA as well as CT imaging heterogeneity analyses.",https://ClinicalTrials.gov/show/NCT02314481
77,NCT00006430,A Safety and Feasibility Study of Active Immunotherapy in Patients With Metastatic Prostate Carcinoma Using Autologous Dendritic Cells Pulsed With Antigen Encoded in Amplified Autologous Tumor RNA,"Active, not recruiting",No Results Available,Prostate Cancer,Biological: Autologous dendritic cells transfected with amplified tumor RNA,National Center for Research Resources (NCRR)|Duke University,Male,"18 Years and older   (Adult, Senior)",Phase 1,null,NIH|Other,Interventional,Primary Purpose: Treatment,NCRR-M01RR00030-0177|M01RR000030,3-Nov-00,null,null,6/23/2005,Feb-02,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00006430
180,NCT01731587,Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer,Withdrawn,No Results Available,Non-small Cell Lung Cancer (NSCLC) Stage III,Other: Biological: MUC1 peptide specific immunotherapy|Drug: Cyclophosphamide (CPA),Merck KGaA,Both,"18 Years and older   (Adult, Senior)",Phase 1,0,Industry,Interventional,Endpoint Classification: Pharmacodynamics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Basic Science,EMR 63325-019|2012-001435-31,11-Oct-12,null,null,2/3/2014,Feb-14,No Study Results Posted,FINGERPRINT,null,"Immune response defined as change from baseline in serum cytokine levels after L-BLP25 administration at Week 1, 4 and 8|Evaluation of a cellular immune response following treatment with L-BLP25|Change from baseline in alternative immune or inflammatory serum soluble immune mediators such as interferon alpha (IFNα), transforming growth factor beta (TGFβ), or C-reactive protein (CRP) at 6, 12, and 24 hours after L-BLP25 administration.|Number of subjects with adverse events (AEs)",https://ClinicalTrials.gov/show/NCT01731587
196,NCT00050388,Phase II Trial of Allovectin-7® for Head and Neck Cancer,Completed,No Results Available,Head and Neck Cancer|Squamous Cell Carcinoma of the Oral Cavity or Oropharynx|Head and Neck Neoplasms|Carcinoma of the Head and Neck,Genetic: Allovectin-7®,Vical,Both,"18 Years and older   (Adult, Senior)",Phase 3,null,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,VCL-1005-207,6-Dec-02,null,6/1/2002,6/20/2008,Jun-08,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00050388
373,NCT00043212,Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.,Withdrawn,No Results Available,Prostate Cancer,Drug: Dendritic cell immunotherapy,Northwest Biotherapeutics,Male,"18 Years and older   (Adult, Senior)",Phase 3,0,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment,"DC3-HRPC, October 2001",6-Aug-02,null,null,4/30/2013,Apr-13,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00043212
635,NCT00108264,Tumor RNA Transfected Dendritic Cell Vaccines,Completed,No Results Available,Prostate Cancer,Biological: Tumor RNA transfected dendritic cells,VA Office of Research and Development,Male,"10 Years and older   (Child, Adult, Senior)",Phase 1,null,U.S. Fed,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label,CLIN-021-02S,14-Apr-05,null,9/1/2005,1/20/2009,May-07,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00108264
676,NCT00780988,Feasibility of Autologous Tumor Cell-TLR9 Agonist Vaccination for Metastatic Colorectal Cancer,Withdrawn,No Results Available,"Colorectal Neoplasms|Anal, Colon, and Rectal Cancers",Biological: Autologous tumor cell + CpG vaccine|Procedure: Autologous hematopoietic and immune cell rescue (transplantation),Stanford University,Both,"18 Years and older   (Adult, Senior)",Phase 1,0,Other,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,SU-09112008-1298|COR0008,23-Oct-08,null,null,1/21/2012,Jan-12,No Study Results Posted,null,null,To assess the feasibility of using an autologous tumor cell vaccine in combination with standard chemotherapy followed by investigational autologous hematopoietic and immune cell rescue in terms of acceptable clinical toxicity.|Preliminary efficacy in terms of response and time to progression|Ex vivo analysis of immune response,https://ClinicalTrials.gov/show/NCT00780988
693,NCT01606358,Influence of Chemotherapy on Gamma-delta T Cells in Patients With Epithelial Ovarian Cancer,Withdrawn,No Results Available,Ovarian Cancer,Drug: Carboplatin and / or taxol chemotherapy,Rennes University Hospital,Female,"18 Years and older   (Adult, Senior)",,0,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,2011-A00214-37,23-May-12,null,null,8/8/2014,Aug-14,No Study Results Posted,IClyCO,May-16,,https://ClinicalTrials.gov/show/NCT01606358
794,NCT00006431,Active Immunotherapy Of Metastatic Renal Cell Carcinoma Using Autologous Dendritic Cells Transfected With Autologous Total Tumor RNA,"Active, not recruiting",No Results Available,Renal Cell Carcinoma,Biological: DC RCC-RNA,National Center for Research Resources (NCRR)|Duke University,Both,"18 Years and older   (Adult, Senior)",Phase 1,null,NIH|Other,Interventional,Primary Purpose: Treatment,NCRR-M01RR00030-0153|M01RR000030,3-Nov-00,null,null,6/23/2005,Nov-01,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00006431
896,NCT00017160,"Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Primary or Recurrent Sarcoma",Withdrawn,No Results Available,Stage III Adult Soft Tissue Sarcoma|Recurrent Adult Soft Tissue Sarcoma|Stage IVA Adult Soft Tissue Sarcoma|Stage IIB Adult Soft Tissue Sarcoma|Stage IIC Adult Soft Tissue Sarcoma,Drug: doxorubicin|Drug: filgrastim|Drug: ifosfamide|Procedure: biological response modifier therapy|Procedure: brachytherapy|Procedure: chemotherapy|Procedure: colony-stimulating factor therapy|Procedure: conventional surgery|Procedure: cytokine therapy|Procedure: intraoperative radiotherapy|Procedure: radiation therapy|Procedure: surgery,Radiation Therapy Oncology Group|National Cancer Institute (NCI),Both,"Child, Adult, Senior",Phase 2,0,Other|NIH,Interventional,Primary Purpose: Treatment,RTOG-S-0124|CDR0000068657,6-Jun-01,null,null,6/25/2013,Jun-13,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00017160
898,NCT02143804,Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer,No longer available,No Results Available,Bladder Cancer|High Grade|Non Muscle Invasive,Biological: oncolytic adenovirus expressing GMCSF,"Cold Genesys, Inc.",Both,"18 Years and older   (Adult, Senior)",,null,Industry,Expanded Access,,exBOND 2.1,19-May-14,null,null,1/27/2015,Jan-15,No Study Results Posted,exBOND,null,,https://ClinicalTrials.gov/show/NCT02143804
941,NCT00979277,Transcriptomal and Molecular Characterization of Tumor Associated Monocytes/Macrophages in Human Cancers,Recruiting,No Results Available,Tumor|Cancer,,"National University Hospital, Singapore",Both,"21 Years and older   (Adult, Senior)",,null,Other,Observational,Observational Model: Cohort|Time Perspective: Prospective,MC03/17/07,15-Sep-09,null,null,1/8/2014,Jan-14,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00979277
1028,NCT00052130,Vaccine Therapy for Patients With Stage III Melanoma,"Active, not recruiting",No Results Available,Malignant Melanoma,Biological: CancerVax vaccine (CANVAXIN),CancerVax Corporation,Both,"18 Years to 80 Years   (Adult, Senior)",Phase 3,1118,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment,CV-MMAIT-3-001|JWCI-MC-3-001A,22-Jan-03,null,null,6/23/2005,Sep-04,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00052130
1031,NCT00052156,Vaccine Therapy for Patients With Stage IV Melanoma,"Active, not recruiting",No Results Available,Malignant Melanoma,Biological: CancerVax vaccine (CANVAXIN),CancerVax Corporation,Both,"18 Years to 80 Years   (Adult, Senior)",Phase 3,670,Industry,Interventional,Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double-Blind|Primary Purpose: Treatment,CV-MMAIT-4-001|JWCI-MC-4-001,23-Jan-03,null,null,6/23/2005,Apr-05,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00052156
1042,NCT00024115,BL22 Immunotoxin in Treating Patients With Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia,Withdrawn,No Results Available,Leukemia|Lymphoma,Drug: BL22 immunotoxin|Procedure: antibody therapy|Procedure: biological response modifier therapy|Procedure: immunotoxin therapy,National Cancer Institute (NCI),Both,"18 Years and older   (Adult, Senior)",Phase 1,0,NIH,Interventional,Primary Purpose: Treatment,CDR0000068892|NCI-01-C-0213|NCI-5336,13-Sep-01,null,null,4/27/2015,Dec-06,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00024115
1155,NCT01196208,A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001,Available,No Results Available,"Disease, Hodgkin|Lymphoma, Large-Cell, Anaplastic|Lymphoma, Non-Hodgkin|Lymphoma, T-Cell, Cutaneous",Drug: brentuximab vedotin,"Seattle Genetics, Inc.|Millennium Pharmaceuticals, Inc.",Both,"6 Years and older   (Child, Adult, Senior)",,null,Industry,Expanded Access,,SGN35-010|2010-020363-21,3-Sep-10,null,8/1/2017,4/12/2016,Jan-16,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT01196208
1171,NCT01069627,A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma,Completed,Has Results,Malignant Melanoma,Drug: bevacizumab [Avastin]|Drug: fotemustine,Hoffmann-La Roche,Both,"18 Years and older   (Adult, Senior)",Phase 2,20,Industry,Interventional,Allocation: Non-Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment,ML19309,15-Dec-09,null,4/1/2010,5/23/2014,May-14,23-May-14,null,Apr-10,"Percentage of Participants With Complete Response (CR) or Partial Response (PR)|Percentage of Participants With Clinical Benefit of CR, PR, or Stable Disease (SD)|Time to Progression (TTP) - Percentage of Participants With an Event|TTP - Time to Event|Duration of CR - Percentage of Participants With an Event|Duration of CR - Time to Event|Duration of Overall Response of CR or PR - Percentage of Participants With an Event|Duration of Overall Response of CR or PR - Time to Event|Duration of Stable Disease - Percentage of Participants With an Event|Duration of Stable Disease - Time to Event|Overall Survival (OS) - Percentage of Participants With an Event|OS - Time to Event|Time to Treatment Failure (TTF) - Percentage of Participants With an Event|TTF - Time to Event|Time to CR - Percentage of Participants With an Event|Time to CR - Time To Event|Time to Overall Response of CR or PR - Percentage of Participants With an Event|Time to Overall Response of CR or PR - Time to Event",https://ClinicalTrials.gov/show/NCT01069627
1240,NCT00001112,The Safety and Effectiveness of Injections of Human Recombinant Interferon-gamma in Patients With AIDS Who Have Taken Zidovudine,Completed,No Results Available,HIV Infections,Drug: Zidovudine|Drug: Interferon gamma-1b,National Institute of Allergy and Infectious Diseases (NIAID),Both,18 Years to 65 Years   (Adult),Phase 1,5,NIH,Interventional,Masking: Open Label|Primary Purpose: Treatment,ACTG 072|11046,2-Nov-99,null,4/1/1993,4/26/2012,Apr-12,No Study Results Posted,null,null,,https://ClinicalTrials.gov/show/NCT00001112
